

**SERINE PROTEASES, NUCLEIC ACIDS
ENCODING SERINE ENZYMES
AND VECTORS AND HOST CELLS INCORPORATING SAME**

The present application claims priority under 35 U.S.C. §119, to co-pending U.S. Provisional Patent Application Serial Number 60/523,609, filed November 19, 2003.

FIELD OF THE INVENTION

The present invention provides novel serine proteases, novel genetic material encoding these enzymes, and proteolytic proteins obtained from *Micrococcineae* spp., including but not limited to *Cellulomonas* spp. and variant proteins developed therefrom. In particular, the present invention provides protease compositions obtained from a *Cellulomonas* spp, DNA encoding the protease, vectors comprising the DNA encoding the protease, host cells transformed with the vector DNA, and an enzyme produced by the host cells. The present invention also provides cleaning compositions (*e.g.*, detergent compositions), animal feed compositions, and textile and leather processing compositions comprising protease(s) obtained from a *Micrococcineae* spp., including but not limited to *Cellulomonas* spp. In alternative embodiments, the present invention provides mutant (*i.e.*, variant) proteases derived from the wild-type proteases described herein. These mutant proteases also find use in numerous applications.

BACKGROUND OF THE INVENTION

Serine proteases are a subgroup of carbonyl hydrolases comprising a diverse class of enzymes having a wide range of specificities and biological functions (*See e.g.*, Stroud, *Sci. Amer.*, 131:74-88). Despite their functional diversity, the catalytic machinery of serine proteases has been approached by at least two genetically distinct families of enzymes: 1) the subtilisins; and 2) the mammalian chymotrypsin-related and homologous bacterial serine proteases (*e.g.*, trypsin and *S. griseus* trypsin). These two families of serine proteases show remarkably similar mechanisms of catalysis (*See e.g.*, Kraut, *Ann. Rev. Biochem.*, 46:331-358 [1977]). Furthermore, although the primary structure is unrelated, the tertiary structure of these two enzyme families brings together a conserved catalytic triad of amino acids consisting of serine, histidine and aspartate. The subtilisins and chymotrypsin-related serine proteases both have a catalytic triad comprising aspartate, histidine and serine. In

- 2 -

the subtilisin-related proteases the relative order of these amino acids, reading from the amino to carboxy terminus, is aspartate-histidine-serine. However, in the chymotrypsin-related proteases, the relative order is histidine-aspartate-serine. Much research has been conducted on the subtilisins, due largely to their usefulness in cleaning and feed applications. Additional work has been focused on the adverse environmental conditions (e.g., exposure to oxidative agents, chelating agents, extremes of temperature and/or pH) which can adversely impact the functionality of these enzymes in various applications. Nonetheless, there remains a need in the art for enzyme systems that are able to resist these adverse conditions and retain or have improved activity over those currently known in the art.

SUMMARY OF THE INVENTION

The present invention provides novel serine proteases, novel genetic material encoding these enzymes, and proteolytic proteins obtained from *Micrococcineae* spp., including but not limited to *Cellulomonas* spp. and variant proteins developed therefrom. In particular, the present invention provides protease compositions obtained from a *Cellulomonas* spp, DNA encoding the protease, vectors comprising the DNA encoding the protease, host cells transformed with the vector DNA, and an enzyme produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising protease(s) obtained from a *Micrococcineae* spp., including but not limited to *Cellulomonas* spp. In alternative embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These mutant proteases also find use in numerous applications.

The present invention provides isolated serine proteases obtained from a member of the *Micrococcineae*. In some embodiments, the proteases are cellulomonadins. In some preferred embodiments, the protease is obtained from an organism selected from the group consisting of *Cellulomonas*, *Oerskovia*, *Cellulosimicrobium*, *Xylanibacterium*, and *Promicromonospora*. In some particularly preferred embodiments, the protease is obtained from *Cellulomonas* 69B4. In further embodiments, the protease comprises the amino acid sequence set forth in SEQ ID NO:8. In additional embodiments, the present invention provides isolated serine proteases comprising at least 45% amino acid identity with serine protease comprising SEQ ID NO:8. In some embodiments, the isolated serine proteases comprise at least 50% identity, preferably at least 55%, more preferably at least 60%, yet more preferably at least 65%, even more preferably at least 70%, more preferably at least

- 3 -

75%, still more preferably at least 80%, more preferably 85%, yet more preferably 90%, even more preferably at least 95%, and most preferably 99% identity.

The present invention also provides compositions comprising isolated serine proteases having immunological cross-reactivity with the serine proteases obtained from the *Micrococcineae*. In some preferred embodiments, the serine proteases have immunological cross-reactivity with serine protease obtained from *Cellulomonas* 69B4. In alternative embodiments, the serine proteases have immunological cross-reactivity with serine protease comprising the amino acid sequence set forth in SEQ ID NO:8. In still further embodiments, the serine proteases have cross-reactivity with fragments (*i.e.*, portions) of any of the serine proteases obtained from the *Micrococcineae*, the *Cellulomonas* 69B4 protease, and/or serine protease comprising the amino acid sequence set forth in SEQ ID NO:8.

In some embodiments, the present invention provides the amino acid sequence set forth in SEQ ID NO:8, wherein the sequence comprises substitutions at least one amino acid position selected from the group comprising positions 2, 8, 10, 11, 12, 13, 14, 15, 16, 24, 26, 31, 33, 35, 36, 38, 39, 40, 43, 46, 49, 51, 54, 61, 64, 65, 67, 70, 71, 76, 78, 79, 81, 83, 85, 86, 90, 93, 99, 100, 105, 107, 109, 112, 113, 116, 118, 119, 121, 123, 127, 145, 155, 159, 160, 163, 165, 170, 174, 179, 183, 184, 185, 186, 187, and 188. In alternative embodiments, the sequence comprises substitutions at least one amino acid position selected from the group comprising positions 1, 4, 22, 27, 28, 30, 32, 41, 47, 48, 55, 59, 63, 66, 69, 75, 77, 80, 84, 87, 88, 89, 92, 96, 110, 111, 114, 115, 117, 128, 134, 144, 143, 146, 151, 154, 156, 158, 161, 166, 176, 177, 181, 182, 187, and 189.

In some preferred embodiments, the present invention provides protease variants having an amino acid sequence comprising at least one substitution of an amino acid made at a position equivalent to a position in a *Cellulomonas* 69B4 protease comprising the amino acid sequence set forth in SEQ ID NO:8. In alternative embodiments, the present invention provides protease variants having an amino acid sequence comprising at least one substitution of an amino acid made at a position equivalent to a position in a *Cellulomonas* 69B4 protease comprising at least a portion of SEQ ID NO:8. In some embodiments, the substitutions are made at positions equivalent to positions 2, 8, 10, 11, 12, 13, 14, 15, 16, 24, 26, 31, 33, 35, 36, 38, 39, 40, 43, 46, 49, 51, 54, 61, 64, 65, 67, 70, 71, 76, 78, 79, 81, 83, 85, 86, 90, 93, 99, 100, 105, 107, 109, 112, 113, 116, 118, 119, 121, 123, 127, 145, 155, 159, 160, 163, 165, 170, 174, 179, 183, 184, 185, 186, 187, and 188 in a *Cellulomonas* 69B4 protease having an amino acid sequence set forth in SEQ ID NO:8. In alternative embodiments, the substitutions are made at positions equivalent to positions 1, 4, 22, 27,

- 4 -

28, 30, 32, 41, 47, 48, 55, 59, 63, 66, 69, 75, 77, 80, 84, 87, 88, 89, 92, 96, 110, 111, 114, 115, 117, 128, 134, 144, 143, 146, 151, 154, 156, 158, 161, 166, 176, 177, 181, 182, 187, and 189, in a *Cellulomonas* 69B4 protease having an amino acid sequence set forth in SEQ ID NO:8. In some preferred embodiments, the protease variants comprise the amino acid sequence comprising SEQ ID NO:8, wherein at least one amino acid position at positions selected from the group consisting of 14, 16, 35, 36, 65, 75, 76, 79, 123, 127, 159, and 179, are substituted with another amino acid. In some particularly preferred embodiments, the proteases comprise at least one mutation selected from the group consisting of R14L, R16L, R16L, R16Q, R35F, T36S, G65Q, Y75G, N76L, N76V, R79T, R123L, R123Q, R127A, R127K, R127Q, R159K, R159Q, and R179Q. In some alternative preferred embodiments, the proteases comprise multiple mutations selected from the group consisting of R16Q/R35F/R159Q, R16Q/R123L, R14L/R127Q/R159Q, R14L/R179Q, R123L/R127Q/R179Q, R16Q/R79T/R127Q, and R16Q/R79T. In some particularly preferred embodiments, the proteases comprise the following mutations R123L, R127Q, and R179Q.

The present invention also provides protease variants having amino acid sequences comprising at least one substitution selected from the group consisting of T36I, A38R, N170Y, N73T, G77T, N24A, T36G, N24E, L69S, T36N, T36S, E119R, N74G, T36W, S76W, N24T, N24Q, T36P, S76Y, T36H, G54D, G78A, S187P, R179V, N24V, V90P, T36D, L69H, G65P, G65R, N7L, W103M, N55F, G186E, A70H, S76V, G186V, R159F, T36Y, T36V, G65V, N24M, S51A, G65Y, Q71I, V66H, P118A, T116F, A38F, N24H, V66D, S76L, G177M, G186I, H85Q, Q71K, Q71G, G65S, A38D, P118F, A38S, G65T, N67G, T36R, P118R, S114G, Y75I, I181H, G65Q, Y75G, T36F, A38H, R179M, T183I, G78S, A64W, Y75F, G77S, N24L, W103I, V3L, Q81V, R179D, G54R, T36L, Q71M, A70S, G49F, G54L, G54H, G78H, R179I, Q81K, V90I, A38L, N67L, T109I, R179N, V66I, G78T, R179Y, S187T, N67K, N73S, E119K, V3I, Q71H, I11Q, A64H, R14E, R179T, L69V, V150L, Q71A, G65L, Q71N, V90S, A64N, I11A, N145I, H85T, A64Y, N145Q, V66L, S92G, S188M, G78D, N67A, N7S, V80H, G54K, A70D, P118H, D2G, G54M, Q81H, D2Q, V66E, R79P, A38N, N145E, R179L, T109H, R179K, V66A, G54A, G78N, T109A, R179A, N7A, R179E, H104K, A64R, and V80L. In further embodiments, wherein the amino acid sequence of the protease variants comprise at least one substitution selected from the group consisting of H85R, H85L, T62I, N67H, G54I, N24F, T40V, T86A, G63V, G54Q, A64F, G77Y, R35F, T129S, R61M, I126L, S76N, T182V, R79G, T109P, R127F, R123E, P118I, T109R, I71S, T183K, N67T, P89N, F1T, A64K, G78I, T109L, G78V, A64M, A64S, T10G, G77N, A64L, N67D, S76T, N42H, D184F, D184R, S76I, S78R, A38K, V72I, V3T, T107S, A38V, F47I, N55Q, S76E, P118Q, T109G, Q71D, P118K, N67S, Q167N, N145G, I28L, I11T, A64I, G49K, G49A, G65A,

- 5 -

N170D, H85K, S185I, I181N, V80F, L69W, S76R, D184H, V150M, T183M, N67Q, S51Q, A38Y, T107V, N145T, Q71F, A83N, S76A, N67R, T151L, T163L, S51F, Q81I, F47M, A41N, P118E, N67Y, T107M, N73H, 67V, G63W, T10K, I181G, S187E, T107H, D2A, L142V, A143N, A8G, S187L, V90A, G49L, N170L, G65H, T36C, G12W, S76Q, A143S, F1A, N7H, S185V, A110T, N55K, N67F, N7I, A110S, N170A, Q81D, A64Q, Q71L, A38I, N112I, V90T, N145L, A64T, I11S, A30S, R123I, D2H, V66M, Q71R, V90L, L68W, N24S, R159E, V66N, D184Q, E133Q, A64V, D2N, G13M, T40S, S76K, G177S, G63Q, S15F, A8K, A70G, and A38G. In some preferred embodiments, these variants have improved casein hydrolysis performance as compared to wild-type *Cellulomonas* 69B4 protease.

The present invention also provides protease variants having amino acid sequences comprising at least one substitution selected from the group consisting of R35E, R35D, R14E, R14D, Q167E, G49C, S15R, S15H, I11W, S15C, G49Q, R35Q, R35V, G49E, R123D, R123Y, G49H, A38D, R35S, F47R, R123C, T151L, R14T, R35T, R123E, G49A, G49V, D56L, R35N, R35A, G12D, R35C, R123N, T46V, R123H, S155C, T121E, R127E, S113C, R123T, R16E, T46F, T121L, A38C, T46E, R123W, T44E, N55G, A8G, E119G, R35P, R14G, F59W, R127S, R61E, R14S, S155W, R123F, R123S, G49N, R127D, E119Y, A48E, N170D, R159T, S99A, G12Q, P118R, F165W, R127Q, R35H, G12N, A22C, G12V, R16T, Y57G, T100A, T46Y, R159E, E119R, T107R, T151C, G54C, E119T, R61V, I11E, R14I, R61M, S15E, A22S, R16C, T36C, R16V, L125Q, M180L, R123Q, R14A, R14Q, R35M, R127K, R159Q, N112P, G124D, R179E, G49L, A41D, G177D, R123V, E119V, T10L, T109E, R179D, G12S, T10C, G91Q, S15Y, S155Y, R14C, T163D, T121F, R14N, F165E, N24E, A41C, R61T, G12I, P118K, T46C, I11T, R159D, N170C, R159V, S155I, I11Q, D2P, T100R, R159S, S114C, R16D, and P134R. In alternative embodiments, the protease variants have amino acid sequences comprising at least one substitution selected from the group consisting of S99G, T100K, R127A, F1P, S155V, T128A, F165H, G177E, A70M, S140P, A87E, D2I, R159K, T36V, R179C, E119N, T10Y, I172A, A8T, F47V, W103L, R61K, D2V, R179V, D2T, R159N, E119A, G54E, R16Q, G49S, R16I, S51L, S155E, S15M, R179I, T10Q, G12H, R159C, R179T, T163C, R159A, A132S, N157D, G13E, L141M, A41T, R123M, R14M, A8R, Q81P, N24T, T10D, A88F, R61Q, S99K, R179Y, T121A, N112E, S155T, T151V, S99Q, T10E, S92T, T109K, T44C, R123A, A87C, S15F, S155F, D56F, T10F, A83H, R179M, T121D, G13D, P118C, G49F, Q174C, S114E, T86E, F1N, T115C, R127C, R123K, V66N, G12Y, S113A, S15N, A175T, R79T, R123G, R179S, R179N, R123I, P118A, S187E, N112D, A70G, E119L, E119S, R159M, R14H, R179F, A64C, A41S, R179W, N24G, T100Q, P118W, Q81G, G49K, R14L, N55A, R35K, R79V, D2M, T160D, A83D, R179L, S51A, G12P, S99H, N42D, S188E, T10M, L125M, T116N, A70P, Q174S,

- 6 -

G65D, S113D, E119Q, A83E, N170L, Q81A, S51C, P118G, Q174T, I28V, S15G, and T116G. In some preferred embodiments, these variants have improved LAS stability as compared to wild-type *Cellulomonas* 69B4 protease.

The present invention also provides protease variants having amino acid sequences comprising at least one substitution selected from the group consisting of G26I, G26K, G26Q, G26V, G26W, F27V, F27W, I28P, T29E, T129W, T40D, T40Q, R43D, P43H, P43K, P43L, A22C, T40H, P89W, G91L, S18E, F59K, A30M, A30N, G31M, C33M, G161L, G161V, P43N, G26E, N73P, G84C, G84P, G45V, C33L, Y9E, Y9P, A147E, C158H, I28W, A48P, A22S, T62R, S137R, S155P, S155R, G156I, G156L, Q81A, R96C, I4D, I4P, A70P, C105E, C105G, C105K, C105M, C105N, C105S, T128A, T128V, T128G, S140P, G12D, C33N, C33E, T164G, G45A, G156P, S99A, Q167L, S155W, I28T, R96F, A30P, R123W, T40P, T39R, C105P, T100A, C105W, S155K, T46Y, R123F, I4G, S155Y, T46V, A93S, Y57N, Q81S, G186S, G31H, T10Y, G31V, A83H, A38D, R123Y, R79T, C158G, G31Y, Q81P, R96E, A30Y, R159K, A22T, T40N, Y57M, G31N, Q81G, T164L, T121E, T10F, Q146P, R123N, V3R, P43G, Q81H, Q81D, G161I, C158M, N24T, T10W, T128S, T160I, Y176P, S155F, T128C, L125A, P168Y, T62G, F166S, S188A, Q81F, T46W, A70G, and A38G. In alternative embodiments, the protease variants have amino acid sequences comprising at least one substitution selected from the group consisting of S188E, S188V, Y117K, Y117Q, Y117R, Y117V, R127K, R127Q, R123L, T86S, R123I, Q81E, L125M, H32A, S188T, N74F, C33D, F27I, A83M, Q71Y, R123T, V90A, F59W, L141C, N170E, T46F, S51V, G162P, S185R, A41S, R79V, T151C, T107S, T129Y, M180L, F166C, C105T, T160E, P89A, R159T, T183P, S188M, T10L, G25S, N24S, E119L, T107L, T107Q, G161K, G15Q, S15R, G153K, G153V, S188G, A83E, G186P, T121D, G49A, S15C, C105Y, C105A, R127F, Q71A, T10C, R179K, T86I, W103N, A87S, F166A, A83F, R123Q, A132C, A143H, T163I, T39V, A93D, V90M, R123K, P134W, G177N, V115I, S155T, T110D, G105L, N170D, T107A, G84V, G84M, L111K, P168I, G154L, T183I, S99G, S15T, A8G, S15N, P189S, S188C, T100Q, A110G, A121A, G12A, R159V, G31A, G154R, T182L, V115L, T160Q, T107F, R159Q, G144A, S92T, T101S, A83R, G12HM, S15H, T116Q, T36V, G154, Q81C, V130T, T183A, P118T, A87E, T86M, V150N, and N24E. In some preferred embodiments, these variants have improved thermostability as compared to wild-type *Cellulomonas* 69B4 protease.

The present invention also provides protease variants having amino acid sequences comprising at least one substitution selected from the group consisting of T36I, I172T, N24E, N170Y, G77T, G186N, I181L, N73T, A38R, N74G, N24A, G54D, S76D, R123E, 159E, N112E, R35E, R179V, R123D, N24T, R179T, R14L, A38D, V90P, R14Q, R123I, R179D, S76V, R79G, R35L, S76E, S76Y, R79D, R79P, R35Q, R179N, N112D, R179E,

- 7 -

G65P, Y75G, V90S, R179M, R35F, R123F, A64I, N24Q, R14I, R179A, R127A, R179I, N170D, R35A, R159F, T109E, R14D, N67D, G49A, N112Q, G78D, T121E, L69S, T116E, V90I, T36S, T36G, N145E, T86D, S51D, R179K, T107E, T129S, L142V, R79A, R79E, A38H, T107S, R123A, N55E, R123L, R159N, G65D, R14N, G65Q, R123Q, N24V, R14G, T116Q, A38N, R159Q, R179Y, A83E, N112L, S99N, G78A, T10N, H85Q, R35Q, N24L, N24H, G49S, R79L, S76T, S76L, G65S, N55F, R79V, G65T, R123N, T86E, Y75F, F1T, S76N, S99V, R79T, N112V, R79M, T107V, R79S, G54E, G65V, R127Q, R159D, T107H, H85T, R35T, T36N, Q81E, R123H, S76I, A38F, V90T, and R14T. In alternative embodiments, the protease variants have amino acid sequences comprising at least one substitution selected from the group consisting of G65L, S99D, T107M, S113T, S99T, G77S, R14M, A64N, R61M, A70D, Q71G, A93D, S92G, N112Y, S15W, R159K, N67G, T10E, R127H, A64Y, R159C, A38L, T160E, T183E, R127S, A8E, S51Q, N7L, G63D, A38S, R35H, R14K, T107I, G12D, A64L, S76W, A41N, R35M, A64V, A38Y, T183I, W103M, A41D, R127K, T36D, R61T, G65Y, G13S, R35Y, R123T, A64H, G49H, A70H, A64F, R127Y, R61E, A64P, T121D, V115A, R123Y, T101S, T182V, H85L, N24M, R127E, N145D, Q71H, S76Q, A64T, G49F, A64Q, T10D, F1D, A70G, R35W, Q71D, N121I, A64M, T36H, A8G, T107N, R35S, N67T, S92A, N170L, N67E, S114A, R14A, R14S, Q81D, S51H, R123S, A93S, R127F, I19V, T40V, S185N, R123G, R179L, S51V, T163D, T109I, A64S, V72I, N67S, R159S, H85M, T109G, Q71S, R61H, T107A, Q81V, V90N, T109A, A38T, N145T, R159A, A110S, Q81H, A48E, S51T, A64W, R159L, N67H, A93E, T116F, R61S, R123V, V3L, and R159Y. In some preferred embodiments, these variants have improved keratin hydrolysis activity as compared to wild-type *Cellulomonas* 69B4 protease.

The present invention also provides protease variants having amino acid sequences comprising at least one substitution selected from the group consisting of T36I, P89D, A93T, A93S, T36N, N73T, T36G, R159F, T36S, A38R, S99W, S76W, T36P, G77T, G54D, R127A, R159E, H85Q, T36D, S76L, S99N, Y75G, S76Y, R127S, N24E, R127Q, D184F, N170Y, N24A, S76T, H85L, Y75F, S76V, L69S, R159K, R127K, G65P, N74G, R159H, G65Q, G186V, A48Q, T36H, N67L, R14I, R127L, T36Y, S76I, S114G, R127H, S187P, V3L, G78D, R123I, I181Q, R35F, H85R, R127Y, N67S, Q81P, R123F, R159N, S99A, S76D, A132V, R127F, A143N, S92A, N24T, R79P, S76N, R14M, G186E, N24Q, N67A, R127T, H85K, G65T, G65Y, R179V, Y75I, I11Q, A38L, T36L, R159Y, R159D, N24V, G65S, N157D, G186I, G54Q, N67Y, R127G, S76A, A38S, T109E, V66H, T116F, R123L, G49A, A64H, T36W, D184H, S99D, G161K, P134E, A64F, N67G, S99T, D2Q, S76E, R16Q, G54N, N67V, R35L, Q71I, N7L, N112E, L69H, N24H, G54I, R16L, N24M, A64Y, S113A, H85F, R79G, I11A, T121D, R61V, and G65L. In alternative embodiments, the protease variants

- 8 -

have amino acid sequences comprising at least one substitution selected from the group consisting of N67Q, S187Q, Q71H, T163D, R61K, R159V, Q71F, V31F, V90I, R79D, T160E, R123Q, A38Y, S113G, A88F, A70G, I11T, G78A, N24L, S92G, R14L, D184R, G54L, N112L, H85Y, R16N, G77S, R179T, V80L, G65V, T121E, Q71D, R16G, P89N, N42H, G49F, I11S, R61M, R159C, G65R, T183I, A93D, L111E, S51Q, G78N, N67T, A38N, T40V, A64W, R159L, T10E, R179K, R123E, V90P, A64N, G161E, H85T, A8G, L142V, A41N, S185I, Q71L, A64T, R16I, A38D, G54M, N112Q, R16A, R14E, V80H, N170D, S99G, R179N, S15E, G49H, A70P, A64S, G54A, S185W, R61H, T10Q, A38F, N170L, T10L, N67F, G12D, D184T, R14N, S187E, R14P, N112D, S140A, N112G, G49S, L111D, N67M, V150L, G12Y, R123K, P89V, V66D, G77N, S51T, A8D, I181H, T86N, R179D, N55F, N24S, D184L, R61S, N67K, G186L, F1T, R159A, I11L, R61T, D184Q, A93E, Q71T, R179E, L69W, T163I, S188Q, L125V, A38V, R35A, P134G, A64V, N145D, V90T, and A143S. In some preferred embodiments, these variants have improved BMI performance as compared to wild-type *Cellulomonas* 69B4 protease.

The present invention also provides protease variants having amino acid sequences comprising at least one substitution selected from the group consisting of T36I, N170Y, A38R, R79P, G77T, L69S, N73T, S76V, S76Y, R179V, T36N, N55F, R159F, G54D, G65P, L69H, T36G, G177M, N24E, N74G, R159E, T36S, Y75G, S76I, S76D, A8R, A24A, V90P, R159C, G65Q, T121E, A8V, S76L, T109E, R179M, A8T, T107N, G186E, S76W, R123E, A38F, T36P, N67G, Y75F, S76N, R179I, S187P, N67V, V90S, R127A, R179Y, R35F, N145S, G65S, R61M, S51A, R179N, R123D, N24T, N55E, R79C, G186V, R123I, G161E, G65Y, A38S, R14L, V90I, R79G, N145E, N67L, R127S, R150Y, M180D, N67T, A93D, T121D, Q81V, T109I, A93E; T107S, R179T, R179L, R179K, R159D; R179A, R79E, R123F, R79D, T36D, A64N, L142V, T109A, I172V, A83N, T85A, R179D, A38L, I126L, R127Q, R127L, L69W, R127K, G65T, R127H, P134A, N67D, R14M, N24Q, A143N, N55S, N67M., S51D, S76E, T163D, A38D, R159K, T183I, G63V, A8S, T107M, H85Q, N112E, N67F, N67S, A64H, T86I, P134E, T182V, N67Y, A64S, G78D, V90T, R61T, R16Q, G65R, T86L, V90N, R159Q, G54I, S76C, R179E, V66D, L69V, R127Y, R35L, R14E, and T86F. In alternative embodiments, the protease variants have amino acid sequences comprising at least one substitution selected from the group consisting of G186I, A64Q, T109G, G64L, N24L, A8E, N112D, A38H, R179W, S114G, R123L, A8L, T129S, N170D, R159N, N67C, S92C, T107A, G54E, T107E, T36V, R127T, A8N, H85L, A110S, N170C, A64R, A132V, T36Y, G63D, W103M, T151V, R123P, W103Y, S76T, S187T, R127F, N67A, P171M, A70S, R159H, S76Q, L125V, G54Q, G49L, R14I, R14Q, A83I, V90L, T183E, R159A, T101S, G65D, G54A, T107Q, Q71M, T86E, N24M, N55Q, R61V, P134D, R96K, A88F, N145Q,

- 9 -

A64M, A64T, N24V, S140A, A8H, A64I, R123Q, T183Q, N24H, A64W, T62I, T129G, R35A, T40V, I11T, A38N, N145G, A175T, G77Q, T109H, A8P, R35E, T109N, A110T, N67Q, G63P, H85R, S92G, A175V, S51Q, G63Q, T116F, G65A, R79L, N145P, L69Q, Q146D, A83D, F166Y, R123A, T121L, R123H, A70P, T182W, S76A, A64F, T107H, G186L, Q81I, R123K, A64L, N67R, V3L, S187E, S161K, T86M, I4M, G77N, G49A, A41N, G54M, T107V, Q81E, A38I, T109L, T183K, A70G, Q71D, T183L, Q81H, A64V, A93Q, S188E, S51F, G186P, G186T, R159L, P134G, N145T, N55V, V66E, R159V, Y176L, and R16L. In some preferred embodiments, these variants have improved BMI performance under low pH conditions, as compared to wild-type *Cellulomonas* 69B4 protease.

The present invention also provides serine proteases comprising at least a portion of an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:9. In some embodiments, the nucleotide sequences encoding these serine proteases comprise a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5. In some embodiments, the serine proteases are variants having amino acid sequences that are similar to that set forth in SEQ ID NO:8. In some preferred embodiments, the proteases are obtained from a member of the *Micrococcineae*. In some particularly preferred embodiments, the proteases are obtained from an organism selected from the group consisting of *Cellulomonas*, *Oerskovia*, *Cellulosimicrobium*, *Xylanibacterium*, and *Promicromonospora*. In some particularly preferred embodiments, the protease is obtained from variants of *Cellulomonas* 69B4.

The present invention also provides isolated protease variants having amino acid sequences comprising at least one substitution of an amino acid made at a position equivalent to a position in a *Cellulomonas* 69B4 protease comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the amino acid of the protease comprises Arg14, Ser15, Arg16, Cys17, His32, Cys33, Phe52, Asp56, Thr100, Val115, Thr116, Tyr117, Pro118, Glu119, Ala132, Glu133, Pro134, Gly135, Asp136, Ser137, Thr151, Ser152, Gly153, Gly154, Ser155, Gly156, Asn157, Thr164, and Phe165. In some embodiments, the catalytic triad of the proteases comprises His 32, Asp56, and Ser137. In alternative embodiments, the proteases comprise Cys131, Ala132, Glu133, Pro134, Gly135, Thr151, Ser152, Gly153, Gly154, Ser155, Gly156, Asn157 and Gly 162, Thr 163, and Thr164. In some preferred embodiments, the amino acid sequence of the proteases comprise Phe52, Tyr117, Pro118 and Glu119. In some particularly preferred embodiments, the amino acids sequences of the proteases have main-chain to main-chain hydrogen bonding from Gly 154 to the substrate main-chain.

- 10 -

In embodiments, the proteases of the present invention comprise three disulfide bonds. In some preferred embodiments, the disulfide bonds are located between C17 and C38, C95 and C105, and C131 and C158. In some particularly preferred embodiments, the disulfide bonds are located between C17 and C38, C95 and C105, and C131 and C158 of SEQ ID NO:8. In alternative protease variant embodiments, the disulfide bonds are located at positions equivalent to the disulfide bonds in SEQ ID NO:8.

The present invention also provides isolated protease variants having amino acid sequences comprising at least one substitution of an amino acid made at a position equivalent to a position in a *Cellulomonas* 69B4 protease comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the variants have altered substrate specificities as compared to wild-type *Cellulomonas* 69B4 protease. In some further preferred embodiments, the variants have altered pIs as compared to wild-type *Cellulomonas* 69B4 protease. In additional preferred embodiments, the variants have improved stability as compared to wild-type *Cellulomonas* 69B4 protease. In still further preferred embodiments, the variants exhibit altered surface properties. In some particularly preferred embodiments, the variants exhibit altered surface properties as compared to wild-type *Cellulomonas* 69B4 protease. In additional particularly preferred embodiments, the variants comprise mutations at least one substitution at sites selected from the group consisting of 1, 2, 4, 7, 8, 10, 11, 12, 13, 14, 15, 16, 22, 24, 25, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 59, 61, 62, 63, 64, 65, 66, 67, 68, 69, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 95, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 123, 124, 126, 127, 128, 130, 131, 132, 133, 134, 135, 137, 143, 144, 145, 146, 147, 148, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 170, 171, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, and 184.

The present invention also provides protease variants having at least one improved property as compared to the wild-type protease. In some particularly preferred embodiments, the variants are variants of a serine protease obtained from a member of the *Micrococcineae*. In some particularly preferred embodiments, the proteases are obtained from an organism selected from the group consisting of *Cellulomonas*, *Oerskovia*, *Cellulosimicrobium*, *Xylanibacterium*, and *Promicromonospora*. In some particularly preferred embodiments, the protease is obtained from variants of *Cellulomonas* 69B4. In some preferred embodiments, at least one improved property is selected from the group consisting of acid stability, thermostability, casein hydrolysis, keratin hydrolysis, cleaning performance, and LAS stability.

- 11 -

The present invention also provides expression vectors comprising a polynucleotide sequence encoding protease variants having amino acid sequences comprising at least one substitution of an amino acid made at a position equivalent to a position in a *Cellulomonas* 69B4 protease comprising the amino acid sequence set forth in SEQ ID NO:8. In further
5 embodiments, the present invention provides host cells comprising these expression vectors. In some particularly preferred embodiments, the host cells are selected from the group consisting of *Bacillus* sp., *Streptomyces* sp., *Aspergillus* sp., and *Trichoderma* sp. The present invention also provides the serine proteases produced by the host cells.

The present invention also provides variant proteases comprising an amino acid
10 sequence selected from the group consisting of SEQ ID NOS:54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, and 78. In some preferred embodiments, the amino acid sequence is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOS:53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77. In further embodiments, the present invention provides expression vectors comprising a polynucleotide sequence
15 encoding at least one protease variant. In additional embodiments, the present invention provides host cells comprising these expression vectors. In some particularly preferred embodiments, the host cells are selected from the group consisting of *Bacillus* sp., *Streptomyces* sp., *Aspergillus* sp., and *Trichoderma* sp. The present invention also provides the serine proteases produced by the host cells.

The present invention also provides compositions comprising at least a portion of an
20 isolated serine protease of obtained from a member of the *Micrococcineae*, wherein the protease is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4. In some preferred embodiments, the sequence comprises at least a portion of SEQ ID NO:1. In further
25 embodiments, the present invention provides host cells comprising these expression vectors. In some particularly preferred embodiments, the host cells are selected from the group consisting of *Bacillus* sp., *Streptomyces* sp., *Aspergillus* sp., and *Trichoderma* sp. The present invention also provides the serine proteases produced by the host cells.

The present invention also provides variant serine proteases, wherein the proteases
30 comprise at least one substitution corresponding to the amino acid positions in SEQ ID NO:8, and wherein variant proteases have better performance in at least one property selected from the group consisting of keratin hydrolysis, thermostability, casein activity, LAS stability, and cleaning, as compared to wild-type *Cellulomonas* 69B4 protease.

The present invention also provides isolated polynucleotides comprising a nucleotide
35 sequence (i) having at least 70% identity to SEQ ID NO:4, or (ii) being capable of hybridizing

- 12 -

to a probe derived from the nucleotide sequence set forth in SEQ ID NO:4, under conditions of intermediate to high stringency, or (iii) being complementary to the nucleotide sequence set forth in SEQ ID NO:4. In embodiments, the present invention provides expression vectors encoding at least one such polynucleotide. In further embodiments, the present invention provides host cells comprising these expression vectors. In some particularly preferred embodiments, the host cells are selected from the group consisting of *Bacillus* sp., *Streptomyces* sp., *Aspergillus* sp., and *Trichoderma* sp. The present invention also provides the serine proteases produced by the host cells. In further embodiments, the present invention provides polynucleotides that are complementary to at least a portion of the sequence set forth in SEQ ID NO:4.

The present invention also provides methods of producing an enzyme having protease activity, comprising: transforming a host cell with an expression vector comprising a polynucleotide having at least 70% sequence identity to SEQ ID NO:4; cultivating the transformed host cell under conditions suitable for host cell. In some embodiments, the host cell is selected from the group consisting of *Streptomyces*, *Aspergillus*, *Trichoderma* and *Bacillus* species.

The present invention also provides probes comprising 4 to 150 nucleotide sequence substantially identical to a corresponding fragment of SEQ ID NO:4, wherein the probe is used to detect a nucleic acid sequence coding for an enzyme having proteolytic activity, and wherein the nucleic acid sequence is obtained from a member of the *Micrococcineae*. In some embodiments, the *Micrococcineae* is a *Cellulomonas* spp. In some preferred embodiments, the *Cellulomonas* is *Cellulomonas* strain 69B4.

The present invention also provides cleaning compositions comprising at least one serine protease obtained from a member of the *Micrococcineae*. In some embodiments, at least one protease is obtained from an organism selected from the group consisting of *Cellulomonas*, *Oerskovia*, *Cellulosimicrobium*, *Xylanibacterium*, and *Promicromonospora*. In some preferred embodiments, the protease is obtained from *Cellulomonas* 69B4. In some particularly preferred embodiments, at least one protease comprises the amino acid sequence set forth in SEQ ID NO:8. In some further embodiments, the present invention provides isolated serine proteases comprising at least 45% amino acid identity with serine protease comprising SEQ ID NO:8. In some embodiments, the isolated serine proteases comprise at least 50% identity, preferably at least 55%, more preferably at least 60%, yet more preferably at least 65%, even more preferably at least 70%, more preferably at least 75%, still more preferably at least 80%, more preferably 85%, yet more preferably 90%, even more preferably at least 95%, and most preferably 99% identity. 75.

- 13 -

The present invention further provides cleaning compositions comprising at least one serine protease, wherein at least one of the serine proteases has immunological cross-reactivity with the serine protease obtained from a member of the *Micrococcineae*. In some preferred embodiments, the serine proteases have immunological cross-reactivity with serine protease obtained from *Cellulomonas* 69B4. In alternative embodiments, the serine proteases have immunological cross-reactivity with serine protease comprising the amino acid sequence set forth in SEQ ID NO:8. In still further embodiments, the serine proteases have cross-reactivity with fragments (*i.e.*, portions) of any of the serine proteases obtained from the *Micrococcineae*, the *Cellulomonas* 69B4 protease, and/or serine protease comprising the amino acid sequence set forth in SEQ ID NO:8.

The present invention further provides cleaning compositions comprising at least one serine protease, wherein the protease is a variant protease having an amino acid sequence comprising at least one substitution of an amino acid made at a position equivalent to a position in a *Cellulomonas* 69B4 protease having an amino acid sequence set forth in SEQ ID NO:8. In some embodiments, the substitutions are made at positions equivalent to positions 2, 8, 10, 11, 12, 13, 14, 15, 16, 24, 26, 31, 33, 35, 36, 38, 39, 40, 43, 46, 49, 51, 54, 61, 64, 65, 67, 70, 71, 76, 78, 79, 81, 83, 85, 86, 90, 93, 99, 100, 105, 107, 109, 112, 113, 116, 118, 119, 121, 123, 127, 145, 155, 159, 160, 163, 165, 170, 174, 179, 183, 184, 185, 186, 187, and 188 in a *Cellulomonas* 69B4 protease comprising an amino acid sequence set forth in SEQ ID NO:8. In alternative embodiments, the substitutions are made at positions equivalent to positions 1, 4, 22, 27, 28, 30, 32, 41, 47, 48, 55, 59, 63, 66, 69, 75, 77, 80, 84, 87, 88, 89, 92, 96, 110, 111, 114, 115, 117, 128, 134, 144, 143, 146, 151, 154, 156, 158, 161, 166, 176, 177, 181, 182, 187, and 189, in a *Cellulomonas* 69B4 protease comprising an amino acid sequence set forth in SEQ ID NO:8. In further embodiments, the protease comprises at least one amino acid substitutions at positions 14, 16, 35, 36, 65, 75, 76, 79, 123, 127, 159, and 179, in an equivalent amino acid sequence to that set forth in SEQ ID NO:8. In still further embodiments, the protease comprises at least one mutation selected from the group consisting of R14L, R16I, R16L, R16Q, R35F, T36S, G65Q, Y75G, N76L, N76V, R79T, R123L, R123Q, R127A, R127K, R127Q, R159K, R159Q, and R179Q. In yet additional embodiments, the protease comprises a set of mutations selected from the group consisting of the sets R16Q/R35F/R159Q, R16Q/R123L, R14L/R127Q/R159Q, R14L/R179Q, R123L/R127Q/R179Q, R16Q/R79T/R127Q, and R16Q/R79T. In some particularly preferred embodiments, the protease comprises the following mutations R123L, R127Q, and R179Q. In some particularly preferred embodiments, the variant serine proteases comprise at least one substitution corresponding to the amino acid positions in

- 14 -

SEQ ID NO:8, and wherein the variant proteases have better performance in at least one property selected from the group consisting of keratin hydrolysis, thermostability, casein activity, LAS stability, and cleaning, as compared to wild-type *Cellulomonas* 69B4 protease. In some embodiments, the variant protease comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, and 78. In alternative embodiments, the variant protease amino acid sequence is encoded by a polynucleotide sequence selected from the group consisting of SEQ ID NOS:53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77.

The present invention also provides cleaning compositions comprising a cleaning effective amount of a proteolytic enzyme, the enzyme comprising an amino acid sequence having at least 70 % sequence identity to SEQ ID NO:4, and a suitable cleaning formulation. In some preferred embodiments, the cleaning compositions further comprise one or more additional enzymes or enzyme derivatives selected from the group consisting of proteases, amylases, lipases, mannanases, pectinases, cutinases, oxidoreductases, hemicellulases, and cellulases.

The present invention also provides compositions comprising at least one serine protease obtained from a member of the *Micrococcineae*, wherein the compositions further comprise at least one stabilizer. In some embodiments, the stabilizer is selected from the group consisting of borax and glycerol. In some embodiments, the present invention provides competitive inhibitors suitable to stabilize the enzyme of the present invention to anionic surfactants. In some embodiments, at least one protease is obtained from an organism selected from the group consisting of *Cellulomonas*, *Oerskovia*, *Cellulosimicrobium*, *Xylanibacterium*, and *Promicromonospora*. In some preferred embodiments, the protease is obtained from *Cellulomonas* 69B4. In some particularly preferred embodiments, at least one protease comprises the amino acid sequence set forth in SEQ ID NO:8.

The present invention further provides compositions comprising at least one serine protease obtained from a member of the *Micrococcineae*, wherein the serine protease is an autolytically stable variant. In some embodiments, at least one variant protease is obtained from an organism selected from the group consisting of *Cellulomonas*, *Oerskovia*, *Cellulosimicrobium*, *Xylanibacterium*, and *Promicromonospora*. In some preferred embodiments, the variant protease is obtained from *Cellulomonas* 69B4. In some particularly preferred embodiments, at least one variant protease comprises the amino acid sequence set forth in SEQ ID NO:8.

The present invention also provides cleaning compositions comprising at least

- 15 -

0.0001 weight percent of the serine protease of the present invention, and optionally, an adjunct ingredient. In some embodiments, the composition comprises an adjunct ingredient. In some preferred embodiments, the composition comprises a sufficient amount of a pH modifier to provide the composition with a neat pH of from about 3 to about 5, the composition being essentially free of materials that hydrolyze at a pH of from about 3 to about 5. In some particularly preferred embodiments, the materials that hydrolyze comprise a surfactant material. In additional embodiments, the cleaning composition is a liquid composition. In further embodiments, the surfactant material comprises a sodium alkyl sulfate surfactant that comprises an ethylene oxide moiety.

The present invention additionally provides cleaning compositions that comprise at least one acid stable enzyme, the cleaning composition comprising a sufficient amount of a pH modifier to provide the composition with a neat pH of from about 3 to about 5, the composition being essentially free of materials that hydrolyze at a pH of from about 3 to about 5. In further embodiments, the materials that hydrolyze comprise a surfactant material. In some preferred embodiments, the cleaning composition being a liquid composition. In yet additional embodiments, the surfactant material comprises a sodium alkyl sulfate surfactant that comprises an ethylene oxide moiety. In some embodiments, the cleaning composition comprises a suitable adjunct ingredient. In some additional embodiments, the composition comprises a suitable adjunct ingredient. In some preferred embodiments, the composition comprises from about 0.001 to about 0.5 weight % of ASP.

In some alternatively preferred embodiments, the composition comprises from about 0.01 to about 0.1 weight percent of ASP.

The present invention also provides methods of cleaning, the comprising the steps of: a) contacting a surface and/or an article comprising a fabric with the cleaning composition comprising the serine protease of the present invention at an appropriate concentration; and b) optionally washing and/or rinsing the surface or material. In alternative embodiments, any suitable composition provided herein finds use in these methods.

The present invention also provides animal feed comprising at least one serine protease obtained from a member of the *Micrococcineae*. In some embodiments, at least one protease is obtained from an organism selected from the group consisting of *Cellulomonas*, *Oerskovia*, *Cellulosimicrobium*, *Xylanibacterium*, and *Promicromonospora*. In some preferred embodiments, the protease is obtained from *Cellulomonas* 69B4. In some particularly preferred embodiments, at least one protease comprises the amino acid

- 16 -

sequence set forth in SEQ ID NO:8.

The present invention provides an isolated polypeptide having proteolytic activity, (e.g., a protease) having the amino acid sequence set forth in SEQ ID NO:8. In some embodiments, the present invention provides isolated polypeptides having approximately 40% to 98% identity with the sequence set forth in SEQ ID NO:8. In some preferred 5 40% to 98% identity with the sequence set forth in SEQ ID NO:8. In some preferred embodiments, the polypeptides have approximately 50% to 95% identity with the sequence set forth in SEQ ID NO:8. In some additional preferred embodiments, the polypeptides have approximately 60% to 90% identity with the sequence set forth in SEQ ID NO:8. In yet additional embodiments, the polypeptides have approximately 65% to 85% identity with the 10 sequence set forth in SEQ ID NO:8. In some particularly preferred embodiments, the polypeptides have approximately 90% to 95% identity with the sequence set forth in SEQ ID NO:8.

The present invention further provides proteases obtained from bacteria of the suborder *Micrococccineae*. In some preferred embodiments, the proteases are obtained 15 from members of the family *Promicromonosporaceae*. In yet further embodiments, the proteases are obtained from any member of the genera *Xylanimicrobium*, *Xylanibacterium*, *Xylanimonas*, *Myceligenans*, and *Promicromonospora*. In some preferred embodiments, the proteases are obtained from members of the family *Cellulomonadaceae*. In some particularly preferred embodiments, the proteases are obtained from members of the genera 20 *Cellulomonas* and *Oerskovia*. In some further preferred embodiments, the proteases are derived from *Cellulomonas* spp. In some embodiments, the *Cellulomonas* spp. is selected from *Cellulomonas fimi*, *Cellulomonas biazotea*, *Cellulomonas cellasea*, *Cellulomonas hominis*, *Cellulomonas flavigena*, *Cellulomonas persica*, *Cellulomonas iranensis*, *Cellulomonas gelida*, *Cellulomonas humilata*, *Cellulomonas turbata*, *Cellulomonas uda*, 25 *Cellulomonas fermentans*, *Cellulomonas xylanilytica*, *Cellulomonas humilata* and *Cellulomonas* strain 69B4 (DSM 16035).

In alternative embodiments, the proteases are derived from *Oerskovia* spp. In some preferred embodiments, the *Oerskovia* spp. is selected from *Oerskovia jenensis*, *Oerskovia paurometabola*, *Oerskovia enterophila*, *Oerskovia turbata* and *Oerskovia turbata* strain DSM 30 20577.

In some embodiments, the proteases have apparent molecular weights of about 17kD to 21kD as determined by a matrix assisted laser desorption/ionization – time of flight (“MALDI-TOF”) spectrophotometer.

The present invention further provides isolated polynucleotides that encode 35 proteases comprise an amino acid sequence comprising at least 40% amino acid sequence

- 17 -

identity to SEQ ID NO:8. In some embodiments, the proteases have at least 50% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 60% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 70% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 80% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 90% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 95% amino acid sequence identity to SEQ ID NO:8. The present invention also provides expression vectors comprising any of the polynucleotides provided above.

The present invention further provides host cells transformed with the expression vectors of the present invention, such that at least one protease is expressed by the host cells. In some embodiments, the host cells are bacteria, while in other embodiments, the host cells are fungi. In some preferred embodiments, the bacterial host cells are selected from the group consisting of the genera *Bacillus* and *Streptomyces*. In some alternative preferred embodiments, the fungal host cells are members of the genus *Trichoderma*, while in other alternative preferred embodiments, the fungal host cells are members of the genus *Aspergillus*.

The present invention also provides isolated polynucleotides comprising a nucleotide sequence (i) having at least 70% identity to SEQ ID NOS:3 or 4, or (ii) being capable of hybridizing to a probe derived from the nucleotide sequence disclosed in SEQ ID NOS: 3 or 4, under conditions of medium to high stringency, or (iii) being complementary to the nucleotide sequence disclosed in SEQ ID NOS:3 or 4. In some embodiments, the present invention provides vectors comprising such polynucleotide. In further embodiments, the present invention provides host cells transformed with such vector.

The present invention further provides methods for producing at least one enzyme having protease activity, comprising: the steps of transforming a host cell with an expression vector comprising a polynucleotide comprising at least 70% sequence identity to SEQ ID NO:4, cultivating the transformed host cell under conditions suitable for the host cell to produce the protease; and recovering the protease. In some preferred embodiments, the host cell is a *Streptomyces* spp, while in other embodiments, the host cell is a *Bacillus* spp., a *Trichoderma* spp., and/or a *Aspergillus* spp. In some embodiments, the *Streptomyces* spp. is *Streptomyces lividans*. In alternative embodiments, the host cell is *T. reesei*. In further embodiments, the *Aspergillus* spp. is *A. niger*.

The present invention also provides fragments (*i.e.*, portions) of the DNA encoding the proteases provided herein. These fragments find use in obtaining partial length DNA

- 18 -

fragments capable of being used to isolate or identify polynucleotides encoding mature protease enzyme described herein from *Cellulomonas* 69B4, or a segment thereof having proteolytic activity. In some embodiments, portions of the DNA provided in SEQ ID NO:1 find use in obtaining homologous fragments of DNA from other species, and particularly from *Micrococcineae* spp. which encode a protease or portion thereof having proteolytic activity.

The present invention further provides at least one probe comprising a polynucleotide substantially identical to a fragment of SEQ ID NOS:1, 2, 3 or 4, wherein the probe is used to detect a nucleic acid sequence coding for an enzyme having proteolytic activity, and wherein the nucleic acid sequence is obtained from a bacterial source. In some embodiments, the bacterial source is a *Cellulomonas* spp. In some preferred embodiments, the bacterial source is *Cellulomonas* strain 69B4.

The present invention further provides compositions comprising at least one of the proteases provided herein. In some preferred embodiments, the compositions are cleaning compositions. In some embodiments, the present invention provides cleaning compositions comprising a cleaning effective amount of at least one protease comprising an amino acid sequence having at least 40% sequence identity to SEQ ID NO:8, at least 90% sequence identity to SEQ ID NO:8, and/or having an amino acid sequence of SEQ ID NO:8. In some embodiments, the cleaning compositions further comprise at least one suitable cleaning adjunct. In some embodiments, the protease is derived from a *Cellulomonas* sp. In some preferred embodiments, the *Cellulomonas* spp. is selected from *Cellulomonas fimi*, *Cellulomonas biazotea*, *Cellulomonas cellasea*, *Cellulomonas hominis*, *Cellulomonas flavigena*, *Cellulomonas persica*, *Cellulomonas iranensis*, *Cellulomonas gelida*, *Cellulomonas humilata*, *Cellulomonas turbata*, *Cellulomonas uda*, and *Cellulomonas* strain 69B4 (DSM 16035). In some particularly preferred embodiments, the *Cellulomonas* spp is *Cellulomonas* strain 69B4. In still further embodiments, the cleaning composition further comprises at least one additional enzymes or enzyme derivatives selected from the group consisting of protease, amylase, lipase, mannanase and cellulase.

The present invention also provides isolated naturally occurring proteases comprising an amino acid sequence having at least 45% sequence identity to SEQ ID NO:8, at least 60% sequence identity to SEQ ID NO:8, at least 75% sequence identity to SEQ ID NO:8, at least 90% sequence identity to SEQ ID NO:8, at least 95% sequence identity to SEQ ID NO:8, and/or having the sequence identity of SEQ ID NO:8, the protease being isolated from a *Cellulomonas* spp.. In some embodiments, the protease is isolated from *Cellulomonas* strain 69B4 (DSM 16035).

- 19 -

In additional embodiments, the present invention provides engineered variants of the serine proteases of the present invention. In some embodiments, the engineered variants are genetically modified using recombinant DNA technologies, while in other embodiments, the variants are naturally occurring. The present invention further encompasses engineered variants of homologous enzymes. In some embodiments, the engineered variant homologous proteases are genetically modified using recombinant DNA technologies, while in other embodiments, the variant homologous proteases are naturally occurring.

The present invention also provides serine proteases that immunologically cross-react with the *Cellulomonas* 69B4 protease (*i.e.*, ASP) of the present invention. Indeed, it is intended that the present invention encompass fragments (*e.g.*, epitopes) of the ASP protease that stimulate an immune response in animals (including, but not limited to humans) and/or are recognized by antibodies of any class. The present invention further encompasses epitopes on proteases that are cross-reactive with ASP epitopes. In some embodiments, the ASP epitopes are recognized by antibodies, but do not stimulate an immune response in animals (including, but not limited to humans), while in other embodiments, the ASP epitopes stimulate an immune response in at least one animal species (including, but not limited to humans) and are recognized by antibodies of any class. The present invention also provides means and compositions for identifying and assessing cross-reactive epitopes.

The present invention further provides at least one polynucleotide encoding a signal peptide (i) having at least 70% sequence identity to SEQ ID NO:9, or (ii) being capable of hybridizing to a probe derived from the polypeptide sequence encoding SEQ ID NO:9, under conditions of medium to high stringency, or (iii) being complementary to the polypeptide sequence provided in SEQ ID NO:9. In further embodiments, the present invention provides at vectors comprising the polynucleotide described above. In yet additional embodiments, a host cell is provided that is transformed with the vector.

The present invention also provides methods for producing proteases, comprising: (a) transforming a host cell with an expression vector comprising a polynucleotide having at least 70% sequence identity to SEQ ID NO:4, at least 95% sequence identity to SEQ ID NO:4, and/or having a polynucleotide sequence of SEQ ID NO:4; (b) cultivating the transformed host cell under conditions suitable for the host cell to produce the protease; and (c) recovering the protease. In some embodiments, the host cell is a *Bacillus* species (*e.g.*, *B. subtilis*, *B. clausii*, or *B. licheniformis*). In alternative embodiments, the host cell is a *Streptomyces spp.*, (*e.g.*, *Streptomyces lividans*). In additional embodiments, the host cell

- 20 -

is a *Trichoderma* spp., (e.g., *Trichoderma reesei*). In yet further embodiments, the host cell is a *Aspergillus* spp. (e.g., *Aspergillus niger*).

As will be appreciated, an advantage of the present invention is that a polynucleotide has been isolated which provides the capability of isolating further polynucleotides which encode proteins having serine protease activity, wherein the backbone is substantially identical to that of the *Cellulomonas* protease of the present invention.

In further embodiments, the present invention provides means to produce host cells that are capable of producing the serine proteases of the present invention in relatively large quantities. In particularly preferred embodiments, the present invention provides means to produce protease with various commercial applications where degradation or synthesis of polypeptides are desired, including cleaning compositions, as well as feed components, textile processing, leather finishing, grain processing, meat processing, cleaning, preparation of protein hydrolysates, digestive aids, microbicidal compositions, bacteriostatic composition, fungistatic compositions, personal care products, including oral care, hair care, and/or skin care.

The present invention further provides enzyme compositions have comparable or improved wash performance, as compared to presently used subtilisin proteases. Other objects and advantages of the present invention are apparent from the present Specification.

The present invention provides an isolated polypeptide having proteolytic activity, (e.g., a protease) having the amino acid sequence set forth in SEQ ID NO:8. In some embodiments, the present invention provides isolated polypeptides having approximately 40% to 98% identity with the sequence set forth in SEQ ID NO:8. In some preferred embodiments, the polypeptides have approximately 50% to 95% identity with the sequence set forth in SEQ ID NO:8. In some additional preferred embodiments, the polypeptides have approximately 60% to 90% identity with the sequence set forth in SEQ ID NO:8. In yet additional embodiments, the polypeptides have approximately 65% to 85% identity with the sequence set forth in SEQ ID NO:8. In some particularly preferred embodiments, the polypeptides have approximately 90% to 95% identity with the sequence set forth in SEQ ID NO:8.

The present invention further provides proteases obtained from bacteria of the suborder *Micrococccineae*. In some preferred embodiments, the proteases are obtained from members of the family *Promicromonosporaceae*. In yet further embodiments, the proteases are obtained from any member of the genera *Xylanimicrobium*, *Xylanibacterium*,

- 21 -

Xylanimonas, *Myceligenans*, and *Promicromonospora*. In some preferred embodiments, the proteases are obtained from members of the family *Cellulomonadaceae*. In some particularly preferred embodiments, the proteases are obtained from members of the genera *Cellulomonas* and *Oerskovia*. In some further preferred embodiments, the proteases are derived from *Cellulomonas* spp. In some embodiments, the *Cellulomonas* spp. is selected from *Cellulomonas fimi*, *Cellulomonas biazotea*, *Cellulomonas cellasea*, *Cellulomonas hominis*, *Cellulomonas flavigena*, *Cellulomonas persica*, *Cellulomonas iranensis*, *Cellulomonas gelida*, *Cellulomonas humilata*, *Cellulomonas turbata*, *Cellulomonas uda*, *Cellulomonas fermentans*, *Cellulomonas xylanilytica*, *Cellulomonas humilata* and *Cellulomonas* strain 69B4 (DSM 16035).

In alternative embodiments, the proteases are derived from *Oerskovia* spp. In some preferred embodiments, the *Oerskovia* spp. is selected from *Oerskovia jenensis*, *Oerskovia paurometabola*, *Oerskovia enterophila*, *Oerskovia turbata* and *Oerskovia turbata* strain DSM 20577.

In some embodiments, the proteases have apparent molecular weights of about 17kD to 21kD as determined by a matrix assisted laser desorption/ionization – time of flight (“MALDI-TOF”) spectrophotometer.

The present invention further provides isolated polynucleotides that encode proteases comprise an amino acid sequence comprising at least 40% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 50% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 60% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 70% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 80% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 90% amino acid sequence identity to SEQ ID NO:8. In some embodiments, the proteases have at least 95% amino acid sequence identity to SEQ ID NO:8. The present invention also provides expression vectors comprising any of the polynucleotides provided above.

The present invention further provides host cells transformed with the expression vectors of the present invention, such that at least one protease is expressed by the host cells. In some embodiments, the host cells are bacteria, while in other embodiments, the host cells are fungi. In some preferred embodiments, the bacterial host cells are selected from the group consisting of the genera *Bacillus* and *Streptomyces*. In some alternative preferred embodiments, the fungal host cells are members of the genus *Trichoderma*, while in other alternative preferred embodiments, the fungal host cells are members of the genus

- 22 -

Aspergillus.

The present invention also provides isolated polynucleotides comprising a nucleotide sequence (i) having at least 70% identity to SEQ ID NOS:3 or 4, or (ii) being capable of hybridizing to a probe derived from the nucleotide sequence disclosed in SEQ ID NOS: 3 or 4, under conditions of medium to high stringency, or (iii) being complementary to the nucleotide sequence disclosed in SEQ ID NOS:3 or 4. In some embodiments, the present invention provides vectors comprising such polynucleotide. In further embodiments, the present invention provides host cells transformed with such vector.

The present invention further provides methods for producing at least one enzyme having protease activity, comprising: the steps of transforming a host cell with an expression vector comprising a polynucleotide comprising at least 70% sequence identity to SEQ ID NO:4, cultivating the transformed host cell under conditions suitable for the host cell to produce the protease; and recovering the protease. In some preferred embodiments, the host cell is a *Streptomyces* spp, while in other embodiments, the host cell is a *Bacillus* spp., a *Trichoderma* spp., and/or a *Aspergillus* spp. In some embodiments, the *Streptomyces* spp. is *Streptomyces lividans*. In alternative embodiments, the host cell is *T. reesei*. In further embodiments, the *Aspergillus* spp. is *A. niger*.

The present invention also provides fragments (*i.e.*, portions) of the DNA encoding the proteases provided herein. These fragments find use in obtaining partial length DNA fragments capable of being used to isolate or identify polynucleotides encoding mature protease enzyme described herein from *Cellulomonas* 69B4, or a segment thereof having proteolytic activity. In some embodiments, portions of the DNA provided in SEQ ID NO:1 find use in obtaining homologous fragments of DNA from other species, and particularly from *Micrococcineae* spp. which encode a protease or portion thereof having proteolytic activity.

The present invention further provides at least one probe comprising a polynucleotide substantially identical to a fragment of SEQ ID NOS:1, 2, 3 or 4, wherein the probe is used to detect a nucleic acid sequence coding for an enzyme having proteolytic activity, and wherein the nucleic acid sequence is obtained from a bacterial source. In some embodiments, the bacterial source is a *Cellulomonas* spp. In some preferred embodiments, the bacterial source is *Cellulomonas* strain 69B4.

The present invention further provides compositions comprising at least one of the proteases provided herein. In some preferred embodiments, the compositions are cleaning compositions. In some embodiments, the present invention provides cleaning compositions comprising a cleaning effective amount of at least one protease comprising an amino acid

- 23 -

sequence having at least 40% sequence identity to SEQ ID NO:8, at least 90% sequence identity to SEQ ID NO:8, and/or having an amino acid sequence of SEQ ID NO:8. In some embodiments, the cleaning compositions further comprise at least one suitable cleaning adjunct. In some embodiments, the protease is derived from a *Cellulomonas* sp. In some preferred embodiments, the *Cellulomonas* spp. is selected from *Cellulomonas fimi*,
5 *Cellulomonas biazotea*, *Cellulomonas cellasea*, *Cellulomonas hominis*, *Cellulomonas flavigena*, *Cellulomonas persica*, *Cellulomonas iranensis*, *Cellulomonas gelida*, *Cellulomonas humilata*, *Cellulomonas turbata*, *Cellulomonas uda*, and *Cellulomonas* strain 69B4 (DSM 16035). In some particularly preferred embodiments, the *Cellulomonas* spp is
10 *Cellulomonas* strain 69B4. In still further embodiments, the cleaning composition further comprises at least one additional enzymes or enzyme derivatives selected from the group consisting of protease, amylase, lipase, mannanase and cellulase.

The present invention also provides isolated naturally occurring proteases comprising an amino acid sequence having at least 45% sequence identity to SEQ ID NO:8, at least 60% sequence identity to SEQ ID NO:8, at least 75% sequence identity to SEQ ID
15 NO:8, at least 90% sequence identity to SEQ ID NO:8, at least 95% sequence identity to SEQ ID NO:8, and/or having the sequence identity of SEQ ID NO:8, the protease being isolated from a *Cellulomonas* spp.. In some embodiments, the protease is isolated from *Cellulomonas* strain 69B4 (DSM 16035).

In additional embodiments, the present invention provides engineered variants of the serine proteases of the present invention. In some embodiments, the engineered variants are genetically modified using recombinant DNA technologies, while in other embodiments, the variants are naturally occurring. The present invention further encompasses engineered variants of homologous enzymes. In some embodiments, the engineered variant
20 homologous proteases are genetically modified using recombinant DNA technologies, while
25 in other embodiments, the variant homologous proteases are naturally occurring.

The present invention also provides serine proteases that immunologically cross-react with the ASP protease of the present invention. Indeed, it is intended that the present invention encompass fragments (e.g., epitopes) of the ASP protease that stimulate an
30 immune response in animals (including, but not limited to humans) and/or are recognized by antibodies of any class. The present invention further encompasses epitopes on proteases that are cross-reactive with ASP epitopes. In some embodiments, the ASP epitopes are recognized by antibodies, but do not stimulate an immune response in animals (including, but not limited to humans), while in other embodiments, the ASP epitopes stimulate an
35 immune response in at least one animal species (including, but not limited to humans) and

- 24 -

are recognized by antibodies of any class. The present invention also provides means and compositions for identifying and assessing cross-reactive epitopes.

The present invention further provides at least one polynucleotide encoding a signal peptide (i) having at least 70% sequence identity to SEQ ID NO:9, or (ii) being capable of hybridizing to a probe derived from the polypeptide sequence encoding SEQ ID NO:9, under conditions of medium to high stringency, or (iii) being complementary to the polypeptide sequence provided in SEQ ID NO:9. In further embodiments, the present invention provides at vectors comprising the polynucleotide described above. In yet additional embodiments, a host cell is provided that is transformed with the vector.

The present invention also provides methods for producing proteases, comprising: (a) transforming a host cell with an expression vector comprising a polynucleotide having at least 70% sequence identity to SEQ ID NO:4, at least 95% sequence identity to SEQ ID NO:4, and/or having a polynucleotide sequence of SEQ ID NO:4; (b) cultivating the transformed host cell under conditions suitable for the host cell to produce the protease; and (c) recovering the protease. In some embodiments, the host cell is a *Bacillus* species (e.g., *B. subtilis*, *B. clausii*, or *B. licheniformis*). In alternative embodiments, the host cell is a *Streptomyces* spp., (e.g., *Streptomyces lividans*). In additional embodiments, the host cell is a *Trichoderma* spp., (e.g., *Trichoderma reesei*). In yet further embodiments, the host cell is a *Aspergillus* spp., (e.g., *Aspergillus niger*).

As will be appreciated, an advantage of the present invention is that a polynucleotide has been isolated which provides the capability of isolating further polynucleotides which encode proteins having serine protease activity, wherein the backbone is substantially identical to that of the *Cellulomonas* protease of the invention.

In further embodiments, the present invention provides means to produce host cells that are capable of producing the serine proteases of the present invention in relatively large quantities. In particularly preferred embodiments, the present invention provides means to produce protease with various commercial applications where degradation or synthesis of polypeptides are desired, including cleaning compositions, as well as feed components, textile processing, leather finishing, grain processing, meat processing, cleaning, preparation of protein hydrolysates, digestive aids, microbicidal compositions, bacteriostatic composition, fungistatic compositions, personal care products, including oral care, hair care, and/or skin care.

The present invention further provides enzyme compositions have comparable or improved wash performance, as compared to presently used subtilisin proteases. Other

objects and advantages of the present invention are apparent from the present Specification.

DESCRIPTION OF THE FIGURES

5 Figure 1 provides an unrooted phylogenetic tree illustrating the relationship of novel strain 69B4 to members of the family *Cellulomonadaceae* and other related genera of the suborder *Micrococcineae*.

Figure 2 provides a phylogenetic tree for ASP protease.

10 Figure 3 provides a MALDI TOF spectrum of a protease derived from *Cellulomonas* strain 69B4

Figure 4 shows the sequence of N-terminal most tryptic peptide from *C. flavigena*

Figure 5 provides the plasmid map of the pSEGCT vector.

Figure 6 provides the plasmid map of the pSEGCT69B4 vector.

Figure 7 provides the plasmid map of the pSEA469BCT vector.

15 Figure 8 provides the plasmid map of the pHPLT-Asp-C1-1 vector.

Figure 9 provides the plasmid map of the pHPLT-Asp-C1-2 vector.

Figure 10 provides the plasmid map of the pHPLT-Asp-C2-1 vector.

Figure 11 provides the plasmid map of the pHPLT-Asp-C2-2 vector.

Figure 12 provides the plasmid map of the pHPLT-ASP-III vector.

20 Figure 13 provides the plasmid map of the pHPLT-ASP-IV vector.

Figure 14 provides the plasmid map of the pHPLT-ASP-VII vector.

Figure 15 provides the plasmid map of the pXX-KpnI vector.

Figure 16 provides the plasmid map of the p2JM103-DNNP1 vector.

Figure 17 provides the plasmid map of the pHPLT vector.

25 Figure 18 provides the map and MXL-prom sequences for the opened pHPLT-ASP-C1-2.

Figure 19 provides the plasmid map of the pENMx3 vector.

Figure 20 provides the plasmid map of the pICatH vector.

Figure 21 provides the plasmid map of the pTREX4 vector.

30 Figure 22 provides the plasmid map of the pSLGAMpR2 vector.

Figure 23 provides the plasmid map of the pRAXdes2-ASP vector.

Figure 28 provides the plasmid map of the pAPDI vector.

Figure 25 provides graphs showing ASP autolysis. Panel A provides a graph

- 26 -

showing the ASP autolysis peptides observed in a buffer without LAS. Panel B provides a graph showing the ASP autolysis peptides observed in a buffer with 0.1% LAS.

Figure 26 compares the cleaning activity (absorbance at 405 nm) dose (ppm) response curves of certain serine proteases (69B4 [-x-]; PURAFECT® [-♦-]; RELEASE™ [-▲-]; and OPTIMASE™ [-■-] in liquid TIDE® detergent under North American wash conditions.

Figure 27 provides a graph that compares the cleaning activity (absorbance at 405 nm) dose (ppm) response curves of certain serine proteases (69B4 [-x-]; PURAFECT® [-♦-]; RELEASE™ [-▲-]; and OPTIMASE™ [-■-] in Detergent Composition III powder detergent (0.66 g/l) North American concentration/detergent formulation under Japanese wash conditions.

Figure 28 provides a graph that compares the cleaning activity (absorbance at 405 nm) dose (ppm) response curves of certain serine proteases (69B4 [-x-]; PURAFECT® [-♦-]; RELEASE™ [-▲-]; and OPTIMASE™ [-■-] in ARIEL® REGULAR detergent powder under European wash conditions.

Figure 29 provides a graph that compares the cleaning activity (absorbance at 405 nm) dose (ppm) response curves of certain serine protease (69B4 [-x-]; PURAFECT® [-♦-]; RELEASE™ [-▲-]; and OPTIMASE™ [-■-] in PURE CLEAN detergent powder under Japanese conditions.

Figure 30 provides a graph that compares the cleaning activity (absorbance at 405 nm) dose (ppm) response curves of certain serine proteases (69B4 [-x-]; PURAFECT® [-♦-]; RELEASE™ [-▲-]; and OPTIMASE™ [-■-] in Detergent Composition III powder (1.00 g/l) under North American conditions.

Figure 31 provides a graph that shows comparative oxidative inactivation of various serine proteases (100 ppm) as a measure of per cent enzyme activity over time (minutes) (69B4 [-x-]; BPN' variant 1 [-♦-]; PURAFECT® [-▲-]; and GG36-variant 1 [-■-]) with 0.1 M H₂O₂ at pH 9.45, 25°C.

Figure 32 provides a graph that shows comparative chelator inactivation of various serine proteases (100 ppm) as a measure of per cent enzyme activity over time (minutes) (69B4 [-x-]; BPN'-variant 1 [-♦-]; PURAFECT® [-▲-]; and GG36-variant 1 [-■-] with 10mM EDTA at pH 8.20, 45°C.

Figure 33 provides a graph that shows comparative thermal inactivation of various serine proteases (100 ppm) as a measure of percent enzyme activity over time (minutes) (69B4 [-x-]; BPN'-variant [-♦-]; PURAFECT® [-▲-]; and GG36-variant 1 [-■-] with 50 mM

- 27 -

Tris at pH 8.0, 45°C.

Figure 34 provides a graph that shows comparative thermal inactivation of certain serine proteases (69B4 [-x-]; BPN'-variant [-♦-]; PURAFECT® [-▲-]; and GG36-variant-1 [-■-] at pH 8.60, over a temperature gradient of 57°C to 62°C.

Figure 35 provides a graph that shows enzyme activity (hydrolysis of di-methyl casein measured by absorbance at 405 nm) of certain serine proteases (2.5 ppm) (69B4 [-■-]; BPN'-variant [-♦-]; PURAFECT® [-▲-]; and GG36-variant 1 [-●-]) at pH's ranging from 5 to 12 at 37°C.

Figure 36 provides a bar graph that shows enzyme stability as indicated by % remaining activity (hydrolysis of di-methyl casein measured by absorbance at 405 nm) of certain serine proteases (2.5 ppm) (69B4, BPN'-variant; PURAFECT® and GG36-variant 1 at pHs ranging from 3 (■), 4 (▨), 5 (▩) to 6 (▧) at 25°, 35°, and 45°C., respectively.

Figure 37 provides a graph that shows enzyme stability as indicated by % remaining activity of a BPN'-variant at pH ranges from 3 (-♦-), 4 (--■--), 5 (--▲--) to 6 (--X--) at 25°, 35°, and 45°C., respectively

Figure 38 provides a graph that shows enzyme stability as indicated by % remaining activity of PURAFECT® TM protease at pH ranges from 3 (-♦-), 4 (--■--), 5 (--▲--) to 6 (--X--) at 25°, 35°, and 45°C., respectively

Figure 39 provides a graph that shows enzyme stability as indicated by % remaining activity of 69B4 protease at pH ranges from 3 (-♦-), 4 (--■--), 5 (--▲--) to 6 (--X--) at 25°, 35° and 45°C., respectively

DESCRIPTION OF THE INVENTION

The present invention provides novel serine proteases, novel genetic material encoding these enzymes, and proteolytic proteins obtained from *Micrococcineae* spp., including but not limited to *Cellulomonas* spp. and variant proteins developed therefrom. In particular, the present invention provides protease compositions obtained from a *Cellulomonas* spp, DNA encoding the protease, vectors comprising the DNA encoding the protease, host cells transformed with the vector DNA, and an enzyme produced by the host cells. The present invention also provides cleaning compositions (e.g., detergent compositions), animal feed compositions, and textile and leather processing compositions comprising protease(s) obtained from a *Micrococcineae* spp., including but not limited to *Cellulomonas* spp. In alternative embodiments, the present invention provides mutant (i.e., variant) proteases derived from the wild-type proteases described herein. These mutant

- 28 -

proteases also find use in numerous applications.

Gram-positive alkalophilic bacteria have been isolated from in and around alkaline soda lakes (See e.g., U.S. Pat. No. 5,401,657, herein incorporated by reference). These alkalophilic were analyzed according to the principles of numerical taxonomy with respect to each other and also a collection of known bacteria, and taxonomically characterized. Six natural clusters or phenons of alkalophilic bacteria were generated. Amongst the strains isolated was a strain identified as 69B4.

Cellulomonas spp. are Gram-positive bacteria classified as members of the family *Cellulomonadaceae*, Suborder *Micrococcineae*, Order *Actinomycetales*, Class *Actinobacteria*. *Cellulomonas* grows as slender, often irregular rods that may occasionally show branching, but no mycelium is formed. In addition, there is no aerial growth and no spores are formed. *Cellulomonas* and *Streptomyces* are only distantly related at a genetic level. The large genetic (genomic) distinction between *Cellulomonas* and *Streptomyces* is reflected in a great difference in phenotypic properties. While serine proteases in *Streptomyces* have been previously examined, there apparently have been no reports of any serine proteases (approx. MW 18,000 to 20,000) secreted by *Cellulomonas* spp. In addition, there apparently have been no previous reports of *Cellulomonas* proteases being used in the cleaning and/or feed industry.

Streptomyces are Gram-positive bacteria classified as members of the Family *Streptomycetaceae*, Suborder *Streptomycineae*, Order *Actinomycetales*, class *Actinobacteria*. *Streptomyces* grows as an extensively branching primary or substrate mycelium and an abundant aerial mycelium that at maturity bear characteristic spores. Streptogrisins are serine proteases secreted in large amounts from a wide variety of *Streptomyces* species. The amino acid sequences of *Streptomyces* proteases have been determined from at least 9 different species of *Streptomyces* including *Streptomyces griseus* Streptogrisin C (accession no. P52320); alkaline proteinase (EC 3.4.21.-) from *Streptomyces* sp. (accession no. PC2053); alkaline serine proteinase I from *Streptomyces* sp. (accession no. S34672), serine protease from *Streptomyces lividans* (accession no. CAD4208); putative serine protease from *Streptomyces coelicolor* A3(2) (accession no. NP_625129); putative serine protease from *Streptomyces avermitilis* MA-4680 (accession no. NP_822175); serine protease from *Streptomyces lividans* (accession no. CAD42809); putative serine protease precursor from *Streptomyces coelicolor* A3(2) (accession no. NP_628830)). A purified native alkaline protease having an apparent molecular weight of 19,000 daltons and isolated from *Streptomyces griseus* var. *alcalophilus* protease and cleaning compositions comprised thereof have been described (See e.g., U.S. Patent No.

- 29 -

5,646,028, incorporated herein by reference).

The present invention provides protease enzymes produced by these organisms. Importantly, these enzymes have good stability and proteolytic activity. These enzymes find use in various applications, including but not limited to cleaning compositions, animal feed, textile processing and etc. The present invention also provides means to produce these enzymes. In some preferred embodiments, the proteases of the present invention are in pure or relatively pure form.

The present invention also provides nucleotide sequences which are suitable to produce the proteases of the present invention in recombinant organisms. In some embodiments, recombinant production provides means to produce the proteases in quantities that are commercially viable.

Unless otherwise indicated, the practice of the present invention involves conventional techniques commonly used in molecular biology, microbiology; and recombinant DNA, which are within the skill of the art. Such techniques are known to those of skill in the art and are described in numerous texts and reference works (See e.g., Sambrook *et al.*, "Molecular Cloning: A Laboratory Manual", Second Edition (Cold Spring Harbor), [1989]); and Ausubel *et al.*, "Current Protocols in Molecular Biology" [1987]). All patents, patent applications, articles and publications mentioned herein, both *supra* and *infra*, are hereby expressly incorporated herein by reference.

Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. For example, Singleton and Sainsbury, *Dictionary of Microbiology and Molecular Biology*, 2d Ed., John Wiley and Sons, NY (1994); and Hale and Marham, *The Harper Collins Dictionary of Biology*, Harper Perennial, NY (1991) provide those of skill in the art with a general dictionaries of many of the terms used in the invention. Although any methods and materials similar or equivalent to those described herein find use in the practice of the present invention, the preferred methods and materials are described herein. Accordingly, the terms defined immediately below are more fully described by reference to the Specification as a whole. Also, as used herein, the singular "a", "an" and "the" includes the plural reference unless the context clearly indicates otherwise. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively. It is to be understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary, depending upon the context they are used by those of skill in the art.

- 30 -

The practice of the present invention employs, unless otherwise indicated, conventional techniques of protein purification, molecular biology, microbiology, recombinant DNA techniques and protein sequencing, all of which are within the skill of those in the art.

Furthermore, the headings provided herein are not limitations of the various aspects or embodiments of the invention which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole. Nonetheless, in order to facilitate understanding of the invention, a number of terms are defined below.

I. Definitions

As used herein, the terms "protease," and "proteolytic activity" refer to a protein or peptide exhibiting the ability to hydrolyze peptides or substrates having peptide linkages. Many well known procedures exist for measuring proteolytic activity (Kalisz, "Microbial Proteinases," *In*: Fiechter (ed.), Advances in Biochemical Engineering/Biotechnology, [1988]). For example, proteolytic activity may be ascertained by comparative assays which analyze the respective protease's ability to hydrolyze a commercial substrate. Exemplary substrates useful in the such analysis of protease or proteolytic activity, include, but are not limited to di-methyl casein (Sigma C-9801), bovine collagen (Sigma C-9879), bovine elastin (Sigma E-1625), and bovine keratin (ICN Biomedical 902111). Colorimetric assays utilizing these substrates are well known in the art (*See e.g.*, WO 99/34011; and U.S. Pat. No. 6,376,450, both of which are incorporated herein by reference. The pNA assay (*See e.g.*, Del Mar *et al.*, *Anal. Biochem.*, 99:316-320 [1979]) also finds use in determining the active enzyme concentration for fractions collected during gradient elution. This assay measures the rate at which *p*-nitroaniline is released as the enzyme hydrolyzes the soluble synthetic substrate, succinyl-alanine-alanine-proline-phenylalanine-*p*-nitroanilide (sAAPF-*p*NA). The rate of production of yellow color from the hydrolysis reaction is measured at 410 nm on a spectrophotometer and is proportional to the active enzyme concentration. In addition, absorbance measurements at 280 nm can be used to determine the total protein concentration. The active enzyme/total-protein ratio gives the enzyme purity.

As used herein, the terms "ASP protease," "Asp protease," and "Asp," refer to the serine proteases described herein. In some preferred embodiments, the Asp protease is the protease designed herein as 69B4 protease obtained from *Cellulomonas* strain 69B4. Thus, in preferred embodiments, the term "69B4 protease" refers to a naturally occurring mature protease derived from *Cellulomonas* strain 69B4 (DSM 16035) having substantially identical amino acid sequences as provided in SEQ ID NO:8. In alternative embodiments,

- 31 -

the present invention provides portions of the ASP protease.

The term "*Cellulomonas* protease homologues" refers to naturally occurring proteases having substantially identical amino acid sequences to the mature protease derived from *Cellulomonas* strain 69B4 or polynucleotide sequences which encode for such naturally occurring proteases, and which proteases retain the functional characteristics of a serine protease encoded by such nucleic acids. In some embodiments, these protease homologues are referred to as "cellulomonadins."

As used herein, the terms "protease variant," "ASP variant," "ASP protease variant," and "69B protease variant" are used in reference to proteases that are similar to the wild-type ASP, particularly in their function, but have mutations in their amino acid sequence that make them different in sequence from the wild-type protease.

As used herein, "*Cellulomonas* ssp." refers to all of the species within the genus "*Cellulomonas*," which are Gram-positive bacteria classified as members of the Family *Cellulomonadaceae*, Suborder *Micrococcineae*, Order *Actinomycetales*, Class *Actinobacteria*. It is recognized that the genus *Cellulomonas* continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified

As used herein, "*Streptomyces* ssp." refers to all of the species within the genus "*Streptomyces*," which are Gram-positive bacteria classified as members of the Family *Streptomycetaceae*, Suborder *Streptomycineae*, Order *Actinomycetales*, class *Actinobacteria*. It is recognized that the genus *Streptomyces* continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified

As used herein, "the genus *Bacillus*" includes all species within the genus "*Bacillus*," as known to those of skill in the art, including but not limited to *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. clausii*, *B. halodurans*, *B. megaterium*, *B. coagulans*, *B. circulans*, *B. lautus*, and *B. thuringiensis*. It is recognized that the genus *Bacillus* continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as *B. stearothermophilus*, which is now named "*Geobacillus stearothermophilus*." The production of resistant endospores in the presence of oxygen is considered the defining feature of the genus *Bacillus*, although this characteristic also applies to the recently named *Alicyclobacillus*, *Amphibacillus*, *Aneurinibacillus*, *Anoxybacillus*, *Brevibacillus*, *Filobacillus*, *Gracilibacillus*, *Halobacillus*, *Paenibacillus*, *Salibacillus*, *Thermobacillus*, *Ureibacillus*, and *Virgibacillus*.

- 32 -

The terms "polynucleotide" and "nucleic acid", used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include, but are not limited to, a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases. The following are non-limiting examples of polynucleotides: genes, gene fragments, chromosomal fragments, ESTs, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. In some embodiments, polynucleotides comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracil, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches. In alternative embodiments, the sequence of nucleotides is interrupted by non-nucleotide components.

As used herein, the terms "DNA construct" and "transforming DNA" are used interchangeably to refer to DNA used to introduce sequences into a host cell or organism. The DNA may be generated *in vitro* by PCR or any other suitable technique(s) known to those in the art. In particularly preferred embodiments, the DNA construct comprises a sequence of interest (*e.g.*, as an incoming sequence). In some embodiments, the sequence is operably linked to additional elements such as control elements (*e.g.*, promoters, etc.). The DNA construct may further comprise a selectable marker. It may further comprise an incoming sequence flanked by homology boxes. In a further embodiment, the transforming DNA comprises other non-homologous sequences, added to the ends (*e.g.*, stuffer sequences or flanks). In some embodiments, the ends of the incoming sequence are closed such that the transforming DNA forms a closed circle. The transforming sequences may be wild-type, mutant or modified. In some embodiments, the DNA construct comprises sequences homologous to the host cell chromosome. In other embodiments, the DNA construct comprises non-homologous sequences. Once the DNA construct is assembled *in vitro* it may be used to: 1) insert heterologous sequences into a desired target sequence of a host cell, and/or 2) mutagenize a region of the host cell chromosome (*i.e.*, replace an endogenous sequence with a heterologous sequence), 3) delete target genes; and/or introduce a replicating plasmid into the host.

As used herein, the terms "expression cassette" and "expression vector" refer to nucleic acid constructs generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell.

- 33 -

The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In preferred embodiments, expression vectors have the ability to incorporate and express heterologous DNA fragments in a host cell. Many prokaryotic and eukaryotic expression vectors are commercially available. Selection of appropriate expression vectors is within the knowledge of those of skill in the art. The term "expression cassette" is used interchangeably herein with "DNA construct," and their grammatical equivalents. Selection of appropriate expression vectors is within the knowledge of those of skill in the art.

As used herein, the term "vector" refers to a polynucleotide construct designed to introduce nucleic acids into one or more cell types. Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, cassettes and the like. In some embodiments, the polynucleotide construct comprises a DNA sequence encoding the protease (*e.g.*, precursor or mature protease) that is operably linked to a suitable prosequence (*e.g.*, secretory, etc.) capable of effecting the expression of the DNA in a suitable host.

As used herein, the term "plasmid" refers to a circular double-stranded (ds) DNA construct used as a cloning vector, and which forms an extrachromosomal self-replicating genetic element in some eukaryotes or prokaryotes, or integrates into the host chromosome.

As used herein in the context of introducing a nucleic acid sequence into a cell, the term "introduced" refers to any method suitable for transferring the nucleic acid sequence into the cell. Such methods for introduction include but are not limited to protoplast fusion, transfection, transformation, conjugation, and transduction (*See e.g.*, Ferrari *et al.*, "*Genetics*," in Hardwood *et al.* (eds.), Bacillus, Plenum Publishing Corp., pages 57-72, [1989]).

As used herein, the terms "transformed" and "stably transformed" refers to a cell that has a non-native (heterologous) polynucleotide sequence integrated into its genome or as an episomal plasmid that is maintained for at least two generations.

As used herein, the term "selectable marker-encoding nucleotide sequence" refers to a nucleotide sequence which is capable of expression in the host cells and where expression of the selectable marker confers to cells containing the expressed gene the ability to grow in the presence of a corresponding selective agent or lack of an essential nutrient.

- 34 -

As used herein, the terms "selectable marker" and "selective marker" refer to a nucleic acid (*e.g.*, a gene) capable of expression in host cell which allows for ease of selection of those hosts containing the vector. Examples of such selectable markers include but are not limited to antimicrobials. Thus, the term "selectable marker" refers to genes that provide an indication that a host cell has taken up an incoming DNA of interest or some other reaction has occurred. Typically, selectable markers are genes that confer antimicrobial resistance or a metabolic advantage on the host cell to allow cells containing the exogenous DNA to be distinguished from cells that have not received any exogenous sequence during the transformation. A "residing selectable marker" is one that is located on the chromosome of the microorganism to be transformed. A residing selectable marker encodes a gene that is different from the selectable marker on the transforming DNA construct. Selective markers are well known to those of skill in the art. As indicated above, preferably the marker is an antimicrobial resistant marker (*e.g.*, amp^R ; phleo^R ; spec^R ; kan^R ; ery^R ; tet^R ; cmp^R ; and neo^R ; See *e.g.*, Guerot-Fleury, *Gene*, 167:335-337 [1995]; Palmeros *et al.*, *Gene* 247:255-264 [2000]; and Trieu-Cuot *et al.*, *Gene*, 23:331-341 [1983]). Other markers useful in accordance with the invention include, but are not limited to auxotrophic markers, such as tryptophan; and detection markers, such as β -galactosidase.

As used herein, the term "promoter" refers to a nucleic acid sequence that functions to direct transcription of a downstream gene. In preferred embodiments, the promoter is appropriate to the host cell in which the target gene is being expressed. The promoter, together with other transcriptional and translational regulatory nucleic acid sequences (also termed "control sequences") is necessary to express a given gene. In general, the transcriptional and translational regulatory sequences include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences.

A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA encoding a secretory leader (*i.e.*, a signal peptide), is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors

- 35 -

or linkers are used in accordance with conventional practice.

As used herein the term "gene" refers to a polynucleotide (*e.g.*, a DNA segment), that encodes a polypeptide and includes regions preceding and following the coding regions as well as intervening sequences (introns) between individual coding segments (exons).

As used herein, "homologous genes" refers to a pair of genes from different, but usually related species, which correspond to each other and which are identical or very similar to each other. The term encompasses genes that are separated by speciation (*i.e.*, the development of new species) (*e.g.*, orthologous genes), as well as genes that have been separated by genetic duplication (*e.g.*, paralogous genes).

As used herein, "ortholog" and "orthologous genes" refer to genes in different species that have evolved from a common ancestral gene (*i.e.*, a homologous gene) by speciation. Typically, orthologs retain the same function during the course of evolution. Identification of orthologs finds use in the reliable prediction of gene function in newly sequenced genomes.

As used herein, "paralog" and "paralogous genes" refer to genes that are related by duplication within a genome. While orthologs retain the same function through the course of evolution, paralogs evolve new functions, even though some functions are often related to the original one. Examples of paralogous genes include, but are not limited to genes encoding trypsin, chymotrypsin, elastase, and thrombin, which are all serine proteinases and occur together within the same species.

As used herein, "homology" refers to sequence similarity or identity, with identity being preferred. This homology is determined using standard techniques known in the art (See *e.g.*, Smith and Waterman, *Adv. Appl. Math.*, 2:482 [1981]; Needleman and Wunsch, *J. Mol. Biol.*, 48:443 [1970]; Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 [1988]; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI); and Devereux *et al.*, *Nucl. Acid Res.*, 12:387-395 [1984]).

As used herein, an "analogous sequence" is one wherein the function of the gene is essentially the same as the gene based on the *Cellulomonas* strain 69B4 protease. Additionally, analogous genes include at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity with the sequence of the *Cellulomonas* strain 69B4 protease. Alternately, analogous sequences have an alignment of between 70 to 100% of the genes found in the *Cellulomonas* strain 69B4 protease region and/or have at least between 5 - 10 genes found in the region aligned with the genes in the *Cellulomonas* strain 69B4 chromosome. In additional embodiments more than one of the

- 36 -

above properties applies to the sequence. Analogous sequences are determined by known methods of sequence alignment. A commonly used alignment method is BLAST, although as indicated above and below, there are other methods that also find use in aligning sequences.

5 One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pair-wise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (Feng and Doolittle, J. Mol. Evol., 35:351-360 [1987]). The method is similar to that
10 described by Higgins and Sharp (Higgins and Sharp, CABIOS 5:151-153 [1989]). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.

Another example of a useful algorithm is the BLAST algorithm, described by Altschul *et al.*, (Altschul *et al.*, J. Mol. Biol., 215:403-410, [1990]; and Karlin *et al.*, Proc. Natl. Acad.
15 Sci. USA 90:5873-5787 [1993]). A particularly useful BLAST program is the WU-BLAST-2 program (See, Altschul *et al.*, Meth. Enzymol., 266:460-480 [1996]). WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11. The HSP S and HSP S2 parameters are dynamic values and are
20 established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. However, the values may be adjusted to increase sensitivity. A % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region. The
25 "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).

Thus, "percent (%) nucleic acid sequence identity" is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues of the starting sequence (*i.e.*, the sequence of interest). A preferred method utilizes the
30 BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

As used herein, the term "hybridization" refers to the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as known in the art.

A nucleic acid sequence is considered to be "selectively hybridizable" to a reference
35 nucleic acid sequence if the two sequences specifically hybridize to one another under

- 37 -

moderate to high stringency hybridization and wash conditions. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe. For example, "maximum stringency" typically occurs at about $T_m-5^\circ\text{C}$ (5° below the T_m of the probe); "high stringency" at about $5-10^\circ\text{C}$ below the T_m ; "intermediate stringency" at about $10-20^\circ\text{C}$ below the T_m of the probe; and "low stringency" at about $20-25^\circ\text{C}$ below the T_m . Functionally, maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe; while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs.

Moderate and high stringency hybridization conditions are well known in the art. An example of high stringency conditions includes hybridization at about 42°C in 50% formamide, 5X SSC, 5X Denhardt's solution, 0.5% SDS and 100 $\mu\text{g/ml}$ denatured carrier DNA followed by washing two times in 2X SSC and 0.5% SDS at room temperature and two additional times in 0.1X SSC and 0.5% SDS at 42°C . An example of moderate stringent conditions include an overnight incubation at 37°C in a solution comprising 20% formamide, 5 x SSC (150mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1x SSC at about $37-50^\circ\text{C}$. Those of skill in the art know how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

As used herein, "recombinant" includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid sequence or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all as a result of deliberate human intervention. "Recombination," "recombining," and generating a "recombined" nucleic acid are generally the assembly of two or more nucleic acid fragments wherein the assembly gives rise to a chimeric gene.

In a preferred embodiment, mutant DNA sequences are generated with site saturation mutagenesis in at least one codon. In another preferred embodiment, site saturation mutagenesis is performed for two or more codons. In a further embodiment, mutant DNA sequences have more than 50%, more than 55%, more than 60%, more than 65%, more than 70%, more than 75%, more than 80%, more than 85%, more than 90%, more than 95%, or more than 98% homology with the wild-type sequence. In alternative embodiments, mutant DNA is generated *in vivo* using any known mutagenic procedure such

- 38 -

as, for example, radiation, nitrosoguanidine and the like. The desired DNA sequence is then isolated and used in the methods provided herein.

As used herein, the term "target sequence" refers to a DNA sequence in the host cell that encodes the sequence where it is desired for the incoming sequence to be inserted into the host cell genome. In some embodiments, the target sequence encodes a functional wild-type gene or operon, while in other embodiments the target sequence encodes a functional mutant gene or operon, or a non-functional gene or operon.

As used herein, a "flanking sequence" refers to any sequence that is either upstream or downstream of the sequence being discussed (*e.g.*, for genes A-B-C, gene B is flanked by the A and C gene sequences). In a preferred embodiment, the incoming sequence is flanked by a homology box on each side. In another embodiment, the incoming sequence and the homology boxes comprise a unit that is flanked by stuffer sequence on each side. In some embodiments, a flanking sequence is present on only a single side (either 3' or 5'), but in preferred embodiments, it is on each side of the sequence being flanked. In some embodiments, a flanking sequence is present on only a single side (either 3' or 5'), while in preferred embodiments, it is present on each side of the sequence being flanked.

As used herein, the term "stuffer sequence" refers to any extra DNA that flanks homology boxes (typically vector sequences). However, the term encompasses any non-homologous DNA sequence. Not to be limited by any theory, a stuffer sequence provides a noncritical target for a cell to initiate DNA uptake.

As used herein, the terms "amplification" and "gene amplification" refer to a process by which specific DNA sequences are disproportionately replicated such that the amplified gene becomes present in a higher copy number than was initially present in the genome. In some embodiments, selection of cells by growth in the presence of a drug (*e.g.*, an inhibitor of an inhibitable enzyme) results in the amplification of either the endogenous gene encoding the gene product required for growth in the presence of the drug or by amplification of exogenous (*i.e.*, input) sequences encoding this gene product, or both.

"Amplification" is a special case of nucleic acid replication involving template specificity. It is to be contrasted with non-specific template replication (*i.e.*, replication that is template-dependent but not dependent on a specific template). Template specificity is here distinguished from fidelity of replication (*i.e.*, synthesis of the proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-) specificity. Template specificity is frequently described in terms of "target" specificity. Target sequences are "targets" in the sense that they are sought to be sorted out from other nucleic acid. Amplification techniques have been designed primarily for this sorting out.

- 39 -

As used herein, the term "co-amplification" refers to the introduction into a single cell of an amplifiable marker in conjunction with other gene sequences (*i.e.*, comprising one or more non-selectable genes such as those contained within an expression vector) and the application of appropriate selective pressure such that the cell amplifies both the amplifiable marker and the other, non-selectable gene sequences. The amplifiable marker may be physically linked to the other gene sequences or alternatively two separate pieces of DNA, one containing the amplifiable marker and the other containing the non-selectable marker, may be introduced into the same cell.

As used herein, the terms "amplifiable marker," "amplifiable gene," and "amplification vector" refer to a gene or a vector encoding a gene which permits the amplification of that gene under appropriate growth conditions.

"Template specificity" is achieved in most amplification techniques by the choice of enzyme. Amplification enzymes are enzymes that, under conditions they are used, will process only specific sequences of nucleic acid in a heterogeneous mixture of nucleic acid. For example, in the case of Q β replicase, MDV-1 RNA is the specific template for the replicase (*See e.g.*, Kacian *et al.*, Proc. Natl. Acad. Sci. USA 69:3038 [1972]). Other nucleic acids are not replicated by this amplification enzyme. Similarly, in the case of T7 RNA polymerase, this amplification enzyme has a stringent specificity for its own promoters (*See*, Chamberlin *et al.*, Nature 228:227 [1970]). In the case of T4 DNA ligase, the enzyme will not ligate the two oligonucleotides or polynucleotides, where there is a mismatch between the oligonucleotide or polynucleotide substrate and the template at the ligation junction (*See*, Wu and Wallace, Genomics 4:560 [1989]). Finally, *Taq* and *Pfu* polymerases, by virtue of their ability to function at high temperature, are found to display high specificity for the sequences bounded and thus defined by the primers; the high temperature results in thermodynamic conditions that favor primer hybridization with the target sequences and not hybridization with non-target sequences.

As used herein, the term "amplifiable nucleic acid" refers to nucleic acids which may be amplified by any amplification method. It is contemplated that "amplifiable nucleic acid" will usually comprise "sample template."

As used herein, the term "sample template" refers to nucleic acid originating from a sample which is analyzed for the presence of "target" (defined below). In contrast, "background template" is used in reference to nucleic acid other than sample template which may or may not be present in a sample. Background template is most often inadvertent. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids

- 40 -

from organisms other than those to be detected may be present as background in a test sample.

As used herein, the term "primer" refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is induced, (*i.e.*, in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.

As used herein, the term "probe" refers to an oligonucleotide (*i.e.*, a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, which is capable of hybridizing to another oligonucleotide of interest. A probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences. It is contemplated that any probe used in the present invention will be labeled with any "reporter molecule," so that is detectable in any detection system, including, but not limited to enzyme (*e.g.*, ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.

As used herein, the term "target," when used in reference to the polymerase chain reaction, refers to the region of nucleic acid bounded by the primers used for polymerase chain reaction. Thus, the "target" is sought to be sorted out from other nucleic acid sequences. A "segment" is defined as a region of nucleic acid within the target sequence.

As used herein, the term "polymerase chain reaction" ("PCR") refers to the methods of U.S. Patent Nos. 4,683,195 4,683,202, and 4,965,188, hereby incorporated by reference, which include methods for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary

- 41 -

to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (*i.e.*, denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the "polymerase chain reaction" (hereinafter "PCR"). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified".

As used herein, the term "amplification reagents" refers to those reagents (deoxyribonucleotide triphosphates, buffer, etc.), needed for amplification except for primers, nucleic acid template and the amplification enzyme. Typically, amplification reagents along with other reaction components are placed and contained in a reaction vessel (test tube, microwell, etc.).

With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (*e.g.*, hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of ³²P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide or polynucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.

As used herein, the terms "PCR product," "PCR fragment," and "amplification product" refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.

As used herein, the term "RT-PCR" refers to the replication and amplification of RNA sequences. In this method, reverse transcription is coupled to PCR, most often using a one enzyme procedure in which a thermostable polymerase is employed, as described in U.S. Patent No. 5,322,770, herein incorporated by reference. In RT-PCR, the RNA template is

- 42 -

converted to cDNA due to the reverse transcriptase activity of the polymerase, and then amplified using the polymerizing activity of the polymerase (*i.e.*, as in other PCR methods).

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

A "restriction site" refers to a nucleotide sequence recognized and cleaved by a given restriction endonuclease and is frequently the site for insertion of DNA fragments. In certain embodiments of the invention restriction sites are engineered into the selective marker and into 5' and 3' ends of the DNA construct.

As used herein, the term "chromosomal integration" refers to the process whereby an incoming sequence is introduced into the chromosome of a host cell. The homologous regions of the transforming DNA align with homologous regions of the chromosome. Subsequently, the sequence between the homology boxes is replaced by the incoming sequence in a double crossover (*i.e.*, homologous recombination). In some embodiments of the present invention, homologous sections of an inactivating chromosomal segment of a DNA construct align with the flanking homologous regions of the indigenous chromosomal region of the *Bacillus* chromosome. Subsequently, the indigenous chromosomal region is deleted by the DNA construct in a double crossover (*i.e.*, homologous recombination).

"Homologous recombination" means the exchange of DNA fragments between two DNA molecules or paired chromosomes at the site of identical or nearly identical nucleotide sequences. In a preferred embodiment, chromosomal integration is homologous recombination.

"Homologous sequences" as used herein means a nucleic acid or polypeptide sequence having 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 88%, 85%, 80%, 75%, or 70% sequence identity to another nucleic acid or polypeptide sequence when optimally aligned for comparison. In some embodiments, homologous sequences have between 85% and 100% sequence identity, while in other embodiments there is between 90% and 100% sequence identity, and in more preferred embodiments, there is 95% and 100% sequence identity.

As used herein "amino acid" refers to peptide or protein sequences or portions thereof. The terms "protein," "peptide," and "polypeptide" are used interchangeably.

As used herein, "protein of interest" and "polypeptide of interest" refer to a protein/polypeptide that is desired and/or being assessed. In some embodiments, the protein of interest is expressed intracellularly, while in other embodiments, it is a secreted polypeptide. In particularly preferred embodiments, these enzymes include the serine

- 43 -

proteases of the present invention. In some embodiments, the protein of interest is a secreted polypeptide which is fused to a signal peptide (*i.e.*, an amino-terminal extension on a protein to be secreted). Nearly all secreted proteins use an amino-terminal protein extension which plays a crucial role in the targeting to and translocation of precursor proteins across the membrane. This extension is proteolytically removed by a signal peptidase during or immediately following membrane transfer.

As used herein, the term "heterologous protein" refers to a protein or polypeptide that does not naturally occur in the host cell. Examples of heterologous proteins include enzymes such as hydrolases including proteases. In some embodiments, the gene encoding the proteins are naturally occurring genes, while in other embodiments, mutated and/or synthetic genes are used.

As used herein, "homologous protein" refers to a protein or polypeptide native or naturally occurring in a cell. In preferred embodiments, the cell is a Gram-positive cell, while in particularly preferred embodiments, the cell is a *Bacillus* host cell. In alternative embodiments, the homologous protein is a native protein produced by other organisms, including but not limited to *E. coli*, *Streptomyces*, *Trichoderma*, and *Aspergillus*. The invention encompasses host cells producing the homologous protein via recombinant DNA technology.

As used herein, an "operon region" comprises a group of contiguous genes that are transcribed as a single transcription unit from a common promoter, and are thereby subject to co-regulation. In some embodiments, the operon includes a regulator gene. In most preferred embodiments, operons that are highly expressed as measured by RNA levels, but have an unknown or unnecessary function are used.

As used herein, an "antimicrobial region" is a region containing at least one gene that encodes an antimicrobial protein.

A polynucleotide is said to "encode" an RNA or a polypeptide if, in its native state or when manipulated by methods known to those of skill in the art, it can be transcribed and/or translated to produce the RNA, the polypeptide or a fragment thereof. The anti-sense strand of such a nucleic acid is also said to encode the sequences.

As is known in the art, a DNA can be transcribed by an RNA polymerase to produce RNA, but an RNA can be reverse transcribed by reverse transcriptase to produce a DNA. Thus a DNA can encode a RNA and vice versa.

The term "regulatory segment" or "regulatory sequence" or "expression control sequence" refers to a polynucleotide sequence of DNA that is operatively linked with a polynucleotide sequence of DNA that encodes the amino acid sequence of a polypeptide

- 44 -

chain to effect the expression of the encoded amino acid sequence. The regulatory sequence can inhibit, repress, or promote the expression of the operably linked polynucleotide sequence encoding the amino acid.

"Host strain" or "host cell" refers to a suitable host for an expression vector comprising DNA according to the present invention.

An enzyme is "overexpressed" in a host cell if the enzyme is expressed in the cell at a higher level than the level at which it is expressed in a corresponding wild-type cell.

The terms "protein" and "polypeptide" are used interchangeably herein. The 3-letter code for amino acids as defined in conformity with the IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) is used throughout this disclosure. It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.

A "prosequence" is an amino acid sequence between the signal sequence and mature protease that is necessary for the secretion of the protease. Cleavage of the prosequence will result in a mature active protease.

The term "signal sequence" or "signal peptide" refers to any sequence of nucleotides and/or amino acids which may participate in the secretion of the mature or precursor forms of the protein. This definition of signal sequence is a functional one, meant to include all those amino acid sequences encoded by the N-terminal portion of the protein gene, which participate in the effectuation of the secretion of protein. They are often, but not universally, bound to the N-terminal portion of a protein or to the N-terminal portion of a precursor protein. The signal sequence may be endogenous or exogenous. The signal sequence may be that normally associated with the protein (e.g., protease), or may be from a gene encoding another secreted protein. One exemplary exogenous signal sequence comprises the first seven amino acid residues of the signal sequence from *Bacillus subtilis* subtilisin fused to the remainder of the signal sequence of the subtilisin from *Bacillus lentus* (ATCC 21536).

The term "hybrid signal sequence" refers to signal sequences in which part of the sequence is obtained from the expression host fused to the signal sequence of the gene to be expressed. In some embodiments, synthetic sequences are utilized.

The term "substantially the same signal activity" refers to the signal activity, as indicated by substantially the same secretion of the protease into the fermentation medium, for example a fermentation medium protease level being at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98% of the secreted protease levels in the fermentation medium as provided by the signal sequence of SEQ ID NOS:5 and/or 9.

- 45 -

The term "mature" form of a protein or peptide refers to the final functional form of the protein or peptide. To exemplify, a mature form of the protease of the present invention at least includes the amino acid sequence identical to residue positions 1-189 of SEQ ID NO:8.

5 The term "precursor" form of a protein or peptide refers to a mature form of the protein having a prosequence operably linked to the amino or carbonyl terminus of the protein. The precursor may also have a "signal" sequence operably linked, to the amino terminus of the prosequence. The precursor may also have additional polynucleotides that are involved in post-translational activity (e.g., polynucleotides cleaved therefrom to leave
10 the mature form of a protein or peptide).

"Naturally occurring enzyme" refers to an enzyme having the unmodified amino acid sequence identical to that found in nature. Naturally occurring enzymes include native enzymes, those enzymes naturally expressed or found in the particular microorganism.

The terms "derived from" and "obtained from" refer to not only a protease produced
15 or producible by a strain of the organism in question, but also a protease encoded by a DNA sequence isolated from such strain and produced in a host organism containing such DNA sequence. Additionally, the term refers to a protease which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the protease in question. To exemplify, "proteases derived from *Cellulomonas*" refers to those enzymes
20 having proteolytic activity which are naturally-produced by *Cellulomonas*, as well as to serine proteases like those produced by *Cellulomonas* sources but which through the use of genetic engineering techniques are produced by non-*Cellulomonas* organisms transformed with a nucleic acid encoding said serine proteases.

A "derivative" within the scope of this definition generally retains the characteristic
25 proteolytic activity observed in the wild-type, native or parent form to the extent that the derivative is useful for similar purposes as the wild-type, native or parent form. Functional derivatives of serine protease encompass naturally occurring, synthetically or recombinantly produced peptides or peptide fragments which have the general characteristics of the serine protease of the present invention.

30 The term "functional derivative" refers to a derivative of a nucleic acid which has the functional characteristics of a nucleic acid which encodes serine protease. Functional derivatives of a nucleic acid which encode serine protease of the present invention encompass naturally occurring, synthetically or recombinantly produced nucleic acids or fragments and encode serine protease characteristic of the present invention. Wild type
35 nucleic acid encoding serine proteases according to the invention include naturally occurring

- 46 -

alleles and homologues based on the degeneracy of the genetic code known in the art.

The term "identical" in the context of two nucleic acids or polypeptide sequences refers to the residues in the two sequences that are the same when aligned for maximum correspondence, as measured using one of the following sequence comparison or analysis algorithms.

The term "optimal alignment" refers to the alignment giving the highest percent identity score.

"Percent sequence identity," "percent amino acid sequence identity," "percent gene sequence identity," and/or "percent nucleic acid/polynucleotide sequence identity," with respect to two amino acid, polynucleotide and/or gene sequences (as appropriate), refer to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 80% amino acid sequence identity means that 80% of the amino acids in two optimally aligned polypeptide sequences are identical.

The phrase "substantially identical" in the context of two nucleic acids or polypeptides thus refers to a polynucleotide or polypeptide that comprising at least 70% sequence identity, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95% , preferably at least 97% , preferably at least 98% and preferably at least 99% sequence identity as compared to a reference sequence using the programs or algorithms (*e.g.*, BLAST, ALIGN, CLUSTAL) using standard parameters. One indication that two polypeptides are substantially identical is that the first polypeptide is immunologically cross-reactive with the second polypeptide. Typically, polypeptides that differ by conservative amino acid substitutions are immunologically cross-reactive. Thus, a polypeptide is substantially identical to a second polypeptide, for example, where the two peptides differ only by a conservative substitution. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions (*e.g.*, within a range of medium to high stringency).

The phrase "equivalent," in this context, refers to serine proteases enzymes that are encoded by a polynucleotide capable of hybridizing to the polynucleotide having the sequence as shown in SEQ ID NO:1, under conditions of medium to maximal stringency. For example, being equivalent means that an equivalent mature serine protease comprises at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% and/or at least 99% sequence identity to the mature *Cellulomonas* serine protease having the amino acid sequence of SEQ ID NO:8.

- 47 -

The term "isolated" or "purified" refers to a material that is removed from its original environment (*e.g.*, the natural environment if it is naturally occurring). For example, the material is said to be "purified" when it is present in a particular composition in a higher or lower concentration than exists in a naturally occurring or wild type organism or in combination with components not normally present upon expression from a naturally occurring or wild type organism. For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector, and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. In preferred embodiments, a nucleic acid or protein is said to be purified, for example, if it gives rise to essentially one band in an electrophoretic gel or blot.

The term "isolated", when used in reference to a DNA sequence, refers to a DNA sequence that has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (*See e.g.*, Dynan and Tijan, *Nature* 316:774-78 [1985]). The term "an isolated DNA sequence" is alternatively referred to as "a cloned DNA sequence".

The term "isolated," when used in reference to a protein, refers to a protein that is found in a condition other than its native environment. In a preferred form, the isolated protein is substantially free of other proteins, particularly other homologous proteins. An isolated protein is more than 10% pure, preferably more than 20% pure, and even more preferably more than 30% pure, as determined by SDS-PAGE. Further aspects of the invention encompass the protein in a highly purified form (*i.e.*, more than 40% pure, more than 60% pure, more than 80% pure, more than 90% pure, more than 95% pure, more than 97% pure, and even more than 99% pure), as determined by SDS-PAGE.

As used herein, the term, "combinatorial mutagenesis" refers to methods in which libraries of variants of a starting sequence are generated. In these libraries, the variants contain one or several mutations chosen from a predefined set of mutations. In addition, the methods provide means to introduce random mutations which were not members of the

- 48 -

predefined set of mutations. In some embodiments, the methods include those set forth in U.S. Patent Appln. Ser. No. 09/699.250, filed October 26, 2000, hereby incorporated by reference. In alternative embodiments, combinatorial mutagenesis methods encompass commercially available kits (*e.g.*, QuikChange® Multisite, Stratagene, San Diego, CA).

5 As used herein, the term "library of mutants" refers to a population of cells which are identical in most of their genome but include different homologues of one or more genes. Such libraries can be used, for example, to identify genes or operons with improved traits.

As used herein, the term "starting gene" refers to a gene of interest that encodes a protein of interest that is to be improved and/or changed using the present invention.

10 As used herein, the term "multiple sequence alignment" ("MSA") refers to the sequences of multiple homologs of a starting gene that are aligned using an algorithm (*e.g.*, Clustal W).

As used herein, the terms "consensus sequence" and "canonical sequence" refer to an archetypical amino acid sequence against which all variants of a particular protein or sequence of interest are compared. The terms also refer to a sequence that sets forth the nucleotides that are most often present in a DNA sequence of interest. For each position of a gene, the consensus sequence gives the amino acid that is most abundant in that position in the MSA.

15 As used herein, the term "consensus mutation" refers to a difference in the sequence of a starting gene and a consensus sequence. Consensus mutations are identified by comparing the sequences of the starting gene and the consensus sequence resulting from an MSA. In some embodiments, consensus mutations are introduced into the starting gene such that it becomes more similar to the consensus sequence. Consensus mutations also include amino acid changes that change an amino acid in a starting gene to an amino acid that is more frequently found in an MSA at that position relative to the frequency of that amino acid in the starting gene. Thus, the term consensus mutation comprises all single amino acid changes that replace an amino acid of the starting gene with an amino acid that is more abundant than the amino acid in the MSA.

20 As used herein, the term "initial hit" refers to a variant that was identified by screening a combinatorial consensus mutagenesis library. In preferred embodiments, initial hits have improved performance characteristics, as compared to the starting gene.

As used herein, the term "improved hit" refers to a variant that was identified by screening an enhanced combinatorial consensus mutagenesis library.

25 As used herein, the terms "improving mutation" and "performance-enhancing mutation" refer to a mutation that leads to improved performance when it is introduced into

- 49 -

the starting gene. In some preferred embodiments, these mutations are identified by sequencing hits that were identified during the screening step of the method. In most embodiments, mutations that are more frequently found in hits are likely to be improving mutations, as compared to an unscreened combinatorial consensus mutagenesis library.

5 As used herein, the term "enhanced combinatorial consensus mutagenesis library" refers to a CCM library that is designed and constructed based on screening and/or sequencing results from an earlier round of CCM mutagenesis and screening. In some embodiments, the enhanced CCM library is based on the sequence of an initial hit resulting from an earlier round of CCM. In additional embodiments, the enhanced CCM is designed
10 such that mutations that were frequently observed in initial hits from earlier rounds of mutagenesis and screening are favored. In some preferred embodiments, this is accomplished by omitting primers that encode performance-reducing mutations or by increasing the concentration of primers that encode performance-enhancing mutations relative to other primers that were used in earlier CCM libraries.

15 As used herein, the term "performance-reducing mutations" refer to mutations in the combinatorial consensus mutagenesis library that are less frequently found in hits resulting from screening as compared to an unscreened combinatorial consensus mutagenesis library. In preferred embodiments, the screening process removes and/or reduces the abundance of variants that contain "performance-reducing mutations."

20 As used herein, the term "functional assay" refers to an assay that provides an indication of a protein's activity. In particularly preferred embodiments, the term refers to assay systems in which a protein is analyzed for its ability to function in its usual capacity. For example, in the case of enzymes, a functional assay involves determining the effectiveness of the enzyme in catalyzing a reaction.

25 As used herein, the term "target property" refers to the property of the starting gene that is to be altered. It is not intended that the present invention be limited to any particular target property. However, in some preferred embodiments, the target property is the stability of a gene product (*e.g.*, resistance to denaturation, proteolysis or other degradative factors), while in other embodiments, the level of production in a production host is altered.
30 Indeed, it is contemplated that any property of a starting gene will find use in the present invention.

The term "property" or grammatical equivalents thereof in the context of a nucleic acid, as used herein, refer to any characteristic or attribute of a nucleic acid that can be selected or detected. These properties include, but are not limited to, a property affecting
35 binding to a polypeptide, a property conferred on a cell comprising a particular nucleic acid,

- 50 -

a property affecting gene transcription (*e.g.*, promoter strength, promoter recognition, promoter regulation, enhancer function), a property affecting RNA processing (*e.g.*, RNA splicing, RNA stability, RNA conformation, and post-transcriptional modification), a property affecting translation (*e.g.*, level, regulation, binding of mRNA to ribosomal proteins, post-translational modification). For example, a binding site for a transcription factor, polymerase, regulatory factor, etc., of a nucleic acid may be altered to produce desired characteristics or to identify undesirable characteristics.

The term "property" or grammatical equivalents thereof in the context of a polypeptide, as used herein, refer to any characteristic or attribute of a polypeptide that can be selected or detected. These properties include, but are not limited to oxidative stability, substrate specificity, catalytic activity, thermal stability, alkaline stability, pH activity profile, resistance to proteolytic degradation, K_M , k_{cat} , k_{cat}/K_M ratio, protein folding, inducing an immune response, ability to bind to a ligand, ability to bind to a receptor, ability to be secreted, ability to be displayed on the surface of a cell, ability to oligomerize, ability to signal, ability to stimulate cell proliferation, ability to inhibit cell proliferation, ability to induce apoptosis, ability to be modified by phosphorylation or glycosylation, ability to treat disease.

As used herein, the term "screening" has its usual meaning in the art and is, in general a multi-step process. In the first step, a mutant nucleic acid or variant polypeptide therefrom is provided. In the second step, a property of the mutant nucleic acid or variant polypeptide is determined. In the third step, the determined property is compared to a property of the corresponding precursor nucleic acid, to the property of the corresponding naturally occurring polypeptide or to the property of the starting material (*e.g.*, the initial sequence) for the generation of the mutant nucleic acid.

It will be apparent to the skilled artisan that the screening procedure for obtaining a nucleic acid or protein with an altered property depends upon the property of the starting material the modification of which the generation of the mutant nucleic acid is intended to facilitate. The skilled artisan will therefore appreciate that the invention is not limited to any specific property to be screened for and that the following description of properties lists illustrative examples only. Methods for screening for any particular property are generally described in the art. For example, one can measure binding, pH, specificity, etc., before and after mutation, wherein a change indicates an alteration. Preferably, the screens are performed in a high-throughput manner, including multiple samples being screened simultaneously, including, but not limited to assays utilizing chips, phage display, and multiple substrates and/or indicators.

As used herein, in some embodiments, screens encompass selection steps in which

- 51 -

variants of interest are enriched from a population of variants. Examples of these embodiments include the selection of variants that confer a growth advantage to the host organism, as well as phage display or any other method of display, where variants can be captured from a population of variants based on their binding or catalytic properties. In a preferred embodiment, a library of variants is exposed to stress (heat, protease, denaturation) and subsequently variants that are still intact are identified in a screen or enriched by selection. It is intended that the term encompass any suitable means for selection. Indeed, it is not intended that the present invention be limited to any particular method of screening.

As used herein, the term "targeted randomization" refers to a process that produces a plurality of sequences where one or several positions have been randomized. In some embodiments, randomization is complete (*i.e.*, all four nucleotides, A, T, G, and C can occur at a randomized position. In alternative embodiments, randomization of a nucleotide is limited to a subset of the four nucleotides. Targeted randomization can be applied to one or several codons of a sequence, coding for one or several proteins of interest. When expressed, the resulting libraries produce protein populations in which one or more amino acid positions can contain a mixture of all 20 amino acids or a subset of amino acids, as determined by the randomization scheme of the randomized codon. In some embodiments, the individual members of a population resulting from targeted randomization differ in the number of amino acids, due to targeted or random insertion or deletion of codons. In further embodiments, synthetic amino acids are included in the protein populations produced. In some preferred embodiments, the majority of members of a population resulting from targeted randomization show greater sequence homology to the consensus sequence than the starting gene. In some embodiments, the sequence encodes one or more proteins of interest. In alternative embodiments, the proteins have differing biological functions. In some preferred embodiments, the incoming sequence comprises at least one selectable marker.

The terms "modified sequence" and "modified genes" are used interchangeably herein to refer to a sequence that includes a deletion, insertion or interruption of naturally occurring nucleic acid sequence. In some preferred embodiments, the expression product of the modified sequence is a truncated protein (*e.g.*, if the modification is a deletion or interruption of the sequence). In some particularly preferred embodiments, the truncated protein retains biological activity. In alternative embodiments, the expression product of the modified sequence is an elongated protein (*e.g.*, modifications comprising an insertion into the nucleic acid sequence). In some embodiments, an insertion leads to a truncated protein

- 52 -

(*e.g.*, when the insertion results in the formation of a stop codon). Thus, an insertion may result in either a truncated protein or an elongated protein as an expression product.

As used herein, the terms "mutant sequence" and "mutant gene" are used interchangeably and refer to a sequence that has an alteration in at least one codon occurring in a host cell's wild-type sequence. The expression product of the mutant sequence is a protein with an altered amino acid sequence relative to the wild-type. The expression product may have an altered functional capacity (*e.g.*, enhanced enzymatic activity).

The terms "mutagenic primer" or "mutagenic oligonucleotide" (used interchangeably herein) are intended to refer to oligonucleotide compositions which correspond to a portion of the template sequence and which are capable of hybridizing thereto. With respect to mutagenic primers, the primer will not precisely match the template nucleic acid, the mismatch or mismatches in the primer being used to introduce the desired mutation into the nucleic acid library. As used herein, "non-mutagenic primer" or "non-mutagenic oligonucleotide" refers to oligonucleotide compositions which will match precisely to the template nucleic acid. In one embodiment of the invention, only mutagenic primers are used. In another preferred embodiment of the invention, the primers are designed so that for at least one region at which a mutagenic primer has been included, there is also non-mutagenic primer included in the oligonucleotide mixture. By adding a mixture of mutagenic primers and non-mutagenic primers corresponding to at least one of the mutagenic primers, it is possible to produce a resulting nucleic acid library in which a variety of combinatorial mutational patterns are presented. For example, if it is desired that some of the members of the mutant nucleic acid library retain their precursor sequence at certain positions while other members are mutant at such sites, the non-mutagenic primers provide the ability to obtain a specific level of non-mutant members within the nucleic acid library for a given residue. The methods of the invention employ mutagenic and non-mutagenic oligonucleotides which are generally between 10-50 bases in length, more preferably about 15-45 bases in length. However, it may be necessary to use primers that are either shorter than 10 bases or longer than 50 bases to obtain the mutagenesis result desired. With respect to corresponding mutagenic and non-mutagenic primers, it is not necessary that the corresponding oligonucleotides be of identical length, but only that there is overlap in the region corresponding to the mutation to be added.

Primers may be added in a pre-defined ratio according to the present invention. For example, if it is desired that the resulting library have a significant level of a certain specific mutation and a lesser amount of a different mutation at the same or different site, by

- 53 -

adjusting the amount of primer added, it is possible to produce the desired biased library. Alternatively, by adding lesser or greater amounts of non-mutagenic primers, it is possible to adjust the frequency with which the corresponding mutation(s) are produced in the mutant nucleic acid library.

5 As used herein, the phrase "contiguous mutations" refers to mutations which are presented within the same oligonucleotide primer. For example, contiguous mutations may be adjacent or nearby each other, however, they will be introduced into the resulting mutant template nucleic acids by the same primer.

10 As used herein, the phrase "discontiguous mutations" refers to mutations which are presented in separate oligonucleotide primers. For example, discontiguous mutations will be introduced into the resulting mutant template nucleic acids by separately prepared oligonucleotide primers.

15 The terms "wild-type sequence," or "wild-type gene" are used interchangeably herein, to refer to a sequence that is native or naturally occurring in a host cell. In some embodiments, the wild-type sequence refers to a sequence of interest that is the starting point of a protein engineering project. The wild-type sequence may encode either a homologous or heterologous protein. A homologous protein is one the host cell would produce without intervention. A heterologous protein is one that the host cell would not produce but for the intervention.

20 As used herein, the term "antibodies" refers to immunoglobulins. Antibodies include but are not limited to immunoglobulins obtained directly from any species from which it is desirable to produce antibodies. In addition, the present invention encompasses modified antibodies. The term also refers to antibody fragments that retain the ability to bind to the epitope that the intact antibody binds and include polyclonal antibodies, monoclonal
25 antibodies, chimeric antibodies, anti-idiotypic (anti-ID) antibodies. Antibody fragments include, but are not limited to the complementarity-determining regions (CDRs), single-chain fragment variable regions (scFv), heavy chain variable region (VH), light chain variable region (VL). Polyclonal and monoclonal antibodies are also encompassed by the present invention. Preferably, the antibodies are monoclonal antibodies.

30 The term "oxidation stable" refers to proteases of the present invention that retain a specified amount of enzymatic activity over a given period of time under conditions prevailing during the proteolytic, hydrolyzing, cleaning or other process of the invention, for example while exposed to or contacted with bleaching agents or oxidizing agents. In some
35 embodiments, the proteases retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% proteolytic activity after contact with a bleaching or oxidizing

- 54 -

agent over a given time period, for example, at least 1 minute, 3 minutes, 5 minutes, 8 minutes, 12 minutes, 16 minutes, 20 minutes, etc. In some embodiments, the stability is measured as described in the Examples.

The term "chelator stable" refers to proteases of the present invention that retain a specified amount of enzymatic activity over a given period of time under conditions prevailing during the proteolytic, hydrolyzing, cleaning or other process of the invention, for example while exposed to or contacted with chelating agents. In some embodiments, the proteases retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% proteolytic activity after contact with a chelating agent over a given time period, for example, at least 10 minutes, 20 minutes, 40 minutes, 60 minutes, 100 minutes, etc. In some embodiments, the chelator stability is measured as described in the Examples.

The terms "thermally stable" and "thermostable" refer to proteases of the present invention that retain a specified amount of enzymatic activity after exposure to identified temperatures over a given period of time under conditions prevailing during the proteolytic, hydrolyzing, cleaning or other process of the invention, for example while exposed altered temperatures. Altered temperatures includes increased or decreased temperatures. In some embodiments, the proteases retain at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% proteolytic activity after exposure to altered temperatures over a given time period, for example, at least 60 minutes, 120 minutes, 180 minutes, 240 minutes, 300 minutes, etc. In some embodiments, the thermostability is determined as described in the Examples.

The term "enhanced stability" in the context of an oxidation, chelator, thermal and/or pH stable protease refers to a higher retained proteolytic activity over time as compared to other serine proteases (*e.g.*, subtilisin proteases) and/or wild-type enzymes.

The term "diminished stability" in the context of an oxidation, chelator, thermal and/or pH stable protease refers to a lower retained proteolytic activity over time as compared to other serine proteases (*e.g.*, subtilisin proteases) and/or wild-type enzymes.

As used herein, the term "cleaning composition" includes, unless otherwise indicated, granular or powder-form all-purpose or "heavy-duty" washing agents, especially cleaning detergents; liquid, gel or paste-form all-purpose washing agents, especially the so-called heavy-duty liquid types; liquid fine-fabric detergents; hand dishwashing agents or light duty dishwashing agents, especially those of the high-foaming type; machine dishwashing agents, including the various tablet, granular, liquid and rinse-aid types for household and institutional use; liquid cleaning and disinfecting agents, including antibacterial hand-wash types, cleaning bars, mouthwashes, denture cleaners, car or carpet shampoos, bathroom

- 55 -

cleaners; hair shampoos and hair-rinses; shower gels and foam baths and metal cleaners; as well as cleaning auxiliaries such as bleach additives and "stain-stick" or pre-treat types.

It is to be understood that the test methods described in the Examples herein are used to determine the respective values of the parameters of the present invention, as such invention is described and claimed herein.

Unless otherwise noted, all component or composition levels are in reference to the active level of that component or composition, and are exclusive of impurities, for example, residual solvents or by-products, which may be present in commercially available sources.

Enzyme components weights are based on total active protein.

All percentages and ratios are calculated by weight unless otherwise indicated. All percentages and ratios are calculated based on the total composition unless otherwise indicated.

It should be understood that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

The term "cleaning activity" refers to the cleaning performance achieved by the protease under conditions prevailing during the proteolytic, hydrolyzing, cleaning or other process of the invention. In some embodiments, cleaning performance is determined by the application of various cleaning assays concerning enzyme sensitive stains, for example grass, blood, milk, or egg protein as determined by various chromatographic, spectrophotometric or other quantitative methodologies after subsection of the stains to standard wash conditions. Exemplary assays include, but are not limited to those described in WO 99/34011, and U.S. Pat. 6,605,458 (both of which are herein incorporated by reference), as well as those methods included in the Examples.

The term "cleaning effective amount" of a protease refers to the quantity of protease described hereinbefore that achieves a desired level of enzymatic activity in a specific cleaning composition. Such effective amounts are readily ascertained by one of ordinary skill in the art and are based on many factors, such as the particular protease used, the cleaning application, the specific composition of the cleaning composition, and whether a liquid or dry (e.g., granular, bar) composition is required, etc.

The term "cleaning adjunct materials," as used herein, means any liquid, solid or

- 56 -

gaseous material selected for the particular type of cleaning composition desired and the form of the product (*e.g.*, liquid, granule, powder, bar, paste, spray, tablet, gel; or foam composition), which materials are also preferably compatible with the protease enzyme used in the composition. In some embodiments, granular compositions are in "compact" form, while in other embodiments, the liquid compositions are in a "concentrated" form.

The term "enhanced performance" in the context of cleaning activity refers to an increased or greater cleaning activity of certain enzyme sensitive stains such as egg, milk, grass or blood, as determined by usual evaluation after a standard wash cycle and/or multiple wash cycles.

The term "diminished performance" in the context of cleaning activity refers to an decreased or lesser cleaning activity of certain enzyme sensitive stains such as egg, milk, grass or blood, as determined by usual evaluation after a standard wash cycle.

The term "comparative performance" in the context of cleaning activity refers to at least 60%, at least 70%, at least 80% at least 90% at least 95% of the cleaning activity of a comparative subtilisin protease (*e.g.*, commercially available proteases), including but not limited to OPTIMASE™ protease (Genencor), PURAFECT™ protease products (Genencor), SAVINASE™ protease (Novozymes), BPN'-variants (*See e.g.*, U.S. Pat. No. Re 34,606), RELEASE™, DURAZYME™, EVERLASE™, KANNASE™ protease (Novozymes), MAXACAL™, MAXAPEM™, PROPERASE™ proteases (Genencor; *See also*, U.S. Pat. No. Re 34,606, U.S. Pat. Nos. 5,700,676; 5,955,340; 6,312,936; 6,482,628), and *B. lentus* variant protease products [for example those described in WO 92/21760, WO 95/23221 and/or WO 97/07770 (Henkel). Exemplary subtilisin protease variants include, but are not limited to those having substitutions or deletions at residue positions equivalent to positions 76, 101, 103, 104, 120, 159, 167, 170, 194, 195, 217, 232, 235, 236, 245, 248, and/or 252 of BPN'. Cleaning performance can be determined by comparing the proteases of the present invention with those subtilisin proteases in various cleaning assays concerning enzyme sensitive stains such as grass, blood or milk as determined by usual spectrophotometric or analytical methodologies after standard wash cycle conditions.

As used herein, a "low detergent concentration" system includes detergents where less than about 800 ppm of detergent components are present in the wash water. Japanese detergents are typically considered low detergent concentration systems, as they have usually have approximately 667 ppm of detergent components present in the wash water.

As used herein, a "medium detergent concentration" systems includes detergents wherein between about 800 ppm and about 2000ppm of detergent components are present

- 57 -

in the wash water. North American detergents are generally considered to be medium detergent concentration systems as they have usually approximately 975 ppm of detergent components present in the wash water. Brazilian detergents typically have approximately 1500 ppm of detergent components present in the wash water.

5 As used herein, "high detergent concentration" systems includes detergents wherein greater than about 2000 ppm of detergent components are present in the wash water. European detergents are generally considered to be high detergent concentration systems as they have approximately 3000-8000 ppm of detergent components in the wash water.

10 As used herein, "fabric cleaning compositions" include hand and machine laundry detergent compositions including laundry additive compositions and compositions suitable for use in the soaking and/or pretreatment of stained fabrics (*e.g.*, clothes, linens, and other textile materials).

15 As used herein, "non-fabric cleaning compositions" include non-textile (*i.e.*, fabric) surface cleaning compositions, including but not limited to dishwashing detergent compositions, oral cleaning compositions, denture cleaning compositions, and personal cleansing compositions.

20 The "compact" form of the cleaning compositions herein is best reflected by density and, in terms of composition, by the amount of inorganic filler salt. Inorganic filler salts are conventional ingredients of detergent compositions in powder form. In conventional detergent compositions, the filler salts are present in substantial amounts, typically 17-35% by weight of the total composition. In contrast, in compact compositions, the filler salt is present in amounts not exceeding 15% of the total composition. In some embodiments, the filler salt is present in amounts that do not exceed 10%, or more preferably, 5%, by weight of the composition. In some embodiments, the inorganic filler salts are selected from the 25 alkali and alkaline-earth-metal salts of sulfates and chlorides. A preferred filler salt is sodium sulfate.

30 II. Serine Protease Enzymes and Nucleic Acid Encoding Serine Protease Enzymes

The present invention provides isolated polynucleotides encoding amino acid sequences, encoding proteases. In some embodiments, these polynucleotides comprise at least 65% amino acid sequence identity, preferably at least 70% amino acid sequence identity, more preferably at least 75% amino acid sequence identity, still more preferably at 35 least 80% amino acid sequence identity, more preferably at least 85% amino acid sequence

- 58 -

identity, even more preferably at least 90% amino acid sequence identity, more preferably at least 92% amino acid sequence identity, yet more preferably at least 95% amino acid sequence identity, more preferably at least 97% amino acid sequence identity, still more preferably at least 98% amino acid sequence identity, and most preferably at least 99% amino acid sequence identity to an amino acid sequence as shown in SEQ ID NOS:6-8, (e.g., at least a portion of the amino acid sequence encoded by the polynucleotide having proteolytic activity, including the mature protease catalyzing the hydrolysis of peptide linkages of substrates), and/or demonstrating comparable or enhanced washing performance under identified wash conditions.

In some embodiments, the percent-identity (amino acid sequence, nucleic acid sequence, gene sequence) is determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the shorter sequence, and multiplying the result by 100. Readily available computer programs find use in these analysis, such as those described above. Programs for determining nucleotide sequence identity are available in the Wisconsin Sequence Analysis Package, Version 8 (Genetics Computer Group, Madison, WI) for example, the BESTFIT, FASTA and GAP programs, which also rely on the Smith and Waterman algorithm. These programs are readily utilized with the default parameters recommended by the manufacturer and described in the Wisconsin Sequence Analysis Package referred to above.

An example of an algorithm that is suitable for determining sequence similarity is the BLAST algorithm, which is described in Altschul, *et al.*, J. Mol. Biol., 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. These initial neighborhood word hits act as starting points to find longer HSPs containing them. The word hits are expanded in both directions along each of the two sequences being compared for as far as the cumulative alignment score can be increased. Extension of the word hits is stopped when: the cumulative alignment score falls off by the quantity X from a maximum achieved value; the cumulative score goes to zero or below; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (See, Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989))

- 59 -

alignments (B) of 50, expectation (E) of 10, M⁵, N⁻⁴, and a comparison of both strands.

The BLAST algorithm then performs a statistical analysis of the similarity between two sequences (*See e.g.*, Karlin and Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 [1993]). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a serine protease nucleic acid of this invention if the smallest sum probability in a comparison of the test nucleic acid to a serine protease nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. Where the test nucleic acid encodes a serine protease polypeptide, it is considered similar to a specified serine protease nucleic acid if the comparison results in a smallest sum probability of less than about 0.5, and more preferably less than about 0.2.

In some embodiments of the present invention, sequences were analyzed by BLAST and protein translation sequence tools. In some experiments, the preferred version was BLAST (Basic BLAST version 2.0). The program chosen was "BlastX", and the database chosen was "nr". Standard/default parameter values were employed.

In some preferred embodiments, the present invention encompasses the approximately 1621 base pairs in length polynucleotide set forth in SEQ. ID NO:1. A start codon is shown in bold in SEQ ID NO:1. In another embodiment of the present invention, the polynucleotides encoding these amino acid sequences comprise a 1485 base pair portion (residues 1-1485 of SEQ ID NO:2) that, if expressed, is believed to encode a signal sequence (nucleotides 1-84 of SEQ ID NO:5) encoding amino acids 1-28 of SEQ ID NO:9; an N-terminal prosequence (nucleotides 84-594 encoding amino acid residues 29-198 of SEQ ID NO:6); a mature protease sequence (nucleotides 595-1161 of SEQ ID NO:2 encoding amino acid residues 1-189 of SEQ ID NO:8); and a C-terminal pro-sequence (nucleotides 1162-1486 encoding amino acid residues 388-495 of SEQ ID NO:6). Alternatively, the signal peptide, the N-terminal pro-sequence, mature serine protease sequence and C-terminal pro-sequence is numbered in relation to the amino acid residues of the mature protease of SEQ ID NO:6 being numbered 1-189, i.e., signal peptide (residues -198 to -171), an N-terminal pro sequence (residues -171 to -1), the mature serine protease sequence (residues 1-189) and a C-terminal pro-sequence (residues 190-298). In another embodiment of the present invention, the polynucleotide encoding an amino acid sequence having proteolytic activity comprises a nucleotide sequence of nucleotides 1 to 1485 of the portion of SEQ ID NO:2 encoding the signal peptide and precursor protease. In another embodiment of the present invention, the polynucleotide encoding an amino acid

- 60 -

sequence comprises the sequence of nucleotides 1 to 1412 of the polynucleotide encoding the precursor *Cellulomonas* protease (SEQ ID NO:3). In yet another embodiment, the polynucleotide encoding an amino acid sequence comprises the sequence of nucleotides 1 to 587 of the portion of the polynucleotide encoding the mature *Cellulomonas* protease (SEQ ID NO:4).

As will be understood by the skilled artisan, due to the degeneracy of the genetic code, a variety of polynucleotides can encode the signal peptide, precursor protease and/or mature protease provided in SEQ ID NOS:6, 7, and/or 8, respectively, or a protease having the % sequence identity described above. Another embodiment of the present invention encompasses a polynucleotide comprising a nucleotide sequence having at least 70% sequence identity, at least 75% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 92% sequence identity, at least 95% sequence identity, at least 97% sequence identity, at least 98% sequence identity and at least 99% sequence identity to the polynucleotide sequence of SEQ ID NOS:2, 3, and/or 4, respectively, encoding the signal peptide and precursor protease, the precursor protease and/or the mature protease, respectively.

In additional embodiments, the present invention provides fragments or portions of DNA that encodes proteases, so long as the encoded fragment retains proteolytic activity. Another embodiment of the present invention encompasses polynucleotides having at least 20% of the sequence length, at least 30% of the sequence length, at least 40% of the sequence length, at least 50% of the sequence length, at least 60% of the sequence length, 70% of the sequence length, at least 75% of the sequence length, at least 80% of the sequence length, at least 85% of the sequence length, at least 90% of the sequence length, at least 92% of the sequence length, at least 95% of the sequence length, at least 97% of the sequence length, at least 98% of the sequence length and at least 99% of the sequence of the polynucleotide sequence of SEQ ID NO:2, or residues 185-1672 of SEQ ID NO:1, encoding the precursor protease. In alternative embodiments, these fragments or portions of the sequence length are contiguous portions of the sequence length, useful for shuffling of the DNA sequence in recombinant DNA sequences (See e.g., U.S. Pat. No. 6,132,970)

Another embodiment of the invention includes fragments of the DNA described herein that find use according to art recognized techniques in obtaining partial length DNA fragments capable of being used to isolate or identify polynucleotides encoding mature protease enzyme described herein from *Cellulomonas* 69B4, or a segment thereof having proteolytic activity. Moreover, the DNA provided in SEQ ID NO:1 finds use in identifying

- 61 -

homologous fragments of DNA from other species, and particularly from *Cellulomonas spp.* which encode a protease or portion thereof having proteolytic activity.

In addition, the present invention encompasses using primer or probe sequences constructed from SEQ ID NO:1, or a suitable portion or fragment thereof (*e.g.*, at least about 5-20 or 10-15 contiguous nucleotides), as a probe or primer for screening nucleic acid of either genomic or cDNA origin. In some embodiments, the present invention provides DNA probes of the desired length (*i.e.*, generally between 100 and 1000 bases in length), based on the sequences in SEQ ID NOS 1, 2, 3, and/or 4.

In some embodiments, the DNA fragments are electrophoretically isolated, cut from the gel, and recovered from the agar matrix of the gel. In preferred embodiments, this purified fragment of DNA is then labeled (using, for example, the Megaprime labeling system according to the instructions of the manufacturer) to incorporate P^{32} in the DNA. The labeled probe is denatured by heating to 95°C for a given period of time (*e.g.*, 5 minutes), and immediately added to the membrane and prehybridization solution. The hybridization reaction proceeds for an appropriate time and under appropriate conditions (*e.g.*, 18 hours at 37 °C), with gentle shaking or rotation. The membrane is rinsed (*e.g.*, twice in SSC/0.3% SDS) and then washed in an appropriate wash solution with gentle agitation. The stringency desired is a reflection of the conditions under which the membrane (filter) is washed. In some embodiments herein, "low-stringency" conditions involve washing with a solution of 0.2X SSC/0.1% SDS at 20°C for 15 minutes, while in other embodiments, "medium-stringency" conditions, involve a further washing step comprising washing with a solution of 0.2X SSC/0.1% SDS at 37°C for 30 minutes, while in other embodiments, "high-stringency" conditions involve a further washing step comprising washing with a solution of 0.2X SSC/0.1% SDS at 37°C for 45 minutes, and in further embodiments, "maximum-stringency" conditions involve a further washing step comprising washing with a solution of 0.2X SSC/0.1% SDS at 37°C for 60 minutes. Thus, various embodiments of the present invention provide polynucleotides capable of hybridizing to a probed derived from the nucleotide sequence provided in SEQ ID NOS:1, 2, 3, 4, and/or 5, under conditions of medium, high and/or maximum stringency.

After washing, the membrane is dried and the bound probe detected. If P^{32} or another radioisotope is used as the labeling agent, the bound probe is detected by autoradiography. Other techniques for the visualization of other probes are well-known to those of skill in the art. The detection of a bound probe indicates a nucleic acid sequence has the desired homology, and therefore identity to SEQ ID NOS:1, 2, 3, 4, and/or 5, and is encompassed by the present invention. Accordingly, the present invention provides

- 62 -

methods for the detection of nucleic acid encoding a protease encompassed by the present invention which comprises hybridizing part or all of a nucleic acid sequence of SEQ ID NOS:1, 2, 3, 4, and/or 5 with other nucleic acid of either genomic or cDNA origin.

As indicated above, in other embodiments, hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex, to confer a defined "stringency" as explained below. "Maximum stringency" typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); "high stringency" at about 5°C to 10°C below T_m ; "intermediate stringency" at about 10°C to 20°C below T_m ; and "low stringency" at about 20°C to 25°C below T_m . As known to those of skill in the art, medium, high and/or maximum stringency hybridization are chosen such that conditions are optimized to identify or detect polynucleotide sequence homologues or equivalent polynucleotide sequences.

In yet additional embodiments, the present invention provides nucleic acid constructs (*i.e.*, expression vectors) comprising the polynucleotides encoding the proteases of the present invention. In further embodiments, the present invention provides host cells transformed with at least one of these vectors.

In further embodiments, the present invention provides polynucleotide sequences further encoding a signal sequence. In some embodiments, invention encompasses polynucleotides having signal activity comprising a nucleotide sequence having at least 65% sequence identity, at least 70% sequence identity, preferably at least 75% sequence identity, more preferably at least 80% sequence identity, still further preferably at least 85% sequence identity, even more preferably at least 90% sequence identity, more preferably at least 95% sequence identity, more preferably at least 97% sequence identity, at least 98% sequence identity, and most preferably at least 99% sequence identity to SEQ ID NO:5. Thus, in these embodiments, the present invention provides a sequence with a putative signal sequence, and polynucleotides being capable of hybridizing to a probe derived from the nucleotide sequence disclosed in SEQ ID NO:5 under conditions of medium, high and/or maximal stringency, wherein the signal sequences have substantially the same signal activity as the signal sequence encoded by the polynucleotide of the present invention.

In some embodiments, the signal activity is indicated by substantially the same level of secretion of the protease into the fermentation medium, as the starting material. For example, in some embodiments, the present invention provides fermentation medium protease levels at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% of the secreted protease levels in the fermentation medium as provided by the signal sequence of SEQ ID NO:3. In some embodiments, the secreted protease levels are ascertained by protease activity analyses such as the pNA assay (See

- 63 -

e.g., Del Mar, [1979], *infra*). Additional means for determining the levels of secretion of a heterologous or homologous protein in a Gram-positive host cell and detecting secreted proteins include using either polyclonal or monoclonal antibodies specific for the protein. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS), as well-known those in the art.

In further embodiments, the present invention provides polynucleotides, encoding an amino acid sequence of a signal peptide (nucleotides 1-84 of SEQ ID NO:5), as shown in SEQ ID NO:9, nucleotide residue positions 1 to 85 of SEQ ID NO:2, and /or SEQ ID NO:5. The invention further encompasses nucleic acid sequences which hybridize to the nucleic acid sequence shown in SEQ ID NO:5 under low, medium, high stringency and/or maximum stringency conditions, but which have substantially the same signal activity as the sequence. The present invention encompasses all such polynucleotides.

In further embodiments, the present invention provides polynucleotides that are complementary to the nucleotide sequences described herein. Exemplary complementary nucleotide sequences include those that are provided in SEQ ID NOS:1-5.

Further aspects of the present invention encompass polypeptides having proteolytic activity comprising 65% amino acid sequence identity, at least 70% sequence identity, at least 75% amino acid sequence identity, at least 80% amino acid sequence identity, at least 85% amino acid sequence identity, at least 90% amino acid sequence identity, at least 92% amino acid sequence identity, at least 95% amino acid sequence identity, at least 97% amino acid sequence identity, at least 98% amino acid sequence identity and at least 99% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 6 (*i.e.*, the signal and precursor protease), SEQ ID NO:7 (*i.e.*, the precursor protease), and/or of SEQ ID NO:8 (*i.e.*, the mature protease). The proteolytic activity of these polypeptides is determined using methods known in the art and include such methods as those used to assess detergent function. In further embodiments, the polypeptides are isolated. In additional embodiments of the present invention, the polypeptides comprise amino acid sequences that identical to amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOS:6, 7, or 8. In some further embodiments, the polypeptides are identical to portions of SEQ ID NOS:6, 7 or 8.

In some embodiments, the present invention provides isolated polypeptides having proteolytic activity, comprising the amino acid sequence approximately 495 amino acids in length, as provided in SEQ ID NO:6. In further embodiments, the present invention encompasses polypeptides having proteolytic activity comprising the amino acid sequence approximately 467 amino acids in length provided in SEQ ID NO:7. In some embodiments,

- 64 -

these amino acid sequences comprise a signal sequence (amino acids 1-28 of SEQ ID NO:9); and a precursor protease (amino acids 1-467 of SEQ ID NO:7). In additional embodiments, the present invention encompasses polypeptides comprising an N-terminal prosequence (amino acids 1-170 of SEQ ID NO:7), a mature protease sequence (amino acids 1-189 of SEQ ID NO:8), and a C-terminal prosequence (amino acids 360-467 of SEQ ID NO:7). In still further embodiments, the present invention encompasses polypeptides comprising a precursor protease sequence (e.g., amino acids 1-467 of SEQ ID NO:7). In yet another embodiment, the present invention encompasses polypeptides comprising a mature protease sequence comprising amino acids (e.g., 1-189 of SEQ ID NO:8).

In further embodiments, the present invention provides polypeptides and/or proteases comprising amino acid sequences of the above described sequence derived from bacterial species including, but not limited to *Micrococcineae* which are identified through amino acid sequence homology studies. In some embodiments, an amino acid residue of a precursor *Micrococcineae* protease is equivalent to a residue of *Cellulomonas* strain 69B4, if it is either homologous (i.e., corresponding in position in either primary or tertiary structure) or analogous to a specific residue or portion of that residue in *Cellulomonas* strain 69B4 protease (i.e., having the same or similar functional capacity to combine, react, or interact chemically).

In some preferred embodiments, in order to establish homology to primary structure, the amino acid sequence of a precursor protease is directly compared to the *Cellulomonas* strain 69B4 mature protease amino acid sequence and particularly to a set of conserved residues which are discerned to be invariant in all or a large majority of *Cellulomonas* like proteases for which sequence is known. After aligning the conserved residues, allowing for necessary insertions and deletions in order to maintain alignment (i.e., avoiding the elimination of conserved residues through arbitrary deletion and insertion), the residues corresponding to particular amino acids in the mature protease (SEQ ID NO:8) and *Cellulomonas* 69B4 protease are determined. Alignment of conserved residues preferably should conserve 100% of such residues. However, alignment of greater than 75% or as little as 45% of conserved residues is also adequate to define equivalent residues. However, conservation of the catalytic triad, His32/Asp56/Ser137 of SEQ ID NO:8 should be maintained.

For example, in some embodiments, the amino acid sequence of proteases from *Cellulomonas* strain 69B4, and other *Micrococcineae* spp. described above are aligned to provide the maximum amount of homology between amino acid sequences. A comparison of these sequences indicates that there are a number of conserved residues contained in

- 65 -

each sequence. These are the residues that are identified and utilized to establish the equivalent residue positions of amino acids identified in the precursor or mature *Micrococcineae* protease in question.

These conserved residues are used to ascertain the corresponding amino acid residues of *Cellulomonas* strain 69B4 protease in one or more in *Micrococcineae* homologues (e.g., *Cellulomonas cellasea* (DSM 20118) and/or a *Cellulomonas* homologue herein). These particular amino acid sequences are aligned with the sequence of *Cellulomonas* 69B4 protease to produce the maximum homology of conserved residues. By this alignment, the sequences and particular residue positions of *Cellulomonas* 69B4 are observed in comparison with other *Cellulomonas* spp. Thus, the equivalent amino acid for the catalytic triad (e.g., in *Cellulomonas* 69B4 protease) is identifiable in the other *Micrococcineae* spp. In some embodiments of the present invention, the protease homologs comprise the equivalent of His32/Asp56/Ser137 of SEQ ID NO:8.

Another indication that two polypeptides are substantially identical is that the first polypeptide is immunologically cross-reactive with the second polypeptide. Methodologies for determining immunological cross-reactivity are described in the art and are described in the Examples herein. Typically, polypeptides that differ by conservative amino acid substitutions are immunologically cross-reactive. Thus, a polypeptide is substantially identical to a second polypeptide, for example, where the two peptides differ only by a conservative substitution.

The present invention encompasses proteases obtained from various sources. In some preferred embodiments, the proteases are obtained from bacteria, while in other embodiments, the proteases are obtained from fungi.

In some particularly preferred embodiments, the bacterial source is selected from the members of the suborder *Micrococcineae*. In some embodiments, the bacterial source is the family *Promicromonosporaceae*. In some preferred embodiments, the *Promicromonosporaceae* spp. includes and/or is selected from the group consisting of *Promicromonospora citrea* (DSM 43110), *Promicromonospora sukumoe* (DSM 44121), *Promicromonospora aerolata* (CCM 7043), *Promicromonospora vindobonensis* (CCM 7044), *Myceligeners xiligouense* (DSM 15700), *Isoptericola variabilis* (DSM 10177, basonym *Cellulosimicrobium variabile*), *Cellulosimicrobium cellulans* (DSM 20424, basonym *Nocardia cellulans*, *Cellulomonas cellulans*), *Cellulosimicrobium funkei*, *Xylanimonas cellulosilytica* (LMG 20990), *Xylanibacterium ulmi* (LMG 21721), and *Xylanimicrobium pachnodae* (DSM 12657, basonym *Promicromonospora pachnodae*).

In other particularly preferred embodiments, the bacterial source is the family

- 66 -

Cellulomonadaceae. In some preferred embodiments, the *Cellulomonadaceae* spp. includes and/or is selected from the group of *Cellulomonas fimi* (ATCC 484, DSM 20113), *Cellulomonas biazotea* (ATCC 486, DSM 20112), *Cellulomonas cellasea* (ATCC 487, 21681, DSM 20118), *Cellulomonas denverensis*, *Cellulomonas hominis* (DSM 9581),
5 *Cellulomonas flavigena* (ATCC 482, DSM 20109), *Cellulomonas persica* (ATCC 700642, DSM 14784), *Cellulomonas iranensis* (ATCC 700643, DSM 14785); *Cellulomonas fermentans* (ATCC 43279, DSM 3133), *Cellulomonas gelida* (ATCC 488, DSM 20111, DSM 20110), *Cellulomonas humilata* (ATCC 25174, basonym *Actinomyces humiferus*),
10 *Cellulomonas uda* (ATCC 491, DSM 20107), *Cellulomonas xylanilytica* (LMG 21723), *Cellulomonas septica*, *Cellulomonas parahominis*, *Oerskovia turbata* (ATCC 25835, DSM 20577, synonym *Cellulomonas turbata*), *Oerskovia jenensis* (DSM 46000), *Oerskovia enterophila* (ATCC 35307, DSM 43852, basonym *Promicromonospora enterophila*), *Oerskovia paurometabola* (DSM 14281), and *Cellulomonas* strain 69B4 (DSM 16035). In further embodiments, the bacterial source also includes and/or is selected from the group of
15 *Thermobifida* spp., *Rarobacter* spp., and/or *Lysobacter* spp. In yet additional embodiments, the *Thermobifida* spp. is *Thermobifida fusca* (basonym *Thermomonospora fusca*) (tfpA, AAC23545; See, Lao *et. al*, Appl. Environ. Microbiol., 62: 4256-4259 [1996]). In an alternative embodiment, the *Rarobacter* spp. is *Rarobacter faecitabidus* (RPI, A45053; See *e.g.*, Shimo *et al.*, J. Biol. Chem., 267:25189-25195 [1992]). In yet another embodiment,
20 the *Lysobacter* spp. is *Lysobacter enzymogenes*.

In further embodiments, the present invention provides polypeptides and/or polynucleotides obtained and/or isolated from fungal sources. In some embodiments, the fungal source includes a *Metarhizium* spp. In some preferred embodiments, the fungal source is a *Metarhizium anisopliae* (CHY1 (CAB60729).

25 In another embodiment, the present invention provides polypeptides and/or polynucleotides derived from a *Cellulomonas* strain selected from cluster 2 of the taxonomic classification described in U.S. Pat. No 5,401,657, herein incorporated by reference. In US Patent 5,401,657, twenty strains of bacteria isolated from in and around alkaline lakes were assigned to the type of bacteria known as Gram-positive bacteria on the basis of: (1) the
30 Dussault modification of the Gram's staining reaction (Dussault, J. Bacteriol., 70:484-485 [1955]); (2) the KOH sensitivity test (Gregersen, Eur. J. Appl. Microbiol. Biotechnol., 5:123-127 [1978]; Halebian *et al.*, J. Clin. Microbiol., 13:444-448 [1981]; and (3) the aminopeptidase reaction (Cerny, Eur. J. Appl. Microbiol., 3:223-225 [1976]; Cerny, Eur. J. Appl. Microbiol., 5:113-122 [1978]). In addition, in most cases, confirmation was also made
35 on the basis of quinone analysis (Collins and Jones, Microbiol. Rev., 45:316-354 [1981])

- 67 -

using the method described by Collins (*See, Collins, In Goodfellow and Minnikin (eds), Chemical Methods in Bacterial Systematics, Academic Press, London [1985], pp. 267-288*). In addition, strains can be tested for 200 characters and the results analyzed using the principles of numerical taxonomy (*See e.g., Sneath and Sokal, Numerical Taxonomy, W.H. Freeman & Co., San Francisco, CA [1973]*). Exemplary characters tested, testing methods, and codification methods are also described in U.S. Pat. 5,401,657.

As described in U.S. Pat. No. 5,401,657, the phenetic data, consisting of 200 unit characters was scored and set out in the form of an "n.times.t" matrix, whose t columns represent the "t" bacterial strains to be grouped on the basis of resemblances, and whose "n" rows are the unit characters. Taxonomic resemblance of the bacterial strains was estimated by means of a similarity coefficient (Sneath and Sokal, *supra*, pp. 114-187). Although many different coefficients have been used for biological classification, only a few have found regular use in bacteriology. Three association coefficients (*See e.g., Sneath and Sokal, supra*, at p. 129), namely, the Gower, Jaccard and Simple Matching coefficients were applied. These have been frequently applied to the analysis of bacteriological data and are widely accepted by those skilled in the art, as they have been shown to result in robust classifications.

The coded data were analyzed using the TAXPAK program package (Sackin; *Meth. Microbiol.*, 19:459-494 [1987]), run on a DEC VAX computer at the University of Leicester, U.K.

A similarity matrix was constructed for all pairs of strains using the Gower Coefficient (S_G) with the option of permitting negative matches (*See, Sneath and Sokal, supra*, at pp. 135-136), using the RTBNSIM program in TAXPAK. As the primary instrument of analysis and the one upon which most of the taxonomic data presented herein are based, the Gower Coefficient was chosen over other coefficients for generating similarity matrices because it is applicable to all types of characters or data, namely, two-state, multistate (ordered and qualitative), and quantitative.

Cluster analysis of the similarity matrix was accomplished using the Unweighted Pair Group Method with Arithmetic Averages (UPGMA) algorithm, also known as the Unweighted Average Linkage procedure, by running the SMATCLST sub-routine in TAXPAK.

Dendrograms illustrate the levels of similarity between bacterial strains. In some embodiments, dendrograms are obtained by using the DENDGR program in TAXPAK. The phenetic data were re-analyzed using the Jaccard Coefficient (S_J) (Sneath and Sokal, *supra*, at p.131) and Simple Matching Coefficient (S_{SM}) (Sneath, P.H.A. and Sokal, R.R., *ibid*, p. 132) by running the RTBNSIM program in TAXPAK. An additional two dendrograms were

- 68 -

obtained by using the SMATCLST with UPGMA option and DENDGR sub-routines in TAXPAK.

Using the S_G /UPGMA method, six natural clusters or phenons of alkalophilic bacteria were generated at the 79% similarity level. These six clusters included 15 of the 20 alkalophilic bacteria isolated from alkaline lakes. Although the choice of 79% for the level of delineation was arbitrary, it was in keeping with current practices in numerical taxonomy (See e.g., Austin Priest, Modern Bacterial Taxonomy, Van Nostrand Reinhold, Wokingham, U.K., [1986], p. 37). Placing the delineation at a lower percentage would combine groups of clearly unrelated organisms whose definition is not supported by the data. At the 79% level, 3 of the clusters exclusively contain novel alkalophilic bacteria representing 13 of the newly isolated strains (potentially representing new taxa). Protease 69B4 was classified as in cluster 2 by this method.

The significance of the clustering at this level was supported by the results of the TESTDEN program. This program tests the significance of all dichotomous pairs of clusters (comprising 4 or more strains) in a UPGMA-generated dendrogram with Squared Euclidean distances, or their complement as a measurement and assuming that the clusters are hyperspherical. The critical overlap was set at 0.25%. The separation of the clusters is highly significant.

The S_J coefficient is a useful adjunct to the S_G coefficient, as it can be used to detect phenons in the latter that are based on negative matches or distortions owing to undue weight being put on potentially subjective qualitative data. Consequently, the S_J coefficient is useful for confirming the validity of clusters defined initially by the use of the S_G coefficient. The Jaccard Coefficient is particularly useful in comparing biochemically unreactive organisms (Austin and Priest, *supra*, at p. 37). In addition, there may be some question about the admissibility of matching negative character states (See, Sneath and Sokal, *supra*, at p. 131), in which case the Simple Matching Coefficient is a widely applied alternative. Strain 69B4 was classified as in cluster 2 by this method.

In the main, all of the clusters (especially the clusters of the new bacteria) generated by the S_G /UPGMA method were recovered in the dendrograms produced by the S_J /UPGMA method (cophenetic correlation, 0.795), and the S_{SM} /UPGMA method (cophenetic correlation, 0.814). The main effect of these transformations was to gather all the *Bacillus* strains in a single large cluster which further serves to emphasize the separation between the alkalophilic *Bacillus* species and the new alkalophilic bacteria, and the uniqueness of the latter. Based on these methodologies, 69B4 is considered to be a cluster 2 bacterium.

In other aspects of the present invention, the polynucleotide is derived from a

bacteria having a 16S rRNA gene nucleotide sequence at least 70%, 75%, 80%, 85%, 88%, 90%, 92%, 95%, 98% sequence identity with the 16S rRNA gene nucleotide sequence of *Cellulomonas* strain 69B4. The sequence of the 16S rRNA gene is deposited at GenBank under Accession Number X92152.

5 Figure 1 provides an unrooted phylogenetic tree illustrating the relationship of novel strain 69B4 to members of the family *Cellulomonadaceae* (including *Cellulomonas* strain 69B4) and other related genera of the suborder *Micrococcineae*. The dendrogram was constructed from aligned 16S rDNA sequences (1374 nt) using TREECONW v.1.3b (Van de Peer and De Wachter, Comput. Appl. Biosci., 10: 569-570 [1994]). Distance estimations
10 were calculated using the substitution rate calibration of Jukes and Cantor (Jukes and Cantor, "Evolution of protein molecules," In, Munro (ed.), Mammalian Protein Metabolism, Academic Press, NY, at pp.21-132, [1969]) and tree topology inferred by the Neighbor-Joining algorithm (Saitou and Nei, Mol. Biol. Evol., 4:406-425 [1987]). The numbers at the nodes refer to bootstrap values from 100 resampled data sets (Felsenstein, Evol., 39:783-
15 789 [1985]) and the scale bar indicates 2 nucleotide substitutions in 100 nt.

The strain 69B4 exhibits the closest 16S rDNA relationship to members of *Cellulomonas* and *Oerskovia* of the family *Cellulomonadaceae*. The closest relatives are believed to be *C. cellasea* (DSM 20118) and *C. fimi* (DSM 20113), with at least 95% sequence identity with the 16S rRNA gene nucleotide sequence of *Cellulomonas* strain
20 69B4 (e.g., 96% and 95% identity respectively) to strain 69B4 16S rRNA gene sequence.

In some preferred embodiments of the present invention, the *Cellulomonas* spp. is *Cellulomonas* strain 69B4 (DSM16035). This strain was originally isolated from a sample of sediment and water from the littoral zone of Lake Bogoria, Kenya at Acacia Camp (Lat. 0° 12'N, Long. 36° 07'E) collected on 10 October 1988. The water temperature was 33°C, pH
25 10.5 with a conductivity of 44 mS/cm. *Cellulomonas* strain 69B4 was determined to have the phenotypic characteristics described below. Fresh cultures were Gram-positive, slender, generally straight, rod-shaped bacteria, approximately 0.5-0.7µm x 1.8-4µm. Older cultures contained mainly short rods and coccoid cells. Cells occasionally occurred in pairs or as V-forms, but primary branching was not observed. Endospores were not detected. On
30 alkaline GAM agar the strain forms opaque, glistening, pale-yellow coloured, circular and convex or domed colonies, with entire margins, about 2 mm in diameter after 2-3 days incubation at 37°C. The colonies were viscous or slimy with a tendency to clump when scraped with a loop. On neutral Tryptone Soya Agar, strain growth was less vigorous, giving translucent yellow colonies, generally <1 mm in diameter. The cultures were
35 facultatively anaerobic, as they were capable of growth under strictly anaerobic conditions.

- 70 -

However, growth under anaerobic conditions was markedly reduced compared to aerobic growth. The strain also appeared to be negative in standard oxidase, urease, aminopeptidase, and KOH tests. In addition, nitrate was not reduced, although the organisms were catalase positive and DNase was produced under alkaline conditions. The preferred temperature range for growth was 20 - 37°C, with an optimum temperature at around 30-37°C. No growth was observed at 15°C or 45°C.

The strain is alkalophilic and slightly halophilic. The strain may also be characterized as having growth occurring at pH values between 6.0 and 10.5 with an optimum around pH 9-10. No growth was observed at pH 11 or pH 5.5. Growth below pH 7 was less vigorous and abundant than that of cultures grown at the optimal temperature. The strain was observed to grow in medium containing 0-8% (w/v) NaCl. Furthermore, the strain may also be characterized as a chemo-organotroph, since it grew on complex substrates such as yeast extract and peptone; and hydrolyzed starch, gelatin, casein, carboxymethylcellulose and amorphous cellulose.

The strain was observed to have metabolism that was respiratory and also fermentative. Acid was produced both aerobically and anaerobically from (API 50CH): L-arabinose, D-xylose, D-glucose, D-fructose, D-mannose, rhamnose (weak), cellobiose, maltose, sucrose, trehalose, gentiobiose, D-turanose, D-lyxose and 5-keto-gluconate (weak). Amygdalin, arbutin, salicin and esculin are also utilized. The strain was unable to utilize: ribose, lactose, galactose, melibiose, D-raffinose, glycogen, glycerol, erythritol, inositol, mannitol, sorbitol, xylitol, arabitol, gluconate and lactate.

The strain was determined to be susceptible to ampicillin, chloramphenicol, erythromycin, fusidic acid, methicillin, novobiocin, streptomycin, tetracycline, sulphafurazole, oleandomycin, polymixin, rifampicin, vancomycin and bacitracin; but resistant to gentamicin, nitrofurantoin, nalidixic acid, sulphmethoxazole, trimethoprim, penicillin G, neomycin and kanamycin.

The following enzymes, aside from the protease of the present invention, were observed to be produced (ApiZym, API Coryne); C4-esterase, C8-esterase/lipase, leucine arylamidase, alpha-chymotrypsin, alpha-glucosidase, beta-glucosidase and pyrazinamidase.

The strain was observed to exhibit the following chemotaxonomic characteristics. Major fatty acids (>10% of total) were C16:1 (28.1%), C18:0 (31.1%), C18:1 (13.9%). N-saturated (79.1%), n-unsaturated (19.9%). Fatty acids with even numbers of carbons accounted for 98%. Main polar lipid components: phosphatidylglycerol (PG) and 3 unidentified glycolipids (alpha-naphthol positive) were present; DPG, PGP, PI and PE were not detected. Menaquinones MK-4, MK-6, MK-7 and MK-9 were the main isoprenoids

- 71 -

present. The cell wall peptidoglycan type was A4 β with L-ornithine as diamino acid and D-aspartic acid in the interpeptide bridge. With regard to toxicity evaluation, there are no known toxicity or pathogenicity issues associated with bacteria of the genus *Cellulomonas*.

Although there may be variations in the sequence of a naturally occurring enzyme within a given species of organism, enzymes of a specific type produced by organisms of the same species generally are substantially identical with respect to substrate specificity and/or proteolytic activity levels under given conditions (e.g., temperature, pH, water hardness, oxidative conditions, chelating conditions, and concentration), etc. Thus, for the purposes of the present invention, it is contemplated that other strains and species of *Cellulomonas* also produce the *Cellulomonas* protease of the present invention and thus provide useful sources for the proteases of the present invention. Indeed, as presented herein, it is contemplated that other members of the *Micrococcineae* will find use in the present invention.

In some embodiments, the proteolytic polypeptides of this invention are characterized physicochemically, while in other embodiments, they are characterized based on their functionality, while in further embodiments, they are characterized using both sets of properties. Physicochemical characterization takes advantages of well known techniques such as SDS electrophoresis, gel filtration, amino acid composition, mass spectrometry (e.g., MALDI-TOF-MS, LC-ES-MS/MS, etc.), and sedimentation to determine the molecular weight of proteins, isoelectric focusing to determine the pI of proteins, amino acid sequencing to determine the amino acid sequences of protein, crystallography studies to determine the tertiary structures of proteins, and antibody binding to determine antigenic epitopes present in proteins.

In some embodiments, functional characteristics are determined by techniques well known to the practitioner in the protease field and include, but are not limited to, hydrolysis of various commercial substrates, such as di-methyl casein ("DMC") and/or AAPF-pNA. This preferred technique for functional characterization is described in greater detail in the Examples provided herein.

In some embodiments of the present invention, the protease has a molecular weight of about 17kD to about 21kD, for example about 18kD to 19kD, for example 18700 daltons to 18800 daltons, for example about 18764 daltons, as determined by MALDI-TOF-MS). In another aspect of the present invention, the protease measured MALDI-TOF-MS spectrum as set forth in Figure 3.

The mature protease also displays proteolytic activity (e.g., hydrolytic activity on a substrate having peptide linkages) such as DMC. In further embodiments, proteases of the

- 72 -

present invention provide enhanced wash performance under identified conditions.

Although the present invention encompasses the protease 69B as described herein, in some embodiments, the proteases of the present invention exhibit at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% proteolytic activity as compared to the proteolytic activity of 69B4. In some embodiments, the proteases display at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% proteolytic activity as compared to the proteolytic activity of proteases sold under the tradenames SAVINASE® (Novozymes) or PURAFECT® (Genencor) under the same conditions. In some embodiments, the proteases of the present invention display comparative or enhanced wash performance under identified conditions as compared to 69B4 under the same conditions. In some preferred embodiments, the proteases of the present invention display comparative or enhanced wash performance under identified conditions, as compared to proteases sold under the tradenames SAVINASE® (Novozymes) or PURAFECT® (Genencor) under the same conditions.

In yet further embodiments, the proteases and/or polynucleotides encoding the proteases of the present invention are provided purified form (*i.e.*, present in a particular composition in a higher or lower concentration than exists in a naturally occurring or wild type organism), or in combination with components not normally present upon expression from a naturally occurring or wild-type organism. However, it is not intended that the present invention be limited to proteases of any specific purity level, as ranges of protease purity find use in various applications in which the proteases of the present invention are suitable.

III. Obtaining Polynucleotides Encoding *Micrococcineae* (*e.g.*, *Cellulomonas*) Proteases of the Present Invention

In some embodiments, nucleic acid encoding a protease of the present invention is obtained by standard procedures known in the art from, for example, cloned DNA (*e.g.*, a DNA "library"), chemical synthesis, cDNA cloning, PCR, cloning of genomic DNA or fragments thereof, or purified from a desired cell, such as a bacterial or fungal species (*See*, for example, Sambrook *et al.*, *supra* [1989]; and Glover and Hames (eds.), DNA Cloning: A Practical Approach, Vols 1 and 2, Second Edition). Synthesis of polynucleotide sequences is well known in the art (*See e.g.*, Beaucage and Caruthers, *Tetrahedron Lett.*, 22:1859-1862 [1981]), including the use of automated synthesizers (*See e.g.*, Needham-VanDevanter *et al.*, *Nucl. Acids Res.*, 12:6159-6168 [1984]). DNA sequences can also be custom made and ordered from a variety of commercial sources. As described in greater

- 73 -

detail herein, in some embodiments, nucleic acid sequences derived from genomic DNA contain regulatory regions in addition to coding regions.

In some embodiments involving the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which comprise at least a portion of the desired gene. In some embodiments, the DNA is cleaved at specific sites using various restriction enzymes. In some alternative embodiments, DNase is used in the presence of manganese to fragment the DNA, or the DNA is physically sheared (*e.g.*, by sonication). The linear DNA fragments created are then be separated according to size and amplified by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis, PCR and column chromatography.

Once nucleic acid fragments are generated, identification of the specific DNA fragment encoding a protease may be accomplished in a number of ways. For example, in some embodiments, a proteolytic hydrolyzing enzyme encoding the *asp* gene or its specific RNA, or a fragment thereof, such as a probe or primer, is isolated, labeled, and then used in hybridization assays well known to those in the art, to detect a generated gene (*See e.g.*, Benton and Davis, Science 196:180 [1977]; and Grunstein and Hogness, Proc. Natl. Acad. Sci. USA 72:3961 [1975]). In preferred embodiments, DNA fragments sharing substantial sequence similarity to the probe hybridize under medium to high stringency.

In some preferred embodiments, amplification is accomplished using PCR, as known in the art. In some preferred embodiments, a nucleic acid sequence of at least about 4 nucleotides and as many as about 60 nucleotides from SEQ ID NOS:1, 2, 3 and/or 4 (*i.e.*, fragments), preferably about 12 to 30 nucleotides, and more preferably about 25 nucleotides are used in any suitable combinations as PCR primer. These same fragments also find use as probes in hybridization and product detection methods.

In some embodiments, isolation of nucleic acid constructs of the invention from a cDNA or genomic library utilizes PCR with using degenerate oligonucleotide primers prepared on the basis of the amino acid sequence of the protein having the amino acid sequence as shown in SEQ ID NOS:1 -5. The primers can be of any segment length, for example at least 4, at least 5, at least 8, at least 15, at least 20, nucleotides in length. Exemplary probes in the present application utilized a primer comprising a TTGWHCGT and a GDSGG polynucleotide sequence as more fully described in Examples.

In view of the above, it will be appreciated that the polynucleotide sequences provided herein and based on the polynucleotide sequences provided in SEQ ID NOS:1-5 are useful for obtaining identical or homologous fragments of polynucleotides from other

- 74 -

species, and particularly from bacteria that encode enzymes having the serine protease activity expressed by protease 69B4.

IV. Expression and Recovery of Serine Proteases of the Present Invention

5 Any suitable means for expression and recovery of the serine proteases of the present invention find use herein. Indeed, those of skill in the art know many methods suitable for cloning a *Cellulomonas*-derived polypeptide having proteolytic activity, as well as an additional enzyme (*e.g.*, a second peptide having proteolytic activity, such as a protease, cellulase, mannanase, or amylase, etc.). Numerous methods are also known in the art for
10 introducing at least one (*e.g.*, multiple) copies of the polynucleotide(s) encoding the enzyme(s) of the present invention in conjunction with any additional sequences desired, into the genes or genome of host cells.

In general, standard procedures for cloning of genes and introducing exogenous proteases encoding regions (including multiple copies of the exogenous encoding regions)
15 into said genes find use in obtaining a *Cellulomonas* 69B4 protease derivative or homologue thereof. Indeed, the present Specification, including the Examples provides such teaching. However, additional methods known in the art are also suitable (*See e.g.*, Sambrook *et al. supra* (1989); Ausubel *et al., supra* [1995]; and Harwood and Cutting, (eds.) Molecular Biological Methods for Bacillus, John Wiley and Sons, [1990]; and WO 96/34946).

20 In some preferred embodiments, the polynucleotide sequences of the present invention are expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employed by that expression vector to transform an appropriate host according to techniques well established in the art. In some embodiments, the polypeptides produced on expression of the DNA sequences of this invention are
25 isolated from the fermentation of cell cultures and purified in a variety of ways according to well established techniques in the art. Those of skill in the art are capable of selecting the most appropriate isolation and purification techniques.

More particularly, the present invention provides constructs, vectors comprising polynucleotides described herein, host cells transformed with such vectors, proteases
30 expressed by such host cells, expression methods and systems for the production of serine protease enzymes derived from microorganisms, in particular, members of the *Micrococcineae*, including but not limited to *Cellulomonas* species. In some embodiments, the polynucleotide(s) encoding serine protease(s) are used to produce recombinant host cells suitable for the expression of the serine protease(s). In some preferred embodiments,

- 75 -

the expression hosts are capable of producing the protease(s) in commercially viable quantities.

IV. Recombinant Vectors

5 As indicated above, in some embodiments, the present invention provides vectors comprising the aforementioned polynucleotides. In some embodiments, the vectors (*i.e.*, constructs) of the invention encoding the protease are of genomic origin (*e.g.*, prepared though use of a genomic library and screening for DNA sequences coding for all or part of the protease by hybridization using synthetic oligonucleotide probes in accordance with
10 standard techniques). In some preferred embodiments, the DNA sequence encoding the protease is obtained by isolating chromosomal DNA from the *Cellulomonas* strain 69B4 and amplifying the sequence by PCR methodology (*See*, the Examples).

In alternative embodiments, the nucleic acid construct of the invention encoding the protease is prepared synthetically by established standard methods (*See e.g.*, Beaucage
15 and Caruthers, Tetra. Lett. 22:1859-1869 [1981]; and Matthes *et al.*, EMBO J., 3:801-805 [1984]). According to the phosphoramidite method, oligonucleotides are synthesized (*e.g.*, in an automatic DNA synthesizer), purified, annealed, ligated and cloned in suitable vectors..

In additional embodiments, the nucleic acid construct is of mixed synthetic and genomic origin. In some embodiments, the construct is prepared by ligating fragments of
20 synthetic or genomic DNA (as appropriate), wherein the fragments correspond to various parts of the entire nucleic acid construct, in accordance with standard techniques.

In further embodiments, the present invention provides vectors comprising at least one DNA construct of the present invention. In some embodiments, the present invention encompasses recombinant vectors. It is contemplated that any suitable vector will find use
25 in the present invention, including autonomously replicating vector as well as vectors that integrate (either transiently or stably) within the host cell genome). Indeed, a wide variety of vectors, and expression cassettes suitable for the cloning, transformation and expression in fungal (mold and yeast), bacterial, insect and plant cells are known to those of skill in the art. Typically, the vector or cassette contains sequences directing transcription and
30 translation of the nucleic acid, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. In some embodiments, suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. These control regions may be derived from genes homologous or heterologous to the host as long as the control region
35 selected is able to function in the host cell.

- 76 -

The vector is preferably an expression vector in which the DNA sequence encoding the protease of the invention is operably linked to additional segments required for transcription of the DNA. In some preferred embodiments, the expression vector is derived from plasmid or viral DNA, or in alternative embodiments, contains elements of both.

Exemplary vectors include, but are not limited to pSEGCT, pSEACT, and/or pSEA4CT, as well as all of the vectors described in the Examples herein. Construction of such vectors is described herein, and methods are well known in the art (*See e.g.*, U.S. Pat. No. 6,287,839; and WO 02/50245). In some preferred embodiments, the vector pSEGCT (about 8302 bp; *See*, Figure 5) finds use in the construction of a vector comprising the polynucleotides described herein (*e.g.*, pSEG69B4T; *See*, Figure 6). In alternative preferred embodiments, the vector pSEA469B4CT (*See*, Figure 7) finds use in the construction of a vector comprising the polynucleotides described herein. Indeed, it is intended that all of the vectors described herein will find use in the present invention.

In some embodiments, the additional segments required for transcription include regulatory segments (*e.g.*, promoters, secretory segments, inhibitors, global regulators, etc.), as known in the art. One example includes any DNA sequence that shows transcriptional activity in the host cell of choice and is derived from genes encoding proteins either homologous or heterologous to the host cell. Specifically, examples of suitable promoters for use in bacterial host cells include but are not limited to the promoter of the *Bacillus stearothermophilus* maltogenic amylase gene, the *Bacillus amyloliquefaciens* (BAN) amylase gene, the *Bacillus subtilis* alkaline protease gene, the *Bacillus clausii* alkaline protease gene the *Bacillus pumilus* xylosidase gene, the *Bacillus thuringiensis* cryIIIA, and the *Bacillus licheniformis* alpha-amylase gene. Additional promoters include the A4 promoter, as described herein. Other promoters that find use in the present invention include, but are not limited to phage Lambda P_R or P_L promoters, as well as the *E. coli* lac, trp or tac promoters.

In some embodiments, the promoter is derived from a gene encoding said protease or a fragment thereof having substantially the same promoter activity as said sequence. The invention further encompasses nucleic acid sequences which hybridize to the promoter sequences under intermediate, high, and/or maximum stringency conditions, or which have at least about 90% homology and preferably about 95% homology to such promoter, but which have substantially the same promoter activity. In some embodiments, this promoter is used to promote the expression of either the protease and/or a heterologous DNA sequence (*e.g.*, another enzyme in addition to the protease of the present invention). In additional embodiments, the vector also comprises at least one selectable marker.

- 77 -

In some embodiments, the recombinant vectors of the invention further comprise a DNA sequence enabling the vector to replicate in the host cell. In some preferred embodiments involving bacterial host cells, these sequences comprise all the sequences needed to allow plasmid replication (*e.g.*, *ori* and/or *rep* sequences).

5 In some particularly preferred embodiments, signal sequences (*e.g.*, leader sequence or pre sequence) are also included in the vector, in order to direct a polypeptide of the present invention into the secretory pathway of the host cells. In some more preferred embodiments, a secretory signal sequence is joined to the-DNA sequence encoding the precursor protease in the correct reading frame (*See e.g.*, SEQ ID NOS:1 and 2).

10 Depending on whether the protease is to be expressed intracellularly or is secreted, a polynucleotide sequence or expression vector of the invention is engineered with or without a natural polypeptide signal sequence or a signal sequence which functions in bacteria (*e.g.*, *Bacillus sp.*), fungi (*e.g.*, *Trichoderma*), other prokaryotes or eukaryotes. In some embodiments, expression is achieved by either removing or partially removing the signal
15 sequence

In some embodiments involving secretion from bacterial cells, the signal peptide is a naturally occurring signal peptide, or a functional part thereof, while in other embodiments, it is a synthetic peptide. Suitable signal peptides include but are not limited to sequences derived from *Bacillus licheniformis* alpha-amylase, *Bacillus clausii* alkaline protease, and
20 *Bacillus amyloliquefaciens* amylase. One preferred signal sequence is the signal peptide derived from *Cellulomonas* strain 69B4, as described herein. Thus, in some particularly preferred embodiments, the signal peptide comprises the signal peptide from the protease described herein. This signal finds use in facilitating the secretion of the 69B4 protease and/or a heterologous DNA sequence (*e.g.* a second protease, such as another wild-type
25 protease, a BPN' variant protease, a GG36 variant protease, a lipase, a cellulase, a mannanase, etc.). In some embodiments, these second enzymes are encoded by the DNA sequence and/or the amino acid sequences known in the art (*See e.g.*, U.S. Pat. Nos. 6,465,235, 6,287,839, 5,965,384, and 5,795,764; as well as WO 98/22500, WO 92/05249, EP 0305216B1, and WO 94/25576). Furthermore, it is contemplated that in some
30 embodiments, the signal sequence peptide is also be operatively linked to an endogenous sequence to activate and secrete such endogenous encoded protease.

The procedures used to ligate the DNA sequences coding for the present protease, the promoter and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to those skilled

- 78 -

in the art. As indicated above, in some embodiments, the nucleic acid construct is prepared using PCR with specific primers.

V. Host Cells

As indicated above, in some embodiments, the present invention also provides host cells transformed with the vectors described above. In some embodiments, the polynucleotide encoding the protease(s) of the present invention that is introduced into the host cell is homologous, while in other embodiments, the polynucleotide is heterologous to the host. In some embodiments in which the polynucleotide is homologous to the host cell (e.g., additional copies of the native protease produced by the host cell are introduced), it is operably connected to another homologous or heterologous promoter sequence. In alternative embodiments, another secretory signal sequence, and/or terminator sequence find use in the present invention. Thus, in some embodiments, the polypeptide DNA sequence comprises multiple copies of a homologous polypeptide sequence, a heterologous polypeptide sequence from another organism, or synthetic polypeptide sequence(s). Indeed, it is not intended that the present invention be limited to any particular host cells and/or vectors.

Indeed, the host cell into which the DNA construct of the present invention is introduced may be any cell which is capable of producing the present alkaline protease, including, but not limited to bacteria, fungi, and higher eukaryotic cells.

Examples of bacterial host cells which find use in the present invention include, but are not limited to Gram-positive bacteria such as *Bacillus*, *Streptomyces*, and *Thermobifida*, for example strains of *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. clausii*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. lautus*, *B. megaterium*, *B. thuringiensis*, *S. griseus*, *S. lividans*, *S. coelicolor*, *S. avermitilis* and *T. fusca*; as well as Gram-negative bacteria such as members of the Enterobacteriaceae (e.g., *Escherichia coli*). In some particularly preferred embodiments, the host cells are *B. subtilis*, *B. clausii*, and/or *B. licheniformis*. In additional preferred embodiments, the host cells are strains of *S. lividans* (e.g., TK23 and/or TK21). Any suitable method for transformation of the bacteria find use in the present invention, including but not limited to protoplast transformation, use of competent cells, etc., as known in the art. In some preferred embodiments, the method provided in U.S. Pat. No. 5,264,366 (incorporated by reference herein), finds used in the present invention. For *S. lividans*, one preferred means for transformation and protein expression is that described by Fernandez-Abalos *et al.* (See, Fernandez-Abalos *et al.*, Microbiol., 149:1623-1632 [2003]; See also, Hopwood, *et al.*,

- 79 -

Genetic Manipulation of *Streptomyces*: Laboratory Manual, Innis [1985], both of which are incorporated by reference herein). Of course, the methods described in the Example herein find use in the present invention.

Examples of fungal host cells which find use in the present invention include, but are not limited to *Trichoderma* spp. and *Aspergillus* spp. In some particularly preferred embodiments, the host cells are *Trichoderma reesei* and/or *Aspergillus niger*. In some embodiments, transformation and expression in *Aspergillus* is performed as described in U.S. Pat. 5,364,770, herein incorporated by reference. Of course, the methods described in the Example herein find use in the present invention.

In some embodiments, particular promoter and signal sequences are needed to provide effective transformation and expression of the protease(s) of the present invention. Thus, in some preferred embodiments involving the use of *Bacillus* host cells, the *aprE* promoter is used in combination with known *Bacillus*-derived signal and other regulatory sequences. In some preferred embodiments involving expression in *Aspergillus*, the *glaA* promoter is used. In some embodiments involving *Streptomyces* host cells, the glucose isomerase (GI) promoter of *Actinoplanes missouriensis* is used, while in other embodiments, the A4 promoter is used.

In some embodiments involving expression in bacteria such as *E. coli*, the protease is retained in the cytoplasm, typically as insoluble granules (*i.e.*, inclusion bodies).

However, in other embodiments, the protease is directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured after which the protease is refolded by diluting the denaturing agent. In the latter case, the protease is recovered from the periplasmic space by disrupting the cells (*e.g.*, by sonication or osmotic shock), to release the contents of the periplasmic space and recovering the protease.

In preferred embodiments, the transformed host cells of the present invention are cultured in a suitable nutrient medium under conditions permitting the expression of the present protease, after which the resulting protease is recovered from the culture. The medium used to culture the cells comprises any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (*e.g.*, in catalogues of the American Type Culture Collection). In some embodiments, the protease produced by the cells is recovered from the culture medium by conventional procedures, including, but not limited to separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the

- 80 -

supernatant or filtrate by means of a salt (*e.g.*, ammonium sulfate), chromatographic purification (*e.g.*, ion exchange, gel filtration, affinity, etc.). Thus, any method suitable for recovering the protease(s) of the present invention will find use. Indeed, it is not intended that the present invention be limited to any particular purification method.

5

VI. Applications for Serine Protease Enzymes

As described in greater detail herein, the proteases of the present invention have important characteristics that make them very suitable for certain applications. For example, the proteases of the present invention have enhanced thermal stability, enhanced oxidative
10 stability, and enhanced chelator stability, as compared to some currently used proteases.

Thus, these proteases find use in cleaning compositions. Indeed, under certain wash conditions, the present proteases exhibit comparative or enhanced wash performance as compared with currently used subtilisin proteases. Thus, it is contemplated that the cleaning and/or enzyme compositions of the present invention will be provided in a variety of
15 cleaning compositions. In some embodiments, the proteases of the present invention are utilized in the same manner as subtilisin proteases (*i.e.*, proteases currently in use). Thus, the present proteases find use in various cleaning compositions, as well as animal feed applications, leather processing (*e.g.*, bating), protein hydrolysis, and in textile uses. The identified proteases also find use in personal care applications.

20 Thus, the proteases of the present invention find use in a number of industrial applications, in particular within the cleaning, disinfecting, animal feed, and textile/leather industries. In some embodiments, the protease(s) of the present invention are combined with detergents, builders, bleaching agents and other conventional ingredients to produce a variety of novel cleaning compositions useful in the laundry and other cleaning arts such as,
25 for example, laundry detergents (both powdered and liquid), laundry pre-soaks, all fabric bleaches, automatic dishwashing detergents (both liquid and powdered), household cleaners, particularly bar and liquid soap applications, and drain openers. In addition, the protease find use in the cleaning of contact lenses, as well as other items, by contacting such materials with an aqueous solution of the cleaning composition. In addition these
30 naturally occurring proteases can be used, for example in peptide hydrolysis, waste treatment, textile applications, medical device cleaning, biofilm removal and as fusion-cleavage enzymes in protein production, etc. The composition of these products is not critical to the present invention, as long as the protease(s) maintain their function in the setting used. In some embodiments, the compositions are readily prepared by combining a
35 cleaning effective amount of the protease or an enzyme composition comprising the

- 81 -

protease enzyme preparation with the conventional components of such compositions in their art recognized amounts.

A. Cleaning Compositions

5 The cleaning composition of the present invention may be advantageously employed for example, in laundry applications, hard surface cleaning, automatic dishwashing applications, as well as cosmetic applications such as dentures, teeth, hair and skin. However, due to the unique advantages of increased effectiveness in lower temperature solutions and the superior color-safety profile, the enzymes of the present invention are
10 ideally suited for laundry applications such as the bleaching of fabrics. Furthermore, the enzymes of the present invention may be employed in both granular and liquid compositions.

The enzymes of the present invention may also be employed in a cleaning additive product. A cleaning additive product including the enzymes of the present invention is
15 ideally suited for inclusion in a wash process when additional bleaching effectiveness is desired. Such instances may include, but are not limited to low temperature solution cleaning application. The additive product may be, in its simplest form, one or more proteases, including ASP. Such additive may be packaged in dosage form for addition to a cleaning process where a source of peroxygen is employed and increased bleaching
20 effectiveness is desired. Such single dosage form may comprise a pill, tablet, gelcap or other single dosage unit such as pre-measured powders or liquids. A filler or carrier material may be included to increase the volume of such composition. Suitable filler or carrier materials include, but are not limited to, various salts of sulfate, carbonate and silicate as well as talc, clay and the like. Filler or carrier materials for liquid compositions
25 may be water or low molecular weight primary and secondary alcohols including polyols and diols. Examples of such alcohols include, but are not limited to, methanol, ethanol, propanol and isopropanol. The compositions may contain from about 5% to about 90% of such materials. Acidic fillers can be used to reduce pH. Alternatively, the cleaning additive may include activated peroxygen source defined below or the adjunct ingredients as fully defined
30 below.

The present cleaning compositions and cleaning additives require an effective amount of the ASP enzyme and/or variants provided herein. The required level of enzyme may be achieved by the addition of one or more species of the enzymes of the present invention. Typically the present cleaning compositions will comprise at least 0.0001 weight
35 percent, from about 0.0001 to about 1, from about 0.001 to about 0.5, or even from about

- 82 -

0.01 to about 0.1 weight percent of at least one of the enzymes of the present invention.

The cleaning compositions herein will typically be formulated such that, during use in aqueous cleaning operations, the wash water will have a pH of from about 5.0 to about 11.5 or even from about 7.5 to about 10.5. Liquid product formulations are typically formulated to have a neat pH from about 3.0 to about 9.0 or even from about 3 to about 5. Granular laundry products are typically formulated to have a pH from about 9 to about 11. Techniques for controlling pH at recommended usage levels include the use of buffers, alkalis, acids, etc., and are well known to those skilled in the art.

Suitable low pH cleaning compositions typically have a neat pH of from about 3 to about 5, and are typically free of surfactants that hydrolyze in such a pH environment. Such surfactants include sodium alkyl sulfate surfactants that comprise at least one ethylene oxide moiety or even from about 1 to 16 moles of ethylene oxide. Such cleaning compositions typically comprise a sufficient amount of a pH modifier, such as sodium hydroxide, monoethanolamine or hydrochloric acid, to provide such cleaning composition with a neat pH of from about 3 to about 5. Such compositions typically comprise at least one acid stable enzyme. Said compositions may be liquids or solids. The pH of such liquid compositions is measured as a neat pH. The pH of such solid compositions is measured as a 10% solids solution of said composition wherein the solvent is distilled water. In these embodiments, all pH measurements are taken at 20°C.

When the serine protease(s) is/are employed in a granular composition or liquid, it may be desirable for the enzyme to be in the form of an encapsulated particle to protect such enzyme from other components of the granular composition during storage. In addition, encapsulation is also a means of controlling the availability of the enzyme during the cleaning process and may enhance performance of the enzymes provided herein. In this regard, the serine proteases of the present invention may be encapsulated with any encapsulating material known in the art.

The encapsulating material typically encapsulates at least part of the catalyst for the enzymes of the present invention. Typically, the encapsulating material is water-soluble and/or water-dispersible. The encapsulating material may have a glass transition temperature (T_g) of 0°C or higher. Glass transition temperature is described in more detail in WO 97/11151, especially from page 6, line 25 to page 7, line 2.

The encapsulating material may be selected from the group consisting of carbohydrates, natural or synthetic gums, chitin and chitosan, cellulose and cellulose derivatives, silicates, phosphates, borates, polyvinyl alcohol, polyethylene glycol, paraffin waxes and combinations thereof. When the encapsulating material is a carbohydrate, it

- 83 -

may be typically selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, and combinations thereof. Typically, the encapsulating material is a starch. Suitable starches are described in EP 0 922 499; US 4,977,252; US 5,354,559 and US 5,935,826.

5 The encapsulating material may be a microsphere made from plastic such as thermoplastics, acrylonitrile, methacrylonitrile, polyacrylonitrile, polymethacrylonitrile and mixtures thereof; commercially available microspheres that can be used are those supplied by Expancel of Stockviksverken, Sweden under the trademark Expancel®, and those supplied by PQ Corp. of Valley Forge, Pennsylvania U.S.A. under the tradename PM 6545,
10 PM 6550, PM 7220, PM 7228, Extendspheres®, Luxsil®, Q-cel® and Spherichel®.

As described herein, the proteases of the present invention find particular use in the cleaning industry, including, but not limited to laundry and dish detergents. These applications place enzymes under various environmental stresses. The proteases of the present invention provide advantages over many currently used enzymes, due to their
15 stability under various conditions.

Indeed, there are a variety of wash conditions including varying detergent formulations, wash water volumes, wash water temperatures, and lengths of wash time, to which proteases involved in washing are exposed. In addition, detergent formulations used in different geographical areas have different concentrations of their relevant components
20 present in the wash water. For example, a European detergent typically has about 4500-5000 ppm of detergent components in the wash water, while a Japanese detergent typically has approximately 667 ppm of detergent components in the wash water. In North America, particularly the United States, detergents typically have about 975 ppm of detergent components present in the wash water.

25 A low detergent concentration system includes detergents where less than about 800 ppm of detergent components are present in the wash water. Japanese detergents are typically considered low detergent concentration system as they have approximately 667 ppm of detergent components present in the wash water.

A medium detergent concentration includes detergents where between about 800
30 ppm and about 2000ppm of detergent components are present in the wash water. North American detergents are generally considered to be medium detergent concentration systems as they have approximately 975 ppm of detergent components present in the wash water. Brazil typically has approximately 1500 ppm of detergent components present in the wash water.

35 A high detergent concentration system includes detergents where greater than about

- 84 -

2000 ppm of detergent components are present in the wash water. European detergents are generally considered to be high detergent concentration systems as they have approximately 4500-5000 ppm of detergent components in the wash water.

Latin American detergents are generally high suds phosphate builder detergents and the range of detergents used in Latin America can fall in both the medium and high detergent concentrations as they range from 1500 ppm to 6000 ppm of detergent components in the wash water. As mentioned above, Brazil typically has approximately 1500 ppm of detergent components present in the wash water. However, other high suds phosphate builder detergent geographies, not limited to other Latin American countries, may have high detergent concentration systems up to about 6000 ppm of detergent components present in the wash water.

In light of the foregoing, it is evident that concentrations of detergent compositions in typical wash solutions throughout the world varies from less than about 800 ppm of detergent composition ("low detergent concentration geographies"), for example about 667 ppm in Japan, to between about 800 ppm to about 2000 ppm ("medium detergent concentration geographies"), for example about 975 ppm in U.S. and about 1500 ppm in Brazil, to greater than about 2000 ppm ("high detergent concentration geographies"), for example about 4500 ppm to about 5000 ppm in Europe and about 6000 ppm in high suds phosphate builder geographies.

The concentrations of the typical wash solutions are determined empirically. For example, in the U.S., a typical washing machine holds a volume of about 64.4 L of wash solution. Accordingly, in order to obtain a concentration of about 975 ppm of detergent within the wash solution about 62.79 g of detergent composition must be added to the 64.4 L of wash solution. This amount is the typical amount measured into the wash water by the consumer using the measuring cup provided with the detergent.

As a further example, different geographies use different wash temperatures. The temperature of the wash water in Japan is typically less than that used in Europe. For example, the temperature of the wash water in North America and Japan can be between 10 and 30°C (e.g., about 20°C), whereas the temperature of wash water in Europe is typically between 30 and 60°C (e.g., about 40°C).

As a further example, different geographies typically have different water hardness. Water hardness is usually described in terms of the grains per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$. Hardness is a measure of the amount of calcium (Ca^{2+}) and magnesium (Mg^{2+}) in the water. Most water in the United States is hard, but the degree of hardness varies. Moderately hard (60-120 ppm) to hard (121-181 ppm) water has 60 to 181 parts per million (parts per million

- 85 -

converted to grains per U.S. gallon is ppm # divided by 17.1 equals grains per gallon) of hardness minerals.

Water	Grains per gallon	Parts per million
Soft	less than 1.0	less than 17
Slightly hard	1.0 to 3.5	17 to 60
Moderately hard	3.5 to 7.0	60 to 120
Hard	7.0 to 10.5	120 to 180
Very hard	greater than 10.5	greater than 180

European water hardness is typically greater than 10.5 (for example 10.5-20.0) grains per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$ (e.g., about 15 grains per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$). North American water hardness is typically greater than Japanese water hardness, but less than European water hardness. For example, North American water hardness can be between 3 to 10 grains, 3-8 grains or about 6 grains. Japanese water hardness is typically lower than North American water hardness, usually less than 4, for example 3 grains-per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$.

Accordingly, in some embodiments, the present invention provides proteases that show surprising wash performance in at least one set of wash conditions (e.g., water temperature, water hardness, and/or detergent concentration). In some embodiments, the proteases of the present invention are comparable in wash performance to subtilisin proteases. In some embodiments, the proteases of the present invention exhibit enhanced wash performance as compared to subtilisin proteases. Thus, in some preferred embodiments of the present invention, the proteases provided herein exhibit enhanced oxidative stability, enhanced thermal stability, and/or enhanced chelator stability.

In some preferred embodiments, the present invention provides the ASP protease, as well as homologues and variants of the protease. These proteases find use in any applications in which it is desired to clean protein based stains from textiles or fabrics.

In some embodiments, the cleaning compositions of the present invention are formulated as hand and machine laundry detergent compositions including laundry additive compositions, and compositions suitable for use in the pretreatment of stained fabrics, rinse-added fabric softener compositions, and compositions for use in general household hard surface cleaning operations, as well as dishwashing operations. Those in the art are familiar with different formulations which can be used as cleaning compositions. In

- 86 -

preferred embodiments, the proteases of the present invention comprise comparative or enhanced performance in detergent compositions (*i.e.*, as compared to other proteases). In some embodiments, cleaning performance is evaluated by comparing the proteases of the present invention with subtilisin proteases in various cleaning assays that utilize enzyme-sensitive stains such as egg, grass, blood, milk, etc., in standard methods. Indeed, those in the art are familiar with the spectrophotometric and other analytical methodologies used to assess detergent performance under standard wash cycle conditions.

Assays that find use in the present invention include, but are not limited to those described in WO 99/34011, and U.S. Pat. No. 6,605,458 (*See e.g.*, Example 3). In U.S. Pat. No. 6,605,458, at Example 3, a detergent dose of 3.0 g/l at pH10.5, wash time 15 minutes, at 15 C, water hardness of 6°dH, 10nM enzyme concentration in 150 ml glass beakers with stirring rod, 5 textile pieces (phi 2.5 cm) in 50 ml, EMPA 117 test material from Center for Test Materials Holland are used. The measurement of reflectance "R" on the test material was done at 460 nm using a Macbeth ColorEye 7000 photometer. Additional methods are provided in the Examples herein. Thus, these methods also find use in the present invention.

The addition of proteases of the invention to conventional cleaning compositions does not create any special use limitation. In other words, any temperature and pH suitable for the detergent is also suitable for the present compositions, as long as the pH is within the range set forth herein, and the temperature is below the described protease's denaturing temperature. In addition, proteases of the present invention find use in cleaning compositions that do not include detergents, again either alone or in combination with builders and stabilizers.

When used in cleaning compositions or detergents, oxidative stability is a further consideration. Thus, in some applications, the stability is enhanced, diminished, or comparable to subtilisin proteases as desired for various uses. In some preferred embodiments, enhanced oxidative stability is desired. Some of the proteases of the present invention find particular use in such applications.

When used in cleaning compositions or detergents, thermal stability is a further consideration. Thus, in some applications, the stability is enhanced, diminished, or comparable to subtilisin proteases as desired for various uses. In some preferred embodiments, enhanced thermostability is desired. Some of the proteases of the present invention find particular use in such applications.

When used in cleaning compositions or detergents, chelator stability is a further consideration. Thus, in some applications, the stability is enhanced, diminished, or

- 87 -

comparable to subtilisin proteases as desired for various uses. In some preferred embodiments, enhanced chelator stability is desired. Some of the proteases of the present invention find particular use in such applications.

In some embodiments of the present invention, naturally occurring proteases are provided which exhibit modified enzymatic activity at different pHs when compared to subtilisin proteases. A pH-activity profile is a plot of pH against enzyme activity and may be constructed as described in the Examples and/or by methods known in the art. In some embodiments, it is desired to obtain naturally occurring proteases with broader profiles (*i.e.*, those having greater activity at range of pHs than a comparable subtilisin protease). In other embodiments, the enzymes have no significantly greater activity at any pH, or naturally occurring homologues with sharper profiles (*i.e.*, those having enhanced activity when compared to subtilisin proteases at a given pH, and lesser activity elsewhere). Thus, in various embodiments, the proteases of the present invention have differing pH optima and/or ranges. It is not intended that the present invention be limited to any specific pH or pH range.

In some embodiments of the present invention, the cleaning compositions comprise, proteases of the present invention at a level from 0.00001 % to 10% of 69B4 and/or other protease of the present invention by weight of the composition and the balance (*e.g.*, 99.999% to 90.0%) comprising cleaning adjunct materials by weight of composition. In other aspects of the present invention, the cleaning compositions of the present invention comprise, the 69B4 and/or other proteases at a level of 0.0001 % to 10%, 0.001% to 5%, 0.001% to 2%, 0.005% to 0.5% 69B4 or other protease of the present invention by weight of the composition and the balance of the cleaning composition (*e.g.*, 99.9999% to 90.0%, 99.999 % to 98%, 99.995% to 99.5% by weight) comprising cleaning adjunct materials.

In some embodiments, preferred cleaning compositions, in addition to the protease preparation of the invention, comprise one or more additional enzymes or enzyme derivatives which provide cleaning performance and/or fabric care benefits. Such enzymes include, but are not limited to other proteases, lipases, cutinases, amylases, cellulases, peroxidases, oxidases (*e.g.* laccases), and/or mannanases.

Any other protease suitable for use in alkaline solutions finds use in the compositions of the present invention. Suitable proteases include those of animal, vegetable or microbial origin. In particularly preferred embodiments, microbial proteases are used. In some embodiments, chemically or genetically modified mutants are included. In some embodiments, the protease is a serine protease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases include subtilisins, especially those

- 88 -

derived from *Bacillus* (e.g., subtilisin, *lentus*, *amyloliquefaciens*, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168). Additional examples include those mutant proteases described in U.S. Pat. Nos. RE 34,606, 5,955,340, 5,700,676, 6,312,936, and 6,482,628, all of which are incorporated herein by reference. Additional protease examples
5 include, but are not limited to trypsin (e.g., of porcine or bovine origin), and the *Fusarium* protease described in WO 89/06270. Preferred commercially available protease enzymes include those sold under the trade names MAXATASE®, MAXACAL™, MAXAPEM™, OPTICLEAN®, OPTIMASE®, PROPERASE®, PURAFECT® and PURAFECT® OXP (Genencor), those sold under the trade names ALCALASE®, SAVINASE®, PRIMASE®,
10 DURAZYM™, RELASE® and ESPERASE® (Novozymes); and those sold under the trade name BLAP™ (Henkel Kommanditgesellschaft auf Aktien, Duesseldorf, Germany. Various proteases are described in WO95/23221, WO 92/21760, and U.S. Pat. Nos. 5,801,039, 5,340,735, 5,500,364, 5,855,625. An additional BPN' variant ("BPN'-var 1" and "BPN-variant 1"; as referred to herein) is described in US RE 34,606. An additional GG36-variant
15 ("GG36-var.1" and "GG36-variant 1"; as referred to herein) is described in US 5,955,340 and 5,700,676. A further GG36-variant is described in US Patents 6,312,936 and 6,482,628. In one aspect of the present invention, the cleaning compositions of the present invention comprise additional protease enzymes at a level from 0.00001 % to 10% of additional protease by weight of the composition and 99.999% to 90.0% of cleaning adjunct
20 materials by weight of composition. In other embodiments of the present invention, the cleaning compositions of the present invention also comprise, proteases at a level of 0.0001 % to 10%, 0.001% to 5%, 0.001% to 2%, 0.005% to 0.5% 69B4 protease (or its homologues or variants) by weight of the composition and the balance of the cleaning composition (e.g., 99.9999% to 90.0%, 99.999 % to 98%, 99.995% to 99.5% by weight) comprising cleaning
25 adjunct materials.

In addition, any lipase suitable for use in alkaline solutions finds use in the present invention. Suitable lipases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are encompassed by the present invention. Examples of useful lipases include *Humicola lanuginosa* lipase (See e.g., EP 258 068, and
30 EP 305 216), *Rhizomucor miehei* lipase (See e.g., EP 238 023), *Candida* lipase, such as *C. antarctica* lipase (e.g., the *C. antarctica* lipase A or B; See e.g., EP 214 761), a *Pseudomonas* lipase such as *P. alcaligenes* and *P. pseudoalcaligenes* lipase (See e.g., EP 218 272), *P. cepacia* lipase (See e.g., EP 331 376), *P. stutzeri* lipase (See e.g., GB 1,372,034), *P. fluorescens* lipase, *Bacillus* lipase (e.g., *B. subtilis* lipase [Dartois et al.,
35 Biochem. Biophys. Acta 1131:253-260 [1993]]; *B. stearothermophilus* lipase [See e.g., JP

- 89 -

64/744992]; and *B. pumilus* lipase [See e.g., WO 91/16422]).

Furthermore, a number of cloned lipases find use in some embodiments of the present invention, including but not limited to *Penicillium camembertii* lipase (See, Yamaguchi *et al.*, Gene 103:61-67 [1991]), *Geotricum candidum* lipase (See, Schimada *et al.*, J. Biochem., 106:383-388 [1989]), and various *Rhizopus* lipases such as *R. delemar* lipase (See, Hass *et al.*, Gene 109:117-113 [1991]), a *R. niveus* lipase (Kugimiya *et al.*, Biosci. Biotech. Biochem. 56:716-719 [1992]) and *R. oryzae* lipase.

Other types of lipolytic enzymes such as cutinases also find use in some embodiments of the present invention, including but not limited to the cutinase derived from *Pseudomonas mendocina* (See, WO 88/09367), or cutinase derived from *Fusarium solani pisi* (See, WO 90/09446).

Additional suitable lipases include commercially available lipases such as M1 LIPASE™, LUMA FAST™, and LIPOMAX™ (Genencor); LIPOLASE® and LIPOLASE® ULTRA (Novozymes); and LIPASE P™ "Amano" (Amano Pharmaceutical Co. Ltd., Japan).

In some embodiments of the present invention, the cleaning compositions of the present invention further comprise lipases at a level from 0.00001 % to 10% of additional lipase by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In other aspects of the present invention, the cleaning compositions of the present invention also comprise, lipases at a level of 0.0001 % to 10%, 0.001% to 5%, 0.001% to 2%, 0.005% to 0.5% lipase by weight of the composition.

Any amylase (alpha and/or beta) suitable for use in alkaline solutions also find use in some embodiments of the present invention. Suitable amylases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments. Amylases that find use in the present invention, include, but are not limited to α -amylases obtained from *B. licheniformis* (See e.g., GB 1,296,839). Commercially available amylases that find use in the present invention include, but are not limited to DURAMYL®, TERMAMYL®, FUNGAMYL® and BAN™ (Novozymes) and RAPIDASE® and MAXAMYL® P (Genencor International).

In some embodiments of the present invention, the cleaning compositions of the present invention further comprise amylases at a level from 0.00001 % to 10% of additional amylase by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In other aspects of the present invention, the cleaning compositions of the present invention also comprise, amylases at a level of 0.0001 % to 10%, 0.001% to 5%, 0.001% to 2%, 0.005% to 0.5% amylase by weight of the composition.

Any cellulase suitable for use in alkaline solutions find use in embodiments of the

- 90 -

present invention. Suitable cellulases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments. Suitable cellulases include, but are not limited to *Humicola insolens* cellulases (See e.g., U.S. Pat. No. 4,435,307). Especially suitable cellulases are the cellulases having color care benefits (See e.g., EP 0 495 257).

Commercially available cellulases that find use in the present include, but are not limited to CELLUZYME® (Novozymes), and KAC-500(B)™ (Kao Corporation). In some embodiments, cellulases are incorporated as portions or fragments of mature wild-type or variant cellulases, wherein a portion of the N-terminus is deleted (See e.g., U.S. Pat. No. 5,874,276).

In some embodiments, the cleaning compositions of the present invention can further comprise cellulases at a level from 0.00001 % to 10% of additional cellulase by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In other aspects of the present invention, the cleaning compositions of the present invention also comprise cellulases at a level of 0.0001 % to 10%, 0.001% to 5%, 0.001% to 2%, 0.005% to 0.5% cellulase by weight of the composition.

Any mannanase suitable for use in detergent compositions and or alkaline solutions find use in the present invention. Suitable mannanases include, but are not limited to those of bacterial or fungal origin. Chemically or genetically modified mutants are included in some embodiments. Various mannanases are known which find use in the present invention (See e.g., U.S. Pat. No. 6,566,114, U.S. Pat. No. 6,602,842, and US Patent No. 6,440,991, all of which are incorporated herein by reference).

In some embodiments, the cleaning compositions of the present invention can further comprise mannanases at a level from 0.00001 % to 10% of additional mannanase by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In other aspects of the present invention, the cleaning compositions of the present invention also comprise, mannanases at a level of 0.0001 % to 10%, 0.001% to 5%, 0.001% to 2%, 0.005% to 0.5% mannanase by weight of the composition.

In some embodiments, peroxidases are used in combination with hydrogen peroxide or a source thereof (e.g., a percarbonate, perborate or persulfate). In alternative embodiments, oxidases are used in combination with oxygen. Both types of enzymes are used for "solution bleaching" (i.e., to prevent transfer of a textile dye from a dyed fabric to another fabric when the fabrics are washed together in a wash liquor), preferably together with an enhancing agent (See e.g., WO 94/12621 and WO 95/01426). Suitable peroxidases/oxidases include, but are not limited to those of plant, bacterial or fungal origin.

- 91 -

Chemically or genetically modified mutants are included in some embodiments.

In some embodiments, the cleaning compositions of the present invention can further comprise peroxidase and/or oxidase enzymes at a level from 0.00001 % to 10% of additional peroxidase and/or oxidase by weight of the composition and the balance of cleaning adjunct materials by weight of composition. In other aspects of the present invention, the cleaning compositions of the present invention also comprise, peroxidase and/or oxidase enzymes at a level of 0.0001 % to 10%, 0.001% to 5%, 0.001% to 2%, 0.005% to 0.5% peroxidase and/or oxidase enzymes by weight of the composition.

Mixtures of the above mentioned enzymes are encompassed herein, in particular a mixture of a the 69B4 enzyme, one or more additional proteases, at least one amylase, at least one lipase, at least one mannanase, and/or at least one cellulase. Indeed, it is contemplated that various mixtures of these enzymes will find use in the present invention.

It is contemplated that the varying levels of the protease and one or more additional enzymes may both independently range to 10%, the balance of the cleaning composition being cleaning adjunct materials. The specific selection of cleaning adjunct materials are readily made by considering the surface, item, or fabric to be cleaned, and the desired form of the composition for the cleaning conditions during use (*e.g.*, through the wash detergent use).

Examples of suitable cleaning adjunct materials include, but are not limited to, surfactants, builders, bleaches, bleach activators, bleach catalysts, other enzymes, enzyme stabilizing systems, chelants, optical brighteners, soil release polymers, dye transfer agents, dispersants, suds suppressors, dyes, perfumes, colorants, filler salts, hydrotropes, photoactivators, fluorescers, fabric conditioners, hydrolyzable surfactants, preservatives, anti-oxidants, anti-shrinkage agents, anti-wrinkle agents, germicides, fungicides, color speckles, silvercare, anti-tarnish and/or anti-corrosion agents, alkalinity sources, solubilizing agents, carriers, processing aids, pigments, and pH control agents (*See e.g.*, U.S. Pat. Nos. 6,610,642, 6,605,458, 5,705,464, 5,710,115, 5,698,504, 5,695,679, 5,686,014 and 5,646,101, all of which are incorporated herein by reference). Embodiments of specific cleaning composition materials are exemplified in detail below.

If the cleaning adjunct materials are not compatible with the proteases of the present invention in the cleaning compositions, then suitable methods of keeping the cleaning adjunct materials and the protease(s) separated (*i.e.*, not in contact with each other) until combination of the two components is appropriate are used. Such separation methods include any suitable method known in the art (*e.g.*, gelcaps, encapsulation, tablets, physical separation, etc.).

- 92 -

Preferably an effective amount of one or more protease(s) provided herein are included in compositions useful for cleaning a variety of surfaces in need of proteinaceous stain removal. Such cleaning compositions include cleaning compositions for such applications as cleaning hard surfaces, fabrics, and dishes. Indeed, in some embodiments, the present invention provides fabric cleaning compositions, while in other embodiments, the present invention provides non-fabric cleaning compositions. Notably, the present invention also provides cleaning compositions suitable for personal care, including oral care (including dentrifices, toothpastes, mouthwashes, etc., as well as denture cleaning compositions), skin, and hair cleaning compositions. It is intended that the present invention encompass detergent compositions in any form (*i.e.*, liquid, granular, bar, semi-solid, gels, emulsions, tablets, capsules, etc.).

By way of example, several cleaning compositions wherein the protease of the present invention find use are described in greater detail below. In embodiments in which the cleaning compositions of the present invention are formulated as compositions suitable for use in laundry machine washing method(s), the compositions of the present invention preferably contain at least one surfactant and at least one builder compound, as well as one or more cleaning adjunct materials preferably selected from organic polymeric compounds, bleaching agents, additional enzymes, suds suppressors, dispersants, lime-soap dispersants, soil suspension and anti-redeposition agents and corrosion inhibitors. In some embodiments, laundry compositions also contain softening agents (*i.e.*, as additional cleaning adjunct materials).

The compositions of the present invention also find use detergent additive products in solid or liquid form. Such additive products are intended to supplement and/or boost the performance of conventional detergent compositions and can be added at any stage of the cleaning process.

In embodiments formulated as compositions for use in manual dishwashing methods, the compositions of the invention preferably contain at least one surfactant and preferably at least one additional cleaning adjunct material selected from organic polymeric compounds, suds enhancing agents, group II metal ions, solvents, hydrotropes and additional enzymes.

In some embodiments, the density of the laundry detergent compositions herein ranges from 400 to 1200 g/liter, while in other embodiments, it ranges from 500 to 950 g/liter of composition measured at 20°C.

In some embodiments, various cleaning compositions such as those provided in U.S. Pat. No. 6,605,458 find use with the proteases of the present invention. Thus, in some

- 93 -

embodiments, the compositions comprising at least one protease of the present invention is a compact granular fabric cleaning composition, while in other embodiments, the composition is a granular fabric cleaning composition useful in the laundering of colored fabrics, in further embodiments, the composition is a granular fabric cleaning composition which provides softening through the wash capacity, in additional embodiments, the composition is a heavy duty liquid fabric cleaning composition.

In some embodiments, the compositions comprising at least one protease of the present invention are fabric cleaning compositions such as those described in U.S. Pat. Nos. 6,610,642 and 6,376,450. In addition, the proteases of the present invention find use in granular laundry detergent compositions of particular utility under European or Japanese washing conditions (*See e.g.*, U.S. Pat. No. 6,610,642).

In alternative embodiments, the present invention provides hard surface cleaning compositions comprising at least one protease provided herein. Thus, in some embodiments, the compositions comprising at least one protease of the present invention is a hard surface cleaning composition such as those described in U.S. Pat. Nos. 6,610,642, 6,376,450, and 6,376,450.

In yet further embodiments, the present invention provides dishwashing compositions comprising at least one protease provided herein. Thus, in some embodiments, the compositions comprising at least one protease of the present invention is a hard surface cleaning composition such as those in U.S. Pat. Nos. 6,610,642 and 6,376,450.

In still further embodiments, the present invention provides dishwashing compositions comprising at least one protease provided herein. Thus, in some embodiments, the compositions comprising at least one protease of the present invention comprise oral care compositions such as those in U.S. Pat. No. 6,376,450, and 6,376,450.

The formulations and descriptions of the compounds and cleaning adjunct materials contained in the aforementioned US Pat. Nos. 6,376,450, 6,605,458, 6,605,458, and 6,610,642, all of which are expressly incorporated by reference herein. Still further examples are set forth in the Examples below.

I) Processes of Making and Using the Cleaning Composition of the Present Invention

The cleaning compositions of the present invention can be formulated into any suitable form and prepared by any process chosen by the formulator, non-limiting examples of which are described in U.S. Pat. Nos. 5,879,584, 5,691,297, 5,574,005, 5,569,645,

- 94 -

5,565,422, 5,516,448, 5,489,392, and 5,486,303, all of which are incorporated herein by reference. When a low pH cleaning composition is desired, the pH of such composition may be adjusted via the addition of a material such as monoethanolamine or an acidic material such as HCl.

II) Adjunct Materials In Addition to the Serine Proteases of the Present Invention

While not essential for the purposes of the present invention, the non-limiting list of adjuncts illustrated hereinafter are suitable for use in the instant cleaning compositions and may be desirably incorporated in certain embodiments of the invention, for example to assist or enhance cleaning performance, for treatment of the substrate to be cleaned, or to modify the aesthetics of the cleaning composition as is the case with perfumes, colorants, dyes or the like. It is understood that such adjuncts are in addition to the serine proteases of the present invention. The precise nature of these additional components, and levels of incorporation thereof, will depend on the physical form of the composition and the nature of the cleaning operation for which it is to be used. Suitable adjunct materials include, but are not limited to, surfactants, builders, chelating agents, dye transfer inhibiting agents, deposition aids, dispersants, additional enzymes, and enzyme stabilizers, catalytic materials, bleach activators, bleach boosters, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric dispersing agents, clay soil removal/anti-redeposition agents, brighteners, suds suppressors, dyes, perfumes, structure elasticizing agents, fabric softeners, carriers, hydrotropes, processing aids and/or pigments. In addition to the disclosure below, suitable examples of such other adjuncts and levels of use are found in U.S. Patent Nos. 5,576,282, 6,306,812, and 6,326,348, that are incorporated by reference. The aforementioned adjunct ingredients may constitute the balance of the cleaning compositions of the present invention.

Surfactants - The cleaning compositions according to the present invention may comprise a surfactant or surfactant system wherein the surfactant can be selected from nonionic surfactants, anionic surfactants, cationic surfactants, ampholytic surfactants, zwitterionic surfactants, semi-polar nonionic surfactants and mixtures thereof. When a low pH cleaning composition, such as composition having a neat pH of from about 3 to about 5, is desired, such composition typically does not contain alkyl ethoxylated sulfate as it is believed that such surfactant may be hydrolyzed by such compositions the acidic contents.

The surfactant is typically present at a level of from about 0.1% to about 60%, from about 1% to about 50% or even from about 5% to about 40% by weight of the subject

- 95 -

cleaning composition.

Builders - The cleaning compositions of the present invention may comprise one or more detergent builders or builder systems. When a builder is used, the subject cleaning composition will typically comprise at least about 1%, from about 3% to about 60% or even
5 from about 5% to about 40% builder by weight of the subject cleaning composition.

Builders include, but are not limited to, the alkali metal, ammonium and alkanolammonium salts of polyphosphates, alkali metal silicates, alkaline earth and alkali metal carbonates, aluminosilicate builders polycarboxylate compounds, ether
10 hydroxypolycarboxylates, copolymers of maleic anhydride with ethylene or vinyl methyl ether, 1, 3, 5-trihydroxy benzene-2, 4, 6-trisulphonic acid, and carboxymethyloxysuccinic acid, the various alkali metal, ammonium and substituted ammonium salts of polyacetic acids such as ethylenediamine tetraacetic acid and nitrilotriacetic acid, as well as polycarboxylates such as mellitic acid, succinic acid, citric acid, oxydisuccinic acid, polymaleic acid, benzene 1,3,5-tricarboxylic acid, carboxymethyloxysuccinic acid; and
15 soluble salts thereof.

Chelating Agents - The cleaning compositions herein may contain a chelating agent, Suitable chelating agents include copper, iron and/or manganese chelating agents and mixtures thereof.

When a chelating agent is used, the cleaning composition may comprise from about
20 0.1% to about 15% or even from about 3.0% to about 10% chelating agent by weight of the subject cleaning composition.

Deposition Aid - The cleaning compositions herein may contain a deposition aid. Suitable deposition aids include, polyethylene glycol, polypropylene glycol, polycarboxylate, soil release polymers such as polytelephthalic acid, clays such as Kaolinite, montmorillonite,
25 atapulgite, illite, bentonite, halloysite, and mixtures thereof.

Dye Transfer Inhibiting Agents - The cleaning compositions of the present invention may also include one or more dye transfer inhibiting agents. Suitable polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole,
30 polyvinylloxazolidones and polyvinylimidazoles or mixtures thereof.

When present in a subject cleaning composition, the dye transfer inhibiting agents may be present at levels from about 0.0001% to about 10%, from about 0.01% to about 5% or even from about 0.1% to about 3% by weight of the cleaning composition.

Dispersants - The cleaning compositions of the present invention can also contain
35 dispersants. Suitable water-soluble organic materials include the homo- or co-polymeric

- 96 -

acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two carbon atoms.

Enzymes - The cleaning compositions can comprise one or more detergent enzymes which provide cleaning performance and/or fabric care benefits. Examples of suitable enzymes include, but are not limited to, hemicellulases, peroxidases, proteases, cellulases, xylanases, lipases, phospholipases, esterases, cutinases, pectinases, keratinases, reductases, oxidases, phenol oxidases, lipoxygenases, ligninases, pullulanases, tannases, pentosanases, malanases, β -glucanases, arabinosidases, hyaluronidase, chondroitinase, laccase, and amylases, or mixtures thereof. A typical combination is cocktail of conventional applicable enzymes like protease, lipase, cutinase and/or cellulase in conjunction with amylase.

Enzyme Stabilizers - Enzymes for use in detergents can be stabilized by various techniques. The enzymes employed herein can be stabilized by the presence of water-soluble sources of calcium and/or magnesium ions in the finished compositions that provide such ions to the enzymes.

Catalytic Metal Complexes - The cleaning compositions of the present invention may include catalytic metal complexes. One type of metal-containing bleach catalyst is a catalyst system comprising a transition metal cation of defined bleach catalytic activity, such as copper, iron, titanium, ruthenium, tungsten, molybdenum, or manganese cations, an auxiliary metal cation having little or no bleach catalytic activity, such as zinc or aluminum cations, and a sequester having defined stability constants for the catalytic and auxiliary metal cations, particularly ethylenediaminetetraacetic acid, ethylenediaminetetra(methylenephosphonic acid) and water-soluble salts thereof. Such catalysts are disclosed in U.S. Pat. No. 4,430,243.

If desired, the compositions herein can be catalyzed by means of a manganese compound. Such compounds and levels of use are well known in the art and include, for example, the manganese-based catalysts disclosed in U.S. Pat. No. 5,576,282.

Cobalt bleach catalysts useful herein are known, and are described, for example, in U.S. Pat. Nos. 5,597,936, and 5,595,967. Such cobalt catalysts are readily prepared by known procedures, such as taught for example in U.S. Pat. Nos. 5,597,936, and 5,595,967.

Compositions herein may also suitably include a transition metal complex of a macropolycyclic rigid ligand - abbreviated as "MRL". As a practical matter, and not by way of limitation, the compositions and cleaning processes herein can be adjusted to provide on the order of at least one part per hundred million of the active MRL species in the aqueous washing medium, and will preferably provide from about 0.005 ppm to about 25 ppm, more preferably from about 0.05 ppm to about 10 ppm, and most preferably from about 0.1 ppm to about 5 ppm, of the MRL in the wash liquor.

- 97 -

Preferred transition-metals in the instant transition-metal bleach catalyst include manganese, iron and chromium. Preferred MRL's herein are a special type of ultra-rigid ligand that is cross-bridged such as 5,12-diethyl-1,5,8,12-tetraazabicyclo[6.6.2]hexadecane.

Suitable transition metal MRLs are readily prepared by known procedures, such as taught for example in WO 00/332601, and U.S. Pat. No. 6,225,464.

III) Processes of Making and Using Cleaning Compositions

The cleaning compositions of the present invention can be formulated into any suitable form and prepared by any process chosen by the formulator, non-limiting examples of which are described in U.S. Pat. Nos. 5,879,584, 5,691,297, 5,574,005, 5,569,645, 5,516,448, 5,489,392, and 5,486,303, all of which are incorporated herein by reference.

IV) Method of Use

The cleaning compositions disclosed herein of can be used to clean a situs *inter alia* a surface or fabric. Typically at least a portion of the situs is contacted with an embodiment of the present cleaning composition, in neat form or diluted in a wash liquor, and then the situs is optionally washed and/or rinsed. For purposes of the present invention, washing includes but is not limited to, scrubbing, and mechanical agitation. The fabric may comprise most any fabric capable of being laundered in normal consumer use conditions. The disclosed cleaning compositions are typically employed at concentrations of from about 500 ppm to about 15,000 ppm in solution. When the wash solvent is water, the water temperature typically ranges from about 5°C to about 90°C and, when the situs comprises a fabric, the water to fabric mass ratio is typically from about 1:1 to about 30:1.

B. Animal Feed

Still further, the present invention provides compositions and methods for the production of a food or animal feed, characterized in that protease according to the invention is mixed with food or animal feed. In some embodiments, the protease is added as a dry product before processing, while in other embodiments it is added as a liquid before or after processing. In some embodiments, in which a dry powder is used, the enzyme is diluted as a liquid onto a dry carrier such as milled grain. The proteases of the present invention find use as components of animal feeds and/or additives such as those described U.S. Pat. No. 5,612,055, U.S. Pat. No. 5,314,692. and U.S. Pat No. 5,147,642, all of which are hereby incorporated by reference.

The enzyme feed additive according to the present invention is suitable for

- 98 -

preparation in a number of methods. For example, in some embodiments, it is prepared simply by mixing different enzymes having the appropriate activities to produce an enzyme mix. In some embodiments; this enzyme mix is mixed directly with a feed, while in other embodiments, it is impregnated onto a cereal-based carrier material such as milled wheat, maize or soya flour. The present invention also encompasses these impregnated carriers, as they find use as enzyme feed additives.

In some alternative embodiments, a cereal-based carrier (*e.g.*, milled wheat or maize) is impregnated either simultaneously or sequentially with enzymes having the appropriate activities. For example, in some embodiments, a milled wheat carrier is first sprayed with a xylanase, secondly with a protease, and optionally with a β -glucanase. The present invention also encompasses these impregnated carriers, as they find use as enzyme feed additives. In preferred embodiments, these impregnated carriers comprise at least one protease of the present invention.

In some embodiments, the feed additive of the present invention is directly mixed with the animal feed, while in alternative embodiments, it is mixed with one or more other feed additives such as a vitamin feed additive, a mineral feed additive, and/or an amino acid feed additive. The resulting feed additive including several different types of components is then mixed in an appropriate amount with the feed.

In some preferred embodiments, the feed additive of the present invention, including cereal-based carriers is normally mixed in amounts of 0.01-50 g per kilogram of feed, more preferably 0.1-10 g/kilogram, and most preferably about 1 g/kilogram.

In alternative embodiments, the enzyme feed additive of the present invention involves construction of recombinant microorganisms that produces the desired enzyme(s) in the desired relative amounts. In some embodiments, this is accomplished by increasing the copy number of the gene encoding at least one protease of the present invention, and/or by using a suitably strong promoter operatively linked to the polynucleotide encoding the protease(s). In further embodiments, the recombinant microorganism strain has certain enzyme activities deleted (*e.g.*, cellulases, endoglucanases, etc.), as desired.

In additional embodiments, the enzyme feed additives provided by the present invention also include other enzymes, including but not limited to at least one xylanase, α -amylase, glucoamylase, pectinase, mannanase, α -galactosidase, phytase, and/or lipase. In some embodiments, the enzymes having the desired activities are mixed with the xylanase and protease either before impregnating these on a cereal-based carrier or alternatively such enzymes are impregnated simultaneously or sequentially on such a cereal-based carrier. The carrier is then in turn mixed with a cereal-based feed to prepare the final feed.

- 99 -

In alternative embodiments, the enzyme feed additive is formulated as a solution of the individual enzyme activities and then mixed with a feed material pre-formed as pellets or as a mash.

In still further embodiments, the enzyme feed additive is included in animals' diets by incorporating it into a second (*i.e.*, different) feed or the animals' drinking water.

Accordingly, it is not essential that the enzyme mix provided by the present invention be incorporated into the cereal-based feed itself, although such incorporation forms a particularly preferred embodiment of the present invention. The ratio of the units of xylanase activity per g of the feed additive to the units of protease activity per g of the feed additive is preferably 1:0.001-1,000, more preferably 1:0.01-100, and most preferably 1:0.1-10. As indicated above, the enzyme mix provided by the present invention is preferably finds use as a feed additive in the preparation of a cereal-based feed.

In some embodiments, the cereal-based feed comprises at least 25% by weight, or more preferably at least 35% by weight, wheat or maize or a combination of both of these cereals. The feed further comprises a protease (*i.e.*, at least one protease of the present invention) in such an amount that the feed includes a protease in such an amount that the feed includes 100-100,000 units of protease activity per kg.

Cereal-based feeds provided the present invention according to the present invention find use as feed for a variety of non-human animals, including poultry (*e.g.*, turkeys, geese, ducks, chickens, etc.), livestock (*e.g.*, pigs, sheep, cattle, goats, etc.), and companion animals (*e.g.*, horses, dogs, cats, rabbits, mice, etc.). The feeds are particularly suitable for poultry and pigs, and in particular broiler chickens.

C. Textile and Leather Treatment

The present invention also provides compositions for the treatment of textiles that include at least one of the proteases of the present invention. In some embodiments, at least one protease of the present invention is a component of compositions suitable for the treatment of silk or wool (*See e.g.*, U.S. RE Pat. No. 216,034, EP 134,267, U.S. Pat. No. 4,533,359, and EP 344,259).

In addition, the proteases of the present invention find use in a variety of applications where it is desirable to separate phosphorous from phytate. Accordingly, the present invention also provides methods producing wool or animal hair material with improved properties. In some preferred embodiments, these methods comprise the steps of pretreating wool, wool fibres or animal hair material in a process selected from the group consisting of plasma treatment processes and the Delhey process; and subjecting the

- 100 -

pretreated wool or animal hair material to a treatment with a proteolytic enzyme (*e.g.*, at least one protease of the present invention) in an amount effective for improving the properties. In some embodiments, the proteolytic enzyme treatment occurs prior to the plasma treatment, while in other embodiments, it occurs after the plasma treatment. In some further embodiments, it is conducted as a separate step, while in other embodiments, it is conducted in combination with the scouring or the dyeing of the wool or animal hair material. In additional embodiments, at least one surfactant and/or at least one softener is present during the enzyme treatment step, while in other embodiments, the surfactant(s) and/or softener(s) are incorporated in a separate step wherein the wool or animal hair material is subjected to a softening treatment.

In some embodiments, the compositions of the present invention find use in methods for shrink-proofing wool fibers (*See e.g.*, JP 4-327274). In some embodiments, the compositions are used in methods for shrink-proofing treatment of wool fibers by subjecting the fibers to a low-temperature plasma treatment, followed by treatment with a shrink-proofing resin such as a block-urethane resin, polyamide epochlorohydrin resin, glyoxalic resin, ethylene-urea resin or acrylate resin, and then treatment with a weight reducing proteolytic enzyme for obtaining a softening effect). In some embodiments, the plasma treatment step is a low-temperature treatment, preferably a corona discharge treatment or a glow discharge treatment.

In some embodiments, the low-temperature plasma treatment is carried out by using a gas, preferably a gas selected from the group consisting of air, oxygen, nitrogen, ammonia, helium, or argon. Conventionally, air is used but it may be advantageous to use any of the other indicated gasses.

Preferably, the low-temperature plasma treatment is carried out at a pressure between about 0.1 torr and 5 torr for from about 2 seconds to about 300 seconds, preferably for about 5 seconds to about 100 seconds, more preferably from about 5 seconds to about 30 seconds.

As indicated above, the present invention finds use in conjunction with methods such as the Delhey process (*See e.g.*, DE-A-43 32 692). In this process, the wool is treated in an aqueous solution of hydrogen peroxide in the presence of soluble wolframate, optionally followed by treatment in a solution or dispersion of synthetic polymers, for improving the anti-felting properties of the wool. In this method, the wool is treated in an aqueous solution of hydrogen peroxide (0.1-35% (w/w), preferably 2-10% (w/w)), in the presence of a 2-60% (w/w), preferably 8-20% (w/w) of a catalyst (preferably Na_2WO_4), and in the presence of a nonionic wetting agent. Preferably, the treatment is carried out at pH 8-11, and room

- 101 -

temperature. The treatment time depends on the concentrations of hydrogen peroxide and catalyst, but is preferably 2 minutes or less. After the oxidative treatment, the wool is rinsed with water. For removal of residual hydrogen peroxide, and optionally for additional bleaching, the wool is further treated in acidic solutions of reducing agents (*e.g.*, sulfites, phosphites etc.).

In some embodiments, the enzyme treatment step carried out for between about 1 minute and about 120 minutes. This step is preferably carried out at a temperature of between about 20°C. and about 60°C., more preferably between about 30°C. and about 50°C. Alternatively, the wool is soaked in or padded with an aqueous enzyme solution and then subjected to steaming at a conventional temperature and pressure, typically for about 30 seconds to about 3 minutes. In some preferred embodiments, the proteolytic enzyme treatment is carried out in an acidic or neutral or alkaline medium which may include a buffer.

In alternative embodiments, the enzyme treatment step is conducted in the presence of one or more conventional anionic, non-ionic (*e.g.*; Dobanol; Henkel AG) or cationic surfactants. An example of a useful nonionic surfactant is Dobanol (from Henkel AG). In further embodiments, the wool or animal hair material is subjected to an ultrasound treatment, either prior to or simultaneous with the treatment with a proteolytic enzyme. In some preferred embodiments, the ultrasound treatment is carried out at a temperature of about 50°C for about 5 minutes. In some preferred embodiments, the amount of proteolytic enzyme used in the enzyme treatment step is between about 0.2 w/w % and about 10 w/w %, based on the weight of the wool or animal hair material. In some embodiments, in order to the number of treatment steps, the enzyme treatment is carried out during dyeing and/or scouring of the wool or animal hair material, simply by adding the protease to the dyeing, rinsing and/or scouring bath. In some embodiments, enzyme treatment is carried out after the plasma treatment but in other embodiments, the two treatment steps are carried out in the opposite order.

Softeners conventionally used on wool are usually cationic softeners, either organic cationic softeners or silicone based products, but anionic or non-ionic softeners are also useful. Examples of useful softeners include, but are not limited to polyethylene softeners and silicone softeners (*i.e.*, dimethyl polysiloxanes (silicone oils)), H-polysiloxanes, silicone elastomers, aminofunctional dimethyl polysiloxanes, aminofunctional silicone elastomers, and epoxyfunctional dimethyl polysiloxanes, and organic cationic softeners (*e.g.* alkyl quarternary ammonium derivatives).

- 102 -

In additional embodiments, the present invention provides compositions for the treatment of an animal hide that includes at least one protease of the present invention. In some embodiments, the proteases of the present invention find use in compositions for treatment of animal hide, such as those described in WO 03/00865 (Insect Biotech Co.,
5 Taejeon-Si, Korea). In additional embodiments, the present invention provides methods for processing hides and/or skins into leather comprising enzymatic treatment of the hide or skin with the protease of the present invention (*See e.g.*, WO 96/11285). In additional embodiments, the present invention provides compositions for the treatment of an animal skin or hide into leather that includes at least one protease of the present invention.

10 Hides and skins are usually received in the tanneries in the form of salted or dried raw hides or skins. The processing of hides or skins into leather comprises several different process steps including the steps of soaking, unhairing and bating. These steps constitute the wet processing and are performed in the beamhouse. Enzymatic treatment utilizing the proteases of the present invention are applicable at any time during the process involved in
15 the processing of leather. However, proteases are usually employed during the wet processing (*i.e.*, during soaking, unhairing and/or bating). Thus, in some preferred embodiments, the enzymatic treatment with at least one of the proteases of the present invention occurs during the wet processing stage.

In some embodiments, the soaking processes of the present invention are
20 performed under conventional soaking conditions (*e.g.*, at a pH in the range pH 6.0 - 11). In some preferred embodiments, the range is pH 7.0 - 10.0. In alternative embodiments, the temperature is in the range of 20-30 °C, while in other embodiments it is preferably in the range 24-28 °C. In yet further embodiments, the reaction time is in the range 2-24 hours, while preferred range is 4-16 hours. In additional embodiments, tensides and/or
25 preservatives are provided as desired.

The second phase of the bating step usually commences with the addition of the bate itself. In some embodiments, the enzymatic treatment takes place during bating. In some preferred embodiments, the enzymatic treatment takes place during bating, after the deliming phase. In some embodiments, the bating process of the presents invention is
30 performed using conventional conditions (*e.g.*, at a pH in the range pH 6.0 - 9.0). In some preferred embodiments, the pH range is 6.0 to 8.5. In further embodiments, the temperature is in the range of 20-30° C, while in preferred embodiments, the temperature is in the range of 25-28°C. In some embodiments, the reaction time is in the range of 20-90 minutes, while in other embodiments, it is in the range 40-80 minutes. Processes for the
35 manufacture of leather are well known to those skilled in the art (*See e.g.*, WO 94/069429

- 103 -

WO 90/1121189, U.S. Pat. No. 3,840,433, EP 505920, GB 2233665, and U.S. Pat. No. 3,986,926, all of which are herein incorporated by reference).

In further embodiments, the present invention provides bates comprising at least one protease of the present invention. A bate is an agent or an enzyme-containing preparation comprising the chemically active ingredients for use in beamhouse processes, in particular in the bating step of a process for the manufacture of leather. In some embodiments, the present invention provides bates comprising protease and suitable excipients. In some embodiments, agents including, but not limited to chemicals known and used in the art, e.g. diluents, emulgators, delimers and carriers. In some embodiments, the bate comprising at least one protease of the present invention is formulated as known in the art (*See e.g.*, GB-A2250289, WO 96/11285, and EP 0784703).

In some embodiments, the bate of the present invention contains from 0.00005 to 0.01 g of active protease per g of bate, while in other embodiments, the bate contains from 0.0002 to 0.004 g of active protease per g of bate.

Thus, the proteases of the present invention find use in numerous applications and settings.

EXPERIMENTAL

The present invention is described in further detail in the following Examples which are not in any way intended to limit the scope of the invention as claimed. The attached Figures are meant to be considered as integral parts of the specification and description of the invention. All references cited are herein specifically incorporated by reference for all that is described therein. The following Examples are offered to illustrate, but not to limit the claimed invention

In the experimental disclosure which follows, the following abbreviations apply: PI (proteinase inhibitor), ppm (parts per million); M (molar); mM (millimolar); μ M (micromolar); nM (nanomolar); mol (moles); mmol (millimoles); μ mol (micromoles); nmol (nanomoles); gm (grams); mg (milligrams); μ g (micrograms); pg (picograms); L (liters); ml and mL (milliliters); μ l and μ L (microliters); cm (centimeters); mm (millimeters); μ m (micrometers); nm (nanometers); U (units); V (volts); MW (molecular weight); sec (seconds); min(s) (minute/minutes); h(s) and hr(s) (hour/hours); °C (degrees Centigrade); QS (quantity sufficient); ND (not done); NA (not applicable); rpm (revolutions per minute); H₂O (water); dH₂O (deionized water); HCl (hydrochloric acid); aa (amino acid); bp (base pair); kb (kilobase pair); kD (kilodaltons); cDNA (copy or complementary DNA); DNA

- 104 -

(deoxyribonucleic acid); ssDNA (single stranded DNA); dsDNA (double stranded DNA); dNTP (deoxyribonucleotide triphosphate); RNA (ribonucleic acid); $MgCl_2$ (magnesium chloride); NaCl (sodium chloride); w/v (weight to volume); v/v (volume to volume); *g* (gravity); OD (optical density); Dulbecco's phosphate buffered solution (DPBS); SOC (2% Bacto-Tryptone, 0.5% Bacto Yeast Extract, 10 mM NaCl, 2.5 mM KCl); Terrific Broth (TB; 12 g/l Bacto Tryptone, 24 g/l glycerol, 2.31 g/l KH_2PO_4 , and 12.54 g/l K_2HPO_4); OD₂₈₀ (optical density at 280 nm); OD₆₀₀ (optical density at 600 nm); A₄₀₅ (absorbance at 405 nm); V_{max} (the maximum initial velocity of an enzyme catalyzed reaction); PAGE (polyacrylamide gel electrophoresis); PBS (phosphate buffered saline [150 mM NaCl, 10 mM sodium phosphate buffer, pH 7.2]); PBST (PBS+0.25% TWEEN® 20); PEG (polyethylene glycol); PCR (polymerase chain reaction); RT-PCR (reverse transcription PCR); SDS (sodium dodecyl sulfate); Tris (tris(hydroxymethyl)aminomethane); HEPES (N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]); HBS (HEPES buffered saline); SDS (sodium dodecylsulfate); Tris-HCl (tris[Hydroxymethyl]aminomethane-hydrochloride); Tricine (N-[tris-(hydroxymethyl)-methyl]-glycine); CHES (2-(N-cyclo-hexylamino) ethane-sulfonic acid); TAPS (3-[[tris-(hydroxymethyl)-methyl]-amino]-propanesulfonic acid); CAPS (3-(cyclo-hexylamino)-propane-sulfonic acid); DMSO (dimethyl sulfoxide); DTT (1,4-dithio-DL-threitol); SA (sinapinic acid (s,5-dimethoxy-4-hydroxy cinnamic acid); TCA (trichloroacetic acid); Glut and GSH (reduced glutathione); GSSG (oxidized glutathione); TCEP (Tris[2-carboxyethyl] phosphine); Ci (Curies); mCi (milliCuries); μ Ci (microCuries); HPLC (high pressure liquid chromatography); RP-HPLC (reverse phase high pressure liquid chromatography); TLC (thin layer chromatography); MALDI-TOF (matrix-assisted laser desorption/ionization--time of flight); Ts (tosyl); Bn (benzyl); Ph (phenyl); Ms (mesyl); Et (ethyl), Me (methyl); *Taq* (*Thermus aquaticus* DNA polymerase); Klenow (DNA polymerase I large (Klenow) fragment); rpm (revolutions per minute); EGTA (ethylene glycol-bis(β -aminoethyl ether) N, N, N', N'-tetraacetic acid); EDTA (ethylenediaminetetracetic acid); bla (β -lactamase or ampicillin-resistance gene); HDL (heavy duty liquid detergent, *i.e.*, laundry detergent); MJ Research (MJ Research, Reno, NV); Baseclear (Baseclear BV, Inc., Leiden, the Netherlands); PerSeptive (PerSeptive Biosystems, Framingham, MA); ThermoFinnigan (ThermoFinnigan, San Jose, CA); Argo (Argo BioAnalytica, Morris Plains, NJ); Seitz EKS (SeitzSchenk Filtersystems GmbH, Bad Kreuznach, Germany); Pall (Pall Corp., East Hills, NY); Spectrum (Spectrum Laboratories, Dominguez Rancho, CA); Molecular Structure (Molecular Structure Corp., Woodlands, TX); Accelrys (Accelrys, Inc., San Diego, CA); Chemical Computing (Chemical Computing Corp., Montreal, Canada); New Brunswick (New Brunswick Scientific, Co., Edison, NJ); CFT (Center for Test Materials, Vlaardingeng, the

- 105 -

Netherlands); Procter & Gamble (Procter & Gamble, Inc., Cincinnati, OH); GE Healthcare (GE Healthcare, Chalfont St. Giles, United Kingdom); DNA2.0 (DNA2.0, Menlo Park, CA); OXOID (Oxoid, Basingstoke, Hampshire, UK); Megazyme (Megazyme International Ireland Ltd., Bray Business Park, Bray, Co., Wicklow, Ireland); Finnzymes (Finnzymes Oy, Espoo, Finland); Kelco (CP Kelco, Wilmington, DE); Corning (Corning Life Sciences, Corning, NY); (NEN (NEN Life Science Products, Boston, MA); Pharma AS (Pharma AS, Oslo, Norway); Dynal (Dynal, Oslo, Norway); Bio-Synthesis (Bio-Synthesis, Lewisville, TX); ATCC (American Type Culture Collection, Rockville, MD); Gibco/BRL (Gibco/BRL, Grand Island, NY); Sigma (Sigma Chemical Co., St. Louis, MO); Pharmacia (Pharmacia Biotech, Piscataway, NJ); NCBI (National Center for Biotechnology Information); Applied Biosystems (Applied Biosystems, Foster City, CA); BD Biosciences and/or Clontech (BD Biosciences CLONTECH Laboratories, Palo Alto, CA); Operon Technologies (Operon Technologies, Inc., Alameda, CA); MWG Biotech (MWG Biotech, High Point, NC); Oligos Etc (Oligos Etc. Inc, Wilsonville, OR); Bachem (Bachem Bioscience, Inc., King of Prussia, PA); Difco (Difco Laboratories, Detroit, MI); Mediatech (Mediatech, Herndon, VA); Santa Cruz (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); Oxoid (Oxoid Inc., Ogdensburg, NY); Worthington (Worthington Biochemical Corp., Freehold, NJ); GIBCO BRL or Gibco BRL (Life Technologies, Inc., Gaithersburg, MD); Millipore (Millipore, Billerica, MA); Bio-Rad (Bio-Rad, Hercules, CA); Invitrogen (Invitrogen Corp., San Diego, CA); NEB (New England Biolabs, Beverly, MA); Sigma (Sigma Chemical Co., St. Louis, MO); Pierce (Pierce Biotechnology, Rockford, IL); Takara (Takara Bio Inc., Otsu, Japan); Roche (Hoffmann-La Roche, Basel, Switzerland); EM Science (EM Science, Gibbstown, NJ); Qiagen (Qiagen, Inc., Valencia, CA); Biodesign (Biodesign Intl., Saco, Maine); Aptagen (Aptagen, Inc., Herndon, VA); Sorvall (Sorvall brand, from Kendro Laboratory Products, Asheville, NC); Molecular Devices (Molecular Devices, Corp., Sunnyvale, CA); R&D Systems (R&D Systems, Minneapolis, MN); Stratagene (Stratagene Cloning Systems, La Jolla, CA); Marsh (Marsh Biosciences, Rochester, NY); Bio-Tek (Bio-Tek Instruments, Winooski, VT); Biacore (Biacore, Inc., Piscataway, NJ); PeproTech (PeproTech, Rocky Hill, NJ); SynPep (SynPep, Dublin, CA); New Objective (New Objective brand; Scientific Instrument Services, Inc., Ringoes, NJ); Waters (Waters, Inc., Milford, MA); Matrix Science (Matrix Science, Boston, MA); Dionex (Dionex, Corp., Sunnyvale, CA); Monsanto (Monsanto Co., St. Louis, MO); Wintershall (Wintershall AG, Kassel, Germany); BASF (BASF Co., Florham Park, NJ); Huntsman (Huntsman Petrochemical Corp., Salt Lake City, UT); Enichem (Enichem Iberica, Barcelona, Spain); Fluka Chemie AG (Fluka Chemie AG, Buchs, Switzerland); Gist-Brocades (Gist-Brocades, NV, Delft, the Netherlands); Dow Corning (Dow Corning Corp., Midland, MI); and

- 106 -

Microsoft (Microsoft, Inc., Redmond, WA).

EXAMPLE 1

Assays

In the following Examples, various assays were used, such as protein determinations, application-based tests, and stability-based tests. For ease in reading, the following assays are set forth below and referred to in the respective Examples. Any deviations from the protocols provided below in any of the experiments performed during the development of the present invention are indicated in the Examples.

Some of the detergents used in the following Examples had the following compositions. In Compositions I and II, the balance (to 100%) is perfume/dye and/or water. The pH of these compositions was from about 5 to about 7 for Composition I, and about 7.5 to about 8.5 Composition II. In Composition III, the balance (to 100%) comprised of water and/or the minors perfume, dye, brightener/SRPI/sodium carboxymethylcellulose/photobleach/MgSO₄/PVPVI/suds suppressor/high molecular PEG/clay.

DETERGENT COMPOSITIONS		
	Composition I	Composition II
LAS	24.0	8.0
C ₁₂ -C ₁₅ AE _{1.8} S	-	11.0
C ₈ -C ₁₀ propyl dimethyl amine	2.0	2.0
C ₁₂ -C ₁₄ alkyl dimethyl amine oxide	-	-
C ₁₂ -C ₁₅ AS	-	7.0
CFAA	-	4.0
C ₁₂ -C ₁₄ Fatty alcohol ethoxylate	12.0	1.0
C ₁₂ -C ₁₈ Fatty acid	3.0	4.0
Citric acid (anhydrous)	6.0	3.0
DETPMP	-	1.0
Monoethanolamine	5.0	5.0
Sodium hydroxide	-	1.0
1 N HCl aqueous solution	#1	-

- 107 -

Propanediol	12.7	10.
Ethanol	1.8	5.4
DTPA	0.5	0.4
Pectin Lyase	-	0.005
Lipase	0.1	-
Amylase	0.001	-
Cellulase	-	0.0002
Protease A	-	-
Aldose Oxidase	-	-
DETCHD	-	0.01
SRP1	0.5	0.3
Boric acid	2.4	2.8
Sodium xylene sulfonate	-	-
DC 3225C	1.0	1.0
2-butyl-octanol	0.03	0.03
Brightener 1	0.12	0.08

Composition III

C ₁₄ -C ₁₅ AS or sodium tallow alkyl sulfate	3.0
LAS	8.0
C ₁₂ -C ₁₅ AE ₃ S	1.0
C ₁₂ -C ₁₅ E ₅ or E ₃	5.0
QAS	-
Zeolite A	11.0
SKS-6 (dry add)	9.0
MA/AA	2.0
AA	-
3Na Citrate 2H ₂ O	-
Citric Acid (Anhydrous)	1.5
DTPA	-
EDDS	0.5
HEDP	0.2
PB1	-

- 108 -

Composition III

Percarbonate	3.8
NOBS	-
NACA OBS	2.0
TAED	2.0
BB1	0.34
BB2	-
Anhydrous Na Carbonate	8.0
Sulfate	2.0
Silicate	-
Protease B	-
Protease C	-
Lipase	-
Amylase	-
Cellulase	-
Pectin Lyase	0.001
Aldose Oxidase	0.05
PAAC	-

A. TCA Assay for Protein Content Determination in 96-well Microtiter Plates

5 This assay was started using filtered culture supernatant from microtiter plates grown 4 days at 33 °C with shaking at 230 RPM and humidified aeration. A fresh 96-well flat bottom plate was used for the assay. First, 100 µL/well of 0.25 N HCl were placed in the wells. Then, 50 µL filtered culture broth were added to the wells. The light scattering/absorbance at 405 nm (use 5 sec mixing mode in the plate reader) was then
 10 determined, in order to provide the "blank" reading.

For the test, 100 µL/well 15% (w/v) TCA was placed in the plates and incubated between 5 and 30 min at room temperature. The light scattering/absorbance at 405 nm (use 5 sec mixing mode in the plate reader) was then determined.

The calculations were performed by subtracting the blank (*i.e.*, no TCA) from the test
 15 reading with TCA. If desired, a standard curve can be created by calibrating the TCA readings with AAPF assays of clones with known conversion factors. However, the TCA results are linear with respect to protein concentration from 50 to 500 ppm and can thus be

- 109 -

plotted directly against enzyme performance for the purpose of choosing good-performing variants.

5 **B. suc-AAPF-pNA Assay of Proteases in 96-well Microtiter Plates**

In this assay system, the reagent solutions used were:

1. 100 mM Tris/HCl, pH 8.6, containing 0.005% TWEEN®-80 (Tris buffer)
2. 100 mM Tris buffer, pH 8.6, containing 10 mM CaCl₂ and 0.005% TWEEN®-80 (Tris buffer)
3. 160 mM suc-AAPF-pNA in DMSO (suc-AAPF-pNA stock solution) (Sigma: S-7388)

10 To prepare suc-AAPF-pNA working solution, 1 ml AAPF stock was added to 100 ml Tris/Ca buffer and mixed well for at least 10 seconds.

The assay was performed by adding 10 µl of diluted protease solution to each well, followed by the addition (quickly) of 190 µl 1 mg/ml AAPF-working solution. The solutions were mixed for 5 sec., and the absorbance change was read at 410 nm in
15 an MTP reader, at 25°C. The protease activity was expressed as AU (activity = $\delta\text{OD} \cdot \text{min}^{-1} \cdot \text{ml}^{-1}$).

20 **C. Keratin Hydrolysis Assay**

In this assay system, the chemical and reagent solutions used were:

Keratin	ICN 902111
Detergent	Detergent Composition II
25	1.6 g. detergent is dissolved in 1000 ml water (pH = 8.2)
	0.6 ml. CaCl ₂ /MgCl ₂ of 10,000 gpg is added as well as 1190 mg HEPES, giving a hardness and buffer strength of 6 gpg and 5 mM respectively. The pH is adjusted to 8.2 with NaOH.
Picrylsulfonic acid (TNBS)	
30	Sigma P-2297 (5% solution in water)
Reagent A	45.4 g Na ₂ B ₄ O ₇ · 10 H ₂ O (Merck 6308) and 15 ml of 4N NaOH are dissolved together to a final volume of 1000 ml (by heating if needed)
Reagent B	35.2 g NaH ₂ PO ₄ · 1H ₂ O (Merck 6346) and 0.6 g Na ₂ SO ₃ (Merck 6657) are dissolved together to a final volume of 1000 ml.

35 **Method:**

Prior to the incubations, keratin was sieved on a 100 µm sieve in small portions at a

- 110 -

time. Then, 10 g of the < 100 μ m keratin was stirred in detergent solution for at least 20 minutes at room temperature with regular adjustment of the pH to 8.2. Finally, the suspension was centrifuged for 20 minutes at room temperature (Sorvall, GSA rotor, 13,000 rpm). This procedure was then repeated. Finally, the wet sediment was suspended in
5 detergent to a total volume of 200 ml., and the suspension was kept stirred during pipetting. Prior to incubation, microtiter plates (MTPs) were filled with 200 μ l substrate per well with a Biohit multichannel pipette and 1200 μ l tip (6 dispenses of 200 μ l and dispensed as fast as possible to avoid settling of keratin in the tips). Then, 10 μ l of the filtered culture was added to the substrate containing MTPs. The plates were covered with tape, placed in an incubator
10 and incubated at 20 °C for 3 hours at 350 rpm (Innova 4330 [New Brunswick]). Following incubation, the plates were centrifuged for 3 minutes at 3000 rpm (iSigma 6K 15 centrifuge). About 15 minutes before removal of the 1st plate from the incubator, the TNBS reagent was prepared by mixing 1 ml TNBS solution per 50 ml of reagent A.

MTPs were filled with 60 μ l TNBS reagent A per well. From the incubated plates, 10
15 μ l was transferred to the MTPs with TNBS reagent A. The plates were covered with tape and shaken for 20 minutes in a bench shaker (BMG ThermoStar) at room temperature and 500 rpm. Finally, 200 μ l of reagent B was added to the wells, mixed for 1 minute on a shaker, and the absorbance at 405 nm was measured with the MTP-reader.

20 **Calculation of the Keratin Hydrolyzing Activity:**

The obtained absorbance value was corrected for the blank value (substrate without enzyme). The resulting absorbance provides a measure for the hydrolytic activity. For each sample (variant) the performance index was calculated. The performance index compares the performance of the variant (actual value) and the standard enzyme (theoretical value) at
25 the same protein concentration. In addition, the theoretical values can be calculated, using the parameters of the Langmuir equation of the standard enzyme. A performance index (PI) that is greater than 1 ($PI > 1$) identifies a better variant (as compared to the standard [e.g., wild-type]), while a PI of 1 ($PI = 1$) identifies a variant that performs the same as the standard, and a PI that is less than 1 ($PI < 1$) identifies a variant that performs worse than the standard.
30 Thus, the PI identifies winners, as well as variants that are less desirable for use under certain circumstances.

D. Microswatch Assay for Testing Protease Performance

35 All of the detergents used in these assays did not contain enzymes.

- 111 -

Detergent Preparations:**1. European Detergent Solution:**

5 Milli-Q water was adjusted to 15 gpg water hardness (Ca/Mg=4/1), add 7.6 g/l ARIEL® Regular detergent and stir the detergent solution vigorously for at least 30 minutes. The detergent was filtered before use in the assay through a 0.22µm filter (e.g. Nalgene top bottle filter).

2. Japanese Detergent Solution

10 Milli-Q water was adjusted to 3 gpg water hardness (Ca/Mg=3/1), add 0.66 g/l Detergent Composition III, the detergent solution was stirred vigorously for at least 30 minutes. The detergent was filtered before use in the assay through a 0.22µm filter (e.g. Nalgene top bottle filter).

3. Cold Water Liquid Detergent (US Conditions):

15 Milli-Q water was adjusted to 6 gpg water hardness (Ca/Mg=3/1), add 1.60 g/l TIDE® LVJ-1 detergent and stir the detergent solution vigorously for at least 15 minutes. Add 5mM Hepes buffer and set pH at 8.2. The detergent was filtered before use in the assay through a 0.22µm filter (e.g. Nalgene top bottle filter).

4. Low pH Liquid Detergent (US Conditions):

20 Milli-Q water was adjusted to 6 gpg water hardness (Ca/Mg=3/1), 1.60 g/l Detergent Composition I, was added and the detergent solution stirred vigorously for at least 15 minutes. The pH was set at 6.0 using 1N NaOH solution. The detergent was filtered before use in the assay through a 0.22µm filter (e.g. Nalgene top bottle filter).

Microswatches:

30 Microswatches of ¼" circular diameter were ordered and delivered by CFT Vlaardingen. The microswatches were pretreated using the fixation method described below. Single microswatches were placed in each well of a 96-well microtiter plate vertically to expose the whole surface area (i.e., not flat on the bottom of the well).

Bleach Fixation ("Superfixed"):

- 112 -

In a 10 L stainless steel beaker containing 10L of water, the water was heated to 60°C for fixation of swatches used in European conditions (=Super fixed). For Japanese condition(s) and other conditions, the swatches were fixed at room temperature (=3K). Then, 10 ml of 30% hydrogen peroxide (1 ml/L of H₂O₂, final conc. of H₂O₂ is 300 ppm) were added. Then, 100 swatches (10 swatches/L) were added to the solution. The solution was allowed to sit for 30 minutes with occasional stirring and monitoring of the temperature. The swatches were rinsed 7-8 times with cold water and placed on bench to dry. A towel was placed on top of swatches, as this prevents the swatches from curling up. For the 3K swatches, the procedure is repeated (except the water was not heated and 10x the amount of hydrogen peroxide was added).

Alternative Fixation ("3K" Swatch Fixation):

This particular swatch fixation was done at room temperature, however the amount of 30% H₂O₂ added is 10X more than in the Superfixed Swatch Fixation. Bubble formation (frothing) will be visible and therefore it is necessary to use a bigger beaker to account for this. First, 8 liters of distilled water are placed in a 10 L beaker, and 80 ml of 30% hydrogen peroxide are added. The water and peroxide are mixed well with a ladle. Then, 40 pieces of EMPA 116 swatches were spread into a fan before adding into the solution to ensure uniform fixation. The swatches were swirled in the solution (using the ladle) for 30 minutes, continuously for the first five minutes and occasionally for the remaining 25 minutes. The solution was discarded and the swatches were rinsed 6 times with approximately 6 liters of distilled water each time. The swatches were placed on top of paper towels to dry. The air-dried swatches were punched using a ¼" circular die on an expulsion press. A single microswatch was placed vertically into each well of a 96-well microtiter plate to expose the whole surface area (i.e. not flat on the bottom of the well).

Enzyme Samples:

The enzyme samples were tested at appropriate concentrations for the respective geography, and diluted in 10 mM NaCl, 0.005% TWEEN®-80 solution.

Test Method:

The incubator was set at the desired temperature: 20°C for cold water liquid conditions; 30°C for low-pH liquid conditions; 40°C for European conditions; 20°C for Japanese and North American conditions. The pretreated and precut swatches were placed into the wells of a 96-well MTP, as described above. The enzyme samples were diluted, if

- 113 -

needed, in 10 mM NaCl, 0.005% TWEEN®-80 to 20x the desired concentration. The desired detergent solutions were prepared as described above. Then, 190 µl of detergent solution were added to each well of the MTP. To this mixture, 10 µl of enzyme solution were added to each well (to provide a total volume to 200 µl/well). The MTP was sealed with a plate sealer and placed in an incubator for 60 minutes, with agitation at 350 rpm. Following incubation under the appropriate conditions, 100 µl of solution from each well were removed and placed into a fresh MTP. The new MTP containing 100 µl of solution/well was read at 405 nm in a MTP reader. Blank controls, as well as a control containing a microswatch and detergent but no enzyme were also included.

Table 1-1 Detergent Composition and Incubation Conditions in the µSwatch Assay.

Geography	Reference Enzyme	Detergent	Water Hardness	Enzyme Dosage [ppm]	Temp.	Swatch
European	ASP GG36	7.6 g/l ARIEL® Regular	15 gpg – Ca/Mg:4/1	0.5 - 4	40°	Superfix
Japanese	ASP GG36	0.66 g/l Detergent Comp. III	3 gpg – Ca/Mg:3/1	0.5 - 4	20°	3K
Cold Water Liquid	ASP	1.6 g/l Tide® LVJ-1	6 gpg - Ca/Mg :3/1	0.5 - 4	20°	3K
Liquid Detergent Comp. I	ASP	1.6 g/l Detergent Comp. I	6 gpg - Ca/Mg:3/1	0.5 - 4	30°	3K

** The stock solution was used at a concentration of 15,000 gpg

stock #1 = Ca/Mg 3:1

(1.92 M Ca^{2+} = 282.3 g/L $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; 0.64 M Mg^{2+} = 30.1 g/L $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$)

stock #2 = Ca/Mg 4:1

(2.05 M Ca^{2+} = 301.4 g/L $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; 0.51 M Mg^{2+} = 103.7 g/L $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$)

Calculation of the BMI Performance:

The obtained absorbance value was corrected for the blank value (obtained after incubation of microswatches in the absence of enzyme). The resulting absorbance was a measure for the hydrolytic activity. For each sample (variant) the performance index was

- 114 -

calculated. The performance index compares the performance of the variant (actual value) and the standard enzyme (theoretical value) at the same protein concentration. In addition, the theoretical values can be calculated, using the parameters of the Langmuir equation of the standard enzyme. A performance index (PI) that is greater than 1 ($PI > 1$) identifies a better variant (as compared to the standard [e.g., wild-type]), while a PI of 1 ($PI = 1$) identifies a variant that performs the same as the standard, and a PI that is less than 1 ($PI < 1$) identifies a variant that performs worse than the standard.

Thus, the PI identifies winners, as well as variants that are less desirable for use under certain circumstances.

D. Dimethylcasein Hydrolysis Assay (96 wells)

In this assay system, the chemical and reagent solutions used were:

Dimethylcasein (DMC):	Sigma C-9801
TWEEN®-80:	Sigma P-8074
PIPES buffer (free acid):	Sigma P-1851; 15.1 g is dissolved in about 960 ml water; pH is adjusted : to 7.0 with 4N NaOH, 1 ml 5% TWEEN®- 80 is added and the volume brought up to 1000 ml. The final concentration of PIPES and TWEEN®-80 is 50 mM and 0.005% respectively.
Picrylsulfonic acid (TNBS):	Sigma P-2297 (5% solution in water)
Reagent A:	45.4 g $\text{Na}_2\text{B}_4\text{O}_7 \cdot 10 \text{H}_2\text{O}$ (Merck 6308) and 15 ml of 4N NaOH are dissolved together to a final volume of 1000 ml (by heating if needed)
Reagent B:	35.2 g $\text{NaH}_2\text{PO}_4 \cdot 1\text{H}_2\text{O}$ (Merck 6346) and 0.6 g Na_2SO_3 (Merck 6657) are dissolved together to a final volume of 1000 ml.

Method:

To prepare the substrate, 4 g DMC were dissolved in 400 ml PIPES buffer. The filtered culture supernatants were diluted with PIPES buffer; the final concentration of the controls in the growth plate was 20 ppm. Then, 10 μl of each diluted supernatant were added to 200 μl substrate in the wells of a MTP. The MTP plate was covered with tape, shaken for a few seconds and placed in an oven at 37°C for 2 hours without agitation.

About 15 minutes before removal of the 1st plate from the oven, the TNBS reagent was prepared by mixing 1 ml TNBS solution per 50 ml of reagent A. MTPs were filled with 60 μl TNBS reagent A per well. The incubated plates were shaken for a few seconds, after which 10 μl were transferred to the MTPs with TNBS reagent A. The plates were covered with tape and shaken for 20 minutes in a bench shaker (BMG ThermoStar) at room temperature

- 115 -

and 500 rpm. Finally, 200 µl reagent B were added to the wells, mixed for 1 minute on a shaker, and the absorbance at 405 nm was determined using an MTP-reader.

Calculation of Dimethylcasein Hydrolyzing Activity:

The obtained absorbance value was corrected for the blank value (substrate without enzyme). The resulting absorbance is a measure for the hydrolytic activity. The (arbitrary) specific activity of a sample was calculated by dividing the absorbance and the determined protein concentration.

E. Thermostability Assay

This assay is based on the dimethylcasein hydrolysis, before and after heating of the buffered culture supernatant. The same chemical and reagent solutions were used as described in the dimethylcasein hydrolysis assay.

Method:

The filtered culture supernatants were diluted to 20 ppm in PIPES buffer (based on the concentration of the controls in the growth plates). Then, 50 µl of each diluted supernatant were placed in the empty wells of a MTP. The MTP plate was incubated in an iEMS incubator/shaker HT (Thermo Labsystems) for 90 minutes at 60°C and 400 rpm. The plates were cooled on ice for 5 minutes. Then, 10 µl of the solution was added to a fresh MTP containing 200 µl dimethylcasein substrate/well. This MTP was covered with tape, shaken for a few seconds and placed in an oven at 37 °C for 2 hours without agitation. The same detection method as used for the DMC hydrolysis assay was used.

Calculation of Thermostability:

The residual activity of a sample was expressed as the ratio of the final absorbance and the initial absorbance, both corrected for blanks.

F. LAS Stability Assay

LAS stability was measured after incubation of the test protease in the presence of 0.06% LAS (dodecylbenzenesulfonate sodium), and the residual activity was determined using the AAPF assay.

- 116 -

Reagents:

Dodecylbenzenesulfonate, Sodium salt (=LAS): Sigma D-2525

TWEEN®-80: Sigma P-8074

TRIS buffer (free acid): Sigma T-1378); 6.35 g is dissolved in about 960 ml water; pH is adjusted to 8.2 with 4N HCl. Final concentration of TRIS is 52.5 mM.

LAS stock solution: Prepare a 10.5 % LAS solution in MQ water (=10.5 g per 100 ml MQ)

TRIS buffer-100 mM / pH 8.6 (100mM Tris/0.005% Tween80)

TRIS-Ca buffer, pH 8.6 (100mM Tris/10mM CaCl₂/0.005% Tween80)

Hardware:

Flat bottom MTPs: Costar (#9017)

Biomek FX

ASYS Multipipettor

Spectramax MTP Reader

iEMS Incubator/Shaker

Innova 4330 Incubator/Shaker

Biohit multichannel pipette

BMG ThermoStar Shaker

Method:

A 10 µl 0.063% LAS solution was prepared in 52.5 mM Tris buffer pH 8.2. The AAPF working solution was prepared by adding 1 ml of 100 mg/ml AAPF stock solution (in DMSO) to 100 ml (100 mM) TRIS buffer, pH 8.6. To dilute the supernatants, flat-bottomed plates were filled with dilution buffer and an aliquot of the supernatant was added and mixed well. The dilution ratio depended on the concentration of the ASP-controls in the growth plates (AAPF activity). The desired protein concentration was 80 ppm.

Ten µl of the diluted supernatant was added to 190 µl 0.063% LAS buffer/well. The MTP was covered with tape, shaken for a few seconds and placed in an incubator (Innova 4230) at 25°C, for 60 minutes at 200 rpm agitation. The initial activity ($t=10$ minutes) was determined after 10 minutes of incubation by transferring 10 µl of the mixture in each well to a fresh MTP containing 190µl AAPF work solution. These solutions were mixed well and the AAPF activity was measured using a MTP Reader (20 readings in 5 minutes and 25°C).

The final activity ($t=60$ minutes) was determined by removing another 10 µl of solution from the incubating plate after 60 minutes of incubation. The AAPF activity was then determined as described above. The calculations were performed as follows: the % Residual Activity was $[t=60 \text{ value}] * 100 / [t=10 \text{ value}]$.

G. Scrambled Egg Hydrolysis Assay

Proteases release insoluble particles from scrambled egg, which was baked into the

- 117 -

wells of 96-well microtiter plates. The scrambled egg coated wells were treated with a mixture of protease containing culture filtrate and ADW (automatic dishwash detergent) to determine the enzyme performance in scrambled egg removal. The rate of turbidity is a measure of the enzyme activity.

Materials:

Water bath
Oven with mechanical air circulation (Mettmert ULE 400)
Incubator/shaker with amplitude of 0.25 cm (Multitron), equipped with MTP-holders and
aluminum covers and bottoms
Biomek FX liquid-handling system (Beckman)
Micro plate reader (Molecular Devices Spectramax 340, SOFTmax Pro Software)
Nichiryo 8800 multi channel syringe dispenser + syringes
Micro titer plate tape
Single and multi channel pipettes with tips
Grade A medium eggs
CaCl₂·2H₂O (Merck 102382); MgCl₂·6H₂O (Merck 105833); Na₂CO₃ (Merck 6392)
ADW product:
LH-powder (= Light House)

Procedure:

Three eggs were stirred with a fork in a glass beaker and 100 ml milk (at 4°C or room temperature) was added. The beaker was placed in an 85°C water bath, and the mixture was stirred constantly with a spoon. As the mixture became thicker, care was taken to scrape the solidifying material continuously from the walls and bottom of the beaker. When the mixture was slightly runny (after about 25 minutes) the beaker was removed from the bath. Another 40 ml milk was added to the mixture and blended with a hand mixer or blender for 2 minutes. The mixture was cooled to room temperature (an ice bath can be used). The substrate was then stirred with an additional amount of 5 to 15% water (usually 7.5%).

Test Method:

First, 50 µl of scrambled egg substrate were dispensed into each well of a MTP. The plates were allowed to dry at room temperature overnight (about 17 hours), baked in oven at 80°C for 2 hours, then cooled to room temperature.

ADW product solution was prepared by dissolving 2.85 g of LH-powder into 1L water. Only about 15 minutes dissolution time was needed and filtration of the solution was not needed. Then, 1.16 mL artificial hardness solution was added and 2120 mg Na₂CO₃

- 118 -

was dissolved in the solution.

Hardness solution was prepared by mixing 188.57g $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ and 86.92g $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ in 1L demi water (equal to 1.28 M Ca + 0.43 M Mg and totally 10000 gpg). The above-mentioned amounts of ADW, CaCl_2 and MgCl_2 were already proportionally increased values (200/190x) because of the addition of 10 μl supernatant to 190 μl ADW solution.

ADW solution (190 μl) was added to each well of the substrate plate. The MTPs were processed by adding 10 μl of supernatant to each well and sealing the plate with tape. The plate was placed in a pre-warmed incubator/shaker and secured with a metal cover and clamp. The plate was then washed for 30 minutes at the appropriate temperature (50°C for US) at 700 rpm. The plate was removed from the incubator/shaker. With gentle up and down movements of the liquid, about 125 μl of the warm supernatant were transferred to an empty flat bottom plate. After cooling, exactly 100 μl of the dispersion was dispensed into the wells of an empty flat bottom plate. The absorbance at 405 nm was determined using a microtiter plate reader.

Calculation of the Scrambled Egg Hydrolyzing Activity:

The obtained absorbance value was corrected for the blank value (substrate without enzyme). The resulting absorbance is a measure for the hydrolytic activity. For each sample (variant) the performance index was calculated. The performance index compares the performance of the variant (actual value) and the standard enzyme (theoretical value) at the same protein concentration. In addition, the theoretical values can be calculated, using the parameters of the Langmuir equation of the standard enzyme. A performance index (PI) that is greater than 1 ($\text{PI} > 1$) identifies a better variant (as compared to the standard [e.g., wild-type]), while a PI of 1 ($\text{PI} = 1$) identifies a variant that performs the same as the standard, and a PI that is less than 1 ($\text{PI} < 1$) identifies a variant that performs worse than the standard. Thus, the PI identifies winners, as well as variants that are less desirable for use under certain circumstances.

EXAMPLE 2

Production of 69B4 protease From the Gram-Positive Alkaliphilic Bacterium 69B4

This Example provides a description of the *Cellulomonas* strain 69B4 used to initially isolate the novel protease 69B4 provided by the present invention. The alkaliphilic micro-organism *Cellulomonas* strain 69B.4, (DSM 16035) was isolated at 37°C on an alkaline

- 119 -

casein medium containing (g L^{-1}) (See e.g., Duckworth *et al.*, FEMS Microbiol. Ecol., 19:181-191 [1996]).

	Glucose (Merck 1.08342)	10
5	Peptone (Difco 0118)	5
	Yeast extract (Difco 0127)	5
	K_2HPO_4	1
	$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	0.2
	NaCl	40
10	Na_2CO_3	10
	Casein	20
	Agar	20

15 An additional alkaline cultivation medium (Grant Alkaliphile Medium) was also used to cultivate Cellulomonas strain 69B.4, as provided below:

Grant Alkaliphile Medium ("GAM") solution A (g L^{-1})

	Glucose (Merck 1.08342)	10
	Peptone (Difco 0118)	5
20	Yeast extract (Difco 0127)	5
	K_2HPO_4	1
	$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	0.2

Dissolved in 800 ml distilled water and sterilized by autoclaving

25 GAM solution B (g L^{-1})

	NaCl	40
	Na_2CO_3	10

Dissolved in 200 ml distilled water and sterilized by autoclaving.

30 Complete GAM medium was prepared by mixing Solution A (800 ml) with Solution B (200 ml). Solid medium is prepared by the addition of agar (2% w/v).

Growth Conditions

35 From a freshly thawed glycerol vial of culture (stored as a frozen glycerol (20% v/v, stock stored at -80°C), the micro-organisms were inoculated using an inoculation loop on

- 120 -

Grant Alkaliphile Medium (GAM) described above in agar plates and grown for at least 2 days at 37 °C. One colony was then used to inoculate a 500 ml shake flask containing 100 ml of GAM at pH 10. This flask was then incubated at 37°C in a rotary shaker at 280 rpm for 1-2 days until good growth (according to visual observation) was obtained. Then, 100 ml of
5 broth culture was subsequently used to inoculate a 7 L fermentor containing 5 liters of GAM. The fermentations were run at 37°C for 2-3 days in order to obtain maximal production of protease. Fully aerobic conditions were maintained throughout by injecting air, at a rate of 5 L/min, into the region of the impeller, which was rotating at about 500 rpm. The pH was set at pH 10 at the start, but was not controlled during the fermentation.

Preparation of 69B4 Crude Enzyme Samples

Culture broth was collected from the fermentor, and cells were removed by centrifugation for 30 min at 5000 x g at 10°C. The resulting supernatant was clarified by depth filtration over Seitz EKS (SeitzSchenk Filtersystems). The resulting sterile culture
15 supernatant was further concentrated approximately 10 times by ultra filtration using an ultra filtration cassette with a 10kDa cut-off (Pall Omega 10kDa Minisette; Pall). The resulting concentrated crude 69B4 samples were frozen and stored at -20°C until further use.

Purification

The cell separated culture broth was dialyzed against 20mM (2-(4-morpholino)-
20 ethane sulfonic acid ("MES"), pH 5.4, 1mM CaCl₂ using 8K Molecular Weight Cut Off (MWCO) Spectra-Por7 (Spectrum) dialysis tubing. The dialysis was performed overnight or until the conductivity of the sample was less than or equal to the conductivity of the MES buffer. The dialyzed enzyme sample was purified using a BioCad VISION (Applied Biosystems) with a 10x100mm (7.845 mL) POROS High Density Sulfo-propyl (HS) 20
25 (20micron) cation-exchange column (PerSeptive Biosystems). After loading the enzyme on the previously equilibrated column at 5mL/min, the column was washed at 40mL/min with a pH gradient from 25mM MES, pH 6.2, 1mM CaCl₂ to 25mM (N-[2-hydroxyethyl] piperazine-N'-[2-ethane] sulfonic acid [C₈H₁₈N₂O₄S, CAS # 7365-45-9]) ("HEPES") pH 8.0, 1mM CaCl₂ in 25 column volumes. Fractions (8mL) were collected across the run. The pH 8.0 wash
30 step was held for 5 column volumes and then the enzyme was eluted using a gradient (0-100 mM NaCl in the same buffer in 35 column volumes). Protease activity in the fractions was monitored using the pNA assay (sAAPF-pNA assay; DelMar, *et al.*, *supra*). Protease activity which eluted at 40mM NaCl was concentrated and buffer exchanged (using a 5K MWCO VIVA Science 20mL concentrator) into 20mM MES, pH 5.8, 1mM CaCl₂. This
35 material was used for further characterization of the enzyme.

- 121 -

EXAMPLE 3

PCR Amplification of a Serine Protease Gene Fragment

In this Example, PCR amplification of a serine protease gene fragment is described.

Degenerate Primer Design

Based on alignments of published serine protease amino acid sequences, a range of degenerate primers were designed against conserved structural and catalytic regions. Such regions included those that were highly conserved among the serine proteases, as well as those known to be important for enzyme structure and function.

During the development of the present invention, protein sequences of nine published serine proteases (*Streptogrisin* C homologues) were aligned, as shown in below. The sequences were *Streptomyces griseus* Streptogrisin C (accession no. P52320); alkaline serine protease precursor from *Thermobifida fusca* (accession no. AAC23545); alkaline proteinase (EC 3.4.21.-) from *Streptomyces* sp. (accession no. PC2053); alkaline serine proteinase I from *Streptomyces* sp. (accession no. S34672); serine protease from *Streptomyces lividans* (accession no. CAD4208); putative serine protease from *Streptomyces coelicolor* A3(2) (accession no. NP_625129); putative serine protease from *Streptomyces avermitilis* MA-4680 (accession no. NP_822175); serine protease from *Streptomyces lividans* (accession no. CAD42809); putative serine protease precursor from *Streptomyces coelicolor* A3(2) (accession no. NP_628830). All of these sequences are publicly available from GenBank. These alignments are provided below. In this alignment, two conserved boxes are underlined and shown in bold.

25	AAC23545	(1)	---MNHSSR---RTTSLLEFTAALAAATLVAATTPAS-----
	PC2053	(1)	---MRHTGR-NAIGAAIAASALAFALVPSQAAAN-----DTLTERAEAAV
	S34672	(1)	---MRLKGRTVAIGSALAASALALSLVPANASSELP-----SAETAKADALV
	CAD42808	(1)	MVGRHAAR-SRRAALTALGALVLTALPSAASAAPPVPGPRPAVARTPDA
	NP_625129	(1)	MVGRHAAR-SRRAALTALGALVLTALPSAASAAPPVPGPRPAVARTPDA
30	NP_822175	(1)	MVHRHVG---AGCAGLSVLATLVLTGLPAAAAIEPP-GPAPAPSAVQPLGA
	CAD42809	(1)	MPHRHRHH-RAVGAAVAATAALLVAGLSGSASAGTAPAGSAPTAETLRT
	NP_628830	(1)	MPHRHRHH-RAVGAAVAATAALLVAGLSGSASAGTAPAGSAPTAETLRT
	P52320	(1)	---MERTT-LRRRALVAGTATVAVGALALAGLTGVASADPAATAAPPVSA
35		51	100
	AAC23545	(31)	-----AQELALKRDLGLSDAEVAELRAAEAEAVELEEELRDSLGSDFGGV
	PC2053	(42)	ADLPAGVLDAMERDLGLSEQEAGLKLVAEHDAALLGETLSADLDAFAGSW
	S34672	(45)	EQLPAGMVDAMERDLGVPAAEVGNQLVAEHEAAVLEESLSEDLSGYAGSW
	CAD42808	(50)	ATAPARMLSAMERDLRLAPGQAAARPVNEAEAGTRAGMLRNTLGDRFAGA
40	NP_625129	(50)	ATAPARMLSAMERDLRLAPGQAAARLVNEAEAGTRAGMLRNTLGDRFAGA
	NP_822175	(48)	GNPSTAVLGALQRDLHLTDTAQKTRLVNEAEAGTRAGRLQNALGKHFGAGA
	CAD42809	(50)	DAAPPALLKAMQRDLGIDRRQAERRLVNEAEAGATAGRLRAALGGDFAGA
	NP_628830	(50)	DAAPPALLKAMQRDLGIDRRQAERRLVNEAEAGATAGRLRAALGGDFAGA
	P52320	(47)	DSLSPGMLAALERDLGLDEDAARSRIANEYRAAAVAAGLEKSLGARYAGA
45		101	150
	AAC23545	(76)	YLDADT-TEITVAVTDPAAVSRVDADDVTVDVDFGETALNDFVASLNAI
	PC2053	(92)	LAEGT---ELVVATTSEAAEAITEAGATAEVDHTLAELEDSVKDALDTA

- 122 -

5	S34672	(95)	IVEGTS--EHVVATTDRAEAAEITAAGATATVVEHSLAELEAVKDILDEA	
	CAD42808	(100)	WVSGATSAELTVATTTDAADTAAIEAQGAKAAVVGRLAELRAVKEKLDAA	
	NP_625129	(100)	WVSGATSAELTVATTTDAADTAAIEAQGAKAAVVGRLAELRAVKEKLDAA	
	NP_822175	(98)	WVHGAASADLTATTHATDI PAITAGGATAVVVKTLDDDLKGAKKLD SA	
	CAD42809	(100)	WVRGAESGTLTVATTDAGDVAAIEARGAEAKVVRHSLADLDAAKARLDTA	
10	NP_628830	(100)	WVRGAESGTLTVATTDAGDVAAIEARGAEAKVVRHSLADLDAAKARLDTA	
	P52320	(97)	RVSGAK--ATLTVATTDASEAARI TEAGARAEVVGHS�DRFEGVKKSLDKA	
		151		200
	AAC23545	(125)	ADT--ADPKVTGWYTDLESDAVITTLRGGTPAAEELAERAGLDERAVRI	
	PC2053	(139)	AES-YDITDAPVWYVDVTNGVLLTSD--VTEAEGFVEAAGVNAAVVDI	
15	S34672	(143)	ATA-NPEDAAPVWYVDVTNEVVVLASD--VPAAEAFVAAAGADASTVRV	
	CAD42808	(150)	AVR-TRTRQTPVWYVDVKTNRVTQATG--ASAAA FVEAAGVPAADVGV	
	NP_625129	(150)	AVR-TRTRQTPVWYVDVKTNRVTQATG--ASAAA FVEAAGVPAADVGV	
	NP_822175	(148)	VAHG GTAVNTPVRYVDVRTNRVTQARS--RAAADALIAAAGVDGSLVDV	
	CAD42809	(150)	AAG-LNTADAPVWYVDTRTNTVVVEAIR--PAAARSLTAAAGVDGSLAHV	
20	NP_628830	(150)	AAG-LNTADAPVWYVDTRTNTVVVEAIR--PAAARSLTAAAGVDGSLAHV	
	P52320	(146)	ALD-KAPKNVPVWYVDVAANRVVNAAS--PAAGQAF LKVAGVDRGLVTV	
		201		250
	AAC23545	(173)	VEEDEEPQSLAAIIGGNPYFNGN-YRCSIGFSVRQGSQTGFATAGHCGST	
	PC2053	(186)	QTSDEQPQAFYDLVGGDAYYMGG-GRCSVGFSVTQGSTPGFATAGHCGTV	
25	S34672	(190)	ERSDESPQPFYDLVGGDAYYIGN-GRCSIGFSVRQGSTPGFVTAGHCGSV	
	CAD42808	(197)	RVSPDQPRVLEDLVGGDAYYIDDQARCSIGFSVTKDDQEGFATAGHCGDP	
	NP_625129	(197)	RVSPDQPRVLEDLVGGDAYYIDDQARCSIGFSVTKDDQEGFATAGHCGDP	
	NP_822175	(196)	KVSEDRPRALFDIRGGDAYYIDNTARCSVGFSVTKGNQQGFATAGHCGRA	
	CAD42809	(197)	KNRTERPRTFYDLRGGEAYYINNSSRCSIGFPITKGTQQGFATAGHCDRA	
30	NP_628830	(197)	KNRTERPRTFYDLRGGEAYYINNSSRCSIGFPITKGTQQGFATAGHCGRA	
	P52320	(193)	ARSAEQPRALADIRGGDAYYMNGSGRCSVGFSVTRGTQNGFATAGHCGRV	
		251		300
	AAC23545	(222)	GTRVS----SPSGTVAGSYFPGRDMGWVRITSADTVTPLVNRNGGTVTV	
	PC2053	(235)	GTSTTGYNQAAQGTFEESFP GDDMAWVSVNSDWNTPPTVNE--GE-VTV	
35	S34672	(239)	GNATTGFNRVSQGTFRGSWFPGRDMAWVAVNSNWTPTSLVRNS-GSGVRV	
	CAD42808	(247)	GATTTGYNEADQGTFOASTFP GKDMAWVGVSNDWTATPDVKAEGGEKIQL	
	NP_625129	(247)	GATTTGYNEADQGTFOASTFP GKDMAWVGVSNDWTATPDVKAEGGEKIQL	
	NP_822175	(246)	GAPTAGFNEVAQGTVOASVFP GHDMAWVGVSNDWTATPDVGAAGQNVSI	
	CAD42809	(247)	GSSTTGANRVAQGTFOGSIFPGRDMAWVATNSSWTATPYVLGAGGQNVQV	
40	NP_628830	(247)	GSSTTGANRVAQGTFOGSIFPGRDMAWVATNSSWTATPYVLGAGGQNVQV	
	P52320	(243)	GTTTNGVNVQAQGTFOGSTFPGRDIAWVATNANWTPRPLVNGYGRGDVTV	
		301		350
	AAC23545	(268)	TGSQEAAATGSSVCRSGATTGWRCGTIQSKNQTVRYAEGTVTGLTRTTACA	
	PC2053	(282)	SGSTEAAVGASICRSGSTTGWHCGTIQQHNTSVTYPEGTITGVTRTSVCA	
45	S34672	(288)	TGSTQATVGSSICRSGSTTGWHCGTIQQHNTSVTYPQGTITGVTRTSACA	
	CAD42808	(297)	AGSVEALVGASVCRSGSTTGWHCGTIQQHNTSVTYPEGTV DGLTGTTVCA	
	NP_625129	(297)	AGSVEALVGASVCRSGSTTGWHCGTIQQHNTSVTYPEGTV DGLTGTTVCA	
	NP_822175	(296)	AGSVQAIVGAAICRSGSTTGWHCGTVEEHNTSVTYEEGTV DGLTRTTVCA	
	CAD42809	(297)	TGSTASPVGASVCRSGSTTGWHCGTVQLNTSVTYQEGTISPVRTTTVCA	
50	NP_628830	(297)	TGSTASPVGASVCRSGSTTGWHCGTVQLNTSVTYQEGTISPVRTTTVCA	
	P52320	(293)	AGSTASVVGASVCRSGSTTGWHCGTIQQLNTSVTYPEGTISGVTRTSVCA	
		351		400
	AAC23545	(318)	EGGDSGGPWL TGSQAQGVTSGGTGDCRSGGITFFQPINPLLSYFGLQLVT	
	PC2053	(332)	EPGDSGGSYISGSQAQGVTSGGSGNCTSGGTTYHQPINPLLSAYGLDLVT	
55	S34672	(338)	QPGDSGGSFISGTQAQGVTSGGSGNCSIGGTTFFHQPVNPLLSQYGLTLVR	
	CAD42808	(347)	EPGDSGGPFVSGVQAQGTTSGGSGDCTNGGTTYQPVNPLLSDFGLTLKT	
	NP_625129	(347)	EPGDSGGPFVSGVQAQGTTSGGSGDCTNGGTTYQPVNPLLSDFGLTLKT	
	NP_822175	(346)	EPGDSGGSFVSGSQAQGVTSGGSGDCTRGGTTYQPVNPLLSYGLTLKT	
	CAD42809	(347)	EPGDSGGSFISGSQAQGVTSGGSGDCRTGGGTTYQPINALLQNYGLTLKT	
60	NP_628830	(347)	EPGDSGGSFISGSQAQGVTSGGSGDCRTGGGTTYQPINALLQNYGLTLKT	
	P52320	(343)	EPGDSGGSYISGSQAQGVTSGGSGNCSGGGTTYQPINPLLQAYGLTLVT	
		401		450
	AAC23545	(368)	G-----	
	PC2053	(382)	G-----	
65	S34672	(388)	S-----	
	CAD42808	(397)	TSAATQT PAPQDNAAA-----DAWTAGRVYEVGTTVSYDGVRYRCLQSH	
	NP_625129	(397)	TSAATQT PAPQDNAAA-----DAWTAGRVYEVGTTVSYDGVRYRCLQSH	
	NP_822175	(396)	STAPTDT PSDPVDQSG-----VWAAGRVYEVGAQVTYAGVTYQCLQSH	
	CAD42809	(397)	TGGDDGGGDDGG-----EEP GG-TWAAGTVYQPGDVTYGGATFRCLQGH	
70	NP_628830	(397)	TGGDDGGGDDGGGDDGGEEP GG-TWAAGTVYQPGDVTYGGATFRCLQGH	
	P52320	(393)	SGGGTPTDPPTTPTDPS---GGT WAGVTAYAAGATVTYGGATYRCLQAH	
		451		468
	AAC23545	(369)	-----	(SEQ ID NO: 648)
	PC2053	(383)	-----	(SEQ ID NO: 649)
75				

- 123 -

S34672	(389)	-----	(SEQ ID NO:650)
CAD42808	(441)	QAQGVGSPASVPALWQRV	(SEQ ID NO:651)
NP_625129	(441)	QAQGVGSPASVPALWQRV	(SEQ ID NO:652)
NP_822175	(439)	QAQGVWQPAATPALWQRL	(SEQ ID NO:653)
CAD42809	(441)	QAYAGWEPPNVPALWQRV	(SEQ ID NO:654)
NP_628830	(446)	QAYAGWEPPNVPALWQRV	(SEQ ID NO:655)
P52320	(440)	TAQPGWTPADVPAALWQRV	(SEQ ID NO:656)

Two particular regions were chosen to meet the criteria above, and a forward and a reverse primer were designed based on these amino acid regions. The specific amino acid regions used to design the primers are highlighted in black in the sequences shown in the alignments directly above. Using the genetic code for codon usage, degenerate nucleotide PCR primers were synthesized by MWG-Biotech. The degenerate primer sequences produced were:

forward primer TTGWXCGT_FW: 5' ACNACSGGSTGGCRGTGCGGCAC 3' (SEQ ID NO:10)

reverse primer GDSGGX_RV: 5'-ANGNGCCGCCGGAGTCNCC-3' (SEQ ID NO:11)

As all primers were synthesized in the 5'-3' direction and standard IUB code for mixed base sites was used (*e.g.*, to designate "N" for A/C/T/G). Degenerate primers TTGWXCGT_FW and GDSGGX_RV successfully amplified a 177 bp region from *Cellulomonas* sp. isolate 69B4 by PCR, as described below.

PCR Amplification of a Serine Protease Gene Fragment

Cellulomonas sp. isolate 69B4 genomic DNA was used as a template for PCR amplification of putative serine protease gene fragments using the above-described primers. PCR was carried out using High Fidelity Platinum *Taq* polymerase (Catalog number 11304-102; Invitrogen). Conditions were determined by individual experiments, but typically thirty cycles were run in a thermal cycler (MJ Research). Successful amplification was verified by electrophoresis of the PCR reaction on a 1% agarose TBE gel. A PCR product that was amplified from *Cellulomonas* sp. 69B4 with the primers TTGWXCGT_FW and GDSGGX_RV was purified by gel extraction using the Qiaquick Spin Gel Extraction kit (Catalogue 28704; Qiagen) according to the manufacturer's instructions. The purified PCR product was cloned into the commercially available pCR2.1TOPO vector System (Invitrogen) according to the manufacturer's instructions, and transformed into competent *E.coli* TOP10 cells. Colonies containing recombinant plasmids were visualized using blue/white selection. For rapid screening of recombinant transformants, plasmid DNA was

- 124 -

prepared from cultures of putative positive (*i.e.*, white) colonies. DNA was isolated using the Qiagen plasmid purification kit, and was sequenced by Baseclear. One of the clones contained a DNA insert of 177 bp that showed some homology with several streptogrisin-like protease genes of various *Streptomyces* species and also with serine protease genes from other bacterial species. The DNA and protein coding sequence of this 177 bp fragment is provided in **Fig. 13**.

Sequence Analysis

The sequences were analyzed by BLAST and other protein translation sequence tools. BLAST comparison at the nucleotide level showed various levels of identity to published serine protease sequences. Initially, nucleotide sequences were submitted to BLAST (Basic BLAST version 2.0). The program chosen was "BlastX", and the database chosen was "nr." Standard/default parameter values were employed. Sequence data for putative *Cellulomonas* 69B4 protease gene fragment was entered in FASTA format and the query submitted to BLAST to compare the sequences of the present invention to those already in the database. The results returned for the 177 bp fragment a high number of hits for protease genes from various *Streptomyces* spp., including *S. griseus*, *S. lividans*, *S. coelicolor*, *S. albogriseolus*, *S. platensis*, *S. fradiae*; and *Streptomyces* sp. It was concluded that further analysis of the 177 bp fragment cloned from *Cellulomonas* sp. isolate 69B4 was desired.

EXAMPLE 4

Isolation of a Polynucleotide Sequence from the Genome of *Cellulomonas* 69B4 Encoding a Serine Protease by Inverse PCR

In this Example, experiments conducted to isolate a polynucleotide sequence encoding a serine protease produced by *Cellulomonas* sp. 69B4 are described.

Inverse PCR of *Cellulomonas* sp. 69B4 Genomic DNA to Isolate the Gene Encoding *Cellulomonas* strain 69B4 Protease

Inverse PCR was used to isolate and clone the full-length serine protease gene from *Cellulomonas* sp. 69B4. Based on the DNA sequence of the 177 bp fragment of the *Cellulomonas* protease gene described in Example 3, novel DNA primers were designed:

- 125 -

69B4int_RV1 5'-CGGGGTAGGTGACCGAGGAGTTGAGCGCAGTG-3' (SEQ ID NO:14)
 69B4int_FW2 5'-GCTCGCCGGCAACCAGGCCAGGGCGTCACGTC-3' (SEQ ID NO:15)

Chromosomal DNA of *Cellulomonas* sp. 69B4 was digested with the restriction
 5 enzymes *Apal*, *Bam*HI, *Bss*HII, *Kpn*I, *Nar*I, *Nco*I, *Nhe*I, *Pvu*I, *Sal*I or *Sst*II, purified using the
 Qiagen PCR purification kit (Qiagen, Catalogue # 28106) and self-ligated with T4 DNA
 ligase (Invitrogen) according to the manufacturers' instructions. Ligation mixtures were
 purified using the Qiagen PCR purification kit, and PCR was performed with primers
 69B4int_RV1 and 69B4int_FW2. PCR on DNA fragments that were digested with *Nco*I, and
 10 then self-ligated, resulting in a PCR product of approximately 1.3 kb. DNA sequence
 analysis (BaseClear) revealed that this DNA fragment covers the main part of a
 streptogrisin-like protease gene from *Cellulomonas*. This protease was designated as
 "69B4 protease," and the gene encoding *Cellulomonas* 69B4 protease was designated as
 the "asp gene." The entire sequence of the *asp* gene was derived by additional inverse
 15 PCR reactions with primer 69B4int_FW2 and an another primer: 69B4-for4 (5' AAC GGC
 GGG TTC ATC ACC GCC GGC CAC TGC GGC C 3' {SEQ ID NO:16). Inverse PCR with
 these primers on *Nco*I, *Bss*HII, *Apal* and *Pvu*I digested and self-ligated DNA fragments of
 genomic DNA of *Cellulomonas* sp. 69B4 resulted in the identification of the entire sequence
 of the *asp* gene.

Nucleotide and Amino Acid Sequences

For convenience, various sequences are included below. First, the DNA sequence
 of the *asp* gene (SEQ ID NO:1) provided below encodes the signal peptide (SEQ ID NO:9)
 and the precursor serine protease (SEQ ID NO:7) derived from *Cellulomonas strain 69B4*
 25 (DSM 16035). The initiating polynucleotide encoding the signal peptide of the *Cellulomonas*
 strain 69B4 protease is in bold (ATG).

1	GCGCGCTGCG	CCCACGACGA	CGCCGTCCGC	CGTTCGCCGG	CGTACCTGCG	TTGGCTCACC
	CGCGCGACGC	GGGTGCTGCT	GCGGCAGGCG	GCAAGCGGCC	GCATGGACGC	AACCGAGTGG
30	61	ACCCACCAGA	TCGACCTCCA	TAACGAGGCC	GTATGACCAG	AAAGGGATCT
		TGGGTGGTCT	AGCTGGAGGT	ATTGCTCCGG	CATACTGGTC	TTTCCCTAGA
		CGGTGGCGGG				
	121	ACCAGCACGC	TCCTAACCTC	CGAGCACCGG	CGACCGCCGG	GTGCGATGAA
		AGGGACGAAC				
		TGGTCGTGCG	AGGATTGGAG	GCTCGTGGCC	GCTGGCGGCC	CACGCTACTT
		TCCCTGCTTG				
	181	CGAGATGACA	CCACGCACAG	TCACGCGGGC	CCTGGCCGTG	GCCACCGCAG
		CCGCCACACT				
35		GCTCTACTGT	GGTGCCTGTC	AGTGCGCCCG	GGACCGGCAC	CGGTGGCGTC
		GGCGGTGTGA				
	241	CCTGGCAGGC	GGCATGGCCG	CCGAGGCCAA	CGAGCCCGCA	CCACCCGGGA
		GCGCGAGCGC				
		GGACCGTCCG	CCGTACCGGC	GGGTCCGGTT	GCTCGGGCGT	GGTGGGCCCT
		CGCGCTCGCG				
	301	ACCGCCACGC	CTGGCCGAGA	AGCTCGACCC	CGACCTCCTC	GAGGCCATGG
		AGCGCGACCT				
		TGGCGGTGCG	GACCGGCTCT	TCGAGCTGGG	GCTGGAGGAG	CTCCGGTACC
		TCCGCTGGA				
40	361	GGGCCTCGAC	GCGAGGAAG	CCGCGGCCAC	CCTGGCGTTC	CAGCACGACG
		CAGCCGAGAC				
		CCCGGAGCTG	CGCCTCCTTC	GGCGGCGGTG	GGACCGCAAG	GTCGTGCTGC
		GTCGGCTCTG				

- 126 -

```

421      CGGCGAGGCC CTGCGCGAAG AGCTCGACGA GGACTTCGCC GGCACCTGGG TCGAGGACGA
      GCCGCTCCGG GAGCGGCTTC TCGAGCTGCT CCTGAAGCGG CCGTGGACCC AGCTCCTGCT
481      CGTCCTGTAC GTCGCCACCA CCGACGAGGA CGCCGTCGAG GAGGTCGAGG GCGAAGGCGC
      GCAGGACATG CAGCGGTGGT GGCTGCTCCT GCGGCAGCTC CTCCAGCTCC CGCTTCCGCG
5      541      CACGGCCGTC ACCGTCGAGC ACTCCCTGGC CGACCTCGAG GCCTGGAAGA CCGTCCTCGA
      GTGCCGGCAG TGGCAGCTCG TGAGGGACCG GCTGGAGCTC CGGACCTTCT GGCAGGAGCT
      601      CGCCGCCCTC GAGGGCCACG ACGACGTGCC CACCTGGTAC GTCGACGTCC CGACCAACAG
      GCGGCGGGAG CTCCCGGTGC TGCTGCACGG GTGGACCATG CAGCTGCAGG GCTGGTTGTC
      661      CGTCGTCTGC GCCGTCAAGG CCGGAGCCCA GGACGTCGCC GCCGGCCTCG TCGAAGGTGC
10      721      GCAGCAGCAG CCGCAGTTCC GGCTCGGGT CCTGCAGCGG CCGCCGGAGC AGCTTCCACG
      781      CGACGTCCCG TCCGACGCCG TGACCTTCGT CGAGACCGAC GAGACCCCGC GGACCATGTT
      GCTGCAGGGC AGGCTGCGGC ACTGGAAGCA GCTCTGGCTG CTCTGGGGCG CCTGGTACAA
      841      CGCGGTCAAC GCGGGGTTC ACGCCCGCG CCACTGCGGC CGCACCGGCG CCACCACCGC
15      901      GCGCCAGTTG CCGCCCAAGT AGTGGCGGCC GTGACGCGG GCGTGGCCGC GGTGGTGGCG
      961      CAACCCACC GGGACCTTGC CCGGCTCCAG CTTCCCGGC AACGACTACG CGTTGCTCCG
      GTTGGGGTGG CCTTGAAGC GGCCAGGTC GAAGGGCCCG TTGCTGATGC GCAAGCAGGC
      1021      TACCGGGGCC GCGGTGAACC TGCTGGCCCA GGTCAACAAC TACTCCGGTG GCCGCGTCCA
20      1081      ATGCCCCCGG CCGCACTTGG ACGACCGGGT CCAGTTGTTG ATGAGGCCAC CGGCGCAGGT
      1141      GGTGCGCGGG CACACCGCGG CCCCCTCGG CTCGGCCGTG TGCCGGTCCG GGTGACCCAC
      CGAGCGGCC GTGTGGCGCC GGGGCGAGCC GAGCCGGCAC ACGGCCAGGC CCAGCTGGTG
      1201      CGGGTGGCAC TGCGGCACCA TCACTGCGCT CAACTCCTCG GTCACCTACC CCGAGGGCAC
      1261      GCCCACCGTG ACGCCGTGGT AGTGACGCGA GTTGAGGAGC CAGTGGATGG GGCTCCCGTG
25      1321      CGTCCGCGGC CTGATCCGCA CCACGCTCTG CGCCGAGCCC GCGGACTCCG GTGGCTCGCT
      1381      GCAGGCGCGG GACTAGGCGT GGTGGCAGAC GCGGCTCGGG CCGTGAGGC CACCGAGCGA
      1441      GCTCGCCGCG AACCAGGCC AGGGCGTCAC GTCCGGCGGC TCCGGCAACT GCCGCACCGG
      1501      CGAGCGCGCG TTGGTCCGGG TCCGCGAGTG CAGGCCGCGG AGGCCGTTGA CCGCGTGGCC
      1561      TGGCACCACG TTCTTCCAGC CGGTCAACCC CATCCTCCAG GCGTACGGCC TGAGGATGAT
30      1621      ACCGTGGTGC AAGAAGGTCG GCCAGTTGGG GTAGGAGGTC CGCATGCCGG ACTCCTACTA
      1681      CACCACGGAC TCGGGCAGCA GCCCGGCCCC TGCAACGACC TCCTGCACCG GCTACGCCCG
      1741      GTGGTGCCTG AGCCCGTCGT CCGGCGCGGG ACGTGGCTGG AGGACGTGGC CGATGCGGGC
      1801      CACCTTCACC GGGACCTTCG CGGCCGCGCG GCGCGCGGCC CAGCCCAACG GGTCTTACGT
      1861      GTGGAAGTGG CCTTGGGAGC GCCGCGCGGC CCGGCGCGCG GTCGGGTTCG CCAGGATGCA
35      1921      GCAGGTCAAC CGGTCCGGGA CCCACAGCGT GTGCCTCAAC GGGCCCTCCG GTGCGGACTT
      1981      CGTCCAGTTG GCCAGGCCCT GGGTGTGCGA CACGGAGTTG CCGGGGAGGC CACGCTTGAA
      2041      CGACCTCTAC GTGCAGCGCT GGAACGGCAG CTCCTGGGTG ACCGTGCGCC AGAGCACCTC
      2101      GCTGGAGATG CACGTGCGCA CTTGCGGTC GAGGACCCAC TGGCAGCGGG TCTCGTGGAG
      2161      CCCC GGCTCC AACGAGACCA TCACCTACCG CGGCAACGCC GGCTACTACC GCTACGTGGT
40      2221      GGGGCGGAGG TTGCTCTGGT AGTGGATGGC GCCGTGCGG CCGATGATGG CGATGCACCA
      2281      CAACGCCGCG TCCGGCTCCG GTGCCTACAC CATGGGGCTC ACCCTCCCTT GACGTAGCGC
      2341      GTTGGCGCGC AGGCCGAGGC CACGGATGTG GTACCCCGAG TGGGAGGGGA CTGCATCGCG (SEQ ID NO:1)

```

The following DNA sequence (SEQ ID NO:2) encodes the signal peptide (SEQ ID NO:9) that is operatively linked to the precursor protease (SEQ ID NO:7) derived from *Cellulomonas strain 69B4* (DSM 16035). The initiating polynucleotide encoding the signal peptide of the *Cellulomonas strain 69B4* protease is in bold (ATG). The asterisk indicates the termination codon (TGA), beginning with residue 1486. Residues 85, 595, and 1162, relate to the initial residues of the N terminal prosequence, mature sequence and Carboxyl terminal prosequence, respectively, are bolded and underlined.

1	ATGACACCAC	GCACAGTCAC	GCGGGCCCTG	GCCGTGGCCA	CCGACGCCGC	CACACTCCTG
	TACTGTGGTG	CGTGTCACTG	CGCCCGGGAC	CGGCACCGGT	GGCGTCGGCG	GTGTGAGGAC
			.85			
61	GCAGGCGGCA	TGGCCGCCCA	GGCCAACGAG	CCCGCACCAC	CCGGGAGCGC	GAGCGCACCG
	CGTCCGCCGT	ACCGGCGGGT	CCGGTTGCTC	GGGCGTGGTG	GGCCCTCGCG	CTCGCGTGGC
121	CCACGCCTGG	CCGAGAAGCT	CGACCCCGAC	CTCCTCGAGG	CCATGGAGCG	CGACCTGGGC
	GGTGGCGACC	GGCTCTTCGA	GCTGGGGCTG	GAGGAGCTCC	GGTACCTCGC	GCTGGACCCG
181	CTCGACGCGG	AGGAAGCCGC	CGCCACCCTG	GCGTTCCAGC	ACGACGCAGC	CGAGACCGGC
	GAGCTGCGCC	TCCTTCGGCG	GCGGTGGGAC	CGCAAGGTCG	TGCTGCGTCG	GCTCTGGCCG
241	GAGGCCCTCG	CCGAAGAGCT	CGACGAGGAC	TTCGCCGGCA	CCTGGGTCTGA	GGACGACGTC
	CTCCGGGAGC	GGCTTCTCTGA	GCTGCTCCTG	AAGCGGCCGT	GGACCCAGCT	CCTGCTGCAG
301	CTGTACGTCG	CCACCACCGA	CGAGGACGCC	GTCGAGGAGG	TCGAGGGCGA	AGGCGCCACG
	GACATGCAGC	GGTGGTGGCT	GCTCTGCGG	CAGCTCTCTC	AGCTCCCGCT	TCCGCGGTGC
361	GCCGTCACCG	TCGAGCACTC	CCTGGCCGAC	CTCGAGGCCT	GGAAGACCGT	CCTCGACGCC
	CGGCAGTGGG	AGCTCGTGAG	GGACCGGCTG	GAGCTCCGGA	CCTTCTGGCA	GGAGCTGCGG
421	GCCCTCGAGG	GCCACGACGA	CGTACCCACC	TGGTACGTCG	ACGTCCCAGC	GACAGCGGTC
	CGGAGCTCTC	CGGTGCTGCT	GACGCGGTGG	ACCATGCAAGC	TCGAGGGCTG	GTTGTGCGAG
481	GTCTGTCGCG	TCAAGGCCCG	AGCCCAGGAC	GTCGCCGCGG	GCCTCGTCTGA	AGGTGCCGAC
	CAGCAGCGGC	AGTTCCGGCC	TCGGGTCTCT	CAGCGGCGGC	CGGAGCAGCT	TCCACGGCTG
						595
541	GTCCCGTCCG	ACGCCGTGAC	CTTCGTCGAG	ACCGACGAGA	CCCCGCGGAC	CATGTTTCGAC
	CAGGGCAGGC	TGCGGCACTG	GAAGCAGCTC	TGGCTGCTCT	GGGGCGCCTG	GTACAAGCTG
601	GTGATCGGCG	GCAACGCCTA	CACCATCGGG	GGGCGCAGCC	GCTGCTCGAT	CGGGTTTCGCG
	CACTAGCCGC	CGTTGCGGAT	GTGGTAGCCC	CCCGCGTCGG	CGACGAGCTA	GCCCAAGCGC
661	GTCAACGCGC	GGTTTATCAC	CGCCGGCCAC	TGCGGCCCGA	CCGCGGCCAC	CACCGCCAAC
	CAGTTGCCCG	CCAAGTAGTG	GCGGCCGGTG	ACGCCCGCGT	GGCCGCGGTG	GTGGCGGTTG
721	CCCACCGGGA	CCTTCGCCCG	GTCCAGCTTC	CCGGGCAACG	ACTACGCGTT	CGTCCGTACC
	GGGTGGCCCT	GGAAGCGGCC	CAGGTCGAAG	GGCCCGTTGC	TGATGCGCAA	GCAGGCATGG
781	GGGGCCGCGC	TGAACCTGCT	GGCCCAGGTC	AACAACACT	CCGGTGGCCG	CGTCCAGGTC
	CCCCGGCCGC	ACTTGGACGA	CCGGGTCCAG	TTGTTGATGA	GGCCACCGGC	GCAGGTCCAG
841	GCCGGGCACA	CCGCGGCCCC	CGTCGGCTCG	GCCGTGTGCC	GGTCCGGGTC	GACCACCGGG
	CGGCCCGTGT	GGCGCCGGCG	GCAGCCGAGC	CGGCACACGC	CAGGCCCGAC	CTGGTGGCCC
901	TGGCACTGCG	GCACATTCAG	TGCGCTCAAC	TCCTCGGTCA	CCTACCCCGA	GGGCACCGTC
	ACCGTGACGC	CGTGGTAGTG	ACCGGAGTTG	AGGAGCCAGT	GGATGGGGCT	CCCGTGGCAG
961	CGCGGCCTGA	TCCGCAACCAC	CGTCTGCGCC	GAGCCCGGCG	ACTCCGGTGG	CTCGCTGCTC
	GCGCCGGAAT	AGGCGTGGTG	GCAGACGCGG	CTCGGGCCGC	TGAGGCCACC	GAGCGACGAG
1021	GCCGGCAACC	AGGCCCAGGG	CGTCACGTCC	GGCGGCTCCG	GCAACTGCCG	CACCGGTGGC
	CGGCCGTTGG	TCCGGGTCCC	GCAGTGCAGG	CCGCCGAGGC	CGTTGACGGC	GTGGCCACCG
1081	ACCACGTTCT	TCCAGCCGGT	CAACCCATC	CTCCAGGCGT	ACGGCCTGAG	GATGATCACC
	TGGTGCAAGA	AGGTGCGCCA	GTTGGGGTAG	GAGGTCCGCA	TGCCGGACTC	CTACTAGTGG
			1162			
1141	ACGGACTCGG	GCAGCAGCCC	GGCCCTTGCA	CCGACCTCCT	GCACCGGCTA	CGCCCGCACC
	TGCCTGAGCC	CGTCGTCGGG	CCGGGGACGT	GGCTGGAGGA	CGTGGCCGAT	GCGGGCGTGG
1201	TTCACCGGGA	CCCTCGCGGC	CGGCCGGGCC	GCCGCCACGC	CCAACGGGTC	CTACGTGCAG
	AAGTGGCCCT	GGGAGCGCCG	GCCGGCCCGG	CGGCGGGTCG	GGTTGCCCCAG	GATGCACGTC
1261	GTCAACCGGT	CCGGGACCCA	CAGCGTGTGC	CTCAACGGGC	CCTCCGGTGC	GGACTTTCGAC
	CAGTTGGCCA	GGCCCTGGGT	GTCGCACACG	GAGTTGCCCG	GGAGGCCACG	CCTGAAGCTG
1321	CTCTACGTGC	AGCGCTGGAA	CGGCAGCTCC	TGGGTGACCG	TCGCCACAGG	CACCTCCCCC
	GAGATGCACG	TCGCGACCTT	GCCGTCGAGG	ACCCACTGGC	AGCGGGTCTC	GTGGAGGGGG
1381	GGCTCCAACG	AGACCATCAC	CTACCGCGGC	AACGCCGGCT	ACTACCGCTA	CGTGGTCAAC
	CCGAGGTTGC	TCTGGTAGTG	GATGGCGCCG	TGCGGGCCGA	TGATGGCGAT	GCACCAAGTTG
					1486*	
1441	GCCGCGTCCG	GCTCCGGTGC	CTACACCATG	GGGCTCACCC	TCCCTTGA	(SEQ ID NO:2)
	CGGCGCAGGC	CGAGGCCACG	GATGTGGTAC	CCCCAGTGGG	AGGGGACT	

- 128 -

The following DNA sequence (SEQ ID NO:3) encodes the precursor protease derived from *Cellulomonas* strain 69B4 (DSM 16035).

```

1   AACGAGCCCG CACCACCCGG GAGCGCGAGC GCACCGCCAC GCCTGGCCGA GAAGCTCGAC
   TTGCTCGGGC GTGGTGGGCC CTCGCGCTCG CGTGGCGGTG CGGACCGGCT CTTCGAGCTG
5   61   CCCGACCTCC TCGAGGCCAT GGAGCGCGAC CTGGGCCTCG ACGCGGAGGA AGCCGCCGCC
   GGGCTGGAGG AGCTCCGGTA CCTCGCGCTG GACCCGGAGC TCGCGCTCCT TCGGCGGCGG
121  ACCCTGGCGT TCCAGCACGA CGCAGCCGAG ACCGGCGAGG CCCTCGCCGA AGAGCTCGAC
   TGGGACCGCA AGGTGCTGCT GCGTCGGCTC TGGCCGCTCC GGGAGCGGCT TCTCGAGCTG
181  GAGGACTTCG CCGGCACCTG GGTGAGGAGC GACGTCCTGT ACGTCGCCAC CACCGACGAG
10   241  CTCTGAAGC GGCCTGGAC CCAGCTCCTG CTGCAGGACA TGCAGCGGTG GTGGCTGCTC
   GACGCCGTCG AGGAGGTGCA GGGCGAAGGC GCCACGGCCG TCACCGTCTGA GCACTCCCTG
   CTGCGGCAGC TCCTCCAGCT CCCGCTTCCG CGGTGCCGGC AGTGGCAGCT CGTGAGGGAC
301  GCCGACCTCG AGGCTTGGAA GACGTCCTC GACCCGCCC TCGAGGGCCA CGACGACGTG
   CGGCTGGAGC TCCGGACCTT CTGGCAGGAG CTGCGGCGGG AGCTCCCGGT GCTGCTGCAC
15   361  CCCACCTGGT ACGTCGACGT CCCGACCAAC AGCGTCGTG TCGCCGTCAA GGCCGGAGCC
   GGGTGGACCA TGCAGCTGCA GGGCTGGTTG TCGCAGCAGC AGCGGCAGTT CCGGCCTCGG
421  CAGGACGTCG CCGCCGGCCT CGTCGAAGGT GCCGACGTCC CGTCCGACGC CGTGACCTTC
   GTCTGACAGC GGCGGCCGGA GCAGCTTCCA CGGCTGCAGG GCAGGCTGCG GCACTGGAAG
481  GTCGAGACCG ACGAGACCCC GCGGACCATG TTCGACGTGA TCGGCGGCAA CGCCTACACC
20   541  CAGCTCTGGC TGCTCTGGGG CGCCTGGTAC AAGCTGCACT AGCCGCCGTT GCGGATGTGG
   ATCGGGGGGC GCAGCCGCTG CTCGATCGGG TTCGCGGTCA ACGGCGGGTT CATCACCGCC
   TAGCCCCCGC CGTCGGCGAC GAGCTAGCCC AAGCGCCAGT TGCCGCCCAA GTAGTGGCGG
601  GGCACACTCG CGCGCACCGG CGCCACCACC GCCAACCCTA CCGGGACCTT CGCCGGGTCC
   CCGGTGACGC CGGCGTGGCC GCGGTGGTGG CGGTTGGGGT GGCCCTGGAA GCGGCCCAGG
25   661  AGCTTCCCGG GCAACGACTA CGCGTTCGTC CGTACCGGGG CCGCGGTGAA CCTGCTGGCC
   TCGAAGGGCC CGTTGCTGAT GCACAAGCAG GCATGGCCCC GGCCGCACTT GGACGACCGG
721  CAGGTCAACA ACTACTCCGG TGCCCGCGTC CAGGTGCGCG GGACACCGC GGCCCCCGTC
   GTCCAGTTGT TGATGAGGCC ACCGGCGCAG GTCCAGCGGC CCGTGTGGCG CCGGGGGCAG
781  GGCTCGGCCG TGTGCCGGTC CGGGTCGACC ACCGGGTGGC ACTGCGGCAC CATCACTGCG
30   841  CCGAGCCGGC ACACGGCCAG GCCAGCTGG TGGCCACCG TGACGCCGTG GTAGTGACGC
   CTCAACTCCT CGGTCACCTA CCCCAGGGC ACCGTCCGCG GCCTGATCCG CACCACCGTC
   GAGTTGAGGA GCCAGTGGAT GGGGCTCCCG TGGCAGGCGC CGGACTAGGC GTGTTGGCAG
901  TCGCGCCGAGC CCGCGCACTC CGGTGGCTCG CTGCTCGCCG GCAACCAGGC CCAGGGCGTC
   ACGCGGCTCG GGCCGCTGAG GCCACCGAGC GACGAGCGGC CGTTGGTCCG GGTCCCGCAG
35   961  ACGTCCGGCG GCTCCGGCAA CTGCCGACC GGTGGCACCA CGTTCTTCCA GCCGCTAAC
   TGCAGGCCGC CGAGGCCGTT GACGGCGTGG CCACCGTGGT GCAAGAAGGT CCGCCAGTTG
1021 CCCATCTCTC AGGCGTACGG CTTGAGGATG ATCACCACGG ACTCGGGCAG CAGCCCGGCC
   GGGTAGGAGG TCCGCATGCC GGACTCTAC TAGTGGTGCC TGAGCCCGTC GTCGGGCCGG
1081 CCTGCACCGA CCTCTGCAC CGGCTACGCC CGCACCTTCA CCGGGACCTT CGCGGCCGGC
40   1141 GGACGTGGCT GGAGGACGTG GCGGATGCGG GCGTGGAAGT GGCCCTGGGA GCGCGGCCCG
   CGGGCCGCGC CCCAGCCCAA CGGGTCTTAC GTGCAGGTCA ACCGGTCCGG GACCCACAGC
   GCGCGCGGCG GGGTCGGGTT GCCCAGGATG CACGTCCAGT TGGCCAGGCC CTGGGTGTGCG
1201 GTGTGCCTCA ACGGGCCCTC CGGTGCGGAC TTCGACCTCT ACGTGCAGCG CTGGAACGGC
   CACACGGAGT TGCCCGGGAG GCCACGCTG AAGCTGGAGA TGACGTCGC GACCTTGCCG
45   1261 AGCTCTGGG TGACCGTCGC CCAGAGCACC TCCCCCGGCT CCAACGAGAC CATCACCTAC
   TCGAGGACCC ACTGGCAGCG GGTCTCGTGG AGGGGGCCGA GGTGCTCTG GTAGTGGATG
1321 CGCGGCAACG CCGGCTACTA CCGCTACGTG GTCAACGCCG CGTCCGGCTC CGGTGCCTAC
   GCGCCGTTGC GGCCGATGAT GCGGATGCAC CAGTTGCGGC GCAGGCCGAG GCCACGGATG
1381 ACCATGGGGC TCACCCTCCC CTGA (SEQ ID NO:3)
50   TGGTACCCCG AGTGGGAGGG GACT

```

The following DNA sequence (SEQ ID NO:4) encodes the mature protease derived

- 129 -

from *Cellulomonas* strain 69B4 (DSM 16035).

```

1      TTCGACGTGA TCGGCGGCAA CGCCTACACC ATCGGGGGGC GCAGCCGCTG CTCGATCGGG
      AAGCTGCACT AGCCGCCGTT GCGGATGTGG TAGCCCCCGG CGTCGGCGAC GAGCTAGCCC
5      61      TTCGCGGTCA ACGGCGGGTT CATCACCGCC GGCCACTGCG GCCGCACCGG CGCCACCACC
      AAGCGCCAGT TGCCGCCCAA GTAGTGGCGG CCGGTGACGC CGGCGTGGCC GCGGTGGTGG
      121      GCCAACCCCA CCGGGACCTT CGCCGGGTCC AGCTTCCCGG GCAACGACTA CGCGTTCGTC
      CGGTGGGGT GGCCCTGGAA GCGGCCAGG TCGAAGGGCC CGTTGCTGAT GCGCAAGCAG

10     181      CGTACCGGGG CCGGCGTGAA CCTGCTGGCC CAGGTCAACA ACTACTCCGG TGGCCGCGTC
      GCATGGCCCC GGCCGCACTT GGACGACCGG GTCCAGTTGT TGATGAGGCC ACCGGCGCAG
      241      CAGGTCGCGG GGCACACCGC GGCCCCGTC GGCTCGGCCG TGTGCCGGTC CGGGTCGACC
      GTCCAGCGGC CCGTGTGGCG CCGGGGGCAG CCGAGCCGGC ACACGGCCAG GCCCAGCTGG
      301      ACCGGGTGGC ACTGCGGCAC CATCACTGCG CTCAACTCCT CGGTACCTA CCCCAGGGG
15     361      TGGCCACCG TGACCCCGTG GTAGTGACGC GAGTTGAGGA GCCAGTGGAT GGGGCTCCCG
      ACCGTCCGCG GCCTGATCCG CACCACCGTC TGCGCCGAGC CCGGCGACTC CCGTGGCTCG
      TGGCAGGCGC CCGACTAGGC GTGGTGGCAG ACGCGGCTCG GGCCGCTGAG GCCACCGAGC
      421      CTGCTCGCGG GCAACCAGGC CCAGGGCGTC ACGTCCGGCG GCTCCGGCAA CTGCCGCACC
      GACGAGCGGC CGTTGGTCCG GGTCCCGCAG TGCAGGCCGC CGAGGCCGTT GACGGCGTGG
20     481      GGTGGCACCA CGTTCTTCCA GCCGTC AAC CCCATCCTCC AGGCGTACGG CCTGAGGATG
      CCACCGTGGT GCAAGAAGGT CCGCCAGTTG GGGTAGGAGG TCCGCATGCC GGA CTCTAC
      561      ATCACCACGG ACTCGGGCAG CAGCCCG (SEQ ID NO:4)
      TAGTGGTGCC TGAGCCCGTC GTCGGGC

```

The following DNA sequence (SEQ ID NO:5) encodes the signal peptide derived from *Cellulomonas* strain 69B4 (DSM 16035)

```

1      ATGACACCAC CACAGTCAC GCGGGCCCTG GCCGTGGCCA CCGCAGCCGC CACACTCCTG
      TACTGTGGTG CGTGTCAGTG CGCCCGGGAC CCGCACCAGT GCGCTCGGCG GTGTGAGGAC
30     61      GCAGGCGGCA TGGCCGCCCA GGCC (SEQ ID NO:5)
      CGTCCGCCGT ACCGGCGGGT CCGG

```

The following sequence is the amino acid sequence (SEQ ID NO:6) of the signal sequence and precursor protease derived from *Cellulomonas* strain 69B4 (DSM 16035), including the signal sequence [segments 1a-c] (residues 1-28 [-198 to -171]), an N-terminal prosequence [segments 2a-r] (residues 29-198 [-170 to -1]), a mature protease [segments 3a-t] (residues 199-387 [1-189]), and a C-terminal prosequence [segments 4a-l] (residues 388-495 [190-398]) encoded by the DNA sequences set forth in SEQ ID NOS:1, 2, 3 and 4.

The N-terminal sequence of the mature protease amino acid sequence is in bold.

```

1      MTPRTVTRAL AVATAAATLL AGGMAAQA NE PAPPGSASAP PRLAEKLDPD
      1a      1b      1c      2a 2b      2c
45     51      LLEAMERDLG LDAEEAAATL AFQHDAAETG EALAEELDED FAGTWVEDDV
      2d      2e      2f      2g      2h
101     LYVATTDEDA VEEVEGEGAT AVTVEHSLAD LEAWKTVLDA ALEGHDDVPT
      2i      2j      2k      2l      2m
151     WYVDVPTNSV VVAVKAGA QD VAAGLVEGAD VPSDAVTFVE TDETPRTM FD

```

- 130 -

	2n	2o	2p	2q	2r
201	3a VIGGNAYTIG	GRSRCSIGFA	VNGGFITAGH	CGRTGATTAN	PTGTFAGSSF
5 251	3b PGNDYAFVRT	3c GAGVNLLAQV	3d NNYSGGRVQV	3e AGHTAAPVGS	3f AVCRSGSTTG
301	3g WHCGTITALN	3h SSVTYPEGTV	3i RGLIRTTVCA	3j EPGDSGGSLL	3k AGNQAQGVTS
351	3l GGSGNCRTGG	3m TTFQFPVNPI	3n LQAYGLRMIT	3o TDSGSSP	3p APA PTSCCTGYART
10 401	3q FTGTLAAGRA	3r AAQPNGSYVQ	3s VNRSGTHSVC	3t LNGPSGADFD	4a 4b LYVQRWNGSS
451	4c WVTVAQSTSP	4d GSNETITYRG	4e NAGYYRYVVN	4f AASGSGAYTM	4g GLTLP (SEQ ID
15 NO:6)	4h	4i	4j	4k	4l

The following sequence (SEQ ID NO:7) is the amino acid sequence of the precursor protease derived from *Cellulomonas strain 69B4* (DSM 16035) (SEQ ID NO:7).

```

1  NEPAPPGSAS APPRLAEKLD PDLLEAMERD LGLDAEEAAA TLAFQHDAAE
51 TGEALAEELD EDFAGTWVED DVLYVATTDE DAVEEVEGEG ATAVTVEHSL
101 ADLEAWKTVL DAALEGHDDV PTWYVDVPTN SVVVAVKAGA QDVAAGLVEG
25 151 ADVPSDAVTF VETDETPRTM FDVIGGNAYT IGGRSRCSIG FAVNNGGFITA
201 GHCGRTGATT ANPTGTFAGS SFPNGDYAFV RTGAGVNLLA QVNNYSGGRV
251 QVAGHTAAPV GSAVCRSGST TGWHCGTITA LNSSVTYPEG TVRGLIRTTV
301 CAEPGDSGGS LLAGNQAQGV TSGGSGNCRT GGTTFQFPVN PILQAYGLRM
351 ITTDSGSSPA PAPTCTGYA RTFTGTLAAG RAAQPNQSY VQVNRSGTHS
30 401 VCLNGPSGAD FDLYVQRWNG SSWVTVAQST SPGSNETITY RGNAGYYRYV
451 VNAASGSGAY TMGLTLP (SEQ ID NO:7)

```

The following sequence (SEQ ID NO:8) is the amino acid sequence of the mature protease derived from *Cellulomonas strain 69B4* (DSM 16035). The catalytic triad residues H32, D56 and S132 are bolded and underlined.

```

1  FDVIGGNAYT IGGRSRCSIG FAVNNGGFITA HCGRTGATT ANPTGTFAGS
40 51 SFPNGDYAFV RTGAGVNLLA QVNNYSGGRV QVAGHTAAPV GSAVCRSGST
101 TGWHCGTITA LNSSVTYPEG TVRGLIRTTV CAEPGDSGGS LLAGNQAQGV
151 TSGGSGNCRT GGTTFQFPVN PILQAYGLRM ITTDSGSSP (SEQ ID NO:8)

```

The following sequence (SEQ ID NO:9) is the amino acid sequence of the signal peptide of the protease derived from *Cellulomonas strain 69B4* (DSM 16035).

```

1  MTPRTVTRAL AVATAAATLL AGGMAAQA (SEQ ID NO:9)

```

- 131 -

The following sequence (SEQ ID NO:10) is the degenerate primer used to identify a 177 bp fragment of the protease of *Cellulomonas* strain 69B4.

TTGWXCGT_FW: 5' ACNACSGGSTGGCRGTGCGGCAC 3' (SEQ ID NO:10)

The following sequence (SEQ ID NO:11) is the reverse primer used to identify a 177 bp fragment of the protease derived from *Cellulomonas* strain 69B4.

GDSGGX_RV: 5'-ANGNGCCGCGGAGTCNCC-3' (SEQ ID NO:11)

The following DNA (SEQ ID NO:13) and amino acid sequence of the 177 bp fragment (SEQ ID NO:12) encoding part of the protease gene derived from *Cellulomonas* strain 69B4. The sequences of the degenerate primers (SEQ ID NOS:10 and 11) are underlined and in bold.

	D	G	W	D	C	G	T	I	T	A	L	N	S	S	V	T	Y	P	E	G	.	
1	<u>ACGACGGCTG</u>	<u>GGACTGCGGC</u>	<u>ACCATCACTG</u>	CGCTCAACTC	CTCGGTCACC	TACCCGAGG																
	TGCTGCCGAC	CCTGACGCCG	TGGTAGTGAC	GCGAGTTGAG	GAGCCAGTGG	ATGGGGCTCC																
25	.	T	V	R	G	L	I	R	T	T	V	C	A	E	P	G	D	S	G	G	S	.
61	GCACCGTCCG	CGGCCTGATC	CGCACCACCG	TCTGCGCCGA	GCCC GGCGAC	TCCGGTGGCT																
	CGTGGCAGGC	GCCGGACTAG	GCGTGGTGGC	AGACGCGGCT	CGGGCCGCTG	AGGCCACCGA																
	.	L	L	A	G	N	Q	A	Q	G	V	T	S	G	D	S	G	G	S			
121	CGCTGCTCGC	CGGCAACCAG	GCCCAGGGCG	TCACGTCCGG	CGACTCCGGC	GGCTCAT																
30	GCGACGAGCG	GCCGTTGGTC	CGGGTCCC GC	AGTGCAGGCC	<u>GCTGAGGCCG</u>	<u>CCGAGTA</u>																

Analysis of the Sequence of *Cellulomonas* sp. 69B4 Protease

A saturated sinapinic acid (3,5-dimethoxy-4-hydroxy cinnamic acid)("SA") solution in a 1:1 v/v acetonitrile ("ACN")/0.1% formic acid solution was prepared. The resulting mixture was vortexed for 60 seconds and then centrifuged for 20 seconds at 14,000 rpm. Then, 5µl of the matrix supernatant was transferred to a 0.5 ml Eppendorf tube and 1 µl of a 10 pmole/µl protease 69B4 sample was added to the SA matrix supernatant and vortexed for 5 seconds. Then, 1 µl of the analyte/matrix solution was transferred onto a sample plate and, after being completely dry, analyzed by a Voyager DE-STR (PerSeptive), matrix assisted laser desorption/ionization – time of flight (MALDI-TOF) mass spectrophotometer, with the following settings: Mode of operation: Linear; Extraction mode: Delayed; Polarity: Positive; Accelerating voltage: 25000 V; Extraction delay time: 350 nsec; Acquisition mass range: 4000- 20000 Da; Number of laser shots: 100/spectrum; and Laser intensity: 2351. The

- 132 -

resulting spectrum is provided in Figure 4.

A tryptic map was produced using methods known in the art (Christianson *et al.*, Anal. Biochem. 223:119-29 [1994]), modified as described herein. The protease solution, containing 10 – 50 µg protease was diluted 1:1 with chilled water in a 1.5 ml microtube. 1.0 N HCl was added to a final concentration of 0.1 N HCl, mixed thoroughly and incubated for 10 minutes on ice. Then, 50% trichloro-acetic acid ("TCA") was added to a final concentration of 10% TCA and mixed. The sample was incubated for 10 minutes on ice, centrifuged for two minutes and the supernatant discarded. Then, 1 ml of cold 90% acetone was added to resuspend the pellet. The resulting sample was then centrifuged for one minute, the supernatant quickly decanted and remaining liquid was removed by vacuum aspiration. The dry pellet was dissolved in 12 µl of 8.0 M urea solution (480 mg urea [Roche, catalog # 1685899]) in 0.65 ml of ammonium bicarbonate solution (final concentration of bicarbonate: 0.5 M) and incubated for 3-5 minutes at 37°C. The solution was slowly diluted with 48 µl of a n-octyl-beta-D-glucopyranoside solution ("o-water") (200 mg of n-octyl-beta-D-glucopyranoside [C₁₄H₂₈O₆, f.w. 292.4] in 200 ml of water). Then, 2.0 µl of trypsin (2.5 mg/ml in 1mM HCl) was added and the mixture was incubated for 15 minutes at 37°C. The proteolytic reaction was quenched with 6 µl of 10% trifluoroacetic acid ("TFA"). Insoluble material and bubbles were removed from the sample by centrifugation for one minute. The tryptic digest was separated by RP-HPLC on 2.1 X 150 mm C-18 column (5µl particle size, 300 angstroms pore size). The elution gradient was formed from 0.1% (v/v) TFA in water and 0.08% (v/v) TFA in acetonitrile at a flow rate of 0.2 ml-min. The column compartment was heated to 50°C. Peptide elution was monitored at 215 nm and data were collected at 215 nm and 280 nm. The samples were then analyzed on a LCQ Advantage mass spectrometer with a Surveyor HPLC (both from Thermo Finnigan). The LCQ mass spectrophotometer was run with the following settings: Spray voltage: 4.5kV; Capillary temperature: 225° C. Data processing was performed using TurboSEQUENT and Xcalibur (ThermoFinnigan). Sequencing of the tryptic digest portions was also performed in part by Argo BioAnalytica.

Analysis of the full sequence of the *asp* gene revealed that it encodes a prosequence protease of 495 amino acids (SEQ ID NO:6). The first 28 amino acids were predicted to form a signal peptide. The mass of the mature chain of 69B4 protease as produced by *Cellulomonas* strain 69B4 has a molecular weight of 18764 (determined by MALDI-TOF). The sequence of the N-terminus of the mature chain was also determined by MALDI-TOF analysis and starts with the sequence FDVIGGNAYTIGGR (SEQ ID NO:17). It is believed that the 69B4 protease has a unique precursor structure with NH₂⁻ and COOH

- 133 -

terminal pro-sequences, as is known to occur with some other enzymes (*e.g.*, *T. aquaticus* aqualysin I; See *e.g.*, Lee *et al.*, FEMS Microbiol. Lett., 1:69-74 [1994]; Sakamoto *et al.*, Biosci. Biotechnol. Biochem., 59:1438-1443 [1995]; Sakamoto *et al.*, Appl. Microbiol. Biotechnol., 45:94-101 [1996]; Kim *et al.*, Biochem. Biophys. Res. Commun., 231:535-539 [1997]; and Oledzka *et al.*, Protein Expr. Purific., 29:223-229 [2003]). The predicted molecular weight of mature 69B4 protease as provided in SEQ ID NO:8, was 18776.42, which corresponds well with the molecular weight of the purified enzyme with proteolytic activity isolated from *Cellulomonas* sp. 69B4 (*i.e.*, 18764). The prediction of the COOH terminal pro-sequence in 69B4 protease was also based on an alignment of the 69B4 protease with *T. aquaticus* aqualysin I, provided below. In this alignment, the amino acid sequence of the *Cellulomonas* 69B4 signal sequence and precursor protease are aligned with the signal sequence and precursor protease Aqualysin I of *Thermus aquaticus* (COOH-terminal pro-sequence of Aqualysin I is underlined and in bold).

15	Aqualysin I	(1)	----MRKTYWLMALFAVLVLGGCQMASRSDPTPTLAEAFWPKEAPVYGLD	
	69B4	(1)	MTFRTVTRALAVATAAATLLAGGMAAQANEPAPPGSASAPPRLAEKLDPD	
	Consensus	(1)	MA A LLAG A DP P A A PK A D	
		51		100
	Aqualysin I	(47)	DPEAIPGRYIVVFKKKGQSLLQGGITTLQARLAPOGVVVTQAYTGALQG	
	69B4	(51)	LLEAMERDLGLDAEEAATLAFQHDAETGEALAE---LDEDFAGTWVE	
20	Consensus	(51)	EAI L A A Q LA L F G	
		101		150
	Aqualysin I	(97)	FAAEMAPQALEAFRQSPDVEFIEADKVVRWATQSPAPWGLDRIDQRLDP	
	69B4	(98)	DDVLYVATTDEDAVEEVEGEGATAVTVEHSLADLEAWKTVLDAALEGHDD	
	Consensus	(101)	E D E A V A A LD	
25		151		200
	Aqualysin I	(147)	LSNSYTYTATGRGVNVYVIDTGIRTTHREFGGRARVGYDALGGNGQDCNG	
	69B4	(148)	VPTWYVDVPTNS--VVAVKAGAQDVAAGLVEGADVPSDAVT--FVETDE	
	Consensus	(151)	L Y T V I G A V DAL D	
		201		250
30	Aqualysin I	(197)	HGTHVAGTIGGVITYGVAKAVNLYAVRVLDNCNGSGSTSGVIAGVDWVTRNH	
	69B4	(194)	TPRTMFDVIGGNAYTIGGRS-----RCSIGFAVNGGFITAGHCGRTG	
	Consensus	(201)	M IGG Y IA C A G R	
		251		300
	Aqualysin I	(247)	RRPAVANMSLGGGVSTALDNAVKNIAAGVVYAAGNDNANACNYS PAR	
35	69B4	(236)	ATTANPTGTTFAGSSFPGNDYAFVRTGAG-----VNLLAQVNNSGGR	
	Consensus	(251)	A S AG A D A S AA N AN NYS AR	
		301		350
	Aqualysin I	(297)	VAEALTVGATTSSDARASFSNYGSCVDLFAPGASIPSAWYTSDTATQTLN	
	69B4	(278)	VQVAGHTAAPVGSACVCRSGSTTGWHCGTIT--ALNSSVTYPEGTVRGLIR	
40	Consensus	(301)	V A AA S S S G A S Y T I	
		351		400
	Aqualysin I	(347)	GTSMATPHVAGVAALYLEQNPSATPASVASAILNGATTGRLSGIGSGSPN	
	69B4	(326)	TTVCAEPGDSGGSLLAGNQAQGVTSGGSGNCRTGGTTFFQPVNPILQAYG	
	Consensus	(351)	T A P AG A L Q T A A G T A	
45		401		450
	Aqualysin I	(397)	RLLYSLLSSGSGSTAPCTSCSYTTGSLSG---PGDYNFQPNGTYYYSP-A	
	69B4	(376)	LRMITTDS-GSSPAPAPTSTCTGYARTFTGTLAGRAAAQPNGSYVQVNRS	
	Consensus	(401)	L S S GS TSCS Y S SG G QPNGSY A	
		451		500
50	Aqualysin I	(443)	<u>GTHRAWLRGPAGTDFDLYLWRWDGSRWLTVGSSTGPTSEESLSYSGTAGY</u>	
	69B4	(425)	GTHSVCLNGPSGADFDLYVQRWNGSSWVTVAQSTSPGSNETITYRGNAGY	
	Consensus	(451)	GTH L GPAG DFDLYL RW GS WLTVA ST P S ESISY G AGY	
		501		521
	Aqualysin I	(493)	<u>YLWRIYAYSGSGMYEFWLQRP</u>	(SEQ ID NO:644)
55	69B4	(475)	YRYVVNAASGSGAYTMGLTLP	(SEQ ID NO:645)
	Consensus	(501)	Y W I A SGSG Y L P	(SEQ ID NO:646)

The sequences of three internal peptides of the purified enzyme from *Cellulomonas*

- 134 -

sp. 69B4 having proteolytic activity were determined by MALDI-TOF analysis. All three peptides were also identified in the translation product of the isolated *asp* gene, confirming the identification of the correct protease gene (See, SEQ ID NO:1, above).

Percentage Identity Comparison Between Asp and Streptogrisin

The deduced polypeptide product of the *asp* gene (mature chain) was used in homology analysis with other serine proteases using the BLAST program and settings as described in Example 3. The preliminary analyses showed identities of from about 44 - 48% (See, Table 4-1, below). Together with analysis of the translated sequence, these results provided evidence that the *asp* gene encodes a protease having less than 50% sequence identity with the mature chains of Streptogrisin-like serine proteases. An alignment of Asp with Streptogrisin A, Streptogrisin B, Streptogrisin C, Streptogrisin D of *Streptomyces griseus* is provided below. In this alignment, the amino acid sequences of *Cellulomonas* 69B4 mature protease ("69B4 mature") are aligned with mature proteases amino acid sequences of Streptogrisin C ("Sq - streptogrisinC_mature"), Streptogrisin B ("Sq - streptogrisinBmature"), Streptogrisin A ("Sq - streptogrisinAmature"), Streptogrisin D ("Sq - streptogrisinDmature") and consensus residues.

		1	50
20	69B4 mature	(1) FDVIGGNAYTIGGRSRCISIGFAVN---GGFITAGHCGRGTGATT-----	
	Sg-StreptogrisinC mature	(1) ADIRGGDAYYMNGSGRCISVGFVTRGTONGFATAGHCGRVGTPTNG--VN	
	Sg-StreptogrisinBmature	(1) --ISGGDAIYSSST--GRCSLGFNVRSSTYYFLTAGHCTDGATTWANSAR	
	Sg-StreptogrisinAmature	(1) --IAGGEAITTGG--SRCSLGFNVSVNGVAHALTAGHCTNISASWS-----	
	Sg-StreptogrisinDmature	(1) --IAGGDAIWGSG--SRCSLGFNVVKGGEFYFLTAGHCTESVTSWSD-TQG	
25	Consensus	(1) IAGGDAIY G SRCSLGFNV G YFLTAGHCT GTTW	
		51	100
	Asp mature	(41) ANPTGTGTFAGSSFPNDYAFVRTGAGVNLLAQVNNYSGGRVQVAGHTAAPV	
	Sg-StreptogrisinC mature	(49) QQAQGTGTFQGSTFPGRDIAWVATNANWT*PRPLVNGYGRGDVTVAGSTASVV	
30	Sg-StreptogrisinBmature	(48) TTVLGTTSGSSFPNDYGI VRYTNTTIPKDGTVGG---QDITSAANATV	
	Sg-StreptogrisinAmature	(43) ---IGTRTGTSTFPNDYGIIRHSNPAAADGRVYLYNGSYQDITTAGNAFV	
	Sg-StreptogrisinDmature	(47) GSEIGANEGSSFPNDYGLVKYTS*TAHPSEVNLYDGSTQAITQAGDATV	
	Consensus	(51) IGT GSSFP NDYGI VRYTA VN Y G Q IT AG A V	
		101	150
35	Asp mature	(91) GSAVCRSGSTTGWHCGTITALNSSVTYPEG--TVRGLIRTTVCAEPGDSGG	
	Sg-StreptogrisinC mature	(99) GASVCRSGSTTGWHCGTIQQLNTSVTYPEG--TISGVTRTSVCAEPGDSGG	
	Sg-StreptogrisinBmature	(94) GMAVTRRGSTTGTHSGSVTALNATVNYGGDVVYGMIRTNVCAEPGDSGG	
	Sg-StreptogrisinAmature	(90) GQAVQRSSTTGTLRSGSVTGLNATVNYGSSGIVYGMITNVCAEPGDSGG	
	Sg-StreptogrisinDmature	(97) GQAVTRSGSTTQVHDGEVTALDATVNYGNGDIVNGLIQTTVCAEPGDSGG	
40	Consensus	(101) G AV RSGSTTG H GSVTALNATVNYG G IV GLIRTTVCAEPGDSGG	
		151	200
	Asp mature	(140) SLLAGNQAGQVTS*GGSGNCRTGGT*FFFQPVNPILQAYGLRMITTDSGSSP	
	Sg-StreptogrisinC mature	(148) SYISGSQAQGVTS*GGSGNCSSGGT*FFQPINPLQAYGLTLVTSGGGTPT	
	Sg-StreptogrisinBmature	(144) PLYSGTRAIGLTS*GGSGNCSSGGT*FFQPVTEALSAYGVSVY-----	
45	Sg-StreptogrisinAmature	(140) SLFAGSTALGLTS*GGSGNCRTGGT*FFQPVTEALSAYGATVL-----	
	Sg-StreptogrisinDmature	(147) ALFAGDTALGLTS*GGSGDCSSGGT*FFQPVPEALAA*YGAIEG-----	
	Consensus	(151) SLFAGS ALGLTS*GGSGNCSSGGT*FFQPV EALSAYGLTVI	
		201	250
	Asp mature	(190) -----	
50	Sg-StreptogrisinC mature	(198) DPPTTPPTDSPGGT*WAVGTAYAAGATV*TYGGATYRCLQAHTAQPGWTPAD	
	Sg-StreptogrisinBmature	(186) -----	
	Sg-StreptogrisinAmature	(182) -----	
	Sg-StreptogrisinDmature	(189) -----	
	Consensus	(201) -----	
55		251	
	Asp mature	(190) -----	(SEQ ID NO:8)

- 135 -

Sg-StreptogrisinC mature (248) VPALWQRV (SEQ ID NO: 639)
 Sg-StreptogrisinBmature (186) ----- (SEQ ID NO: 640)
 Sg-StreptogrisinAmature (182) ----- (SEQ ID NO: 641)
 Sg-StreptogrisinDmature (189) ----- (SEQ ID NO: 642)
 Consensus (251) ----- (SEQ ID NO: 643)

Table 4-1. Percentage Identity: Comparison between *Cellulomonas* sp. 69B4 Protease Encoded by *asp* and Other Serine Proteases (identity between the mature chains)

	Streptogrisin A <i>S. griseus</i>	Streptogrisin B <i>S. griseus</i>	Streptogrisin C <i>S. griseus</i>	Streptogrisin D <i>S. griseus</i>	Alphalytic endopeptidase <i>Lyso bacter</i> <i>enzymogenes</i>
Asp protease <i>Cellulomonas</i> sp. Isolate 69B4	48%	45%	47%	46%	44%

Additionnel protease sequences were also investigated. In these analyses, proteases homologous in protein sequence to the mature domain of ASP were searched for using BLAST. Those identified were then aligned using the multiple sequence alignment program clustalW. The numbers on the top of the alignment below refer to the amino-acid sequence of the mature ASP protease. The numbers at the side of the alignment are sequence identifiers, as described at the bottom of the alignment.

```

Sequence 1      10      20      30      40
ASP            FDVIGGNAYTIGGRSRCISIGFAVN-----GGFITAGHCGRTGATTANPTG-----TF
2              TPLIAGGEAITTGGSRCISLGFNV-SVNGVAHALTAGHCTNISASWS-----IGTR
3              --IAGGEAIYAAGGGRCSLGFNVRSSSGATYALTAGHCTEIASTWYTNSGQTSLS--LGTR
4              NKLIQGGDAIYASSWRCISLGFNVRTSSGAIEYFLTAGHCTDGAGAWRASSGGTV---IGQT
25             NKLIQGGDAIYASSWRCISLGFNVRTSSGAIEYFLTAGHCTDGAGAWRASSGGTV---IGQT
6              TKLIQGGDAIYASSWRCISLGFNVRSSSGVDFYFLTAGHCTDGAGTWYSNSARTTA--IGST
7              TKLISGGDAIYSSSTGRCSLGFNVRSVS-TYYFLTAGHCTDGATTWWANSARTTV--LGTT
8              ---VLGGGAIYGGGSRCISAAFNV-TKGGARYFVTAGHCTNISANWSASSGGSV---VGVR
9              QREVAGGDAIYGGGSRCISAAFNV-TKNGVRYFLTAGHCTNLSSTWSSTSGGTS---IGVR
30             KPFIAGGDAITNGGRCISLGFNVTKG-GEPHFLTAGHCTEGISTWSDSSG--QV--IGEN
11             KPFVAGGDAITGGGGRCSLGFNVTKG-GEPIYFITAGHCTESISTWSDSSG--NV--IGEN
12             TPLIAGGDAIWGSGSRCISLGFNVVKG-GEPIYFLTAGHCTESVTSWSDTQGG-SE--IGAN
13             KTFASGGDAIFGGGARCISLGFNVTAGDGSAAFLTRGHCGGGATMWSDAQGGQPI--ATVD
14             KTFASGGDAIFGGGARCISLGFNVTAGDGSPAFLTAGHCGVAADQWSDAQGGQPI--ATVD
35             -----
16             TTRLNGAEPILSTAGRCSAGFNVTGD-TSDFILTAGHCGPTGSVWFGRPGDQ--VGRT
17             ATVQGGDVYYINRSSRCISIGFAVT-----TGFSVAGHCGGSGASATTSSGEAL----GTF
18             ADIRGGDAYYMNGSGRCISVGFSVTRG-TQNGFATAGHCGRVGTTTNGVNQQAQ----GTF
19             YDLRGGEAYYINNSSRCISIGFPITKG-TQQGFATAGHCGRAGSSTTGANRVAQ----GTF
40             YDLVGGDAYYIGN-GRCSIGFSVRQG-STPGFVTAGHCGSVGNATTGFNRSQ----GTF
21             YDLVGGDAYYMGG-GRCSVGFSVTQG-STPGFATAGHCGTVGTSTTGYNQAAQ----GTF
22             EDLVGGDAYYIDDQARCSIGFSVTKD-DQEGFATAGHCGDPGATTTGYNEADQ----GTF
23             LAAIIGGNPYFYGNRYCSIGFSVRQG-SQTGFATAGHCGSTGTRVSSPSG-----TV
24             ANIVGGIEYSINNASLCSVGFSVTRG-ATKGFVTAGHCGTVNATARIGGAVV-----GTF
45             AAGTVGGDPYYTGNVRCISIGFSVH-----GGFVTAGHCGRAGAGVSGWDRSYI----GTF
26             VIVPVRDYWGGDALSGCTLAFPVYGG-----FLTAGHCAVEGKGHILKTEMTGGQ-IGTV
27             DPPLRSGLAIYGTNVRCSSAFMAYSG-SSYYMMTAGHCAEDSSYWEVPTYSYGYQGVGHV
  
```

- 136 -

50 60 70 80 90 100
ASP AGSSFPGN-DYAFVRTGAGVNLLAQVNNYSGGR-VQVAGHTAAPVGSVAVCRSGSTTGWHC
2 TGTSPFNNDYGIIRHSNPAAA--DGRVLYNGSYQDITTAGNAFVGQAVQVRSGSTTGLRS
3 AGTSFPNDYGLIRHSNASAA--DGRVLYNGSYRDITGAGNAYVQGTQVRSGSTTGLHS
5 4 AGSSFPNDYGIVQYTGS-----VSRPGTANGVDITRAATPSVGTTVIRDGSTTGTHS
5 AGSSFPNDYGIVQYTGS-----VSRPGTANGVDITRAATPSVGTTVIRDGSTTGTHS
6 AGSSFPNDYGIVRYTGS-----VSRPGTANGVDITRAATPSVGTTVIRDGSTTGTHS
7 SGSSFPNDYGIVRYTNTT-----IPKDGTVGGQDITSAANATVGMATVRRGSTTGTHS
8 EGTSFPNDYGIVRYTDGSSP--AGTVDLYNGSTQDISSAANAVVGQAIIKSGSTTKVTS
10 9 EGTSFPNDYGIVRYTTTTNV--DGRVNLNGGYQDIASAADAVVGQAIIKSGSTTKVTS
10 AASSFPGDDYGLVKYTADVAH--PSQVNLVDGSSQISGAEEAAVGMQVTRSGSTTQVHS
11 AASSFPNDYGLVKYTADVDH--PSEVNLYNGSSQAISGAEEATVGMQVTRSGSTTQVHD
12 EGSSFPENDYGLVKYTSDBAH--PSEVNLYDGSTQAITQAGDATVGGQAVTRSGSTTQVHD
13 QAVFPPEGDFGLVRYDGPSTE--APSEVDLGDQTLPISGAAEASVGQEVFRMGSTTGLAD
15 14 QAVFPPEGDFALVRYDDPATE--APSEVDLGDQTLPISGAAEAAVGQEVFRMGSTTGLAD
15 -----
16 VAGSFPGDDFSLVEYANGKAGDGADVAVGDGKGVRTGAGEPAVGQVRVFRSGSTSGLRD
17 SGSVFPGSADMAVVRTVSGTVLRGYINGYGQGS-FPVSGSSEAAVGASICRSGSTTQVHC
18 QGSTFPGR-DIAWVATNANWTPRPLVNGYGRGD-VTVAGSTASVVGASVCRSGSTTGWHC
20 19 QGSIFPGR-DMAWVATNSSWTATPYVLGAGGQN-VQVTGSTASPVGASVCRSGSTTGWHC
20 RGSWFPGR-DMAWVAVNSNWTPPTSLVRNSGSG--VRVTGSTQATVGSIIKSGSTTGWRC
21 EESSFPGD-DMAWVSVNSDWNTPPTVNEGE---VTVSGSTEAAVGASICRSGSTTGWHC
22 QASTFPGR-DMAWVGVSNDWTATPDVKAEGGEK-IQLAGSVEALVGASVCRSGSTTGWHC
23 AGSYFPGR-DMGWVRTSADTVPLVNRNGGT-VTVTGSQEAATGSSVCRSGATTGWRC
25 24 AARVFPGR-DRAWVSLTSAQTLLPRVANGSSF--VTVRGSTEAAVGAACVCRSGRTTGYYQC
25 QGSFPNDY-DYAWVSVGSGWWTVPVVLGWGTVSDQLVRGNSVAPVGASICRSGSTTHWHC
26 EASQFGDGIDAAWAKNYGDWNGRGRVTHWNGGGGVDIKGSNEAAVGAHMCKSGRTTKWTC
27 ADYTFGGYGD SAIVRVDDPGF---WQPRGWVYPSTRITNWDYDYGQYVCKQGSTTGYTC

30 110 120 130 140 150
ASP GTITALNSSSVTYPEGTV-RGLIRTTVCAEPGDSGGSLLAGN-QAQVTSGGG-----
2 GSVTGLNATVNYGSSGIVYGMITNVCAEPGDSGGSLF-AGSTALGLTSGGS-----
3 GRVTGLNATVNYGGGDIVSGLIQTNVCAEPGDSGGALF-AGSTALGLTSGGS-----
4 GRVTALNATVNYGGGDVVGGLIQTTVCAEPGDSGGSLYGSNGTAYGLTSGGS-----
35 5 GRVTALNATVNYGGGDVVGGLIQTTVCAEPGDSGGSLYGSNGTAYGLTSGGS-----
6 GRVTALNATVNYGGGDIVSGLIQTTVCAEPGDSGGPLYGSNGTAYGLTSGGS-----
7 GSVTALNATVNYGGGDVYGMIRTNVCAEPGDSGGPLY-SGTRAILTSGGS-----
8 GTVTAVNVTVNYGDGP-VYGMVRTTAC SAGGDSGGAHF-AGSVALGIHSGSS-----
9 GTVSAVNVTVNYSDGP-VYGMVRTTAC SAGGDSGGAHF-AGSVALGIHSGSS-----
40 10 GTVTGLDATVNYGNGDIVNGLIQTVDCAEPGDSGGSLFSGDK-AVGLTSGGS-----
11 GTVTGLDATVNYGNGDIVNGLIQTVDCAEPGDSGGSLFSGDQ-AIGLTSGGS-----
12 GEVTALDATVNYGNGDIVNGLIQTTVCAEPGDSGGALFAGDT-ALGLTSGGS-----
13 GQVLGLDVTVNYPEG-TVTGLIQTVDCAEPGDSGGSLFTRDGLAIRLTSGGT-----
14 GQVLGLDATVNYPEG-MVTGLIQTVDCAEPGDSGGSLFTRDGLAIRLTSGGS-----
45 15 -----VDGLIQTVDCAEPGDSGGALFDGDA-AIGLTSGGS-----
16 GRVTALDATVNYPEG-TVTGLIETDCAEPGDSGGPMFSEGV-ALGVTSGGS-----
17 GTIGAKGATVNYPQGA-SGLTRTSVCAEPGDSGGSFYSGS-QAQVTSGGG-----
18 GTIQQLNTSVTYPEGTI-SGLTRTSVCAEPGDSGGSYISGS-QAQVTSGGG-----
19 GTVTQLNTSVTYQGTI-SPVTRTTVCAEPGDSGGSFISGS-QAQVTSGGG-----
50 20 GTIQQHNTSVTYPQGTI-TGVTRTSACAQPGDSGGSFISGT-QAQVTSGGG-----
21 GTIQQHNTSVTYPEGTI-TGVTRTSVCAEPGDSGGSYISGS-QAQVTSGGG-----
22 GTIQHNTSVTYPEGTV-DGLTETTVCAEPGDSGGPFVSGV-QAQGTSGGG-----
23 GTIQSKNQTVRYAEGTV-TGLTRTTACAEGGDSGGPWLTS-QAQVTSGGT-----
24 GTITAKNVTANYAEGAV-RGLTQGNACMGRGDSGGSWITSAGQAQGVMSGGNVQSNNGNC
55 25 GTVLAHNETVNYSDGSVVHQLTKTSVCAEGGDSGGSFISGD-QAQVTSGGW-----
26 GYLLRKDVSVNYGNHGI-VTLNETSACALGGDSGGAYVWND-QAQGITSN-----
27 QGITETNATVSYPGRTL-TGMTWSTACDAPGDSGGGVYDGSTAHGILSGGPN-----

160 170 180 189
60 ASP GNCRTGGTTFQPVNPILQAYGLRMITTDSGSSP (SEQ ID NO:18)
2 GNCRTGGTTFYQPVTEALSAYGATVL----- (SEQ ID NO:19)
3 GNCRTGGTT----- (SEQ ID NO:20)
4 GNCSSGGTTFQPVTEALSAYGVSVY----- (SEQ ID NO:21)
5 GNCSSGGTTFQPVTEALSAYGVSVY----- (SEQ ID NO:22)
65 6 GNCSSGGTTFQPVTEALSAYGVSVY----- (SEQ ID NO:23)
7 GNCSSGGTTFQPVTEALSAYGVSVY----- (SEQ ID NO:24)
8 GCSGTAGSAIHQPVTKALSAYGVTVYL----- (SEQ ID NO:25)

- 137 -

9	GCTGTNGSAIHQPVREALSAYGVNVY-----	(SEQ ID NO: 26)
10	GDCTSGGTTFFQPVTEALSATGTQIG-----	(SEQ ID NO: 27)
11	GDCTSGGTTFFQPVTEALSATGTQIG-----	(SEQ ID NO: 28)
12	GDCSSGGTTFFQPVPEALAAAYGAIEG-----	(SEQ ID NO: 29)
5 13	RDCTSGGTTFFQPVTTALAAVGGTLGGEDGGDG-	(SEQ ID NO: 30)
14	GDCTVGGETTFFQPVTTALAAVGATLGGEDGGAGA	(SEQ ID NO: 31)
15	GDCSQGGTTFFQPVTEALKAYGAQIGGGQGEPPE	(SEQ ID NO: 32)
16	GDCAKGGTTFFQPLPEAMASLGVRLIVPGREGAA	(SEQ ID NO: 33)
17	GDCSRGGTTYFQPVNRLQTYGLTLVTA-----	(SEQ ID NO: 34)
10 18	GNCSSGGTTYFQPINPLLQAYGLTLVTSGG--GT	(SEQ ID NO: 35)
19	GDCRTGGTTFFQPINALLQNYGLTLKTTGGDDGG	(SEQ ID NO: 36)
20	GNCSSGGTTYFQPINPLLSQYGLTLVRS-----	(SEQ ID NO: 37)
21	GNCTSGGTTYHQPINPLLSAYGLDLVTG-----	(SEQ ID NO: 38)
22	GDCTNGGTTYFQPVNPLLSDFGLTLKTTSA----	(SEQ ID NO: 39)
15 23	GDCRSGGITFFQPINPLLSYFGLQLVTG-----	(SEQ ID NO: 40)
24	GIPASQRSSLFERLQPIQLSQYGLSLVTG-----	(SEQ ID NO: 41)
25	GNCSSGGTTWFQPVNEILNRYGLTLHTA-----	(SEQ ID NO: 42)
26	-MDTNCRSFFQPVNTVLNKWKLSTVSTDTTTS	(SEQ ID NO: 43)
27	----SGCGMIHEPISRALADRGVTTLLAG-----	(SEQ ID NO: 44)

In the above listing, the numbers correspond as follows:

- | | |
|-------|---|
| 1 | ASP Protease |
| 2 | Streptogrisin A (<i>Streptomyces griseus</i>) |
| 25 3 | Glutamyl endopeptidase (<i>Streptomyces fradiae</i>) |
| 4 | Streptogrisin B (<i>Streptomyces lividans</i>) |
| 5 | SAM-P20 (<i>Streptomyces coelicolor</i>) |
| 6 | SAM-P20 (<i>Streptomyces albogriseolus</i>) |
| 7 | Streptogrisin B (<i>Streptomyces griseus</i>) |
| 30 8 | Glutamyl endopeptidase II (<i>Streptomyces griseus</i>) |
| 9 | Glutamyl endopeptidase II (<i>Streptomyces fradiae</i>) |
| 10 | Streptogrisin D (<i>Streptomyces albogriseolus</i>) |
| 11 | Streptogrisin D (<i>Streptomyces coelicolor</i>) |
| 12 | Streptogrisin D (<i>Streptomyces griseus</i>) |
| 35 13 | Subfamily S1E unassigned peptidase (SalO protein) (<i>Streptomyces lividans</i>) |
| 14 | Subfamily S1E unassigned peptidase (SALO protein) (<i>Streptomyces coelicolor</i>) |
| 15 | Streptogrisin D (<i>Streptomyces platensis</i>) |
| 16 | Subfamily S1E unassigned peptidase (3SC5B7.10 protein) (<i>Streptomyces coelicolor</i>) |
| 17 | CHY1 protease (<i>Metarhizium anisopliae</i>) |
| 40 18 | Streptogrisin C (<i>Streptomyces griseus</i>) |
| 19 | Streptogrisin C (SCD40A.16c protein) (<i>Streptomyces coelicolor</i>) |
| 20 | Subfamily S1E unassigned peptidase (I) (<i>Streptomyces sp.</i>) |
| 21 | Subfamily S1E unassigned peptidase (II) (<i>Streptomyces sp.</i>) |
| 22 | Subfamily S1E unassigned peptidase (SCF43A.19 protein) (<i>Streptomyces coelicolor</i>) |
| 45 23 | Subfamily S1E unassigned peptidase (<i>Thermobifida fusca</i> ; basonym) |

- 138 -

Thermomonospora fusca)24 Alpha-lytic endopeptidase (*Lysobacter enzymogenes*)25 Subfamily S1E unassigned peptidase (SC10G8.13C protein) (*Streptomyces coelicolor*)5 26 Yeast-lytic endopeptidase (*Rarobacter faecitabidus*)27 Subfamily S1E unassigned peptidase (SC10A5.18 protein) (*Streptomyces coelicolor*)10 **EXAMPLE 5****Screening for Novel Homologues of 69B4 Protease by PCR**

In this Example, methods used to screen for novel homologues of 69B4 protease are described. Bacterial strains of the suborder *Micrococcineae*, and in particular from the family *Cellulomonadaceae* and *Promicromonosporaceae* were ordered from the German culture collection, DSMZ (Braunschweig) and received as freeze dried cultures. Additional strains were received from the Belgian Coordinated Collections of Microorganisms, BCCM™/LMG (University of Ghent). The freeze-dried ampoules were opened according to DSMZ instructions and the material rehydrated with sterile physiological saline (1.5 ml) for 1h. Well-mixed, rehydrated cell suspensions (300 µL) were transferred to sterile Eppendorf tubes for subsequent PCR.

PCR Methods**i) Pretreatment of the Samples**

The rehydrated microbial cell suspensions were placed in boiling water bath for 10 min. The suspensions were then centrifuged at 16000 rpm for 5 min. (Sigma 1-15 centrifuge) to remove cell debris and remaining cells, the clear supernatant fraction serving as template for the PCR reaction.

(ii) PCR Test Conditions

The DNA from these types of bacteria (*Actinobacteria*) is characteristically highly GC rich (typically >55 mol%), so addition of DMSO is a necessity. The chosen concentration based on earlier work with the *Cellulomonas* sp. strain 69B4 was 4% v/v DMSO.

(iii) PCR Primers (chosen from the following pairs)

- 139 -

Prot-int_FW1 5'-TGCGCCGAGCCCGGCGACTC-3' (SEQ ID NO:45)
 Prot-int_RV1 5'-GAGTCGCGCGGGCTCGGCGCA-3' (SEQ ID NO:46)

Prot-int_FW2 5'-TTCCCCGGCAACGACTACGCGTGGGT-3' (SEQ ID NO:47)
 Prot-int_RV2 5'-ACCCACGCGTAGTCGTTGCCGGGGAA-3' (SEQ ID NO:48)

Cellu-FW1 5'-GCCGCTGCTCGATCGGGTTC-3' (SEQ ID NO:49)
 Cellu-RV1 5'-GCAGTTGCCGGAGCCGCCGGACGT-3' (SEQ ID NO:50)

(iv) **PCR Mixture (all materials supplied by Invitrogen)**

Template DNA	4μl
10x PCR buffer	5μl
50mM MgSO ₄	2μl
10mM dNTP's	1μl
Primers (10μM soln.)	1μl each
Platinum <i>Taq</i> hifi polymerase	0.5μl
DMSO	2μl
MilliQ water	33.5μl

(v) **PCR Protocol**

- 1) 94°C 5 min
- 2) 94°C 30 sec
- 3) 55°C 30 sec
- 4) 68°C 3 min
- 5) Repeat steps 2-4 repeat for 29 cycles
- 6) 68°C 10 min
- 7) 15°C 1 min

The amplified PCR products were examined by agarose gel electrophoresis. Distinct bands for each organism were excised from the gel, purified using the Qiagen gel extraction kit, and sequenced by BaseClear, using the same primer combinations.

(vi) **Sequence Analysis**

Nucleotide sequence data were analyzed and the DNA sequences were translated into amino acid sequences to review the homology to 69B4-mature protein. Sequence alignments were performed using AlignX, a component of Vector NTI suite 9.0.0. The results are compiled in Table 5-1. The numbering is that used in SEQ ID NO:8.

<p>Table 5-1. Percent Identity of (translated) Amino Acid Sequences found in Natural Isolate Strains Compared to 69B4 Mature Protease</p>
--

- 140 -

Microorganism	No. of Amino Acids	Overlap Position	% Identity
<i>Cellulomonas flavigena</i> DSM 20109	101	34 - 134	62
<i>Cellulomonas biazotea</i> DSM 20112	114	26 - 139	68
<i>Cellulomonas fimi</i> DSM20113	109	32 - 140	72
<i>Cellulomonas gelida</i> DSM 20111	48	142 - 189	69
<i>Cellulomonas iranensis</i> DSM 14785	85	52 - 123	66
<i>Cellulomonas cellasea</i> DSM 20109	102	32 - 133	63
<i>Cellulomonas xylanilytica</i> LMG 21723	143	16 - 158	73
<i>Oerskovia turbata</i> DSM 20577	111	34 - 144	74
<i>Oerskovia jenensis</i> DSM 46000	129	22 - 150	70
<i>Cellulosimicrobium cellulans</i> DSM 20424	134	35 - 168	53
<i>Promicromonospora citrea</i> DSM 43110	85	52 - 136	75
<i>Promicromonospora sukumoe</i> DSM 44121	85	52 - 136	73
<i>Xylanibacterium ulmi</i> LMG 21721	141	16 - 156	64
<i>Streptomyces griseus</i> ATCC 27001	No PCR product detected homologous to 69B4 protease		
<i>Streptomyces griseus</i> ATCC 10137			
<i>Streptomyces griseus</i> ATCC 23345			
<i>Streptomyces fradiae</i> ATCC 14544			
<i>Streptomyces coelicolor</i> ATCC 10147			
<i>Streptomyces lividans</i> TK23			

These results show that PCR primers based on polynucleotide sequences of the 69B4 protease gene (mature chain), SEQ ID NO:4 are successful in detecting homologous genes in bacterial strains of the suborder *Micrococcineae*, and in particular from the family *Cellulomonadaceae* and *Promicromonosporaceae*.

Figure 2 provides a phylogeny tree of ASP protease. The phylogeny of this protease was examined by a variety of approaches from mature sequences of similar members of the chymotrypsin superfamily of proteins and ASP homologues for which significant mature sequence has been deduced. Using protein distance methods known in the art (See e.g., Kimura, The Neutral Theory of Molecular Evolution, Cambridge University Press, Cambridge, UK [1983]) similar trees were obtained either including or excluding gaps. The phylogenetic tree of Figure 2 was constructed from aligned sequences (positions 16 –181 of SEQ ID NO:8) using TREECONW v.1.3b (Van de Peer and De Wachter, Comput. Appl. Biosci., 10:569 - 570 [1994]) and with tree topology inferred by the Neighbor-Joining algorithm (Saitou and Nei, Mol. Biol. Evol., 4:406 - 425 [1987]). As indicated by this tree, the data indicate that the ASP series of homologous proteases ("cellulomonadins") forms a separate subfamily of proteins. In Figure 2, the numbers provided in brackets correspond to

- 141 -

the sequences provided herein.

The following is an alignment between the *Cellulomonas* 69B4 ASP protease and homologous proteases of related genera described herein.

6	1	50
69B4 (ASP) complete	(1)	MTPTVTTRALAVATAAAATLLAGGMAAQANEPAPPGSASAPPRLAEKLPDP
Cellulomonas gelida	(1)	-----
Cellulomonas flavigena	(1)	-----
Cellulomonas biazotea	(1)	-----
10 Cellulomonas fimi	(1)	-----
Cellulomonas iranensis	(1)	-----
Cellulomonas cellasea	(1)	-----
C. xylanilytica	(1)	-----
Oerskovia turbata	(1)	MARSFWRTLATAACAATLVAGPAALTANAATPTPTPTVSPQTSSKVSPE
15 Oerskovia jenensis	(1)	-----
Cm. cellulans	(1)	-----
Pm. citrea	(1)	-----
Pm. sukumoe	(1)	-----
69B4 (ASP) mature	(1)	-----
20 Consensus	(1)	-----
	51	100
69B4 (ASP) complete	(51)	LLEAMERDLGLDAEEAAATLAFQHDAETGEALAEELDEDF-AGTWVEDD
Cellulomonas gelida	(1)	-----
25 Cellulomonas flavigena	(1)	-----
Cellulomonas biazotea	(1)	-----
Cellulomonas fimi	(1)	-----
Cellulomonas iranensis	(1)	-----
Cellulomonas cellasea	(1)	-----V
30 C. xylanilytica	(1)	-----
Oerskovia turbata	(51)	VLRLQRDLGLSAKDARKLAFQSDAATEDALADSLDAYAGAWVDPARN
Oerskovia jenensis	(1)	-----
Cm. cellulans	(1)	-----PRAAGRAARSSGSRASAS
Pm. citrea	(1)	-----
Pm. sukumoe	(1)	-----
35 69B4 (ASP) mature	(1)	-----
Consensus	(51)	-----
	101	150
69B4 (ASP) complete	(100)	VLYVATTDDEDAVEEVEGEGATAVTVEHSLADLEAWKTVLDAALEGHDDVP
Cellulomonas gelida	(1)	-----
Cellulomonas flavigena	(1)	-----
Cellulomonas biazotea	(1)	-----KQTASEFVIRLTIGELNLAAANSPLPIGHAWSTAL
Cellulomonas fimi	(1)	-----
45 Cellulomonas iranensis	(1)	-----
Cellulomonas cellasea	(2)	GRVRQLPLRGHDVLPARERDPAGLRASRPGLTRSRRARLDAAGPSARVA
C. xylanilytica	(1)	-----
Oerskovia turbata	(101)	TLYVGVDRAEAKVRSAGATPVVVDHTLAELDTWKAALDGLNDPAGVP
Oerskovia jenensis	(1)	-----
50 Cm. cellulans	(19)	TSPGPTSVTASASSCGRATGRRQRWTFEADGTVRAGGKCMDVAWAPRPTA
Pm. citrea	(1)	-----
Pm. sukumoe	(1)	-----
69B4 (ASP) mature	(1)	-----
Consensus	(101)	-----
	151	200
69B4 (ASP) complete	(150)	TWYVDVPTNSVVVAVKAGAQDVAAGLVEGADVPSDAVTFVETDETPRTMF
Cellulomonas gelida	(1)	-----
Cellulomonas flavigena	(1)	-----V
60 Cellulomonas biazotea	(36)	GWYVDVTTNTVVVNATALAVAQATEIVAAATVPADAVRVVETTEAPRTFI
Cellulomonas fimi	(1)	-----V
Cellulomonas iranensis	(1)	-----
Cellulomonas cellasea	(52)	AWYVDVPTNKLVVESVG--DTAAAADAVAAAGLPADAVTLATTEAPRTFV
C. xylanilytica	(1)	-----
65 Oerskovia turbata	(151)	SWFVDVTTNQVVNVHDGGRALAEALAAASAGVPADAITVYTTTEAPRPLV
O. jenenensis rev	(1)	-----
Cm. cellulans	(69)	RRSSRTARQRGPEVRAQRGRPRVGAGEQSASTPPGAHRGTRGAVRAHG
Pm. citrea	(1)	-----
Pm. sukumoe	(1)	-----
70 69B4 (ASP) mature	(1)	-----F
Consensus	(151)	-----

- 142 -

5	69B4 (ASP) complete	(200)	DVIGGNAYTIGGRSR-----CSIGFAVNGGFFITAGHCGRGTGA-----TTA	
	Cellulomonas gelida	(1)	-----	
	Cellulomonas flavigena	(2)	DVIGGNAYYIGSRSR-----CSIGFAVEGGFVTAGHCGRAGA-----STS	
	Cellulomonas biazotea	(86)	DVIGGNRYRINNTSR-----CSVGFAVSGGFVTAGHCGRGTGA-----TTT	
	C. fimi. revi	(2)	DVIGGDAYYIGGRSR-----CSIGFAVTGGFVTAGHCGRGTGA-----ATT	
10	C. iranensis revi	(1)	-----	
	Cellulomonas cellasea	(100)	DVIGGNAYYINASSR-----CSVGFAVEGGFVTAGHCGRAGA-----STS	
	C. xylanilytica	(1)	-----R-----CSIGFAVTGGFVTAGHCGRSGA-----TTT	
	Oerskovia turbata	(201)	DVVGGNAYTMGSGGR-----CSVGFAVNGGFFITAGHCGRSVGT-----RTS	
	Oerskovia jenensis	(1)	-----R-----CSVGFAVNGGFFVTAGHCGRVTGT-----RTS	
15	Cm. cellulans	(119)	DVRGGDRYITRDPGASSGSACSIGYAVQGGFVTAGHCGRGGTRRVLTAWS	
	Pm. citrea	(1)	-----	
	Pm. sukumoe	(1)	-----	
	69B4 (ASP) mature	(2)	DVIGGNAYTIGGRSR-----CSIGFAVNGGFFITAGHCGRGTGA-----TTA	
	Consensus	(201)	DVIGG Y I R CSIGFAV GGFVTAGHCGR GA TS	
				251 300
20	69B4 (ASP) complete	(240)	NPTGTFAGSSFFPGNDYAFVRTGAGVNLLAQVNNSGGRVQVAGHTAAPVG	
	Cellulomonas gelida	(1)	-----	
	Cellulomonas flavigena	(42)	SPSGTFRGSSFFPGNDYAWVQVAGSNTPRGLVNNHSGGTVRVTGSQQAAGV	
	Cellulomonas biazotea	(126)	KPSGTFAGSSFFPGNDYAWVRVASGNTPVGAVNNYSGGTVAVAGSTQATVG	
	Cellulomonas fimi	(42)	SPSGTFRGSSFFPGNDYAWVRVASGNTPVGAVNNYSGGTVAVAGSTQAAVG	
25	Cellulomonas iranensis	(1)	-----FPGNDYAWVQVGSDDTPRGLVNNYAGGTVRVTGSQQAAGV	
	Cellulomonas cellasea	(140)	SPSGTFRGSSFFPGNDYAWVQVAGSNTPRGLVNNHSGGTVRVTGSQQAAGV	
	C. xylanilytica	(27)	SPSGTFRGSSFFPGNDYAWVRAASGNTPVGAVNNYDGSRTVAGSTDAAGV	
	Oerskovia turbata	(241)	GPGGTFRGSSFFPGNDYAWVQVDAAGTNPVAVNNYSGGRVAVAGSTAAAPVG	
	Oerskovia jenensis	(27)	GPGGTFRGSSFFPGNDYAWVQVDAAGTNPVAVNNYSGGRVAVAGSTAAAPVG	
30	Cm. cellulans	(169)	ARMGTVQAASFPGHDYAWVRVDAGFSPVPRVNNYAGGTVDVAGSAEAPVG	
	Pm. citrea	(1)	-----FPGNDYAWVNTGTDLTVGAVNNYSGGTVNVAGSTRAAVG	
	Pm. sukumoe	(1)	-----FPGNDYAWVNVGSDDTPIGAVNNYSGGTVNVAGSTQAAVG	
	69B4 (ASP) mature	(42)	NPTGTFAGSSFFPGNDYAFVRTGAGVNLLAQVNNSGGRVQVAGHTAAPVG	
	Consensus	(251)	P GTF GSSFFPGNDYAWVQVAGSNTPVGAVNNYSGGTV VAGST AAVG	
				301 350
35	69B4 (ASP) complete	(290)	SAVCRSGSTTGWHCGTITALNSSSVTYPEPGTVRGLIRTTVCAEPGDSGGSL	
	Cellulomonas gelida	(1)	-----	
	Cellulomonas flavigena	(92)	SYVCRSGSTTGWRCGYVRAYNNTTVRYAEGSVSGLIRTSVCAEPGDSGGSL	
	Cellulomonas biazotea	(176)	ASVCRSGSTTGWRCGTIAAFNSTVNYAAGSVSGLIRTNVCAEPGDSGGSL	
	Cellulomonas fimi	(92)	ATVCRSGSTTGWRCGTIAAFNATVNYAEGSVSGLIRTNVCAEPGDSGGSL	
40	Cellulomonas iranensis	(41)	AYVCRSGSTTGWRCGTVQAYNASVRYAEGTVSGLIRTNVCAEPGD-----	
	Cellulomonas cellasea	(190)	SYVCRSGSTTGWRCGYVRAYNNTTVRYAEGSVSGLIRTSVCAEPGDSGGSL	
	C. xylanilytica	(77)	AAVCRSGSTTGWRCGTIQRGASVTYAQGTVSGLIRTNVCAEPGDSGGSL	
	Oerskovia turbata	(291)	ASVCRSGSTTGWHCGTIGAYNTSVTYPQGTVSGLIRTNVCAEPGDSGGSL	
	Oerskovia jenensis	(77)	SSVCRSGSTTGWRCGTIAAYNSSSVTYPQGTVSGLIRTNVCAEPGDSGGSL	
45	Cm. cellulans	(219)	ASVCRSGATTGWRCGVIEQKNITVNYGNDVPGLVRGSACAEGGDSGGSV	
	Pm. citrea	(41)	ATVCRSGSTTGWHCGTIALNASVTYAEGTVSGLIRTNVCAEPGD-----	
	Pm. sukumoe	(41)	STVCRSGSTTGWHCGTIAAFNASVTYAEGTVSGLIRTNVCAEPGD-----	
	69B4 (ASP) mature	(92)	SAVCRSGSTTGWHCGTITALNSSSVTYPEPGTVRGLIRTTVCAEPGDSGGSL	
	Consensus	(301)	ASVCRSGSTTGWHRCGTI AYNASV YAEGTVSGLIRTNVCAEPGDSGGSL	
				351 400
55	69B4 (ASP) complete	(340)	LAGNQAQGVTSGGSGNCRTGGTTFQPVNPILQAYGLRMITT-DSGSSPA	
	Cellulomonas gelida	(1)	LAGNQAQGVTSGGSGNCSSGGTTYFQPVNEALRVYGLTLVTS-DGGGTE-	
	Cellulomonas flavigena	(142)	VAGTQAQGVTSGGSGNCRYGTTYFQPVNEILQDQPGPSTTR-AL-----	
	Cellulomonas biazotea	(226)	LAGNQAQGLTSGGSGNCTTGGTTYFQPVNEALSAYGLTLVTS-SGGGGGGG	
	Cellulomonas fimi	(142)	VAG-----	
60	Cellulomonas iranensis	(86)	-----	
	Cellulomonas cellasea	(240)	VAGTQAQGVTSGGSGNCRYGTTYFQPVNEILQAYGLRLVLG-HARGGPS	
	C. xylanilytica	(127)	IAGTQAQGVTSGGSGNC-----	
	Oerskovia turbata	(341)	LAGNQAQGVTSGGSGNCSSGGTTYFQPVNEALGGYGLTLVTS-DGGGPPSR	
	Oerskovia jenensis	(127)	LAGNQAQGLTSGGSGNCTTGGTTYFQPVNEALSAYGLTLVTS-SGGRGNC--	
65	Cm. cellulans	(269)	ISGNQAQGVTSGRINDCSNGGKFLYQPDRRPVARDHGRRVQGRARRARGQ	
	Pm. citrea	(86)	-----	
	Pm. sukumoe	(86)	-----	
	69B4 (ASP) mature	(142)	LAGNQAQGVTSGGSGNCRTGGTTFQPVNPILQAYGLRMITTDSGSSP--	
	Consensus	(351)	LAGNQAQGVTSGGSGNC GGTTFYQPVN L YGL LV	
				70
70	69B4 (ASP) complete	(389)	-PAPTSCTGYARTFTGTLAAGRAAAQPNGSYVQVNRSGTHSVCLNGPSGA	
	Cellulomonas gelida	(49)	-PPPTGCGQYARTYQGSVSAGTSVAQPNGSYVTTG-GGTHRVCLSGPAGT	
	Cellulomonas flavigena	(186)	-----	
	Cellulomonas biazotea	(276)	-----TTCTGYARTYTGSLASRQSAVQPSGSYVTVGSSGTIRVCLDGPST	
	Cellulomonas fimi	(145)	-----	
75	Cellulomonas iranensis	(86)	-----	
	Cellulomonas cellasea	(289)	-PARRAPAPPARA-----	
	C. xylanilytica	(144)	-----	

- 143 -

	Oerskovia turbata	(391)	RPGARAMRGPTRAASRPGRRSRSERFVRHDRGRATGCA-----	
	Oerskovia jenensis	(175)	-----	
	Cm. cellulans	(319)	VHRRPRVRLQ-----	
	Pm. citrea	(86)	-----	
5	Pm. sukumoe	(86)	-----	
	69B4 (ASP) mature	(190)	-----	
	Consensus	(401)	-----	
			451	500
10	69B4 (ASP) complete	(438)	DFDLYVQRWNGSSWVTVAQSTSPGSNETITYRGNAGYYRYVVNAASGSGA	
	Cellulomonas gelida	(97)	DLDLYLQKWNGYSWASVAQSTSPGATEAVTYTGTAGYYRYVVHAYAGSGA	
	Cellulomonas flavigena	(186)	-----	
	Cellulomonas biazotea	(322)	DFDLYLQKWNGSAW-----	
	Cellulomonas fimi	(145)	-----	
15	Cellulomonas iranensis	(86)	-----	
	Cellulomonas cellasea	(301)	-----	
	C. xylanilytica	(144)	-----	
	Oerskovia turbata	(429)	-----	
	Oerskovia jenensis	(175)	-----	
20	Cm. cellulans	(329)	-----	
	Pm. citrea	(86)	-----	
	Pm. sukumoe	(86)	-----	
	69B4 (ASP) mature	(190)	-----	
	Consensus	(451)	-----	
25			501	
	69B4 (ASP) complete	(488)	YTMGLTLP	(SEQ ID NO:6)
	Cellulomonas gelida	(147)	YTLGATTP	(SEQ ID NO:60)
	Cellulomonas flavigena	(186)	-----	(SEQ ID NO:54)
30	Cellulomonas biazotea	(336)	-----	(SEQ ID NO:56)
	Cellulomonas fimi	(145)	-----	(SEQ ID NO:58)
	Cellulomonas iranensis	(86)	-----	(SEQ ID NO:62)
	Cellulomonas cellasea	(301)	-----	(SEQ ID NO:64)
	C. xylanilytica	(144)	-----	(SEQ ID NO:66)
35	Oerskovia turbata	(429)	-----	(SEQ ID NO:68)
	Oerskovia jenensis	(175)	-----	(SEQ ID NO:70)
	Cm. cellulans	(329)	-----	(SEQ ID NO:72)
	Pm. citrea	(86)	-----	(SEQ ID NO:74)
	Pm. sukumoe	(86)	-----	(SEQ ID NO:76)
40	69B4 (ASP) mature	(190)	-----	(SEQ ID NO:8)
	Consensus	(501)	-----	(SEQ ID NO:647)

45

EXAMPLE 6

Detection of Novel Homologues of 69B4 Protease by Immunoblotting

In this Example, immunoblotting experiments used to detect homologues of 69B4 are described. The following organisms were used in these experiments :

- 50 1. *Cellulomonas biazotea* DSM 20112
2. *Cellulomonas flavigena* DSM 20109
3. *Cellulomonas fimi* DSM 20113
4. *Cellulomonas cellasea* DSM 20118
5. *Cellulomonas uda* DSM 20107
- 55 6. *Cellulomonas gelida* DSM 20111
7. *Cellulomonas xylanilytica* LMG 21723
8. *Cellulomonas iranensis* DSM 14785
9. *Oerskovia jenensis* DSM 46000
10. *Oerskovia turbata* DSM 20577
- 60 11. *Cellulosimicrobium cellulans* DSM 20424
12. *Xylanibacterium ulmi* LMG21721
13. *Isoptericola variabilis* DSM 10177
14. *Xylanimicrobium pachnodae* DSM 12657

- 144 -

15. *Promicromonospora citrea* DSM 43110
16. *Promicromonospora sukumoe* DSM 44121
17. *Agromyces ramosus* DSM 43045

The strains were first grown on Heart Infusion/skim milk agar plates (72 h, 30°C) to confirm strain purity, protease reaction by clearing of the skim milk and to serve as inoculum. Bacterial strains were cultivated on Brain Heart Infusion broth supplemented with casein (0.8% w/v) in 100/500 Erlenmeyer flasks with baffles at 230 rpm, 30°C for 5 days. Microbial growth was checked by microscopy. Supernatants were separated from cells by centrifugation for 30 min at 4766 x g. Further solids were removed by centrifugation at 9500 rpm. Supernatants were concentrated using Vivaspinn 20 ml concentrator (Vivascience), cutoff 10 kDa, by centrifugation at 4000 x g. Concentrates were stored in aliquots of 0.5 mL at -20°C.

Primary antibody

The primary antibody (EP034323) for the immunoblotting reaction, prepared by Eurogentec (Liège Science Park, Seraing, Belgium) was raised against 2 peptides consisting of amino acids 151-164 and 178-189 in the 69B4 mature protease (SEQ ID NO:8), namely:

TSGGSGNCRTGGTT (epitope 1; SEQ ID NO:51) and LRMITTDSGSSP (epitope 2; SEQ ID NO:52) as shown below in the amino acid sequence of 69B4 mature protease:

```

1   FDVIGGNAYT IGGRSRCISG FAVNGGFITA GHCGRTGATT ANPTGTFAGS
51  SFPGNDYAFV RTGAGVNLLA QVNNYSGGRV QVAGHTAAPV GSAVCRSGST
101 TGWHCGTITA LNSSVTYPEG TVRGLIRTTV CAEPGDSGGS LLAGNQAQGV
151 TSGGSGNCRT GGTTFQPVN PILQAYGLRMITTDSGSSP (SEQ ID NO:8)

```

Electrophoresis and Immunoblotting

Sample preparation

1. Concentrated culture supernatant (50 µL)
 2. PMSF (1 µL; 20 mg/ml)
 3. 1M HCl (25 µL)
 4. Nu PAGE LDS sample buffer (25 µL) (Invitrogen, Carlsbad, CA, USA)
- Mixed and heated at 90°C for 10 min.

Electrophoresis

SDS-PAGE was performed in duplicate using NuPAGE 10% Bis-Tris gels (Invitrogen) with MES-SDS running buffer at 100 v for 5 min. and 200 v constant. Where

- 145 -

possible, 25 μ L sample were loaded in each slot. One gel of each pair was stained with Coomassie Blue and the other gel was used for immunoblotting using the Boehringer Mannheim chromogenic Western blotting protocol (Roche).

Immunoblotting

The transfer buffer used was Transfer buffer: Tris (0.25M) – glycine (1.92M) – methanol (20% v/v). The PVDF membrane was pre-wetted by successive moistening in methanol, deionized water, and finally transfer buffer.

The PAGE gel was briefly washed in deionized water and transferred to blotting pads soaked in transfer buffer, covered with pre-wetted PVDF membrane and pre-soaked blotting pads. Blotting was performed in transfer buffer at 400 mA constant for 2.5-3 h. The membrane was briefly washed (2x) in Tris buffered saline (TBS) (0.5M Tris, 0.15M NaCl, pH7.5). Non-specific antibody binding was prevented by incubating the membrane in 1% v/v mouse/rabbit Blocking Reagent (Roche) in maleic acid solution (100 mM maleic acid, 150 mM NaCl, pH7.5) overnight at 4°C.

The primary antibody used in these reactions was EP034323 diluted 1:1000. The reaction was performed with the Ab diluted in 1% Blocking Solution with a 30 min. action time. The membrane was washed 4x 10 min. in TBST (TSB + 0.1% v/v Tween 20).

The secondary antibody consisted of anti-mouse/anti-rabbit IgG (Roche) 73 μ L in 20 ml in 1% Blocking Solution with a reaction time of 30 min. The membrane was washed 4x 15 min. in TBST and the substrate reaction (alkaline phosphatase) performed with BM Chromogenic Western Blotting Reagent (Roche) until staining occurred.

The results of the cross-reactivity with primary polyclonal antibody are shown in Table 6-1.

Table 6-1. Immunoblotting Results

Strain	Immuno-Blot Result	Estimated Molecular Mass kDa	% Sequence Identity to 69B4 Mature Protease	Protease Activity On HI-Skim Milk Agar
<i>C. flavigena</i> DSM 20109	positive	21	66	positive
<i>C. biazotea</i> DSM 20112	negative		65	positive
<i>C. fimi</i> DSM 20112	negative		72	weak +
<i>C. gelida</i> DSM 20111	positive	20	69	weak +

- 146 -

<i>C. uda</i> DSM 20107	negative			weak +
<i>C. iranensis</i> DSM 14785	negative		33	weak +
<i>C. cellasea</i> DSM 20118	positive	27	61	positive
<i>C. xylanilytica</i> LMG 21723	negative		69	positive
<i>O. turbata</i> DSM 20577	positive	18	73	positive
<i>O. jenensis</i> DSM 46000	positive	35	78	positive
<i>C. cellulans</i> DSM 20424	negative		48	positive
<i>P. citrea</i> DSM 43110	negative		28	positive
<i>P. sukumoe</i> DSM 44121	negative		69	positive
<i>X. ulmi</i> LMG21721	negative		72	negative
<i>I. variabilis</i> DSM 10177	negative			positive
<i>X. pachnodae</i> DSM 12657	negative			weak +
<i>A. ramosus</i> DSM 43045	negative			weak +

Based on these results, it is clear that the antibody used in these experiments is highly specific at detecting homologues with a very high percentage of amino acid sequence identity to 69B4 protease. Furthermore, these results indicate that the C-terminal portion of the 69B4 mature protease chain is fairly variable especially in the region of the 2-peptide epitopes. In these experiments, it was determined that in cases where there were more than 2 amino acid differences in this region a negative Western blotting reaction resulted.

EXAMPLE 7

Inverse PCR and Genome Walking

In this Example, experiments conducted to elucidate polynucleotide sequences of ASP are described. The microorganisms utilized in these experiments were :

1. *Cellulomonas biazotea* DSM 20112
2. *Cellulomonas flavigena* DSM 20109
3. *Cellulomonas fimi* DSM 20113
4. *Cellulomonas cellasea* DSM 20118
5. *Cellulomonas gelida* DSM 20111
6. *Cellulomonas iranensis* (DSM 14785)
7. *Oerskovia jenensis* DSM 46000

- 147 -

8. *Oerskovia turbata* DSM 20577
9. *Cellulosimicrobium cellulans* DSM 20424
10. *Promicromonospora citrea* DSM 43110
11. *Promicromonospora sukumoe* DSM 44121

These bacterial strains were cultivated on Brain Heart Infusion broth or Tryptone Soya broth in 100/500 Erlenmeyer flasks with baffles at 230 rpm, 30°C for 2 days. Cells were separated from the culture broth by centrifugation for 30 min at 4766 x g.

Chromosomal DNA was obtained by standard phenol/chloroform extraction method known in the art from cells digested by lysozyme/EDTA (See e.g., Sambrook *et al.*, *supra*). Chromosomal DNA was digested with the restriction enzymes selected from the following list: *Apal*, *BamHI*, *BssHII*, *KpnI*, *NarI*, *NcoI*, *NheI*, *PvuI*, *SalI* or *SstII*.

The nucleotide and amino acid sequences of these organisms are provided below. In these listings, the mature protease is indicated in bold and the signal sequence is underlined.

C. flavigena (DSM 20109)

```

1  GTCGACGTCA TCGGGGGCAA CGCGTACTAC ATCGGGGTCGC GCTCGCGGTG
   CAGCTGCAGT AGCCCCCGTT GCGCATGATG TAGCCAGCG CGAGCGCCAC

51  CTCGATCGGG TTCGCGGTGCG AGGGCGGGTT CGTCACCGCG GGGCACTGCG
   GAGCTAGCCC AAGCGCCAGC TCCCGCCCAA GCAGTGGCGC CCCGTGACGC

101 GCGCGCGGGG CGCGAGCAGC TCGTCACCGT CGGGGACCTT CCGCGGCTCG
   CCGCGCGCCC GCGCTCGTGC AGCAGTGGCA GCCCCTGGAA GGCGCCGAGC

151 TCGTTCCCCG GCAACGACTA CGCGTGGGTC CAGGTCGCCT CGGGCAACAC
   AGCAAGGGGC CGTTGCTGAT GCGCACCCAG GTCCAGCGGA GCCCGTTGTG

201 GCCGCGCGGG CTGGTGAACA ACCACTCGGG CGGCACGGTG CGCGTCACCG
   CGGCGCGCCC GACCACTTGT TGGTGAGCCC GCCGTGCCAC GCGCAGTGGC

251 GCTCGCAGCA GGCCGCGGTC GGCTCGTACG TGTGCCGATC GGGCAGCACG
   CGAGCGTCGT CCGGCGCCAG CCGAGCATGC ACACGGCTAG CCCGTCGTGC

301 ACGGGATGGC GGTGCGGCTA CGTCCGGGCG TACAACACGA CCGTGCGGTA
   TGCCCTACCG CCACGCCGAT GCAGGCCCGC ATGTTGTGCT GGCACGCCAT

351 CGCGGAGGGC TCGGTCTCGG GCCTCATCCG CACGAGCGTG TCGCCGAGC
   GCGCCTCCCG AGCCAGAGCC CGGAGTAGGC GTGCTCGCAC ACGCGGCTCG

401 CGGGCGACTC CGGCGGCTCG CTGGTCGCCG GCACGCAGGC CCAGGGCGTC
   GCCCGCTGAG GCCGCCGAGC GACCAGCGGC CGTGCGTCCG GGTCCCGCAG

451 ACGTCGGGCG GGTCCGGCAA CTGCCGCTAC GGGGGCACGA CGTACTTCCA

```

- 148 -

TGCAGCCCCG C CAGGCCGTT GACGGCGATG CCCCCGTGCT GCATGAAGGT

501 GCGCGTGAAC GAGATCCTGC AGGACCAGCC CGGGCCGTCG ACCACGCGTG
CGGGCACTTG CTCTAGGACG TCCTGGTCGG GCCCGGCAGC TGGTGCGCAC

551 CCCTA
GGGAT (SEQ ID NO:53)

Cellulomonas flavigena (DSM 20109)

1 VDVIGGNAYY IGSRSRCSIG FAVEGGFVTA GHCGRAGAST SSPSGTFRGS
51 SFPGNDYAWV QVASGNTPRG LVNNHSGGTV RVTGSQQAAY GSYVCRSGST
101 TGWRGCGYVRA YNTTVRYAEG SVSGLIRTSV CAEPGDSGGS LVAGTQAQGV
151 TSGGSGNCRY GGTTFYQPVN EILQDQPGPS TTRAL (SEQ ID NO:54)

Cellulomonas biazotea (DSM 20112)

1 TAAAACAGAC GGCCAGTGAA TTTGTAATAC GACTCACTAT AGGCGAATTG
ATTTTGTCTG CCGGTCACCT AAACATTATG CTGAGTGATA TCCGCTTAAC
51 AATTTAGCGG CCGCGAATTC GCCCTTACCT ATAGGGCACG CGTGGTCGAC
TTAAATCGCC GCGGCTTAAG CGGGAATGGA TATCCCGTGC GCACCAGCTG
101 GGCCCTGGGC TGGTACGTCG ACGTCACTAC CAACACGGTC GTCGTCAACG
CCGGGACCCG ACCATGCAGC TGCAGTGATG GTTGTGCCAG CAGCAGTTGC
151 CCACCGCCCT CGCCGTGGCC CAGGCGACCG AGATCGTCGC CGCCGCAACG
GGTGGCGGGA GCGGCACCGG GTCCGCTGGC TCTAGCAGCG GCGGCGTTGC
201 GTGCCCCCGG ACGCCGTCCG GGTGTCGAG ACCACCGAGG CGCCCCGCAC
CACGGGCGGC TGCGGCAGGC CCAGCAGCTC TGGTGGCTCC GCGGGGCGTG
251 GTTCATCGAC GTCATCGGCG GCAACCGTTA CCGGATCAAC AACACCTCGC
CAAGTAGCTG CAGTAGCCGC CGTTGGCAAT GGCTAGTTG TTGTGGAGCG
301 GCTGCTCGGT CGGCTTCGCC GTCAGCGGCG GCTTCGTCAC CGCCGGGCAC
CGACGAGCCA GCCGAAGCGG CAGTCGCCGC CGAAGCAGTG GCGGCCCCGTG
351 TGCGGCACGA CCGGCGCGAC CACGACGAAA CCGTCCGGCA CGTTCCGCCG
ACGCCGTGCT GGCCGCGCTG GTGCTGCTTT GGCAGGCCGT GCAAGCGGCC
401 CTCGTCGTTT CCCGGCAACG ACTACGCGTG GGTGCGCGTC GCGTCCGGCA
GAGCAGCAAG GGGCCGTTGC TGATGCGCAC CCACGCGCAG CGCAGGCCGT
451 ACACCCCGGT CGGCGCCGTG AACAACTACA GCGGCGGCAC CGTGGCCGTC
TGTGGGGCCA GCCGCGGCAC TTGTTGATGT CGCCGCCGTG GCACCGGCAG
501 GCGGCTCGA CGCAGGCGAC CGTCGGTGCG TCCGTCTGCC GCTCCGGCTC
CGGCCGAGCT GCGTCCGCTG GCAGCCACGC AGGCAGACGG CGAGGCCGAG
551 CACCACGGGG TGGCGCTGCG GGACGATCCA GCGGTTCAAC TCCACCGTCA
GTGGTGCCCC ACCGCGACGC CCTGCTAGGT CCGCAAGTTG AGGTGGCAGT

- 149 -

601 ACTACGCGCA GGGCAGCGTC TCCGGCCTCA TCCGCACGAA CGTGTGCGCC
 TGATGCGCGT CCCGTCGCAG AGGCCGGAGT AGGCGTGCTT GCACACGCGG
 5 651 GAGCCCGGCG ACTCCGGCGG CTCGCTCATC GCCGGCAACC AGGCCAGGG
 CTCGGGCCGC TGAGGCCGCC GAGCGAGTAG CGGCCGTGG TCCGGGTCCC
 701 CCTGACGTCC GGCGGGTCGG GCAACTGCAC CACCGGCGGG ACGACGTACT
 GGACTGCAGG CCGCCCAGCC CGTTGACGTG GTGGCCGCC TGCTGCATGA
 10 751 TCCAGCCCGT CAACGAGGCG CTCTCCGCCT ACGGCCTGAC GCTCGTCACG
 AGGTCGGGCA GTTGCTCCGC GAGAGGCGGA TGCCGGACTG CGAGCAGTGC
 801 TCGTCCGGCG GCGGCGGTGG CGGCGGCACG ACCTGCACCG GGTACGCGCG
 AGCAGGCCCG CGCCGCCACC GCCGCCGTGC TGGACGTGGC CCATGCGCGC
 15 851 GACCTACACC GGCTCGCTCG CCTCGCGGCA GTCCGCCGTC CAGCCGTCCG
 CTGGATGTGG CCGAGCGAGC GGAGCGCCGT CAGGCGGCAG GTCGGCAGGC
 901 GCAGCTATGT GACCGTCGGG TCCAGCGGCA CCATCCGCGT CTGCCTCGAC
 20 CGTCGATACA CTGGCAGCCC AGGTCGCCGT GGTAGGCGCA GACGGAGCTG
 951 GGCCCGAGCG GGACGGACTT CGACCTGTAC CTGCAGAAAGT GGAACGGGTC
 CCGGGCTCGC CCTGCCTGAA GCTGGACATG GACGTCTTCA CCTTGCCCAG
 25 1001 CGCGTGGGC (SEQ ID NO:55)
 GCGCACCCG

Cellulomonas biazotea (DSM 20112)

30 1 KQTASEFVIR LTIGELNLAA ANSPLPIGHA WSTALGWYVD VTTNTVVVNA
 51 TALAVAQATE IVAAATVPAD AVRUVETTEA PRTFIDVIGG NRYRINNTSR
 101 CSVGFAVSGG FVTAGHCGTT GATTTKPSGT FAGSSFPND YAWVRVASGN
 151 TPVGAVNNYS GGTVAVAGST QATVGASVCR SGSTTGWRCG TIQAFNSTVN
 201 YAQGSVSLI RTNVCAEPGD SGGSLIAGNQ AQGLTSGGSG NCTTGGTTFYF
 35 251 QPVNEALSAY GLTLVTSSGG GGGGGTTCTG YARTYTGSLA SRQSAVQPSG
 301 SYVTVGSSGT IRVCLDGPST TDFDLYLQKW NGSAA (SEQ ID NO:56)

Cellulomonas fimi (DSM 20113)

40 1 GTGGACGTGA TCGGCGGCGA CGCCTACTAC ATCGGCGGCC GCAGCCGCTG
 CACCTGCACT AGCCGCCGCT GCGGATGATG TAGCCGCCGG CGTCGGCGAC
 45 51 TTCGATCGGG TTCGCCGTCA CCGGGGGCTT CGTGACCGCC GGGCACTGCG
 AAGCTAGCCC AAGCGGCAGT GGCCCCGAA GCACTGGCGG CCCGTGACGC
 101 GCCGCACCGG CGCGGCCACG ACGAGCCCGT CGGGCACGTT CGCCGGCTCG
 CGGCGTGGCC GCGCCGGTGC TGCTCGGGCA GCCCGTGCAA GCGGCCGAGC
 50 151 AGCTTCCCGG GCAACGACTA CGCGTGGGTG CGGGTCGCGT CGGGCAACAC
 TCGAAGGGCC CGTTGCTGAT GCGCACCCAC GCCAGCGCA GCCCGTTGTG

- 150 -

201 GCCCGTCGGC GCGGTGAACA ACTACAGCGG CGGCACGGTC GCCGTCGCCG
CGGGCAGCCG CGCCACTTGT TGATGTCGCC GCCGTGCCAG CGGCAGCGGC

251 GCTCGACCCA GGCCGCCGTC GGTGCGACCG TGTGCCGCTC GGGCTCCACC
CGAGCTGGGT CCGGCGGCAG CCACGCTGGC ACACGGCGAG CCCGAGGTGG

301 ACCGGCTGGC GGTGCGGCAC CATCCAGGCG TTCAACGCGA CCGTCAACTA
TGGCCGACCG CCACGCCGTG GTAGGTCCGC AAGTTGCGCT GGCAGTTGAT

351 CGCCGAGGGC AGCGTCTCCG GCCTCATCCG CACGAACGTG TGCGCCGAGC
GCGGCTCCCG TCGCAGAGGC CGGAGTAGGC GTGCTTGAC ACGCGGCTCG

401 CCGGCGACTC GGGCGGCTCG CTCGTCGCCG GCAACCAGGC GCAGGGCATG
GGCCGCTGAG CCCGCCGAGC GAGCAGCGGC CGTTGGTCCG CGTCCCGTAC

451 ACGTCCGGCG GCTCCGACAA CTGC (SEQ ID NO:57)
TGCAGGCCGC CGAGGCTGTT GACG

Cellulomonas fimi (DSM 20113)

1 VDVIGGDAYY IGGRSRCSIG FAVTGGFVTA GHCGRTGAAT TSPSGTFAGS
51 SFPGNDYAWV RVASGNTPVG AVNNYSGGTV AVAGSTQAAV GATVCRSGST
101 TGWRCGTIQA FNATVNYAEG SVSGLIRTNV CAEPGDSGGS LVAG (SEQ ID
NO:58)

Cellulomonas gelida (DSM 20111)

1 CTCGCGGGCA ACCAGGCGCA GGGCGTGACG TCGGGCGGGT CGGGCAACTG
GAGCGCCCGT TGGTCCGCGT CCCGCACTGC AGCCCGCCCA GCCCGTTGAC

51 CTCGTCGGGC GGGACGACGT ACTTCCAGCC CGTCAACGAG GCCCTCCGGG
GAGCAGCCCG CCCTGCTGCA TGAAGGTCGG GCAGTTGCTC CGGGAGGCC

101 TGTACGGGCT CACGCTCGTG ACCTCTGACG GTGGGGGCAC CGAGCCGCCG
ACATGCCCGA GTGCGAGCAC TGGAGACTGC CACCCCGTG GCTCGGCGGC

151 CCGACCGGGT GCCAGGGCTA TGC GCGGACC TACCAGGGCA GCGTCTCGGC
GGCTGGCCCA CGGTCCCGAT ACGCGCCTGG ATGGTCCCGT CGCAGAGCCG

201 CGGGACGTCG GTCGCGCAGC CGAACGGTTC GTACGTCACG ACCGGGGGCG
GCCCTGCAGC CAGCGCGTCG GCTTGCCAAG CATGCAGTGC TGGCCCCCGC

251 GGACGCACCG GGTGTGCCTG AGCGGACCGG CGGGCACGGA CCTGGACCTG
CCTGCGTGGC CCACACGGAC TCGCCTGGCC GCCCGTGCCT GGACCTGGAC

301 TACCTGCAGA AGTGGAACGG GTACTCGTGG GCCAGCGTCG CGCAGTCGAC
ATGGACGTCT TCACCTTGCC CATGAGCACC CGGTGCGCAGC GCGTCAGCTG

351 GTCGCCTGGT GCCACGGAGG CGGTACGTA CACCGGGACC GCCGGCTACT
CAGCGGACCA CGGTGCCTCC GCCAGTGCAT GTGGCCCTGG CGGCCGATGA

401 ACCGCTACGT GGTCCACGCG TACGCGGGTT CGGGGGCGTA CACCCTGGGG
TGGCGATGCA CCAGGTGCGC ATGCGCCCAA GCCCCGCGAT GTGGGACCCC

- 151 -

451 GCGACGACCC CG (SEQ ID NO:59)
CGCTGCTGGG GC

5 *Cellulomonas gelida* (DSM 20111)

1 LAGNQAQGVV SGGSGNCSSG GTTYFQPVNE ALRVYGLTLV TSDGGGTEPP
51 PTGCQGYART YQGSVSAGTS VAQPNGSYVT TGGGTHRVCL SGPAGTDLDL
101 YLQKWNGYSW ASVAQSTSPG ATEAVTYTGT AGYYRYVVHA YAGSGAYTLG
151 ATTP (SEQ ID NO:60)

10

Cellulomonas iranensis (DSM 14785)

1 TTCCCCGGCA ACGACTACGC GTGGGTCCAG GTCGGGTCGG GCGACACCCC
15 AAGGGGCCGT TGCTGATGCG CACCCAGGTC CAGCCAGCC CGCTGTGGGG
51 CCGCGGCCTG GTCAACAAC TACGCGGGCGG CACCGTGCGG GTCACCGGGT
GGCGCCGGAC CAGTTGTTGA TGCGCCCGCC GTGGCACGCC CAGTGGCCCA
20 101 CCGCAGCAGG CCGGGTCGGC GCGTACGTCT GCCGGTCGGG CAGCAGCAGC
GCGTCGTCCG GCGCCAGCCG CGCATGCAGA CGGCCAGCCC GTCGTGCTGC
151 GGCTGGCGCT GCGGCACCGT GCAGGCCTAC AACGCGTCGG TCCGCTACGC
CCGACCGCGA CGCCGTGGCA CGTCCGGATG TTGCGCAGCC AGGCGATGCG
25 201 CGAGGGCACC GTCTCGGGCC TCATCCGCAC CAACGTCTGC GCCGAGCCCG
GCTCCCCTGG CAGAGCCCGG AGTAGGCGTG GTTGCAGACG CGGCTCGGGC
251 GCGACTC (SEQ ID NO:61)
30 CGCTGAG

30

Cellulomonas iranensis (DSM 14785)

35 1 FPGNDYAWVQ VSGSDTPRGL VNNYAGGTVR VTGSQQAAGV AYVCRSGSTT
51 GWRCGTVQAY NASVRYAEGT VSGLIRTNVC AEPGD (SEQ ID NO:62)

40 *Cellulomonas cellasea* (DSM 20118)

1 GTCGGGCGGG TCCGGCAACT GCCGCTACGG GGGCACGACG TACTTCCAGC
CAGCCC GCCC AGGCCGTTGA CGGCGATGCC CCCGTGCTGC ATGAAGGTGC
45 51 CCGTGAACGA GATCCTGCAG GCCTACGGTC TGCGTCTCGT CCTGGGCTGA
GGCACTTGCT CTAGGACGTC CGGATGCCAG ACGCAGAGCA GGACCCGACT
101 CACGCTCGCG GCGGGCCCCG CTCGACGCGG CCGGCCCGTC GGCCCGGGTC
GTGCGAGCGC CGCCCGGGCC GAGCTGCGCC GGCCGGGCAG CCGGGCCAG
50 151 GCCGCCTGGT ACGTCGACGT GCCGACCAAC AAGCTCGTCG TCGAGTCGGT
CGGCGGACCA TGCAGCTGCA CGGCTGGTTG TTCGAGCAGC AGCTCAGCCA

- 152 -

201 CGGCGACACC GCGGCGGCCG CCGACGCCGT CGCCGCCGCG GGCCTGCCTG
 GCCGCTGTGG CGCCGCCGCG GGCTGCGGCA GCGGCGGCGC CCGGACGGAC
 5 251 CCGACGCCGT GACGCTCGCG ACCACCGAGG CGCCACGGAC GTTCGTCGAC
 GGCTGCGGCA CTGCGAGCGC TGGTGGCTCC GCGGTGCCTG CAAGCAGCTG
 301 GTCATCGGCG GCAACGCGTA CTACATCAAC GCGAGCAGCC GCTGCTCGGT
 CAGTAGCCGC CGTTGCGCAT GATGTAGTTG CGCTCGTCGG CGACGAGCCA
 10 351 CGGCTTCGCG GTCGAGGGCG GGTTCGTCAC CGCGGGCCAC TGCGGGCGCG
 GCCGAAGCGC CAGCTCCCGC CCAAGCAGTG GCGCCCGGTG ACGCCCGCGC
 401 CGGGCGCGAG CACGTCGTCA CCGTCGGGGA CCTTCCGCGG CTCGTCGTTT
 15 GCCCGCGCTC GTGCAGCAGT GGCAGCCCTT GGAAGGCGCC GAGCAGCAAG
 451 CCCGGCAACG ACTACGCGTG GGTCCAGGTC GCCTCGGGCA ACACGCCGCG
 GGGCCGTTGC TGATGCGCAC CCAGGTCCAG CGGAGCCCGT TGTGCGGCGC
 20 501 CGGGCTGGTG AACAACTACT CGGGCGGCAC GGTGCGCGTC ACCGGCTCGC
 GCCCGACCAC TTGTTGGTGA GCCCGCCGTG CCACGCGCAG TGGCCGAGCG
 551 AGCAGGCCGC GGTGCGGCTCG TACGTGTGCC GATCGGGCAG CACGACGGGA
 TCGTCCGGCG CCAGCCGAGC ATGCACACGG CTAGCCCGTC GTGCTGCCCT
 25 601 TGGCGGTGCG GCTACGTCCG GCGGTACAAC ACGACCGTGC GGTACGCGGA
 ACCGCCACGC CGATGCAGGC CCGCATGTTG TGCTGGCACG CCATGCGCCT
 651 GGGCTCGGTC TCGGGCCTCA TCCGCACGAG CGTGTGCGCC GAGCCGGGCG
 30 CCCGAGCCAG AGCCCGGAGT AGGCGTGCTC GCACACGCGG CTCGGCCCGC
 701 ACTCCGGCGG CTCGCTGGTC GCCGGCACGC AGGCCAGGG CGTCACGTCTG
 TGAGGCCCGC GAGCGACCAG CGGCCGTGCG TCCGGGTCCC GCAGTGCAGC
 35 751 GCGGGGTCCG GCAACTGCCG CTACGGGGGC ACGACGTACT TCCAGCCCGT
 CCGCCAGGC CGTTGACGGC GATGCCCCCG TGCTGCATGA AGGTGCGGCA
 801 GAACGAGATC CTGCAGGCCT ACGGTCTGCG TCTCGTCCTG GGCTGACACG
 CTTGCTCTAG GACGTCCGGA TGCCAGACGC AGAGCAGGAC CCGACTGTGC
 40 851 CTCGCGGCGG GCCCTCCCCCT GCCCGTCGCG CGCCGGCCCC ACCAGCCCGG
 GAGCGCCGCC CCGGAGGGGA CGGGCAGCGC GCGGCCGGGG TGGTCGGGCC
 901 GCCG (SEQ ID NO:63)
 45 CGGC

Cellulomonas cellasea (DSM 20118)

1 VGRVRQLPLR GHDVLPARER DPAGLRSASR PGLTRSRRAR LDAAGPSARV
 50 51 AAAYVDVPTN KLVVESVGDT AAAADAVAAA GLPADAVTLA TTEAPRTFVD
 101 VIGGNAYYIN ASSRCSVGFA VEGGFVTAGH CGRAGASTSS PSGTFRGSSF
 151 PGNDYAWVQV ASGNTPRGLV NNHSGGTVRV TGSQQAAGVS YVCRSGSTTG
 201 WRCGYVRAYN TTVRYAEGSV SGLIRTSVCA EPGDSGGSLV AGTQAQGVTS

- 153 -

251 GSGNCRYGG TTYFQPVNEI LQAYGLRLVL G*HARGGPSP ARRAPAPPAR
 301 A (SEQ ID NO:64)

5

Cellulomonas xylanilytica (LMG 21723)

1 CGCTGCTCGA TCGGGTTCGC CGTGACGGGC GGCTTCGTGA CCGCCGGCCA
 CTGCGGACGG TCCGGCGCGA CGACGACGTC GCCGAGCGGC ACGTTCGCCG
 10 GCGACGAGCT AGCCCAAGCG GCACTGCCCCG CCGAAGCACT GGCGGCCGGT
 GACGCCTGCC AGGCCGCGCT GCTGCTGCAG CCGCTCGCCG TGCAAGCGGC
 101 GGTCCAGCTT TCCCGGCAAC GACTACGCCT GGGTCCGCGC GGCCTCGGGC
 15 AACACGCCGG TCGGTGCGGT GAACCGCTAC GACGGCAGCC GGGTGACCGT
 CCAGGTCGAA AGGGCCGTTG CTGATGCGGA CCGAGGCGCG CCGGAGCCCG
 TTGTGCGGCC AGCCACGCCA CTTGGCGATG CTGCCGTCGG CCCACTGGCA
 20 201 GGCCGGGTCC ACCGACGCGG CCGTCGGTGC CGCGGTCTGC CGGTCGGGGT
 CGACGACCGC GTGGGGCTGC GGCACGATCC AGTCCC CGCG
 CGCGAGCGTC
 CCGGCCCAGG TGGCTGCGCC GGCAGCCACG GCGCCAGACG GCCAGCCCCA
 GCTGCTGGCG CACCCCGACG CCGTGCTAGG TCAGGGCGCC GCGCTCGCAG
 25 301 ACGTACGCCC AGGGCACCGT CAGCGGGCTC ATCCGCACCA ACGTGTGCGC
 CGAGCCGGGT GACTCCGGGG GGTGCTGAT CGCGGGCACC CAGGCGCGGG
 TGCATGCGGG TCCCGTGGCA GTCGCCCCGAG TAGGCGTGGT TGCACACGCG
 30 GCTCGGCCCA CTGAGGCCCC CCAGCGACTA GCGCCCGTGG GTCCGCGCCC
 401 GCGTGACGTC CGGCGGCTCC GGCAACTGC (SEQ ID NO:65)
 CGCACTGCAG GCCGCCGAGG CCGTTGACG

35

Cellulomonas xylanilytica (LMG 21723)

1 RCSI GFAVTG GFVTAGHCGR SGATTTSPSG TFAGSSFPNG DYAWVRAASG
 51 NTFVGAVNRY DGSRVTVAGS TDAAVGAAVC RSGSTTAWGC GTIQSRGASV
 101 TYAQGTVSGL IRTNVCAEPG DSGGSLIAGT QARGVTS GGS (SEQ ID
 40 NO:66)

Oerskovia turbata (DSM 20577)

1 ATGGCACGAT CATTCTGGAG GACGCTCGCC ACGGCGTGCG CCGCGACGGC
 TACCGTGCTA GTAAGACCTC CTGCGAGCGG TGCCGCACGC GGCGCTGCCG
 51 ACTGGTTGCC GGCCCCGCGAG CGCTCACC GC GAACGCCGCG ACGCCCACCC
 50 TGACCAACGG CCGGGGCGTC GCGAGTGGCG CTGCGGCGC TGCGGGTGGG
 101 CCGACACCCC GACCGTTTCA CCCCAGACCT CCTCGAAGGT CTCGCCCCGAG
 GGCTGTGGGG CTGGCAAAGT GGGGTCTGGA GGAGCTTCCA GAGCGGGCTC

- 154 -

151	GTGCTCCGCG	CCCTCCAGCG	GGACCTGGGG	CTGAGCGCCA	AGGACGCGAC
	CACGAGGCGC	GGGAGGTCGC	CCTGGACCCC	GACTCGCGGT	TCCTGCGCTG
5	201	GAAGCGTCTG	GCGTTCCAGT	CCGACGCGGC	GAGCACCGAG
		CTTCGCAGAC	CGCAAGGTCA	GGCTGCGCCG	CTCGTGGCTC
				CTGCGAGAGC	
	251	CCGACAGCCT	GGACGCCTAC	GCGGGCGCCT	GGGTGACCCC
		GGCTGTCTGA	CCTGCGGATG	CGCCCGCGGA	CCCAGCTGGG
10				ACGCTCCTTG	
	301	ACCCTGTACG	TCGGCGTCGC	CGACAGGGCC	GAGGCCAAGG
		TGGGACATGC	AGCCGCAGCG	GCTGTCCCGG	CTCCGGTTCC
				TCCAGGCAAG	
	351	GGCCGGAGCG	ACCCCCGTGG	TCGTCGACCA	CACGCTCGCC
15		CCGGCCTCGC	TGGGGGCACC	AGCAGCTGGT	GTGCGAGCGG
				CTCGAGCTGT	
	401	CGTGGAAGGC	GGCGCTCGAC	GGTGAGCTCA	ACGACCCCGC
		GCACCTTCCG	CCGCGAGCTG	CCACTCGAGT	TGCTGGGGCG
				CCCGCAGGGC	
20	451	AGCTGGTTTC	TCGACGTCAC	GACCAACCAG	GTCGTGCTCA
		TCGACCAAGC	AGCTGCAGTG	CTGGTTGGTC	CAGCAGCAGT
				TGCACGTGCT	
	501	CGGCGGACGC	GCCCTCGCGG	AGCTGGCTGC	CGCGAGCGCG
		GCCGCCTGCG	CGGGAGCGCC	TCGACCGACG	GCGCTCGCGC
25				CCGCACGGGC	
	551	CCGACGCCAT	CACCTACGTG	ACGACGACCG	AGGCTCCTCG
		GGCTGCGGTA	GTGGATGCAC	TGCTGCTGGC	TCCGAGGAGC
				AGGGGAGCAG	
	601	GACGTGGTGG	GCGGCAACGC	GTACACCATG	GGTTCGGGCG
30		CTGCACCACC	CGCCGTTGCG	CATGTGGTAC	CCAAGCCCGC
				CCGCGACGAG	
	651	GGTCGGCTTC	GCGGTGAACG	GGGGCTTCAT	CACGGCCGGG
		CCAGCCGAAG	CGCCACTTGC	CCCCGAAGTA	GTGCCGGCCC
				GTGACGCCGA	
35	701	CGGTCGGCAC	CCGCACCTCG	GGGCCGGGCG	GCACGTTCCG
		GCCAGCCGTG	GGCGTGAGAG	CCCGGCCCGC	CGTGCAAGGC
				CCCCAGCTTG	
	751	TTCCCCGGCA	ACGACTACGC	CTGGGTGCAG	GTCGACGCGG
		AAGGGGCCGT	TGCTGATGCG	GACCCACGTC	CAGCTGCGCC
40				CATTGTGGGG	
	801	GGTCGGCGCG	GTCAACAAC	ACAGCGGTGG	GCGCGTCGCG
		CCAGCCGCGC	CAGTTGTTGA	TGTCGCCACC	GCGCGAGCGC
				CAGCGTCCCA	
	851	CGACGGCCGC	GCCCGTGGGG	GCCTCGGTCT	GCCGGTCCGG
45		GCTGCCGGCG	CGGGCACCCC	CGGAGCCAGA	CGGCCAGGCC
				AAGGTGCTGC	
	901	GGCTGGCACT	GCGGCACCAT	CGGCGCGTAC	AACACCTCGG
		CCGACCGTGA	CGCCGTGGTA	GCCGCGCATG	TTGTGGAGCC
				ACTGCATGGG	
50	951	GCAGGGCACC	GTCTCGGGGC	TCATCCGCAC	GAACGTGTGC
		CGTCCCGTGG	CAGAGCCCCG	AGTAGGCGTG	CTTGACACAG
				CGGCTCGGGC	
	1001	GCGACTCGGG	CGGCTCGCTC	CTCGCGGGCA	ACCAGGCGCA
		CGCTGAGCCC	GCCGAGCGAG	GAGCGCCCGT	TGGTCCGCGT
				CCCGCACTGG	

- 155 -

1051 TCGGGCGGGT CGGGCAACTG CTCGTCGGGC GGGACGACGT ACTTCCAGCC
AGCCCGCCCA GCCCGTTGAC GAGCAGCCCC CCCTGCTGCA TGAAGGTCGG

5 1101 CGTCAACGAG GCCCTCGGGG GGTACGGGCT CACGCTCGTG ACCTCTGACG
GCAGTTGCTC CGGGAGCCCC CCATGCCCCG GTGCGAGCAC TGGAGACTGC

1151 GTGGGGGGCCC GAGCCGCCGC CGACCGGGTG CCAGGGCTAT GCGCGGACCT
CACCCCCGGG CTCGGCGGCG GCTGGCCCCAC GGTCCCGATA CGCGCCTGGA

10 1201 ACCAGGGCAG CGTCTCGGCC GGGACGTCGG TCGCGCAGCG AACGGTTCGT
TGGTCCCGTC GCAGAGCCGG CCCTGCAGCC AGCGCGTCGC TTGCCAAGCA

1251 ACGTCACGAC CGGGGGCGGG CGACCGGGTG TGCC (SEQ ID NO:67)
15 TGCAGTGCTG GCCCCCGCCC GCTGGCCCCAC AC GG

Oerskovia turbata (DSM 20577)

1 MARSEFWRTLA TACAATALVA GPAALTANAA TPTPDTPTVS PQTSSKVSPE
20 51 VLRALQRD LG LSAKDATKRL AFQSDAASTE DALADSLDAY AGAWVDPARN
101 TLYVGVADRA EAKEVRSAGA TPVVVDHTLA ELDTWKAALD GELNDPAGVP
151 SWFVDVTTNQ VVVNVHDGGR ALAELAAASA GVPADAITV TTTEAPRPLV
201 DVVGGNAYTM GSGGRCSVGF AVNGGFITAG HCGSVGTRTS GPGGTFRGSN
251 FPGNDYAWVQ VDAGNTPVGA VNNYSGGRVA VAGSTAAPVG ASVCRSGSTT
25 301 GWHCGTIGAY NTSVTYPQGT VSGLIRTNVC AEPGDSGGSL LAGNQAQGV
351 SGGSGNCSSG GTTYFQPVNE ALGGYGLTLV TSDGGGPSRR RPGARAMRGP
401 TRAASRPGR SRSERFVRHD RGRATGCA (SEQ ID NO:68)

Oerskovia jenensis (DSM 46000)

1 GCCGCTGCTC GGTCTGGCTTC GCGGTGAACG GCGGCTTCGT CACCGCAGGC
CGGCGACGAG CCAGCCGAAG CGCCACTTGC CGCCGAAGCA GTGGCGTCCG

35 51 CACTGCGGGA CGGTGGGCAC CCGCACCTCG GGGCCGGGCG GCACGTTCGG
GTGACGCCCT GCCACCCGTG GCGGTGGAGC CCCGGCCCCG CGTGCAAGGC

101 CGGGTCGAGC TTCCCCGGCA ACGACTACGC CTGGGTGCAG GTCGACGCGG
GCCAGCTCG AAGGGGCCGT TGCTGATGCG GACCCACGTC CAGCTGCGCC

40 151 GGAACACCCC GGTCGGGGCC GTCAACAAC TACAGCGGTGG ACGCGTCGCG
CCTTGTGGGG CCAGCCCCGG CAGTTGTTGA TGTGCGCCACC TGCGCAGCGC

201 GTCGCGGGCT CGACGGCCGC ACCCGTGGGT TCCTCGGTCT GCCGGTCCGG
45 CAGCGCCCGA GCTGCCGGCG TGGGCACCCA AGGAGCCAGA CGGCCAGGCC

251 TTCCACGACG GGCTGGCGCT GCGGCACGAT CGCGGCCTAC AACAGCTCGG
AAGGTGCTGC CCGACCGCGA CGCCGTGCTA GCGCCGGATG TTGTGACAGC

50 301 TGACGTACCC GCAGGGGACC GTCTCCGGGC TCATCCGCAC CAACGTGTGC
ACTGCATGGG CGTCCCCTGG CAGAGGCCCG AGTAGGCGTG GTTGCACACG

351 GCCGAGCCGG GCGACTCGGG CGGCTCGCTC CTCGCGGGCA ACCAGGCACA

- 156 -

CGGCTCGGCC CGCTGAGCCC GCCGAGCGAG GAGCGCCCGT TGGTCCGTGT

401 GGGCCTGACG TCGGGCGGGT CGGGCAACTG CTCGTCGGGC GGCACGACGT
 CCCGGACTGC AGCCCGCCCA GCCCGTTGAC GAGCAGCCCG CCGTGCTGCA

5 451 ACTTCCAGCC CGTCAACGAG GCGCTCTCGG CCTACGGCCT CACGCTCGTG
 TGAAGGTCGG GCAGTTGCTC CGCGAGAGCC GGATGCCGGA GTGCGAGCAC

501 ACCTCCGGCG GCAGGGGCAA CTGC (SEQ ID NO:69)
 10 TGGAGGCCGC CGTCCCCGTT GACG

Oerskovia jenensis (DSM 46000)

1 RCSVGFAVNG GFVTAGHCGT VGTRTSGPBG TFRGSSFPNG DYAWVQVDAG

15 51 NTPVGAVNNY SGGRVAVAGS TAAPVGSSVC RSGSTTGWRC GTIAAYNSSV
 101 TYPQGTVSGL IRTNVCAEPG DSGGSLLAGN QAQGLTSGGS GNCSSGGTTY
 151 FQPVNEALSA YGLTLVTSBG RGNC (SEQ ID NO:70)

Cellulosimicrobium cellulans (DSM 20424)

1 CCACGGGCGG CGGGTCGGG AGCGCGCTCG TCGGGCTCGC GGGCAAGTGC
 25 GGTGCCCGCC GCCCAGCCCG TCGCGCGAGC AGCCCGAGCG CCCGTTACG

51 ATCGACGTCC CCGGGTCCGA CTTCACTGAC GGCAAGCGCC TCCAGCTGTG
 TAGCTGCAGG GGCCAGGCT GAAGTCACTG CCGTTCGCGG AGGTGACAC

101 GACGTGCAAC GGGTCGCAGG CAGCGCTGGA CGTTCGAAGC CGACGGCACC
 30 CTGCACGTTG CCCAGCGTCC GTCGCGACCT GCAAGCTTCG GCTGCCGTGG

151 GTACGCGCGG GCGGCAAGTG CATGGACGTC GCGTGGGCGC CGCGGCCGAC
 CATGCGCGCC CGCCGTTTAC GTACCTGCAG CGCACCCGCG GCGCCGGCTG

35 201 GGCACGGCGC TCCAGCTCGC GAACTGCACG GCAACGCGGC CCAGAAGTTC
 CCGTGCCGCG AGGTCGAGCG CTTGACGTGC CGTTGCGCCG GGTCTTCAAG

251 GTGCTCAACG GCGCGGGCGA CCTCGTGTGCG GTGCTGGCGA ACAAGTGC
 CACGAGTTGC CGCGCCCGCT GGAGCACAGC CACGACCGCT TGTTTCACGC

40 301 TCGACGCCGC CCGGTGCGCA CCGAGGTACT CGCGGCGCCG TACGAGCTCA
 AGCTGCGGCG GCCCAGCGT GGCTCCATGA GCGCCGCGGC ATGCTCGAGT

351 CCGCGACGTG CGCGGCGGCG ACCGCTACAT CACACGGGAC CCGGGCGCGT
 45 GCCGCTGCAC GCGCCGCGCG TGGCGATGTA GTGTGCCCTG GGCCCGCGCA

401 CGTCGGGCTC GGCCTGCTCG ATCGGGTACG CCGTCCAGGG CGGCTTCGTC
 GCAGCCCGAG CCGGACGAGC TAGCCCATGC GGCAGGTCCC GCCGAAGCAG

50 451 ACGGCGGGGC ACTGCGGACG CGGCGGGACA AGGAGAGTGC TCACCGCGAG
 TGCCGCCCCG TGACGCCTGC GCCGCCCTGT TCCTCTCACG AGTGGCGCTC

501 CTGGGCGCGC ATGGGGACGG TCCAGGCGGC GTCGTTCCCC GGCCACGACT

- 157 -

GACCCGCGCG TACCCCTGCC AGGTCCGCCG CAGCAAGGGG CCGGTGCTGA
 551 ACGCGTGGGT GCGCGTCGAC GCCGGGTTCCT CCCCCGTCCC GCGGGTGAAC
 TGCGCACCCA CGCGCAGCTG CGGCCAAGA GGGGGCAGGG CGCCCACTTG
 5 601 AACTACGCCG GCGGCACCGT CGACGTCGCC GGCTCGGCCG AGGCGCCCGT
 TTGATGCGGC CGCCGTGGCA GCTGCAGCGG CCGAGCCGGC TCCGCGGGCA
 651 GGGTGCCTCG GTGTGCCGCT CGGGCGCCAC GACCGGCTGG CGCTGCGGCG
 10 CCCACGCAGC CACACGGCGA GCCCGCGGTG CTGGCCGACC GCGACGCCGC
 701 TCATCGAGCA GAAGAACATC ACCGTCAACT ACGGCAACGG CGACGTTCCC
 AGTAGCTCGT CTTCTTGTA TGGCAGTTGA TGCCGTTGCC GCTGCAAGGG
 15 751 GGCCTCGTGC GCGGCAGCGC GTGCGCGGAG GGCGGCGACT CGGGCGGGTC
 CCGGAGCACG CGCCGTCGCG CACGCGCCTC CCGCCGCTGA GCCCGCCAG
 801 GGTGATCTCC GGCAACCAGG CGCAGGGCGT CACGTCGGGC AGGATCAACG
 CCAC TAGAGG CCGTTGGTCC GCGTCCCGCA GTGCAGCCCG TCCTAGTTGC
 20 851 ACTGCTCGAA CGGCGGCAAG TTCCTCTACC AGCCCGATCG ACGGCCTGTC
 TGACGAGCTT GCCGCCGTTT AAGGAGATGG TCGGGCTAGC TGCCGGACAG
 901 GCTCGTGACC ACGGGCGGGC GGTGCGGGCAG CGCGCTCGTC GGGCTCGCGG
 25 CGAGCACTGG TGCCCGCCGC CCAGCCCGTC GCGCGAGCAG CCCGAGCGCC
 951 GCAAGTGCAT CGACGTCCCC GGGTCCGACT TCAG (SEQ ID NO:71)
 CGTTCACGTA GCTGCAGGGG CCCAGGCTGA AGTC

Cellulosimicrobium cellulans (DSM 20424)

1 PRAAGRAARS SGSRASASTS PGPTSVTASA SSCGRATGRR QRWTFEADGT
 51 VRAGGKCMDV AWAPRPTARR SSSRTARQRG PEVRAQRRGR PRVGAGEQSA
 35 101 STPPGAHRGT RGAVRAHGDV RGGDRYITRD PGASSGSACS IGYAVQGGFV
 151 TAGHCGRGGT RRVLTASWAR MGTVQAASFP GHDYAWVRVD AGFSPVPRVN
 201 NYAGGTVDVA GSAEAPVGAS VCRSGATTGW RCGVIEQKNI TVNYGNGDVP
 251 GLVRGSACAE GGDSSGGSVIS GNQAQGVTSR RINDCSNGGK FLYQPDRRPV
 301 ARDHGRRVGQ RARRARGQVH RRPRVRLQ (SEQ ID NO:72)

Promicromonospora citrea (DSM 43110)

1 TTCCCCGGCA ACGACTACGC GTGGGTGAAC ACGGGCACGG ACGACACCCT
 45 AAGGGGCCGT TGCTGATGCG CACCCACTTG TGCCCGTGCC TGCTGTGGGA
 51 CGTCGGCGCC GTGAACAACT ACAGCGGCGG CACGGTCAAC GTCGCGGGCT
 GCAGCCGCGG CACTTGTTGA TGTCGCCGCC GTGCCAGTTG CAGCGCCCGA
 50 101 CGACCCGTGC CGCCGTCGGC GCGACGGTCT GCCGCTCGGG CTCCACGACC
 GCTGGGCACG GCGGCAGCCG CGCTGCCAGA CGGCGAGCCC GAGGTGCTGG
 151 GGCTGGCACT GCGGCACCAT CCAGGCGCTG AACGCGTCGG TCACCTACGC

- 158 -

CCGACCGTGA CGCCGTGGTA GGTCCGCGAC TTGCGCAGCC AGTGGATGCG

201 CGAGGGCACC GTGAGCGGCC TCATCCGCAC CAACGTGTGC GCCGAGCCCG
GCTCCCGTGG CACTCGCCGG AGTAGGCGTG GTTGCACACG CGGCTCGGGC

251 GCGACTC (SEQ ID NO:73)
CGCTGAG

Promicromonospora citrea (DSM 43110)

1 FPGNDYAWVN TGTDDTLVGA VNNYSGGTVN VAGSTRAAVG ATVCRSGSTT
51 GWHCGTIQAL NASVTYAEGT VSGLIRTNVC AEPGD (SEQ ID NO:74)

Promicromonospora sukumoe (DSM 44121)

1 TTCCCCGGCA ACGACTACGC GTGGGTGAAC GTCGGCTCCG ACGACACCCC
AAGGGGCCGT TGCTGATGCG CACCCACTTG CAGCCGAGGC TGCTGTGGGG

51 GATCGGTGCG GTCAACAAC TACAGCGCGG CACCGTGAAC GTCGCGGGCT
CTAGCCACGC CAGTTGTTGA TGTGCGCCGC GTGGCACTTG CAGCGCCCGA

101 CGACCCAGGC CGCCGTCGGC TCCACCGTCT GCCGCTCCGG TTCCACGACC
25 GCTGGGTCCG GCGGCAGCCG AGGTGGCAGA CCGCGAGGCC AAGGTGCTGG

151 GGCTGGCACT GCGGCACCAT CCAGGCCTTC AACGCGTCGG TCACCTACGC
CCGACCGTGA CGCCGTGGTA GGTCCGGAAG TTGCGCAGCC AGTGGATGCG

30 201 CGAGGGCACC GTGTCCGGCC TGATCCGCAC CAACGTCTGC GCCGAGCCCG
GCTCCCGTGG CACAGGCCGG ACTAGGCGTG GTTGCAGACG CGGCTCGGGC

251 GCGACTC (SEQ ID NO:75)
CGCTGAG

Promicromonospora sukumoe (DSM 44121)

1 FPGNDYAWVN VGSDDTPIGA VNNYSGGTVN VAGSTQAAVG STVCRSGSTT
51 GWHCGTIQAF NASVTYAEGT VSGLIRTNVC AEPGD (SEQ ID NO:76)

Xylanibacterium ulmi (LMG 21721)

1 GCCGCTGCTC GATCGGGTTC GCCGTGACGG GCGGCTTCGT GACCGCCGGC
45 CGGCGACGAG CTAGCCCAAG CGGCACTGCC CGCCGAAGCA CTGGCGGGCC

51 CACTGCGGAC GGTCCGGCGC GACGACGACG TCCGCGAGCG GCACGTTTCG
GTGACGCCTG CCAGGCCGCG CTGCTGCTGC AGGCGCTCGC CGTGCAAGCG

50 101 CGGGTCCAGC TTTCCCGGCA ACGACTACGC CTGGGTCCGC GCGGCCTCGG
GCCCAGGTCG AAAGGGCCGT TGCTGATGCG GACCCAGGCG CGCCGGAGCC

- 159 -

151 GAACACGCCG GTCGGTGCGG TGAACCGCTA CGACGGCAGC CGGGTGACCG
CTTGTGCGGC CAGCCACGCC ACTTGGCGAT GCTGCCGTCG GCCACTGGC

201 TGGCCGGGTC CACCGACGCG GCCGTCGGTG CCGCGGTCTG CCGGTCGGGG
ACCGGCCAG GTGGCTGCGC CGGCAGCCAC GGCGCCAGAC GGCCAGCCCC

251 TCGACGACCG CGTGGCGCTG CGGCACGATC CAGTCCCGCG GCGCGACGGT
AGCTGCTGGC GCACCGCGAC GCCGTGCTAG GTCAGGGCGC CGCGCTGCCA

301 CACGTACGCC CAGGGCACCG TCAGCGGGCT CATCCGCACC AACGTGTGCG
GTGCATGCGG GTCCCGTGGC AGTCGCCCCA GTAGGCGTGG TTGCACACGC

351 CCGAGCCGGG TGA CTCCGGG GGGTCGCTGA TCGCGGGCAC CCAGGCGCAG
GGCTCGGCC ACTGAGGCC CCCAGCGACT AGCGCCCGTG GGTCCGCGTC

401 GCGGTGACGT CCGGCGGCTC CGGCAACTGC (SEQ ID NO:77)
CCGCACTGCA GGCCGCCGAG GCCGTTGACG

Xylanibacterium ulmi. (LMG 21721)

1 RCSIGFAVTG GFVTAGHCGR SGATTTASG TFAGSSFPNG DYAWVRAASG
51 NTPVGAVNRY DGSRVTVAGS TDAAVGA AVC RSGSTTAWRC GTIQSRGATV
101 TYAQGTVSGL IRTNVCAEPG DSGGSLIAGT QAQGVTSGGS G (SEQ ID NO:78)

Inverse PCR

Inverse PCR was used to determine the full-length serine protease genes from chromosomal DNA of bacterial strains of the suborder *Micrococcineae* shown by PCR or immunoblotting to be novel homologues of the new *Cellulomonas* sp. 69B4 protease described herein.

Digested DNA was purified using the PCR purification kit (Qiagen, Catalogue # 28106), and self-ligated with T4 DNA ligase (Invitrogen) according to the manufacturers' instructions. Ligation mixtures were purified with the PCR purification kit (Qiagen) and a PCR was performed with primers selected from the following list;

RV-1 Rest 5' - ACCCACGCGTAGTCGTTGCC - 3' (SEQ ID NO:79)
RV-1 Cellul 5' - ACCCACGCGTAGTCGTKGCCGGGG - 3' (SEQ ID NO:80)
RV-2 biaz-fimi 5' - TCGTCGTGGTCGCGCCGG - 3' (SEQ ID NO:81)
RV-2 cella-flavi 5' - CGACGTGCTCGCGCCCG - 3' (SEQ ID NO:82)
RV-2 cellul 5' - CGCGCCCAGCTCGCGGTG - 3' (SEQ ID NO:83)
RV-2 turb 5' - CGGCCCCGAGGTGCGGGTGCCG - 3' (SEQ ID NO:84)
Fw-1 biaz-fimi 5' - CAGCGTCTCCGGCCTCATCCGC - 3' (SEQ ID NO:85)
Fw-1 cella-flavi 5' - CTCGGTCTCGGGCCTCATCCGC - 3' (SEQ ID NO:86)
Fw-1 cellul 5' - CGACGTTCCCGGCCTCGTGCGC - 3' (SEQ ID NO:87)
Fw-1 turb 5' - CACCGTCTCGGGGCTCATCCGC - 3' (SEQ ID NO:88)

- 160 -

Fw-2 rest 5' – AGCARCGTGTGCGCCGAGCC - 3' (SEQ ID NO:89)
 Fw-2 cellul 5' - GGCAGCGCGTGC GCGGAGGG - 3' (SEQ ID NO:90)
 Fw-1 gelida 5' – GCCGCTGCTCGATCGGGTTC - 3' (SEQ ID NO:91)
 Rv-1 gelida 5' – GCAGTTGCCGGAGCCGCCGGACGT - 3'. (SEQ ID NO:92)

The amplified PCR products were examined by agarose gel electrophoresis (0.8% agarose in TBE buffer (Invitrogen)). Distinct bands in the range 1.3 – 2.2 kbp for each organism were excised from the gel, purified using the Qiagen gel extraction kit and the sequence analyzed by BaseClear. Sequence analysis revealed that these DNA fragments covered some additional parts of protease gene homologues to the *Cellulomonas* 69B4 protease gene.

Genome Walking Using Rapid Amplification of Genomic Ends (RAGE)

A genome walking methodology (RAGE) known in the art was used to determine the full-length serine protease genes from chromosomal DNA of bacterial strains of the suborder *Micrococcineae* shown by PCR or immunoblotting to be novel homologues of the new *Cellulomonas* sp. 69B4 protease. RAGE was performed using the Universal GenomeWalker™ Kit (BD Biosciences Clontech), some with modifications to the manufacturer's protocol (BD Biosciences user manual PT3042-1, Version # PR03300). Modifications to the manufacturer's protocol included addition of DMSO (3 µL) to the reaction mixture in 50 µL total volume due to the high GC content of the template DNA and use of Advantage™ – GC Genomic Polymerase Mix (BD Biosciences Clontech) for the PCR reactions which were performed as follows;

	PCR 1	PCR 2
99°C - 0.05 sec		
94°C - 0.25 sec/72°C - 3.00 min	7 cycles	4 cycles
94°C - 0.25 sec/67°C - 4.00 min	39 cycles	24 cycles
67°C - 7.00 min		
15°C - 1.00 min		

PCR was performed with primers (Invitrogen, Paisley, UK) selected from the following list (listed in 5' to 3' orientation);

RV-1 Rest ACCCACGCGTAGTCGTTGCC (SEQ ID NO:79)
 RV-1 Cellul ACCCACGCGTAGTCGTKGCCGGGG (SEQ ID NO:80)
 RV-2 biaz-fimi TCGTCGTGGTCGCGCCGG (SEQ ID NO:81)
 RV-2 cella-flavi CGACGTGCTCGCGCCCG (SEQ ID NO:82)
 RV-2 cellul CGCGCCCAGCTCGCGGTG (SEQ ID NO:83)
 RV-2 turb CGGCCCCGAGGTGCGGGTGCCG (SEQ ID NO:84)
 Fw-1 biaz-fimi CAGCGTCTCCGGCCTCATCCGC (SEQ ID NO:85)
 Fw-1 cella-flavi CTCGGTCTCGGGCCTCATCCGC (SEQ ID NO:86)
 Fw-1 cellul CGACGTTCCCGGCCTCGTGCGC (SEQ ID NO:87)

- 161 -

Fw-1 turb CACCGTCTCGGGGCTCATCCGC (SEQ ID NO:88)
 Fw-2 rest AGCARCGTGTGCGCCGAGCC (SEQ ID NO:89)
 Fw-2 cellul GGCAGCGCGTGC GCGGAGGG (SEQ ID NO:90)
 Fw-1 gelida GCCGCTGCTCGATCGGGTTC (SEQ ID NO:91)
 5 Rv-1 gelida GCAGTTGCCGGAGCCGCCGGACGT (SEQ ID NO:92)
 Flavi FW1 TGCGCCGAGCCCGGCGACTCCGGC (SEQ ID NO:93)
 Flavi FW2 GGCACGACGTACTTCCAGCCCGTGAAC (SEQ ID NO:94)
 Flavi RV1 GACCCACGCGTAGTCGTTGCCGGGGAACGACGA (SEQ ID NO:95)
 Flavi RV2 GAAGGTCCCCGACGGTGACGACGTGCTCGCGCC (SEQ ID NO:96)
 10 Turb FW1 CAGGCGCAGGGCGTGACCTCGGGCGGGTTCG (SEQ ID NO:97)
 Turb FW2 GGCGGGACGACGTACTTCCAGCCCGTCAA (SEQ ID NO:98)
 Cellu RV1 CACCCACGCGTAGTCGTGGCCGGGGAACGA (SEQ ID NO:99)
 Cellu RV2 GAAGCCGCCCTGGACGGCGTACCCGATCGAGCA (SEQ ID NO:100)
 Cellu FW1 TGCGCGGAGGGCGGCGACTCGGGCGGGTTCG (SEQ ID NO:101)
 15 Cellu FW2 TTCCTCTACCAGCCCGTCAACCCGATCCTA (SEQ ID NO:102)
 Cella RV2 CGCCGCGGGGACGAACCCGCCCTCGACCGCGAA (SEQ ID NO:103)
 Cella RV1 CGCGTAGTCGTTGCCGGGGAACGACGAGCC (SEQ ID NO:104)
 Cella FW1 GGCCTCATCCGCACGAGCGTGTGCGCCGAG (SEQ ID NO:105)
 Cella FW2 ACGTCGGGCGGGTCCGGCAACTGCCGCTACGGGGGC (SEQ ID
 20 NO:106)
 Gelida RV1 GAGCCCGTACACCCGGAGGGCCTCGTTGACGGGCTGGAA (SEQ ID
 NO:107)
 Gelida RV2 CGTCACGCCCTGCGCCTGGTTGCCCGCGAG (SEQ ID NO:108)
 Gelida FW1 TCCAGCCCGTCAACGAGGCCCTCCGGGTGTACGGGCTC (SEQ ID
 25 NO:109)
 Gelida FW2 ACGTCGGTCGCGCAGCCGAACGGTTCGTACGTC (SEQ ID NO:110)
 Biazot RV1 CGTGGTCGCGCCGGTTCGTGCCGCACTGCCC (SEQ ID NO:111)
 Biazot RV2 GACGACGACCGTGTTGGTAGTGACGTCGACGTACCA (SEQ ID NO:112)
 Biazot FW1 TCCACCACGGGGTGGCGCTGCGGGACGATC (SEQ ID NO:113)
 30 Biazot FW2 GTGTGCGCCGAGCCCGGCGACTCCGGCGGC (SEQ ID NO:114)
 Turb RV C-mature
 GCTCGGGCCCCCACCCTCAGAGGTCACGAGCGTGAG (SEQ ID
 NO:115)
 Turb FW signal
 35 ATGGCACGATCATTCTGGAGGACGCTCGCCACGGCG (SEQ ID NO:116)
 Cellu internal FW
 TGCTCGATCGGGTACGCCGTCCAGGGCGGGCTTC (SEQ ID NO:117)
 Cellu internal RV
 TAGGATCGGGTTGACGGGCTGGTAGAGGAA (SEQ ID NO:118)
 40 Biazot Int Fw TGGTACGTCGACGTCACTACCAACACGGTCGTCGTC (SEQ ID NO:119)
 Biazot Int Rv 5' - GCCGCCGGAGTCGCCGGGCTCGGCGCACAC (SEQ ID NO:120)
 flavi Nterm 5' - GTSGACGTSATCGGSGGSAACGCSTACTAC (SEQ ID NO:121)
 flavi Cterm 5' - SGCSGTSGCSGGNGANGA (SEQ ID NO:122)
 fimi Nterm 5' - GTSGAYGTSATCGGCGGCAYGCSTAC (SEQ ID NO:123)
 45 fimi Cterm 5' - SGASGCGTANCCCTGNCC (SEQ ID NO:124)

The PCR products were subcloned in the pCR4-TOPO TA cloning vector (Invitrogen)
 and transformed to *E.coli* Top10 one-shot electrocompetent cells (Invitrogen). The
 transformants were incubated (37°C, 260 rpm, 16 hours) in 2xTY medium with 100 µg/ml
 50 ampicillin. The isolated plasmid DNA (isolated using the Qiagen Qiaprep pDNA isolation kit)

- 162 -

was sequenced by BaseClear.

Sequence Analysis

Full length polynucleotide sequences were assembled from PCR fragment sequences using the ContigExpress and AlignX programs in Vector NTI suite v. 9.0.0 (Invitrogen) using the original polynucleotide sequence obtained in Example 4 as template and the ASP mature protease and ASP full-length sequence for alignment. The results for the polynucleotide sequences are displayed in Table 7-1 and the translated amino acid sequences are displayed in Table 7-2. For each of the natural bacterial strains the polynucleotide sequences and translated amino acid sequences for each of the homologous proteases are provided above.

Table 7-1 provides comparison information between ASP protease and various other sequences obtained from other bacterial strains. Amino acid sequence information for Asp-mature-protease homologues is available from 13 species:

1. *Cellulomonas biazotea* DSM 20112
2. *Cellulomonas flavigena* DSM 20109
3. *Cellulomonas fimi* DSM 20113
4. *Cellulomonas cellasea* DSM 20118
5. *Cellulomonas gelida* DSM 20111
6. *Cellulomonas iranensis* DSM 14784
7. *Cellulomonas xylanilytica* LMG 21723
8. *Oerskovia jenensis* DSM 46000
9. *Oerskovia turbata* DSM 20577
9. *Oerskovia turbata* DSM 20577
10. *Cellulosimicrobium cellulans* DSM 20424
11. *Promicromonospora citrea* DSM 43110
12. *Promicromonospora sukumoe* DSM 44121
13. *Xylanibacterium ulmi* LMG 21721

Notably, the sequence from *Cellulomonas gelida* at 48 amino acids is too short for useful consensus alignment. Sequence alignment against Asp-mature for the remaining 12 species are provided herein. To date, complete mature sequence has been determined for *Oerskovia turbata*, *Cellulomonas cellasea*, *Cellulomonas biazotea* and *Cellulosimicrobium cellulans*. However, there are some problems and sequence fidelity is not guaranteed for the sequence information known to the public, *Cellulomonas cellasea* protease is clearly

- 163 -

homologous to Asp (61.4% identity). However, the sequencing of 10 independent PCR fragments of the C-terminal region all gives a **stop** codon at position 184, suggesting that there is no C-terminal prosequence. In addition, *Cellulosimicrobium cellulans* is a close relative of *Cellulomonas* and clearly has an Asp homologous protease. However, the sequence identity is low, only 47.7%. It contains an insertion of 4 amino acids at position 43-44 and it is uncertain where the N-terminus of the protein begins. Nonetheless, the data provided here clearly show that there are enzymes homologous to the ASP protease described herein. Thus, it is intended that the present invention encompass the ASP protease isolated from *Cellulomonas* strain 69B4, as well as other homologous proteases.

In this Table, the nucleotide numbering is based on full-length gene of 69B4 protease (SEQ ID NO:2), where nt 1 – 84 encode the signal peptide, nt 85 – 594 encode the N-terminal prosequence, nt 595 – 1161 encode the mature 69B4 protease, and nt 1162 – 1485 encode the C-terminal prosequence.

Table 7-1. Percent Identity of Homologous Polynucleotide Sequences from Natural Isolate Strains Compared with ASP Mature Protease Gene Sequence			
Strain	Total Base Pairs	Overlap*	% Identity Overlap Mature Protease
69B4 (ASP) Protease	1485	1-1485	
<i>Cellulomonas flavigena</i> DSM20109	555	595-1156	72.3
<i>Cellulomonas biazotea</i> DSM 20112	627	332-1355	73.7
<i>Cellulomonas fimi</i> DSM 20113	474	595-1068	78.7
<i>Cellulomonas gelida</i> DSM 20118	462	1018-1485	72.2
<i>Cellulomonas iranensis</i> DSM14784	257	748-1004	75.2
<i>Cellulomonas cellasea</i> DSM 20118	904	294-1201	72.7
<i>Cellulomonas xylanilytica</i> LMG 21723	429	640-1068	75.1
<i>Oerskovia turbata</i> DSM 20577	1284	1-1291	73.1
<i>Oerskovia jenensis</i> DSM 46000	387	638-1158	72.7
<i>Cellulosimicrobium cellulans</i> DSM20424	984	251-1199	63.1

- 164 -

<i>Promicromonospora citrea</i> DSM 43110	257	748-1004	75.9
<i>Promicromonospora sukumoe</i> DSM 44121	257	748-1004	77.4
<i>Xylanibacterium ulmi</i> LMG21721	430	638-1068	77.0

The following Table (Table 7-2) provides information regarding the translated amino acid sequence data in natural isolate strains compared with full-length ASP.

Table 7-2. Translated Amino Acid Sequence Data Comparisons					
Strain	Total amino acids	Signal peptide overlap: position	N-terminal pro overlap: position	Mature protease overlap: position	C-terminal pro overlap: position
69B4 (ASP) Protease	495	28 (1 – 28)	170 (29 – 198)	189 (199 – 387)	108 (388 – 495)
<i>Cellulomonas flavigena</i> DSM20109	185			185 (199 – 383) id 68.6%	
<i>Cellulomonas biazotea</i> DSM 20112	335		84 (104 – 198) id 35.8%	189 (199 – 387) id 70.4% complete	62 (388 – 451) id 64.1%
<i>Cellulomonas fimi</i> DSM 20113	144			144 (199 – 342) id 74.3%	
<i>Cellulomonas gelida</i> DSM 20118	154			48 (340 – 387) id 68.8%	106 (388 – 495) id 63.9% complete
<i>Cellulomonas iranensis</i> DSM14784	85			85 (250 – 334) id 65.9%	
<i>Cellulomonas cellasea</i> DSM 20118	301		98 (99 – 198) id 31.0%	189 (199 – 387) id 68.3% complete	13 (388 – 400) id 30.8%
<i>Cellulomonas xylanilytica</i> LMG 21723	143			143 (214 – 356) id 73.4%	
<i>Oerskovia turbata</i> DSM 20577	428	29 (2 – 30) id 43.3%	171 (31 – 198) id 44.4%	188 (201 – 389) id 73.0% complete	40 (390 – 429) id 10.0%
<i>Oerskovia jenensis</i> DSM 46000	174			174 (214 – 334) id 73.6%	
<i>Cellulosimicrobium cellulans</i> DSM20424	328		117 (82 – 198) id 6%	199 (199 – 387) id 47.7% complete	12 (388 – 399)
<i>Promicromonospora citrea</i> DSM 43110	85			85 (250 – 334) id 75.3%	
<i>Promicromonospora sukumoe</i> DSM 44121	85			85 (250 – 334) id 64.7%	
<i>Xylanibacterium ulmi</i> LMG21721	141			141 (214 – 354) id 72.3%	

- 165 -

These results clearly show that bacterial strains of the suborder Micrococccineae, including the families *Cellulomonadaceae* and *Promicromonosporaceae* possess genes that are homologous with the 69B4 protease. Over the region of the mature 69B protease, the gene sequence identities range from about 60%-80%. The amino acid sequences of these homologous sequences exhibit about 45%-80% identity with the mature 69B4 protease protein. In contrast to the majority of streptogrisin proteases derived from members of the suborder *Streptomycineae*, these 69B4 (Asp) protease homologues from the suborder *Micrococccineae* possess six cysteine residues, which form three disulfide bridges in the mature 69B4 protease protein.

Indeed, in spite of the incomplete sequences provided herein and questions regarding fidelity, the present invention provides essential elements of the Asp group of proteases and comparisons with streptogrisins. Asp is uniquely characterized, along with Streptogrisin C, as having 3 disulfide bridges. In the following sequence, the Asp amino acids are printed in bold and the fully conserved residues are underlined. The active site residues are marked with # and double underlined. The cysteine residues are marked with * and underlined. The disulfide bonds are located between C17 and C38, C95 and C105, and C131 and C158.

```

1      5      8 17      20      25      30 32
X D V [I, V] G G [N, D] [X9] C* S [I, V] G [F, Y] A V X G G F [I, V] T A G H#
33 35 40 45 50 55 60
C* G [X2] G [X2] T/V [X4] G T F X G S S F P G N D# Y A [F, W] V [X4]
65 72 75 80
[G, D] [X2] [L, P] [X3] V N [N, R] [Y, H] [S, D] G [G, S] [R, T] V X V [A, T] G
85 90 95 100 105
[H, S] [T, Q] X A X V G [S, A] X V C* R S G [S, A] T T [G, A] W [H, R] C* G
112 115 120 125
[T, Y] [I, V] [X3] [N, G] X [S, T] V X Y [P, A] [E, Q] G [T, S, D] V [R, S] G L
130 131 135 137 140
[I, V] R [T, G] [T, N, S] [V, A] C* A E [P, G] G D S# G G S [L, V] [L, V, I] [A, S]
145 150 155 158
G [N, T] Q A [Q, R] G [V, L] T S G [G, R] [S, I] [G, N] [N, D] C* [X2] G
162 167 169 189
G [X4] Q P [X21]

```

(SEQ ID NO:125)

- 166 -

Table 7-3 (below) indicates the positions where ASP and Streptogrisin C differ:

Table 7-3. Positions At Which ASP and Streptogrisin C Differ			
ASP Position	ASP Amino Acid	ASP Homologs	Streptogrisin C Amino Acid
22	A	R?	S
25	G	G	N
28	I	V	A
51	S	N?	T
55	N	H?	R
57	Y	Y	I
65	G	D	N
74	N	R	G
76	S	D	G
77	G	G	R
79	R	T	D
88	A	A	S
122	V	V	I
125	L	L	V
126	I	V	T
141	L	V	Y
145	N	T	S

EXAMPLE 8

Mass Spectrometric Sequencing of ASP Homologues

In this Example, experiments conducted to confirm the DNA-derived sequence as well as verify/establish the N-terminal and C-terminal sequences of the mature ASP homologues are described. The microorganisms utilized in these experiments were the following:

1. *Cellulomonas biazotea* DSM 20112
2. *Cellulomonas flavigena* DSM 20109
3. *Cellulomonas fimi* DSM 20113
4. *Cellulomonas cellasea* DSM 20118
7. *Oerskovia jenensis* DSM 46000
8. *Oerskovia turbata* DSM 20577
9. *Cellulosimicrobium cellulans* DSM 20424

The micropurified ASP homologues were subjected to mass spectrometry-based protein sequencing procedures which consisted of these major steps: micropurification, gel electrophoresis, in-gel proteolytic digestion, capillary liquid chromatography electrospray

- 167 -

tandem mass spectrometry (nanoLC-ESI-MS/MS), database searching of the mass spectrometric data, and *de novo* sequencing. Details of these steps are described what follows. As described previously in Example 6, concentrated culture sample (about 200 ml) was added to 500ml 1M CaCl₂ and centrifuged at 14,000 rpm (model 5415C Eppendorf) for 5 min. The supernatant was cooled on ice and acidified with 200 ml 1N HCl. After 5 min, 200 ml 50% trichloroacetic acid were added and the sample was centrifuged for 4 min at 14,000 rpm (model 5415C Eppendorf). The supernatant was discarded and the pellet was washed first with water and then with 90% acetone. The pellet, after being dried in the speed vac, was dissolved in 2X Protein Preparation (Tris-Glycine Sample Buffer; Novex) buffer and diluted 1 + 1 with water before being applied to the SDS-PAGE gel. SDS-PAGE was run with NuPAGE MES SDS Running Buffer. SDS-PAGE gel (1 mm NuPAGE 10% Bis-Tris; Novex) was developed and stained using standard protocols known in the art. Following SDS-PAGE, bands corresponding to ASP homologues were excised and processed for mass spectrometric peptide sequencing using standard protocols in the art.

Peptide mapping and sequencing was performed using capillary liquid chromatography electrospray tandem mass spectrometry (nanoLC-ESI-MS/MS). This analysis systems consisted of capillary HPLC system (model CapLC; Waters) and mass spectrometer (model Qtof Ultima API; Waters). Peptides were loaded on a pre-column (PepMap100 C18, 5µm, 100A, 300µm ID x 1mm; Dionex) and chromatographed on capillary columns (Biobasic C18 75µm x 10cm; New Objectives) using a gradient from 0 to 100% solvent B in 45min at a flow rate of 200nL/min (generated using a static split from a pump flow rate of 5µL/min). Solvent A consisted of 0.1% formic acid in water; and solvent B was 0.1% formic acid in acetonitrile. The mass spectrometer was operated with the following parameters: spray voltage of 3.1kV, desolvation zone at 150°C, mass spectra acquired from 400 to 1900 m/z, resolution of 6000 in v-mode. Tandem MS spectra were acquired in data dependent mode with two most intense peaks selected and fragmented with mass dependent collision energy (as specified by vendor) and collision gas (argon) at 2.5x10⁻⁵ torr.

The identities of the peptides were determined using a database search program (Mascot, Matrix Science) using a database containing ASP homologue DNA-obtained sequences. Database searches were performed with the following parameters: no enzyme selected, peptide error of 2.5Da, MS/MS ions error of 0.1Da, and variable modification of carboxyaminoethyl cysteine). For unmatched MS/MS spectra, manual *de novo* sequence assignments were performed. For example, Figure 4 shows the sequence of N-terminal most tryptic peptide from *C. flavigena* determined from this tandem mass spectrum. In

- 168 -

Table 8-1, the percentage of the sequence verified on the protein level for various homologues are reported along with N-terminal and C-terminal peptide sequences.

Table 8-1. Mass Spec. Sequencing of ASP Homologues		
ASP Homologue	Sequence Verified % Trypsin, Chymotrypsin Digests	N-terminal and C-terminal Sequences (Peptide Mass in Da)
<i>Cellulomonas cellasea</i>	81, 81	[IY]AWDAFAENVVDWSSR (SEQ ID NO:126) (2026.7) YGGTTYFQPVNEILQAY (SEQ ID NO:127)(1961.8)
<i>Cellulomonas flavigena</i>	70, 50	VDVI/LGGNAYYI/L[...]R (SEQ ID NO:128)(1697.7)
<i>Cellulomonas fimi</i>	21, ND	VDVI/LGGDAY[...]R (SEQ ID NO:129) (1697.6)
Notes: ND: not determined sequence not determined indicated in [...] sequence order not determined indicated by [] isobaric residues not distinguished indicated by I/L		

5

10

15

EXAMPLE 9**Protease Production in *Streptomyces lividans***

This Example describes experiments conducted to develop methods for production

- 169 -

of protease by *S. lividans*. Thus, a plasmid comprising a polypeptide encoding a polypeptide having proteolytic activity was constructed and used such vector to transform *Streptomyces lividans* host cells. The methods used for this transformation are more fully described in US Patent No. 6,287,839 and WO 02/50245, both of which are herein expressly incorporated by reference.

One plasmid developed during these experiments was designated as "pSEG69B4T." The construction of this plasmid made use of one pSEGCT plasmid vector (See, WO 02/50245). A glucose isomerase ("GI") promoter operably linked to the structural gene encoding the 69B4 protease was used to drive the expression of the protease. A fusion between the GI-promoter and the 69B4 signal-sequence, N-terminal prosequence and mature sequence was constructed by fusion-PCR techniques as a *Xba*I-*Bam*HI fragment. The fragment was ligated into plasmid pSEGCT digested with *Xba*I and *Bam*HI, resulting in plasmid pSEG69B4T (See, Figure 6). Although the present Specification provides specific expression vectors, it is contemplated that additional vectors utilizing different promoters and/or signal sequences combined with various prosequences of the 69B4 protease will find use in the present invention.

An additional plasmid developed during the experiments was designated as "pSEA469B4CT" (See, Figure 7). As with the pSEG69B4T plasmid, one pSEGCT plasmid vector was used to construct this plasmid. To create the pSEA469B4CT, the *Aspergillus niger* (regulatory sequence) ("A4") promoter was operably linked to the structural gene encoding the 69B4 protease, and used to drive the expression of the protease. A fusion between the A4-promoter and the Cel A (from *Streptomyces coelicolor*) signal-sequence, the *asp*-N-terminal prosequence and the *asp* mature sequence was constructed by fusion-PCR techniques, as a *Xba*I-*Bam*HI fragment. The fragment was ligated into plasmid pSEA4GCT digested with *Xba*I and *Bam*HI, resulting in plasmid pSEA469B4CT (See, Figure 7). The sequence of the A4 (*A. niger*) promoter region is:

```

1          TCGAA CTTCAT GTTCGA GTTCTT GTTCAC GTAGAA GCCGGA GATGTG AGAGGT
          AGCTT GAAGTA CAAGCT CAAGAA CAAGTG CATCTT CGGCCT CTACAC TCTCCA
30 61 GATCTG GAACTG CTCACC CTCGTT GGTGGT GACCTG GAGGTA AAGCAA GTGACC CTTCTG
          CTAGAC CTTGAC GAGTGG GAGCAA CCACCA CTGGAC CTCCAT TTCGTT CACTGG GAAGAC
121 GCCGAG GTGGTA AGGAAC GGGGTT CCACGG GGAGAG AGAGAT GGCCTT GACGGT CTTGGG
          CGCCTC CACCAT TCCTTG CCCCAG GGTGCC CCTCTC TCTCTA CCGGAA CTGCCA GAACCC
181 AAGGGG AGCTTC NGCGCG GGGGAG GATGGT CTTGAG AGAGGG GGAGCT AGTAAT GTCGTA
35 TTCCCC TCGAAG NCGCGC CCCCTC CTACCA GAACTC TCTCCC CCTCGA TCATTA CAGCAT
241 CTTGGA CAGGGA GTGCTC CTTCTC CGACGC ATCAGC CACCTC AGCGGA GATGGC ATCGTG
          GAACCT GTCCCT CACGAG GAAGAG GCTGCG TAGTCG GTGGAG TCGCCT CTACCG TAGCAC
301 CAGAGA CAGACC
          GTCTCT GTCTGG (SEQ ID NO:130)

```

- 170 -

In these experiments, the host *Streptomyces lividans* TK23 was transformed with either of the vectors described above using protoplast methods known in the art (See e.g., Hopwood, *et al.*, Genetic Manipulation of *Streptomyces*, A Laboratory Manual, The John Innes Foundation, Norwich, United Kingdom [1985]).

5 The transformed culture was expanded to provide two fermentation cultures. At various time points, samples of the fermentation broths were removed for analysis. For the purposes of this experiment, a skimmed milk procedure was used to confirm successful cloning. In these methods, 30 µl of the shake flask supernatant was spotted in punched out holes in skim milk agar plates and incubated at 37°C. The incubated plates were visually
10 reviewed after overnight incubation for the presence of halos. For purposes of this experiment, the same samples were also assayed for protease activity and for molecular weight (SDS-PAGE). At the end of the fermentation run, full length protease was observed by SDS-PAGE.

A sample of the fermentation broth was assayed as follows: 10µl of the diluted
15 supernatant was taken and added to 190 µl AAPF substrate solution (conc. 1 mg/ml, in 0.1 M Tris/0.005% TWEEN, pH 8.6). The rate of increase in absorbance at 410 nm due to release of *p*-nitroaniline was monitored (25°C). The assay results of the fermentation broth of 3 clones (X, Y, W) obtained using the pSEG69B4T and two clones using the pSEA469B4T indicated that Asp was expressed by both constructs. able XXI. Results for
20 Two Clones (pSEA469B4T). Indeed, the results obtained in these experiments showed that the polynucleotide encoding a polypeptide having proteolytic activity was expressed in *Streptomyces lividans*, using both of these expression vectors. Although two vectors are described in this Example, it is contemplated that additional expression vectors using different promoters and/or signal sequences combined with different combinations of 69B4
25 protease: + / - N terminal and C terminal prosequence in the pSEA4CT backbone (vector), as well as other constructs will find use in the present invention.

EXAMPLE 10

Protease Production in *B. subtilis*

30 In this Example, experiments conducted to produce protease 69B4 (also referred to herein as "ASP," "Asp," and "ASP protease," and "Asp protease") in *B. subtilis* are described. In this Example, the transformation of plasmid pHPLT-ASP-C1-2 (See, Table 10-1; and Figure 9), into *B. subtilis* is described. Transformation was performed as known
35 in the art (See e.g., WO 02/14490, incorporated herein by reference. To optimize ASP

- 171 -

expression in *B. subtilis* a synthetic DNA sequence was produced by DNA2.0, and utilized in these expression experiments. The DNA sequence (synthetic ASP DNA sequence) provided below, with codon usage adapted for *Bacillus* species, encodes the wild type ASP precursor protein:

5
 ATGACACCACGAACTGTCACAAGAGCTCTGGCTGTGGCAACAGCAGCTGCTACACTCTTGGCTGGGGGTAT
 GGCAGCACAAGCTAACGAACCGGCTCCTCCAGGATCTGCATCAGCCCCTCCACGATTAGCTGAAAACTTGA
CCCTGACTTACTTGAAGCAATGGAACGCGATCTGGGGTTAGATGCAGAGGAAGCAGCTGCAACGTTAGCTTT
TCAGCATGACGCAGCTGAAACGGGAGAGGCTCTTGCTGAGGAACTCGACGAAGATTCGCGGGCACGTGGG
 10 TTGAAGATGATGTGCTGTATGTTGCAACCACTGATGAAGATGCTGTTGAAGAAGTCGAAGGCGAAGGAGCAA
CTGCTGTGACTGTTGAGCATTCTCTTGCTGATTTAGAGGCGTGGAAGACGGTTTTGGATGCTGCGCTGGAGG
GTCATGATGATGTGCCTACGTGGTACGTGCGCTGACGTCGCTACGAATTCGGTAGTCGTTGCTGTAAAGGCAGGAG
CGCAGGATGTAGCTGCAGGACTTGTGGAAGGCGCTGATGTGCCATCAGATGCGGTCACCTTTTGTAGAAACG
GACGAAACGCCTAGAACGATGTTTCGACGTAATTGGAGGCAACGCATATACTATTGGCGGCCGGTCTAGATG
 15 TTCTATCGGATTCGCAGTAAACGGTGGCTTCATTACTGCCGGTCACTGCGGAAGAACAGGAGCCACTACTG
CCAATCCGACTGGCACATTTGCAGGTAGCTCGTTCCGGGAAATGATTATGCATTCGTCGGAACAGGGGCA
GGAGTAAATTTGCTTGCCCAAGTCAATAACTACTCGGGCGGCAGAGTCCAAGTAGCAGGACATACGGCCG
CACCAGTTGGATCTGCTGTATGCCGCTCAGGTAGCACTACAGGTTGGCATTGCGGAACATACAGGCGCT
GAATTCGTCTGTACGTATCCAGAGGGAACAGTCCGAGGACTTATCCGCACGACGGTTTGTGCCGAACCA
 20 GGTGATAGCGGAGGTAGCCTTTTAGCGGGAAATCAAGCCCAAGGTGTCACGTCAGGTGGTTCTGGAAATT
GTCGGACGGGGGGAACAACATTCTTTCAACCAGTCAACCCGATTTTGCAGGCTTACGGCCTGAGAATGATT
ACGACTGACTCTGGAAGTTCCCTTGCTCCAGCACCTACATCATGTACAGGCTACGCAAGAACGTTACAGG
AACCTCGCAGCAGGAAGAGCAGCAGCTCAACCGAACGGTAGCTATGTTCAAGTCAACCGGAGCGGTACAC
ATTCCGTCTGTCTCAATGGACCTAGCGGTGCGGACTTTGATTTGTATGTGCAGCGATGGAATGGCAGTAGCT
 25 GGGTAACCGTCGCTCAATCGACATCGCCGGGAAGCAATGAAACCATTACGTACCGCGGAAATGCTGGATATT
ATCGCTACGTGGTTAACGCTGCGTCAGGATCAGGAGCTTACACAATGGGACTCACCTCCCTGA (SEQ ID
 NO:131)

In the above sequence, bold indicates the DNA that encodes the mature protease, standard font indicates the leader sequence, and the underline indicates the N-terminal and C-terminal prosequences.

Expression of the Synthetic ASP Gene

Asp expression cassettes were constructed in the pXX-KpnI (See, Figure 15) or p2JM103-DNNDPI (See, Figure 16) vectors and subsequently cloned into the pHPLT vector (See, Figure 17) for expression of ASP in *B. subtilis*. pXX-KpnI is a pUC based vector with the *aprE* promoter (*B. subtilis*) driving expression, a *cat* gene, and a duplicate *aprE* promoter for amplification of the copy number in *B. subtilis*. The *bla* gene allows selective growth in *E. coli*. The *KpnI*, introduced in the ribosomal binding site, downstream of the *aprE* promoter region, together with the *HindIII* site enables cloning of Asp expression cassettes in pXX-

- 172 -

KpnI. The vector p2JM103-DNNDPI contains the *aprE* promoter (*B. subtilis*) to drive expression of the BCE103 cellulase core (endo-cellulase from an obligatory alkaliphilic *Bacillus*; See, Shaw *et al.*, J. Mol. Biol., 320:303-309 [2002]), in frame with an acid labile linker (DDNDPI [SEQ ID NO:132]; See, Segalas *et al.*, FEBS Lett., 371:171-175 [1995]).

The ASP expression cassette (*Bam*HI and *Hind*III) was fused to BCE103-DDNDPI fusion protein. When secreted, ASP is cleaved of the cellulase core to turn into the mature protease

pHPLT (See, Figure 17; and Solingen *et al.*, Extremophiles 5:333-341 [2001]) contains the thermostable amylase LAT promoter (P_{LAT}) of *Bacillus licheniformis*, followed by *Xba*I and *Hpa*I restriction sites for cloning ASP expression constructs. The following sequence is that of the BCE103 cellulase core with DNNDPI acid labile linker. In this sequence, the bold indicates the acid-labile linker, while the standard font indicates the BCE103 core.

```

15      1      V R S K K L W I S L L F A L T L I F T M
      1      GTGAGA AGCAAA AAATTG TGGATC AGCTTG TTGTTT GCGTTA ACGTTA ATCTTT ACGATG
      2      CACTCT TCGTTT TTTAAC ACCTAG TCGAAC AACAAA CGCAAT TGCAAT TAGAAA TGCTAC
      3      A F S N M S A Q A D D Y S V V E E H G Q
      61     61     GCGTTC AGCAAC ATGAGC GCGCAG GCTGAT GATTAT TCAGTT GTAGAG GAACAT GGGCAA
      20     20     CGCAAG TCGTTG TACTCG CGCGTC CGACTA CTAATA AGTCAA CATCTC CTTGTA CCCGTT
      3      L S I S N G E L V N E R G E Q V Q L K G
      121    121    CTAAGT ATTAGT AACGGT GAATTA GTCAAT GAACGA GGCGAA CAAGTT CAGTTA AAAGGG
      4      GATTCA TAATCA TTGCCA CTTAAT CAGTTA CTTGCT CCGCTT GTTCAA GTCAAT TTTCCC
      5      M S S H G L Q W Y G Q F V N Y E S M K W
      25     25     181    ATGAGT TCCCAT GGTFTG CAATGG TACGGT CAATTT GTAAAC TATGAA AGCATG AAATGG
      6      TACTCA AGGGTA CCAAAC GTTACC ATGCCA GTTAAA CATTTG ATACTT TCGTAC TTTACC
      7      L R D D W G I T V F R A A M Y T S S G G
      241    241    CTAAGA GATGAT TGGGGA ATAACT GTATTTC CGAGCA GCAATG TATACC TCTTCA GGAGGA
      8      GATTCT CTACTA ACCCCT TATTGA CATAAG GCTCGT CGTTAC ATATGG AGAAGT CCTCCT
      30     30     301    Y I D D P S V K E K V K E T V E A A I D
      9      TATATT GACGAT CCATCA GTAAAG GAAAAA GTAAAA GAGACT GTTGAG GCTGCG ATAGAC
      10     10     ATATAA CTGCTA GGTAGT CATTTC CTTTTT CATTGA CACTC CGACGC TATCTG
      11     11     L G I Y V I I D W H I L S D N D P N I Y
      361    361    CTTGCG ATATAT GTGATC ATTGAT TGGCAT ATCCTT TCAGAC AATGAC CCGAAT ATATAT
      35     35     421    GAACCG TATATA CACTAG TAACTA ACCGTA TAGGAA AGTCTG TTACTG GGCTTA TATATA
      12     12     K E E A K D F F D E M S E L Y G D Y P N
      13     13     421    AAAGAA GAAGCG AAGGAT TTCTTT GATGAA ATGTCA GAGTTG TATGGA GACTAT CCGAAT
      14     14     TTTCTT CTTCGC TTCCTA AAGAAA CTACTT TACAGT CTCAAC ATACCT CTGATA GGCTTA
      15     15     V I Y E I A N E P N G S D V T W D N Q I
      40     40     481    GTGATA TACGAA ATTGCA AATGAA CCGAAT GGTAAT GATGTT ACGTGG GACAAT CAAATA
      16     16     CACTAT ATGCTT TAACGT TTACTT GGCTTA CCATCA CTACAA TGCACC CTGTTA GTTTAT
      17     17     K P Y A E E V I P V I R D N D P N N I V
      541    541    AAACCG TATGCA GAAGAA GTGATT CCGGTT ATTCTG GACAAAT GACCCT AATAAT ATTGTT
      18     18     TTTGCG ATACGT CTTCTT CACTAA GGCCAA TAAGCA CTGTTA CTGGGA TTATTG TAACAA
      45     45     601    I V G T G T W S Q D V H H A A D N Q L A
      19     19     ATTGTA GGTACA GGTACA TGGAGT CAGGAT GTCCAT CATGCA GCCGAT AATCAG CTTGCA
      20     20     TAACAT CCATGT CCATGT ACCTCA GTCCTA CAGGTA GTACGT CGGCTA TTAGCT GAACGT
      21     21     D P N V M Y A F H F Y A G T H G Q N L R
      661    661    GATCCT AACGTC ATGTAT GCATTT CATTTT TATGCA GGAACA CATGGA CAAAAT TTACGA
      50     50     CTAGGA TTGCAG TACATA CGTAAA GTAAAA ATACGT CCTTGT GTACCT GTTTTA AATGCT
      22     22     D Q V D Y A L D Q G A A I F V S E W G T
      721    721    GACCAA GTAGAT TATGCA TTAGAT CAAGGA GCAGCG ATATTT GTTAGT GAATGG GGGACA
      23     23     CTGGTT CATCTA ATACGT AATCTA GTTCCT CGTCGC TATAAA CAATCA CTTACC CCCTGT
      24     24     S A A T G D G G V F L D E A Q V W I D F
      55     55     781    AGTGCA GCTACA GGTGAT GGTGGT GTGTTT TTAGAT GAAGCA CAAGTG TGGATT GACTTT

```

- 173 -

841 TCACGT CGATGT CCACTA CCACCA CACAAA AATCTA CTTCGT GTTCAC ACCTAA CTGAAA
 M D E R N L S W A N W S L T H K D E S S
 5 ATGGAT GAAAGA AATTTA AGCTGG GCCAAC TGGTCT CTAACG CATAAG GATGAG TCATCT
 TACCTA CTTTCT TTAAAT TCGACC CGGTTG ACCAGA GATTGC GTATTG CTACTC AGTAGA
 901 A A L M P G A N P T G G W T E A E L S P
 GCAGCG TTAATG CCAGGT GCAAAT CCAACT GGTGGT TGGACA GAGGCT GAACTA TCTCCA
 CGTCGC AATTAC GGTCCA CGTTTA GGTGTA CCACCA ACCTGT CTCCGA CTTGAT AGAGGT
 S G T F V R E K I R E S A S D N N D P I
 961 TCTGGT ACATTT GTGAGG GAAAAA ATAAGA GAATCA GCATCT GACAAC AATGAT CCCATA
 10 AGACCA TGTAAA CACTCC CTTTTT TATTCT CTTAGT CGTAGA CTGTTG TTACTA GGGTAT
 (DNA; SEQ ID NO:133) and (Amino Acid; SEQ ID NO:134)

The Asp expression cassettes were cloned in the pXX-KpnI vector containing DNA
 encoding the wild type Asp signal peptide, or a hybrid signal peptide constructed of 5
 15 subtilisin AprE N-terminal signal peptide amino acids fused to the 25 Asp C-terminal signal
 peptide amino acids (MRSKKRTVTRALAVATAAATLLAGGMAAQA (SEQ ID NO:135), or a
 hybrid signal peptide constructed of 11 subtilisin AprE N-terminal signal peptide amino acids
 fused to the 19 *asp* C-terminal signal peptide amino acids
 (MRSKKLWISLLLAVATAAATLLAGGMAAQA (SEQ ID NO:136). These expression
 20 cassettes were also constructed with the *asp* C-terminal prosequence encoding DNA in
 frame. Another expression cassette, for cloning in the p2JM103-DNNDPI vector, encodes
 the ASP N-terminal pro- and mature sequence.

The Asp expression cassettes cloned in the pXX-KpnI or p2JM103-DNNDPI vector
 were transformed into *E.coli* (Electromax DH10B, Invitrogen, Cat.No. 12033-015). The
 25 primers and cloning strategy used are provided in Table 10-1. Subsequently, the
 expression cassettes were cloned from these vectors and introduced in the pHPLT
 expression vector for transformation into a *B. subtilis* ($\Delta aprE$, $\Delta nprE$, *oppA*, $\Delta spoII E$,
degUHy32, $\Delta amyE::(xylR,pxyIA-comK)$ strain. The primers and cloning strategy for ASP
 expression cassettes cloning in pHPLT are provided in Table 10-2. Transformation to *B.*
 30 *subtilis* was performed as described in WO 02/14490, incorporated herein by reference.
 Figures 12-21 provide plasmid maps for various plasmids described herein.

Table 10-1. ASP in pXX-KpnI and p2JM103-DNNDPI

Vector Construct	Signal Peptide	ASP C-Terminal prosequence	Primers	DNA Template	Host vector	Restriction Sites Used for Cloning
pXX-ASP-1	ASP	In frame	<p>pXX-ASP-III/IV-Fw CTAGCTAGGTACCATGACA CCACGAACTGTCACAAGAG CT (SEQ ID NO:137)</p> <p>ASP-syntc-ProC-RV GTGTGCAAGCTTTCAGGG GAGGGTGAGTCCCATTGT</p>	ASP synthetic gene G00222	pXX-KpnI	KpnI and HindIII

- 174 -

pXX-ASP-2	ASP	not incorporated	GTAA (SEQ ID NO:138) pXX-ASP-III/IV-Fw CTAGCTAGGTACCATGACA CCACGAAGTGTACAAGAG CT (SEQ ID NO:139) ASP-syntc-mature-RV GTGTGCAAGCTTTCAAGGG GAACTTCCAGAGTCAGTC (SEQ ID NO:140)	ASP synthetic gene G00222	pXX-KpnI	KpnI and HindIII
pXX-ASP-3	MRSKK RTVTR ALAVA TAAATL LAGGM AAQA (SEQ ID NO:135)	In frame	ASP-PreCross-I-FW TCATGCAGGGTACCATGAG AAGCAAGAAGCGAACTGTC ACAAGAGCTCTGGCT (SEQ ID NO:141) ASP-syntc-ProC-RV GTGTGCAAGCTTTCAAGGG GAGGGTGAGTCCCATTGT GTAA (SEQ ID NO:142)	ASP synthetic gene G00222	pXX-KpnI	KpnI and HindIII
pXX-ASP-4	MRSKK RTVTR ALAVA TAAATL LAGGM AAQA (SEQ ID NO:135)	not incorporated	ASP-PreCross-I-FW TCATGCAGGGTACCATGAG AAGCAAGAAGCGAACTGTC ACAAGAGCTCTGGCT (SEQ ID NO:143) ASP-syntc-mature-RV GTGTGCAAGCTTTCAAGGG GAACTTCCAGAGTCAGTC (SEQ ID NO:144)	ASP synthetic gene G00222	pXX-KpnI	KpnI and HindIII
pXX-ASP-5	MRSKK LWISLL LAVAT AAATLL AGGMA AQA (SEQ ID NO:136)	In frame	ASP-PreCross-II-FW TCATGCAGGGTACCATGAG AAGCAAGAAGTTGTGGATC AGTTTGCTGCTGGCTGTGG CAACAGCAGCTGCTACA (SEQ ID NO:145) ASP-syntc-ProC-RV GTGTGCAAGCTTTCAAGGG GAGGGTGAGTCCCATTGT GTAA (SEQ ID NO:146)	ASP synthetic gene G00222	pXX-KpnI	KpnI and HindIII
pXX-ASP-6	MRSKK LWISLL LAVAT AAATLL AGGMA AQA (SEQ ID NO:136)	not incorporated	ASP-PreCross-II-FW TCATGCAGGGTACCATGAG AAGCAAGAAGTTGTGGATC AGTTTGCTGCTGGCTGTGG CAACAGCAGCTGCTACA (SEQ ID NO:147) ASP-syntc-mature-RV GTGTGCAAGCTTTCAAGGG GAACTTCCAGAGTCAGTC (SEQ ID NO:148)	ASP synthetic gene G00222	pXX-KpnI	KpnI and HindIII
p2JM-103 ASP	BCE103 cellulase core + acid labile linker	not incorporated	DPI-ASP-syntc-ProN-FW CCATACCGGATCCAAACGA ACCGGCTCCTCCAGGATCT (SEQ ID NO:149) DPI-ASP-syntc-Mature-RV CTCGAGTTAAGCTTTTAAG	ASP synthetic gene G00222	p2JM103-DNNDPI	BamHI and HindIII

- 175 -

			GGGAACTTCCAGAGTCAGT C (SEQ ID NO:150)			
--	--	--	--	--	--	--

5

Table 10-2. ASP Expression Cassettes in pHPLT				
Vector construct	Primers	DNA template	Host vector	Restriction sites used for cloning
pHPLT-ASP-III	ASP-III&IV-FW TGAGCTGCTAGCAAAAGGAGAGGGTA AAGAATGACACCACGAACTGTC (SEQ ID NO:151) <u>pHPLT-ASPproC-RV</u> CGTACATCCCGGGTCAGGGGAGGGTG AGTCCCATTG (SEQ ID NO:152)	pXX-ASP-1	pHPLT (<i>Xba</i> I x <i>Hpa</i> I)	<i>Nhe</i> I x <i>Sma</i> I
pHPLT-ASP-IV	ASP-III&IV-FW TGAGCTGCTAGCAAAAGGAGAGGGTA AAGAATGACACCACGAACTGTC (SEQ ID NO:153) <u>pHPLT-ASPmat-RV</u> CATGCATCCCGGGTTAAGGGGAACTT CCAGAGTCAGTC (SEQ ID NO:154)	pXX-ASP-2	pHPLT (<i>Xba</i> I x <i>Hpa</i> I)	<i>Nhe</i> I x <i>Sma</i> I
pHPLT-ASP-C1-1	ASP-Cross-1&2-FW TGAGCTGCTAGCAAAAGGAGAGGGTA AAGAATGAGAAGCAAGAAG (SEQ ID NO:155) <u>pHPLT-ASPproC-RV</u> CGTACATCCCGGGTCAGGGGAGGGTG AGTCCCATTG (SEQ ID NO:156)	pXX-ASP-3	pHPLT (<i>Xba</i> I x <i>Hpa</i> I)	<i>Nhe</i> I x <i>Sma</i> I
pHPLT-ASP-C1-2	ASP-Cross-1&2-FW TGAGCTGCTAGCAAAAGGAGAGGGTA AAGAATGAGAAGCAAGAAG (SEQ ID NO:157) <u>pHPLT-ASPmat-RV</u> CATGCATCCCGGGTTAAGGGGAACTT CCAGAGTCAGTC (SEQ ID NO:158)	pXX-ASP-4	pHPLT (<i>Xba</i> I x <i>Hpa</i> I)	<i>Nhe</i> I x <i>Sma</i> I
pHPLT-ASP-C2-1	ASP-Cross-1&2-FW TGAGCTGCTAGCAAAAGGAGAGGGTA AAGAATGAGAAGCAAGAAG (SEQ ID NO:159) <u>pHPLT-ASPproC-RV</u> CGTACATCCCGGGTCAGGGGAGGGTG AGTCCCATTG (SEQ ID NO:160)	pXX-ASP-5	pHPLT (<i>Xba</i> I x <i>Hpa</i> I)	<i>Nhe</i> I x <i>Sma</i> I
pHPLT-ASP-C2-2	ASP-Cross-1&2-FW TGAGCTGCTAGCAAAAGGAGAGGGTA	pXX-ASP-6	pHPLT (<i>Xba</i> I x <i>Hpa</i> I)	<i>Nhe</i> I x <i>Sma</i> I

- 176 -

	AAGAATGAGAAGCAAGAAG (SEQ ID NO:161) pHPLT-ASPmat-RV CATGCATCCCGGGTTAAGGGGAACTT CCAGAGTCAGTC (SEQ ID NO:162)			
pHPLT-ASP-VII	pHPLT-BCE/ASP-FW TGCAGTCTGCTAGCAAAAGGAGAGGG TAAAGAGTGAGAAG (SEQ ID NO:163) pHPLT-ASPmat-RV CATGCATCCCGGGTTAAGGGGAACTT CCAGAGTCAGTC (SEQ ID NO:164)	p2JM103-ASP	pHPLT	NheI x SmaI

Primers were obtained from MWG and Invitrogen. Invitrogen Platinum *Taq* DNA polymerase High Fidelity (Cat.No. 11304-029) was used for PCR amplification (0.2 μ M primers, 25 up to 30 cycles) according to the Invitrogen's protocol. Ligase reactions of ASP expression cassettes and host vectors were completed by using Invitrogen T4 DNA Ligase (Cat. No. 15224-025), utilizing Invitrogen's protocol as recommended for general cloning of cohesive ends).

Selective growth of *B. subtilis* ($\Delta aprE$, $\Delta nprE$, *oppA*, $\Delta spoII E$, *degUHy32*, $\Delta amyE::(xylR,pxyIA-comK)$) transformants harboring the p2JM103-ASP vector or one of the pHPLT-ASP vectors was performed in shake flasks containing 25 ml Synthetic Maxatase Medium (SMM), with 0.97 g/l $CaCl_2 \cdot 6H_2O$ instead of 0.5 g/l $CaCl_2$ (See, U.S. Pat. No. 5,324,653, herein incorporated by reference) with either 25 mg/L chloramphenicol or 20 mg/L neomycin. This growth resulted in the production of secreted ASP protease with proteolytic activity. However. Gel analysis was performed using NuPage Novex 10% Bis-Tris gels (Invitrogen, Cat.No. NP0301BOX). To prepare samples for analysis, 2 volumes of supernatant were mixed with 1 volume 1M HCl, 1 volume 4xLDS sample buffer (Invitrogen, Cat.No. NP0007), and 1% PMSF (20 mg/ml) and subsequently heated for 10 minutes at 70°C. Then, 25 μ L of each sample was loaded onto the gel, together with 10 μ L of SeeBlue plus 2 pre-stained protein standards (Invitrogen, Cat.No.LC5925). The results clearly demonstrated that all *asp* cloning strategies described in this Example yield sufficient amounts of active Asp produced by *B. subtilis*.

In addition, samples of the same fermentation broths were assayed as follows: 10 μ L of the diluted supernatant was taken and added to 190 μ L AAPF substrate solution (conc. 1 mg/ml, in 0.1 M Tris/0.005% TWEEN®, pH 8.6). The rate of increase in absorbance at 410 nm due to release of *p*-nitroaniline was monitored (25°C), as it provides a measure of the ASP concentration produced. These results indicated that all of the constructs resulted in the production of measurable ASP protease.

The impact of the synthetic *asp* gene was investigated in *Bacillus subtilis* comparing

- 177 -

the expression levels of the pHPLT-ASP-c-1-2 construct with the synthetic and native *asp* gene in a *B. subtilis* ($\Delta aprE$, $\Delta nprE$, *oppA*, $\Delta spoII E$, *degUHy32*, $\Delta amyE::(xylR,pxyIA-comK)$) strain. The native gene was amplified from plasmid containing the native *asp* gene, using platinum *pfx* polymerase (Invitrogen) with the following primers:

AK04-12.1: *NheI* thru RBS

TTATGCGAGGCTAGCAAAAGGAGAGGGTAAAGAGTGAGAAGCAAAAAACG (SEQ ID NO:165)

AK04-11: RBS thru 5 aa *aprE* for ASP native C1 fusion in pHPLT
taaagagtgaagaagcaaaaaacgcacagtcacgcgggccctg (SEQ ID NO:166)

AK04-13: *HpaI* 3' of native ASP mature
gtcctctgtaacttacgggctgctgcccgagtcc (SEQ ID NO:167)

The following conditions were used for these PCRs: 94°C for 2 min.; followed by 25 cycles of 94°C for 45 sec., 60°C for 30 sec., and 68°C for 2 min. for 30 sec.; followed by 68°C for 5 min. The resulting PCR product was run on an E-gel (Invitrogen), excised, and purified with a gel extraction kit (Qiagen). Ligase reaction of this fragment containing the native ASP with the pHPLT vector was completed by using ligated (T4 DNA Ligase, NEB) and transformed directly into *B. subtilis* ($\Delta aprE$, $\Delta nprE$, *oppA*, $\Delta spoII E$, *degUHy32*, $\Delta amyE::(xylR,pxyIA-comK)$). Transformation to *B. subtilis* was performed as described in WO 02/14490 A2, herein incorporated by reference.

The Asp protein was produced by growth in shake flasks at 37°C in medium containing the following ingredients; 0.03 g/L MgSO₄, 0.22 g/L K₂HPO₄, 21.3 g/L NA₂HPO₄*7H₂O, 6.1 g/L NaH₂PO₄*H₂O, 3.6 g/L Urea, 7 g/L soymeal, 70 g/L Maltrin M150, and 42 g/L glucose, with a final pH7.5. In these experiments, the production level of the host carrying the synthetic gene cassette was found to be 3-fold higher than the host carrying the native gene cassette.

In additional experiments, expression of ASP was investigated in *Bacillus subtilis* using the *sacB* promoter and *aprE* signal peptide. The gene was amplified from plasmid containing the synthetic *asp* gene using TGO polymerase (Roche) and the primers:

CF 520 (+) Fuse ASP (pro) to *aprE* ss

GCAACATGTCTGCGCAGGCTAACGAACCGGCTCCTCCAGGA (SEQ ID NO:168)

CF 525 (-) End of Asp gene *HindIII* GACATGACATAAGCTTAAGGGGAACTTCCAGAGTC

- 178 -

(SEQ ID NO:169)

The *sacB* promoter (*Bacillus subtilis*), the start of the messenger RNA (+1) from *aprE*, and the *aprE* signal peptide were amplified from the plasmid pJHsacBJ2 using TGO polymerase (Roche) and the primers:

CF 161 (+)*EcoRI* at start of *sacB* promoter

GAGCCGAATTCATATACCTGCCGTT (SEQ ID NO:170)

CF 521 (-) Reverse complement of CF 520

TCCTGGAGGAGCCGGTTCGTTAGCCTGCGCAGACATGTTGC (SEQ ID NO:171)

The following PCR conditions were used to amplify both pieces:

94°C for 2 min. ; followed by 30 cycles of 94°C for 30 sec., 50°C for 1 min., and 66°C for 1 min. ; followed by 72°C for 7 min. The resulting PCR products were run on an E-gel (Invitrogen), excised, and purified with a gel extraction kit (Qiagen).

In addition, a PCR overlap extension fusion (Ho, Gene, 15:51-59 [1989]) was used to fuse the above gene fragment to the *sacB* promoter-*aprE* signal peptide fragment with PFX polymerase (Invitrogen) using the following primers:

CF 161 (+)*EcoRI* at start of *sacB* promoter

GAGCCGAATTCATATACCTGCCGTT (SEQ ID NO:170)

CF 525 (-) End of *Asp* gene *HindIII* GACATGACATAAGCTTAAGGGGAACTTCCAGAGTC (SEQ ID NO:169)

The following conditions were used for these PCRs:

94°C for 2 min.; followed by 25 cycles of 94°C for 45 sec., 60°C for 30 sec., and 68°C for 2 min. 30 sec.; followed 68°C for 5 min. The resulting PCR fusion products were run on an E-gel (Invitrogen), excised, and purified with a gel extraction kit (Qiagen). The purified fusions were cut (*EcoRI/HindIII*) and ligated (T4 DNA Ligase, NEB) into an *EcoRI/HindIII* pJH101 (Ferrari *et al.*, J. Bacteriol., 152:809-814 [1983]) vector containing a strong transcriptional terminator. The ligation mixture was transformed into competent *E. coli* cells (Top 10 chemically competent cells, Invitrogen) and plasmid preps were done to retrieve the plasmid (Qiagen spin-prep).

The plasmid, pJHsacB-ASP (1-96 *sacB* promoter; 97-395 *aprE* +1 through end of *aprE* ss; and 396-1472 pro+ mature *asp*; See, sequence provided below) was transformed to *B. subtilis*. Transformation to *B. subtilis* ($\Delta aprE$, $\Delta nprE$, *oppA*, $\Delta spoII E$, *degUHy32*,

- 179 -

ΔamyE::(xylR,pxylA-comK) strain was performed as described in WO 02/14490 A2, herein incorporated by reference. The chromosomal DNA was extracted from an overnight culture of the strain (grown in LB media) then transformed to strain BG 3594 and named "CF 202." This strain produced a clear halo on the indicator plate (LA + 1.6% skim milk).

pJHsacB-ASP Sequence:

```
CATCACATATACCTGCCGTTCACTATTATTTAGTGAAATGAGATATTATGATATTTTCTG
AATTGTGATTAAAAAGGCAACTTTATGCCCATGCAACAGAACTATAAAAAATACAGAGA
ATGAAAAGAAACAGATAGATTTTTTAGTTCTTTAGGCCCGTAGTCTGCAAATCCTTTTAT
GATTTTCTATCAAACAAAAGAGGAAAAATAGACCAGTTGCAATCCAAACGAGAGTCTAAT
AGAATGAGGTCAcagaAATAGTCTTTTAAGTAAGTCTACTCTGAATTTTTTAAAGGAGA
GGGTAAAGAgtgAGAAGCAAAAAATTGTGGATCAGCTTGTTGTTTGCCTTAACGTTAATC
TTTACGATGGCGTTTCAcAACATGTCTGCGCAGGCTaacgaaccggctcctccaggatctgcatcag
cccctccacgattagctgaaaaacttgaccctgacttactgaagcaatggaacgcgatctggggttagatgcagaggaagca
gctgcaacgtagctttcagcatgacgcagctgaaacgggagaggctcttgctgaggaactcgacgaagatttcgcgggcac
gtgggtgaagatgatgtgctgtatgttgcaaccactgatgaagatgctgttgaagaagtcgaaggcgaaggagcaactgctgt
gactgtgagcattctcttgctgattlagaggcgtggaagacgggtttggatgctgcgctggagggatcatgatgtgcctacgtg
gtacgtcgacgtgcctacgaattcggtatgctgtgttaaaggcaggagcgcaggatgtagctgcaggactgtggaaggcg
ctgatgtgccatcagatgcggtcactttgtagaacggacgaaacgcctagaacgatgttcgacgtaattggaggcaacgcata
atactattggcgccgggtctagatgttctatcggttcgcagtaaacgggtggcttcattactgccggctactgcggaagaacagg
agccactactgccaatccgactggcacatttcaggttagctcgtttccgggaaatgattatgcattcgtccgaacagggggcagg
agtaaatttgcttgcccaagtcaataactactcgggcggcagagtcgaagtagcaggacatacggccgcaccagttggatctg
ctgatgccgctcaggtagcactacaggttggcattgcggaactatcacggcgctgaattcgtctgtcacgtatccagagggaac
agtccgaggactatccgcacgacggttgtgccgaaccaggtgatagcggaggttagccttttagcgggaaatcaagcccaag
gtgcacgtcaggtggttctggaattgtcggacggggggaacaacattcttcaaccagtcaaccgatttgcagggttacggc
ctgagaatgattacgactgactctggaagttcccctTAAGCTTAAAAAACCGGCCTTGGCCCCGCGCGTT
TTTTATTATTTTCTTCCCTCCGCATGTTCAATCCGCTCCATAATCGACGGATGGCTCCCT
CTGAAAATTTTAACGAGAAACGGCGGGTTGACCCGGCTCAGTCCCGTAACGGCCAAGT
CCTGAAACGTCTCAATCGCCGCTTCCCGGTTTCCGGTCAGCTCAATGCCGTAACGGTC
GGCGGCGTTTTCTTGATACCGGGAGACGGCATTCTGTAATCGGATCCCGGACGCATCG
TGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCA
CCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTCGGCGTGG
GTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCAC
CATTCTTGGCGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAAT
GCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGT
CAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTC
TTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGG
ACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTT
GCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCC GCCACCAAACGTTTCGGCGAGAA
GCAGGCCATTATCGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTT
CGCGACGCGAGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATC
GGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGA
CAGCTTCAAGGATCGCTCGCGGCTCTTACCAGCCTAACTTCGATCACTGGACCGCTGA
TCGTACGGCGGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTG
AGGCGCCGCCCTATACCTTATTTATGTTACAGTAATATTGACTTTTTAAAAAGGATTGAT
TCTAATGAAGAAAGCAGACAAGTAAGCCTCCTAAATTCATTTAGATAAAAAATTTAGGAG
GCATATCAAATGAACTTTAATAAAATTGATTTAGACAATTGGAAGAGAAAAGAGATATTT
AATCATTATTTGAACCAACAAACGACTTTTAGTATAACCAACAGAAATTGATATTAGTGTTT
```

- 180 -

TATACCGAAACATAAAACAAGAAGGATATAAATTTTACCCTGCATTTATTTTCTTAGTGA
CAAGGGTGATAAACTCAAATACAGCTTTTAGAACTGGTTACAATAGCGACGGAGAGTTA
GGTTATTGGGATAAGTTAGAGCCACTTTATACAATTTTGGATGGTGTATCTAAAACATTC
TCTGGTATTTGGACTCCTGTAAAGAATGACTTCAAAGAGTTTTATGATTTATACCTTTCT
5 GATGTAGAGAAATATAATGGTTCGGGGAAATTGTTTCCCAAAACACCTATACCTGAAAA
TGCTTTTTCTCTTTCTATTATTCCATGGACTTCATTTACTGGGTTTAACTTAAATATCAAT
AATAATAGTAATTACCTTCTACCCATTATTACAGCAGGAAAATTCATTAATAAAGGTAATT
CAATATATTTACCGCTATCTTTACAGGTACATCATTCTGTTTGTGATGGTTATCATGCAG
GATTGTTTATGAACTCTATTCAGGAATTGTCAGATAGGCCTAATGACTGGCTTTTATAAT
10 ATGAGATAATGCCGACTGTACTTTTTACAGTCGGTTTTCTAATGTCACTAACCTGCCCC
GTTAGTTGAAGAAGGTTTTATATTACAGCTCCAGATCCTGCCTCGCGCGTTTCGGTGA
TGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAA
GCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTG
TCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGGCTTAAC
15 TATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGC
ACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGA
CTCGCTGCGCTCGGTCTGTTCCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGT
AATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGC
CAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCC
20 GCCCCCTGACGAGCATCAAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGA
CAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGT
TCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGCGC
CTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTTCGCTCCAAGCT
GGGCTGTGTGCACGAACCCCCCGTTTACGCCGACCGCTGCGCCTTATCCGGTAACCTA
25 TCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGT
AACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGG
CCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAG
TTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAG
CGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAG
30 ATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACCTCACGTTAAGGG
ATTTTGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTAATAATGA
AGTTTTAAATCAATCTAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTA
ATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACT
CCCCGTCTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCA
35 ATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCCAGCCAG
CCGGAAGGGCCGAGCGCAGAAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTAT
TAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGGCGCAACGTTG
TTGCCATTGCTGCAGGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTTCAG
CTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCG
40 GTTAGCTCCTTCGGTCTCCGATCGTTGTGAGAAGTAAGTTGGCCGCAGTGTTATCAC
TCATGGTTATGGCAGCACTGCATAATTCTTACTGTCATGCCATCCGTAAGATGCTTT
TCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGA
GTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAA
AGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTG
45 TTGAGATCCAGTTCGATGTAACCCACTCGTGACCCAACTGATCTTCAGCATCTTTTAC
TTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGA
ATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGC
ATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAA
CAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCA
50 TTATTATCATGACATTAACCTATAAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAA
(SEQ ID NO:172)

- 181 -

Expression of the *asp* gene was investigated in a nine-protease delete *Bacillus subtilis* host. The plasmid pHPLT-ASP-C1-2 (See, Table 10-2, and Figure 9), was transformed into *B. subtilis* ($\Delta aprE$, $\Delta nprE$, Δepr , $\Delta ispA$, Δbpr , Δvpr , $\Delta wprA$, $\Delta mpr-ybfJ$, $\Delta nprB$) and (*degU*^{Hy32}, *oppA*, $\Delta spoII E3501$, *amyE:(xylRPxylAcomK-ermC)*). Transformation was performed as known in the art (See e.g., WO 02/14490, incorporated herein by reference). The Asp protein was produced by growth in shake flasks at 37°C in MBD medium, a MOPS based defined medium. MBD medium was made essentially as known in the art (See, Neidhardt *et al.*, J. Bacteriol., 119: 736-747 [1974]), except NH₄Cl₂, FeSO₄, and CaCl₂ were left out of the base medium, 3 mM K₂HPO₄ was used, and the base medium was supplemented with 60 mM urea, 75 g/L glucose, and 1 % soytone. Also, the micronutrients were made up as a 100 X stock containing in one liter, 400 mg FeSO₄ .7H₂O, 100 mg MnSO₄ .H₂O, 100 mg ZnSO₄.7H₂O, 50 mg CuCl₂.2H₂O, 100 mg CoCl₂.6H₂O, 100 mg NaMoO₄.2H₂O, 100 mg Na₂B₄O₇.10H₂O, 10 ml of 1M CaCl₂ , and 10 ml of 0.5 M sodium citrate. The expression levels obtained in these experiments were found to be fairly high.

In additional embodiments, "consensus" promoters such as those developed through site-saturation mutagenesis to create promoters that more perfectly conform to the established consensus sequences for the "-10" and "-35" regions of the vegetative "sigma A-type" promoters for *B. subtilis* (See, Voskuil *et al.*, Mol. Microbiol., 17:271-279 [1995]) find use in the present invention. However, it is not intended that the present invention be limited to any particular consensus promoter, as it is contemplated that other promoters that function in *Bacillus* cells will find use in the present invention.

EXAMPLE 11

Protease Production in *Bacillus clausii*

In this Example, experiments conducted to produce protease 69B4 (also referred to as "Asp" herein) in *B. clausii* are described. In order to express the Asp protein in *Bacillus clausii*, it was necessary to use a promoter that works in this alkaliphilic microorganism due to its unique regulation systems. The production profile of the alkaline serine protease of *B. clausii* PB92 (MAXACAL[®] protease) has shown that it has to have a strong promoter (referred to as "MXL-prom." herein; SEQ ID NOS:173, 174, and 175, See, Figure 18) with a delicate regulation. Besides the promoter region, also signal sequences (leader sequences) are known to be very important for secreting proteins in *B. clausii*. Therefore, 3 constructs were designed with the MAXACAL[®] protease promoter region and separate fusions of the

- 182 -

MAXACAL® protease leader sequence and the Asp leader sequence in front of the N-terminal Pro and the mature Asp protein with 3, 6 and 27 amino acids of the MAXACAL® protease leader fused to 25, 25 and 0 amino acids of the Asp leader, respectively.

To make these constructs, amplification of DNA fragments needed to be done in order to enable the fusion. Therefore, PCRs were performed on both MAXACAL® protease and Asp template DNA with Phusion high fidelity polymerase (Finnzymes) according to the manufacturer's instructions.

PCR reactions were executed with the following primers (bold indicates the MAXACAL® protease part of the primer) synthesized at MWG-Biotech AG:

- 1: B. clau-3F: **agggaaccgaatgaagaaacgaactgtcacaagagctctg** (SEQ ID NO:176)
- 2: B. clau-3R: **cagagctctgtgacagttcgtttcttcattcggttccct** (SEQ ID NO:177)
- 3: B. clau-6F: **aatgaagaaaccgttggggcgaactgtcacaagagctctg** (SEQ ID NO:178)
- 4: B. clau-6R: **cagagctctgtgacagttcgtttcttcatt** (SEQ ID NO:179)
- 5: B. clau-27F: **agttcatcgatcgcatcggctaacgaaccggctcctccagga** (SEQ ID NO:180)
- 6: B. clau-27R: **tcttgaggagccggttcgttagccgatcgcatgaact** (SEQ ID NO:181)
- 7: B. clau-vector 5': **tcagggggatcctagattctgttaacttaacgtt**. (SEQ ID NO:182)

This primer contains the *HpaI*-site (GTTAAC) from the promoter region and a *Bam*HI-site (GGATCC) for cloning reasons (both underlined).

- 8: pHPLT-*Hind*III-R: **gtgctgtttatcctttacctgtctcc**. (SEQ ID NO:183). The sequence of this primer lays just upstream of the *Hind*III-site of pHPLT-ASP-C1-2 (See, Table10-2).

Table 11-1. PCR Setup to Create Fused MAXACAL® Protease–Asp Leader Fragments			
Template DNA	Primer 1	Primer 2	Fragment Name
pHPLT-ASP-C1-2	1	8	3F
pHPLT-ASP-C1-2	3	8	6F
pHPLT-ASP-C1-2	5	8	27F
pMAX4	2	7	3R
pMAX4	4	7	6R
pMAX4	6	7	27R
3F + 3R	7	8	3F3R
6F + 6R	7	8	6F6R
27F + 27R	7	8	27F27R

- 183 -

In Table 11-1, "pMAX4" refers to the template described in WO 88/06623, herein incorporated by reference. PCR fragments 3F3R, 6F6R, 27F27R were digested with both *Bam*HI and *Hind*III. The digested PCR fragments were ligated with T4 ligase (Invitrogen) into *Bam*HI + *Hind*III-opened plasmid pHPLT-ASP-C1-2 (See, Figure 18). The ligation product was transformed to competent *B. subtilis* cells (($\Delta aprE$, $\Delta nprE$, *oppA*, $\Delta spoII E$, *degUHy32*, $\Delta amyE::(xylR, pxyIA-comK)$; See e.g., WO 02/14490, incorporated herein by reference) and selected on neomycin (20 mg/l). Heart Infusion-agar plates containing neomycin were used to identify neomycin resistant colonies. DNA of the *B. subtilis* transformants was isolated using Qiagen's plasmid isolation kit according to manufacture's instructions, and were tested on the appearance of the fused MAXACAL® protease-Asp fragment by their pattern after digestion with both *Nco*I + *Hpa*I together in one tube. The restriction enzymes used in this Example (i.e., *Bam*HI, *Hind*III, *Nco*I and *Hpa*I) were all purchased from NEB, and used following the instructions of the supplier. DNA of *B. subtilis* transformants that showed 2 bands with restriction enzymes (*Nco*I + *Hpa*I) was used to transform protease negative *B. clausii* strain PBT142 protoplast cells (these were derived from PB92).

The protoplast transformation of *B. clausii* strain PBT142 was performed according to the protocol mentioned for the protoplast transformation of *B. alkalophilus* (renamed *B. clausii*) strain PB92 in patent WO88/06623, herein incorporated by reference. A modification to this protocol was the use of an alternative recipe for the regeneration plates, in that instead of 1.5% agar, 8.0 g/l Gelrite gellam gum (Kelco) was used. In addition, instead of 1000 mg/l neomycin, 20 mg/l neomycin was used as described by Van der Laan *et al.*, (Van der Laan *et al.*, Appl. Environ. Microbiol., 57:901-909 [1991]).

DNA from all 3 constructs isolated from *B. subtilis* (see above) was transformed into *B. clausii* PBT142 protoplasts using the same protocol as above. Transformants in *B. clausii* PBT142 were selected by replica-plating on Heart Infusion agar plates containing 20 mg/l neomycin. The *B. clausii* strains with the different construct were produced as indicated in Table 11-2.

Table 11-2. <i>B. clausii</i> Constructs	
Construct (length MAXACAL® protease leader)	<i>B. clausii</i> Strain
3 MXL/25ASP	PMAX-ASP3
6 MXL/25ASP	PMAX-ASP2

- 184 -

27 MXL/0ASP	PMAX-ASP1
-------------	-----------

These 3 strains were fermented in shake flasks containing 100 ml Synthetic Maxatase Medium (SMM) (See, U.S. Pat. No. 5,324,653, herein incorporated by reference). However, instead of 0.97 g/l $\text{CaCl}_2 \cdot 6\text{H}_2\text{O}$, 0.5 g/l CaCl_2 was used. Also, instead of 0.5 ml/l antifoam 5693, 0.25 ml/l Basildon was used. The 100 ml SSM shake flasks were inoculated with 0.2 ml of a pre-culture of the 3 *B. clausii* strains containing the leader constructs in 10 ml TSB (Tryptone Soya Broth) with 20 mg/l neomycin. The protease production values were measured via the AAPF-assay (as described above) after growth in the shake flasks for 3 days. The results indicated that these constructs were able to express protease with proteolytic activity.

In an additional experiment, integration of the leader construct with the entire MAXACAL® protease leader length (27 amino acids) was investigated. However, it is not intended that the present invention be limited to any particular mechanism.

Stable integration of heterologous DNA in the *B. alcalophilus* (now, *B. clausii*) chromosome is described in several publications (See e.g., WO 88/06623, and Van der Laan *et al.*, *supra*). The procedure described in patent WO 88/06623 for integration of 1 or 2 copies of the MAXACAL® protease gene in the chromosome of *B. alcalophilus* (now, *B. clausii*) was used to integrate at least 1 copy of the *asp* gene in the chromosome of *B. clausii* PBT142. However, a derivative of pE194-neo: pENM#3 (See, Figure 19) was used instead of the integration vector pE194-neo (to make pMAX4 containing the MAXACAL® protease gene). In the integration vector pENM#3, the Asp leader PCR product 27F27R was cloned in the unique blunt end site *HpaI* in between the 5' and the 3' flanking regions of the MAXACAL® protease gene. Therefore, 27F27R was made blunt-ended as follows: it was first digested with *HpaI* (5'end), purified with the Qiagen PCR purification kit, and then digested with *HindIII* (3'end). This treated PCR fragment 27F27R was purified again after *HindIII* digestion (using the same Qiagen kit) and filled in with dNTP's using T4 polymerase (Invitrogen) and purified again with Qiagen kit. The *HpaI*-opened pENM#3 and the blunt-ended PCR product 27F27R were ligated with T4 ligase (Invitrogen). The ligation product was transformed directly to *B. clausii* PBT142 protoplasts and selected after replica-plating on HI agar plates with 20 mg/l neomycin. Two transformants with the correct orientation of the *asp* gene in the integration vector were identified and taken into the integration procedure as described in patent WO 88/06623. Selections were done at 2 mg/l and 20 mg/l neomycin for integration in the MAXACAL® protease locus and at an illegitimate locus, respectively. These results indicated that *B. clausii* is also suitable as an expression host

- 185 -

for the Asp protease.

EXAMPLE 12

Protease Production in *B. licheniformis*

In this Example, experiments conducted to produce protease 69B4 in *B. licheniformis* are described. During these experiments, various expression constructs were created to produce protease 69B4 protease (also referred to as "ASP protease") in *Bacillus licheniformis*. Constructs were cloned into expression plasmid pHPLT (replicating in *Bacillus*) and/or into integration vector pICatH. Plasmid pHPLT (See, Figure 17; and U.S. Pat. No. 6,562,612 [herein incorporated by reference]) is a pUB110 derivative, has a neomycin resistance marker for selection, and contains the *B. licheniformis* α -amylase (LAT) promoter (P_{LAT}), a sequence encoding the LAT signal peptide (preLAT), followed by *Pst*I and *Hpa*I restriction sites for cloning and the LAT transcription terminator. The pICatH vector (See, Figure 20) contains a temperature sensitive origin of replication (ori pE194, for replication in *Bacillus*), ori pBR322 (for amplification in *E. coli*), a neomycin resistance gene for selection, and the native *B. licheniformis* chloramphenicol resistance gene (cat) with repeats for selection, chromosomal integration and cassette amplification.

Construct ASPc1 was created as a *Pst*I-*Hpa*I fragment by fusion PCR with High Fidelity Platinum *Taq* Polymerase (Invitrogen) according to the manufacturer's instructions, and with the following primers:

pHPLT-*Bgl*II_FW AGTTAAGCAATCAGATCTTCTTCAGGTTA (SEQ ID NO:184)

fusionC1_FW CATTGAAAGGGGAGGAGAATCATGAGAAGCAAGAAGCGAACTGTCAC (SEQ ID NO:185)

fusionC1_RV GTGACAGTTCGCTTCTTGCTTCTCATGATTCTCCTCCCCTTTCAATG (SEQ ID NO:186)

pHPLT-*Hind*III_RV CTTTACCTTGTCTCCAAGCTTAAAATAAAAAACGG (SEQ ID NO:187)

These primers were obtained from MWG Biotech. PCR reactions were typically

- 186 -

performed on a thermocycler for 30 cycles with High Fidelity Platinum *Taq* polymerase (Invitrogen) according to the manufacturer's instructions, with annealing temperature of 55°C. PCR-I was performed with the primers pHPLT-BglII_FW and fusionC1_RV on pHPLT as template DNA. PCR-II was performed with primers fusionC1_FW and pHPLTHindIII_RV on plasmid pHPLT-ASP-C1-2. The fragments from PCR-I and PCR-II were assembled in a fusion PCR with the primers pHPLT-BglII_FW and pHPLT-HindIII_RV. This final PCR fragment was purified using the Qiagen PCR purification kit, digested with *Bgl*II and *Hind*III, and ligated with T4 DNA ligase according to the manufacturers' instructions into *Bgl*II and *Hind*III digested pHPLT. The ligation mixture was transformed into *B. subtilis* strain OS14 as known in the art (See, U.S. Pat. Appl. No. US20020182734 and WO 02/14490, both of which are incorporated herein by reference). Correct transformants produced a halo on a skimmed milk plate and one of them was selected to isolate plasmid pHPLT-ASPc1. This plasmid was introduced into *B. licheniformis* host BML780 (BRA7 derivative, cat-, amyL-, spo-, aprL-, endoGluC-) by protoplast transformation as known in the art (See, Pragai *et al.*, Microbiol., 140:305-310 [1994]). Neomycin resistant transformants formed halos on skim plates, whereas the parent strain without pHPLT-ASPc1 did not. This result shows that *B. licheniformis* is capable of expressing and secreting ASP protease when expression is driven by the LAT promoter and when it is fused to a hybrid signal peptide (MRSKKRTVTRALAVATAAATLLAGGMAAQA; SEQ ID NO:135).

Construct ASPc3 was created as a *Pst*I-*Hpa*I fragment by fusion PCR (necessary to remove the internal *Pst*I site in the synthetic *asp* gene) as described above with the following primers:

ASPdel*Pst*I_FW GCGCAGGATGTAGCAGCTGGACTTGTGG (SEQ ID NO:188)

ASPdel*Pst*I_RV CCACAAGTCCAGCTGCTACATCCTGCGC (SEQ ID NO:189)

Asp*Pst*I_FW GCCTCATTCTGCAGCTTCAGCAAACGAACCGGCTCCTCCAGG
(SEQ ID NO:190)

Asp*Hpa*I_RV CGTCCTCTGTAACTCAGTCGTCACCTCCAGAGTCAGTCGTAATC
(SEQ ID NO:191)

After purification, the PCR product was digested with *Pst*I-*Hpa*I and ligated into *Pst*I and *Hpa*I digested pHPLT and then transformed into *B. subtilis* strain OS14. Plasmid pHPLT-ASPc3 was isolated from a neomycin resistant that formed a relatively (compared to other transformants) large halo on a skim milk plate. Plasmid DNA was isolated using the Qiagen plasmid purification kit and sequenced by BaseClear.

- 187 -

Sequencing confirmed that the ASPc3 construct encodes mature ASP that has two aspartic acid residues at the extreme C-terminal end (S188D, P189D). These mutations were deliberately introduced by PCR to make the C-terminus of ASP less susceptible against proteolytic degradation (See, WO 02055717). It also appeared that two mutations were introduced into the coding region of the N-terminal pro region by the PCR methods. These mutations caused two amino acid changes in the N-terminal pro-region: L42I and Q141P. Since this particular clone with these two pro(N) mutations gives a somewhat larger halo than other clones without these mutations, it was contemplated that expression and/or secretion of ASP protease in *Bacillus* is positively affected by these N-terminal pro mutations. However, it is not intended that the present invention be limited to these specific mutations, as it is also contemplated that further mutations will find use in the present invention.

Next, pHPLT-ASPc3 was transformed into BML780 as described above. In contrast to the parental strain without the plasmid, BML780(pHPLT-ASPc3) produced a halo on a skim milk plate indicating that also this ASPc3 construct leads to ASP expression in *B. licheniformis*. To make an integrated, amplified strain containing the ASPc3 expression cassette, the C3 construct was amplified from pHPLT-ASPc3 with the following primers:

EBS2XhoI_FW ATCCTACTCGAGGCTTTTCTTTTGGGAAGAAAATATAGGG (SEQ ID NO:192)

EBS2XhoI_RV TGGAATCTCGAGGTTTTATCCTTTACCTTGTCTCC (SEQ ID NO:193)

The PCR product was digested with *XhoI*, ligated into *XhoI*-digested pICatH (See, Figure 20) and transformed into *B. subtilis* OS14 as described above. The plasmid from an ASP expressing clone (judged by halo formation on skim milk plates) was isolated and designated pICatH-ASPc3. DNA sequencing by BaseClear confirmed that no further mutations were introduced in the ASPc3 cassette in pICatH-ASPc3. The plasmid was then transformed into BML780 at the permissive temperature (37 °C) and one neomycin resistant (neoR) and chloramphenicol resistant (capR) transformant were selected and designated BML780(pICatH-ASPc3). The plasmid in BML780(pICatH-ASPc3) was integrated into the cat region on the *B. licheniformis* genome by growing the strain at a non-permissive temperature (50 °C) in medium with chloramphenicol. One capR resistant clone was selected and designated BML780-pICatH-ASPc3. BML780-pICatH-ASPc3 was grown again at the permissive temperature for several generations without antibiotics to loop-out vector sequences and then one neomycin sensitive (neoS), capR clone was selected. In this

- 188 -

clone, vector sequences of pICatH on the chromosome were excised (including the neomycin resistance gene) and only the ASPc3-cat cassette was left. Note that the cat gene is a native *B. licheniformis* gene and that the *asp* gene is the only heterologous piece of DNA introduced into the host. Next, the ASPc3-cat cassette on the chromosome was amplified by growing the strain in/on media with increasing concentrations of chloramphenicol. After various rounds of amplification, one clone (resistant against 75 µg/ml chloramphenicol) was selected and designated "BML780-ASPC3." This clone produced a clear halo on a skim milk plate, whereas the parental strain BML780 did not, indicating that ASP protease is produced and secreted by the BML780-ASPC3 strain.

Construct ASPc4 is similar to ASPc3, but ASP protease expressed from ASPc4 does not have two aspartic acid residues at the C-terminal end of the mature chain. ASPc4 was created by amplification of the *asp* gene in pHPLT-ASPC3 with the following Hypur primers from MWG Biotech (Germany):

XhoPlatPRElat_FW

acccccctcgaggcttttcttttgaagaaaatatagggaaaatggtactgttaaaaattcgggaatattataacaatatcatatgttc
acattgaaaggggaggagaatcatgaaacaacaaaaacggccttac (SEQ ID NO:194)

ASPEndTERMXhol_RV

gtcgacctcgagggttttatcctttacctgtctccaagcttaaaataaaaaaacggatttccttcaggaaatccgtcctctgtaactc
aaggggaactccagagtcagtcgtaatc (SEQ ID NO:195)

The ASPc4 PCR product was purified and digested with *XhoI*, ligated into *XhoI*-digested pICatH, and transformed into *B. subtilis* OS14 as described above for ASPc3. Plasmid was isolated from a neoR, capR clone and designated pICatH-ASPC4. pICatH-ASPC4 was transformed into BML780, integrated in the genome, vector sequences were excised, and the cat-ASPC4 cassette was amplified as described above for the ASPc3 construct. Strains with the ASPc4 cassette did not produce smaller halos on skim milk plates than strains with the ASPc3 cassette, suggesting that the polarity of the C-terminus of ASP mature is not a significant factor for ASP production, secretion and/or stability in *Bacillus*. However, it is not intended that the present invention be limited to any particular method.

To explore whether the native ASP signal peptide can drive export in *Bacillus*, ASPc5 was constructed. PCR was performed on the synthetic *asp* gene of DNA2.0 with primers ASPEndTERMXhol_RV (above) and XhoPlatPREasp_FW.

- 189 -

XhoPlatPREasp_FW

:acccccctcgaggcttttcttttgaagaaaatatagggaaaatgggtactgttaaaaattcggaatattatacaatatcatatgttt
cacattgaaaggggaggagaatcatgacaccacgaactgtcacaag (SEQ ID NO:196)

5

The ASPc5 PCR product was purified and digested with *XhoI*, ligated into *XhoI* digested pICatH, and transformed into *B. subtilis* OS14 as described above for ASPc3. Plasmid was isolated from a neoR, capR clone and designated "pICatH-ASPc5." DNA sequencing confirmed that no unwanted mutations were introduced into the *asp* gene by the PCR. pICatH-ASPc5 was transformed into BML780, integrated in the genome, vector sequences were excised, and the cat-ASPc5 cassette was amplified as described above for the ASPc3 construct. It was observed that *B. licheniformis* strains with the ASPc5 construct also form halos on skim milk plates, confirming that the native signal peptide of ASP functions as a secretion signal in *Bacillus* species.

15

Finally, construct ASPc6 was created. It has the *B. licheniformis* subtilisin (*aprL*) promoter, RBS and signal peptide sequence fused in-frame to the DNA sequence encoding mature ASP from the optimized DNA2.0 gene. It was created by a fusion PCR with primer ASPendTERMXhoI_RV and the following primers:

20

AprLupXhoI_FW attagtctcgaggatcgaccggaccgcaacctcc (SEQ ID NO:197)

AprLasp_FW cgatggcattcagcgattccgcttctgctaacgaaccggctcctccaggatctgc (SEQ ID NO:198)

AprLasp_RV gcagatcctggaggagccggttcgtagcagaagcggaatcgctgaatgccatcg (SEQ ID NO:199)

25

PCR-I was performed with the primers AprLupXhoI_FW and AprLasp_RV on chromosomal DNA of BRA7 as template DNA. PCR-II was performed with primers AprLasp_FW and ASPendTERMXhoI_RV on the synthetic *asp* gene of DNA2.0. The fragments from PCR-I and PCR-II were assembled in a fusion PCR with the primers ASPendTERMXhoI_RV and AprLupXhoI_FW. This final PCR fragment was purified using Qiagen's PCR purification kit (according to the manufacturer's instructions), digested with *XhoI*, ligated into pICatH, and transformed into *B. subtilis* OS14, as described above for ASPc3. Plasmid was isolated from a neoR, capR clone and designated "pICatH-ASPc6." DNA sequencing confirmed that no unwanted mutations were introduced into the *asp* gene

30

- 190 -

or *aprL* region by the PCRs. pICatH-ASPc6 was transformed into BML780, integrated in the genome, vector sequences were excised, and the cat-ASPc6 cassette was amplified as described above for the ASPc3 construct. *B. licheniformis* strains with the ASPc6 construct also formed halos on skim milk plates, indicating that the *aprL* promoter in combination with the AprL signal peptide drives expression/secretion of ASP protease in *B. licheniformis*.

EXAMPLE 13

Protease Production in *T. reesei*

In this Example, experiments conducted to produce protease 69B4 in *T. reesei* are described. In these experiments, three different fungal constructs (fungal expression vectors comprising cbhl fusions) were developed. One contained the ASP 5' pro region, mature gene, and 3' pro region; the second contained the ASP 5' pro region and the mature gene; and the third contained only the ASP mature gene.

The following primer pairs were used to PCR (in the presence of 10% DMSO), the different fragments from the chromosomal DNA K25.10, carrying the ASP gene and introduced *SpeI*-*Ascl* sites to clone the fragments into the vector pTREX4 (See, Figure 21) digested with *SpeI* and *Ascl* restriction enzymes.

1. CBHI fusion with the ASP 5'pro region, mature gene, and 3'pro region:

AspproF forward primer (*SpeI*-Kexin site-ATG-pro sequence):

5'-ACTAGTAAGCGGATGAACGAGCCCGCACCAACCGGGAGCGCGAGC (SEQ ID NO:200)

AspproR reverse primer (*Ascl* site; C-term pro region from the TAA stop codon to the end of the gene):

5'-GGCGCGCC TTA GGGGAGGGTGAGCCCCATGGTGTAGGCACCG (SEQ ID NO:201)

2. The ASP 5'pro region and mature gene:

AspproF forward primer (*SpeI*-Kexin site-ATG-pro sequence):

5'-ACTAGTAAGCGGATGAACGAGCCCGCACCAACCGGGAGCGCGAGC (SEQ ID NO:202)

- 191 -

AspmatR reverse primer (Ascl site: TAA stop to the end of the mature sequence)
 5'- GGCGCGCC TTA CGGGCTGCTGCCCCGAGTCCGTGGTGATCA-3' (SEQ ID
 NO:203)

3. The ASP mature gene only:

AspmatF forward primer *SpeI*-Kexin site-ATG-mature:
 5'-ACTAGT AAGCGG ATG TTCGACGTGATCGGCGGCAACGCCTACACCAT
 (SEQ ID NO:204)

AspmatR Reverse Primer (Ascl site: TAA stop to end of mature sequence)
 5'- GGCGCGCC TTA CGGGCTGCTGCCCCGAGTCCGTGGTGATCA-3' (SEQ ID
 NO:205)

After construction, the different plasmids were transformed into a *Trichoderma reesei* strain with disruptions in the *cbh1*, *cbh2*, *egl1*, and *egl2* genes, using biolistic transformation methods known in the art. Stable transformants were screened, based on morphology. Ten stable transformants for each construct were screened in shake flasks. The initial inoculum media used contained 30g/L α -lactose, 6.5g/L $(\text{NH}_4)_2\text{SO}_4$, 2g/L KH_2PO_4 , 0.3g/L $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.2g/L CaCl_2 , 1ml/L 1000X *T. reesei* Trace Salts, 2 mL/L 10% TWEEN®-80, 22.5 g/L Proflo, and 0.72g/L CaCO_3 , in which the transformants were grown for approximately 48 hr. After this incubation period, 10% of the culture was transferred into flasks containing minimal medium known in the art (See, Foreman *et al.*, J. Biol. Chem., 278:31988-31997 [2003]), with 16g/L of lactose to induce expression. The flasks were placed in a 28°C shaker. Four-day samples were run on NuPAGE 4-12% gels, and stained with Coomassie Blue. After five-days the protease activity was measured by adding 10 μ l of the supernatant to 190 μ l AAPF substrate solution (conc. 1 mg/ml, in 0.1 M Tris/0.005% TWEEN, pH 8.6). The rate of increase in absorbance at 410 nm due to release of *p*-nitroaniline was monitored (25°C)

The activity data showed that there was a 5x higher production over the control strain (*i.e.*, the parent strain), indicating that *T. reesei* is suitable for the expression of ASP protease.

EXAMPLE 14

Protease Production in *A. niger*

In this Example, experiments conducted to produce protease 69B4 in *Aspergillus niger var. awamori* (PCT WO90/00192) are described. In these experiments, four different

- 192 -

5 fungal constructs (fungal expression vectors comprising glaA fusions) were developed. One contained the ASP pre-region, 5' pro-region, mature gene, and the 3' pro-region; the second contained the ASP pre-region, 5' pro-region, and the mature gene; the third contained the ASP 5' pro-region, mature gene, and the 3' pro-region; the fourth contained the ASP 5' pro-region, and the mature gene.

Selected from the following primer pairs, primers were used to PCR (in the presence of 10% DMSO) the different fragments from the chromosomal DNA 69B4 carrying the *asp* gene and introduced the *Nhe* 1-*Bst*ElI sites to clone the fragments into the vector pSLGAMpR2 (See, Figure 22) digested with *Nhe*1 and *Bst*ElI restriction enzymes.

10 Primers Anforward 01 and Anforward 02 contained attB1 Gateway cloning sequences (Invitrogen) at the 5' end of the primer. Primers Anreversed 01 and Anreversed 02 contained attB2 Gateway cloning sequences (Invitrogen) at the 5' end of the primer. These primers were used to PCR (in the presence of 10% DMSO) the different fragments from the chromosomal DNA 69B4 carrying the ASP genes.

15 The different constructs were transferred to a *A. niger* Gateway compatible destination vector pRAXdes2 (See, Figure 23; See also, U.S. Pat. Appln. Ser. No. 10/804,785, and PCT Appln. No. US04/08520, both of which are incorporated herein by reference).

20 Anforward 01 (without the attB1 sequence)
5'- ATGACACCACGAACTGTCACAAGAGCTCTG-3' (SEQ ID NO:206)

Anforward 02 (without the attB1 sequence)
5'- AACGAACCGGCTCCTCCAGGATCTGCATCA-3' (SEQ ID NO:207)

25 Anreversed 01 (without the attB2 sequence)
5'- AGGGGAACTTCCAGAGTCAGTCGTAATCATTCTCAGGCC-3' (SEQ ID NO:208)

Anreversed 02 (without the attB1 sequence)
30 5'- GGGGAGGGTGAGTCCCATTGTGTAAGCTCCTGA-3' (SEQ ID NO:209)

pSLGAM-NT_FW
5'-
35 ACCGCGACTGCTAGCAACGTCATCTCCAAGCGCGGCGGTGGCAACGAACCGGCTCCT
CCAGGATCt-3' (SEQ ID NO:210)

pSLGAM-MAT_FW
5'-
ACCGCGACTGCTAGCAACGTCATCTCCAAGCGCGGCGGTGGCAACGAACCGGCTCCT

- 193 -

CCAGGATCT-3'(SEQ ID NO:211)

pSLGAM-MAT_RV

5' - CCGCCAGGTGTCGGTCACCTAAGGGGAACTTCCAGAGTCAGTCGTAATCATTCT-3'
(SEQ ID NO:212)

PCR conditions were as follows: 5 μ L of 10X PCR reaction buffer (Invitrogen); 20 mM $MgSO_4$; 0.2 mM each of dATP, dTTP, dGTP, dCTP (final concentration), 1 μ L of 10 ng/ μ L genomic DNA, 1 μ L of High Fidelity *Taq* polymerase (Invitrogen) at 1 unit per μ L, 0.2 μ M of each primer (final concentration), 5 μ L DMSO and water to 50 μ L. The PCR protocol was: 94°C for 5 min.; followed by 30 cycles of 94°C for 30 sec., 55°C for 30 sec., and 68°C for 3 min; followed by 68°C for 10 min., and 15°C for 1 min.

After construction, the different plasmids and a helper plasmid (HM 396 pAPDI) were transformed into *Aspergillus niger* var *awamori* (Delta Ap4 strain), using protoplast transformation methods known in the art. Stable transformants were screened, based on morphology. Ten stable transformants for each construct were screened in shake flasks. After this period, a piece of agar containing the strain was transferred into flasks containing RoboSoy medium or the formula 12 g/l Tryptone, 8 g/l Soytone, 15 g/l Ammonium sulfate, 12.1 g/l $NaH_2PO_4 \cdot H_2O$, 2.19 g/l Na_2HPO_4 , 5 ml 20% $MgSO_4 \cdot 7H_2O$, 10 ml 10% Tween 80, 500 ml 30% Maltose and 50 ml 1M phosphate buffer pH 5.8 and 2 g/l uridine to induce expression. The flasks were placed in a 28°C shaker. Four-day samples were run on NuPAGE 10% Bis Tris protein gels, and stained with Coomassie Blue. Five-day samples were assayed for protease activity using the AAPF method.

The amount of ASP expressed was found to be low, such that it could not be detected in the Coomassie stained gel. Colonies on plates however showed a clear halo formation on skim milk plate agar plates that were significantly larger than the control strain. Thus, although the expression was low, these results clearly indicate that *A. niger* is suitable for the expression of ASP protease.

EXAMPLE 15

Generation of Asp Site-Saturated Mutagenesis (SSM) Libraries

In this Example, experiments conducted to develop site-saturation mutagenesis libraries of *asp* are described. Site saturated Asp libraries each contained 96 *B. subtilis*

- 194 -

($\Delta aprE$, $\Delta nprE$, $oppA$, $\Delta spoII E$, $degU Hy32$, $\Delta amyE::(xylR, p xylA-comK)$ clones harboring the pHPLT-ASP-c1-2 expression vector. This vector, containing the Asp expression cassette composed of the synthetic DNA sequence (See, Example 10) encoding the Asp hybrid Signal peptide and the Asp N-terminal pro and mature protein were found to enable
 5 expression of the protein indicated below (the signal peptide and precursor protease) and secretion of the mature Asp protease.

DNA Sequence encoding synthetic Asp hybrid signal peptide:

ATGAGAAGCAAGAAGCGAACTGTCACAAGAGCTCTGGCTGTGGCAACAGCAGCTGCTA
 10 CACTCTTGGCTGGGGGTATGGCAGCACAAAGCT (SEQ ID NO:213)

The signal peptide and precursor protease are provided in the following sequence (SEQ ID NO:214) (in this sequence, bold indicates the mature protease, underlining indicates the N-terminal prosequence, and the standard font indicates the signal peptide):

15 MRSKKRTVTRALAVATAAATLLAGGMAAQANEPAPPGSASAPPRLAEKLDLPDLLEAMERDL
GLDAEEAAATLAFQHDA AETGEALAEELDEDFAGTWVEDDVLVYVATTDEDAVEEVEGE GA
TAVTVEHSLADLEAWKTVLDAALEGHDDVPTWYVDVPTNSVVAVKAGA QDVAAGLVEGA
DVPSDAVTFVETDETPRTMFDVIGGNAYTIGGRSRC SIGFAVNGGFITAGHCGRTGATTAN
 20 **PTGTFAGSSFP GNDYAFVRTGAGVNLLAQVNNYSGGRVQVAGHTAAPVGS AVCRSGSTT**
GW HCGTITALNSSVTY PEGTVRGLIRTTVCAEPGDSGGSLLAGNQAQGVTS GGS GNCRT
GGT TFFQPVNPILQAYGLRMITTD SGSSP (SEQ ID NO:214)

Construction of the 189 *asp* site saturated mutagenesis libraries was completed by
 25 using the pHPLT-ASP-C1-2 expression vector as template and primers listed in Table 15-1.
 The mutagenesis primers used in these experiments all contain the triple DNA sequence code NNS (N = A, C, T or G and S = C or G) at the position that corresponds with the codon of the Asp mature sequence to be mutated and guaranteed random incorporation of
 nucleotides at that position. Construction of each SSM library started with two PCR
 30 amplifications using pHPLT-BgIII-FW primer and a specific Reverse mutagenesis primer,
 and pHPLT-BgIII-RV primer and a specific Forward mutagenesis primer (equal positions for the mutagenesis primers). Platinum *Taq* DNA polymerase High Fidelity (Cat.No. 11304-029; Invitrogen) was used for PCR amplification (0.2 μ M primers, 20 up to 30 cycles)
 according to protocol provided by Invitrogen. Briefly, 1 μ L amplified DNA fragment of both
 35 specific PCR mixes, both targeted the same codon, was added to 48 μ L of fresh PCR

- 195 -

reaction solution together with primers pHPLT-BgIII-FW and pHPLT-BgIII-RV. This fusion PCR amplification (22 cycles) resulted in a linear pHPLT-ASP-c1-2 DNA fragment with a specific Asp mature codon randomly mutated and a unique *Bgl*II restriction site on both ends. Purification of this DNA fragment (Qiagen PCR purification kit, Cat.No. 28106),
 5 digesting it with *Bgl*II, performing an additional purification step and a ligation reaction (Invitrogen T4 DNA Ligase (Cat.No. 15224-025) generated circular and multimeric DNA that was subsequently transformed into *B. subtilis* ($\Delta aprE$, $\Delta nprE$, *oppA*, $\Delta spoII E$, *degU*Hy32, $\Delta amyE::(xylR,pxy)A-comK$). For each library, after overnight incubation at 37°C, 96 single colonies were picked from Heart Infusion agar plates with 20 mg/L neomycin and grown for
 10 4 days at 37°C in MOPS media with 20 mg/ml neomycin and 1.25 g/L yeast extract (See, WO.03/062380, incorporated herein by reference, for the exact medium formulation used herein) for sequence analysis (BaseClear) and protease expression for screening purposes. The library numbers ranged from 1 up to 189, with each number representing the codon of the mature *asp* sequence that is randomly mutated. After selection, each library included a
 15 maximum of 20 Asp protease variants.

Table 15-1. Primers Used to Generate Synthetic ASP SSM Libraries

pHPLT-BgIII-FW	GCAATCAGATCTTCCTTCAGGTTATGACC (SEQ ID N215)
pHPLT-BgIII-RV	GCATCGAAGATCTGATTGCTTAAGTCTTC (SEQ ID NO:216)
Forward Mutagenesis Primer	DNA sequence, 5' to 3'
asp1F	GAAACGCCTAGAACGATGNNSGACGTAATTGGAGGCAAC (SEQ ID NO:217)
asp2F	ACGCCTAGAACGATGTTCNNSGTAATTGGAGGCAACGCA (SEQ ID NO:218)
asp3F	CCTAGAACGATGTTCGACNNSATTGGAGGCAACGCATAT (SEQ ID NO:219)
asp4F	AGAACGATGTTCGACGTANNSGGAGGCAACGCATATACT (SEQ ID NO:220)
asp5F	ACGATGTTCGACGTAATTNNSGGCAACGCATATACTATT (SEQ ID NO:221)
asp6F	ATGTTCGACGTAATTGGANNSAACGCATATACTATTGGC (SEQ ID NO:222)
asp7F	TTCGACGTAATTGGAGGCNNSGCATATACTATTGGCGGC (SEQ ID NO:223)
asp8F	GACGTAATTGGAGGCAACNNSTATACTATTGGCGGCCGG

- 196 -

asp9F (SEQ ID NO:224)
GTAATTGGAGGCAACGCANNSACTATTGGCGGCCGGTCT
(SEQ ID NO:225)
ATTGGAGGCAACGCATATNNSATTGGCGGCCGGTCTAGA
asp10F (SEQ ID NO:226)
GGAGGCAACGCATATACTNNSGGCGGCCGGTCTAGATGT
asp11F (SEQ ID NO:227)

asp12F GGCAACGCATATACTATTNNSGGCCGGTCTAGATGTTCT
(SEQ ID NO:228)
AACGCATATACTATTGGCNSCGGTCTAGATGTTCTATC
asp13F (SEQ ID NO:229)
GCATATACTATTGGCGGCNNSTCTAGATGTTCTATCGGA
asp14F (SEQ ID NO:230)
TATACTATTGGCGGCCGGNNSAGATGTTCTATCGGATTC
asp15F (SEQ ID NO:231)
ACTATTGGCGGCCGGTCTNNSTGTTCTATCGGATTCGCA
asp16F (SEQ ID NO:232)
ATTGGCGGCCGGTCTAGANNSTCTATCGGATTCGCAGTA
asp17F (SEQ ID NO:233)
GGCGGCCGGTCTAGATGTNNSATCGGATTCGCAGTAAAC
asp18F (SEQ ID NO:234)
GGCCGGTCTAGATGTTCTNNSGGATTCGCAGTAAACGGT
asp19F (SEQ ID NO:235)
CGGTCTAGATGTTCTATCNNSTTCGCAGTAAACGGTGCC
asp20F (SEQ ID NO:236)
TCTAGATGTTCTATCGGANNSGCAGTAAACGGTGGCTTC
asp21F (SEQ ID NO:237)
AGATGTTCTATCGGATTCNNSGTAAACGGTGGCTTCATT
asp22F (SEQ ID NO:238)
TGTTCTATCGGATTCGCANNSAACGGTGGCTTCATTACT
asp23F (SEQ ID NO:239)
TCTATCGGATTCGCAGTANNSGGTGGCTTCATTACTGCC
asp24F (SEQ ID NO:240)
ATCGGATTCGCAGTAAACNNSGGCTTCATTACTGCCGGT
asp25F (SEQ ID NO:241)
GGATTCGCAGTAAACGGTNNSTTCATTACTGCCGGTCAC
asp26F (SEQ ID NO:242)
TTCGCAGTAAACGGTGGCNSATTACTGCCGGTCACTGC
asp27F (SEQ ID NO:243)
GCAGTAAACGGTGGCTTCNNSACTGCCGGTCACTGCGGA
asp28F (SEQ ID NO:244)
GTAAACGGTGGCTTCATTNNSGCCGGTCACTGCGGAAGA
asp29F (SEQ ID NO:245)
AACGGTGGCTTCATTACTNNSGGTCACTGCGGAAGAACA
asp30F (SEQ ID NO:246)
GGTGGCTTCATTACTGCCNNSCACTGCGGAAGAACAGGA
asp31F (SEQ ID NO:247)

- 197 -

asp32F GGCTTCATTACTGCCGGTNNSTGCGGAAGAACAGGAGCC
(SEQ ID NO:248)
TTCATTACTGCCGGTCACNNSGGAAGAACAGGAGCCACT
asp33F (SEQ ID NO:249)
ATTACTGCCGGTCACTGCNNSAGAACAGGAGCCACTACT
asp34F (SEQ ID NO:250)
ACTGCCGGTCACTGCGGANNSACAGGAGCCACTACTGCC
asp35F (SEQ ID NO:251)
GCCGGTCACTGCGGAAGANNSGGAGCCACTACTGCCAAT
asp36F (SEQ ID NO:252)
GGTCACTGCGGAAGAACANNSGCCACTACTGCCAATCCG
asp37F (SEQ ID NO:253)
CACTGCGGAAGAACAGGANNSACTACTGCCAATCCGACT
asp38F (SEQ ID NO:254)
TGCGGAAGAACAGGAGCCNNSACTGCCAATCCGACTGGC
asp39F (SEQ ID NO:255)
GGAAGAACAGGAGCCACTNNSGCCAATCCGACTGGCACA
asp40F (SEQ ID NO:256)
AGAACAGGAGCCACTACTNNSAATCCGACTGGCACATTT
asp41F (SEQ ID NO:257)
ACAGGAGCCACTACTGCCNNSCCGACTGGCACATTTGCA
asp42F (SEQ ID NO:258)
GGAGCCACTACTGCCAATNNSACTGGCACATTTGCAGGT
asp43F (SEQ ID NO:259)
GCCACTACTGCCAATCCGNNSGGCACATTTGCAGGTAGC
asp44F (SEQ ID NO:260)
ACTACTGCCAATCCGACTNNSACATTTGCAGGTAGCTCG
asp45F (SEQ ID NO:261)
ACTGCCAATCCGACTGGCENNSTTTGCAGGTAGCTCGTTT
asp46F (SEQ ID NO:262)
GCCAATCCGACTGGCACANNSGCAGGTAGCTCGTTTCCG
asp47F (SEQ ID NO:263)
AATCCGACTGGCACATTTNNSGGTAGCTCGTTTCCGGGA
asp48F (SEQ ID NO:264)
CCGACTGGCACATTTGCANNSAGCTCGTTTCCGGGAAAT
asp49F (SEQ ID NO:265)
ACTGGCACATTTGCAGGTNNSTCGTTTCCGGGAAATGAT
asp50F (SEQ ID NO:266)
GGCACATTTGCAGGTAGCENNSTTTCCGGGAAATGATTAT
asp51F (SEQ ID NO:267)
ACATTTGCAGGTAGCTCGNNSCCGGGAAATGATTATGCA
asp52F (SEQ ID NO:268)
TTTGCAGGTAGCTCGTTTNNSGGAAATGATTATGCATTC
asp53F (SEQ ID NO:269)
GCAGGTAGCTCGTTTCCGNNSAATGATTATGCATTCGTC
asp54F (SEQ ID NO:270)
GGTAGCTCGTTTCCGGGANNSGATTATGCATTCGTCCGA
asp55F (SEQ ID NO:271)
AGCTCGTTTCCGGGAAATNNSTATGCATTCGTCCGAACA
asp56F (SEQ ID NO:272)
asp57F TCGTTTCCGGGAAATGATNNSGCATTCTCGTCCGAACAGGG

- 198 -

(SEQ ID NO:273)
asp58F TTTCCGGGAAATGATTATNNSTTCGTCCGAACAGGGGCA
(SEQ ID NO:274)
asp59F CCGGGAAATGATTATGCANNSGTCCGAACAGGGGCAGGA
(SEQ ID NO:275)
asp60F GGAAATGATTATGCATTCNNSCGAACAGGGGCAGGAGTA
(SEQ ID NO:276)
asp61F AATGATTATGCATTCGTTCNNSACAGGGGCAGGAGTAAAT
(SEQ ID NO:277)
asp62F GATTATGCATTCGTCCGANNSGGGGCAGGAGTAAATTTG
(SEQ ID NO:278)
asp63F TATGCATTCGTCCGAACANNSGCAGGAGTAAATTTGCTT
(SEQ ID NO:279)
asp64F GCATTCGTCCGAACAGGGNNSGGAGTAAATTTGCTTGCC
(SEQ ID NO:280)
asp65F TTCGTCCGAACAGGGGCANNSGTAAATTTGCTTGCCCAA
(SEQ ID NO:281)
asp66F GTCCGAACAGGGGCAGGANNSAATTTGCTTGCCCAAGTC
(SEQ ID NO:282)
asp67F CGAACAGGGGCAGGAGTANNSTTGCTTGCCCAAGTCAAT
(SEQ ID NO:283)
asp68F ACAGGGGCAGGAGTAAATNNSCTTGCCCAAGTCAATAAC
(SEQ ID NO:284)
asp69F GGGGCAGGAGTAAATTTGNNSGCCCAAGTCAATAACTAC
(SEQ ID NO:285)
asp70F GCAGGAGTAAATTTGCTTNNSCAAGTCAATAACTACTCG
(SEQ ID NO:286)
asp71F GGAGTAAATTTGCTTGCCNNSGTCAATAACTACTCGGGC
(SEQ ID NO:287)
asp72F GTAAATTTGCTTGCCCAANNSAATAACTACTCGGGCGGC
(SEQ ID NO:288)
asp73F AATTTGCTTGCCCAAGTCNNSAATAACTACTCGGGCGGCAGA
(SEQ ID NO:289)
asp74F TTGCTTGCCCAAGTCAATNNSTACTCGGGCGGCAGAGTC
(SEQ ID NO:290)
asp75F CTTGCCCAAGTCAATAACNNSTCGGGCGGCAGAGTCCAA
(SEQ ID NO:291)
asp76F GCCCAAGTCAATAACTACNNSGGCGGCAGAGTCCAAGTA
(SEQ ID NO:292)
asp77F CAAGTCAATAACTACTCGNNSGGCAGAGTCCAAGTAGCA
(SEQ ID NO:293)
asp78F GTCAATAACTACTCGGGCNNSAGAGTCCAAGTAGCAGGA
(SEQ ID NO:294)
asp79F AATAACTACTCGGGCGGCNNSGTCCAAGTAGCAGGACAT
(SEQ ID NO:295)
asp80F AACTACTCGGGCGGCAGANNSCAAGTAGCAGGACATACG
(SEQ ID NO:296)
asp81F TACTCGGGCGGCAGAGTCNNSGTAGCAGGACATACGGCC
(SEQ ID NO:297)
asp82F TCGGGCGGCAGAGTCCAANNSGCAGGACATACGGCCGCA
(SEQ ID NO:298)

- 199 -

asp83F GCGGGCAGAGTCCAAGTANNSSGGACATACGGCCGCACCA
(SEQ ID NO:299)
asp84F GGCAGAGTCCAAGTAGCANNSCATACGGCCGCACCAGTT
(SEQ ID NO:300)
asp85F AGAGTCCAAGTAGCAGGANNSACGGCCGCACCAGTTGGA
(SEQ ID NO:301)
asp86F GTCCAAGTAGCAGGACATNNSGCCGCACCAGTTGGATCT
(SEQ ID NO:302)
asp87F CAAGTAGCAGGACATACGNNSGCACCAGTTGGATCTGCT
(SEQ ID NO:303)
asp88F GTAGCAGGACATACGGCCNNSCCAGTTGGATCTGCTGTA
(SEQ ID NO:304)
asp89F GCAGGACATACGGCCGCANNSGTTGGATCTGCTGTATGC
(SEQ ID NO:305)
asp90F GGACATACGGCCGCACCANNSGGATCTGCTGTATGCCGC
(SEQ ID NO:306)
asp91F CATACGGCCGCACCAGTTNNSTCTGCTGTATGCCGCTCA
(SEQ ID NO:307)
asp92F ACGGCCGCACCAGTTGGANNSGCTGTATGCCGCTCAGGT
(SEQ ID NO:308)
asp93F GCCGCACCAGTTGGATCTNNSGTATGCCGCTCAGGTAGC
(SEQ ID NO:309)
asp94F GCACCAGTTGGATCTGCTNNSTGCCGCTCAGGTAGCACT
(SEQ ID NO:310)
asp95F CCAGTTGGATCTGCTGTANNSCGCTCAGGTAGCACTACA
(SEQ ID NO:311)
asp96F GTTGGATCTGCTGTATGCNNSTCAGGTAGCACTACAGGT
(SEQ ID NO:312)
asp97F GGATCTGCTGTATGCCGCNNSGGTAGCACTACAGGTTGG
(SEQ ID NO:313)
asp98F TCTGCTGTATGCCGCTCANNSAGCACTACAGGTTGGCAT
(SEQ ID NO:314)
asp99F GCTGTATGCCGCTCAGGTNNSACTACAGGTTGGCATTGC
(SEQ ID NO:315)
asp100F GTATGCCGCTCAGGTAGCNNSACAGGTTGGCATTGCGGA
(SEQ ID NO:316)
asp101F TGCCGCTCAGGTAGCACTNNSGGTTGGCATTGCGGAACT
(SEQ ID NO:317)
asp102F CGCTCAGGTAGCACTACANNSTGGCATTGCGGAACTATC
(SEQ ID NO:318)
asp103F TCAGGTAGCACTACAGGTNNSCATTGCGGAACTATCACG
(SEQ ID NO:319)
asp104F GGTAGCACTACAGGTTGGNNSTGCGGAACTATCACGGCG
(SEQ ID NO:320)
asp105F AGCACTACAGGTTGGCATNNSGGA ACTATCACGGCGCTG
(SEQ ID NO:321)
asp106F ACTACAGGTTGGCATTGCNNSACTATCACGGCGCTGAAT
(SEQ ID NO:322)
asp107F ACAGGTTGGCATTGCGGANNSATCACGGCGCTGAATTG
(SEQ ID NO:323)
asp108F GGTGTTGGCATTGCGGAACTNNSACGGCGCTGAATTCGTCT

- 200 -

(SEQ ID NO:324)
asp109F TGGCATTGCGGAACTATCENNSGCGCTGAATTCGTCTGTC
(SEQ ID NO:325)
asp110F CATTGCGGAACTATCACGNNSTGAATTCGTCTGTCACG
(SEQ ID NO:326)
asp111F TGCGGAACTATCACGGCGNNNSAATTCGTCTGTCACGTAT
(SEQ ID NO:327)
asp112F GGAAGTATCACGGCGCTGNNSTCGTCTGTCACGTATCCA
(SEQ ID NO:328)
asp113F ACTATCACGGCGCTGAATNNSTCTGTCACGTATCCAGAG
(SEQ ID NO:329)
asp114F ATCACGGCGCTGAATTCGNNSGTCACGTATCCAGAGGGA
(SEQ ID NO:330)
asp115F ACGGCGCTGAATTCGTCTNNNSACGTATCCAGAGGGAACA
(SEQ ID NO:331)
asp116F GCGCTGAATTCGTCTGTCNNSTATCCAGAGGGAACAGTC
(SEQ ID NO:332)
asp117F CTGAATTCGTCTGTCACGNNSCCAGAGGGAACAGTCCGA
(SEQ ID NO:333)
asp118F AATTCGTCTGTCACGTATNNNSGAGGGAACAGTCCGAGGA
(SEQ ID NO:334)
asp119F TCGTCTGTCACGTATCCANNSSGGAACAGTCCGAGGACTT
(SEQ ID NO:335)
asp120F TCTGTCACGTATCCAGAGNNNSACAGTCCGAGGACTTATC
(SEQ ID NO:336)
asp121F GTCACGTATCCAGAGGGANNNSGTCCGAGGACTTATCCGC
(SEQ ID NO:337)
asp122F ACGTATCCAGAGGGAACANNNSCGAGGACTTATCCGCACG
(SEQ ID NO:338)
asp123F TATCCAGAGGGAACAGTCNNSSGACTTATCCGCACGACG
(SEQ ID NO:339)
asp124F CCAGAGGGAACAGTCCGANNNSCTTATCCGCACGACGGTT
(SEQ ID NO:340)
asp125F GAGGGAACAGTCCGAGGANNNSATCCGCACGACGGTTTGT
(SEQ ID NO:341)
asp126F GGAACAGTCCGAGGACTTNNNSCGCACGACGGTTTGTGCC
(SEQ ID NO:342)
asp127F ACAGTCCGAGGACTTATCENNSACGACGGTTTGTGCCGAA
(SEQ ID NO:343)
asp128F GTCCGAGGACTTATCCGCNNNSACGGTTTGTGCCGAACCA
(SEQ ID NO:344)
asp129F CGAGGACTTATCCGCACGNNNSGTTTGTGCCGAACCAGGT
(SEQ ID NO:345)
asp130F GGAAGTATCCGCACGACGNNSTGTGCCGAACCAGGTGAT
(SEQ ID NO:346)
asp131F CTTATCCGCACGACGGTTNNNSGCCGAACCAGGTGATAGC
(SEQ ID NO:347)
asp132F ATCCGCACGACGGTTTGTNNNSGAACCAGGTGATAGCGGA
(SEQ ID NO:348)
asp133F CGCACGACGGTTTGTGCCNNNSCCAGGTGATAGCGGAGGT
(SEQ ID NO:349)

- 201 -

asp134F ACGACGGTTTGTGCCGAANNSSGGTGATAGCGGAGGTAGC
(SEQ ID NO:350)
asp135F ACGGTTTGTGCCGAACCANNSGATAGCGGAGGTAGCCTT
(SEQ ID NO:351)
GTTTGTGCCGAACCAGGTNNSAGCGGAGGTAGCCTTTTA
asp136F (SEQ ID NO:352)
TGTGCCGAACCAGGTGATNNSGGAGGTAGCCTTTTAGCG
asp137F (SEQ ID NO:353)
GCCGAACCAGGTGATAGCNNSGGTAGCCTTTTAGCGGGA
asp138F (SEQ ID NO:354)
GAACCAGGTGATAGCGGANNSAGCCTTTTAGCGGGAAAT
asp139F (SEQ ID NO:355)
CCAGGTGATAGCGGAGGTNNSCTTTTAGCGGGAAATCAA
asp140F (SEQ ID NO:356)
GGTGATAGCGGAGGTAGCNNSTTAGCGGGAAATCAAGCC
asp141F (SEQ ID NO:357)
GATAGCGGAGGTAGCCTTNNSGCGGGAAATCAAGCCCAA
asp142F (SEQ ID NO:358)
AGCGGAGGTAGCCTTTTANNSGGAAATCAAGCCCAAGGT
asp143F (SEQ ID NO:359)
GGAGGTAGCCTTTTAGCGNNSAATCAAGCCCAAGGTGTC
asp144F (SEQ ID NO:360)
GGTAGCCTTTTAGCGGGANNSCAAGCCCAAGGTGTCACG
asp145F (SEQ ID NO:361)
AGCCTTTTAGCGGGAAATNNSGCCCAAGGTGTCACGTCA
asp146F (SEQ ID NO:362)
CTTTTAGCGGGAAATCAANNNSCAAGGTGTCACGTCAGGT
asp147F (SEQ ID NO:363)
TTAGCGGGAAATCAAGCCNNSGGTGTCACGTCAGGTGGT
asp148F (SEQ ID NO:364)
GCGGGAAATCAAGCCCAANNNSGTCACGTCAGGTGGTTCT
asp149F (SEQ ID NO:365)
GGAAATCAAGCCCAAGGTNNSACGTCAGGTGGTTCTGGA
asp150F (SEQ ID NO:366)
AATCAAGCCCAAGGTGTCNNSTCAGGTGGTTCTGGAAAT
asp151F (SEQ ID NO:367)
CAAGCCCAAGGTGTCACGNNSGGTGGTTCTGGAAATTGT
asp152F (SEQ ID NO:368)
GCCCAAGGTGTCACGTCANNSGGTTCTGGAAATTGTGCG
asp153F (SEQ ID NO:369)
CAAGGTGTCACGTCAGGTNNSTCTGGAAATTGTGCGGACG
asp154F (SEQ ID NO:370)
GGTGTCACGTCAGGTGGTNNSGGAAATTGTGCGGACGGGG
asp155F (SEQ ID NO:371)
GTCACGTCAGGTGGTTCTNNSAATTGTGCGGACGGGGGGA
asp156F (SEQ ID NO:372)
ACGTCAGGTGGTTCTGGANNSTGTGCGGACGGGGGGGAACA
asp157F (SEQ ID NO:373)
TCAGGTGGTTCTGGAAATNNSCGGACGGGGGGGAACAACA
asp158F (SEQ ID NO:374)
asp159F GGTGGTTCTGGAAATTGTNNSACGGGGGGGAACAACATTC

- 202 -

(SEQ ID NO:375)
asp160F GGTTCCTGGAAATTGTCGGNNSGGGGGAACAACATTCTTT
(SEQ ID NO:376)
TCTGGAAATTGTCGGACGNNSGGAACAACATTCTTTCAA
asp161F (SEQ ID NO:377)
GGAAATTGTCGGACGGGGGNNSACAACATTCTTTCAACCA
asp162F (SEQ ID NO:378)
AATTGTCGGACGGGGGGANNSACATTCTTTCAACCAGTC
asp163F (SEQ ID NO:379)
TGTCGGACGGGGGGGAACANNSTTCTTTCAACCAGTCAAC
asp164F (SEQ ID NO:380)
CGGACGGGGGGGAACAACANNSTTTCAACCAGTCAACCCG
asp165F (SEQ ID NO:381)
ACGGGGGGGAACAACATTCNNSCAACCAGTCAACCCGATT
asp166F (SEQ ID NO:382)
GGGGGAACAACATTCTTTNNSCCAGTCAACCCGATTTTG
asp167F (SEQ ID NO:383)
GGAACAACATTCTTTCAANNSTGTCACCCGATTTTGCAG
asp168F (SEQ ID NO:384)
ACAACATTCTTTCAACCANNNSAACCCGATTTTGCAGGCT
asp169F (SEQ ID NO:385)
ACATTCTTTCAACCAGTCNNSCCGATTTTGCAGGCTTAC
asp170F (SEQ ID NO:386)
TTCTTTCAACCAGTCAACNNSATTTTGCAGGCTTACGGC
asp171F (SEQ ID NO:387)
TTTCAACCAGTCAACCCGNNSTTGCAGGCTTACGGCCTG
asp172F (SEQ ID NO:388)
CAACCAGTCAACCCGATTNNSCAGGCTTACGGCCTGAGA
asp173F (SEQ ID NO:389)
CCAGTCAACCCGATTTTGNNSGCTTACGGCCTGAGAATG
asp174F (SEQ ID NO:390)
GTCAACCCGATTTTGCAGNNSTACGGCCTGAGAATGATT
asp175F (SEQ ID NO:391)
AACCCGATTTTGCAGGCTNNSGGCCTGAGAATGATTACG
asp176F (SEQ ID NO:392)
CCGATTTTGCAGGCTTACNNSCTGAGAATGATTACGACT
asp177F (SEQ ID NO:393)
ATTTTGCAGGCTTACGGCNNSAGAATGATTACGACTGAC
asp178F (SEQ ID NO:394)
TTGCAGGCTTACGGCCTGNNSATGATTACGACTGACTCT
asp179F (SEQ ID NO:395)
CAGGCTTACGGCCTGAGANNSATTACGACTGACTCTGGA
asp180F (SEQ ID NO:396)
GCTTACGGCCTGAGAATGNNSACGACTGACTCTGGAAGT
asp181F (SEQ ID NO:397)
TACGGCCTGAGAATGATTNNSACTGACTCTGGAAGTTCC
asp182F (SEQ ID NO:398)
GGCCTGAGAATGATTACGNNSGACTCTGGAAGTTCCCCT
asp183F (SEQ ID NO:399)
CTGAGAATGATTACGACTNNSTCTGGAAGTTCCCCTTAA
asp184F (SEQ ID NO:400)

- 203 -

asp185F	AGAATGATTACGACTGACNNSGGAAGTTCCCCTTAACCC (SEQ ID NO:401)
asp186F	ATGATTACGACTGACTCTNNSAGTTCCCCTTAACCCAAC (SEQ ID NO:402)
asp187F	ATTACGACTGACTCTGGANNSTCCCCTTAACCCAACAGA (SEQ ID NO:403)
asp188F	ACGACTGACTCTGGAAGTNNSCCTTAACCCAACAGAGGA (SEQ ID NO:404)
asp189F	ACTGACTCTGGAAGTTCCNNSTAACCCAACAGAGGACGG (SEQ ID NO:405)
Reverse mutagenesis primer	DNA sequence, 5'-3'
asp1R	GTTGCCTCCAATTACGTCSNNCATCGTTCTAGGCGTTTC (SEQ ID NO:406)
asp2R	TGCGTTGCCTCCAATTACSNNGAACATCGTTCTAGGCGT (SEQ ID NO:407)
asp3R	ATATGCGTTGCCTCCAATSNNGTCGAACATCGTTCTAGG (SEQ ID NO:408)
asp4R	AGTATATGCGTTGCCTCCSNNACGTGCGAACATCGTTCT (SEQ ID NO:409)
asp5R	AATAGTATATGCGTTGCCSNNATTACGTGCGAACATCGT (SEQ ID NO:410)
asp6R	GCCAATAGTATATGCGTTSNNTCCAATTACGTGCGAACAT (SEQ ID NO:411)
asp7R	GCCGCCAATAGTATATGCSNNGCCTCCAATTACGTGCGAA (SEQ ID NO:412)
asp8R	CCGGCCGCCAATAGTATASNNGTTGCCTCCAATTACGTG (SEQ ID NO:413)
asp9R	AGACCGGCCGCCAATAGTSNNTGCGTTGCCTCCAATTAC (SEQ ID NO:414)
asp10R	TCTAGACCGGCCGCCAATSNNATATGCGTTGCCTCCAAT (SEQ ID NO:415)
asp11R	ACATCTAGACCGGCCGCSNNAGTATATGCGTTGCCTCC (SEQ ID NO:416)
asp12R	AGAACATCTAGACCGGCCSNNATTAGTATATGCGTTGCC (SEQ ID NO:417)
asp13R	GATAGAACATCTAGACCGSNNGCCAATAGTATATGCGTT (SEQ ID NO:418)
asp14R	TCCGATAGAACATCTAGASNNGCCGCCAATAGTATATGC (SEQ ID NO:419)
asp15R	GAATCCGATAGAACATCTSNNCCGGCCGCCAATAGTATA (SEQ ID NO:420)
asp16R	TGCGAATCCGATAGAACASNNAGACCGGCCGCCAATAGT (SEQ ID NO:421)
asp17R	TACTGCGAATCCGATAGASNNTCTAGACCGGCCGCCAAT (SEQ ID NO:422)
asp18R	GTTTACTGCGAATCCGATSNNACATCTAGACCGGCCGCC (SEQ ID NO:423)
asp19R	ACCGTTTACTGCGAATCCSNNAGAACATCTAGACCGGCC

- 204 -

(SEQ ID NO:424)
asp20R GCCACCGTTTACTGCGAASNNGATAGAACATCTAGACCG
(SEQ ID NO:425)
asp21R GAAGCCACCGTTTACTGCSNNTCCGATAGAACATCTAGA
(SEQ ID NO:426)
asp22R AATGAAGCCACCGTTTACSNNGAATCCGATAGAACATCT
(SEQ ID NO:427)
asp23R AGTAATGAAGCCACCGTTSNNTGCGAATCCGATAGAAC
(SEQ ID NO:428)
asp24R GGCAGTAATGAAGCCACCSNNTACTGCGAATCCGATAGA
(SEQ ID NO:429)
asp25R ACCGGCAGTAATGAAGCCSNNGTTTACTGCGAATCCGAT
(SEQ ID NO:430)
asp26R GTGACCGGCAGTAATGAASNNAACCGTTTACTGCGAATCC
(SEQ ID NO:431)
asp27R GCAGTGACCGGCAGTAATSNNGCCACCGTTTACTGCGAA
(SEQ ID NO:432)
asp28R TCCGCAGTGACCGGCAGTSNNGAAGCCACCGTTTACTGC
(SEQ ID NO:433)
asp29R TCTTCCGCAGTGACCGGCSNNAATGAAGCCACCGTTTAC
(SEQ ID NO:434)
asp30R TGTTCTTCCGCAGTGACCSNNAGTAATGAAGCCACCGTT
(SEQ ID NO:435)
asp31R TCCTGTTCTTCCGCAGTGSNNGGCAGTAATGAAGCCACC
(SEQ ID NO:436)
asp32R GGCTCCTGTTCTTCCGCASNNAACCGGCAGTAATGAAGCC
(SEQ ID NO:437)
asp33R AGTGGCTCCTGTTCTTCCSNNGTGACCGGCAGTAATGAA
(SEQ ID NO:438)
asp34R AGTAGTGGCTCCTGTTCTSNNGCAGTGACCGGCAGTAAT
(SEQ ID NO:439)
asp35R GGCAGTAGTGGCTCCTGTSNNTCCGCAGTGACCGGCAGT
(SEQ ID NO:440)
asp36R ATTGGCAGTAGTGGCTCCSNNTCTTCCGCAGTGACCGGC
(SEQ ID NO:441)
asp37R CGGATTGGCAGTAGTGGCSNNTGTTCTTCCGCAGTGACC
(SEQ ID NO:442)
asp38R AGTCGGATTGGCAGTAGTSNNTCCTGTTCTTCCGCAGTG
(SEQ ID NO:443)
asp39R GCCAGTCGGATTGGCAGTSNNGGCTCCTGTTCTTCCGCA
(SEQ ID NO:444)
asp40R TGTGCCAGTCGGATTGGCSNNAAGTGGCTCCTGTTCTTCC
(SEQ ID NO:445)
asp41R AAATGTGCCAGTCGGATTSNNAGTAGTGGCTCCTGTTCT
(SEQ ID NO:446)
asp42R TGCAAATGTGCCAGTCGGSNNGGCAGTAGTGGCTCCTGT
(SEQ ID NO:447)
asp43R ACCTGCAAATGTGCCAGTSNNATTGGCAGTAGTGGCTCC
(SEQ ID NO:448)
asp44R GCTACCTGCAAATGTGCCSNNCGGATTGGCAGTAGTGGC
(SEQ ID NO:449)

- 205 -

asp45R CGAGCTACCTGCAAATGTSNNAGTCGGATTGGCAGTAGT
(SEQ ID NO:450)
asp46R AAACGAGCTACCTGCAAASNNGCCAGTCGGATTGGCAGT
(SEQ ID NO:451)
asp47R CGGAAACGAGCTACCTGCSNNTGTGCCAGTCGGATTGGC
(SEQ ID NO:452)
asp48R TCCCGGAAACGAGCTACCSNNAATGTGCCAGTCGGATT
(SEQ ID NO:453)
asp49R ATTTCCCGGAAACGAGCTSNNTGCAAATGTGCCAGTCGG
(SEQ ID NO:454)
asp50R ATCATTTCCTCGGAAACGASNNACCTGCAAATGTGCCAGT
(SEQ ID NO:455)
asp51R ATAATCATTTCCTCGGAAASNNGCTACCTGCAAATGTGCC
(SEQ ID NO:456)
asp52R TGCATAATCATTTCCTCGGSNNCGAGCTACCTGCAAATGT
(SEQ ID NO:457)
asp53R GAATGCATAATCATTTCCTCSNNAACGAGCTACCTGCAAA
(SEQ ID NO:458)
asp54R GACGAATGCATAATCATTSNNCGGAAACGAGCTACCTGC
(SEQ ID NO:459)
asp55R TCGGACGAATGCATAATCSNNTCCCGGAAACGAGCTACC
(SEQ ID NO:460)
asp56R TGTTCGGACGAATGCATASNNTTTCCCGGAAACGAGCT
(SEQ ID NO:461)
asp57R CCCTGTTTCGGACGAATGCSNNATCATTTCCTCGGAAACGA
(SEQ ID NO:462)
asp58R TGCCCTGTTTCGGACGAASNATAATCATTTCCTCGGAAA
(SEQ ID NO:463)
asp59R TCCTGCCCCTGTTTCGGACSNNTGCATAATCATTTCCTCGG
(SEQ ID NO:464)
asp60R TACTCCTGCCCCTGTTTCGSNNGAATGCATAATCATTTC
(SEQ ID NO:465)
asp61R ATTTACTCCTGCCCCTGTSNNGACGAATGCATAATCATT
(SEQ ID NO:466)
asp62R CAAATTTACTCCTGCCCCSNNTCGGACGAATGCATAATC
(SEQ ID NO:467)
asp63R AAGCAAATTTACTCCTGCSNNTGTTTCGGACGAATGCATA
(SEQ ID NO:468)
asp64R GGCAAGCAAATTTACTCCSNNCCCTGTTTCGGACGAATGC
(SEQ ID NO:469)
asp65R TTGGGCAAGCAAATTTACSNNTGCCCTGTTTCGGACGAA
(SEQ ID NO:470)
asp66R GACTTGGGCAAGCAAATTSNNTCCTGCCCTGTTTCGGAC
(SEQ ID NO:471)
asp67R ATTGACTTGGGCAAGCAASNNTACTCCTGCCCTGTTTCG
(SEQ ID NO:472)
asp68R GTTATTGACTTGGGCAAGSNNTTTACTCCTGCCCTGT
(SEQ ID NO:473)
asp69R GTAGTTATTGACTTGGGCSNNCAAATTTACTCCTGCCCC
(SEQ ID NO:474)
asp70R CGAGTAGTTATTGACTTGSNNAAGCAAATTTACTCCTGC

- 206 -

(SEQ ID NO:475)
GCCCCGAGTAGTTATTGACSNNGGCAAGCAAATTTACTCC
asp71R (SEQ ID NO:476)
GCCGCCCCGAGTAGTTATTSNNTTGGGCAAGCAAATTTAC
asp72R (SEQ ID NO:477)
TCTGCCGCCCCGAGTAGTTSNNGACTTGGGCAAGCAAATT
asp73R (SEQ ID NO:478)
GACTCTGCCGCCCCGAGTASNNATTGACTTGGGCAAGCAA
asp74R (SEQ ID NO:479)
TTGGACTCTGCCGCCCCGASNNGTTATTGACTTGGGCAAG
asp75R (SEQ ID NO:480)
TACTTGGACTCTGCCGCCSNNGTAGTTATTGACTTGGGC
asp76R (SEQ ID NO:481)
TGCTACTTGGACTCTGCCSNNCGAGTAGTTATTGACTTG
asp77R (SEQ ID NO:482)
TCCTGCTACTTGGACTCTSNNGCCCGAGTAGTTATTGAC
asp78R (SEQ ID NO:483)
ATGTCCTGCTACTTGGACSNNGCCGCCCGAGTAGTTATT
asp79R (SEQ ID NO:484)
CGTATGTCCTGCTACTTGSNNTCTGCCGCCCCGAGTAGTT
asp80R (SEQ ID NO:485)
GGCCGTATGTCCTGCTACSNNGACTCTGCCGCCCCGAGTA
asp81R (SEQ ID NO:486)
TGCGGCCGTATGTCCTGCSNNTTGGACTCTGCCGCCCCGA
asp82R (SEQ ID NO:487)
TGGTGCGGCCGTATGTCCSNNTACTTGGACTCTGCCGCC
asp83R (SEQ ID NO:488)
AACTGGTGCGGCCGTATGSNNTGCTACTTGGACTCTGCC
asp84R (SEQ ID NO:489)
TCCAACCTGGTGCGGCCGTSNNTCCTGCTACTTGGACTCT
asp85R (SEQ ID NO:490)
AGATCCAACCTGGTGCGGCSNNATGTCCTGCTACTTGGAC
asp86R (SEQ ID NO:491)
AGCAGATCCAACCTGGTGCSNNCGTATGTCCTGCTACTTG
asp87R (SEQ ID NO:492)
TACAGCAGATCCAACCTGGSNNGGCCGTATGTCCTGCTAC
asp88R (SEQ ID NO:493)
GCATACAGCAGATCCAACSNNTGCGGCCGTATGTCCTGC
asp89R (SEQ ID NO:494)
GCGGCATACAGCAGATCCSNNTGGTGCGGCCGTATGTCC
asp90R (SEQ ID NO:495)
TGAGCGGCATACAGCAGASNNAACCTGGTGCGGCCGTATG
asp91R (SEQ ID NO:496)
ACCTGAGCGGCATACAGCSNNTCCAACCTGGTGCGGCCGT
asp92R (SEQ ID NO:497)
GCTACCTGAGCGGCATACSNNAGATCCAACCTGGTGCGGC
asp93R (SEQ ID NO:498)
AGTGCTACCTGAGCGGCASNAGCAGATCCAACCTGGTG
asp94R (SEQ ID NO:499)
TGTAGTGCTACCTGAGCGSNNTACAGCAGATCCAACCTGG
asp95R (SEQ ID NO:500)

- 207 -

asp96R ACCTGTAGTGCTACCTGASNNGCATACAGCAGATCCAAC
(SEQ ID NO:501)
asp97R CCAACCTGTAGTGCTACCSNNGCGGCATACAGCAGATCC
(SEQ ID NO:502)
asp98R ATGCCAACCTGTAGTGCTSNNTGAGCGGCATACAGCAGA
(SEQ ID NO:503)
asp99R GCAATGCCAACCTGTAGTSNNACCTGAGCGGCATACAGC
(SEQ ID NO:504)
asp100R TCCGCAATGCCAACCTGTSNNGCTACCTGAGCGGCATAC
(SEQ ID NO:505)
asp101R AGTTCCGCAATGCCAACCSNNAGTGCTACCTGAGCGGCA
(SEQ ID NO:506)
asp102R GATAGTTCCGCAATGCCASNNTGTAGTGCTACCTGAGCG
(SEQ ID NO:507)
asp103R CGTGATAGTTCCGCAATGSNNACCTGTAGTGCTACCTGA
(SEQ ID NO:508)
asp104R CGCCGTGATAGTTCCGCASNCCAACCTGTAGTGCTACC
(SEQ ID NO:509)
asp105R CAGCGCCGTGATAGTTCCSNNATGCCAACCTGTAGTGCT
(SEQ ID NO:510)
asp106R ATTCAGCGCCGTGATAGTSNNGCAATGCCAACCTGTAGT
(SEQ ID NO:511)
asp107R CGAATTCAGCGCCGTGATSNNNTCCGCAATGCCAACCTGT
(SEQ ID NO:512)
asp108R AGACGAATTCAGCGCCGTSNNAGTTCCGCAATGCCAACC
(SEQ ID NO:513)
asp109R GACAGACGAATTCAGCGCSNNGATAGTTCCGCAATGCCA
(SEQ ID NO:514)
asp110R CGTGACAGACGAATTCAGSNNCGTGATAGTTCCGCAATG
(SEQ ID NO:515)
asp111R ATACGTGACAGACGAATTSNNCGCCGTGATAGTTCCGCA
(SEQ ID NO:516)
asp112R TGGATACGTGACAGACGASNNCAGCGCCGTGATAGTTCC
(SEQ ID NO:517)
asp113R CTCTGGATACGTGACAGASNNATTCAGCGCCGTGATAGT
(SEQ ID NO:518)
asp114R TCCCTCTGGATACGTGACSNNCGAATTCAGCGCCGTGAT
(SEQ ID NO:519)
asp115R TGTTCCCTCTGGATACGTSNNAGACGAATTCAGCGCCGT
(SEQ ID NO:520)
asp116R GACTGTTCCCTCTGGATASNNGACAGACGAATTCAGCGC
(SEQ ID NO:521)
asp117R TCGGACTGTTCCCTCTGGSNNCGTGACAGACGAATTCAG
(SEQ ID NO:522)
asp118R TCCTCGGACTGTTCCCTCSNNATACGTGACAGACGAATT
(SEQ ID NO:523)
asp119R AAGTCCTCGGACTGTTCCSNNCTGGATACGTGACAGACGA
(SEQ ID NO:524)
asp120R GATAAGTCCTCGGACTGTSNNCTCTGGATACGTGACAGA
(SEQ ID NO:525)
asp121R GCGGATAAGTCCTCGGACSNNTCCCTCTGGATACGTGAC

- 208 -

(SEQ ID NO:526)
asp122R CGTGCGGATAAGTCCTCGSNNTGTTCCCTCTGGATACGT
(SEQ ID NO:527)
asp123R CGTCGTGCGGATAAGTCCSNNGACTGTTCCCTCTGGATA
(SEQ ID NO:528)
asp124R AACCGTCGTGCGGATAAGSNNTCGGACTGTTCCCTCTGG
(SEQ ID NO:529)
asp125R ACAAACCGTCGTGCGGATSNNTCCTCGGACTGTTCCCTC
(SEQ ID NO:530)
asp126R GGCACAAACCGTCGTGCGSNNAAGTCCTCGGACTGTTCC
(SEQ ID NO:531)
asp127R TTCGGCACAAACCGTCGTSNNGATAAGTCCTCGGACTGT
(SEQ ID NO:532)
asp128R TGGTTCGGCACAAACCGTSNNGCGGATAAGTCCTCGGAC
(SEQ ID NO:533)
asp129R ACCTGGTTCGGCACAAACSNNGCGGATAAGTCCTCG
(SEQ ID NO:534)
asp130R ATCACCTGGTTCGGCACASNNGTCGTGCGGATAAGTCC
(SEQ ID NO:535)
asp131R GCTATCACCTGGTTCGGCSNNAACCGTCGTGCGGATAAG
(SEQ ID NO:536)
asp132R TCCGCTATCACCTGGTTCNNACAAACCGTCGTGCGGAT
(SEQ ID NO:537)
asp133R ACCTCCGCTATCACCTGGSNNGGCACAAACCGTCGTGCG
(SEQ ID NO:538)
asp134R GCTACCTCCGCTATCACCSNNTTCGGCACAAACCGTCGT
(SEQ ID NO:539)
asp135R AAGGCTACCTCCGCTATCSNNTGGTTCGGCACAAACCGT
(SEQ ID NO:540)
asp136R TAAAAGGCTACCTCCGCTSNNACCTGGTTCGGCACAAAC
(SEQ ID NO:541)
asp137R CGCTAAAAGGCTACCTCCSNNATCACCTGGTTCGGCACA
(SEQ ID NO:542)
asp138R TCCCGCTAAAAGGCTACCSNNGCTATCACCTGGTTCGGC
(SEQ ID NO:543)
asp139R ATTTCCCGCTAAAAGGCTSNNTCCGCTATCACCTGGTTC
(SEQ ID NO:544)
asp140R TTGATTTCCCGCTAAAAGSNNACCTCCGCTATCACCTGG
(SEQ ID NO:545)
asp141R GGCTTGATTTCCCGCTAASNNGCTACCTCCGCTATCACC
(SEQ ID NO:546)
asp142R TTGGGCTTGATTTCCCGCSNNAAGGCTACCTCCGCTATC
(SEQ ID NO:547)
asp143R ACCTTGGGCTTGATTTCCSNNTAAAAGGCTACCTCCGCT
(SEQ ID NO:548)
asp144R GACACCTTGGGCTTGATTSNNGCTAAAAGGCTACCTCC
(SEQ ID NO:549)
asp145R CGTGACACCTTGGGCTTGSNNTCCCGCTAAAAGGCTACC
(SEQ ID NO:550)
asp146R TGACGTGACACCTTGGGCSNNATTTCCCGCTAAAAGGCT
(SEQ ID NO:551)

- 209 -

asp147R ACCTGACGTGACACCTTGSNNTTGATTTCCTCGCTAAAAG
(SEQ ID NO:552)

asp148R ACCACCTGACGTGACACCSNNGGCTTGATTTCCTCGCTAA
(SEQ ID NO:553)

asp149R AGAACCACCTGACGTGACSNNTTGGGCTTGATTTCCTCGC
(SEQ ID NO:554)

asp150R TCCAGAACCACCTGACGTSNNACCTTGGGCTTGATTTC
(SEQ ID NO:555)

asp151R ATTTCCAGAACCACCTGASNNGACACCTTGGGCTTGATT
(SEQ ID NO:556)

asp152R ACAATTTCCAGAACCACCSNNCGTGACACCTTGGGCTTG
(SEQ ID NO:557)

asp153R CCGACAATTTCCAGAACCSNNTGACGTGACACCTTGGGC
(SEQ ID NO:558)

asp154R CGTCCGACAATTTCCAGASNACCTGACGTGACACCTTG
(SEQ ID NO:559)

asp155R CCCCCGTCCGACAATTTCCSNNACCACCTGACGTGACACC
(SEQ ID NO:560)

asp156R TCCCCCGTCCGACAATTSNNAGAACCACCTGACGTGAC
(SEQ ID NO:561)

asp157R TGTTCCCCCGTCCGACASNNTCCAGAACCACCTGACGT
(SEQ ID NO:562)

asp158R TGTTGTTCCCCCGTCCGSNNATTTCCAGAACCACCTGA
(SEQ ID NO:563)

asp159R GAATGTTGTTCCCCCGTSNNACAATTTCCAGAACCACC
(SEQ ID NO:564)

asp160R AAAGAATGTTGTTCCCCCSNNCCGACAATTTCCAGAACC
(SEQ ID NO:565)

asp161R TTGAAAGAATGTTGTTCCSNNCGTCCGACAATTTCCAGA
(SEQ ID NO:566)

asp162R TGGTTGAAAGAATGTTGTSNNCCCCGTCCGACAATTTCC
(SEQ ID NO:567)

asp163R GACTGGTTGAAAGAATGTSNNTCCCCCGTCCGACAATT
(SEQ ID NO:568)

asp164R GTTGACTGGTTGAAAGAASNNTGTTCCCCCGTCCGACA
(SEQ ID NO:569)

asp165R CGGGTTGACTGGTTGAAASNNTGTTGTTCCCCCGTCCG
(SEQ ID NO:570)

asp166R AATCGGGTTGACTGGTTGSNNGAATGTTGTTCCCCCGT
(SEQ ID NO:571)

asp167R CAAAATCGGGTTGACTGGSNNAAAGAATGTTGTTCCCCC
(SEQ ID NO:572)

asp168R CTGCAAAATCGGGTTGACSNNTTGAAAGAATGTTGTTCC (SEQ
ID NO:573)

asp169R AGCCTGCAAAATCGGGTTSNNTGGTTGAAAGAATGTTGT (SEQ
ID NO:574)

asp170R GTAAGCCTGCAAAATCGGSNNGACTGGTTGAAAGAATGT
(SEQ ID NO:575)

asp171R GCCGTAAGCCTGCAAAATSNNGTTGACTGGTTGAAAGAA
(SEQ ID NO:576)

asp172R CAGGCCGTAAGCCTGCAASNCGGGTTGACTGGTTGAAA

- 210 -

	(SEQ ID NO:577)
asp173R	TCTCAGGCCGTAAGCCTGSNNAATCGGGTTGACTGGTTG
	(SEQ ID NO:578)
asp174R	CATTCTCAGGCCGTAAGCSNNCAAATCGGGTTGACTGG
	(SEQ ID NO:579)
asp175R	AATCATTCTCAGGCCGTASNNCTGCAAAATCGGGTTGAC
	(SEQ ID NO:580)
asp176R	CGTAATCATTCTCAGGCCSNNAGCCTGCAAAATCGGGTT
	(SEQ ID NO:581)
asp177R	AGTCGTAATCATTCTCAGSNNGTAAAGCCTGCAAAATCGG
	(SEQ ID NO:582)
asp178R	GTCAGTCGTAATCATTCTSNNGCCGTAAGCCTGCAAAAT
	(SEQ ID NO:583)
asp179R	AGAGTCAGTCGTAATCATSNNCAGGCCGTAAGCCTGCAA
	(SEQ ID NO:584)
asp180R	TCCAGAGTCAGTCGTAATSNNTCTCAGGCCGTAAGCCTG
	(SEQ ID NO:585)
asp181R	ACTTCCAGAGTCAGTCGTSNNCATTCTCAGGCCGTAAGC
	(SEQ ID NO:586)
asp182R	GGAAGTTCCAGAGTCAGTSNNAATCATTCTCAGGCCGTA
	(SEQ ID NO:587)
asp183R	AGGGGAACTTCCAGAGTCSNNCGTAATCATTCTCAGGCC
	(SEQ ID NO:588)
asp184R	TTAAGGGGAACTTCCAGASNNAGTCGTAATCATTCTCAG
	(SEQ ID NO:589)
asp185R	GGGTAAAGGGGAACTTCCSNNGTAGTCGTAATCATTCT
	(SEQ ID NO:590)
asp186R	GTTGGGTAAAGGGGAACTSNNAGAGTCAGTCGTAATCAT
	(SEQ ID NO:591)
asp187R	TCTGTTGGGTAAAGGGGASNNTCCAGAGTCAGTCGTAAT
	(SEQ ID NO:592)
asp188R	TCCTCTGTTGGGTAAAGGSNNACTTCCAGAGTCAGTCGT
	(SEQ ID NO:593)
asp189R	CCGTCCTCTGTTGGGTASNNGGAAGTTCCAGAGTCAGT
	(SEQ ID NO:594)

EXAMPLE 16

Construction of Arginine and Cysteine Combinatorial Mutants

5 In this Example, the construction of multiple arginine and cysteine mutants of ASP is described. These experiments were conducted in order to determine whether the use of surface arginine and cysteine combinatorial libraries would lead to mutants with increased expression at the protein level.

10 The QuikChange® multi site-directed mutagenesis (QCMS) kit (Stratagene) was used to construct the two libraries. The 5' phosphorylated primers used to create the two libraries are shown in Table 16-1. It was noted that HPLC, PAGE or any other type of

- 211 -

purified primers gave far better results in terms of incorporation of full length primers as well as significant reduction in primer-containing errors. However, in these experiments, purified primers were not used, probably resulting in the production of 12% of clones had undesired mutations.

5

Table 16-1. Primers and Sequences	
Primer name	Primer sequence
ASPR14L	gcatatactattggcggcctgtctagatgttctatcgga (SEQ ID NO:595)
ASPR16Q	actattggcggccggtctcagtgttctatcggattcgc (SEQ ID NO:596)
ASPR35F	ctgccggtcactgcggatttacaggagccactactgc (SEQ ID NO:597)
ASPR61S	atgattatgcattcgtctcaacaggggcaggagtaa (SEQ ID NO:598)
ASPR79T	ataactactcggcggcacagtccaagtagcaggacatac (SEQ ID NO:599)
ASPR123L	atccagagggaacagtcctgggacttatccgcacgac (SEQ ID NO:600)
ASPR127Q	cagtcggaggacttatccagacgacggtttgtgccgaac (SEQ ID NO:601)
ASPR159Q	gtggttctggaaattgtcagacggggggaacaacattc (SEQ ID NO:602)
ASPR179Q	tgcaggcttacggcctgcagatgattacgactgactc (SEQ ID NO:603)
ASPC17S	ttggcggccggtctagatcatctatcggattcgcagta (SEQ ID NO:604)
ASPC33S	tcattactgccggtcactcaggaagaacaggagccact (SEQ ID NO:605)
ASPC95S	cagttggatctgctgtatctcgtcaggtagcactac (SEQ ID NO:606)
ASPC105S	cactacaggttggcattcaggaactatcacggcgctg (SEQ ID NO:607)
ASPC131S	cttatccgcacgacggttcagccgaaccaggtgatag (SEQ ID NO:608)
ASPC158S	caggtggttctggaaattcacggacggggggaacaac (SEQ ID NO:609)
ASPSEQF1	tgctcacattgtgccac (SEQ ID NO:610)
ASPSEQF4	caggatgtagctgcaggac (SEQ ID NO:611)
ASPSEQR4	ctcggttatgagttagttc (SEQ ID NO:612)

10 pHPLT-ASP-C1-2 Plasmid Preparation and *In vitro* Methylation

To construct the cysteine and arginine libraries using the QCMS kit, the template plasmid pHPLT-ASP-C1-2 was first methylated *in vitro* since it was derived from a *Bacillus* strain that does not methylate DNA at GATC sites. This method was used because the more common approach of ensuring methylation in plasmids used in the QCMS protocol involving deriving DNA from *dam*⁺ *E. coli* strains was not an option here, because the

15

plasmid pHPLT-ASP-C1-2 does not grow in *E. coli*.
 Miniprep DNA was prepared from *Bacillus* cells harboring the pHPLT-ASP-C1-2 plasmid. Specifically, the strain was grown overnight in 5 mL of LB with 10ppm of neomycin, after which the cells were spun down. The Qiagen spin miniprep DNA kit was used for

- 212 -

preparing the plasmid DNA with an additional step wherein 100uL of 10mg/mL lysozyme was added after the addition of 250uL of P1 buffer from the kit. The sample was incubated at 37°C for 15 min with shaking, after which the remaining steps outlined in the Qiagen miniprep kit manual were carried out. The miniprep DNA was eluted with 30uL of Qiagen
5 buffer EB provided in the kit.

Next, the pHPLT-ASP-C1-2 plasmid DNA was methylated *in vitro* using a *dam* methylase kit from NEB (NEB catalog # MO222S). Briefly, 25uL of the miniprep DNA (about 1-2 µg) was incubated with 20uL of the 10x NEB *dam* methylase buffer, 0.5uL of S-adenosylmethionine (80µM), 4uL of the *dam* methylase and 150.5uL of sterile distilled
10 water. The reaction was incubated at 37°C for 4 hours, after which the DNA was purified using a Qiagen PCR purification kit. The methylated DNA was eluted with 40uL of buffer EB provided in the kit. To confirm methylation of the DNA, 4uL of the purified, methylated DNA was digested with *Mbol* (NEB; this enzyme cuts unmethylated GATC sites) or *DpnI* (Roche; this enzyme cuts methylated GATC sites) in a 20uL reaction using 2uL of each enzyme.
15 The reactions were incubated at 37°C for 2 hours and they were analyzed on a 1.2% E-gel (Invitrogen). A small molecular weight DNA smear/ladder was observed for the *DpnI* digest, whereas the *Mbol* digest showed intact DNA, which indicated that the pHPLT-ASP-C1-2 plasmid was successfully methylated.

20 Library Construction

The cysteine (cys) and arginine (arg) combinatorial libraries were constructed as outlined in the Stratagene QCMS kit, with the exception of the primer concentration used in the reactions. Specifically, 4uL of the methylated, purified pHPLT-ASP-C1-2 plasmid (about 25 to 50ng) was mixed with 15uL of sterile distilled water, 1.5uL of dNTP, 2.5uL of 10x
25 buffer, 1uL of the enzyme blend and 1.0uL arginine or cysteine mutant primer mix (*i.e.*, for a total of 100ng of primers). The primer mix was prepared using 10uL of each of the nine arginine primers (100ng/µL) or each of the six cysteine primers (100ng/µL); adding 50ng of each primer for both the arg and cys libraries as recommended in the Stratagene manual resulted in less than 50% of the clones containing mutations in a previous round of
30 mutagenesis. Thus, the protocol was modified in the present round of mutagenesis to include a total of 100ng of primers in each reaction. The cycling conditions were 95°C for 1 min, followed by 30 cycles of 95°C for 1 min, 55°C for 1 min, and 65°C for 9 min, in an MJ Research thermocycler using thin-walled 0.2mL PCR tubes. The reaction product was digested with 1uL of *DpnI* from the QCMS kit by incubating at 37°C overnight. An additional
35 0.5uL of *DpnI* was added, and the reaction was incubated for 1 hour.

- 213 -

To transform the library DNA directly into *Bacillus* cells with out going through *E. coli*, the library DNA (single-stranded QCMS product) was amplified using the TempliPhi kit (Amersham cat. #25-6400), because *Bacillus* requires double-stranded multimeric DNA for transformation. For this purpose, 1 μ L of the arginine or cysteine QCMS reaction was mixed with 5 μ L of sample buffer from the TempliPhi kit and heated for 3 minutes at 95°C to denature the DNA. The reaction was placed on ice to cool for 2 minutes and then spun down briefly. Next, 5 μ L of reaction buffer and 0.2 μ L of phi29 polymerase from the TempliPhi kit were added, and the reactions were incubated at 30°C in an MJ Research PCR machine for 4 hours. The phi29 enzyme was heat inactivated in the reactions by incubation at 65°C for 10 min in the PCR machine.

For transformation of the libraries into *Bacillus*, 0.5 μ L of the TempliPhi amplification reaction product was mixed with 100 μ L of *comK* competent cells followed by vigorous shaking at 37°C for 1 hour. The transformation was serially diluted up to 10⁵ fold, and 50 μ L of each dilution was plated on LA plates containing 10 ppm neomycin and 1.6% skim milk. Twenty-four clones from each library were picked for sequencing. Briefly, the colonies were resuspended in 20 μ L of sterile distilled water and 2 μ L was then used for PCR with ReadyTaq beads (Amersham) in a total volume of 25 μ L. Primers ASPF1 and ASPR4 were added at a concentration of 0.5 μ M. Cycling conditions were 94°C for 4 min once, followed by 30 cycles of 94°C for 1min, 55°C for 1 min, and 72°C for 1min, followed by one round at 72°C for 7 min. A 1.5kb fragment was obtained in each case and the product was purified using a Qiagen PCR purification kit. The purified PCR products were sequenced with ASPF4 and ASPR4 primers.

A total of 48 clones were sequenced (24 from each library). The mutagenesis worked quite well in that only about 15% of the clones were WT. But 20% of the clones had mixed sequences because the plate was crowded with colonies or the TempliPhi amplification resulted in very concentrated DNA for transformation. Also, as indicated above, about 12% of clones had extra mutations. The remaining clones were all mutant, and of these about 60-80% were unique mutants. The sequencing results for the arginine and cysteine libraries are provided below in Tables 16-2, and 16-3.

Table 16-2. Arginine Library Sequencing and Skim Milk Plate Results

Colony	Halo	R14L	R16Q	R35F	R61S	R79T	R123L	R127Q	R159Q	R179Q
R1	medium		X	X					X	
R2	yes								X	
R3	yes		X				X			

- 214 -

R4	yes		X			X			
R5	yes		X			X			
R6	yes		X			X			
R7	yes	X					X	X	
R8	yes		X			X			
R9	yes								
R10	yes	X							X
R11	yes								
R12	medium		X	X				X	
R13	yes				X				
R14	yes								
R15	yes								
R16	medium								
R17	no				X	X	X		
R18	medium					X	X		X
R19	medium								
R20	yes	X					X	X	
R21	medium		X		X		X		
R22	small								
R23	yes		X		X				
R24	yes								

Table 16-3. Cysteine Library Sequencing and Skim Milk Plate Results							
Colony	Halo?	C17S	C33S	C95S	C105S	C131S	C158S
C1	no	X	X				
C2	no						
C3	yes						
C4	yes						
C5	no	X		X			
C6	small	X			X		
C7	no			X	X	X	
C8	yes						
C9	no						
C10	no						
C11	small						
C12	no						
C13	no	X		X			
C14	no	X	X	X			X
C15	no						
C16	no						X
C17	no						X
C18	no	X		X	X		X
C19	yes						
C20	no						
C21	no						
C22	no				X		
C23	no	X		X			

- 215 -

C24	yes						
-----	-----	--	--	--	--	--	--

Of the mutants identified in sequencing, the following mutants from the arginine library (See, Table 16-4) were found to be of interest. See the Examples below for additional data regarding the properties of these mutants.

Table 16-4. Arginine Mutants of Interest	
MUTANT	SEQUENCE
R1	R16Q R35F R159Q
R2	R159Q
R3	R16Q R123L
R7	R14L R127Q R159Q
R10B	R14L R179Q
R18	R123L R127Q R179Q
R21	R16Q R79T R127Q
R23	R16Q R79T
R10	R14L R79T

Importantly, the activity results indicated that mutations in the cysteine residues produced ASP proteases with very low or no activity, suggesting that the disulfide bridges play an important role in the stability of the molecule. However, it is not intended that the present invention be limited to any particular mechanism(s).

EXAMPLE 17

Expression of Homologous *O. turbata* Protease in *S. lividans*

In this Example, expression of protease produced by *O. turbata* that is homologous to the protease 69B4 in *S. lividans* is described. Thus, this Example describes plasmids comprising polynucleotides encoding a polypeptide having proteolytic activity and used such vectors to transform a *Streptomyces lividans* host cell. The transformation methods used herein are known in the art (See e.g., U.S. Pat. No. 6,287,839; and WO 02/50245, herein incorporated by reference).

The vector (i.e., plasmid) used in these experiments comprised a polynucleotide

- 216 -

encoding a protease of the present invention obtained from *Oerskovia turbata* DSM 20577. This plasmid was used to transform *Streptomyces lividans*. The final plasmid vector is referred to herein as "pSEA4CT-O.turbata."

As with previous vectors, the construction of pSEA4CT-O.turbata made use of the pSEGCT plasmid vector (See, above).

An *Aspergillus niger* ("A4") regulatory sequence operably linked to the structural gene encoding the *Oerskovia turbata* protease (Otp) was used to drive the expression of the protease. A fusion between the A4-regulatory sequence and the *Oerskovia turbata* signal-sequence, N-terminal prosequence and mature protease sequence (*i.e.*, without the C-terminal prosequence) was constructed by fusion-PCR techniques known in the art, as an *XbaI*-*Bam*HI fragment. The polynucleotide primers for the cloning of *Oerskovia turbata* protease (Otp) in pSEA4CT were based on SEQ ID NO:67. The primer sequences used were:

A4-turb Fw
5'-CAGAGACAGACCCCCGGAGGTAACCATGGCACGATCATTCTGGAGGACGC-3' (SEQ ID NO:613)

A4- turb RV
5'-GCGTCCTCCAGAATGATCGTGCCATGGTTACCTCCGGGGGTCTGTCTCTG-3' (SEQ ID NO:614)

A4- turb *Bam* Rv
5'-ATCCGCTCGCGGATCCCCATTGTCAGCTCGGGCCCCCACCCTCAGAGGTCACGAG-3' (SEQ ID NO:615)

A4- *Xba*I-FW
5'-GCAGCCTGAACTAGTTGCGATCCTCTAGAGATCGAACTTCAT-3' (SEQ ID NO:616)

The fragment was ligated into plasmid pSEA4CT digested with *XbaI* and *Bam*HI, resulting in plasmid pSEA4CT-O.turbata.

The host *Streptomyces lividans* TK23 was transformed with plasmid vector pSEA4CT-O.turbata using the protoplast method described in the previous Example (*i.e.*, using the method of Hopwood *et al.*, *supra*).

The transformed culture was expanded to provide two fermentation cultures in TS* medium. The composition of TS* medium was (g/L) tryptone (Difco) 16, soytone (Difco) 4, casein hydrolysate (Merck) 20, K₂HPO₄ 10, glucose 15, Basildon antifoam 0.6, pH 7.0. At various time points, samples of the fermentation broths were removed for analysis. For the

- 217 -

purposes of this experiment, a skim milk procedure was used to confirm successful cloning. 30 μ L of the shake flask supernatant was pipetted in punched out holes in skim milk agar plates and incubated at 37°C.

The incubated plates were visually reviewed after overnight incubation for the presence of clearing zones (halos) indicating the expression of proteolytic enzyme. For purposes of this experiment, the samples were also assayed for protease activity and for molecular weight (SDS-PAGE). At the end of the fermentation, full length protease was observed by SDS-PAGE.

A sample of the fermentation broth was assayed as follows: 10 μ L of the diluted supernatant was collected and analyzed using the Dimethylcasein Hydrolysis Assay described in Example 1. The assay results of the fermentation broth of 2 clones clearly show that the polynucleotide from *Oerskovia turbata* encoding a polypeptide having proteolytic activity was expressed in *Streptomyces lividans*.

EXAMPLE 18

Expression of Homologous *Cellulomonas* and *Cellulosimicrobium* Proteases in *S. lividans*

In this Example, expression of proteases produced by *Cellulomonas cellasea* DSM 20118 and *Cellulosimicrobium cellulans* DSM 204244 that are homologous to the protease 69B4 in *S. lividans* is described. Thus, this Example describes plasmids comprising polynucleotides encoding a polypeptide having proteolytic activity and used such vectors to transform a *Streptomyces lividans* host cell. The transformation methods used herein are known in the art (See e.g., U.S. Pat. No. 6,287,839; and WO 02/50245, herein incorporated by reference).

The final plasmid vectors are referred to as pSEA4CT-C.cellasea and pSEA4CT-Cm.cellulans. The construction of pSEA4CT-C.cellasea and pSEA4CT-Cm.cellulans made use of the pSEGCT plasmid vector described above.

An *Aspergillus niger* ("A4") regulatory sequence operably linked to the structural gene encoding the *Cellulomonas cellasea* mature protease (Ccp) or alternatively, the structural gene encoding the *Cellulosimicrobium cellulans* mature protease (Cmcp) was used to drive the expression of the protease. A fusion between the A4-regulatory sequence and the 69B4 protease signal-sequence, N-terminal prosequence of the 69B4 protease

- 218 -

gene and mature sequence of the native protease gene obtained from genomic DNA of a strain of *Micrococcineae* (herein, *Cellulomonas cellasea* or *Cellulosimicrobium cellulans*) was constructed by fusion-PCR techniques, as a *XbaI-BamHI* fragment. The polynucleotide primers for the cloning of *Cellulomonas cellasea* protease (Ccp) in pSEA4CT were based on
5 SEQ ID NO:63, and are as follows:

Asp-npro fw-cell

5'-

AGACCGACGAGACCCCGCGGACCATGGTTCGACGTCATCGGCGGCAACGCGTACTAC-
10 3' (SEQ ID NO:617)

Cell-BH1-rv

5'-

TCAGCCGATCCGCTCGCGGATCCCCATTGTCAGCCCAGGACGAGACGCAGACCGTA-3'
15 (SEQ ID NO:618)

Asp-npro rv-cell

5'-

GTAGTACGCGTTGCCGCCGATGACGTCGACCATGGTCCGCGGGGTCTCGTCGGTCT-
20 3' (SEQ ID NO:619)

Xba-1 fw A4

5'-GCAGCCTGAACTAGTTGCGATCCTCTAGAGATCGAACTTCATGTTCTGA-3' (SEQ ID
NO:620)
25

The polynucleotide primers for the cloning of *Cellulosimicrobium cellulans* protease (Cmcp) in pSEA4CT were based on SEQ ID NO:71, and are as follows,

ASP-npro fw cellu

5'-ACCGACGAGACCCCGCGGACCATGCACGGCGACGTGCGCGGCGGCGACCGCTA-3'
30 (SEQ ID NO:621)

ASP-npro rv cellu

5'-TAGCGGTCGCCGCCGCGCACGTCGCCGTGCATGGTCCGCGGGGTCTCGTCGGT-3'
35 (SEQ ID NO:622)

- 219 -

Cellu-BH1-rv

5'-

TCAGCCGATCCGCTCGCGGATCCCCATTGTCAGCGAGCCCGACGAGCGCGCTGCCCCG
AC-3' (SEQ ID NO:623)

5

Xba-1 fw A4

5'-GCAGCCTGAACTAGTTGCGATCCTCTAGAGATCGAACTTCATGTTCTGA-3' (SEQ ID
NO:620)

10

The host *Streptomyces lividans* TK23 was transformed with plasmid vector pSEA4CT using the protoplast method described above (*i.e.*, Hopwood *et al.*, *supra*). The transformed culture was expanded to provide two fermentation cultures in TS* medium. The composition of TS* medium was (g/L) tryptone (Difco) 16, soytone (Difco) 4, casein hydrolysate (Merck) 20, K₂HPO₄ 10, glucose 15, Basildon antifoam 0.6, pH 7.0. At various
15 time points, samples of the fermentation broths were removed for analysis. For the purposes of this experiment, a skim milk procedure was used to confirm successful cloning. 30 µL of the shake flask supernatant was pipetted in punched out holes in skim milk agar plates and incubated at 37°C.

15

The incubated plates were visually reviewed after overnight incubation for the
20 presence of clearing zones (halos) indicating the expression of proteolytic enzyme. For purposes of this experiment, the samples were also assayed for protease activity and for molecular weight (SDS-PAGE). At the end of the fermentation full length protease was observed by SDS-PAGE.

20

A sample of the fermentation broth was assayed as follows: 10µL of the diluted
25 supernatant was taken and added to 190 µL AAPF substrate solution (conc. 1 mg/ml, in 0.1 M Tris/0.005% Tween 80, pH 8.6). The rate of increase in absorbance at 410 nm due to release of *p*-nitroaniline was monitored (25°C).

25

As in previous Examples, the results obtained clearly indicated that the polynucleotide from *Cellulomonas cellasea* or from *Cellulosimicrobium cellulans*, both
30 encoding polypeptides having proteolytic activity were expressed in *Streptomyces lividans*.

30

EXAMPLE 19

Determination of the Crystal Structure of ASP Protease

In this Example, methods used to determine the crystal structure of ASP protease
35 are described. Indeed, high quality single crystals were obtained from purified ASP

35

- 220 -

protease. The crystallization conditions were as follows: 25% PEG 8000, 0.2M ammonium sulphate, and 15% glycerol. These crystallization conditions are cryo-protective, so transfer to a cryoprotectant was not required. The crystals were frozen in liquid nitrogen, and kept frozen during data collection using an Xstream (Molecular Structure). Data were collected with a R-axis IV (Molecular Structure), equipped with focusing mirrors. X-ray reflection data were obtained to 1.9Å resolution. The space group was P2₁2₁2₁, with cell dimensions a=35.65Å, b=51.82 Å and c=76.86Å. There was one molecule per asymmetric unit.

The crystal structure was solved using the molecular replacement method. The program used was X-MR (Accelrys Inc.). The starting model for the molecular replacement calculations was Streptogrisin. It is clear from the electron density map obtained from X-MR that the molecular replacement solution is correct. Thus, 98% of the model was built correctly, with some minor errors that were fixed manually. The R-factor for data to 1.9Å was 0.23.

The structure was found to largely consist of β-sheets, with 2 very short α-helices, and a longer helix toward the C-terminal end. There are two sets of β-sheets, with a considerable interface between them. The active-site is found in a cleft formed at this interface. The catalytic triad is formed by His 32, Asp 56, and Ser 137. Table 19-1 provides the atomic coordinates identified for ASP.

Table 19-1 Atomic Coordinates for ASP

CRYST1	35.770	51.730	76.650	90.00	90.00	90.00	P212121	
ATOM	1	N	PHE A	1	2.421	18.349	15.176	1.00 16.78 N
ATOM	2	CA	PHE A	1	3.695	18.087	15.905	1.00 18.18 C
ATOM	3	CB	PHE A	1	4.875	18.550	15.048	1.00 16.73 C
ATOM	4	C	PHE A	1	3.700	18.810	17.249	1.00 16.36 C
ATOM	5	O	PHE A	1	3.443	20.011	17.315	1.00 17.91 O
ATOM	6	CG	PHE A	1	6.214	18.292	15.664	1.00 17.42 C
ATOM	7	CD2	PHE A	1	6.955	17.180	15.296	1.00 19.42 C
ATOM	8	CD1	PHE A	1	6.736	19.160	16.611	1.00 16.13 C
ATOM	9	CE2	PHE A	1	8.200	16.933	15.863	1.00 18.08 C
ATOM	10	CE1	PHE A	1	7.977	18.922	17.180	1.00 18.34 C
ATOM	11	CZ	PHE A	1	8.710	17.807	16.806	1.00 19.32 C
ATOM	12	N	ASP A	2	3.984	18.076	18.321	1.00 13.94 N
ATOM	13	CA	ASP A	2	4.015	18.670	19.654	1.00 15.04 C
ATOM	14	CB	ASP A	2	3.527	17.677	20.714	1.00 15.13 C
ATOM	15	C	ASP A	2	5.403	19.149	20.063	1.00 14.43 C
ATOM	16	O	ASP A	2	6.381	18.408	19.966	1.00 11.44 O
ATOM	17	CG	ASP A	2	2.088	17.243	20.502	1.00 18.25 C
ATOM	18	OD2	ASP A	2	1.721	16.150	20.986	1.00 19.05 O
ATOM	19	OD1	ASP A	2	1.320	17.996	19.874	1.00 15.33 O
ATOM	20	N	VAL A	3	5.479	20.393	20.523	1.00 12.30 N
ATOM	21	CA	VAL A	3	6.740	20.979	20.959	1.00 11.83 C
ATOM	22	CB	VAL A	3	6.812	22.480	20.603	1.00 11.52 C
ATOM	23	C	VAL A	3	6.766	20.795	22.470	1.00 13.77 C
ATOM	24	O	VAL A	3	5.912	21.321	23.183	1.00 11.14 O
ATOM	25	CG1	VAL A	3	7.987	23.133	21.309	1.00 15.13 C
ATOM	26	CG2	VAL A	3	6.968	22.637	19.101	1.00 14.21 C
ATOM	27	CB	ILE A	4	7.561	18.267	24.642	1.00 14.73 C
ATOM	28	CG2	ILE A	4	7.799	17.929	26.099	1.00 14.20 C
ATOM	29	CG1	ILE A	4	6.103	17.995	24.267	1.00 16.79 C
ATOM	30	CD1	ILE A	4	5.774	16.518	24.166	1.00 19.32 C

- 221 -

	ATOM	31	C	ILE	A	4	9.334	20.031	24.816	1.00	14.04	C
	ATOM	32	O	ILE	A	4	10.289	19.660	24.140	1.00	11.09	O
	ATOM	33	N	ILE	A	4	7.745	20.033	22.945	1.00	10.83	N
	ATOM	34	CA	ILE	A	4	7.903	19.750	24.365	1.00	13.46	C
5	ATOM	35	N	GLY	A	5	9.475	20.681	25.965	1.00	11.82	N
	ATOM	36	CA	GLY	A	5	10.800	20.995	26.467	1.00	9.81	C
	ATOM	37	C	GLY	A	5	11.700	19.785	26.644	1.00	11.77	C
	ATOM	38	O	GLY	A	5	11.256	18.737	27.114	1.00	9.20	O
	ATOM	39	N	GLY	A	6	12.966	19.927	26.255	1.00	10.03	N
10	ATOM	40	CA	GLY	A	6	13.917	18.836	26.397	1.00	8.54	C
	ATOM	41	C	GLY	A	6	14.070	17.979	25.156	1.00	9.57	C
	ATOM	42	O	GLY	A	6	15.020	17.200	25.042	1.00	7.69	O
	ATOM	43	N	ASN	A	7	13.131	18.119	24.224	1.00	9.01	N
	ATOM	44	CA	ASN	A	7	13.168	17.359	22.985	1.00	10.51	C
15	ATOM	45	CB	ASN	A	7	11.780	17.293	22.349	1.00	14.65	C
	ATOM	46	CG	ASN	A	7	10.897	16.250	22.981	1.00	10.35	C
	ATOM	47	OD1	ASN	A	7	9.715	16.144	22.644	1.00	13.61	O
	ATOM	48	ND2	ASN	A	7	11.456	15.470	23.896	1.00	6.66	N
	ATOM	49	C	ASN	A	7	14.130	17.952	21.976	1.00	12.30	C
20	ATOM	50	O	ASN	A	7	14.424	19.146	21.991	1.00	15.93	O
	ATOM	51	N	ALA	A	8	14.608	17.107	21.079	1.00	11.08	N
	ATOM	52	CA	ALA	A	8	15.532	17.564	20.063	1.00	14.32	C
	ATOM	53	CB	ALA	A	8	16.336	16.392	19.541	1.00	14.61	C
	ATOM	54	C	ALA	A	8	14.766	18.202	18.914	1.00	11.23	C
25	ATOM	55	O	ALA	A	8	13.567	17.987	18.747	1.00	12.54	O
	ATOM	56	N	TYR	A	9	15.468	19.021	18.145	1.00	9.75	N
	ATOM	57	CA	TYR	A	9	14.899	19.691	16.988	1.00	12.42	C
	ATOM	58	CB	TYR	A	9	14.279	21.059	17.334	1.00	12.79	C
	ATOM	59	CG	TYR	A	9	15.216	22.150	17.790	1.00	14.12	C
30	ATOM	60	CD2	TYR	A	9	15.485	22.333	19.139	1.00	10.17	C
	ATOM	61	CE2	TYR	A	9	16.302	23.366	19.572	1.00	12.49	C
	ATOM	62	CD1	TYR	A	9	15.791	23.029	16.877	1.00	9.02	C
	ATOM	63	CE1	TYR	A	9	16.604	24.066	17.294	1.00	10.92	C
	ATOM	64	CZ	TYR	A	9	16.857	24.230	18.644	1.00	13.93	C
35	ATOM	65	OH	TYR	A	9	17.661	25.261	19.070	1.00	12.50	O
	ATOM	66	C	TYR	A	9	16.127	19.792	16.101	1.00	12.21	C
	ATOM	67	O	TYR	A	9	17.247	19.589	16.583	1.00	11.38	O
	ATOM	68	N	THR	A	10	15.946	20.055	14.816	1.00	11.44	N
	ATOM	69	CA	THR	A	10	17.105	20.144	13.946	1.00	13.35	C
40	ATOM	70	CB	THR	A	10	17.114	18.998	12.916	1.00	14.07	C
	ATOM	71	OG1	THR	A	10	15.952	19.098	12.086	1.00	13.63	O
	ATOM	72	CG2	THR	A	10	17.121	17.648	13.620	1.00	12.60	C
	ATOM	73	C	THR	A	10	17.267	21.452	13.194	1.00	14.66	C
	ATOM	74	O	THR	A	10	16.299	22.161	12.907	1.00	12.64	O
45	ATOM	75	N	ILE	A	11	18.520	21.749	12.881	1.00	14.05	N
	ATOM	76	CA	ILE	A	11	18.889	22.954	12.157	1.00	18.00	C
	ATOM	77	CB	ILE	A	11	19.649	23.931	13.068	1.00	17.58	C
	ATOM	78	CG2	ILE	A	11	19.919	25.230	12.323	1.00	20.00	C
	ATOM	79	CG1	ILE	A	11	18.825	24.212	14.327	1.00	21.47	C
50	ATOM	80	CD1	ILE	A	11	19.560	25.031	15.377	1.00	23.61	C
	ATOM	81	C	ILE	A	11	19.802	22.485	11.030	1.00	16.40	C
	ATOM	82	O	ILE	A	11	20.913	22.014	11.278	1.00	17.72	O
	ATOM	83	N	GLY	A	12	19.330	22.603	9.794	1.00	18.83	N
	ATOM	84	CA	GLY	A	12	20.132	22.155	8.673	1.00	17.69	C
55	ATOM	85	C	GLY	A	12	20.359	20.659	8.791	1.00	18.86	C
	ATOM	86	O	GLY	A	12	21.395	20.141	8.376	1.00	19.71	O
	ATOM	87	N	GLY	A	13	19.391	19.964	9.380	1.00	17.62	N
	ATOM	88	CA	GLY	A	13	19.509	18.525	9.529	1.00	16.37	C
	ATOM	89	C	GLY	A	13	20.352	18.060	10.703	1.00	17.10	C
60	ATOM	90	O	GLY	A	13	20.470	16.861	10.946	1.00	15.94	O
	ATOM	91	N	ARG	A	14	20.931	19.002	11.438	1.00	17.27	N
	ATOM	92	CA	ARG	A	14	21.772	18.667	12.585	1.00	15.15	C
	ATOM	93	CB	ARG	A	14	23.017	19.558	12.586	1.00	19.68	C
	ATOM	94	C	ARG	A	14	21.030	18.842	13.908	1.00	16.27	C
65	ATOM	95	O	ARG	A	14	20.423	19.882	14.159	1.00	12.16	O
	ATOM	96	CG	ARG	A	14	24.009	19.273	13.699	1.00	25.94	C
	ATOM	97	CD	ARG	A	14	24.879	18.069	13.393	1.00	31.69	C
	ATOM	98	NE	ARG	A	14	25.964	17.928	14.360	1.00	40.26	N
	ATOM	99	CZ	ARG	A	14	25.802	17.572	15.630	1.00	42.65	C
70	ATOM	100	NH1	ARG	A	14	26.852	17.483	16.435	1.00	45.09	N
	ATOM	101	NH2	ARG	A	14	24.592	17.302	16.091	1.00	41.89	N
	ATOM	102	N	SER	A	15	21.075	17.821	14.756	1.00	14.36	N
	ATOM	103	CA	SER	A	15	20.407	17.892	16.047	1.00	18.05	C
	ATOM	104	CB	SER	A	15	20.033	16.488	16.524	1.00	19.52	C
75	ATOM	105	C	SER	A	15	21.402	18.533	17.011	1.00	18.51	C
	ATOM	106	O	SER	A	15	21.966	17.870	17.882	1.00	16.89	O
	ATOM	107	OG	SER	A	15	19.311	16.542	17.742	1.00	24.25	O
	ATOM	108	N	ARG	A	16	21.625	19.829	16.842	1.00	15.76	N

- 222 -

	ATOM	109	CA	ARG	A	16	22.560	20.544	17.695	1.00	18.30	C
	ATOM	110	CB	ARG	A	16	23.077	21.795	16.976	1.00	22.82	C
	ATOM	111	C	ARG	A	16	22.006	20.952	19.050	1.00	17.05	C
	ATOM	112	O	ARG	A	16	22.760	21.064	20.015	1.00	11.60	O
5	ATOM	113	CG	ARG	A	16	23.892	21.498	15.729	1.00	30.78	C
	ATOM	114	CD	ARG	A	16	24.503	22.758	15.131	1.00	36.12	C
	ATOM	115	NE	ARG	A	16	23.494	23.756	14.789	1.00	41.88	N
	ATOM	116	CZ	ARG	A	16	23.737	24.839	14.058	1.00	44.68	C
	ATOM	117	NH2	ARG	A	16	24.954	25.057	13.579	1.00	46.43	N
10	ATOM	118	NH1	ARG	A	16	22.762	25.698	13.796	1.00	44.09	N
	ATOM	119	N	CYS	A	17	20.695	21.152	19.130	1.00	12.26	N
	ATOM	120	CA	CYS	A	17	20.085	21.562	20.388	1.00	11.02	C
	ATOM	121	CB	CYS	A	17	19.949	23.079	20.394	1.00	11.05	C
	ATOM	122	C	CYS	A	17	18.744	20.946	20.756	1.00	8.62	O
15	ATOM	123	O	CYS	A	17	18.178	20.154	20.008	1.00	10.24	O
	ATOM	124	SG	CYS	A	17	21.542	23.945	20.503	1.00	10.83	S
	ATOM	125	N	SER	A	18	18.246	21.338	21.926	1.00	9.44	N
	ATOM	126	CA	SER	A	18	16.976	20.849	22.441	1.00	10.14	C
	ATOM	127	CB	SER	A	18	17.226	20.053	23.726	1.00	11.06	C
20	ATOM	128	OG	SER	A	18	18.198	19.042	23.516	1.00	11.13	O
	ATOM	129	C	SER	A	18	16.019	22.004	22.736	1.00	10.28	C
	ATOM	130	O	SER	A	18	16.439	23.152	22.882	1.00	12.80	O
	ATOM	131	N	ILE	A	19	14.731	21.689	22.806	1.00	8.87	N
	ATOM	132	CA	ILE	A	19	13.698	22.676	23.087	1.00	9.04	C
25	ATOM	133	CB	ILE	A	19	12.278	22.070	22.951	1.00	9.94	C
	ATOM	134	CG2	ILE	A	19	11.236	23.126	23.287	1.00	10.60	C
	ATOM	135	CG1	ILE	A	19	12.053	21.514	21.543	1.00	12.49	C
	ATOM	136	CD1	ILE	A	19	12.083	22.554	20.439	1.00	10.46	C
	ATOM	137	C	ILE	A	19	13.840	23.154	24.530	1.00	9.36	C
30	ATOM	138	O	ILE	A	19	14.039	22.346	25.442	1.00	7.81	O
	ATOM	139	N	GLY	A	20	13.748	24.466	24.729	1.00	6.59	N
	ATOM	140	CA	GLY	A	20	13.827	25.024	26.067	1.00	7.48	C
	ATOM	141	C	GLY	A	20	12.424	25.027	26.649	1.00	10.12	C
	ATOM	142	O	GLY	A	20	12.047	24.128	27.400	1.00	9.28	O
35	ATOM	143	N	PHE	A	21	11.636	26.037	26.293	1.00	11.70	N
	ATOM	144	CA	PHE	A	21	10.262	26.132	26.770	1.00	9.99	C
	ATOM	145	CB	PHE	A	21	10.182	27.019	28.009	1.00	12.23	C
	ATOM	146	CG	PHE	A	21	10.891	26.455	29.197	1.00	12.14	C
	ATOM	147	CD1	PHE	A	21	10.282	25.493	29.985	1.00	10.45	C
40	ATOM	148	CD2	PHE	A	21	12.174	26.873	29.517	1.00	11.10	C
	ATOM	149	CE1	PHE	A	21	10.943	24.953	31.078	1.00	9.63	C
	ATOM	150	CE2	PHE	A	21	12.841	26.339	30.606	1.00	10.44	C
	ATOM	151	CZ	PHE	A	21	12.225	25.377	31.390	1.00	5.44	C
	ATOM	152	C	PHE	A	21	9.378	26.721	25.692	1.00	11.93	C
45	ATOM	153	O	PHE	A	21	9.838	27.500	24.861	1.00	11.86	O
	ATOM	154	N	ALA	A	22	8.105	26.346	25.709	1.00	8.59	N
	ATOM	155	CA	ALA	A	22	7.171	26.861	24.722	1.00	10.98	C
	ATOM	156	CB	ALA	A	22	5.978	25.920	24.580	1.00	9.33	C
	ATOM	157	C	ALA	A	22	6.708	28.233	25.200	1.00	9.72	C
50	ATOM	158	O	ALA	A	22	6.452	28.431	26.390	1.00	10.20	O
	ATOM	159	N	VAL	A	23	6.621	29.178	24.270	1.00	9.39	N
	ATOM	160	CA	VAL	A	23	6.186	30.542	24.579	1.00	11.79	C
	ATOM	161	CB	VAL	A	23	7.369	31.545	24.567	1.00	8.77	C
	ATOM	162	CG1	VAL	A	23	8.373	31.176	25.644	1.00	12.30	C
55	ATOM	163	CG2	VAL	A	23	8.034	31.557	23.195	1.00	9.56	C
	ATOM	164	C	VAL	A	23	5.197	30.943	23.496	1.00	12.96	C
	ATOM	165	O	VAL	A	23	5.047	30.234	22.507	1.00	15.51	O
	ATOM	166	N	ASN	A	24	4.509	32.066	23.668	1.00	15.64	N
	ATOM	167	CA	ASN	A	24	3.559	32.472	22.642	1.00	18.48	C
60	ATOM	168	CB	ASN	A	24	2.848	33.772	23.048	1.00	23.96	C
	ATOM	169	C	ASN	A	24	4.304	32.661	21.319	1.00	18.42	C
	ATOM	170	O	ASN	A	24	5.277	33.410	21.251	1.00	16.60	O
	ATOM	171	CG	ASN	A	24	3.800	34.949	23.182	1.00	23.94	C
	ATOM	172	OD1	ASN	A	24	4.697	34.951	24.025	1.00	23.82	O
65	ATOM	173	ND2	ASN	A	24	3.602	35.964	22.345	1.00	25.51	N
	ATOM	174	N	GLY	A	25	3.868	31.956	20.278	1.00	19.39	N
	ATOM	175	CA	GLY	A	25	4.509	32.086	18.978	1.00	18.25	C
	ATOM	176	C	GLY	A	25	5.628	31.106	18.649	1.00	18.73	C
	ATOM	177	O	GLY	A	25	6.103	31.065	17.515	1.00	18.70	O
70	ATOM	178	N	GLY	A	26	6.064	30.318	19.624	1.00	14.44	N
	ATOM	179	CA	GLY	A	26	7.123	29.362	19.348	1.00	15.00	C
	ATOM	180	C	GLY	A	26	7.779	28.822	20.602	1.00	11.05	C
	ATOM	181	O	GLY	A	26	7.095	28.457	21.554	1.00	10.68	O
	ATOM	182	N	PHE	A	27	9.107	28.759	20.599	1.00	11.66	N
75	ATOM	183	CA	PHE	A	27	9.832	28.268	21.761	1.00	11.72	C
	ATOM	184	CB	PHE	A	27	10.056	26.748	21.679	1.00	10.14	C
	ATOM	185	C	PHE	A	27	11.169	28.960	21.934	1.00	10.62	C
	ATOM	186	O	PHE	A	27	11.727	29.509	20.985	1.00	12.74	O

- 223 -

	ATOM	187	CG	PHE	A	27	11.000	26.309	20.580	1.00	9.74	C
	ATOM	188	CD1	PHE	A	27	10.524	26.006	19.308	1.00	12.75	C
	ATOM	189	CD2	PHE	A	27	12.361	26.158	20.832	1.00	11.98	C
	ATOM	190	CE1	PHE	A	27	11.384	25.555	18.312	1.00	8.90	C
5	ATOM	191	CE2	PHE	A	27	13.228	25.707	19.837	1.00	10.80	C
	ATOM	192	CZ	PHE	A	27	12.740	25.406	18.580	1.00	9.83	C
	ATOM	193	N	ILE	A	28	11.675	28.948	23.162	1.00	12.44	N
	ATOM	194	CA	ILE	A	28	12.956	29.573	23.442	1.00	10.82	C
	ATOM	195	CB	ILE	A	28	12.903	30.454	24.707	1.00	10.35	C
10	ATOM	196	C	ILE	A	28	13.992	28.469	23.590	1.00	12.26	C
	ATOM	197	O	ILE	A	28	13.667	27.335	23.960	1.00	11.25	O
	ATOM	198	CG2	ILE	A	28	12.081	31.701	24.434	1.00	7.92	C
	ATOM	199	CG1	ILE	A	28	12.278	29.690	25.873	1.00	12.08	C
	ATOM	200	CD1	ILE	A	28	12.175	30.526	27.129	1.00	10.36	C
15	ATOM	201	N	THR	A	29	15.238	28.804	23.283	1.00	11.02	N
	ATOM	202	CA	THR	A	29	16.327	27.845	23.364	1.00	11.15	C
	ATOM	203	CB	THR	A	29	16.348	26.988	22.052	1.00	13.72	C
	ATOM	204	OG1	THR	A	29	17.364	25.981	22.124	1.00	11.80	O
	ATOM	205	CG2	THR	A	29	16.594	27.875	20.841	1.00	9.32	C
20	ATOM	206	C	THR	A	29	17.630	28.628	23.555	1.00	10.10	C
	ATOM	207	O	THR	A	29	17.595	29.818	23.888	1.00	8.90	O
	ATOM	208	N	ALA	A	30	18.771	27.974	23.353	1.00	8.93	N
	ATOM	209	CA	ALA	A	30	20.069	28.630	23.511	1.00	8.72	C
	ATOM	210	CB	ALA	A	30	21.135	27.602	23.862	1.00	9.30	C
25	ATOM	211	C	ALA	A	30	20.476	29.388	22.252	1.00	8.30	C
	ATOM	212	O	ALA	A	30	20.243	28.925	21.133	1.00	11.59	O
	ATOM	213	N	GLY	A	31	21.097	30.547	22.448	1.00	10.82	N
	ATOM	214	CA	GLY	A	31	21.527	31.366	21.330	1.00	10.68	C
	ATOM	215	C	GLY	A	31	22.626	30.770	20.469	1.00	12.90	C
30	ATOM	216	O	GLY	A	31	22.656	31.014	19.259	1.00	12.57	O
	ATOM	217	N	HIS	A	32	23.529	29.991	21.065	1.00	9.76	N
	ATOM	218	CA	HIS	A	32	24.615	29.409	20.285	1.00	9.96	C
	ATOM	219	CB	HIS	A	32	25.747	28.891	21.194	1.00	11.85	C
	ATOM	220	CG	HIS	A	32	25.442	27.602	21.896	1.00	9.52	C
35	ATOM	221	CD2	HIS	A	32	25.495	26.319	21.464	1.00	11.42	C
	ATOM	222	ND1	HIS	A	32	25.093	27.545	23.226	1.00	12.01	N
	ATOM	223	CE1	HIS	A	32	24.945	26.281	23.588	1.00	12.23	C
	ATOM	224	NE2	HIS	A	32	25.185	25.518	22.538	1.00	12.81	N
	ATOM	225	C	HIS	A	32	24.138	28.301	19.355	1.00	8.20	C
40	ATOM	226	O	HIS	A	32	24.917	27.768	18.569	1.00	10.19	O
	ATOM	227	N	CYS	A	33	22.850	27.977	19.430	1.00	8.42	N
	ATOM	228	CA	CYS	A	33	22.270	26.933	18.589	1.00	9.80	C
	ATOM	229	CB	CYS	A	33	20.894	26.536	19.117	1.00	11.66	C
	ATOM	230	SG	CYS	A	33	20.964	25.864	20.798	1.00	13.22	S
45	ATOM	231	C	CYS	A	33	22.131	27.410	17.152	1.00	14.10	C
	ATOM	232	O	CYS	A	33	22.338	26.649	16.212	1.00	14.43	O
	ATOM	233	N	GLY	A	34	21.775	28.676	16.982	1.00	14.60	N
	ATOM	234	CA	GLY	A	34	21.622	29.202	15.643	1.00	13.42	C
	ATOM	235	C	GLY	A	34	21.365	30.690	15.632	1.00	13.64	C
50	ATOM	236	O	GLY	A	34	20.989	31.278	16.652	1.00	12.12	O
	ATOM	237	N	ARG	A	35	21.565	31.299	14.467	1.00	12.90	N
	ATOM	238	CA	ARG	A	35	21.360	32.728	14.301	1.00	15.08	C
	ATOM	239	CB	ARG	A	35	22.458	33.322	13.416	1.00	14.13	C
	ATOM	240	C	ARG	A	35	20.003	33.020	13.673	1.00	11.11	C
55	ATOM	241	O	ARG	A	35	19.367	32.144	13.084	1.00	14.43	O
	ATOM	242	CG	ARG	A	35	22.408	32.854	11.971	1.00	19.31	C
	ATOM	243	CD	ARG	A	35	23.430	33.597	11.123	1.00	21.41	C
	ATOM	244	NE	ARG	A	35	24.800	33.232	11.469	1.00	22.20	N
	ATOM	245	CZ	ARG	A	35	25.410	32.135	11.032	1.00	22.78	C
60	ATOM	246	NH1	ARG	A	35	26.658	31.875	11.400	1.00	21.47	N
	ATOM	247	NH2	ARG	A	35	24.779	31.305	10.215	1.00	23.65	N
	ATOM	248	N	THR	A	36	19.566	34.265	13.803	1.00	12.06	N
	ATOM	249	CA	THR	A	36	18.291	34.688	13.251	1.00	10.87	C
	ATOM	250	CB	THR	A	36	18.123	36.212	13.411	1.00	14.79	C
65	ATOM	251	C	THR	A	36	18.212	34.305	11.774	1.00	11.54	C
	ATOM	252	O	THR	A	36	19.195	34.414	11.043	1.00	10.69	O
	ATOM	253	OG1	THR	A	36	18.002	36.522	14.802	1.00	19.95	O
	ATOM	254	CG2	THR	A	36	16.889	36.705	12.679	1.00	17.55	C
	ATOM	255	N	GLY	A	37	17.047	33.839	11.339	1.00	11.25	N
70	ATOM	256	CA	GLY	A	37	16.896	33.446	9.950	1.00	10.63	C
	ATOM	257	C	GLY	A	37	17.140	31.965	9.705	1.00	16.44	C
	ATOM	258	O	GLY	A	37	16.711	31.421	8.688	1.00	13.24	O
	ATOM	259	N	ALA	A	38	17.837	31.306	10.624	1.00	16.27	N
	ATOM	260	CA	ALA	A	38	18.101	29.877	10.481	1.00	17.14	C
75	ATOM	261	C	ALA	A	38	16.781	29.118	10.602	1.00	15.01	C
	ATOM	262	O	ALA	A	38	15.943	29.447	11.442	1.00	14.04	O
	ATOM	263	CB	ALA	A	38	19.074	29.416	11.559	1.00	16.54	C
	ATOM	264	N	THR	A	39	16.588	28.107	9.764	1.00	15.44	N

- 224 -

	ATOM	265	CA	THR	A	39	15.355	27.329	9.811	1.00	16.44	C
	ATOM	266	CB	THR	A	39	14.867	26.956	8.397	1.00	16.50	C
	ATOM	267	OG1	THR	A	39	15.848	26.146	7.746	1.00	22.08	O
	ATOM	268	CG2	THR	A	39	14.615	28.209	7.578	1.00	17.88	C
5	ATOM	269	C	THR	A	39	15.522	26.052	10.622	1.00	14.04	C
	ATOM	270	O	THR	A	39	16.603	25.467	10.669	1.00	13.48	O
	ATOM	271	N	THR	A	40	14.437	25.626	11.256	1.00	14.41	N
	ATOM	272	CA	THR	A	40	14.445	24.421	12.072	1.00	12.76	C
	ATOM	273	CB	THR	A	40	14.081	24.735	13.536	1.00	13.70	C
10	ATOM	274	OG1	THR	A	40	12.745	25.260	13.601	1.00	11.68	O
	ATOM	275	CG2	THR	A	40	15.043	25.752	14.118	1.00	10.97	C
	ATOM	276	C	THR	A	40	13.437	23.399	11.566	1.00	12.70	C
	ATOM	277	O	THR	A	40	12.554	23.717	10.773	1.00	15.30	O
	ATOM	278	N	ALA	A	41	13.592	22.164	12.033	1.00	12.69	N
15	ATOM	279	CA	ALA	A	41	12.713	21.062	11.667	1.00	13.39	C
	ATOM	280	C	ALA	A	41	12.425	20.346	12.986	1.00	13.08	C
	ATOM	281	O	ALA	A	41	13.234	20.403	13.912	1.00	13.32	O
	ATOM	282	CB	ALA	A	41	13.403	20.121	10.682	1.00	12.91	C
	ATOM	283	N	ASN	A	42	11.280	19.680	13.075	1.00	13.98	N
20	ATOM	284	CA	ASN	A	42	10.909	18.966	14.296	1.00	15.22	C
	ATOM	285	C	ASN	A	42	11.074	19.886	15.507	1.00	15.41	C
	ATOM	286	O	ASN	A	42	11.835	19.580	16.426	1.00	14.69	O
	ATOM	287	CB	ASN	A	42	11.792	17.727	14.507	1.00	18.61	C
	ATOM	288	CG	ASN	A	42	11.862	16.826	13.282	1.00	22.16	C
25	ATOM	289	OD1	ASN	A	42	10.893	16.685	12.536	1.00	20.39	O
	ATOM	290	ND2	ASN	A	42	13.017	16.192	13.085	1.00	21.80	N
	ATOM	291	N	PRO	A	43	10.319	20.994	15.558	1.00	12.16	N
	ATOM	292	CA	PRO	A	43	9.329	21.449	14.579	1.00	13.99	C
	ATOM	293	CB	PRO	A	43	8.328	22.178	15.454	1.00	14.60	C
30	ATOM	294	C	PRO	A	43	9.863	22.387	13.508	1.00	14.85	C
	ATOM	295	O	PRO	A	43	10.949	22.950	13.633	1.00	12.84	O
	ATOM	296	CD	PRO	A	43	10.287	21.862	16.751	1.00	11.35	C
	ATOM	297	CG	PRO	A	43	9.259	22.940	16.356	1.00	12.54	C
	ATOM	298	N	THR	A	44	9.074	22.556	12.454	1.00	12.78	N
35	ATOM	299	CA	THR	A	44	9.454	23.436	11.370	1.00	13.48	C
	ATOM	300	CB	THR	A	44	8.441	23.349	10.217	1.00	15.07	C
	ATOM	301	C	THR	A	44	9.387	24.818	12.010	1.00	13.36	C
	ATOM	302	O	THR	A	44	8.430	25.127	12.721	1.00	12.32	O
	ATOM	303	OG1	THR	A	44	8.582	22.082	9.565	1.00	17.67	O
40	ATOM	304	CG2	THR	A	44	8.660	24.473	9.216	1.00	14.97	C
	ATOM	305	N	GLY	A	45	10.412	25.631	11.787	1.00	12.10	N
	ATOM	306	CA	GLY	A	45	10.423	26.958	12.369	1.00	13.77	C
	ATOM	307	C	GLY	A	45	11.557	27.824	11.865	1.00	12.84	C
	ATOM	308	O	GLY	A	45	12.340	27.412	11.006	1.00	14.31	O
45	ATOM	309	N	THR	A	46	11.648	29.033	12.404	1.00	12.18	N
	ATOM	310	CA	THR	A	46	12.686	29.970	12.001	1.00	15.03	C
	ATOM	311	CB	THR	A	46	12.141	30.953	10.952	1.00	15.90	C
	ATOM	312	OG1	THR	A	46	11.528	30.219	9.884	1.00	20.72	O
	ATOM	313	CG2	THR	A	46	13.257	31.821	10.392	1.00	18.41	C
50	ATOM	314	C	THR	A	46	13.167	30.777	13.203	1.00	13.19	C
	ATOM	315	O	THR	A	46	12.352	31.331	13.944	1.00	10.72	O
	ATOM	316	N	PHE	A	47	14.480	30.835	13.407	1.00	11.27	N
	ATOM	317	CA	PHE	A	47	15.009	31.596	14.527	1.00	10.95	C
	ATOM	318	CB	PHE	A	47	16.541	31.508	14.596	1.00	11.26	C
55	ATOM	319	CG	PHE	A	47	17.054	30.306	15.346	1.00	12.89	C
	ATOM	320	CD2	PHE	A	47	17.559	30.442	16.633	1.00	8.64	C
	ATOM	321	CD1	PHE	A	47	17.036	29.046	14.767	1.00	12.80	C
	ATOM	322	CE2	PHE	A	47	18.040	29.342	17.331	1.00	12.73	C
	ATOM	323	CE1	PHE	A	47	17.514	27.941	15.457	1.00	12.73	C
60	ATOM	324	CZ	PHE	A	47	18.017	28.088	16.740	1.00	14.16	C
	ATOM	325	C	PHE	A	47	14.590	33.041	14.291	1.00	12.22	C
	ATOM	326	O	PHE	A	47	14.737	33.563	13.182	1.00	13.19	O
	ATOM	327	N	ALA	A	48	14.058	33.673	15.330	1.00	11.62	N
	ATOM	328	CA	ALA	A	48	13.613	35.059	15.240	1.00	12.91	C
65	ATOM	329	CB	ALA	A	48	12.092	35.126	15.261	1.00	13.93	C
	ATOM	330	C	ALA	A	48	14.184	35.856	16.400	1.00	15.66	C
	ATOM	331	O	ALA	A	48	13.470	36.598	17.072	1.00	21.12	O
	ATOM	332	N	GLY	A	49	15.482	35.700	16.622	1.00	15.68	N
	ATOM	333	CA	GLY	A	49	16.139	36.407	17.701	1.00	16.25	C
70	ATOM	334	C	GLY	A	49	17.156	35.500	18.352	1.00	15.88	C
	ATOM	335	O	GLY	A	49	16.820	34.403	18.799	1.00	13.45	O
	ATOM	336	N	SER	A	50	18.404	35.947	18.405	1.00	13.85	N
	ATOM	337	CA	SER	A	50	19.454	35.144	19.012	1.00	13.96	C
	ATOM	338	CB	SER	A	50	20.014	34.156	17.984	1.00	17.08	C
75	ATOM	339	OG	SER	A	50	21.045	33.365	18.541	1.00	14.72	O
	ATOM	340	C	SER	A	50	20.574	36.026	19.543	1.00	16.90	C
	ATOM	341	O	SER	A	50	21.082	36.894	18.835	1.00	16.85	O
	ATOM	342	N	SER	A	51	20.941	35.802	20.801	1.00	15.23	N

- 225 -

	ATOM	343	CA	SER	A	51	22.003	36.561	21.447	1.00	14.67	
	ATOM	344	CB	SER	A	51	21.440	37.431	22.570	1.00	15.96	C
	ATOM	345	OG	SER	A	51	22.474	38.172	23.187	1.00	18.34	O
	ATOM	346	C	SER	A	51	23.062	35.622	22.017	1.00	11.74	C
5	ATOM	347	O	SER	A	51	22.809	34.888	22.969	1.00	12.45	O
	ATOM	348	N	PHE	A	52	24.247	35.655	21.419	1.00	8.44	N
	ATOM	349	CA	PHE	A	52	25.367	34.822	21.842	1.00	11.84	C
	ATOM	350	CB	PHE	A	52	25.090	33.344	21.557	1.00	9.85	C
	ATOM	351	CG	PHE	A	52	26.264	32.450	21.837	1.00	14.45	C
10	ATOM	352	CD1	PHE	A	52	26.561	32.056	23.133	1.00	14.77	C
	ATOM	353	CD2	PHE	A	52	27.095	32.037	20.808	1.00	14.93	C
	ATOM	354	CE1	PHE	A	52	27.665	31.267	23.400	1.00	12.39	C
	ATOM	355	CE2	PHE	A	52	28.203	31.250	21.067	1.00	13.03	C
	ATOM	356	CZ	PHE	A	52	28.489	30.864	22.364	1.00	15.39	C
15	ATOM	357	C	PHE	A	52	26.595	35.245	21.051	1.00	11.09	C
	ATOM	358	O	PHE	A	52	26.523	35.416	19.830	1.00	10.06	O
	ATOM	359	N	PRO	A	53	27.737	35.427	21.732	1.00	13.84	N
	ATOM	360	CD	PRO	A	53	29.034	35.610	21.055	1.00	13.82	C
	ATOM	361	CA	PRO	A	53	27.919	35.257	23.177	1.00	11.97	C
20	ATOM	362	CB	PRO	A	53	29.433	35.114	23.319	1.00	15.91	C
	ATOM	363	CG	PRO	A	53	29.953	35.957	22.201	1.00	16.14	C
	ATOM	364	C	PRO	A	53	27.345	36.429	23.972	1.00	13.65	C
	ATOM	365	O	PRO	A	53	26.411	37.085	23.516	1.00	12.98	O
	ATOM	366	N	GLY	A	54	27.909	36.706	25.144	1.00	13.22	N
25	ATOM	367	CA	GLY	A	54	27.385	37.778	25.975	1.00	13.41	C
	ATOM	368	C	GLY	A	54	26.291	37.112	26.781	1.00	13.11	C
	ATOM	369	O	GLY	A	54	26.403	36.931	27.995	1.00	12.76	O
	ATOM	370	N	ASN	A	55	25.223	36.740	26.083	1.00	13.05	N
	ATOM	371	CA	ASN	A	55	24.110	36.013	26.681	1.00	14.39	C
30	ATOM	372	CB	ASN	A	55	22.761	36.681	26.396	1.00	12.65	C
	ATOM	373	CG	ASN	A	55	22.758	38.153	26.682	1.00	11.23	C
	ATOM	374	OD1	ASN	A	55	22.521	38.967	25.784	1.00	16.09	O
	ATOM	375	ND2	ASN	A	55	23.001	38.516	27.933	1.00	11.47	N
	ATOM	376	C	ASN	A	55	24.141	34.721	25.888	1.00	15.51	C
35	ATOM	377	O	ASN	A	55	25.076	34.485	25.123	1.00	11.36	O
	ATOM	378	N	ASP	A	56	23.124	33.890	26.072	1.00	14.13	N
	ATOM	379	CA	ASP	A	56	23.039	32.631	25.346	1.00	11.90	C
	ATOM	380	CB	ASP	A	56	23.881	31.522	25.993	1.00	9.70	C
	ATOM	381	CG	ASP	A	56	24.053	30.320	25.070	1.00	9.97	C
40	ATOM	382	OD1	ASP	A	56	24.712	29.330	25.459	1.00	12.57	O
	ATOM	383	OD2	ASP	A	56	23.526	30.365	23.938	1.00	8.45	O
	ATOM	384	C	ASP	A	56	21.578	32.216	25.279	1.00	9.86	C
	ATOM	385	O	ASP	A	56	21.158	31.254	25.920	1.00	11.82	O
	ATOM	386	N	TYR	A	57	20.798	32.969	24.509	1.00	8.71	N
45	ATOM	387	CA	TYR	A	57	19.379	32.677	24.351	1.00	10.51	C
	ATOM	388	CB	TYR	A	57	18.523	33.480	25.348	1.00	12.30	C
	ATOM	389	CG	TYR	A	57	18.650	34.992	25.271	1.00	12.51	C
	ATOM	390	CD1	TYR	A	57	19.275	35.708	26.291	1.00	11.12	C
	ATOM	391	CE1	TYR	A	57	19.366	37.094	26.244	1.00	11.36	C
50	ATOM	392	CD2	TYR	A	57	18.121	35.706	24.197	1.00	13.29	C
	ATOM	393	CE2	TYR	A	57	18.209	37.096	24.144	1.00	10.62	C
	ATOM	394	CZ	TYR	A	57	18.832	37.783	25.169	1.00	13.60	C
	ATOM	395	OH	TYR	A	57	18.921	39.162	25.122	1.00	12.04	O
	ATOM	396	C	TYR	A	57	18.912	32.963	22.933	1.00	10.26	C
55	ATOM	397	O	TYR	A	57	19.573	33.674	22.172	1.00	10.59	O
	ATOM	398	N	ALA	A	58	17.767	32.393	22.578	1.00	9.32	N
	ATOM	399	CA	ALA	A	58	17.200	32.583	21.254	1.00	7.41	C
	ATOM	400	CB	ALA	A	58	17.943	31.732	20.241	1.00	7.89	C
	ATOM	401	C	ALA	A	58	15.727	32.207	21.271	1.00	10.96	C
60	ATOM	402	O	ALA	A	58	15.260	31.510	22.175	1.00	11.10	O
	ATOM	403	N	PHE	A	59	15.002	32.702	20.277	1.00	11.71	N
	ATOM	404	CA	PHE	A	59	13.578	32.435	20.136	1.00	12.26	C
	ATOM	405	CB	PHE	A	59	12.748	33.707	20.333	1.00	10.18	C
	ATOM	406	CG	PHE	A	59	11.321	33.576	19.859	1.00	11.71	C
65	ATOM	407	CD2	PHE	A	59	10.871	34.297	18.764	1.00	11.51	C
	ATOM	408	CD1	PHE	A	59	10.441	32.709	20.490	1.00	10.35	C
	ATOM	409	CE2	PHE	A	59	9.566	34.156	18.307	1.00	15.38	C
	ATOM	410	CE1	PHE	A	59	9.140	32.563	20.044	1.00	14.84	C
	ATOM	411	CZ	PHE	A	59	8.700	33.286	18.949	1.00	13.16	C
70	ATOM	412	C	PHE	A	59	13.361	31.931	18.722	1.00	11.77	C
	ATOM	413	O	PHE	A	59	13.887	32.507	17.771	1.00	13.80	O
	ATOM	414	N	VAL	A	60	12.600	30.852	18.590	1.00	10.53	N
	ATOM	415	CA	VAL	A	60	12.310	30.278	17.285	1.00	11.14	C
	ATOM	416	CB	VAL	A	60	12.738	28.796	17.209	1.00	15.19	C
75	ATOM	417	CG1	VAL	A	60	12.337	28.212	15.856	1.00	10.78	C
	ATOM	418	CG2	VAL	A	60	14.248	28.670	17.421	1.00	11.44	C
	ATOM	419	C	VAL	A	60	10.801	30.363	17.082	1.00	11.30	C
	ATOM	420	O	VAL	A	60	10.034	29.905	17.924	1.00	8.90	O

- 226 -

	ATOM	421	N	ARG	A	61	10.372	30.964	15.979	1.00	12.67	N
	ATOM	422	CA	ARG	A	61	8.944	31.083	15.716	1.00	11.18	C
	ATOM	423	CB	ARG	A	61	8.655	32.314	14.844	1.00	12.63	C
	ATOM	424	CG	ARG	A	61	7.194	32.398	14.379	1.00	17.12	C
5	ATOM	425	CD	ARG	A	61	6.967	33.527	13.376	1.00	20.85	C
	ATOM	426	NE	ARG	A	61	5.563	33.614	12.971	1.00	24.18	N
	ATOM	427	CZ	ARG	A	61	4.949	32.744	12.171	1.00	24.05	C
	ATOM	428	NH2	ARG	A	61	3.665	32.904	11.884	1.00	25.34	N
	ATOM	429	NH1	ARG	A	61	5.609	31.708	11.670	1.00	25.91	N
10	ATOM	430	C	ARG	A	61	8.424	29.831	15.011	1.00	12.67	C
	ATOM	431	O	ARG	A	61	9.070	29.316	14.096	1.00	11.46	O
	ATOM	432	N	THR	A	62	7.274	29.333	15.461	1.00	13.58	N
	ATOM	433	CA	THR	A	62	6.666	28.147	14.865	1.00	13.24	C
	ATOM	434	CB	THR	A	62	6.495	26.995	15.884	1.00	11.66	C
15	ATOM	435	OG1	THR	A	62	5.729	27.450	17.007	1.00	13.55	O
	ATOM	436	CG2	THR	A	62	7.853	26.485	16.349	1.00	13.26	C
	ATOM	437	C	THR	A	62	5.289	28.558	14.335	1.00	13.42	C
	ATOM	438	O	THR	A	62	4.727	29.568	14.770	1.00	16.80	O
	ATOM	439	N	GLY	A	63	4.748	27.778	13.406	1.00	16.51	N
20	ATOM	440	CA	GLY	A	63	3.455	28.108	12.834	1.00	15.85	C
	ATOM	441	C	GLY	A	63	2.387	27.033	12.894	1.00	16.64	C
	ATOM	442	O	GLY	A	63	2.137	26.432	13.938	1.00	12.21	O
	ATOM	443	N	ALA	A	64	1.753	26.788	11.753	1.00	15.51	N
	ATOM	444	CA	ALA	A	64	0.678	25.810	11.663	1.00	15.84	C
25	ATOM	445	C	ALA	A	64	1.090	24.378	11.977	1.00	15.00	C
	ATOM	446	O	ALA	A	64	2.228	23.977	11.742	1.00	15.60	O
	ATOM	447	CB	ALA	A	64	0.052	25.866	10.279	1.00	16.27	C
	ATOM	448	N	GLY	A	65	0.144	23.614	12.510	1.00	17.17	N
	ATOM	449	CA	GLY	A	65	0.390	22.217	12.828	1.00	19.41	C
30	ATOM	450	C	GLY	A	65	1.369	21.946	13.953	1.00	19.21	C
	ATOM	451	O	GLY	A	65	1.691	20.790	14.234	1.00	22.10	O
	ATOM	452	N	VAL	A	66	1.842	23.001	14.603	1.00	15.20	N
	ATOM	453	CA	VAL	A	66	2.788	22.844	15.697	1.00	15.99	C
	ATOM	454	CB	VAL	A	66	4.018	23.746	15.501	1.00	15.02	C
35	ATOM	455	C	VAL	A	66	2.116	23.195	17.016	1.00	18.46	C
	ATOM	456	O	VAL	A	66	1.769	24.349	17.257	1.00	16.96	O
	ATOM	457	CG1	VAL	A	66	4.961	23.602	16.688	1.00	13.36	C
	ATOM	458	CG2	VAL	A	66	4.725	23.375	14.195	1.00	11.46	C
	ATOM	459	N	ASN	A	67	1.931	22.193	17.866	1.00	15.34	N
40	ATOM	460	CA	ASN	A	67	1.294	22.407	19.158	1.00	16.12	C
	ATOM	461	CB	ASN	A	67	0.474	21.177	19.539	1.00	21.01	C
	ATOM	462	C	ASN	A	67	2.332	22.704	20.228	1.00	17.24	C
	ATOM	463	O	ASN	A	67	3.172	21.862	20.554	1.00	17.97	O
	ATOM	464	CG	ASN	A	67	-0.465	20.748	18.431	1.00	29.21	C
45	ATOM	465	OD1	ASN	A	67	-1.308	21.527	17.976	1.00	33.32	O
	ATOM	466	ND2	ASN	A	67	-0.323	19.505	17.982	1.00	33.03	N
	ATOM	467	N	LEU	A	68	2.260	23.915	20.767	1.00	13.94	N
	ATOM	468	CA	LEU	A	68	3.175	24.378	21.807	1.00	14.43	C
	ATOM	469	CB	LEU	A	68	3.317	25.896	21.707	1.00	13.70	C
50	ATOM	470	C	LEU	A	68	2.638	23.985	23.178	1.00	15.01	C
	ATOM	471	O	LEU	A	68	1.670	24.568	23.664	1.00	16.08	O
	ATOM	472	CG	LEU	A	68	3.835	26.395	20.358	1.00	8.95	C
	ATOM	473	CD1	LEU	A	68	3.736	27.910	20.284	1.00	8.47	C
	ATOM	474	CD2	LEU	A	68	5.270	25.931	20.179	1.00	12.27	C
55	ATOM	475	N	LEU	A	69	3.284	23.005	23.805	1.00	12.99	N
	ATOM	476	CA	LEU	A	69	2.861	22.529	25.119	1.00	12.18	C
	ATOM	477	CB	LEU	A	69	2.888	20.997	25.134	1.00	12.27	C
	ATOM	478	CG	LEU	A	69	2.075	20.310	24.029	1.00	16.54	C
	ATOM	479	CD1	LEU	A	69	2.251	18.802	24.113	1.00	17.85	C
60	ATOM	480	CD2	LEU	A	69	0.611	20.679	24.170	1.00	19.65	C
	ATOM	481	C	LEU	A	69	3.665	23.050	26.307	1.00	14.39	C
	ATOM	482	O	LEU	A	69	4.879	23.239	26.228	1.00	14.53	O
	ATOM	483	N	ALA	A	70	2.969	23.271	27.416	1.00	12.89	N
	ATOM	484	CA	ALA	A	70	3.594	23.761	28.635	1.00	14.83	C
65	ATOM	485	CB	ALA	A	70	2.585	24.547	29.457	1.00	18.71	C
	ATOM	486	C	ALA	A	70	4.042	22.519	29.391	1.00	12.67	C
	ATOM	487	O	ALA	A	70	3.638	22.293	30.523	1.00	11.15	O
	ATOM	488	N	GLN	A	71	4.876	21.711	28.742	1.00	13.59	N
	ATOM	489	CA	GLN	A	71	5.382	20.483	29.334	1.00	14.04	C
70	ATOM	490	CB	GLN	A	71	4.591	19.282	28.809	1.00	14.08	C
	ATOM	491	CG	GLN	A	71	3.114	19.283	29.157	1.00	17.65	C
	ATOM	492	CD	GLN	A	71	2.378	18.099	28.560	1.00	19.50	C
	ATOM	493	OE1	GLN	A	71	1.421	17.592	29.143	1.00	24.87	O
	ATOM	494	NE2	GLN	A	71	2.815	17.658	27.386	1.00	17.48	N
75	ATOM	495	C	GLN	A	71	6.849	20.255	29.011	1.00	16.23	C
	ATOM	496	O	GLN	A	71	7.375	20.786	28.035	1.00	15.48	O
	ATOM	497	N	VAL	A	72	7.501	19.451	29.840	1.00	13.56	N
	ATOM	498	CA	VAL	A	72	8.907	19.133	29.648	1.00	12.57	C

- 227 -

	ATOM	499	CB	VAL	A	72	9.792	19.754	30.748	1.00	10.81	
	ATOM	500	CG1	VAL	A	72	11.193	19.162	30.677	1.00	12.46	C
	ATOM	501	CG2	VAL	A	72	9.862	21.271	30.563	1.00	10.56	C
	ATOM	502	C	VAL	A	72	9.007	17.610	29.695	1.00	10.65	C
5	ATOM	503	O	VAL	A	72	8.415	16.968	30.565	1.00	11.44	O
	ATOM	504	N	ASN	A	73	9.736	17.036	28.746	1.00	11.79	N
	ATOM	505	CA	ASN	A	73	9.913	15.586	28.673	1.00	10.87	C
	ATOM	506	CB	ASN	A	73	10.633	15.229	27.369	1.00	12.22	C
	ATOM	507	CG	ASN	A	73	10.598	13.743	27.065	1.00	12.04	C
10	ATOM	508	OD1	ASN	A	73	10.411	12.916	27.959	1.00	11.92	O
	ATOM	509	ND2	ASN	A	73	10.790	13.397	25.798	1.00	10.15	N
	ATOM	510	C	ASN	A	73	10.751	15.098	29.863	1.00	11.93	C
	ATOM	511	O	ASN	A	73	11.854	15.597	30.092	1.00	11.67	O
	ATOM	512	N	ASN	A	74	10.239	14.137	30.631	1.00	12.17	N
15	ATOM	513	CA	ASN	A	74	11.010	13.640	31.766	1.00	9.29	C
	ATOM	514	CB	ASN	A	74	10.109	13.275	32.958	1.00	13.70	C
	ATOM	515	CG	ASN	A	74	9.162	12.126	32.662	1.00	16.27	C
	ATOM	516	OD1	ASN	A	74	9.432	11.274	31.815	1.00	14.62	O
	ATOM	517	ND2	ASN	A	74	8.048	12.088	33.384	1.00	18.77	N
20	ATOM	518	C	ASN	A	74	11.853	12.435	31.359	1.00	11.15	C
	ATOM	519	O	ASN	A	74	12.528	11.823	32.189	1.00	10.62	O
	ATOM	520	N	TYR	A	75	11.813	12.115	30.069	1.00	13.30	N
	ATOM	521	CA	TYR	A	75	12.556	10.998	29.495	1.00	13.21	C
	ATOM	522	CB	TYR	A	75	14.039	11.363	29.386	1.00	10.04	C
25	ATOM	523	CG	TYR	A	75	14.313	12.223	28.170	1.00	11.82	C
	ATOM	524	CD1	TYR	A	75	14.424	11.652	26.907	1.00	10.82	C
	ATOM	525	CE1	TYR	A	75	14.591	12.435	25.775	1.00	12.83	C
	ATOM	526	CD2	TYR	A	75	14.381	13.608	28.271	1.00	10.15	C
	ATOM	527	CE2	TYR	A	75	14.545	14.402	27.142	1.00	10.33	C
30	ATOM	528	CZ	TYR	A	75	14.648	13.805	25.898	1.00	9.45	C
	ATOM	529	OH	TYR	A	75	14.793	14.579	24.770	1.00	10.77	O
	ATOM	530	C	TYR	A	75	12.380	9.652	30.188	1.00	16.68	C
	ATOM	531	O	TYR	A	75	13.298	8.835	30.228	1.00	18.39	O
	ATOM	532	N	SER	A	76	11.185	9.433	30.723	1.00	18.33	N
35	ATOM	533	CA	SER	A	76	10.846	8.193	31.411	1.00	20.49	C
	ATOM	534	CB	SER	A	76	10.811	8.390	32.926	1.00	21.53	C
	ATOM	535	OG	SER	A	76	12.121	8.424	33.457	1.00	25.72	O
	ATOM	536	C	SER	A	76	9.470	7.775	30.919	1.00	21.06	C
	ATOM	537	O	SER	A	76	8.843	6.868	31.473	1.00	20.62	O
40	ATOM	538	N	GLY	A	77	9.013	8.452	29.870	1.00	17.80	N
	ATOM	539	CA	GLY	A	77	7.715	8.156	29.295	1.00	18.95	C
	ATOM	540	C	GLY	A	77	6.649	9.128	29.752	1.00	17.33	C
	ATOM	541	O	GLY	A	77	5.464	8.942	29.470	1.00	16.27	O
	ATOM	542	N	GLY	A	78	7.059	10.173	30.462	1.00	15.79	N
45	ATOM	543	CA	GLY	A	78	6.088	11.142	30.939	1.00	16.07	C
	ATOM	544	C	GLY	A	78	6.499	12.585	30.734	1.00	17.80	C
	ATOM	545	O	GLY	A	78	7.481	12.876	30.041	1.00	15.22	O
	ATOM	546	N	ARG	A	79	5.742	13.492	31.342	1.00	17.07	N
	ATOM	547	CA	ARG	A	79	6.025	14.914	31.226	1.00	19.85	C
50	ATOM	548	CB	ARG	A	79	5.199	15.528	30.090	1.00	23.00	C
	ATOM	549	CG	ARG	A	79	5.711	15.176	28.701	1.00	29.54	C
	ATOM	550	CD	ARG	A	79	4.683	14.404	27.910	1.00	35.50	C
	ATOM	551	NE	ARG	A	79	5.207	13.941	26.626	1.00	39.02	N
	ATOM	552	CZ	ARG	A	79	6.223	13.094	26.493	1.00	41.51	C
55	ATOM	553	NH1	ARG	A	79	6.838	12.611	27.566	1.00	38.71	N
	ATOM	554	NH2	ARG	A	79	6.620	12.716	25.285	1.00	43.02	N
	ATOM	555	C	ARG	A	79	5.784	15.695	32.510	1.00	18.62	C
	ATOM	556	O	ARG	A	79	4.968	15.313	33.353	1.00	16.21	O
	ATOM	557	N	VAL	A	80	6.517	16.793	32.646	1.00	15.48	N
60	ATOM	558	CA	VAL	A	80	6.412	17.660	33.810	1.00	14.56	C
	ATOM	559	CB	VAL	A	80	7.806	18.040	34.349	1.00	14.30	C
	ATOM	560	CG1	VAL	A	80	7.666	18.967	35.542	1.00	16.79	C
	ATOM	561	CG2	VAL	A	80	8.580	16.787	34.729	1.00	18.13	C
	ATOM	562	C	VAL	A	80	5.690	18.930	33.375	1.00	15.88	C
65	ATOM	563	O	VAL	A	80	6.106	19.588	32.421	1.00	14.01	O
	ATOM	564	N	GLN	A	81	4.602	19.270	34.057	1.00	15.03	N
	ATOM	565	CA	GLN	A	81	3.863	20.472	33.698	1.00	18.02	C
	ATOM	566	CB	GLN	A	81	2.503	20.512	34.403	1.00	21.88	C
	ATOM	567	CG	GLN	A	81	1.422	19.659	33.760	1.00	29.23	C
70	ATOM	568	CD	GLN	A	81	1.161	20.030	32.311	1.00	29.08	C
	ATOM	569	OE1	GLN	A	81	0.928	21.194	31.984	1.00	31.12	O
	ATOM	570	NE2	GLN	A	81	1.192	19.034	31.434	1.00	32.61	N
	ATOM	571	C	GLN	A	81	4.654	21.722	34.067	1.00	17.67	C
	ATOM	572	O	GLN	A	81	5.278	21.786	35.128	1.00	18.79	O
75	ATOM	573	N	VAL	A	82	4.636	22.709	33.179	1.00	15.10	N
	ATOM	574	CA	VAL	A	82	5.345	23.960	33.411	1.00	17.88	C
	ATOM	575	CB	VAL	A	82	5.973	24.494	32.107	1.00	16.36	C
	ATOM	576	CG1	VAL	A	82	6.710	25.792	32.374	1.00	19.17	C

- 228 -

	ATOM	577	CG2	VAL	A	82	6.927	23.454	31.534	1.00	15.85	C
	ATOM	578	C	VAL	A	82	4.309	24.952	33.930	1.00	18.78	C
	ATOM	579	O	VAL	A	82	3.512	25.494	33.163	1.00	19.15	O
	ATOM	580	N	ALA	A	83	4.321	25.175	35.240	1.00	20.30	N
5	ATOM	581	CA	ALA	A	83	3.382	26.091	35.879	1.00	20.84	C
	ATOM	582	CB	ALA	A	83	3.230	25.725	37.348	1.00	20.26	C
	ATOM	583	C	ALA	A	83	3.734	27.568	35.751	1.00	20.34	C
	ATOM	584	O	ALA	A	83	2.849	28.405	35.594	1.00	21.44	O
	ATOM	585	N	GLY	A	84	5.021	27.886	35.826	1.00	18.33	N
10	ATOM	586	CA	GLY	A	84	5.445	29.267	35.721	1.00	15.96	C
	ATOM	587	C	GLY	A	84	6.946	29.381	35.558	1.00	18.35	C
	ATOM	588	O	GLY	A	84	7.599	28.433	35.117	1.00	16.24	O
	ATOM	589	N	HIS	A	85	7.495	30.534	35.924	1.00	16.53	N
	ATOM	590	CA	HIS	A	85	8.931	30.767	35.798	1.00	14.08	C
15	ATOM	591	CB	HIS	A	85	9.219	31.528	34.498	1.00	14.33	C
	ATOM	592	C	HIS	A	85	9.534	31.510	36.988	1.00	14.07	C
	ATOM	593	O	HIS	A	85	10.349	32.413	36.818	1.00	15.60	O
	ATOM	594	CG	HIS	A	85	8.399	32.770	34.323	1.00	18.31	C
	ATOM	595	ND1	HIS	A	85	8.937	34.035	34.404	1.00	21.61	N
20	ATOM	596	CD2	HIS	A	85	7.079	32.936	34.064	1.00	19.95	C
	ATOM	597	NE2	HIS	A	85	6.848	34.289	33.994	1.00	18.84	N
	ATOM	598	CE1	HIS	A	85	7.983	34.929	34.202	1.00	22.08	C
	ATOM	599	N	THR	A	86	9.128	31.124	38.193	1.00	14.33	N
	ATOM	600	CA	THR	A	86	9.640	31.758	39.405	1.00	13.94	C
25	ATOM	601	CB	THR	A	86	8.754	31.449	40.612	1.00	15.26	C
	ATOM	602	C	THR	A	86	11.044	31.243	39.690	1.00	14.65	C
	ATOM	603	O	THR	A	86	11.249	30.042	39.855	1.00	11.10	O
	ATOM	604	OG1	THR	A	86	7.424	31.904	40.347	1.00	16.89	O
	ATOM	605	CG2	THR	A	86	9.289	32.147	41.854	1.00	16.68	C
30	ATOM	606	N	ALA	A	87	12.005	32.157	39.756	1.00	15.86	N
	ATOM	607	CA	ALA	A	87	13.396	31.801	40.016	1.00	17.16	C
	ATOM	608	C	ALA	A	87	13.633	31.152	41.375	1.00	19.39	C
	ATOM	609	O	ALA	A	87	13.113	31.608	42.395	1.00	18.84	O
	ATOM	610	CB	ALA	A	87	14.272	33.034	39.877	1.00	17.44	C
35	ATOM	611	N	ALA	A	88	14.431	30.088	41.373	1.00	16.82	N
	ATOM	612	CA	ALA	A	88	14.766	29.352	42.584	1.00	14.95	C
	ATOM	613	C	ALA	A	88	16.112	29.832	43.119	1.00	15.66	C
	ATOM	614	O	ALA	A	88	17.004	30.204	42.355	1.00	15.62	O
	ATOM	615	CB	ALA	A	88	14.827	27.861	42.291	1.00	10.05	C
40	ATOM	616	N	PRO	A	89	16.275	29.822	44.447	1.00	15.05	N
	ATOM	617	CA	PRO	A	89	17.510	30.259	45.100	1.00	16.15	C
	ATOM	618	CB	PRO	A	89	17.060	30.498	46.535	1.00	16.59	C
	ATOM	619	C	PRO	A	89	18.661	29.260	45.022	1.00	17.33	C
	ATOM	620	O	PRO	A	89	18.461	28.076	44.741	1.00	14.79	O
45	ATOM	621	CD	PRO	A	89	15.236	29.522	45.448	1.00	17.98	C
	ATOM	622	CG	PRO	A	89	16.040	29.425	46.728	1.00	15.94	C
	ATOM	623	N	VAL	A	90	19.873	29.751	45.257	1.00	18.24	N
	ATOM	624	CA	VAL	A	90	21.046	28.894	45.221	1.00	17.32	C
	ATOM	625	CB	VAL	A	90	22.312	29.658	45.672	1.00	16.39	C
50	ATOM	626	CG1	VAL	A	90	23.449	28.678	45.932	1.00	19.70	C
	ATOM	627	CG2	VAL	A	90	22.711	30.665	44.609	1.00	18.18	C
	ATOM	628	C	VAL	A	90	20.764	27.770	46.211	1.00	17.15	C
	ATOM	629	O	VAL	A	90	20.153	28.005	47.254	1.00	17.16	O
	ATOM	630	N	GLY	A	91	21.192	26.556	45.878	1.00	13.56	N
55	ATOM	631	CA	GLY	A	91	20.971	25.420	46.755	1.00	13.61	C
	ATOM	632	C	GLY	A	91	19.787	24.583	46.314	1.00	14.54	C
	ATOM	633	O	GLY	A	91	19.652	23.422	46.695	1.00	13.48	O
	ATOM	634	N	SER	A	92	18.928	25.175	45.497	1.00	12.12	N
	ATOM	635	CA	SER	A	92	17.741	24.486	45.014	1.00	13.41	C
60	ATOM	636	CB	SER	A	92	16.846	25.457	44.239	1.00	10.87	C
	ATOM	637	OG	SER	A	92	16.334	26.463	45.090	1.00	12.36	O
	ATOM	638	C	SER	A	92	18.040	23.284	44.134	1.00	13.34	C
	ATOM	639	O	SER	A	92	19.015	23.268	43.383	1.00	9.90	O
	ATOM	640	N	ALA	A	93	17.189	22.274	44.252	1.00	11.16	N
65	ATOM	641	CA	ALA	A	93	17.324	21.057	43.475	1.00	14.34	C
	ATOM	642	CB	ALA	A	93	16.554	19.925	44.136	1.00	14.73	C
	ATOM	643	C	ALA	A	93	16.713	21.389	42.119	1.00	14.46	C
	ATOM	644	O	ALA	A	93	15.605	21.920	42.047	1.00	13.83	O
	ATOM	645	N	VAL	A	94	17.440	21.092	41.048	1.00	14.27	N
70	ATOM	646	CA	VAL	A	94	16.946	21.370	39.707	1.00	9.84	C
	ATOM	647	CB	VAL	A	94	17.617	22.629	39.113	1.00	11.32	C
	ATOM	648	CG1	VAL	A	94	17.204	23.859	39.904	1.00	9.34	C
	ATOM	649	CG2	VAL	A	94	19.140	22.467	39.126	1.00	10.97	C
	ATOM	650	C	VAL	A	94	17.216	20.209	38.763	1.00	9.69	C
75	ATOM	651	O	VAL	A	94	18.139	19.421	38.976	1.00	10.59	O
	ATOM	652	N	CYS	A	95	16.398	20.094	37.727	1.00	10.10	N
	ATOM	653	CA	CYS	A	95	16.573	19.027	36.752	1.00	9.94	C
	ATOM	654	CB	CYS	A	95	15.468	17.983	36.845	1.00	11.63	C

- 229 -

	ATOM	655	SG	CYS	A	95	15.412	17.059	38.410	1.00	13.27	S
	ATOM	656	C	CYS	A	95	16.566	19.624	35.359	1.00	10.91	C
	ATOM	657	O	CYS	A	95	15.808	20.551	35.061	1.00	11.33	O
	ATOM	658	N	ARG	A	96	17.424	19.070	34.515	1.00	9.30	N
5	ATOM	659	CA	ARG	A	96	17.570	19.496	33.135	1.00	7.08	C
	ATOM	660	CB	ARG	A	96	19.050	19.767	32.827	1.00	9.79	C
	ATOM	661	CG	ARG	A	96	19.326	20.069	31.353	1.00	10.80	C
	ATOM	662	CD	ARG	A	96	20.808	19.966	31.011	1.00	10.58	C
	ATOM	663	NE	ARG	A	96	21.355	18.643	31.312	1.00	11.86	N
10	ATOM	664	CZ	ARG	A	96	20.957	17.506	30.747	1.00	10.78	C
	ATOM	665	NH1	ARG	A	96	19.995	17.500	29.831	1.00	10.18	N
	ATOM	666	NH2	ARG	A	96	21.529	16.365	31.103	1.00	12.39	N
	ATOM	667	C	ARG	A	96	17.068	18.397	32.211	1.00	9.14	C
	ATOM	668	O	ARG	A	96	17.237	17.214	32.499	1.00	10.81	O
15	ATOM	669	N	SER	A	97	16.442	18.792	31.104	1.00	8.35	N
	ATOM	670	CA	SER	A	97	15.925	17.841	30.134	1.00	8.67	C
	ATOM	671	CB	SER	A	97	14.406	17.976	29.984	1.00	10.18	C
	ATOM	672	OG	SER	A	97	13.893	16.991	29.094	1.00	10.36	O
	ATOM	673	C	SER	A	97	16.607	18.169	28.810	1.00	9.06	C
20	ATOM	674	O	SER	A	97	16.564	19.313	28.353	1.00	10.38	O
	ATOM	675	N	GLY	A	98	17.243	17.168	28.209	1.00	9.45	N
	ATOM	676	CA	GLY	A	98	17.939	17.365	26.947	1.00	8.70	C
	ATOM	677	C	GLY	A	98	17.853	16.131	26.070	1.00	11.12	C
	ATOM	678	O	GLY	A	98	17.689	15.021	26.569	1.00	9.32	O
25	ATOM	679	N	SER	A	99	17.993	16.320	24.762	1.00	13.12	N
	ATOM	680	CA	SER	A	99	17.884	15.222	23.805	1.00	13.49	C
	ATOM	681	CB	SER	A	99	17.628	15.784	22.414	1.00	16.87	C
	ATOM	682	OG	SER	A	99	18.805	16.381	21.906	1.00	16.57	O
	ATOM	683	C	SER	A	99	19.073	14.272	23.709	1.00	13.85	C
30	ATOM	684	O	SER	A	99	18.972	13.230	23.060	1.00	10.18	O
	ATOM	685	N	THR	A	100	20.195	14.617	24.331	1.00	9.80	N
	ATOM	686	CA	THR	A	100	21.365	13.749	24.266	1.00	12.00	C
	ATOM	687	CB	THR	A	100	22.645	14.572	24.075	1.00	13.43	C
	ATOM	688	OG1	THR	A	100	22.564	15.297	22.844	1.00	15.69	O
35	ATOM	689	CG2	THR	A	100	23.860	13.667	24.044	1.00	13.71	C
	ATOM	690	C	THR	A	100	21.547	12.845	25.477	1.00	13.37	C
	ATOM	691	O	THR	A	100	21.888	11.667	25.332	1.00	9.57	O
	ATOM	692	N	THR	A	101	21.319	13.389	26.668	1.00	11.47	N
	ATOM	693	CA	THR	A	101	21.468	12.613	27.893	1.00	10.42	C
40	ATOM	694	CB	THR	A	101	22.469	13.277	28.851	1.00	12.08	C
	ATOM	695	OG1	THR	A	101	22.031	14.607	29.151	1.00	10.91	O
	ATOM	696	CG2	THR	A	101	23.847	13.334	28.216	1.00	11.99	C
	ATOM	697	C	THR	A	101	20.153	12.410	28.633	1.00	13.44	C
	ATOM	698	O	THR	A	101	20.078	11.617	29.566	1.00	12.54	O
45	ATOM	699	N	GLY	A	102	19.119	13.128	28.217	1.00	10.42	N
	ATOM	700	CA	GLY	A	102	17.829	12.979	28.860	1.00	9.53	C
	ATOM	701	C	GLY	A	102	17.578	13.835	30.087	1.00	10.82	C
	ATOM	702	O	GLY	A	102	17.846	15.041	30.096	1.00	8.61	O
	ATOM	703	N	TRP	A	103	17.067	13.190	31.132	1.00	9.62	N
50	ATOM	704	CA	TRP	A	103	16.716	13.845	32.383	1.00	11.61	C
	ATOM	705	CB	TRP	A	103	15.370	13.289	32.865	1.00	11.52	C
	ATOM	706	CG	TRP	A	103	14.837	13.868	34.145	1.00	13.15	C
	ATOM	707	CD2	TRP	A	103	13.964	14.998	34.282	1.00	12.58	C
	ATOM	708	CE2	TRP	A	103	13.680	15.147	35.655	1.00	15.29	C
55	ATOM	709	CE3	TRP	A	103	13.387	15.896	33.375	1.00	11.72	C
	ATOM	710	CD1	TRP	A	103	15.050	13.397	35.404	1.00	16.94	C
	ATOM	711	NE1	TRP	A	103	14.357	14.156	36.320	1.00	16.85	N
	ATOM	712	CZ2	TRP	A	103	12.852	16.155	36.147	1.00	11.23	C
	ATOM	713	CZ3	TRP	A	103	12.561	16.900	33.865	1.00	12.19	C
60	ATOM	714	CH2	TRP	A	103	12.303	17.019	35.240	1.00	13.20	C
	ATOM	715	C	TRP	A	103	17.790	13.659	33.448	1.00	12.90	C
	ATOM	716	O	TRP	A	103	18.082	12.539	33.872	1.00	9.69	O
	ATOM	717	N	HIS	A	104	18.386	14.768	33.872	1.00	10.38	N
	ATOM	718	CA	HIS	A	104	19.434	14.724	34.890	1.00	12.11	C
65	ATOM	719	CB	HIS	A	104	20.806	14.734	34.226	1.00	12.14	C
	ATOM	720	CG	HIS	A	104	21.106	13.474	33.477	1.00	12.45	C
	ATOM	721	CD2	HIS	A	104	20.822	13.110	32.204	1.00	14.29	C
	ATOM	722	ND1	HIS	A	104	21.684	12.375	34.072	1.00	13.64	N
	ATOM	723	CE1	HIS	A	104	21.740	11.384	33.197	1.00	14.53	C
70	ATOM	724	NE2	HIS	A	104	21.222	11.804	32.058	1.00	12.11	N
	ATOM	725	C	HIS	A	104	19.283	15.898	35.839	1.00	12.75	C
	ATOM	726	O	HIS	A	104	18.959	17.014	35.426	1.00	10.16	O
	ATOM	727	N	CYS	A	105	19.545	15.650	37.114	1.00	10.52	N
	ATOM	728	CA	CYS	A	105	19.408	16.703	38.102	1.00	13.24	C
75	ATOM	729	CB	CYS	A	105	18.278	16.318	39.049	1.00	13.49	C
	ATOM	730	SG	CYS	A	105	16.817	15.612	38.216	1.00	14.12	S
	ATOM	731	C	CYS	A	105	20.657	17.057	38.896	1.00	13.65	C
	ATOM	732	O	CYS	A	105	21.720	16.465	38.720	1.00	13.71	O

- 230 -

	ATOM	733	N	GLY	A	106	20.511	18.042	39.770	1.00	11.96	N
	ATOM	734	CA	GLY	A	106	21.619	18.499	40.583	1.00	8.39	C
	ATOM	735	C	GLY	A	106	21.112	19.662	41.404	1.00	8.29	C
	ATOM	736	O	GLY	A	106	19.919	19.720	41.723	1.00	9.88	O
5	ATOM	737	N	THR	A	107	21.997	20.587	41.748	1.00	10.00	N
	ATOM	738	CA	THR	A	107	21.593	21.749	42.529	1.00	10.90	C
	ATOM	739	CB	THR	A	107	21.979	21.607	44.021	1.00	15.03	C
	ATOM	740	OG1	THR	A	107	23.401	21.490	44.138	1.00	19.34	O
	ATOM	741	CG2	THR	A	107	21.324	20.379	44.630	1.00	19.07	C
10	ATOM	742	C	THR	A	107	22.230	23.021	42.003	1.00	11.41	C
	ATOM	743	O	THR	A	107	23.274	22.986	41.349	1.00	10.42	O
	ATOM	744	N	ILE	A	108	21.590	24.150	42.282	1.00	9.46	N
	ATOM	745	CA	ILE	A	108	22.116	25.430	41.835	1.00	8.75	C
	ATOM	746	CB	ILE	A	108	21.050	26.533	41.895	1.00	10.61	C
15	ATOM	747	CG2	ILE	A	108	21.696	27.892	41.613	1.00	8.96	C
	ATOM	748	CG1	ILE	A	108	19.926	26.214	40.905	1.00	11.64	C
	ATOM	749	CD1	ILE	A	108	18.797	27.223	40.898	1.00	10.98	C
	ATOM	750	C	ILE	A	108	23.240	25.788	42.798	1.00	12.89	C
	ATOM	751	O	ILE	A	108	23.030	25.842	44.010	1.00	12.63	O
20	ATOM	752	N	THR	A	109	24.432	26.026	42.263	1.00	12.30	N
	ATOM	753	CA	THR	A	109	25.570	26.372	43.109	1.00	12.21	C
	ATOM	754	CB	THR	A	109	26.814	25.557	42.714	1.00	16.03	C
	ATOM	755	OG1	THR	A	109	27.027	25.662	41.304	1.00	16.72	O
	ATOM	756	CG2	THR	A	109	26.623	24.097	43.079	1.00	19.29	C
25	ATOM	757	C	THR	A	109	25.916	27.855	43.094	1.00	14.26	C
	ATOM	758	O	THR	A	109	26.590	28.353	43.994	1.00	15.02	O
	ATOM	759	N	ALA	A	110	25.440	28.563	42.078	1.00	13.73	N
	ATOM	760	CA	ALA	A	110	25.708	29.985	41.967	1.00	14.67	C
	ATOM	761	CB	ALA	A	110	27.186	30.215	41.668	1.00	15.41	C
30	ATOM	762	C	ALA	A	110	24.853	30.611	40.879	1.00	12.70	C
	ATOM	763	O	ALA	A	110	24.367	29.924	39.982	1.00	13.13	O
	ATOM	764	N	LEU	A	111	24.664	31.921	40.982	1.00	13.52	N
	ATOM	765	CA	LEU	A	111	23.876	32.680	40.019	1.00	11.96	C
	ATOM	766	CB	LEU	A	111	22.639	33.286	40.689	1.00	15.77	C
35	ATOM	767	CG	LEU	A	111	21.638	32.338	41.357	1.00	19.65	C
	ATOM	768	CD1	LEU	A	111	20.593	33.151	42.113	1.00	17.73	C
	ATOM	769	CD2	LEU	A	111	20.970	31.462	40.313	1.00	14.60	C
	ATOM	770	C	LEU	A	111	24.775	33.798	39.501	1.00	15.77	C
	ATOM	771	O	LEU	A	111	25.753	34.169	40.151	1.00	15.15	O
40	ATOM	772	N	ASN	A	112	24.443	34.330	38.332	1.00	12.74	N
	ATOM	773	CA	ASN	A	112	25.219	35.409	37.729	1.00	17.38	C
	ATOM	774	CB	ASN	A	112	25.168	36.663	38.605	1.00	24.14	C
	ATOM	775	CG	ASN	A	112	23.756	37.053	38.980	1.00	26.37	C
	ATOM	776	OD1	ASN	A	112	23.279	36.726	40.067	1.00	33.64	O
45	ATOM	777	ND2	ASN	A	112	23.072	37.744	38.076	1.00	34.88	N
	ATOM	778	C	ASN	A	112	26.672	35.023	37.495	1.00	16.99	C
	ATOM	779	O	ASN	A	112	27.572	35.850	37.643	1.00	14.78	O
	ATOM	780	N	SER	A	113	26.896	33.766	37.131	1.00	16.31	N
	ATOM	781	CA	SER	A	113	28.245	33.280	36.872	1.00	19.39	C
50	ATOM	782	CB	SER	A	113	28.315	31.757	37.020	1.00	18.03	C
	ATOM	783	OG	SER	A	113	28.262	31.349	38.374	1.00	21.23	O
	ATOM	784	C	SER	A	113	28.637	33.650	35.450	1.00	19.59	C
	ATOM	785	O	SER	A	113	27.780	33.946	34.620	1.00	20.53	O
	ATOM	786	N	SER	A	114	29.938	33.634	35.180	1.00	20.43	N
55	ATOM	787	CA	SER	A	114	30.454	33.957	33.857	1.00	21.50	C
	ATOM	788	CB	SER	A	114	31.256	35.259	33.878	1.00	23.57	C
	ATOM	789	OG	SER	A	114	30.407	36.384	34.009	1.00	27.72	O
	ATOM	790	C	SER	A	114	31.356	32.824	33.406	1.00	21.25	C
	ATOM	791	O	SER	A	114	32.019	32.181	34.222	1.00	21.50	O
60	ATOM	792	N	VAL	A	115	31.364	32.569	32.106	1.00	19.94	N
	ATOM	793	CA	VAL	A	115	32.188	31.515	31.542	1.00	19.21	C
	ATOM	794	CB	VAL	A	115	31.394	30.203	31.350	1.00	20.02	C
	ATOM	795	CG1	VAL	A	115	30.768	29.782	32.663	1.00	23.26	C
	ATOM	796	CG2	VAL	A	115	30.335	30.380	30.276	1.00	19.81	C
65	ATOM	797	C	VAL	A	115	32.675	31.986	30.183	1.00	17.61	C
	ATOM	798	O	VAL	A	115	32.065	32.857	29.561	1.00	16.06	O
	ATOM	799	N	THR	A	116	33.783	31.419	29.729	1.00	15.49	N
	ATOM	800	CA	THR	A	116	34.330	31.791	28.441	1.00	15.82	C
	ATOM	801	CB	THR	A	116	35.750	32.380	28.569	1.00	16.00	C
70	ATOM	802	OG1	THR	A	116	35.697	33.577	29.355	1.00	19.34	O
	ATOM	803	CG2	THR	A	116	36.312	32.721	27.189	1.00	13.81	C
	ATOM	804	C	THR	A	116	34.364	30.572	27.535	1.00	16.67	C
	ATOM	805	O	THR	A	116	35.031	29.576	27.828	1.00	15.27	O
	ATOM	806	N	TYR	A	117	33.604	30.663	26.451	1.00	14.40	N
75	ATOM	807	CA	TYR	A	117	33.500	29.609	25.453	1.00	18.79	C
	ATOM	808	CB	TYR	A	117	32.077	29.553	24.886	1.00	16.32	C
	ATOM	809	CG	TYR	A	117	30.993	29.168	25.871	1.00	19.43	C
	ATOM	810	CD1	TYR	A	117	29.875	29.977	26.057	1.00	17.65	C

- 231 -

	ATOM	811	CE1	TYR	A	117	28.844	29.594	26.911	1.00	19.53	C
	ATOM	812	CD2	TYR	A	117	31.053	27.967	26.569	1.00	19.30	C
	ATOM	813	CE2	TYR	A	117	30.029	27.577	27.421	1.00	23.56	C
5	ATOM	814	CZ	TYR	A	117	28.926	28.392	27.588	1.00	21.66	C
	ATOM	815	OH	TYR	A	117	27.898	27.991	28.417	1.00	18.29	O
	ATOM	816	C	TYR	A	117	34.462	29.985	24.330	1.00	16.91	C
	ATOM	817	O	TYR	A	117	34.968	31.107	24.288	1.00	18.67	O
	ATOM	818	N	PRO	A	118	34.727	29.058	23.400	1.00	17.80	N
	ATOM	819	CA	PRO	A	118	35.644	29.417	22.317	1.00	18.47	C
10	ATOM	820	CB	PRO	A	118	35.655	28.165	21.434	1.00	19.17	C
	ATOM	821	C	PRO	A	118	35.210	30.679	21.567	1.00	22.88	C
	ATOM	822	O	PRO	A	118	36.052	31.426	21.064	1.00	22.73	O
	ATOM	823	CD	PRO	A	118	34.280	27.663	23.277	1.00	19.00	C
	ATOM	824	CG	PRO	A	118	34.390	27.442	21.799	1.00	22.37	C
15	ATOM	825	N	GLU	A	119	33.900	30.923	21.509	1.00	21.24	N
	ATOM	826	CA	GLU	A	119	33.375	32.101	20.819	1.00	22.24	C
	ATOM	827	CB	GLU	A	119	31.888	31.930	20.495	1.00	23.42	C
	ATOM	828	C	GLU	A	119	33.539	33.356	21.665	1.00	24.28	C
	ATOM	829	O	GLU	A	119	33.672	34.464	21.142	1.00	24.95	O
20	ATOM	830	CG	GLU	A	119	31.561	30.815	19.522	1.00	25.42	C
	ATOM	831	CD	GLU	A	119	31.812	29.443	20.104	1.00	29.77	C
	ATOM	832	OE1	GLU	A	119	31.546	29.252	21.310	1.00	28.43	O
	ATOM	833	OE2	GLU	A	119	32.260	28.552	19.350	1.00	28.50	O
	ATOM	834	N	GLY	A	120	33.517	33.181	22.979	1.00	21.77	N
25	ATOM	835	CA	GLY	A	120	33.658	34.323	23.857	1.00	21.24	C
	ATOM	836	C	GLY	A	120	33.028	34.099	25.215	1.00	18.48	C
	ATOM	837	O	GLY	A	120	32.613	32.991	25.549	1.00	16.77	O
	ATOM	838	N	THR	A	121	32.944	35.169	25.994	1.00	15.75	N
	ATOM	839	CA	THR	A	121	32.388	35.098	27.332	1.00	15.58	C
30	ATOM	840	CB	THR	A	121	33.050	36.151	28.242	1.00	20.73	C
	ATOM	841	OG1	THR	A	121	34.472	35.973	28.218	1.00	22.66	O
	ATOM	842	CG2	THR	A	121	32.548	36.020	29.675	1.00	19.40	C
	ATOM	843	C	THR	A	121	30.876	35.292	27.393	1.00	13.13	C
	ATOM	844	O	THR	A	121	30.307	36.105	26.665	1.00	12.67	O
35	ATOM	845	N	VAL	A	122	30.235	34.523	28.263	1.00	10.86	N
	ATOM	846	CA	VAL	A	122	28.789	34.591	28.460	1.00	11.99	C
	ATOM	847	CB	VAL	A	122	28.095	33.263	28.093	1.00	10.42	C
	ATOM	848	CG1	VAL	A	122	26.641	33.290	28.534	1.00	11.35	C
	ATOM	849	CG2	VAL	A	122	28.176	33.044	26.587	1.00	7.40	C
40	ATOM	850	C	VAL	A	122	28.616	34.875	29.951	1.00	13.37	C
	ATOM	851	O	VAL	A	122	29.219	34.199	30.786	1.00	13.64	O
	ATOM	852	N	ARG	A	123	27.801	35.870	30.288	1.00	14.96	N
	ATOM	853	CA	ARG	A	123	27.581	36.221	31.691	1.00	17.69	C
	ATOM	854	CB	ARG	A	123	27.936	37.693	31.903	1.00	19.72	C
45	ATOM	855	CG	ARG	A	123	29.309	38.079	31.374	1.00	28.94	C
	ATOM	856	CD	ARG	A	123	29.620	39.545	31.642	1.00	34.45	C
	ATOM	857	NE	ARG	A	123	30.913	39.934	31.084	1.00	34.81	N
	ATOM	858	CZ	ARG	A	123	31.148	40.109	29.787	1.00	37.65	C
	ATOM	859	NH1	ARG	A	123	30.175	39.936	28.901	1.00	40.89	N
50	ATOM	860	NH2	ARG	A	123	32.362	40.450	29.373	1.00	35.27	N
	ATOM	861	C	ARG	A	123	26.160	35.970	32.188	1.00	15.87	C
	ATOM	862	O	ARG	A	123	25.297	35.538	31.430	1.00	14.52	O
	ATOM	863	N	GLY	A	124	25.942	36.231	33.477	1.00	14.67	N
	ATOM	864	CA	GLY	A	124	24.629	36.064	34.084	1.00	12.41	C
55	ATOM	865	C	GLY	A	124	24.058	34.659	34.085	1.00	13.04	C
	ATOM	866	O	GLY	A	124	22.841	34.477	34.106	1.00	11.06	O
	ATOM	867	N	LEU	A	125	24.937	33.666	34.092	1.00	10.63	N
	ATOM	868	CA	LEU	A	125	24.520	32.270	34.063	1.00	11.37	C
	ATOM	869	CB	LEU	A	125	25.556	31.455	33.293	1.00	10.04	C
60	ATOM	870	CG	LEU	A	125	25.729	31.810	31.820	1.00	8.76	C
	ATOM	871	CD1	LEU	A	125	26.853	30.973	31.236	1.00	12.07	C
	ATOM	872	CD2	LEU	A	125	24.430	31.559	31.072	1.00	10.99	C
	ATOM	873	C	LEU	A	125	24.290	31.595	35.413	1.00	11.50	C
	ATOM	874	O	LEU	A	125	24.887	31.958	36.424	1.00	13.58	O
65	ATOM	875	N	ILE	A	126	23.412	30.595	35.398	1.00	9.91	N
	ATOM	876	CA	ILE	A	126	23.078	29.829	36.586	1.00	10.95	C
	ATOM	877	CB	ILE	A	126	21.649	29.253	36.502	1.00	12.17	C
	ATOM	878	CG2	ILE	A	126	21.379	28.348	37.704	1.00	11.45	C
	ATOM	879	CG1	ILE	A	126	20.631	30.394	36.417	1.00	12.38	C
70	ATOM	880	CD1	ILE	A	126	19.207	29.931	36.143	1.00	11.96	C
	ATOM	881	C	ILE	A	126	24.066	28.668	36.579	1.00	11.47	C
	ATOM	882	O	ILE	A	126	24.109	27.898	35.620	1.00	11.84	O
	ATOM	883	N	ARG	A	127	24.874	28.557	37.627	1.00	12.21	N
	ATOM	884	CA	ARG	A	127	25.854	27.478	37.716	1.00	14.56	C
75	ATOM	885	CB	ARG	A	127	27.106	27.969	38.444	1.00	14.59	C
	ATOM	886	CG	ARG	A	127	28.195	26.921	38.616	1.00	23.58	C
	ATOM	887	CD	ARG	A	127	29.308	27.473	39.493	1.00	26.48	C
	ATOM	888	NE	ARG	A	127	30.349	26.489	39.769	1.00	36.15	N

- 232 -

	ATOM	889	CZ	ARG	A	127	31.209	26.033	38.865	1.00	38.33	
	ATOM	890	NH2	ARG	A	127	32.127	25.139	39.211	1.00	41.31	C
	ATOM	891	NH1	ARG	A	127	31.156	26.472	37.616	1.00	41.25	N
	ATOM	892	C	ARG	A	127	25.221	26.324	38.485	1.00	12.51	N
5	ATOM	893	O	ARG	A	127	24.554	26.548	39.495	1.00	10.73	C
	ATOM	894	N	THR	A	128	25.434	25.098	38.011	1.00	11.75	O
	ATOM	895	CA	THR	A	128	24.867	23.924	38.667	1.00	11.43	N
	ATOM	896	CB	THR	A	128	23.547	23.501	37.998	1.00	12.42	C
	ATOM	897	OG1	THR	A	128	23.835	22.848	36.751	1.00	11.64	C
10	ATOM	898	CG2	THR	A	128	22.668	24.719	37.728	1.00	8.69	O
	ATOM	899	C	THR	A	128	25.778	22.698	38.622	1.00	13.02	C
	ATOM	900	O	THR	A	128	26.790	22.680	37.914	1.00	12.78	C
	ATOM	901	N	THR	A	129	25.391	21.674	39.381	1.00	11.69	O
	ATOM	902	CA	THR	A	129	26.132	20.419	39.456	1.00	12.47	N
15	ATOM	903	CB	THR	A	129	26.099	19.827	40.878	1.00	12.66	C
	ATOM	904	OG1	THR	A	129	24.737	19.612	41.277	1.00	11.15	C
	ATOM	905	CG2	THR	A	129	26.782	20.766	41.859	1.00	12.84	O
	ATOM	906	C	THR	A	129	25.503	19.399	38.506	1.00	15.23	C
	ATOM	907	O	THR	A	129	25.820	18.211	38.564	1.00	10.87	O
20	ATOM	908	N	VAL	A	130	24.601	19.870	37.646	1.00	14.09	N
	ATOM	909	CA	VAL	A	130	23.923	19.006	36.680	1.00	12.55	C
	ATOM	910	CB	VAL	A	130	22.662	19.694	36.103	1.00	13.46	C
	ATOM	911	CG1	VAL	A	130	21.913	18.730	35.195	1.00	15.05	C
	ATOM	912	CG2	VAL	A	130	21.755	20.178	37.234	1.00	10.45	C
25	ATOM	913	C	VAL	A	130	24.872	18.692	35.521	1.00	13.62	C
	ATOM	914	O	VAL	A	130	25.655	19.546	35.120	1.00	17.44	O
	ATOM	915	N	CYS	A	131	24.804	17.468	34.997	1.00	10.87	N
	ATOM	916	CA	CYS	A	131	25.658	17.047	33.886	1.00	12.09	C
	ATOM	917	CB	CYS	A	131	25.939	15.541	33.966	1.00	12.10	C
30	ATOM	918	SG	CYS	A	131	24.447	14.512	33.745	1.00	14.96	S
	ATOM	919	C	CYS	A	131	24.957	17.343	32.568	1.00	12.93	C
	ATOM	920	O	CYS	A	131	23.739	17.506	32.532	1.00	11.56	O
	ATOM	921	N	ALA	A	132	25.723	17.403	31.486	1.00	13.76	N
	ATOM	922	CA	ALA	A	132	25.141	17.676	30.181	1.00	14.09	C
35	ATOM	923	CB	ALA	A	132	24.724	19.141	30.089	1.00	13.62	C
	ATOM	924	C	ALA	A	132	26.086	17.337	29.042	1.00	17.97	C
	ATOM	925	O	ALA	A	132	27.294	17.179	29.237	1.00	15.14	O
	ATOM	926	N	GLU	A	133	25.508	17.215	27.853	1.00	13.21	N
	ATOM	927	CA	GLU	A	133	26.243	16.900	26.639	1.00	18.49	C
40	ATOM	928	CB	GLU	A	133	25.732	15.592	26.039	1.00	21.95	C
	ATOM	929	CG	GLU	A	133	26.808	14.614	25.652	1.00	27.91	C
	ATOM	930	CD	GLU	A	133	27.336	13.850	26.840	1.00	31.31	C
	ATOM	931	OE1	GLU	A	133	27.870	14.494	27.767	1.00	28.79	O
	ATOM	932	OE2	GLU	A	133	27.214	12.606	26.846	1.00	28.57	O
45	ATOM	933	C	GLU	A	133	25.919	18.051	25.693	1.00	15.23	C
	ATOM	934	O	GLU	A	133	24.915	18.738	25.866	1.00	16.37	O
	ATOM	935	N	PRO	A	134	26.761	18.276	24.680	1.00	16.75	N
	ATOM	936	CA	PRO	A	134	26.527	19.366	23.725	1.00	17.31	C
	ATOM	937	CB	PRO	A	134	27.558	19.082	22.638	1.00	17.01	C
50	ATOM	938	C	PRO	A	134	25.093	19.449	23.177	1.00	18.87	C
	ATOM	939	O	PRO	A	134	24.468	20.515	23.204	1.00	21.16	O
	ATOM	940	CD	PRO	A	134	28.022	17.572	24.385	1.00	14.41	C
	ATOM	941	CG	PRO	A	134	28.708	18.528	23.429	1.00	15.96	C
	ATOM	942	N	GLY	A	135	24.577	18.329	22.683	1.00	13.73	N
55	ATOM	943	CA	GLY	A	135	23.228	18.315	22.138	1.00	11.51	C
	ATOM	944	C	GLY	A	135	22.114	18.674	23.112	1.00	12.22	C
	ATOM	945	O	GLY	A	135	20.982	18.933	22.696	1.00	10.70	O
	ATOM	946	N	ASP	A	136	22.425	18.676	24.405	1.00	9.59	N
	ATOM	947	CA	ASP	A	136	21.451	19.019	25.441	1.00	10.66	C
60	ATOM	948	CB	ASP	A	136	21.957	18.550	26.808	1.00	9.43	C
	ATOM	949	C	ASP	A	136	21.239	20.533	25.485	1.00	9.56	C
	ATOM	950	O	ASP	A	136	20.270	21.018	26.076	1.00	7.80	O
	ATOM	951	CG	ASP	A	136	21.907	17.044	26.969	1.00	12.00	C
	ATOM	952	OD2	ASP	A	136	21.038	16.399	26.348	1.00	14.65	O
65	ATOM	953	OD1	ASP	A	136	22.732	16.510	27.737	1.00	11.73	O
	ATOM	954	N	SER	A	137	22.159	21.270	24.867	1.00	11.68	N
	ATOM	955	CA	SER	A	137	22.089	22.728	24.831	1.00	9.45	C
	ATOM	956	CB	SER	A	137	23.167	23.298	23.902	1.00	12.71	C
	ATOM	957	C	SER	A	137	20.723	23.231	24.381	1.00	12.56	C
70	ATOM	958	O	SER	A	137	20.110	22.671	23.470	1.00	9.42	O
	ATOM	959	OG	SER	A	137	24.460	23.160	24.466	1.00	11.89	O
	ATOM	960	N	GLY	A	138	20.264	24.298	25.027	1.00	12.50	N
	ATOM	961	CA	GLY	A	138	18.974	24.873	24.698	1.00	10.84	C
	ATOM	962	C	GLY	A	138	17.863	24.228	25.497	1.00	11.17	C
75	ATOM	963	O	GLY	A	138	16.759	24.774	25.583	1.00	10.27	O
	ATOM	964	N	GLY	A	139	18.171	23.075	26.090	1.00	9.62	N
	ATOM	965	CA	GLY	A	139	17.202	22.326	26.877	1.00	11.99	C
	ATOM	966	C	GLY	A	139	16.675	22.997	28.135	1.00	9.04	C

- 233 -

	ATOM	967	O	GLY	A	139	17.243	23.968	28.632	1.00	11.52	O
	ATOM	968	N	SER	A	140	15.588	22.444	28.668	1.00	9.88	N
	ATOM	969	CA	SER	A	140	14.942	22.990	29.858	1.00	10.08	C
	ATOM	970	CB	SER	A	140	13.507	22.456	29.977	1.00	9.88	C
5	ATOM	971	OG	SER	A	140	12.972	22.057	28.729	1.00	11.61	O
	ATOM	972	C	SER	A	140	15.628	22.710	31.187	1.00	9.54	C
	ATOM	973	O	SER	A	140	16.253	21.670	31.369	1.00	8.61	O
	ATOM	974	N	LEU	A	141	15.492	23.660	32.108	1.00	11.67	N
	ATOM	975	CA	LEU	A	141	16.057	23.559	33.453	1.00	10.92	C
10	ATOM	976	CB	LEU	A	141	17.184	24.554	33.718	1.00	10.21	C
	ATOM	977	CG	LEU	A	141	17.665	24.342	35.164	1.00	9.58	C
	ATOM	978	CD1	LEU	A	141	18.252	22.936	35.290	1.00	7.62	C
	ATOM	979	CD2	LEU	A	141	18.682	25.407	35.575	1.00	8.11	C
	ATOM	980	C	LEU	A	141	14.867	23.916	34.330	1.00	10.82	C
15	ATOM	981	O	LEU	A	141	14.325	25.021	34.240	1.00	10.91	O
	ATOM	982	N	LEU	A	142	14.455	22.972	35.161	1.00	7.99	N
	ATOM	983	CA	LEU	A	142	13.327	23.175	36.046	1.00	11.41	C
	ATOM	984	CB	LEU	A	142	12.235	22.140	35.741	1.00	12.37	C
	ATOM	985	CG	LEU	A	142	11.432	22.235	34.449	1.00	13.83	C
20	ATOM	986	CD1	LEU	A	142	10.710	20.914	34.195	1.00	16.69	C
	ATOM	987	CD2	LEU	A	142	10.443	23.391	34.562	1.00	13.02	C
	ATOM	988	C	LEU	A	142	13.675	23.050	37.518	1.00	10.11	C
	ATOM	989	O	LEU	A	142	14.631	22.377	37.904	1.00	13.30	O
	ATOM	990	N	ALA	A	143	12.875	23.731	38.326	1.00	10.55	N
25	ATOM	991	CA	ALA	A	143	12.992	23.746	39.775	1.00	12.59	C
	ATOM	992	CB	ALA	A	143	13.306	25.141	40.284	1.00	14.58	C
	ATOM	993	C	ALA	A	143	11.539	23.388	40.061	1.00	13.64	C
	ATOM	994	O	ALA	A	143	10.677	24.258	40.124	1.00	15.86	O
	ATOM	995	N	GLY	A	144	11.260	22.098	40.178	1.00	14.54	N
30	ATOM	996	CA	GLY	A	144	9.890	21.681	40.396	1.00	18.53	C
	ATOM	997	C	GLY	A	144	9.156	21.932	39.092	1.00	18.05	C
	ATOM	998	O	GLY	A	144	9.570	21.445	38.040	1.00	18.26	O
	ATOM	999	N	ASN	A	145	8.071	22.695	39.144	1.00	17.01	N
35	ATOM	1000	CA	ASN	A	145	7.316	23.001	37.940	1.00	17.28	C
	ATOM	1001	CB	ASN	A	145	5.821	22.829	38.199	1.00	24.24	C
	ATOM	1002	CG	ASN	A	145	5.380	23.471	39.497	1.00	34.66	C
	ATOM	1003	OD1	ASN	A	145	5.502	24.685	39.682	1.00	36.73	O
	ATOM	1004	ND2	ASN	A	145	4.868	22.655	40.413	1.00	41.73	N
	ATOM	1005	C	ASN	A	145	7.589	24.425	37.477	1.00	16.30	C
40	ATOM	1006	O	ASN	A	145	6.844	24.966	36.671	1.00	13.74	O
	ATOM	1007	N	GLN	A	146	8.667	25.022	37.976	1.00	13.23	N
	ATOM	1008	CA	GLN	A	146	9.022	26.388	37.609	1.00	13.97	C
	ATOM	1009	CB	GLN	A	146	9.283	27.205	38.876	1.00	17.49	C
	ATOM	1010	CG	GLN	A	146	8.116	27.191	39.850	1.00	17.44	C
45	ATOM	1011	CD	GLN	A	146	6.920	27.948	39.324	1.00	19.58	C
	ATOM	1012	OE1	GLN	A	146	5.781	27.478	39.412	1.00	18.02	O
	ATOM	1013	NE2	GLN	A	146	7.166	29.135	38.781	1.00	13.47	N
	ATOM	1014	C	GLN	A	146	10.238	26.469	36.692	1.00	13.36	C
	ATOM	1015	O	GLN	A	146	11.332	26.026	37.052	1.00	9.49	O
50	ATOM	1016	N	ALA	A	147	10.036	27.037	35.508	1.00	10.85	N
	ATOM	1017	CA	ALA	A	147	11.107	27.187	34.527	1.00	11.86	C
	ATOM	1018	CB	ALA	A	147	10.560	27.790	33.231	1.00	9.60	C
	ATOM	1019	C	ALA	A	147	12.212	28.077	35.079	1.00	12.02	C
	ATOM	1020	O	ALA	A	147	11.947	29.181	35.559	1.00	11.92	O
55	ATOM	1021	N	GLN	A	148	13.450	27.595	34.990	1.00	9.31	N
	ATOM	1022	CA	GLN	A	148	14.608	28.334	35.478	1.00	8.96	C
	ATOM	1023	CB	GLN	A	148	15.502	27.426	36.317	1.00	9.82	C
	ATOM	1024	CG	GLN	A	148	14.814	26.838	37.532	1.00	9.18	C
	ATOM	1025	CD	GLN	A	148	14.193	27.914	38.392	1.00	8.87	C
60	ATOM	1026	OE1	GLN	A	148	12.974	27.953	38.581	1.00	13.35	O
	ATOM	1027	NE2	GLN	A	148	15.024	28.797	38.916	1.00	6.09	N
	ATOM	1028	C	GLN	A	148	15.449	28.925	34.353	1.00	9.54	C
	ATOM	1029	O	GLN	A	148	15.874	30.073	34.424	1.00	10.41	O
	ATOM	1030	N	GLY	A	149	15.707	28.130	33.322	1.00	9.02	N
65	ATOM	1031	CA	GLY	A	149	16.522	28.620	32.226	1.00	11.94	C
	ATOM	1032	C	GLY	A	149	16.762	27.559	31.172	1.00	10.03	C
	ATOM	1033	O	GLY	A	149	16.130	26.505	31.198	1.00	11.61	O
	ATOM	1034	N	VAL	A	150	17.670	27.840	30.241	1.00	8.37	N
	ATOM	1035	CA	VAL	A	150	17.977	26.885	29.185	1.00	10.02	C
70	ATOM	1036	CB	VAL	A	150	17.557	27.428	27.796	1.00	8.22	C
	ATOM	1037	CG1	VAL	A	150	16.058	27.733	27.799	1.00	9.61	C
	ATOM	1038	CG2	VAL	A	150	18.343	28.682	27.452	1.00	6.21	C
	ATOM	1039	C	VAL	A	150	19.465	26.542	29.211	1.00	11.57	C
	ATOM	1040	O	VAL	A	150	20.309	27.391	29.504	1.00	9.64	O
75	ATOM	1041	N	THR	A	151	19.773	25.283	28.925	1.00	11.95	N
	ATOM	1042	CA	THR	A	151	21.153	24.805	28.923	1.00	11.13	C
	ATOM	1043	CB	THR	A	151	21.195	23.325	28.552	1.00	9.19	C
	ATOM	1044	OG1	THR	A	151	20.223	22.622	29.340	1.00	6.16	O

- 234 -

	ATOM	1045	CG2	THR	A	151	22.578	22.748	28.828	1.00	8.56	
	ATOM	1046	C	THR	A	151	22.086	25.577	27.999	1.00	11.68	C
	ATOM	1047	O	THR	A	151	21.838	25.677	26.801	1.00	8.62	O
	ATOM	1048	N	SER	A	152	23.172	26.107	28.560	1.00	11.36	N
5	ATOM	1049	CA	SER	A	152	24.133	26.869	27.771	1.00	10.56	C
	ATOM	1050	CB	SER	A	152	24.480	28.183	28.479	1.00	13.70	C
	ATOM	1051	OG	SER	A	152	25.434	28.928	27.735	1.00	11.67	O
	ATOM	1052	C	SER	A	152	25.407	26.080	27.503	1.00	12.67	C
	ATOM	1053	O	SER	A	152	25.873	26.005	26.369	1.00	11.22	O
10	ATOM	1054	N	GLY	A	153	25.967	25.485	28.547	1.00	11.74	N
	ATOM	1055	CA	GLY	A	153	27.185	24.719	28.374	1.00	13.59	C
	ATOM	1056	C	GLY	A	153	27.807	24.348	29.699	1.00	13.34	C
	ATOM	1057	O	GLY	A	153	27.226	24.590	30.758	1.00	11.10	O
	ATOM	1058	N	GLY	A	154	29.001	23.769	29.644	1.00	12.77	N
15	ATOM	1059	CA	GLY	A	154	29.669	23.370	30.862	1.00	14.55	C
	ATOM	1060	C	GLY	A	154	30.763	22.360	30.583	1.00	16.81	C
	ATOM	1061	O	GLY	A	154	31.228	22.235	29.452	1.00	15.66	O
	ATOM	1062	N	SER	A	155	31.171	21.631	31.615	1.00	16.15	N
	ATOM	1063	CA	SER	A	155	32.230	20.641	31.472	1.00	16.05	C
20	ATOM	1064	CB	SER	A	155	33.475	21.113	32.214	1.00	16.89	C
	ATOM	1065	OG	SER	A	155	33.181	21.338	33.582	1.00	23.41	O
	ATOM	1066	C	SER	A	155	31.799	19.291	32.026	1.00	16.84	C
	ATOM	1067	O	SER	A	155	30.783	19.187	32.714	1.00	14.62	O
	ATOM	1068	N	GLY	A	156	32.588	18.262	31.731	1.00	15.26	N
25	ATOM	1069	CA	GLY	A	156	32.279	16.928	32.211	1.00	13.85	C
	ATOM	1070	C	GLY	A	156	31.211	16.256	31.376	1.00	14.91	C
	ATOM	1071	O	GLY	A	156	30.935	16.667	30.251	1.00	17.56	O
	ATOM	1072	N	ASN	A	157	30.613	15.213	31.931	1.00	14.60	N
	ATOM	1073	CA	ASN	A	157	29.566	14.471	31.248	1.00	16.61	C
30	ATOM	1074	CB	ASN	A	157	30.179	13.445	30.289	1.00	16.79	C
	ATOM	1075	CG	ASN	A	157	31.168	12.525	30.974	1.00	16.85	C
	ATOM	1076	OD1	ASN	A	157	30.808	11.768	31.876	1.00	17.38	O
	ATOM	1077	ND2	ASN	A	157	32.429	12.585	30.545	1.00	19.44	N
	ATOM	1078	C	ASN	A	157	28.694	13.773	32.283	1.00	16.81	C
35	ATOM	1079	O	ASN	A	157	28.936	13.888	33.487	1.00	14.11	O
	ATOM	1080	N	CYS	A	158	27.679	13.057	31.812	1.00	16.33	N
	ATOM	1081	CA	CYS	A	158	26.773	12.348	32.704	1.00	17.79	C
	ATOM	1082	CB	CYS	A	158	25.406	12.202	32.048	1.00	19.95	C
	ATOM	1083	SG	CYS	A	158	24.578	13.802	31.845	1.00	17.50	S
40	ATOM	1084	C	CYS	A	158	27.257	10.989	33.174	1.00	19.67	C
	ATOM	1085	O	CYS	A	158	26.591	10.333	33.971	1.00	21.67	O
	ATOM	1086	N	ARG	A	159	28.403	10.554	32.672	1.00	18.94	N
	ATOM	1087	CA	ARG	A	159	28.948	9.267	33.070	1.00	19.35	C
	ATOM	1088	CB	ARG	A	159	29.835	8.700	31.953	1.00	19.37	C
45	ATOM	1089	CG	ARG	A	159	29.074	8.300	30.702	1.00	24.85	C
	ATOM	1090	CD	ARG	A	159	30.003	7.779	29.615	1.00	25.44	C
	ATOM	1091	NE	ARG	A	159	30.852	8.831	29.068	1.00	26.55	N
	ATOM	1092	CZ	ARG	A	159	30.414	9.821	28.296	1.00	28.60	C
	ATOM	1093	NH1	ARG	A	159	29.130	9.901	27.971	1.00	28.12	N
50	ATOM	1094	NH2	ARG	A	159	31.264	10.734	27.848	1.00	25.81	N
	ATOM	1095	C	ARG	A	159	29.775	9.461	34.345	1.00	19.70	C
	ATOM	1096	O	ARG	A	159	29.653	8.704	35.309	1.00	20.82	O
	ATOM	1097	N	THR	A	160	30.608	10.494	34.355	1.00	16.93	N
	ATOM	1098	CA	THR	A	160	31.445	10.762	35.517	1.00	18.57	C
55	ATOM	1099	CB	THR	A	160	32.937	10.775	35.109	1.00	18.72	C
	ATOM	1100	OG1	THR	A	160	33.136	11.696	34.028	1.00	19.41	O
	ATOM	1101	CG2	THR	A	160	33.372	9.387	34.654	1.00	23.02	C
	ATOM	1102	C	THR	A	160	31.097	12.055	36.267	1.00	17.76	C
	ATOM	1103	O	THR	A	160	31.730	12.391	37.269	1.00	14.64	O
60	ATOM	1104	N	GLY	A	161	30.079	12.767	35.792	1.00	15.51	N
	ATOM	1105	CA	GLY	A	161	29.666	14.000	36.444	1.00	18.63	C
	ATOM	1106	C	GLY	A	161	30.199	15.264	35.791	1.00	17.91	C
	ATOM	1107	O	GLY	A	161	31.178	15.231	35.047	1.00	17.74	O
	ATOM	1108	N	GLY	A	162	29.556	16.392	36.070	1.00	17.00	N
65	ATOM	1109	CA	GLY	A	162	30.008	17.633	35.475	1.00	15.39	C
	ATOM	1110	C	GLY	A	162	29.373	18.881	36.048	1.00	14.86	C
	ATOM	1111	O	GLY	A	162	28.607	18.824	37.013	1.00	12.41	O
	ATOM	1112	N	THR	A	163	29.716	20.014	35.445	1.00	11.47	N
	ATOM	1113	CA	THR	A	163	29.203	21.318	35.847	1.00	12.96	C
70	ATOM	1114	CB	THR	A	163	30.343	22.255	36.285	1.00	15.39	C
	ATOM	1115	OG1	THR	A	163	31.024	21.685	37.409	1.00	15.28	O
	ATOM	1116	CG2	THR	A	163	29.793	23.622	36.664	1.00	11.49	C
	ATOM	1117	C	THR	A	163	28.532	21.921	34.619	1.00	13.39	C
	ATOM	1118	O	THR	A	163	29.168	22.081	33.577	1.00	15.12	O
75	ATOM	1119	N	THR	A	164	27.252	22.253	34.741	1.00	10.11	N
	ATOM	1120	CA	THR	A	164	26.518	22.833	33.624	1.00	10.81	C
	ATOM	1121	CB	THR	A	164	25.362	21.914	33.192	1.00	8.40	C
	ATOM	1122	OG1	THR	A	164	25.878	20.612	32.891	1.00	6.91	O

- 235 -

	ATOM	1123	CG2	THR	A	164	24.675	22.471	31.955	1.00	6.07	
	ATOM	1124	C	THR	A	164	25.950	24.203	33.967	1.00	10.82	C
	ATOM	1125	O	THR	A	164	25.401	24.402	35.053	1.00	9.66	C
	ATOM	1126	N	PHE	A	165	26.092	25.139	33.034	1.00	9.84	O
5	ATOM	1127	CA	PHE	A	165	25.600	26.502	33.210	1.00	10.47	C
	ATOM	1128	CB	PHE	A	165	26.669	27.513	32.796	1.00	11.30	C
	ATOM	1129	CG	PHE	A	165	27.940	27.419	33.597	1.00	14.89	C
	ATOM	1130	CD1	PHE	A	165	28.871	26.429	33.335	1.00	15.07	C
	ATOM	1131	CD2	PHE	A	165	28.188	28.311	34.626	1.00	16.48	C
10	ATOM	1132	CE1	PHE	A	165	30.030	26.330	34.085	1.00	16.20	C
	ATOM	1133	CE2	PHE	A	165	29.341	28.219	35.379	1.00	16.91	C
	ATOM	1134	CZ	PHE	A	165	30.264	27.223	35.108	1.00	16.17	C
	ATOM	1135	C	PHE	A	165	24.344	26.725	32.373	1.00	11.04	C
	ATOM	1136	O	PHE	A	165	24.224	26.204	31.263	1.00	9.74	O
15	ATOM	1137	N	PHE	A	166	23.417	27.517	32.901	1.00	7.30	N
	ATOM	1138	CA	PHE	A	166	22.177	27.796	32.195	1.00	8.16	C
	ATOM	1139	CB	PHE	A	166	20.990	27.127	32.901	1.00	7.36	C
	ATOM	1140	CG	PHE	A	166	21.148	25.650	33.093	1.00	7.82	C
	ATOM	1141	CD2	PHE	A	166	20.436	24.758	32.302	1.00	10.08	C
20	ATOM	1142	CD1	PHE	A	166	22.018	25.148	34.050	1.00	10.99	C
	ATOM	1143	CE2	PHE	A	166	20.591	23.383	32.463	1.00	9.63	C
	ATOM	1144	CE1	PHE	A	166	22.179	23.777	34.218	1.00	7.63	C
	ATOM	1145	CZ	PHE	A	166	21.464	22.894	33.422	1.00	9.75	C
	ATOM	1146	C	PHE	A	166	21.871	29.277	32.077	1.00	9.41	C
25	ATOM	1147	O	PHE	A	166	22.183	30.070	32.967	1.00	9.92	O
	ATOM	1148	N	GLN	A	167	21.247	29.634	30.963	1.00	9.95	N
	ATOM	1149	CA	GLN	A	167	20.866	31.010	30.690	1.00	9.14	C
	ATOM	1150	CB	GLN	A	167	20.777	31.231	29.176	1.00	8.25	C
	ATOM	1151	CG	GLN	A	167	19.911	32.403	28.738	1.00	11.98	C
30	ATOM	1152	CD	GLN	A	167	20.487	33.751	29.110	1.00	13.09	C
	ATOM	1153	OE1	GLN	A	167	21.590	34.111	28.690	1.00	12.87	O
	ATOM	1154	NE2	GLN	A	167	19.746	34.505	29.905	1.00	10.51	N
	ATOM	1155	C	GLN	A	167	19.492	31.178	31.337	1.00	10.77	C
	ATOM	1156	O	GLN	A	167	18.542	30.483	30.977	1.00	7.43	O
35	ATOM	1157	N	PRO	A	168	19.375	32.085	32.318	1.00	10.69	N
	ATOM	1158	CD	PRO	A	168	20.431	32.933	32.897	1.00	11.76	C
	ATOM	1159	CA	PRO	A	168	18.092	32.310	32.996	1.00	11.69	C
	ATOM	1160	CB	PRO	A	168	18.392	33.482	33.924	1.00	12.25	C
	ATOM	1161	CG	PRO	A	168	19.837	33.296	34.241	1.00	14.30	C
40	ATOM	1162	C	PRO	A	168	16.988	32.628	31.994	1.00	11.80	C
	ATOM	1163	O	PRO	A	168	17.222	33.317	31.006	1.00	9.94	O
	ATOM	1164	N	VAL	A	169	15.784	32.133	32.261	1.00	10.31	N
	ATOM	1165	CA	VAL	A	169	14.650	32.358	31.373	1.00	12.92	C
	ATOM	1166	CB	VAL	A	169	13.528	31.331	31.662	1.00	17.07	C
45	ATOM	1167	CG1	VAL	A	169	13.026	31.491	33.088	1.00	15.81	C
	ATOM	1168	CG2	VAL	A	169	12.394	31.505	30.678	1.00	19.48	C
	ATOM	1169	C	VAL	A	169	14.028	33.757	31.358	1.00	12.62	C
	ATOM	1170	O	VAL	A	169	13.648	34.253	30.302	1.00	11.62	O
	ATOM	1171	N	ASN	A	170	13.927	34.405	32.510	1.00	12.76	N
50	ATOM	1172	CA	ASN	A	170	13.328	35.736	32.537	1.00	15.21	C
	ATOM	1173	CB	ASN	A	170	13.268	36.249	33.976	1.00	13.89	C
	ATOM	1174	CG	ASN	A	170	12.353	35.396	34.841	1.00	19.50	C
	ATOM	1175	OD1	ASN	A	170	11.367	34.848	34.347	1.00	19.07	O
	ATOM	1176	ND2	ASN	A	170	12.667	35.283	36.128	1.00	18.85	N
55	ATOM	1177	C	ASN	A	170	13.948	36.764	31.591	1.00	12.70	C
	ATOM	1178	O	ASN	A	170	13.235	37.554	30.977	1.00	14.77	O
	ATOM	1179	N	PRO	A	171	15.278	36.778	31.458	1.00	15.34	N
	ATOM	1180	CD	PRO	A	171	16.339	36.181	32.282	1.00	16.10	C
	ATOM	1181	CA	PRO	A	171	15.826	37.772	30.530	1.00	16.08	C
60	ATOM	1182	CB	PRO	A	171	17.336	37.710	30.790	1.00	17.98	C
	ATOM	1183	CG	PRO	A	171	17.539	36.351	31.399	1.00	23.99	C
	ATOM	1184	C	PRO	A	171	15.457	37.465	29.077	1.00	15.20	C
	ATOM	1185	O	PRO	A	171	15.464	38.355	28.228	1.00	10.27	O
	ATOM	1186	N	ILE	A	172	15.139	36.203	28.794	1.00	11.01	N
65	ATOM	1187	CA	ILE	A	172	14.769	35.813	27.437	1.00	10.79	C
	ATOM	1188	CB	ILE	A	172	14.784	34.282	27.247	1.00	8.59	C
	ATOM	1189	CG2	ILE	A	172	14.453	33.943	25.792	1.00	10.32	C
	ATOM	1190	CG1	ILE	A	172	16.152	33.712	27.617	1.00	7.68	C
	ATOM	1191	CD1	ILE	A	172	16.184	32.189	27.604	1.00	6.34	C
70	ATOM	1192	C	ILE	A	172	13.355	36.310	27.145	1.00	9.04	C
	ATOM	1193	O	ILE	A	172	13.074	36.849	26.070	1.00	9.00	O
	ATOM	1194	N	LEU	A	173	12.461	36.112	28.107	1.00	10.13	N
	ATOM	1195	CA	LEU	A	173	11.080	36.544	27.951	1.00	12.20	C
	ATOM	1196	CB	LEU	A	173	10.249	36.103	29.157	1.00	9.16	C
75	ATOM	1197	CG	LEU	A	173	10.233	34.595	29.436	1.00	10.30	C
	ATOM	1198	CD1	LEU	A	173	9.469	34.304	30.717	1.00	9.41	C
	ATOM	1199	CD2	LEU	A	173	9.598	33.873	28.268	1.00	11.50	C
	ATOM	1200	C	LEU	A	173	11.049	38.061	27.824	1.00	13.01	C

- 236 -

	ATOM	1201	O	LEU	A	173	10.295	38.608	27.026	1.00	17.74	O
	ATOM	1202	N	GLN	A	174	11.885	38.733	28.608	1.00	16.26	N
	ATOM	1203	CA	GLN	A	174	11.962	40.190	28.592	1.00	14.31	C
	ATOM	1204	CB	GLN	A	174	12.817	40.681	29.769	1.00	19.36	C
5	ATOM	1205	CG	GLN	A	174	12.968	42.198	29.866	1.00	25.15	C
	ATOM	1206	CD	GLN	A	174	11.695	42.891	30.315	1.00	30.84	C
	ATOM	1207	OE1	GLN	A	174	10.628	42.684	29.743	1.00	30.46	O
	ATOM	1208	NE2	GLN	A	174	11.805	43.723	31.348	1.00	34.53	N
	ATOM	1209	C	GLN	A	174	12.556	40.694	27.282	1.00	15.28	C
10	ATOM	1210	O	GLN	A	174	12.104	41.694	26.722	1.00	10.15	O
	ATOM	1211	N	ALA	A	175	13.567	39.994	26.786	1.00	13.61	N
	ATOM	1212	CA	ALA	A	175	14.210	40.393	25.544	1.00	16.01	C
	ATOM	1213	CB	ALA	A	175	15.372	39.453	25.234	1.00	14.76	C
	ATOM	1214	C	ALA	A	175	13.245	40.427	24.363	1.00	17.13	C
15	ATOM	1215	O	ALA	A	175	13.221	41.387	23.598	1.00	14.51	O
	ATOM	1216	N	TYR	A	176	12.426	39.391	24.229	1.00	16.19	N
	ATOM	1217	CA	TYR	A	176	11.481	39.329	23.124	1.00	17.75	C
	ATOM	1218	CB	TYR	A	176	11.595	37.947	22.476	1.00	15.30	C
	ATOM	1219	CG	TYR	A	176	13.033	37.599	22.138	1.00	15.11	C
20	ATOM	1220	CD1	TYR	A	176	13.818	38.482	21.415	1.00	16.28	C
	ATOM	1221	CE1	TYR	A	176	15.134	38.186	21.101	1.00	13.92	C
	ATOM	1222	CD2	TYR	A	176	13.605	36.395	22.548	1.00	12.95	C
	ATOM	1223	CE2	TYR	A	176	14.925	36.086	22.238	1.00	12.38	C
	ATOM	1224	CZ	TYR	A	176	15.682	36.990	21.512	1.00	13.61	C
25	ATOM	1225	OH	TYR	A	176	16.983	36.705	21.184	1.00	13.98	O
	ATOM	1226	C	TYR	A	176	10.030	39.653	23.461	1.00	14.14	C
	ATOM	1227	O	TYR	A	176	9.155	39.546	22.604	1.00	16.16	O
	ATOM	1228	N	GLY	A	177	9.780	40.057	24.701	1.00	14.82	N
	ATOM	1229	CA	GLY	A	177	8.424	40.392	25.105	1.00	16.43	C
30	ATOM	1230	C	GLY	A	177	7.500	39.207	24.933	1.00	16.44	C
	ATOM	1231	O	GLY	A	177	6.376	39.340	24.439	1.00	17.81	O
	ATOM	1232	N	LEU	A	178	7.987	38.046	25.361	1.00	14.56	N
	ATOM	1233	CA	LEU	A	178	7.261	36.789	25.258	1.00	15.86	C
	ATOM	1234	CB	LEU	A	178	8.209	35.686	24.778	1.00	15.44	C
35	ATOM	1235	CG	LEU	A	178	8.886	35.807	23.415	1.00	19.21	C
	ATOM	1236	CD1	LEU	A	178	10.030	34.805	23.331	1.00	18.33	C
	ATOM	1237	CD2	LEU	A	178	7.870	35.553	22.311	1.00	21.44	C
	ATOM	1238	C	LEU	A	178	6.670	36.350	26.586	1.00	16.50	C
	ATOM	1239	O	LEU	A	178	7.086	36.808	27.650	1.00	16.26	O
40	ATOM	1240	N	ARG	A	179	5.700	35.447	26.504	1.00	17.69	N
	ATOM	1241	CA	ARG	A	179	5.040	34.911	27.684	1.00	15.79	C
	ATOM	1242	CB	ARG	A	179	3.565	35.312	27.729	1.00	21.75	C
	ATOM	1243	CG	ARG	A	179	3.321	36.700	28.298	1.00	30.60	C
	ATOM	1244	CD	ARG	A	179	1.837	36.960	28.493	1.00	37.51	C
45	ATOM	1245	NE	ARG	A	179	1.586	38.213	29.199	1.00	47.17	N
	ATOM	1246	CZ	ARG	A	179	2.011	39.405	28.790	1.00	49.75	C
	ATOM	1247	NH1	ARG	A	179	2.715	39.516	27.672	1.00	52.12	N
	ATOM	1248	NH2	ARG	A	179	1.731	40.488	29.500	1.00	50.23	N
	ATOM	1249	C	ARG	A	179	5.153	33.398	27.640	1.00	15.02	C
50	ATOM	1250	O	ARG	A	179	5.039	32.787	26.574	1.00	14.80	O
	ATOM	1251	N	MET	A	180	5.401	32.800	28.799	1.00	13.59	N
	ATOM	1252	CA	MET	A	180	5.529	31.356	28.909	1.00	16.64	C
	ATOM	1253	CB	MET	A	180	5.991	30.969	30.316	1.00	17.26	C
	ATOM	1254	CG	MET	A	180	7.358	31.449	30.714	1.00	22.61	C
55	ATOM	1255	SD	MET	A	180	8.603	30.324	30.120	1.00	24.38	S
	ATOM	1256	CE	MET	A	180	8.143	28.828	30.998	1.00	21.48	C
	ATOM	1257	C	MET	A	180	4.156	30.739	28.706	1.00	16.31	C
	ATOM	1258	O	MET	A	180	3.167	31.255	29.225	1.00	17.83	O
	ATOM	1259	N	ILE	A	181	4.076	29.656	27.942	1.00	14.71	N
60	ATOM	1260	CA	ILE	A	181	2.778	29.019	27.740	1.00	13.74	C
	ATOM	1261	CB	ILE	A	181	2.794	28.044	26.559	1.00	16.62	C
	ATOM	1262	CG2	ILE	A	181	1.570	27.130	26.622	1.00	15.86	C
	ATOM	1263	CG1	ILE	A	181	2.829	28.835	25.247	1.00	17.95	C
	ATOM	1264	CD1	ILE	A	181	2.732	27.982	24.009	1.00	26.87	C
65	ATOM	1265	C	ILE	A	181	2.589	28.256	29.049	1.00	15.69	C
	ATOM	1266	O	ILE	A	181	3.452	27.469	29.438	1.00	13.45	O
	ATOM	1267	N	THR	A	182	1.468	28.483	29.727	1.00	17.74	N
	ATOM	1268	CA	THR	A	182	1.210	27.812	30.998	1.00	23.56	C
	ATOM	1269	C	THR	A	182	0.141	26.728	31.019	1.00	26.44	C
70	ATOM	1270	O	THR	A	182	-0.071	26.088	32.052	1.00	29.65	O
	ATOM	1271	CB	THR	A	182	0.841	28.841	32.073	1.00	24.55	C
	ATOM	1272	OG1	THR	A	182	-0.378	29.497	31.701	1.00	27.19	O
	ATOM	1273	CG2	THR	A	182	1.940	29.877	32.211	1.00	28.36	C
	ATOM	1274	N	THR	A	183	-0.540	26.517	29.901	1.00	27.09	N
75	ATOM	1275	CA	THR	A	183	-1.573	25.494	29.866	1.00	33.19	C
	ATOM	1276	C	THR	A	183	-1.835	25.008	28.447	1.00	33.29	C
	ATOM	1277	O	THR	A	183	-1.707	25.765	27.484	1.00	34.57	O
	ATOM	1278	CB	THR	A	183	-2.888	26.020	30.477	1.00	33.38	C

- 237 -

	ATOM	1279	OG1	THR	A	183	-3.822	24.942	30.602	1.00	39.37		O
	ATOM	1280	CG2	THR	A	183	-3.486	27.105	29.600	1.00	36.39		C
	ATOM	1281	N	ASP	A	184	-2.210	23.739	28.330	1.00	33.90		N
	ATOM	1282	CA	ASP	A	184	-2.489	23.133	27.035	1.00	36.90		C
5	ATOM	1283	C	ASP	A	184	-3.988	23.017	26.769	1.00	36.93		C
	ATOM	1284	O	ASP	A	184	-4.744	23.965	26.985	1.00	38.19		O
	ATOM	1285	CB	ASP	A	184	-1.841	21.749	26.980	1.00	36.49		C
	ATOM	1286	CG	ASP	A	184	-0.497	21.713	27.682	1.00	39.84		C
	ATOM	1287	OD1	ASP	A	184	0.341	22.597	27.400	1.00	40.10		O
10	ATOM	1288	OD2	ASP	A	184	-0.279	20.804	28.515	1.00	34.43		O
	TER	1289		ASP	A	184							
	ATOM	1290	O	*1		1	13.322	21.904	47.897	1.00	25.15	LIGA	O
	ATOM	1291	H	*1		1	12.748	22.438	47.362	1.00	20.00	LIGA	H
	ATOM	1292	S	*1		1	14.827	22.185	47.500	1.00	22.18	LIGA	S
15	ATOM	1293	O	*1		1	15.755	21.317	48.284	1.00	26.48	LIGA	O
	ATOM	1294	O	*1		1	15.030	21.926	46.041	1.00	26.21	LIGA	O
	ATOM	1295	O	*1		1	15.058	23.692	47.860	1.00	25.81	LIGA	O
	ATOM	1296	H	*1		1	15.899	23.969	47.521	1.00	20.00	LIGA	H
	TER	1297		*1		1							
20	ATOM	1298	O	*1		1	8.257	10.233	23.934	1.00	51.93	LIGA	O
	ATOM	1299	H	*1		1	8.965	10.771	24.260	1.00	20.00	LIGA	H
	ATOM	1300	S	*1		1	7.968	9.064	24.968	1.00	52.38	LIGA	S
	ATOM	1301	O	*1		1	6.699	8.342	24.628	1.00	53.41	LIGA	O
	ATOM	1302	O	*1		1	9.106	8.094	25.015	1.00	51.29	LIGA	O
25	ATOM	1303	O	*1		1	7.802	9.828	26.339	1.00	52.66	LIGA	O
	ATOM	1304	H	*1		1	7.532	9.218	27.014	1.00	20.00	LIGA	H
	TER	1305		*1		1							
	ATOM	1306	O	*1		1	31.870	41.807	26.377	1.00	77.97	LIGA	O
	ATOM	1307	H	*1		1	32.101	42.067	27.259	1.00	20.00	LIGA	H
30	ATOM	1308	S	*1		1	33.167	41.279	25.641	1.00	81.24	LIGA	S
	ATOM	1309	O	*1		1	33.774	40.123	26.382	1.00	80.04	LIGA	O
	ATOM	1310	O	*1		1	32.867	40.862	24.230	1.00	80.50	LIGA	O
	ATOM	1311	O	*1		1	34.119	42.548	25.670	1.00	79.65	LIGA	O
	ATOM	1312	H	*1		1	34.951	42.330	25.269	1.00	20.00	LIGA	H
35	TER	1313		*1		1							
	ATOM	1314	O	HOH	W	1	19.154	20.019	28.345	1.00	14.14	S	O
	ATOM	1315	O	HOH	W	2	23.228	15.643	36.576	1.00	16.94	S	O
	ATOM	1316	O	HOH	W	3	9.851	19.721	10.708	1.00	13.00	S	O
	ATOM	1317	O	HOH	W	4	8.807	18.269	21.008	1.00	14.72	S	O
40	ATOM	1318	O	HOH	W	5	4.955	20.914	9.889	1.00	26.47	S	O
	ATOM	1319	O	HOH	W	6	17.303	10.248	31.329	1.00	20.21	S	O
	ATOM	1320	O	HOH	W	7	21.419	36.535	33.815	1.00	20.37	S	O
	ATOM	1321	O	HOH	W	8	17.558	29.940	39.867	1.00	20.33	S	O
	ATOM	1322	O	HOH	W	9	6.195	26.062	12.062	1.00	15.73	S	O
45	ATOM	1323	O	HOH	W	10	27.195	16.076	37.425	1.00	23.27	S	O
	ATOM	1324	O	HOH	W	11	7.569	24.195	27.699	1.00	15.49	S	O
	ATOM	1325	O	HOH	W	12	9.918	10.244	27.897	1.00	14.73	S	O
	ATOM	1326	O	HOH	W	13	18.578	40.541	22.823	1.00	17.35	S	O
	ATOM	1327	O	HOH	W	14	12.929	31.417	36.841	1.00	14.91	S	O
50	ATOM	1328	O	HOH	W	15	18.919	21.848	17.030	1.00	16.90	S	O
	ATOM	1329	O	HOH	W	16	16.648	20.485	10.072	1.00	19.27	S	O
	ATOM	1330	O	HOH	W	17	22.460	33.500	36.980	1.00	16.01	S	O
	ATOM	1331	O	HOH	W	18	3.488	17.715	36.292	1.00	27.12	S	O
	ATOM	1332	O	HOH	W	19	19.370	14.862	9.712	1.00	13.10	S	O
55	ATOM	1333	O	HOH	W	20	19.355	40.188	27.351	1.00	20.79	S	O
	ATOM	1334	O	HOH	W	21	16.874	12.423	21.691	1.00	24.23	S	O
	ATOM	1335	O	HOH	W	22	18.521	38.452	20.251	1.00	22.43	S	O
	ATOM	1336	O	HOH	W	23	10.797	19.540	36.865	1.00	27.07	S	O
	ATOM	1337	O	HOH	W	24	11.234	19.209	19.064	1.00	21.16	S	O
60	ATOM	1338	O	HOH	W	25	11.110	10.795	24.566	1.00	21.70	S	O
	ATOM	1339	O	HOH	W	26	10.089	25.686	42.195	1.00	27.30	S	O
	ATOM	1340	O	HOH	W	27	5.885	26.924	28.544	1.00	17.14	S	O
	ATOM	1341	O	HOH	W	28	22.189	13.924	20.647	1.00	19.65	S	O
	ATOM	1342	O	HOH	W	29	2.839	15.407	25.779	1.00	24.76	S	O
65	ATOM	1343	O	HOH	W	30	20.416	36.872	30.702	1.00	22.38	S	O
	ATOM	1344	O	HOH	W	31	14.010	25.569	46.267	1.00	20.18	S	O
	ATOM	1345	O	HOH	W	32	19.103	14.781	19.716	1.00	25.71	S	O
	ATOM	1346	O	HOH	W	33	14.999	33.688	35.037	1.00	17.93	S	O
	ATOM	1347	O	HOH	W	35	23.578	36.561	29.922	1.00	21.76	S	O
70	ATOM	1348	O	HOH	W	36	20.341	32.322	45.950	1.00	21.47	S	O
	ATOM	1349	O	HOH	W	37	0.497	25.775	19.401	1.00	26.47	S	O
	ATOM	1350	O	HOH	W	38	11.741	34.995	39.424	1.00	22.41	S	O
	ATOM	1351	O	HOH	W	39	22.467	9.409	26.630	1.00	15.84	S	O
	ATOM	1352	O	HOH	W	40	22.662	11.866	36.367	1.00	45.41	S	O
75	ATOM	1353	O	HOH	W	41	3.122	26.816	16.542	1.00	23.85	S	O
	ATOM	1354	O	HOH	W	42	6.805	20.983	12.758	1.00	24.18	S	O
	ATOM	1355	O	HOH	W	43	29.143	24.285	40.975	1.00	26.61	S	O
	ATOM	1356	O	HOH	W	44	24.253	18.985	43.742	1.00	21.24	S	O

- 238 -

	ATOM	1357	O	HOH	W	45	16.923	33.119	42.439	1.00	24.24	S	O
	ATOM	1358	O	HOH	W	46	-0.710	24.821	24.871	1.00	22.41	S	O
	ATOM	1359	O	HOH	W	47	28.123	37.039	34.996	1.00	23.29	S	O
	ATOM	1360	O	HOH	W	48	22.509	29.264	12.288	1.00	22.20	S	O
5	ATOM	1361	O	HOH	W	49	18.268	20.963	47.186	1.00	27.23	S	O
	ATOM	1362	O	HOH	W	50	25.603	33.211	43.598	1.00	26.97	S	O
	ATOM	1363	O	HOH	W	51	20.065	33.475	8.796	1.00	27.50	S	O
	ATOM	1364	O	HOH	W	52	27.258	11.820	29.311	1.00	24.08	S	O
	ATOM	1365	O	HOH	W	53	10.875	28.986	41.865	1.00	23.77	S	O
10	ATOM	1366	O	HOH	W	54	5.763	34.393	31.210	1.00	25.54	S	O
	ATOM	1367	O	HOH	W	55	13.975	14.195	21.784	1.00	27.82	S	O
	ATOM	1368	O	HOH	W	56	12.541	23.538	8.045	1.00	22.43	S	O
	ATOM	1369	O	HOH	W	57	24.567	16.480	39.993	1.00	26.58	S	O
	ATOM	1370	O	HOH	W	58	24.532	38.285	35.829	1.00	57.74	S	O
15	ATOM	1371	O	HOH	W	59	25.710	22.863	22.059	1.00	31.50	S	O
	ATOM	1372	O	HOH	W	60	12.323	34.306	43.203	1.00	31.10	S	O
	ATOM	1373	O	HOH	W	61	4.395	14.949	17.739	1.00	29.65	S	O
	ATOM	1374	O	HOH	W	62	6.745	20.043	6.966	1.00	84.14	S	O
	ATOM	1375	O	HOH	W	63	5.532	20.170	37.794	1.00	41.49	S	O
20	ATOM	1376	O	HOH	W	64	26.003	16.001	22.248	1.00	29.03	S	O
	ATOM	1377	O	HOH	W	65	5.525	35.401	19.570	1.00	33.21	S	O
	ATOM	1378	O	HOH	W	66	31.845	33.895	37.644	1.00	34.28	S	O
	ATOM	1379	O	HOH	W	67	20.183	13.414	38.159	1.00	27.70	S	O
	ATOM	1380	O	HOH	W	68	20.038	18.219	20.060	1.00	50.13	S	O
25	ATOM	1381	O	HOH	W	70	0.763	17.179	17.010	1.00	37.46	S	O
	ATOM	1382	O	HOH	W	71	24.671	21.255	26.579	1.00	25.15	S	O
	ATOM	1383	O	HOH	W	72	8.061	13.765	23.048	1.00	31.32	S	O
	ATOM	1384	O	HOH	W	73	21.384	36.182	15.238	1.00	25.91	S	O
	ATOM	1385	O	HOH	W	74	32.543	19.236	37.104	1.00	32.62	S	O
30	ATOM	1386	O	HOH	W	75	3.201	29.276	38.786	1.00	44.04	S	O
	ATOM	1387	O	HOH	W	76	2.482	32.835	31.391	1.00	47.33	S	O
	ATOM	1388	O	HOH	W	77	22.558	9.563	30.212	1.00	60.39	S	O
	ATOM	1389	O	HOH	W	78	24.502	25.394	46.538	1.00	35.15	S	O
	ATOM	1390	O	HOH	W	79	7.028	39.862	28.058	1.00	31.57	S	O
35	ATOM	1391	O	HOH	W	80	33.571	14.425	35.307	1.00	26.04	S	O
	ATOM	1392	O	HOH	W	81	2.732	10.198	34.775	1.00	30.67	S	O
	ATOM	1393	O	HOH	W	82	34.746	11.362	31.655	1.00	34.37	S	O
	ATOM	1394	O	HOH	W	83	27.003	10.835	24.556	1.00	34.40	S	O
	ATOM	1395	O	HOH	W	84	11.607	15.263	18.090	1.00	53.18	S	O
40	ATOM	1396	O	HOH	W	85	18.961	26.409	8.948	1.00	30.64	S	O
	ATOM	1397	O	HOH	W	86	8.329	30.456	11.682	1.00	24.79	S	O
	ATOM	1398	O	HOH	W	87	28.267	25.545	24.816	1.00	34.18	S	O
	ATOM	1399	O	HOH	W	88	27.826	26.788	46.520	1.00	45.31	S	O
	ATOM	1400	O	HOH	W	89	13.822	23.152	43.665	1.00	23.81	S	O
45	ATOM	1401	O	HOH	W	90	15.013	32.301	6.825	1.00	36.86	S	O
	ATOM	1402	O	HOH	W	91	7.321	15.444	19.576	1.00	38.03	S	O
	ATOM	1403	O	HOH	W	92	9.274	4.160	30.626	1.00	34.25	S	O
	ATOM	1404	O	HOH	W	93	1.045	23.765	33.021	1.00	29.72	S	O
	ATOM	1405	O	HOH	W	94	0.274	28.435	36.491	1.00	39.40	S	O
50	ATOM	1406	O	HOH	W	95	26.351	23.628	18.493	1.00	37.43	S	O
	ATOM	1407	O	HOH	W	96	34.940	15.280	30.014	1.00	38.02	S	O
	ATOM	1408	O	HOH	W	97	20.426	30.014	49.201	1.00	33.87	S	O
	ATOM	1409	O	HOH	W	98	13.509	20.866	41.132	1.00	41.63	S	O
	ATOM	1410	O	HOH	W	99	28.366	18.133	31.889	1.00	32.04	S	O
55	ATOM	1411	O	HOH	W	100	0.422	36.030	31.986	1.00	42.04	S	O
	ATOM	1412	O	HOH	W	103	13.872	24.846	4.468	1.00	45.22	S	O
	ATOM	1413	O	HOH	W	104	25.742	19.925	19.691	1.00	41.00	S	O
	ATOM	1414	O	HOH	W	105	5.894	32.368	37.453	1.00	28.07	S	O
	ATOM	1415	O	HOH	W	108	27.692	30.529	45.176	1.00	36.94	S	O
60	ATOM	1416	O	HOH	W	109	30.999	38.392	25.165	1.00	26.39	S	O
	ATOM	1417	O	HOH	W	111	13.400	10.503	34.273	1.00	29.92	S	O
	ATOM	1418	O	HOH	W	112	20.748	36.914	39.970	1.00	40.16	S	O
	ATOM	1419	O	HOH	W	113	24.634	31.190	17.336	1.00	36.87	S	O
	ATOM	1420	O	HOH	W	114	5.642	30.898	42.120	1.00	38.57	S	O
65	ATOM	1421	O	HOH	W	115	8.972	40.592	30.979	1.00	32.13	S	O
	ATOM	1422	O	HOH	W	116	2.047	31.605	35.777	1.00	62.75	S	O
	ATOM	1423	O	HOH	W	117	27.060	7.939	28.519	1.00	31.51	S	O
	ATOM	1424	O	HOH	W	118	4.134	24.143	10.395	1.00	19.77	S	O
	ATOM	1425	O	HOH	W	119	17.406	32.729	38.273	1.00	19.77	S	O
70	ATOM	1426	O	HOH	W	120	21.370	42.268	22.477	1.00	19.75	S	O
	ATOM	1427	O	HOH	W	121	23.854	15.724	43.136	1.00	19.76	S	O
	ATOM	1428	O	HOH	W	122	19.654	34.836	37.602	1.00	19.76	S	O
	ATOM	1429	O	HOH	W	123	21.170	42.930	27.470	1.00	19.75	S	O
	ATOM	1430	O	HOH	W	124	25.304	8.005	25.551	1.00	19.75	S	O
75	ATOM	1431	O	HOH	W	125	20.739	40.152	30.476	1.00	19.73	S	O
	ATOM	1432	O	HOH	W	126	19.238	15.779	6.587	1.00	19.76	S	O
	ATOM	1433	O	HOH	W	127	7.151	28.097	9.617	1.00	19.75	S	O
	ATOM	1434	O	HOH	W	128	7.122	17.869	11.543	1.00	19.75	S	O

- 239 -

	ATOM	1435	O	HOH W 129	9.467	35.418	37.012	1.00	19.76	S	O
	ATOM	1436	O	HOH W 130	5.720	23.417	6.558	1.00	19.76	S	O
	ATOM	1437	O	HOH W 131	3.123	12.568	32.283	1.00	19.76	S	O
	ATOM	1438	O	HOH W 132	12.909	18.142	39.232	1.00	19.75	S	O
5	ATOM	1439	O	HOH W 133	18.190	34.668	45.077	1.00	19.77	S	O
	ATOM	1440	O	HOH W 134	16.371	23.490	8.743	1.00	19.77	S	O
	ATOM	1441	O	HOH W 135	25.889	26.341	15.721	1.00	19.77	S	O
	ATOM	1442	O	HOH W 138	18.831	37.368	35.694	1.00	19.75	S	O
	ATOM	1443	O	HOH W 139	-1.837	27.004	34.243	1.00	19.78	S	O
10	ATOM	1444	O	HOH W 140	29.965	21.328	39.814	1.00	19.75	S	O
	ATOM	1445	O	HOH W 141	29.084	22.512	22.380	1.00	19.74	S	O
	ATOM	1446	O	HOH W 144	26.825	34.183	16.982	1.00	19.75	S	O
	ATOM	1447	O	HOH W 146	28.060	21.125	26.874	1.00	19.76	S	O
	ATOM	1448	O	HOH W 147	7.953	28.465	43.320	1.00	19.76	S	O
15	ATOM	1449	O	HOH W 148	25.139	13.555	38.510	1.00	19.76	S	O
	ATOM	1450	O	HOH W 154	27.898	15.263	40.931	1.00	19.75	S	O
	ATOM	1451	O	HOH W 157	29.305	18.029	39.665	1.00	19.76	S	O
	ATOM	1452	O	HOH W 158	22.038	30.753	9.108	1.00	19.76	S	O
	ATOM	1453	O	HOH W 159	18.399	11.163	36.207	1.00	19.76	S	O
20	ATOM	1454	O	HOH W 164	26.335	11.937	35.945	1.00	19.75	S	O
	ATOM	1455	O	HOH W 165	1.758	29.855	17.357	1.00	19.75	S	O
	ATOM	1456	O	HOH W 166	24.163	39.471	32.170	1.00	19.76	S	O
	ATOM	1457	O	HOH W 170	16.077	17.918	7.749	1.00	19.75	S	O
	ATOM	1458	O	HOH W 172	32.921	14.044	27.295	1.00	19.76	S	O
25	ATOM	1459	O	HOH W 177	32.795	38.969	32.954	1.00	19.77	S	O
	ATOM	1460	O	HOH W 179	4.059	6.708	28.892	1.00	19.75	S	O
	ATOM	1461	O	HOH W 180	25.397	29.865	14.090	1.00	19.76	S	O
	ATOM	1462	O	HOH W 182	11.078	20.731	43.859	1.00	19.77	S	O
	ATOM	1463	O	HOH W 184	30.825	30.779	39.402	1.00	19.77	S	O
30	ATOM	1464	O	HOH W 187	10.289	21.108	7.474	1.00	19.75	S	O
	ATOM	1465	O	HOH W 189	27.314	38.906	38.135	1.00	19.76	S	O
	ATOM	1466	O	HOH W 197	25.884	26.959	11.320	1.00	19.70	S	O
	ATOM	1467	O	HOH W 209	9.364	16.866	38.731	1.00	19.73	S	O
	ATOM	1468	O	HOH W 219	32.352	16.134	38.786	1.00	19.73	S	O
35	ATOM	1469	O	HOH W 221	15.972	35.898	37.609	1.00	19.69	S	O
	ATOM	1470	O	HOH W 223	3.319	35.758	13.483	1.00	19.71	S	O
	TER	1471		HOH W 223							
	END										

40

The surface accessible residues of ASP were determined from the crystallographic coordinates provided above, using the program DS Modeling (Accelrys), using the default settings. The total surface accessibility (SA) for ASP was found to be 8044.777 Angstroms. Table 19-2 provides the total SA, side chain SA, and percent SAS is the percentage of an amino acid's total surface that is accessible to solvent.

Table 19-2. Total Surface Accessibility of ASP

50

	Residue	Total SA ang ²	SideChain SA ang ²	Percent SAS
	asp 1:Phe	89.992	66.420	36.954
	asp 2:Asp	85.970	68.625	48.199
	asp 4:Ile	17.921	12.076	9.714
55	asp 7:Asn	40.541	40.541	21.246
	asp 8:Ala	41.497	24.153	35.259
	asp 10:Thr	35.846	35.846	21.190
	asp 11:Ile	29.424	18.114	17.028
	asp 12:Gly	81.658	30.191	73.513
60	asp 13:Gly	75.236	18.114	67.615
	asp 14:Arg	124.289	124.289	55.664
	asp 15:Ser	29.424	29.424	19.554
	asp 16:Arg	105.411	88.447	38.127
	asp 22:Ala	11.690	0.000	9.932
65	asp 24:Asn	71.105	65.067	47.079
	asp 25:Gly	53.190	30.191	43.325
	asp 32:His	34.693	17.728	19.568

- 240 -

	asp 34:Gly	18.114	12.076	20.656
	asp 35:Arg	177.087	171.242	69.918
	asp 36:Thr	87.506	64.886	45.401
	asp 37:Gly	58.465	24.153	55.659
5	asp 38:Ala	18.114	12.076	16.195
	asp 39:Thr	99.579	87.889	55.002
	asp 40:Thr	11.310	0.000	6.469
	asp 41:Ala	36.229	36.229	38.182
	asp 42:Asn	86.537	74.844	43.919
10	asp 43:Pro	6.038	0.000	4.599
	asp 44:Thr	111.082	99.582	59.375
	asp 45:Gly	6.038	6.038	5.436
	asp 46:Thr	52.427	52.427	28.958
	asp 47:Phe	5.655	0.000	2.715
15	asp 48:Ala	58.848	30.191	52.705
	asp 49:Gly	12.076	12.076	12.937
	asp 50:Ser	51.274	0.000	37.049
	asp 51:Ser	17.348	17.348	11.573
	asp 52:Phe	52.040	12.076	25.034
20	asp 53:Pro	53.193	36.229	40.511
	asp 54:Gly	30.191	30.191	27.274
	asp 55:Asn	34.499	34.499	18.613
	asp 57:Tyr	28.658	28.658	11.861
	asp 59:Phe	18.114	18.114	9.808
25	asp 61:Arg	146.706	141.051	59.429
	asp 62:Thr	22.619	5.655	12.939
	asp 63:Gly	17.538	6.038	17.646
	asp 64:Ala	112.229	60.381	90.564
	asp 65:Gly	70.535	30.191	60.226
30	asp 66:Val	16.965	0.000	10.967
	asp 67:Asn	69.002	62.964	39.692
	asp 68:Leu	34.503	6.038	16.536
	asp 69:Leu	42.267	42.267	20.295
	asp 71:Gln	39.774	39.774	18.552
35	asp 73:Asn	17.345	17.345	8.760
	asp 74:Asn	41.301	41.301	25.351
	asp 75:Tyr	93.544	47.922	37.830
	asp 76:Ser	97.666	52.044	76.965
	asp 77:Gly	81.275	24.153	73.294
40	asp 78:Gly	17.921	12.076	18.067
	asp 79:Arg	139.911	94.292	56.632
	asp 80:Val	36.229	30.191	22.621
	asp 81:Gln	82.421	70.921	37.295
	asp 83:Ala	41.117	24.153	33.386
45	asp 84:Gly	12.076	12.076	12.151
	asp 85:His	71.298	65.454	36.451
	asp 86:Thr	111.082	93.544	65.517
	asp 87:Ala	64.886	42.267	52.523
	asp 88:Ala	12.076	6.038	10.760
50	asp 89:Pro	90.572	78.496	58.405
	asp 90:Val	94.694	66.420	53.062
	asp 91:Gly	58.082	18.114	49.593
	asp 92:Ser	34.886	23.003	27.450
	asp 93:Ala	83.381	60.381	70.846
55	asp 95:Cys	26.565	26.565	15.773
	asp 99:Ser	39.584	0.000	29.907
	asp 100:Thr	87.123	47.155	48.121
	asp 101:Thr	34.696	6.038	22.060
	asp 102:Gly	12.076	12.076	13.771
60	asp 103:Trp	70.728	47.919	27.630
	asp 104:His	47.726	41.687	23.152
	asp 105:Cys	54.609	31.799	33.796
	asp 106:Gly	23.386	12.076	23.531
	asp 107:Thr	47.155	47.155	29.873
65	asp 108:Ile	5.655	0.000	2.888
	asp 109:Thr	64.503	30.191	35.741
	asp 110:Ala	24.153	24.153	21.668
	asp 111:Leu	71.115	48.305	36.142
	asp 112:Asn	138.770	104.841	66.301
70	asp 113:Ser	17.731	11.693	12.794
	asp 114:Ser	92.391	52.427	63.967
	asp 115:Val	30.191	24.153	18.166

- 241 -

	asp 116:Thr	128.237	82.618	66.534
	asp 117:Tyr	35.846	24.153	15.603
	asp 118:Pro	159.964	102.648	93.188
	asp 119:Glu	132.745	87.123	63.766
5	asp 120:Gly	18.114	18.114	20.611
	asp 121:Thr	93.924	76.579	48.828
	asp 123:Arg	129.748	129.748	59.619
	asp 124:Gly	29.231	12.076	26.315
	asp 126:Ile	6.038	6.038	3.084
10	asp 127:Arg	99.943	99.943	36.957
	asp 128:Thr	5.655	0.000	3.450
	asp 129:Thr	76.579	59.615	45.219
	asp 130:Val	0.000	0.000	0.000
	asp 131:Cys	25.568	19.723	18.583
15	asp 132:Ala	11.693	6.038	9.495
	asp 133:Glu	40.734	29.041	20.057
	asp 134:Pro	114.531	102.648	68.994
	asp 135:Gly	11.883	6.038	11.979
	asp 137:Ser	5.655	5.655	3.915
20	asp 143:Ala	17.731	6.038	18.763
	asp 144:Gly	59.612	36.229	63.599
	asp 145:Asn	81.832	70.142	44.061
	asp 146:Gln	52.810	52.810	27.510
	asp 147:Ala	5.655	0.000	4.797
25	asp 148:Gln	11.500	5.845	5.335
	asp 152:Ser	5.655	0.000	4.092
	asp 153:Gly	24.153	18.114	25.819
	asp 154:Gly	63.927	12.076	64.322
	asp 155:Ser	88.656	70.541	69.864
30	asp 156:Gly	52.807	18.114	50.090
	asp 157:Asn	35.263	35.263	20.195
	asp 158:Cys	34.312	6.038	21.893
	asp 159:Arg	199.716	154.094	79.090
	asp 160:Thr	135.044	89.422	85.862
35	asp 161:Gly	35.462	24.153	33.699
	asp 162:Gly	23.576	6.038	21.225
	asp 163:Thr	46.005	46.005	25.438
	asp 164:Thr	5.655	5.655	3.127
	asp 165:Phe	24.153	24.153	10.669
40	asp 167:Gln	5.845	5.845	3.042
	asp 168:Pro	48.305	48.305	31.227
	asp 170:Asn	59.032	53.377	31.882
	asp 171:Pro	59.615	42.267	42.027
	asp 173:Leu	17.731	12.076	8.274
45	asp 174:Gln	145.572	122.569	80.497
	asp 175:Ala	52.044	6.038	44.291
	asp 176:Tyr	64.886	36.229	29.811
	asp 177:Gly	69.775	24.153	70.340
	asp 178:Leu	11.693	6.038	5.788
50	asp 179:Arg	182.932	182.932	72.390
	asp 180:Met	34.886	12.076	17.253
	asp 181:Ile	36.229	30.191	19.053
	asp 182:Thr	99.389	76.579	60.785
	asp 183:Thr	104.854	93.544	68.979
55	asp 184:Asp	122.008	23.386	52.822

The ASP co-ordinates, and those of homologous structures were loaded into MOE (Chemical Computing Group). Co-ordinates for waters and ligands were removed. Using MOE align, the structures were aligned using actual secondary structure, with structural alignment enabled and superpose chains enabled. This resulted in the following structural alignment. The numbers indicated refer to the mature ASP protease amino-acid sequence.

- 242 -

		1	10	20	30	40
	ASP	FDVIGGNAYTIG-GRSRC	SIGFAVN-----GGFITAGHCGRTGATTAN-----	PTGTFA		
	1HPG	--VLGGGAIYGG-GSR-CSAAFNVTK-GGARYFVTAGHCTNISANWSASS-GGSVVG	VRE			
	1SGP	--ISGGDAIYSS-TGR-CSLGFNVRS-GSTYYFLTAGHCTDGATWWANSARTTVLGTTS				
5	1TAL	ANIVGGIEYSINNASL-CSVGFSVTR-GATKGFVTAGHCGTVNATARIG--GAVVG	TFA			
	2SFA	--IAGGEAIYAAGGGR-CSLGFNVRS	SSGATYALTAGHCTEIASTWYTNSGQTSLLGT	TRA		
	2SGA	--IAGGEAITT-GGSR-CSLGFNVSV-NGVAHALTAGHCTNISASWS-----	IGTRT			
	PDB ID					
10		50	60	70	80	90
	ASP	GSSFFPGNDYAFVRTGAG-VNLLAQVNNYSGGRVQVAGHTAAPVGS	AVCRSGSTTGWHCCT			
	1HPG	GTSPFTNDYGIVRYTDG-SSPAGTVDLYNGSTQDISSAANAVVGQA	IKKSGSTTKVTS	GT		
	1SGP	GSSFFPNNDYGIVRYTNTTIPKDGTVG-----GQDITSAANATV	GMAVTRRGSTTGTHSGS			
	1TAL	ARVFPGNDRAWSLTSA-QTLLPRVANG-SSFVTVRGSTEAAVGA	AVCRSGRTTG	YQCCT		
15	2SFA	GTSPFPNDYGLIRHSNA-SAADGRVLYNGSYRDITGAGNAYVGQ	TVQRSGSTTGLHSGR			
	2SGA	GTSPFPNDYGIIIRHSNP-AAADGRVLYNGSYQDITTAGNAFVGQ	AVQRSGSTTGLRSGS			
	PDB ID					
		110	120	130	140	150
20	ASP	ITALNSSSVTYPE-GTVRGLIRTTVCAEPGDSGGSLLA-GNQAQ	GVTS	GGSG-----NCRT		
	1HPG	VTAVNVTVNYGD-GPVYNMVRTTACSAGGDSGGAHFA-GSVALGI	HSGSSG-----CSG			
	1SGP	VTALNATVNYGGDVVYGMIRTNVCAEPGDSGGPLYSG-TRA	IGLTS	GGSG-----NCSS		
	1TAL	ITAKNVTANYAE-GAVRGLTQGNACMGRGDSGGSWITSAGQAQ	GVMSGGNVQSN	GNNGCI		
	2SFA	VTGLNATVNYGGDIVSGLIQTNVCAEPGDSGGALFA-GSTALGL	TS	GGSG-----NCRT		
25	2SGA	VTGLNATVNYGSSGIVYGMIQTNVCAQPGDSGGSLFA-GSTALGL	TS	GGSG-----NCRT		
	PDB ID					
		170	180			
	ASP	G---GTTFFQPVNPILQAYGLRMITTD	(SEQ ID NO: 624)			
30	1HPG	TA--GSAIHQPVTEALSAYGVTVY---	(SEQ ID NO: 625)			
	1SGP	G---GTTFFQPVTEALVAYGVSVY---	(SEQ ID NO: 626)			
	1TAL	PASQRSSLFERLQPILSQYGLSLVTG-	(SEQ ID NO: 627)			
	2SFA	G---GTTFFQPVTEALSAYGVSI---	(SEQ ID NO: 628)			
	2SGA	G---GTTFFQPVTEALSAYGATVL---	(SEQ ID NO: 629)			
35						

In the above alignment, the codes are as follows:

1HPG = Streptomyces griseus glutamic acid specific protease.

1SGP = Streptomyces griseus proteinase B

1SGT = Streptomyces griseus strain K1 trypsin

1TAL = Lysobacter enzymogenes alpha-lytic protease

2SFA = Streptomyces fradiae serine proteinase

2SGA = Streptomyces griseus protease A

EXAMPLE 20

Enzyme Substrate Modeling and Mapping of the ASP Active-Site

In this Example, enzyme-substrate modeling and mapping of the ASP active site methods are described. Preliminary inspection of the active-site revealed a large P1 binding pocket that is large enough to accommodate large hydrophobic groups such as the side-chains of Trp, Tyr, and Phe.

The crystal structure of Streptogrisin A with the turkey third domain of the ovomucoid inhibitor (pdb code 2SGB) was been determined. 2SGB was structurally aligned to ASP, using MOE (Chemical Computing Corp), which places the inhibitor in the active-site of ASP.

- 243 -

All of the 2SGB co-ordinates were removed, except for those which define a hexa-peptide bound in the ASP active-site, corresponding to binding at the S4 to S2' binding sites. The Pro-ASP protein self-cleaves the pro domain-mature domain junction, to release the mature protease enzyme. The last four residues of the pro domain are expected to occupy the S1-S4 sites, and the first two residues of the mature protease occupy the S1' and S2' sites. Therefore the hexapeptide in the active-site was *in-silico* mutated to sequence PRTMFD (SEQ ID NO:630).

From inspection of the structure of the initial substrate bound model, the backbone amide of Gly135 and Asp136 would be expected to form the oxy-anion hole. However, the amide nitrogen of Gly135 appears to point in the wrong direction. Comparison with streptogrisin A confirms this. Thus, it is presumed that a conformational change in ASP is required to form the oxy-anion hole. However, it is not intended that the present invention be limited by any particular mechanism nor hypothesis. The peptide backbone between residues 134 and 135 was altered to that of a similar orientation to that of structurally equivalent atoms in the streptogrisin A structure. The enzyme substrate model was then energy minimized.

Residues within 6 Å of the modeled substrate were determined using the proximity tools within the program QUANTA. These residues were identified as: Arg14, Ser15, Arg16, Cys17, His32, Cys33, Phe52, Asp56, Thr100, Val115, Thr116, Tyr117, Pro118, Glu119, Ala132, Glu133, Pro134, Gly135, Asp136, Ser137, Thr151, Ser152, Gly153, Gly154, Ser155, Gly156, Asn157, Thr164, Phe165. Of these, His 32, Asp56, and Ser137 form the catalytic triad.

The P1 pocket is formed by Cys131, Ala132, Glu133, Pro134, Gly135, Thr151, Ser152, Gly153, Gly154, Ser155, Gly156, Asn157 and Gly 162, Thr 163, Thr164. The P2 pocket is defined by Phe52, Tyr117, Pro118 and Glu119. The P3 pocket has main-chain to main chain hydrogen bonding from Gly 154 to the substrate main-chain. The P1' pocket is defined by Arg16, and His32. The P2' pocket is defined by Thr100, and Pro134. The atomic coordinates of ASP with the modeled octapeptide substrate are provided in Table 20-1 below.

Table 20-1. Atomic Coordinates of ASP with the Modeled Octapeptide Substrate

ATOM	1	N	PHE	A	1	2.452	18.495	15.165	0.00	N1+
ATOM	2	CA	PHE	A	1	3.712	18.208	15.901	0.00	C
ATOM	3	CB	PHE	A	1	4.906	18.646	15.055	0.00	C
ATOM	4	C	PHE	A	1	3.743	18.914	17.254	0.00	C
ATOM	5	O	PHE	A	1	3.539	20.133	17.340	0.00	O
ATOM	6	CG	PHE	A	1	6.232	18.405	15.707	0.00	C
ATOM	7	CD2	PHE	A	1	6.963	17.268	15.411	0.00	C

- 244 -

	ATOM	8	CD1	PHE	A	1	6.750	19.312	16.618	0.00	
	ATOM	9	CE2	PHE	A	1	8.192	17.035	16.010	0.00	C
	ATOM	10	CE1	PHE	A	1	7.981	19.086	17.222	0.00	C
	ATOM	11	CZ	PHE	A	1	8.702	17.946	16.917	0.00	C
5	ATOM	12	N	ASP	A	2	4.000	18.148	18.311	0.00	N
	ATOM	13	CA	ASP	A	2	4.052	18.708	19.659	0.00	C
	ATOM	14	CB	ASP	A	2	3.584	17.678	20.688	0.00	C
	ATOM	15	C	ASP	A	2	5.422	19.210	20.066	0.00	C
	ATOM	16	O	ASP	A	2	6.415	18.508	19.925	0.00	O
10	ATOM	17	CG	ASP	A	2	2.109	17.354	20.560	0.00	C
	ATOM	18	OD2	ASP	A	2	1.597	16.558	21.379	0.00	O1-
	ATOM	19	OD1	ASP	A	2	1.459	17.889	19.638	0.00	O
	ATOM	20	N	VAL	A	3	5.464	20.440	20.562	0.00	N
	ATOM	21	CA	VAL	A	3	6.707	21.057	21.009	0.00	C
15	ATOM	22	CB	VAL	A	3	6.736	22.574	20.718	0.00	C
	ATOM	23	C	VAL	A	3	6.737	20.837	22.513	0.00	C
	ATOM	24	O	VAL	A	3	5.806	21.233	23.216	0.00	O
	ATOM	25	CG1	VAL	A	3	7.921	23.222	21.425	0.00	C
	ATOM	26	CG2	VAL	A	3	6.840	22.810	19.220	0.00	C
20	ATOM	27	CB	ILE	A	4	7.602	18.448	24.730	0.00	C
	ATOM	28	CG2	ILE	A	4	7.684	18.189	26.227	0.00	C
	ATOM	29	CG1	ILE	A	4	6.196	18.137	24.220	0.00	C
	ATOM	30	CD1	ILE	A	4	5.768	16.711	24.456	0.00	C
	ATOM	31	C	ILE	A	4	9.379	20.168	24.911	0.00	C
25	ATOM	32	O	ILE	A	4	10.346	19.836	24.229	0.00	O
	ATOM	33	N	ILE	A	4	7.801	20.200	22.997	0.00	N
	ATOM	34	CA	ILE	A	4	7.955	19.916	24.423	0.00	C
	ATOM	35	N	GLY	A	5	9.499	20.743	26.103	0.00	N
	ATOM	36	CA	GLY	A	5	10.807	21.030	26.653	0.00	C
30	ATOM	37	C	GLY	A	5	11.655	19.787	26.819	0.00	C
	ATOM	38	O	GLY	A	5	11.171	18.750	27.277	0.00	O
	ATOM	39	N	GLY	A	6	12.927	19.885	26.443	0.00	N
	ATOM	40	CA	GLY	A	6	13.817	18.747	26.572	0.00	C
	ATOM	41	C	GLY	A	6	14.007	17.948	25.294	0.00	C
35	ATOM	42	O	GLY	A	6	14.990	17.217	25.157	0.00	O
	ATOM	43	N	ASN	A	7	13.069	18.082	24.359	0.00	N
	ATOM	44	CA	ASN	A	7	13.155	17.351	23.100	0.00	C
	ATOM	45	CB	ASN	A	7	11.784	17.247	22.450	0.00	C
	ATOM	46	CG	ASN	A	7	10.918	16.210	23.102	0.00	C
40	ATOM	47	OD1	ASN	A	7	9.741	16.069	22.760	0.00	O
	ATOM	48	ND2	ASN	A	7	11.492	15.464	24.049	0.00	N
	ATOM	49	C	ASN	A	7	14.124	17.933	22.086	0.00	C
	ATOM	50	O	ASN	A	7	14.466	19.114	22.119	0.00	O
	ATOM	51	N	ALA	A	8	14.561	17.077	21.176	0.00	N
45	ATOM	52	CA	ALA	A	8	15.486	17.487	20.138	0.00	C
	ATOM	53	CB	ALA	A	8	16.212	16.271	19.577	0.00	C
	ATOM	54	C	ALA	A	8	14.716	18.174	19.023	0.00	C
	ATOM	55	O	ALA	A	8	13.509	17.988	18.874	0.00	O
	ATOM	56	N	TYR	A	9	15.423	18.993	18.262	0.00	N
50	ATOM	57	CA	TYR	A	9	14.847	19.714	17.143	0.00	C
	ATOM	58	CB	TYR	A	9	14.253	21.064	17.580	0.00	C
	ATOM	59	CG	TYR	A	9	15.221	22.148	17.963	0.00	C
	ATOM	60	CD2	TYR	A	9	15.517	22.398	19.301	0.00	C
	ATOM	61	CE2	TYR	A	9	16.341	23.443	19.663	0.00	C
55	ATOM	62	CD1	TYR	A	9	15.785	22.972	16.993	0.00	C
	ATOM	63	CE1	TYR	A	9	16.609	24.021	17.343	0.00	C
	ATOM	64	CZ	TYR	A	9	16.883	24.255	18.678	0.00	C
	ATOM	65	OH	TYR	A	9	17.688	25.309	19.029	0.00	O
	ATOM	66	C	TYR	A	9	16.072	19.837	16.262	0.00	C
60	ATOM	67	O	TYR	A	9	17.188	19.678	16.753	0.00	O
	ATOM	68	N	THR	A	10	15.886	20.077	14.970	0.00	N
	ATOM	69	CA	THR	A	10	17.034	20.183	14.082	0.00	C
	ATOM	70	CB	THR	A	10	17.031	19.031	13.041	0.00	C
	ATOM	71	OG1	THR	A	10	15.822	19.082	12.269	0.00	O
65	ATOM	72	CG2	THR	A	10	17.129	17.676	13.741	0.00	C
	ATOM	73	C	THR	A	10	17.205	21.488	13.329	0.00	C
	ATOM	74	O	THR	A	10	16.249	22.243	13.104	0.00	O
	ATOM	75	N	ILE	A	11	18.453	21.734	12.938	0.00	N
	ATOM	76	CA	ILE	A	11	18.828	22.930	12.197	0.00	C
70	ATOM	77	CB	ILE	A	11	19.609	23.914	13.093	0.00	C
	ATOM	78	CG2	ILE	A	11	19.855	25.221	12.343	0.00	C
	ATOM	79	CG1	ILE	A	11	18.811	24.187	14.369	0.00	C
	ATOM	80	CD1	ILE	A	11	19.546	25.036	15.385	0.00	C
	ATOM	81	C	ILE	A	11	19.712	22.442	11.054	0.00	C
75	ATOM	82	O	ILE	A	11	20.772	21.856	11.284	0.00	O
	ATOM	83	N	GLY	A	12	19.274	22.668	9.821	0.00	N
	ATOM	84	CA	GLY	A	12	20.048	22.193	8.689	0.00	C
	ATOM	85	C	GLY	A	12	20.344	20.705	8.845	0.00	C

- 245 -

	ATOM	86	O	GLY	A	12	21.439	20.239	8.523	0.00	O
	ATOM	87	N	GLY	A	13	19.373	19.957	9.361	0.00	N
	ATOM	88	CA	GLY	A	13	19.564	18.531	9.545	0.00	C
	ATOM	89	C	GLY	A	13	20.373	18.127	10.769	0.00	C
5	ATOM	90	O	GLY	A	13	20.438	16.945	11.103	0.00	O
	ATOM	91	N	ARG	A	14	20.984	19.091	11.449	0.00	N
	ATOM	92	CA	ARG	A	14	21.787	18.782	12.627	0.00	C
	ATOM	93	CB	ARG	A	14	23.036	19.670	12.669	0.00	C
	ATOM	94	C	ARG	A	14	21.018	18.938	13.935	0.00	C
10	ATOM	95	O	ARG	A	14	20.441	19.982	14.212	0.00	O
	ATOM	96	CG	ARG	A	14	24.251	19.072	11.964	0.00	C
	ATOM	97	CD	ARG	A	14	24.065	19.084	10.450	0.00	C
	ATOM	98	NE	ARG	A	14	24.173	17.752	9.858	0.00	N1+
	ATOM	99	CZ	ARG	A	14	25.316	17.100	9.660	0.00	C
15	ATOM	100	NH1	ARG	A	14	26.474	17.655	10.004	0.00	N
	ATOM	101	NH2	ARG	A	14	25.302	15.886	9.120	0.00	N
	ATOM	102	N	SER	A	15	21.016	17.878	14.733	0.00	N
	ATOM	103	CA	SER	A	15	20.335	17.870	16.017	0.00	C
	ATOM	104	CB	SER	A	15	20.062	16.429	16.454	0.00	C
20	ATOM	105	C	SER	A	15	21.312	18.525	16.983	0.00	C
	ATOM	106	O	SER	A	15	21.933	17.849	17.803	0.00	O
	ATOM	107	OG	SER	A	15	19.396	16.382	17.701	0.00	O
	ATOM	108	N	ARG	A	16	21.454	19.841	16.867	0.00	N
	ATOM	109	CA	ARG	A	16	22.362	20.594	17.724	0.00	C
25	ATOM	110	CB	ARG	A	16	22.741	21.927	17.073	0.00	C
	ATOM	111	C	ARG	A	16	21.815	20.907	19.104	0.00	C
	ATOM	112	O	ARG	A	16	22.550	20.867	20.088	0.00	O
	ATOM	113	CG	ARG	A	16	23.719	21.851	15.915	0.00	C
	ATOM	114	CD	ARG	A	16	24.200	23.253	15.549	0.00	C
30	ATOM	115	NE	ARG	A	16	24.625	23.984	16.745	0.00	N1+
	ATOM	116	CZ	ARG	A	16	25.242	25.166	16.739	0.00	C
	ATOM	117	NH2	ARG	A	16	25.581	25.735	17.888	0.00	N
	ATOM	118	NH1	ARG	A	16	25.528	25.781	15.597	0.00	N
	ATOM	119	N	CYS	A	17	20.526	21.215	19.178	0.00	N
35	ATOM	120	CA	CYS	A	17	19.928	21.546	20.455	0.00	C
	ATOM	121	CB	CYS	A	17	19.800	23.068	20.553	0.00	C
	ATOM	122	C	CYS	A	17	18.599	20.911	20.803	0.00	C
	ATOM	123	O	CYS	A	17	18.071	20.077	20.071	0.00	O
	ATOM	124	SG	CYS	A	17	21.393	23.932	20.696	0.00	S
40	ATOM	125	N	SER	A	18	18.066	21.348	21.942	0.00	N
	ATOM	126	CA	SER	A	18	16.799	20.865	22.455	0.00	C
	ATOM	127	CB	SER	A	18	17.042	20.053	23.723	0.00	C
	ATOM	128	OG	SER	A	18	18.081	19.111	23.521	0.00	O
	ATOM	129	C	SER	A	18	15.871	22.030	22.769	0.00	C
45	ATOM	130	O	SER	A	18	16.312	23.175	22.890	0.00	O
	ATOM	131	N	ILE	A	19	14.584	21.728	22.892	0.00	N
	ATOM	132	CA	ILE	A	19	13.582	22.737	23.195	0.00	C
	ATOM	133	CB	ILE	A	19	12.150	22.152	23.125	0.00	C
	ATOM	134	CG2	ILE	A	19	11.133	23.215	23.532	0.00	C
50	ATOM	135	CG1	ILE	A	19	11.852	21.634	21.715	0.00	C
	ATOM	136	CD1	ILE	A	19	11.832	22.709	20.655	0.00	C
	ATOM	137	C	ILE	A	19	13.794	23.273	24.614	0.00	C
	ATOM	138	O	ILE	A	19	14.070	22.505	25.545	0.00	O
	ATOM	139	N	GLY	A	20	13.670	24.589	24.774	0.00	N
55	ATOM	140	CA	GLY	A	20	13.818	25.185	26.088	0.00	C
	ATOM	141	C	GLY	A	20	12.443	25.203	26.722	0.00	C
	ATOM	142	O	GLY	A	20	12.122	24.389	27.585	0.00	O
	ATOM	143	N	PHE	A	21	11.616	26.137	26.274	0.00	N
	ATOM	144	CA	PHE	A	21	10.253	26.258	26.763	0.00	C
60	ATOM	145	CB	PHE	A	21	10.196	27.160	27.992	0.00	C
	ATOM	146	CG	PHE	A	21	10.855	26.559	29.195	0.00	C
	ATOM	147	CD1	PHE	A	21	10.269	25.491	29.857	0.00	C
	ATOM	148	CD2	PHE	A	21	12.086	27.025	29.638	0.00	C
	ATOM	149	CE1	PHE	A	21	10.898	24.898	30.936	0.00	C
65	ATOM	150	CE2	PHE	A	21	12.713	26.435	30.715	0.00	C
	ATOM	151	CZ	PHE	A	21	12.122	25.370	31.366	0.00	C
	ATOM	152	C	PHE	A	21	9.391	26.825	25.664	0.00	C
	ATOM	153	O	PHE	A	21	9.865	27.597	24.830	0.00	O
	ATOM	154	N	ALA	A	22	8.131	26.413	25.646	0.00	N
70	ATOM	155	CA	ALA	A	22	7.194	26.882	24.647	0.00	C
	ATOM	156	CB	ALA	A	22	6.014	25.915	24.533	0.00	C
	ATOM	157	C	ALA	A	22	6.719	28.230	25.138	0.00	C
	ATOM	158	O	ALA	A	22	6.416	28.388	26.320	0.00	O
	ATOM	159	N	VAL	A	23	6.677	29.202	24.239	0.00	N
75	ATOM	160	CA	VAL	A	23	6.233	30.546	24.582	0.00	C
	ATOM	161	CB	VAL	A	23	7.402	31.570	24.551	0.00	C
	ATOM	162	CG1	VAL	A	23	8.328	31.338	25.728	0.00	C
	ATOM	163	CG2	VAL	A	23	8.182	31.442	23.248	0.00	C

- 246 -

	ATOM	164	C	VAL	A	23	5.206	30.945	23.545	0.00	C
	ATOM	165	O	VAL	A	23	5.053	30.267	22.526	0.00	O
	ATOM	166	N	ASN	A	24	4.495	32.036	23.791	0.00	N
5	ATOM	167	CA	ASN	A	24	3.492	32.476	22.832	0.00	C
	ATOM	168	CB	ASN	A	24	2.807	33.759	23.328	0.00	C
	ATOM	169	C	ASN	A	24	4.177	32.715	21.484	0.00	C
	ATOM	170	O	ASN	A	24	5.050	33.576	21.365	0.00	O
	ATOM	171	CG	ASN	A	24	3.737	34.963	23.334	0.00	O
10	ATOM	172	OD1	ASN	A	24	4.697	35.029	24.107	0.00	O
	ATOM	173	ND2	ASN	A	24	3.451	35.927	22.462	0.00	N
	ATOM	174	N	GLY	A	25	3.801	31.929	20.477	0.00	N
	ATOM	175	CA	GLY	A	25	4.396	32.084	19.158	0.00	C
	ATOM	176	C	GLY	A	25	5.503	31.104	18.788	0.00	C
	ATOM	177	O	GLY	A	25	5.925	31.054	17.635	0.00	O
15	ATOM	178	N	GLY	A	26	5.989	30.327	19.748	0.00	N
	ATOM	179	CA	GLY	A	26	7.043	29.377	19.433	0.00	C
	ATOM	180	C	GLY	A	26	7.702	28.795	20.666	0.00	C
	ATOM	181	O	GLY	A	26	7.028	28.328	21.582	0.00	O
20	ATOM	182	N	PHE	A	27	9.028	28.813	20.688	0.00	N
	ATOM	183	CA	PHE	A	27	9.757	28.294	21.832	0.00	C
	ATOM	184	CB	PHE	A	27	9.973	26.783	21.710	0.00	C
	ATOM	185	C	PHE	A	27	11.103	28.975	21.954	0.00	C
	ATOM	186	O	PHE	A	27	11.660	29.459	20.963	0.00	O
	ATOM	187	CG	PHE	A	27	10.949	26.376	20.624	0.00	C
25	ATOM	188	CD1	PHE	A	27	10.504	26.078	19.336	0.00	C
	ATOM	189	CD2	PHE	A	27	12.306	26.246	20.905	0.00	C
	ATOM	190	CE1	PHE	A	27	11.391	25.650	18.352	0.00	C
	ATOM	191	CE2	PHE	A	27	13.202	25.819	19.926	0.00	C
	ATOM	192	CZ	PHE	A	27	12.742	25.518	18.648	0.00	C
30	ATOM	193	N	ILE	A	28	11.615	29.020	23.180	0.00	N
	ATOM	194	CA	ILE	A	28	12.904	29.640	23.445	0.00	C
	ATOM	195	CB	ILE	A	28	12.843	30.524	24.704	0.00	C
	ATOM	196	C	ILE	A	28	13.953	28.542	23.603	0.00	C
	ATOM	197	O	ILE	A	28	13.640	27.426	24.011	0.00	O
35	ATOM	198	CG2	ILE	A	28	11.915	31.688	24.450	0.00	C
	ATOM	199	CG1	ILE	A	28	12.350	29.718	25.904	0.00	C
	ATOM	200	CD1	ILE	A	28	12.270	30.524	27.176	0.00	C
	ATOM	201	N	THR	A	29	15.195	28.866	23.265	0.00	N
	ATOM	202	CA	THR	A	29	16.293	27.916	23.353	0.00	C
40	ATOM	203	CB	THR	A	29	16.329	27.054	22.052	0.00	C
	ATOM	204	OG1	THR	A	29	17.423	26.126	22.095	0.00	O
	ATOM	205	CG2	THR	A	29	16.459	27.950	20.831	0.00	C
	ATOM	206	C	THR	A	29	17.601	28.695	23.538	0.00	C
	ATOM	207	O	THR	A	29	17.565	29.881	23.842	0.00	O
45	ATOM	208	N	ALA	A	30	18.743	28.029	23.362	0.00	N
	ATOM	209	CA	ALA	A	30	20.059	28.662	23.510	0.00	C
	ATOM	210	CB	ALA	A	30	21.121	27.601	23.765	0.00	C
	ATOM	211	C	ALA	A	30	20.447	29.486	22.282	0.00	C
	ATOM	212	O	ALA	A	30	20.232	29.061	21.141	0.00	O
50	ATOM	213	N	GLY	A	31	21.028	30.659	22.520	0.00	N
	ATOM	214	CA	GLY	A	31	21.427	31.522	21.423	0.00	C
	ATOM	215	C	GLY	A	31	22.508	30.942	20.528	0.00	C
	ATOM	216	O	GLY	A	31	22.527	31.212	19.322	0.00	O
	ATOM	217	N	HIS	A	32	23.410	30.143	21.099	0.00	N
55	ATOM	218	CA	HIS	A	32	24.490	29.558	20.310	0.00	C
	ATOM	219	CB	HIS	A	32	25.648	29.091	21.215	0.00	C
	ATOM	220	CG	HIS	A	32	25.412	27.772	21.885	0.00	C
	ATOM	221	CD2	HIS	A	32	24.715	27.451	23.001	0.00	C
	ATOM	222	ND1	HIS	A	32	25.946	26.589	21.419	0.00	N
60	ATOM	223	CE1	HIS	A	32	25.590	25.601	22.218	0.00	C
	ATOM	224	NE2	HIS	A	32	24.842	26.098	23.188	0.00	N
	ATOM	225	C	HIS	A	32	24.029	28.401	19.413	0.00	C
	ATOM	226	O	HIS	A	32	24.805	27.870	18.630	0.00	O
	ATOM	227	N	CYS	A	33	22.762	28.025	19.525	0.00	N
65	ATOM	228	CA	CYS	A	33	22.210	26.940	18.723	0.00	C
	ATOM	229	CB	CYS	A	33	20.836	26.522	19.251	0.00	C
	ATOM	230	SG	CYS	A	33	20.853	25.876	20.942	0.00	S
	ATOM	231	C	CYS	A	33	22.062	27.395	17.283	0.00	C
	ATOM	232	O	CYS	A	33	22.149	26.603	16.356	0.00	O
70	ATOM	233	N	GLY	A	34	21.822	28.680	17.095	0.00	N
	ATOM	234	CA	GLY	A	34	21.664	29.181	15.749	0.00	C
	ATOM	235	C	GLY	A	34	21.360	30.656	15.763	0.00	C
	ATOM	236	O	GLY	A	34	20.984	31.213	16.794	0.00	O
	ATOM	237	N	ARG	A	35	21.523	31.288	14.608	0.00	N
75	ATOM	238	CA	ARG	A	35	21.284	32.716	14.478	0.00	C
	ATOM	239	CB	ARG	A	35	22.417	33.355	13.680	0.00	C
	ATOM	240	C	ARG	A	35	19.951	33.012	13.798	0.00	C
	ATOM	241	O	ARG	A	35	19.348	32.138	13.173	0.00	O

- 247 -

	ATOM	242	CG	ARG	A	35	22.437	32.937	12.219	0.00	C
	ATOM	243	CD	ARG	A	35	23.488	33.715	11.458	0.00	C
	ATOM	244	NE	ARG	A	35	24.832	33.237	11.755	0.00	N1+
	ATOM	245	CZ	ARG	A	35	25.406	32.207	11.139	0.00	C
5	ATOM	246	NH1	ARG	A	35	26.634	31.832	11.471	0.00	N
	ATOM	247	NH2	ARG	A	35	24.759	31.559	10.178	0.00	N
	ATOM	248	N	THR	A	36	19.513	34.258	13.918	0.00	N
	ATOM	249	CA	THR	A	36	18.259	34.714	13.335	0.00	C
	ATOM	250	CB	THR	A	36	18.124	36.242	13.522	0.00	C
10	ATOM	251	C	THR	A	36	18.161	34.353	11.856	0.00	C
	ATOM	252	O	THR	A	36	19.123	34.512	11.099	0.00	O
	ATOM	253	OG1	THR	A	36	18.120	36.536	14.923	0.00	O
	ATOM	254	CG2	THR	A	36	16.844	36.773	12.880	0.00	O
	ATOM	255	N	GLY	A	37	16.999	33.855	11.449	0.00	N
15	ATOM	256	CA	GLY	A	37	16.813	33.479	10.059	0.00	C
	ATOM	257	C	GLY	A	37	17.046	32.001	9.799	0.00	C
	ATOM	258	O	GLY	A	37	16.521	31.451	8.839	0.00	O
	ATOM	259	N	ALA	A	38	17.842	31.349	10.640	0.00	N
	ATOM	260	CA	ALA	A	38	18.095	29.924	10.470	0.00	C
20	ATOM	261	C	ALA	A	38	16.745	29.222	10.565	0.00	C
	ATOM	262	O	ALA	A	38	15.881	29.657	11.324	0.00	O
	ATOM	263	CB	ALA	A	38	19.026	29.426	11.566	0.00	C
	ATOM	264	N	THR	A	39	16.553	28.151	9.800	0.00	N
	ATOM	265	CA	THR	A	39	15.281	27.432	9.842	0.00	C
25	ATOM	266	CB	THR	A	39	14.779	27.066	8.425	0.00	C
	ATOM	267	OG1	THR	A	39	15.582	26.012	7.887	0.00	O
	ATOM	268	CG2	THR	A	39	14.857	28.277	7.504	0.00	C
	ATOM	269	C	THR	A	39	15.433	26.157	10.664	0.00	C
	ATOM	270	O	THR	A	39	16.533	25.637	10.821	0.00	O
30	ATOM	271	N	THR	A	40	14.328	25.649	11.186	0.00	N
	ATOM	272	CA	THR	A	40	14.382	24.437	11.990	0.00	C
	ATOM	273	CB	THR	A	40	14.143	24.753	13.473	0.00	C
	ATOM	274	OG1	THR	A	40	12.807	25.242	13.636	0.00	O
	ATOM	275	CG2	THR	A	40	15.124	25.799	13.962	0.00	C
35	ATOM	276	C	THR	A	40	13.332	23.421	11.581	0.00	C
	ATOM	277	O	THR	A	40	12.345	23.760	10.927	0.00	O
	ATOM	278	N	ALA	A	41	13.546	22.178	11.994	0.00	N
	ATOM	279	CA	ALA	A	41	12.629	21.084	11.698	0.00	C
	ATOM	280	C	ALA	A	41	12.368	20.368	13.030	0.00	C
40	ATOM	281	O	ALA	A	41	13.211	20.394	13.936	0.00	O
	ATOM	282	CB	ALA	A	41	13.247	20.133	10.684	0.00	C
	ATOM	283	N	ASN	A	42	11.206	19.734	13.149	0.00	N
	ATOM	284	CA	ASN	A	42	10.839	19.022	14.370	0.00	C
	ATOM	285	C	ASN	A	42	11.037	19.959	15.555	0.00	C
45	ATOM	286	O	ASN	A	42	11.861	19.693	16.424	0.00	O
	ATOM	287	CB	ASN	A	42	11.720	17.780	14.584	0.00	C
	ATOM	288	CG	ASN	A	42	11.686	16.812	13.408	0.00	C
	ATOM	289	OD1	ASN	A	42	10.687	16.713	12.695	0.00	O
	ATOM	290	ND2	ASN	A	42	12.779	16.076	13.217	0.00	N
50	ATOM	291	N	PRO	A	43	10.258	21.046	15.635	0.00	N
	ATOM	292	CA	PRO	A	43	9.206	21.493	14.718	0.00	C
	ATOM	293	CB	PRO	A	43	8.274	22.244	15.649	0.00	C
	ATOM	294	C	PRO	A	43	9.697	22.416	13.612	0.00	C
	ATOM	295	O	PRO	A	43	10.816	22.920	13.660	0.00	O
55	ATOM	296	CD	PRO	A	43	10.319	21.934	16.809	0.00	C
	ATOM	297	CG	PRO	A	43	9.278	23.008	16.480	0.00	C
	ATOM	298	N	THR	A	44	8.841	22.652	12.621	0.00	N
	ATOM	299	CA	THR	A	44	9.208	23.533	11.522	0.00	C
	ATOM	300	CB	THR	A	44	8.225	23.421	10.345	0.00	C
60	ATOM	301	C	THR	A	44	9.142	24.934	12.110	0.00	C
	ATOM	302	O	THR	A	44	8.162	25.293	12.772	0.00	O
	ATOM	303	OG1	THR	A	44	8.437	22.176	9.671	0.00	O
	ATOM	304	CG2	THR	A	44	8.423	24.566	9.366	0.00	C
	ATOM	305	N	GLY	A	45	10.196	25.710	11.893	0.00	N
65	ATOM	306	CA	GLY	A	45	10.233	27.057	12.425	0.00	C
	ATOM	307	C	GLY	A	45	11.421	27.851	11.920	0.00	C
	ATOM	308	O	GLY	A	45	12.226	27.355	11.120	0.00	O
	ATOM	309	N	THR	A	46	11.537	29.084	12.401	0.00	N
	ATOM	310	CA	THR	A	46	12.615	29.979	11.998	0.00	C
70	ATOM	311	CB	THR	A	46	12.134	30.919	10.867	0.00	C
	ATOM	312	OG1	THR	A	46	11.720	30.132	9.741	0.00	O
	ATOM	313	CG2	THR	A	46	13.246	31.872	10.438	0.00	C
	ATOM	314	C	THR	A	46	13.097	30.831	13.171	0.00	C
	ATOM	315	O	THR	A	46	12.287	31.407	13.909	0.00	O
75	ATOM	316	N	PHE	A	47	14.412	30.903	13.358	0.00	N
	ATOM	317	CA	PHE	A	47	14.954	31.702	14.451	0.00	C
	ATOM	318	CB	PHE	A	47	16.478	31.585	14.530	0.00	C
	ATOM	319	CG	PHE	A	47	16.959	30.410	15.339	0.00	C

- 248 -

	ATOM	320	CD2	PHE	A	47	17.538	30.606	16.590	0.00	C
	ATOM	321	CD1	PHE	A	47	16.843	29.115	14.857	0.00	C
	ATOM	322	CE2	PHE	A	47	17.996	29.532	17.345	0.00	C
	ATOM	323	CE1	PHE	A	47	17.300	28.030	15.608	0.00	C
5	ATOM	324	CZ	PHE	A	47	17.878	28.241	16.855	0.00	C
	ATOM	325	C	PHE	A	47	14.567	33.160	14.226	0.00	C
	ATOM	326	O	PHE	A	47	14.665	33.686	13.111	0.00	O
	ATOM	327	N	ALA	A	48	14.102	33.795	15.291	0.00	N
	ATOM	328	CA	ALA	A	48	13.690	35.184	15.245	0.00	C
10	ATOM	329	CB	ALA	A	48	12.161	35.280	15.133	0.00	C
	ATOM	330	C	ALA	A	48	14.174	35.828	16.532	0.00	C
	ATOM	331	O	ALA	A	48	13.389	36.116	17.433	0.00	O
	ATOM	332	N	GLY	A	49	15.481	36.038	16.609	0.00	N
	ATOM	333	CA	GLY	A	49	16.072	36.635	17.791	0.00	C
15	ATOM	334	C	GLY	A	49	17.068	35.674	18.415	0.00	C
	ATOM	335	O	GLY	A	49	16.698	34.589	18.867	0.00	O
	ATOM	336	N	SER	A	50	18.333	36.073	18.438	0.00	N
	ATOM	337	CA	SER	A	50	19.387	35.248	18.999	0.00	C
	ATOM	338	CB	SER	A	50	19.976	34.360	17.899	0.00	C
20	ATOM	339	OG	SER	A	50	21.019	33.552	18.406	0.00	O
	ATOM	340	C	SER	A	50	20.484	36.112	19.633	0.00	C
	ATOM	341	O	SER	A	50	20.999	37.045	19.012	0.00	O
	ATOM	342	N	SER	A	51	20.832	35.794	20.877	0.00	N
	ATOM	343	CA	SER	A	51	21.860	36.529	21.603	0.00	C
25	ATOM	344	CB	SER	A	51	21.228	37.337	22.741	0.00	C
	ATOM	345	OG	SER	A	51	22.179	38.189	23.359	0.00	O
	ATOM	346	C	SER	A	51	22.938	35.596	22.162	0.00	C
	ATOM	347	O	SER	A	51	22.700	34.819	23.089	0.00	O
	ATOM	348	N	PHE	A	52	24.127	35.692	21.579	0.00	N
30	ATOM	349	CA	PHE	A	52	25.277	34.889	21.970	0.00	C
	ATOM	350	CB	PHE	A	52	25.031	33.414	21.643	0.00	C
	ATOM	351	CG	PHE	A	52	26.204	32.518	21.941	0.00	C
	ATOM	352	CD1	PHE	A	52	26.485	32.124	23.238	0.00	C
	ATOM	353	CD2	PHE	A	52	27.034	32.081	20.922	0.00	C
35	ATOM	354	CE1	PHE	A	52	27.575	31.312	23.516	0.00	C
	ATOM	355	CE2	PHE	A	52	28.131	31.266	21.193	0.00	C
	ATOM	356	CZ	PHE	A	52	28.400	30.883	22.492	0.00	C
	ATOM	357	C	PHE	A	52	26.468	35.390	21.167	0.00	C
	ATOM	358	O	PHE	A	52	26.370	35.589	19.960	0.00	O
40	ATOM	359	N	PRO	A	53	27.612	35.603	21.827	0.00	N
	ATOM	360	CD	PRO	A	53	28.893	35.756	21.110	0.00	C
	ATOM	361	CA	PRO	A	53	27.831	35.405	23.266	0.00	C
	ATOM	362	CB	PRO	A	53	29.351	35.249	23.361	0.00	C
	ATOM	363	CG	PRO	A	53	29.851	36.088	22.223	0.00	C
45	ATOM	364	C	PRO	A	53	27.268	36.543	24.132	0.00	C
	ATOM	365	O	PRO	A	53	26.346	37.235	23.713	0.00	O
	ATOM	366	N	GLY	A	54	27.814	36.744	25.328	0.00	N
	ATOM	367	CA	GLY	A	54	27.288	37.777	26.211	0.00	C
	ATOM	368	C	GLY	A	54	26.143	37.138	26.980	0.00	C
50	ATOM	369	O	GLY	A	54	26.210	36.964	28.197	0.00	O
	ATOM	370	N	ASN	A	55	25.079	36.806	26.254	0.00	N
	ATOM	371	CA	ASN	A	55	23.922	36.103	26.810	0.00	C
	ATOM	372	CB	ASN	A	55	22.579	36.740	26.404	0.00	C
	ATOM	373	CG	ASN	A	55	22.516	38.240	26.641	0.00	C
55	ATOM	374	OD1	ASN	A	55	22.161	39.005	25.734	0.00	O
	ATOM	375	ND2	ASN	A	55	22.833	38.667	27.857	0.00	N
	ATOM	376	C	ASN	A	55	24.011	34.788	26.037	0.00	C
	ATOM	377	O	ASN	A	55	24.998	34.538	25.333	0.00	O
	ATOM	378	N	ASP	A	56	22.980	33.958	26.171	0.00	N
60	ATOM	379	CA	ASP	A	56	22.917	32.682	25.473	0.00	C
	ATOM	380	CB	ASP	A	56	23.774	31.595	26.119	0.00	C
	ATOM	381	CG	ASP	A	56	23.987	30.395	25.179	0.00	C
	ATOM	382	OD1	ASP	A	56	24.631	29.408	25.585	0.00	O
	ATOM	383	OD2	ASP	A	56	23.504	30.443	24.024	0.00	O1-
65	ATOM	384	C	ASP	A	56	21.470	32.221	25.379	0.00	C
	ATOM	385	O	ASP	A	56	21.078	31.195	25.930	0.00	O
	ATOM	386	N	TYR	A	57	20.672	33.008	24.671	0.00	N
	ATOM	387	CA	TYR	A	57	19.266	32.693	24.485	0.00	C
	ATOM	388	CB	TYR	A	57	18.396	33.484	25.463	0.00	C
70	ATOM	389	CG	TYR	A	57	18.527	34.993	25.374	0.00	C
	ATOM	390	CD1	TYR	A	57	19.153	35.711	26.390	0.00	C
	ATOM	391	CE1	TYR	A	57	19.231	37.092	26.352	0.00	C
	ATOM	392	CD2	TYR	A	57	17.986	35.706	24.303	0.00	C
	ATOM	393	CE2	TYR	A	57	18.060	37.093	24.255	0.00	C
75	ATOM	394	CZ	TYR	A	57	18.682	37.781	25.289	0.00	C
	ATOM	395	OH	TYR	A	57	18.732	39.165	25.286	0.00	O
	ATOM	396	C	TYR	A	57	18.820	32.998	23.062	0.00	C
	ATOM	397	O	TYR	A	57	19.438	33.800	22.355	0.00	O

- 249 -

	ATOM	398	N	ALA	A	58	17.742	32.344	22.652	0.00	N
	ATOM	399	CA	ALA	A	58	17.187	32.532	21.323	0.00	C
	ATOM	400	CB	ALA	A	58	17.899	31.645	20.312	0.00	C
	ATOM	401	C	ALA	A	58	15.706	32.191	21.360	0.00	C
5	ATOM	402	O	ALA	A	58	15.228	31.521	22.284	0.00	O
	ATOM	403	N	PHE	A	59	14.989	32.683	20.359	0.00	N
	ATOM	404	CA	PHE	A	59	13.564	32.453	20.225	0.00	C
	ATOM	405	CB	PHE	A	59	12.762	33.735	20.438	0.00	C
	ATOM	406	CG	PHE	A	59	11.333	33.629	19.970	0.00	C
10	ATOM	407	CD2	PHE	A	59	10.859	34.437	18.947	0.00	C
	ATOM	408	CD1	PHE	A	59	10.475	32.698	20.531	0.00	C
	ATOM	409	CE2	PHE	A	59	9.553	34.316	18.491	0.00	C
	ATOM	410	CE1	PHE	A	59	9.175	32.573	20.084	0.00	C
	ATOM	411	CZ	PHE	A	59	8.712	33.382	19.063	0.00	C
15	ATOM	412	C	PHE	A	59	13.294	31.942	18.816	0.00	C
	ATOM	413	O	PHE	A	59	13.693	32.562	17.820	0.00	O
	ATOM	414	N	VAL	A	60	12.616	30.809	18.731	0.00	N
	ATOM	415	CA	VAL	A	60	12.308	30.253	17.434	0.00	C
	ATOM	416	CB	VAL	A	60	12.702	28.776	17.340	0.00	C
20	ATOM	417	CG1	VAL	A	60	12.503	28.279	15.908	0.00	C
	ATOM	418	CG2	VAL	A	60	14.147	28.593	17.796	0.00	C
	ATOM	419	C	VAL	A	60	10.816	30.361	17.236	0.00	C
	ATOM	420	O	VAL	A	60	10.043	29.927	18.087	0.00	O
	ATOM	421	N	ARG	A	61	10.406	30.960	16.126	0.00	N
25	ATOM	422	CA	ARG	A	61	8.987	31.098	15.851	0.00	C
	ATOM	423	CB	ARG	A	61	8.704	32.313	14.962	0.00	C
	ATOM	424	CG	ARG	A	61	7.255	32.374	14.480	0.00	C
	ATOM	425	CD	ARG	A	61	7.019	33.543	13.521	0.00	C
	ATOM	426	NE	ARG	A	61	5.615	33.660	13.118	0.00	N1+
30	ATOM	427	CZ	ARG	A	61	4.989	32.815	12.303	0.00	C
	ATOM	428	NH2	ARG	A	61	3.711	33.007	12.004	0.00	N
	ATOM	429	NH1	ARG	A	61	5.636	31.777	11.787	0.00	N
	ATOM	430	C	ARG	A	61	8.509	29.847	15.128	0.00	C
	ATOM	431	O	ARG	A	61	9.193	29.338	14.238	0.00	O
35	ATOM	432	N	THR	A	62	7.338	29.357	15.527	0.00	N
	ATOM	433	CA	THR	A	62	6.740	28.170	14.923	0.00	C
	ATOM	434	CB	THR	A	62	6.514	27.046	15.956	0.00	C
	ATOM	435	OG1	THR	A	62	5.808	27.570	17.089	0.00	O
	ATOM	436	CG2	THR	A	62	7.845	26.460	16.396	0.00	C
40	ATOM	437	C	THR	A	62	5.391	28.597	14.352	0.00	C
	ATOM	438	O	THR	A	62	4.857	29.645	14.724	0.00	O
	ATOM	439	N	GLY	A	63	4.837	27.791	13.455	0.00	N
	ATOM	440	CA	GLY	A	63	3.562	28.146	12.859	0.00	C
	ATOM	441	C	GLY	A	63	2.522	27.046	12.880	0.00	C
45	ATOM	442	O	GLY	A	63	2.375	26.326	13.873	0.00	O
	ATOM	443	N	ALA	A	64	1.806	26.909	11.767	0.00	N
	ATOM	444	CA	ALA	A	64	0.744	25.916	11.643	0.00	C
	ATOM	445	C	ALA	A	64	1.213	24.496	11.895	0.00	C
	ATOM	446	O	ALA	A	64	2.370	24.154	11.651	0.00	O
50	ATOM	447	CB	ALA	A	64	0.111	26.009	10.268	0.00	C
	ATOM	448	N	GLY	A	65	0.291	23.672	12.381	0.00	N
	ATOM	449	CA	GLY	A	65	0.596	22.281	12.657	0.00	C
	ATOM	450	C	GLY	A	65	1.469	22.050	13.877	0.00	C
	ATOM	451	O	GLY	A	65	1.797	20.908	14.199	0.00	O
55	ATOM	452	N	VAL	A	66	1.837	23.119	14.572	0.00	N
	ATOM	453	CA	VAL	A	66	2.699	22.976	15.736	0.00	C
	ATOM	454	CB	VAL	A	66	3.946	23.854	15.595	0.00	C
	ATOM	455	C	VAL	A	66	2.031	23.307	17.063	0.00	C
	ATOM	456	O	VAL	A	66	1.737	24.467	17.337	0.00	O
60	ATOM	457	CG1	VAL	A	66	4.832	23.683	16.818	0.00	C
	ATOM	458	CG2	VAL	A	66	4.698	23.482	14.324	0.00	C
	ATOM	459	N	ASN	A	67	1.806	22.283	17.882	0.00	N
	ATOM	460	CA	ASN	A	67	1.176	22.454	19.185	0.00	C
	ATOM	461	CB	ASN	A	67	0.403	21.188	19.564	0.00	C
65	ATOM	462	C	ASN	A	67	2.240	22.745	20.237	0.00	C
	ATOM	463	O	ASN	A	67	3.120	21.920	20.491	0.00	O
	ATOM	464	CG	ASN	A	67	-0.405	20.634	18.404	0.00	C
	ATOM	465	OD1	ASN	A	67	-1.160	21.361	17.750	0.00	O
	ATOM	466	ND2	ASN	A	67	-0.253	19.340	18.140	0.00	N
70	ATOM	467	N	LEU	A	68	2.148	23.923	20.845	0.00	N
	ATOM	468	CA	LEU	A	68	3.087	24.366	21.876	0.00	C
	ATOM	469	CB	LEU	A	68	3.279	25.883	21.759	0.00	C
	ATOM	470	C	LEU	A	68	2.571	23.996	23.273	0.00	C
	ATOM	471	O	LEU	A	68	1.620	24.597	23.770	0.00	O
75	ATOM	472	CG	LEU	A	68	3.688	26.430	20.380	0.00	C
	ATOM	473	CD1	LEU	A	68	3.724	27.950	20.406	0.00	C
	ATOM	474	CD2	LEU	A	68	5.051	25.888	19.987	0.00	C
	ATOM	475	N	LEU	A	69	3.218	23.027	23.917	0.00	N

- 250 -

	ATOM	476	CA	LEU	A	69	2.803	22.584	25.250	0.00	C
	ATOM	477	CB	LEU	A	69	2.769	21.052	25.286	0.00	C
	ATOM	478	CG	LEU	A	69	2.045	20.369	24.116	0.00	C
	ATOM	479	CD1	LEU	A	69	2.109	18.857	24.274	0.00	C
5	ATOM	480	CD2	LEU	A	69	0.604	20.841	24.050	0.00	C
	ATOM	481	C	LEU	A	69	3.612	23.078	26.449	0.00	C
	ATOM	482	O	LEU	A	69	4.835	23.216	26.394	0.00	O
	ATOM	483	N	ALA	A	70	2.907	23.332	27.544	0.00	N
	ATOM	484	CA	ALA	A	70	3.534	23.796	28.773	0.00	C
10	ATOM	485	CB	ALA	A	70	2.507	24.496	29.646	0.00	C
	ATOM	486	C	ALA	A	70	4.048	22.539	29.473	0.00	C
	ATOM	487	O	ALA	A	70	3.712	22.273	30.618	0.00	O
	ATOM	488	N	GLN	A	71	4.862	21.763	28.770	0.00	N
	ATOM	489	CA	GLN	A	71	5.408	20.536	29.325	0.00	C
15	ATOM	490	CB	GLN	A	71	4.618	19.333	28.808	0.00	C
	ATOM	491	CG	GLN	A	71	3.169	19.299	29.255	0.00	C
	ATOM	492	CD	GLN	A	71	2.407	18.116	28.692	0.00	C
	ATOM	493	OE1	GLN	A	71	1.460	17.634	29.308	0.00	O
	ATOM	494	NE2	GLN	A	71	2.809	17.646	27.515	0.00	N
20	ATOM	495	C	GLN	A	71	6.869	20.310	28.998	0.00	C
	ATOM	496	O	GLN	A	71	7.395	20.825	28.009	0.00	O
	ATOM	497	N	VAL	A	72	7.520	19.529	29.850	0.00	N
	ATOM	498	CA	VAL	A	72	8.924	19.199	29.676	0.00	C
	ATOM	499	CB	VAL	A	72	9.809	19.799	30.777	0.00	C
25	ATOM	500	CG1	VAL	A	72	11.240	19.342	30.580	0.00	C
	ATOM	501	CG2	VAL	A	72	9.726	21.309	30.758	0.00	C
	ATOM	502	C	VAL	A	72	8.997	17.685	29.772	0.00	C
	ATOM	503	O	VAL	A	72	8.419	17.086	30.680	0.00	O
	ATOM	504	N	ASN	A	73	9.699	17.075	28.824	0.00	N
30	ATOM	505	CA	ASN	A	73	9.867	15.629	28.771	0.00	C
	ATOM	506	CB	ASN	A	73	10.543	15.250	27.452	0.00	C
	ATOM	507	CG	ASN	A	73	10.513	13.756	27.182	0.00	C
	ATOM	508	OD1	ASN	A	73	10.470	12.947	28.106	0.00	O
	ATOM	509	ND2	ASN	A	73	10.551	13.387	25.906	0.00	N
35	ATOM	510	C	ASN	A	73	10.735	15.146	29.931	0.00	C
	ATOM	511	O	ASN	A	73	11.843	15.651	30.123	0.00	O
	ATOM	512	N	ASN	A	74	10.244	14.175	30.703	0.00	N
	ATOM	513	CA	ASN	A	74	11.028	13.663	31.823	0.00	C
	ATOM	514	CB	ASN	A	74	10.151	13.368	33.049	0.00	C
40	ATOM	515	CG	ASN	A	74	9.191	12.217	32.830	0.00	C
	ATOM	516	OD1	ASN	A	74	9.486	11.265	32.108	0.00	O
	ATOM	517	ND2	ASN	A	74	8.032	12.291	33.477	0.00	N
	ATOM	518	C	ASN	A	74	11.791	12.408	31.417	0.00	C
	ATOM	519	O	ASN	A	74	12.332	11.695	32.266	0.00	O
45	ATOM	520	N	TYR	A	75	11.830	12.156	30.112	0.00	N
	ATOM	521	CA	TYR	A	75	12.514	11.005	29.528	0.00	C
	ATOM	522	CB	TYR	A	75	14.008	11.321	29.354	0.00	C
	ATOM	523	CG	TYR	A	75	14.268	12.239	28.181	0.00	C
	ATOM	524	CD1	TYR	A	75	14.228	11.756	26.873	0.00	C
50	ATOM	525	CE1	TYR	A	75	14.371	12.597	25.792	0.00	C
	ATOM	526	CD2	TYR	A	75	14.466	13.599	28.370	0.00	C
	ATOM	527	CE2	TYR	A	75	14.608	14.451	27.290	0.00	C
	ATOM	528	CZ	TYR	A	75	14.557	13.945	26.005	0.00	C
	ATOM	529	OH	TYR	A	75	14.679	14.796	24.931	0.00	O
55	ATOM	530	C	TYR	A	75	12.326	9.680	30.260	0.00	C
	ATOM	531	O	TYR	A	75	13.253	8.875	30.378	0.00	O
	ATOM	532	N	SER	A	76	11.112	9.464	30.747	0.00	N
	ATOM	533	CA	SER	A	76	10.773	8.244	31.458	0.00	C
	ATOM	534	CB	SER	A	76	10.737	8.471	32.968	0.00	C
60	ATOM	535	OG	SER	A	76	12.053	8.566	33.475	0.00	O
	ATOM	536	C	SER	A	76	9.407	7.816	30.963	0.00	C
	ATOM	537	O	SER	A	76	8.784	6.905	31.512	0.00	O
	ATOM	538	N	GLY	A	77	8.960	8.483	29.905	0.00	N
	ATOM	539	CA	GLY	A	77	7.671	8.180	29.320	0.00	C
65	ATOM	540	C	GLY	A	77	6.610	9.168	29.755	0.00	C
	ATOM	541	O	GLY	A	77	5.464	9.090	29.311	0.00	O
	ATOM	542	N	GLY	A	78	6.992	10.102	30.622	0.00	N
	ATOM	543	CA	GLY	A	78	6.043	11.087	31.101	0.00	C
	ATOM	544	C	GLY	A	78	6.492	12.522	30.887	0.00	C
70	ATOM	545	O	GLY	A	78	7.545	12.775	30.293	0.00	O
	ATOM	546	N	ARG	A	79	5.687	13.462	31.375	0.00	N
	ATOM	547	CA	ARG	A	79	5.986	14.879	31.240	0.00	C
	ATOM	548	CB	ARG	A	79	5.099	15.537	30.166	0.00	C
	ATOM	549	CG	ARG	A	79	5.396	15.117	28.732	0.00	C
75	ATOM	550	CD	ARG	A	79	4.770	13.772	28.432	0.00	C
	ATOM	551	NE	ARG	A	79	4.975	13.348	27.048	0.00	N1+
	ATOM	552	CZ	ARG	A	79	6.081	12.764	26.593	0.00	C
	ATOM	553	NH1	ARG	A	79	7.095	12.529	27.412	0.00	N

- 251 -

	ATOM	554	NH2	ARG	A	79	6.165	12.399	25.319	0.00	N
	ATOM	555	C	ARG	A	79	5.797	15.627	32.550	0.00	C
	ATOM	556	O	ARG	A	79	5.129	15.149	33.466	0.00	O
	ATOM	557	N	VAL	A	80	6.398	16.809	32.620	0.00	N
5	ATOM	558	CA	VAL	A	80	6.317	17.656	33.794	0.00	C
	ATOM	559	CB	VAL	A	80	7.714	17.891	34.389	0.00	C
	ATOM	560	CG1	VAL	A	80	7.630	18.858	35.546	0.00	C
	ATOM	561	CG2	VAL	A	80	8.300	16.566	34.853	0.00	C
	ATOM	562	C	VAL	A	80	5.682	18.989	33.398	0.00	C
10	ATOM	563	O	VAL	A	80	6.182	19.701	32.517	0.00	O
	ATOM	564	N	GLN	A	81	4.561	19.307	34.036	0.00	N
	ATOM	565	CA	GLN	A	81	3.846	20.546	33.760	0.00	C
	ATOM	566	CB	GLN	A	81	2.518	20.579	34.527	0.00	C
	ATOM	567	CG	GLN	A	81	1.415	19.722	33.930	0.00	C
15	ATOM	568	CD	GLN	A	81	1.138	20.067	32.473	0.00	C
	ATOM	569	OE1	GLN	A	81	1.086	21.239	32.101	0.00	O
	ATOM	570	NE2	GLN	A	81	0.950	19.044	31.644	0.00	N
	ATOM	571	C	GLN	A	81	4.650	21.785	34.126	0.00	C
	ATOM	572	O	GLN	A	81	5.333	21.817	35.154	0.00	O
20	ATOM	573	N	VAL	A	82	4.578	22.798	33.272	0.00	N
	ATOM	574	CA	VAL	A	82	5.288	24.047	33.510	0.00	C
	ATOM	575	CB	VAL	A	82	5.925	24.610	32.219	0.00	C
	ATOM	576	CG1	VAL	A	82	6.695	25.885	32.535	0.00	C
	ATOM	577	CG2	VAL	A	82	6.841	23.580	31.605	0.00	C
25	ATOM	578	C	VAL	A	82	4.222	25.022	34.003	0.00	C
	ATOM	579	O	VAL	A	82	3.399	25.500	33.221	0.00	O
	ATOM	580	N	ALA	A	83	4.242	25.305	35.302	0.00	N
	ATOM	581	CA	ALA	A	83	3.277	26.213	35.919	0.00	C
	ATOM	582	CB	ALA	A	83	3.009	25.768	37.342	0.00	C
30	ATOM	583	C	ALA	A	83	3.677	27.688	35.909	0.00	C
	ATOM	584	O	ALA	A	83	2.820	28.571	35.886	0.00	O
	ATOM	585	N	GLY	A	84	4.975	27.960	35.934	0.00	N
	ATOM	586	CA	GLY	A	84	5.413	29.339	35.930	0.00	C
	ATOM	587	C	GLY	A	84	6.913	29.458	35.790	0.00	C
35	ATOM	588	O	GLY	A	84	7.601	28.463	35.536	0.00	O
	ATOM	589	N	HIS	A	85	7.426	30.673	35.960	0.00	N
	ATOM	590	CA	HIS	A	85	8.856	30.903	35.841	0.00	C
	ATOM	591	CB	HIS	A	85	9.154	31.684	34.557	0.00	C
	ATOM	592	C	HIS	A	85	9.476	31.610	37.037	0.00	C
40	ATOM	593	O	HIS	A	85	10.275	32.530	36.866	0.00	O
	ATOM	594	CG	HIS	A	85	8.328	32.920	34.391	0.00	C
	ATOM	595	ND1	HIS	A	85	8.864	34.188	34.455	0.00	N
	ATOM	596	CD2	HIS	A	85	7.006	33.083	34.147	0.00	C
	ATOM	597	NE2	HIS	A	85	6.772	34.434	34.067	0.00	N
45	ATOM	598	CE1	HIS	A	85	7.909	35.078	34.256	0.00	C
	ATOM	599	N	THR	A	86	9.115	31.163	38.243	0.00	N
	ATOM	600	CA	THR	A	86	9.631	31.738	39.491	0.00	C
	ATOM	601	CB	THR	A	86	8.743	31.356	40.683	0.00	C
	ATOM	602	C	THR	A	86	11.055	31.244	39.779	0.00	C
50	ATOM	603	O	THR	A	86	11.289	30.047	39.908	0.00	O
	ATOM	604	OG1	THR	A	86	7.417	31.837	40.456	0.00	O
	ATOM	605	CG2	THR	A	86	9.283	31.957	41.971	0.00	C
	ATOM	606	N	ALA	A	87	11.996	32.175	39.894	0.00	N
	ATOM	607	CA	ALA	A	87	13.391	31.830	40.160	0.00	C
55	ATOM	608	C	ALA	A	87	13.621	31.173	41.519	0.00	C
	ATOM	609	O	ALA	A	87	13.145	31.649	42.546	0.00	O
	ATOM	610	CB	ALA	A	87	14.265	33.077	40.032	0.00	C
	ATOM	611	N	ALA	A	88	14.360	30.074	41.517	0.00	N
	ATOM	612	CA	ALA	A	88	14.653	29.360	42.747	0.00	C
60	ATOM	613	C	ALA	A	88	16.009	29.831	43.263	0.00	C
	ATOM	614	O	ALA	A	88	16.904	30.156	42.482	0.00	O
	ATOM	615	CB	ALA	A	88	14.662	27.855	42.490	0.00	C
	ATOM	616	N	PRO	A	89	16.173	29.877	44.592	0.00	N
	ATOM	617	CA	PRO	A	89	17.404	30.310	45.260	0.00	C
65	ATOM	618	CB	PRO	A	89	16.939	30.560	46.690	0.00	C
	ATOM	619	C	PRO	A	89	18.545	29.304	45.204	0.00	C
	ATOM	620	O	PRO	A	89	18.323	28.106	45.007	0.00	O
	ATOM	621	CD	PRO	A	89	15.136	29.511	45.576	0.00	C
	ATOM	622	CG	PRO	A	89	15.917	29.473	46.886	0.00	C
70	ATOM	623	N	VAL	A	90	19.767	29.809	45.361	0.00	N
	ATOM	624	CA	VAL	A	90	20.960	28.973	45.343	0.00	C
	ATOM	625	CB	VAL	A	90	22.197	29.747	45.873	0.00	C
	ATOM	626	CG1	VAL	A	90	23.347	28.779	46.162	0.00	C
	ATOM	627	CG2	VAL	A	90	22.623	30.803	44.858	0.00	C
75	ATOM	628	C	VAL	A	90	20.680	27.810	46.279	0.00	C
	ATOM	629	O	VAL	A	90	19.988	27.976	47.287	0.00	O
	ATOM	630	N	GLY	A	91	21.205	26.635	45.954	0.00	N
	ATOM	631	CA	GLY	A	91	20.976	25.482	46.806	0.00	C

- 252 -

	ATOM	632	C	GLY	A	91	19.734	24.699	46.425	0.00	C
	ATOM	633	O	GLY	A	91	19.576	23.550	46.836	0.00	O
	ATOM	634	N	SER	A	92	18.853	25.314	45.642	0.00	N
	ATOM	635	CA	SER	A	92	17.620	24.659	45.210	0.00	C
5	ATOM	636	CB	SER	A	92	16.720	25.634	44.438	0.00	C
	ATOM	637	OG	SER	A	92	16.414	26.792	45.196	0.00	O
	ATOM	638	C	SER	A	92	17.929	23.479	44.306	0.00	C
	ATOM	639	O	SER	A	92	18.881	23.512	43.521	0.00	O
	ATOM	640	N	ALA	A	93	17.117	22.435	44.417	0.00	N
10	ATOM	641	CA	ALA	A	93	17.301	21.247	43.600	0.00	C
	ATOM	642	CB	ALA	A	93	16.576	20.054	44.231	0.00	C
	ATOM	643	C	ALA	A	93	16.715	21.559	42.226	0.00	C
	ATOM	644	O	ALA	A	93	15.669	22.202	42.126	0.00	O
	ATOM	645	N	VAL	A	94	17.396	21.125	41.170	0.00	N
15	ATOM	646	CA	VAL	A	94	16.916	21.371	39.814	0.00	C
	ATOM	647	CB	VAL	A	94	17.544	22.639	39.212	0.00	C
	ATOM	648	CG1	VAL	A	94	17.072	23.872	39.971	0.00	C
	ATOM	649	CG2	VAL	A	94	19.050	22.534	39.241	0.00	C
	ATOM	650	C	VAL	A	94	17.204	20.211	38.867	0.00	C
20	ATOM	651	O	VAL	A	94	18.143	19.432	39.071	0.00	O
	ATOM	652	N	CYS	A	95	16.378	20.090	37.834	0.00	N
	ATOM	653	CA	CYS	A	95	16.548	19.030	36.851	0.00	C
	ATOM	654	CB	CYS	A	95	15.428	17.983	36.942	0.00	C
	ATOM	655	SG	CYS	A	95	15.344	17.009	38.470	0.00	S
25	ATOM	656	C	CYS	A	95	16.552	19.647	35.464	0.00	C
	ATOM	657	O	CYS	A	95	15.820	20.598	35.194	0.00	O
	ATOM	658	N	ARG	A	96	17.391	19.092	34.598	0.00	N
	ATOM	659	CA	ARG	A	96	17.531	19.551	33.228	0.00	C
	ATOM	660	CB	ARG	A	96	19.003	19.840	32.935	0.00	C
30	ATOM	661	CG	ARG	A	96	19.300	20.110	31.465	0.00	C
	ATOM	662	CD	ARG	A	96	20.778	19.955	31.151	0.00	C
	ATOM	663	NE	ARG	A	96	21.272	18.625	31.499	0.00	N1+
	ATOM	664	CZ	ARG	A	96	20.875	17.493	30.927	0.00	C
	ATOM	665	NH1	ARG	A	96	19.967	17.507	29.960	0.00	N
35	ATOM	666	NH2	ARG	A	96	21.377	16.341	31.341	0.00	N
	ATOM	667	C	ARG	A	96	17.027	18.487	32.258	0.00	C
	ATOM	668	O	ARG	A	96	17.160	17.288	32.509	0.00	O
	ATOM	669	N	SER	A	97	16.458	18.924	31.142	0.00	N
	ATOM	670	CA	SER	A	97	15.950	17.983	30.157	0.00	C
40	ATOM	671	CB	SER	A	97	14.418	18.054	30.082	0.00	C
	ATOM	672	OG	SER	A	97	13.913	17.133	29.134	0.00	O
	ATOM	673	C	SER	A	97	16.564	18.272	28.797	0.00	C
	ATOM	674	O	SER	A	97	16.429	19.378	28.267	0.00	O
	ATOM	675	N	GLY	A	98	17.246	17.265	28.251	0.00	N
45	ATOM	676	CA	GLY	A	98	17.900	17.390	26.960	0.00	C
	ATOM	677	C	GLY	A	98	17.767	16.133	26.115	0.00	C
	ATOM	678	O	GLY	A	98	17.481	15.042	26.624	0.00	O
	ATOM	679	N	SER	A	99	17.997	16.290	24.814	0.00	N
	ATOM	680	CA	SER	A	99	17.865	15.196	23.864	0.00	C
50	ATOM	681	CB	SER	A	99	17.547	15.749	22.478	0.00	C
	ATOM	682	OG	SER	A	99	18.663	16.457	21.968	0.00	O
	ATOM	683	C	SER	A	99	19.067	14.279	23.740	0.00	C
	ATOM	684	O	SER	A	99	18.992	13.275	23.039	0.00	O
	ATOM	685	N	THR	A	100	20.174	14.612	24.396	0.00	N
55	ATOM	686	CA	THR	A	100	21.358	13.766	24.307	0.00	C
	ATOM	687	CB	THR	A	100	22.641	14.602	24.125	0.00	C
	ATOM	688	OG1	THR	A	100	22.516	15.417	22.953	0.00	O
	ATOM	689	CG2	THR	A	100	23.860	13.690	23.967	0.00	C
	ATOM	690	C	THR	A	100	21.531	12.872	25.524	0.00	C
60	ATOM	691	O	THR	A	100	21.890	11.697	25.388	0.00	O
	ATOM	692	N	THR	A	101	21.269	13.422	26.707	0.00	N
	ATOM	693	CA	THR	A	101	21.401	12.662	27.950	0.00	C
	ATOM	694	CB	THR	A	101	22.375	13.340	28.936	0.00	C
	ATOM	695	OG1	THR	A	101	21.791	14.549	29.441	0.00	O
65	ATOM	696	CG2	THR	A	101	23.692	13.642	28.244	0.00	C
	ATOM	697	C	THR	A	101	20.083	12.442	28.677	0.00	C
	ATOM	698	O	THR	A	101	19.990	11.581	29.548	0.00	O
	ATOM	699	N	GLY	A	102	19.068	13.227	28.342	0.00	N
	ATOM	700	CA	GLY	A	102	17.784	13.044	28.985	0.00	C
70	ATOM	701	C	GLY	A	102	17.522	13.868	30.231	0.00	C
	ATOM	702	O	GLY	A	102	17.759	15.075	30.245	0.00	O
	ATOM	703	N	TRP	A	103	17.023	13.207	31.274	0.00	N
	ATOM	704	CA	TRP	A	103	16.681	13.847	32.540	0.00	C
	ATOM	705	CB	TRP	A	103	15.339	13.286	33.027	0.00	C
75	ATOM	706	CG	TRP	A	103	14.790	13.876	34.311	0.00	C
	ATOM	707	CD2	TRP	A	103	13.889	14.989	34.434	0.00	C
	ATOM	708	CE2	TRP	A	103	13.601	15.141	35.807	0.00	C
	ATOM	709	CE3	TRP	A	103	13.293	15.858	33.517	0.00	C

- 253 -

	ATOM	710	CD1	TRP	A	103	15.010	13.424	35.581	0.00	C
	ATOM	711	NE1	TRP	A	103	14.295	14.179	36.483	0.00	N
	ATOM	712	CZ2	TRP	A	103	12.749	16.138	36.284	0.00	C
	ATOM	713	CZ3	TRP	A	103	12.444	16.848	33.991	0.00	C
5	ATOM	714	CH2	TRP	A	103	12.178	16.977	35.363	0.00	C
	ATOM	715	C	TRP	A	103	17.776	13.652	33.593	0.00	C
	ATOM	716	O	TRP	A	103	18.112	12.526	33.955	0.00	O
	ATOM	717	N	HIS	A	104	18.333	14.762	34.074	0.00	N
	ATOM	718	CA	HIS	A	104	19.391	14.731	35.081	0.00	C
10	ATOM	719	CB	HIS	A	104	20.755	14.780	34.405	0.00	C
	ATOM	720	CG	HIS	A	104	21.064	13.554	33.619	0.00	C
	ATOM	721	CD2	HIS	A	104	20.741	13.202	32.352	0.00	C
	ATOM	722	ND1	HIS	A	104	21.704	12.465	34.167	0.00	N
	ATOM	723	CE1	HIS	A	104	21.759	11.496	33.273	0.00	C
15	ATOM	724	NE2	HIS	A	104	21.181	11.917	32.162	0.00	N
	ATOM	725	C	HIS	A	104	19.229	15.894	36.038	0.00	C
	ATOM	726	O	HIS	A	104	18.859	16.995	35.636	0.00	O
	ATOM	727	N	CYS	A	105	19.512	15.647	37.309	0.00	N
	ATOM	728	CA	CYS	A	105	19.373	16.692	38.303	0.00	C
20	ATOM	729	CB	CYS	A	105	18.223	16.317	39.234	0.00	C
	ATOM	730	SG	CYS	A	105	16.804	15.602	38.342	0.00	S
	ATOM	731	C	CYS	A	105	20.635	17.014	39.099	0.00	C
	ATOM	732	O	CYS	A	105	21.665	16.361	38.964	0.00	O
	ATOM	733	N	GLY	A	106	20.533	18.046	39.923	0.00	N
25	ATOM	734	CA	GLY	A	106	21.642	18.487	40.739	0.00	C
	ATOM	735	C	GLY	A	106	21.125	19.693	41.490	0.00	C
	ATOM	736	O	GLY	A	106	19.916	19.805	41.707	0.00	O
	ATOM	737	N	THR	A	107	22.011	20.598	41.888	0.00	N
	ATOM	738	CA	THR	A	107	21.572	21.784	42.603	0.00	C
30	ATOM	739	CB	THR	A	107	21.865	21.681	44.117	0.00	C
	ATOM	740	OG1	THR	A	107	23.250	21.386	44.328	0.00	O
	ATOM	741	CG2	THR	A	107	21.021	20.583	44.746	0.00	C
	ATOM	742	C	THR	A	107	22.215	23.046	42.058	0.00	C
	ATOM	743	O	THR	A	107	23.238	23.001	41.372	0.00	O
35	ATOM	744	N	ILE	A	108	21.588	24.178	42.344	0.00	N
	ATOM	745	CA	ILE	A	108	22.103	25.452	41.886	0.00	C
	ATOM	746	CB	ILE	A	108	21.039	26.550	41.982	0.00	C
	ATOM	747	CG2	ILE	A	108	21.651	27.904	41.614	0.00	C
	ATOM	748	CG1	ILE	A	108	19.850	26.200	41.091	0.00	C
40	ATOM	749	CD1	ILE	A	108	18.691	27.166	41.228	0.00	C
	ATOM	750	C	ILE	A	108	23.216	25.803	42.852	0.00	C
	ATOM	751	O	ILE	A	108	23.001	25.774	44.065	0.00	O
	ATOM	752	N	THR	A	109	24.399	26.118	42.331	0.00	N
	ATOM	753	CA	THR	A	109	25.516	26.472	43.197	0.00	C
45	ATOM	754	CB	THR	A	109	26.787	25.662	42.849	0.00	C
	ATOM	755	OG1	THR	A	109	27.055	25.748	41.443	0.00	O
	ATOM	756	CG2	THR	A	109	26.599	24.201	43.244	0.00	C
	ATOM	757	C	THR	A	109	25.827	27.965	43.128	0.00	C
	ATOM	758	O	THR	A	109	26.599	28.481	43.928	0.00	O
50	ATOM	759	N	ALA	A	110	25.214	28.664	42.181	0.00	N
	ATOM	760	CA	ALA	A	110	25.457	30.090	42.053	0.00	C
	ATOM	761	CB	ALA	A	110	26.949	30.348	41.846	0.00	C
	ATOM	762	C	ALA	A	110	24.650	30.767	40.946	0.00	C
	ATOM	763	O	ALA	A	110	24.191	30.132	40.001	0.00	O
55	ATOM	764	N	LEU	A	111	24.491	32.078	41.092	0.00	N
	ATOM	765	CA	LEU	A	111	23.755	32.893	40.145	0.00	C
	ATOM	766	CB	LEU	A	111	22.550	33.530	40.844	0.00	C
	ATOM	767	CG	LEU	A	111	21.547	32.545	41.465	0.00	C
	ATOM	768	CD1	LEU	A	111	20.462	33.315	42.227	0.00	C
60	ATOM	769	CD2	LEU	A	111	20.925	31.681	40.371	0.00	C
	ATOM	770	C	LEU	A	111	24.688	33.970	39.593	0.00	C
	ATOM	771	O	LEU	A	111	25.661	34.363	40.243	0.00	O
	ATOM	772	N	ASN	A	112	24.380	34.439	38.390	0.00	N
	ATOM	773	CA	ASN	A	112	25.171	35.468	37.719	0.00	C
65	ATOM	774	CB	ASN	A	112	25.123	36.788	38.490	0.00	C
	ATOM	775	CG	ASN	A	112	23.725	37.149	38.930	0.00	C
	ATOM	776	OD1	ASN	A	112	23.244	36.663	39.950	0.00	O
	ATOM	777	ND2	ASN	A	112	23.057	37.994	38.155	0.00	N
	ATOM	778	C	ASN	A	112	26.629	35.074	37.507	0.00	C
70	ATOM	779	O	ASN	A	112	27.526	35.891	37.680	0.00	O
	ATOM	780	N	SER	A	113	26.870	33.820	37.144	0.00	N
	ATOM	781	CA	SER	A	113	28.237	33.383	36.916	0.00	C
	ATOM	782	CB	SER	A	113	28.375	31.875	37.126	0.00	C
	ATOM	783	OG	SER	A	113	28.149	31.522	38.479	0.00	O
75	ATOM	784	C	SER	A	113	28.604	33.726	35.480	0.00	C
	ATOM	785	O	SER	A	113	27.733	34.045	34.663	0.00	O
	ATOM	786	N	SER	A	114	29.899	33.691	35.192	0.00	N
	ATOM	787	CA	SER	A	114	30.403	33.985	33.859	0.00	C

- 254 -

	ATOM	788	CB	SER	A	114	31.288	35.234	33.847	0.00	C
	ATOM	789	OG	SER	A	114	30.524	36.417	33.962	0.00	O
	ATOM	790	C	SER	A	114	31.237	32.795	33.440	0.00	C
5	ATOM	791	O	SER	A	114	31.708	32.027	34.277	0.00	O
	ATOM	792	N	VAL	A	115	31.400	32.631	32.138	0.00	N
	ATOM	793	CA	VAL	A	115	32.185	31.535	31.611	0.00	C
	ATOM	794	CB	VAL	A	115	31.342	30.241	31.427	0.00	C
	ATOM	795	CG1	VAL	A	115	30.850	29.751	32.772	0.00	C
	ATOM	796	CG2	VAL	A	115	30.174	30.492	30.485	0.00	C
10	ATOM	797	C	VAL	A	115	32.678	32.010	30.266	0.00	C
	ATOM	798	O	VAL	A	115	32.121	32.945	29.691	0.00	O
	ATOM	799	N	THR	A	116	33.735	31.387	29.768	0.00	N
	ATOM	800	CA	THR	A	116	34.268	31.779	28.482	0.00	C
	ATOM	801	CB	THR	A	116	35.671	32.359	28.634	0.00	C
15	ATOM	802	OG1	THR	A	116	35.602	33.538	29.446	0.00	O
	ATOM	803	CG2	THR	A	116	36.247	32.726	27.277	0.00	C
	ATOM	804	C	THR	A	116	34.278	30.589	27.535	0.00	C
	ATOM	805	O	THR	A	116	34.931	29.573	27.787	0.00	O
	ATOM	806	N	TYR	A	117	33.512	30.721	26.459	0.00	N
20	ATOM	807	CA	TYR	A	117	33.397	29.691	25.443	0.00	C
	ATOM	808	CB	TYR	A	117	31.972	29.664	24.885	0.00	C
	ATOM	809	CG	TYR	A	117	30.892	29.244	25.874	0.00	C
	ATOM	810	CD1	TYR	A	117	29.803	30.072	26.134	0.00	C
	ATOM	811	CE1	TYR	A	117	28.780	29.675	26.981	0.00	C
25	ATOM	812	CD2	TYR	A	117	30.930	27.998	26.499	0.00	C
	ATOM	813	CE2	TYR	A	117	29.908	27.589	27.353	0.00	C
	ATOM	814	CZ	TYR	A	117	28.834	28.432	27.590	0.00	C
	ATOM	815	OH	TYR	A	117	27.814	28.036	28.431	0.00	O
	ATOM	816	C	TYR	A	117	34.368	30.064	24.333	0.00	C
30	ATOM	817	O	TYR	A	117	34.922	31.161	24.329	0.00	O
	ATOM	818	N	PRO	A	118	34.609	29.151	23.384	0.00	N
	ATOM	819	CA	PRO	A	118	35.541	29.528	22.318	0.00	C
	ATOM	820	CB	PRO	A	118	35.655	28.249	21.472	0.00	C
	ATOM	821	C	PRO	A	118	35.080	30.751	21.520	0.00	C
35	ATOM	822	O	PRO	A	118	35.875	31.369	20.805	0.00	O
	ATOM	823	CD	PRO	A	118	34.313	27.711	23.347	0.00	C
	ATOM	824	CG	PRO	A	118	34.472	27.405	21.890	0.00	C
	ATOM	825	N	GLU	A	119	33.804	31.109	21.651	0.00	N
	ATOM	826	CA	GLU	A	119	33.266	32.265	20.935	0.00	C
40	ATOM	827	CB	GLU	A	119	31.785	32.079	20.612	0.00	C
	ATOM	828	C	GLU	A	119	33.416	33.514	21.789	0.00	C
	ATOM	829	O	GLU	A	119	33.498	34.634	21.275	0.00	O
	ATOM	830	CG	GLU	A	119	31.470	30.985	19.611	0.00	C
	ATOM	831	CD	GLU	A	119	31.686	29.606	20.179	0.00	C
45	ATOM	832	OE1	GLU	A	119	31.593	29.460	21.415	0.00	O1-
	ATOM	833	OE2	GLU	A	119	31.932	28.667	19.393	0.00	O
	ATOM	834	N	GLY	A	120	33.437	33.315	23.102	0.00	N
	ATOM	835	CA	GLY	A	120	33.575	34.438	24.002	0.00	C
	ATOM	836	C	GLY	A	120	32.984	34.167	25.368	0.00	C
50	ATOM	837	O	GLY	A	120	32.714	33.020	25.727	0.00	O
	ATOM	838	N	THR	A	121	32.782	35.233	26.133	0.00	N
	ATOM	839	CA	THR	A	121	32.233	35.110	27.471	0.00	C
	ATOM	840	CB	THR	A	121	32.932	36.084	28.435	0.00	C
	ATOM	841	OG1	THR	A	121	34.319	35.733	28.527	0.00	O
55	ATOM	842	CG2	THR	A	121	32.293	36.026	29.831	0.00	C
	ATOM	843	C	THR	A	121	30.739	35.358	27.526	0.00	C
	ATOM	844	O	THR	A	121	30.198	36.160	26.771	0.00	O
	ATOM	845	N	VAL	A	122	30.075	34.632	28.417	0.00	N
	ATOM	846	CA	VAL	A	122	28.635	34.754	28.607	0.00	C
60	ATOM	847	CB	VAL	A	122	27.899	33.451	28.196	0.00	C
	ATOM	848	CG1	VAL	A	122	26.412	33.553	28.519	0.00	C
	ATOM	849	CG2	VAL	A	122	28.091	33.207	26.695	0.00	C
	ATOM	850	C	VAL	A	122	28.515	35.016	30.103	0.00	C
	ATOM	851	O	VAL	A	122	29.182	34.363	30.902	0.00	O
65	ATOM	852	N	ARG	A	123	27.689	35.978	30.493	0.00	N
	ATOM	853	CA	ARG	A	123	27.546	36.282	31.915	0.00	C
	ATOM	854	CB	ARG	A	123	27.917	37.748	32.153	0.00	C
	ATOM	855	CG	ARG	A	123	26.856	38.724	31.655	0.00	C
	ATOM	856	CD	ARG	A	123	25.712	38.852	32.671	0.00	C
70	ATOM	857	NE	ARG	A	123	24.459	39.336	32.089	0.00	N1+
	ATOM	858	CZ	ARG	A	123	24.345	40.426	31.336	0.00	C
	ATOM	859	NH1	ARG	A	123	25.414	41.162	31.054	0.00	N
	ATOM	860	NH2	ARG	A	123	23.156	40.796	30.877	0.00	N
	ATOM	861	C	ARG	A	123	26.151	36.018	32.468	0.00	C
75	ATOM	862	O	ARG	A	123	25.252	35.605	31.739	0.00	O
	ATOM	863	N	GLY	A	124	25.991	36.272	33.767	0.00	N
	ATOM	864	CA	GLY	A	124	24.714	36.080	34.438	0.00	C
	ATOM	865	C	GLY	A	124	24.094	34.712	34.238	0.00	C

- 255 -

	ATOM	866	O	GLY	A	124	22.910	34.603	33.936	0.00	O
	ATOM	867	N	LEU	A	125	24.891	33.666	34.415	0.00	N
	ATOM	868	CA	LEU	A	125	24.412	32.304	34.238	0.00	C
	ATOM	869	CB	LEU	A	125	25.411	31.495	33.406	0.00	C
5	ATOM	870	CG	LEU	A	125	25.597	31.779	31.913	0.00	C
	ATOM	871	CD1	LEU	A	125	26.780	30.977	31.383	0.00	C
	ATOM	872	CD2	LEU	A	125	24.333	31.411	31.152	0.00	C
	ATOM	873	C	LEU	A	125	24.189	31.574	35.554	0.00	C
	ATOM	874	O	LEU	A	125	24.828	31.869	36.573	0.00	O
10	ATOM	875	N	ILE	A	126	23.270	30.615	35.516	0.00	N
	ATOM	876	CA	ILE	A	126	22.949	29.813	36.685	0.00	C
	ATOM	877	CB	ILE	A	126	21.506	29.276	36.600	0.00	C
	ATOM	878	CG2	ILE	A	126	21.268	28.230	37.672	0.00	C
	ATOM	879	CG1	ILE	A	126	20.517	30.441	36.754	0.00	C
15	ATOM	880	CD1	ILE	A	126	19.074	30.045	36.578	0.00	C
	ATOM	881	C	ILE	A	126	23.947	28.646	36.668	0.00	C
	ATOM	882	O	ILE	A	126	24.009	27.881	35.701	0.00	O
	ATOM	883	N	ARG	A	127	24.746	28.536	37.723	0.00	N
	ATOM	884	CA	ARG	A	127	25.738	27.473	37.831	0.00	C
20	ATOM	885	CB	ARG	A	127	26.989	28.007	38.528	0.00	C
	ATOM	886	CG	ARG	A	127	28.129	27.015	38.679	0.00	C
	ATOM	887	CD	ARG	A	127	29.261	27.678	39.441	0.00	C
	ATOM	888	NE	ARG	A	127	30.312	26.748	39.830	0.00	N1+
	ATOM	889	CZ	ARG	A	127	31.098	26.112	38.971	0.00	C
25	ATOM	890	NH2	ARG	A	127	32.033	25.279	39.417	0.00	N
	ATOM	891	NH1	ARG	A	127	30.949	26.310	37.669	0.00	N
	ATOM	892	C	ARG	A	127	25.132	26.328	38.633	0.00	C
	ATOM	893	O	ARG	A	127	24.507	26.553	39.676	0.00	O
	ATOM	894	N	THR	A	128	25.325	25.103	38.151	0.00	N
30	ATOM	895	CA	THR	A	128	24.784	23.929	38.828	0.00	C
	ATOM	896	CB	THR	A	128	23.447	23.475	38.189	0.00	C
	ATOM	897	OG1	THR	A	128	23.718	22.755	36.977	0.00	O
	ATOM	898	CG2	THR	A	128	22.568	24.674	37.863	0.00	C
	ATOM	899	C	THR	A	128	25.720	22.729	38.782	0.00	C
35	ATOM	900	O	THR	A	128	26.763	22.759	38.135	0.00	O
	ATOM	901	N	THR	A	129	25.317	21.667	39.472	0.00	N
	ATOM	902	CA	THR	A	129	26.084	20.429	39.533	0.00	C
	ATOM	903	CB	THR	A	129	26.055	19.838	40.946	0.00	C
	ATOM	904	OG1	THR	A	129	24.691	19.639	41.355	0.00	O
40	ATOM	905	CG2	THR	A	129	26.758	20.779	41.924	0.00	C
	ATOM	906	C	THR	A	129	25.474	19.411	38.565	0.00	C
	ATOM	907	O	THR	A	129	25.792	18.227	38.607	0.00	O
	ATOM	908	N	VAL	A	130	24.589	19.886	37.696	0.00	N
	ATOM	909	CA	VAL	A	130	23.930	19.027	36.722	0.00	C
45	ATOM	910	CB	VAL	A	130	22.663	19.707	36.164	0.00	C
	ATOM	911	CG1	VAL	A	130	21.972	18.790	35.162	0.00	C
	ATOM	912	CG2	VAL	A	130	21.715	20.054	37.308	0.00	C
	ATOM	913	C	VAL	A	130	24.857	18.691	35.561	0.00	C
	ATOM	914	O	VAL	A	130	25.623	19.536	35.109	0.00	O
50	ATOM	915	N	CYS	A	131	24.790	17.449	35.086	0.00	N
	ATOM	916	CA	CYS	A	131	25.626	17.016	33.975	0.00	C
	ATOM	917	CB	CYS	A	131	25.889	15.507	34.034	0.00	C
	ATOM	918	SG	CYS	A	131	24.399	14.468	33.874	0.00	S
	ATOM	919	C	CYS	A	131	24.893	17.340	32.690	0.00	C
55	ATOM	920	O	CYS	A	131	23.670	17.436	32.678	0.00	O
	ATOM	921	N	ALA	A	132	25.636	17.514	31.607	0.00	N
	ATOM	922	CA	ALA	A	132	25.020	17.821	30.329	0.00	C
	ATOM	923	CB	ALA	A	132	24.707	19.313	30.237	0.00	C
	ATOM	924	C	ALA	A	132	25.920	17.404	29.176	0.00	C
60	ATOM	925	O	ALA	A	132	27.113	17.139	29.356	0.00	O
	ATOM	926	N	GLU	A	133	25.323	17.353	27.992	0.00	N
	ATOM	927	CA	GLU	A	133	26.017	16.981	26.774	0.00	C
	ATOM	928	CB	GLU	A	133	25.434	15.686	26.219	0.00	C
	ATOM	929	CG	GLU	A	133	26.457	14.695	25.730	0.00	C
65	ATOM	930	CD	GLU	A	133	27.077	13.909	26.862	0.00	C
	ATOM	931	OE1	GLU	A	133	27.702	14.533	27.741	0.00	O1-
	ATOM	932	OE2	GLU	A	133	26.937	12.667	26.871	0.00	O
	ATOM	933	C	GLU	A	133	25.750	18.114	25.792	0.00	C
	ATOM	934	O	GLU	A	133	24.778	18.851	25.946	0.00	O
70	ATOM	935	N	PRO	A	134	26.602	18.268	24.769	0.00	N
	ATOM	936	CA	PRO	A	134	26.395	19.343	23.789	0.00	C
	ATOM	937	CB	PRO	A	134	27.471	19.059	22.742	0.00	C
	ATOM	938	C	PRO	A	134	24.975	19.390	23.185	0.00	C
	ATOM	939	O	PRO	A	134	24.331	20.446	23.159	0.00	O
75	ATOM	940	CD	PRO	A	134	27.856	17.539	24.501	0.00	C
	ATOM	941	CG	PRO	A	134	28.586	18.478	23.572	0.00	C
	ATOM	942	N	GLY	A	135	24.490	18.250	22.708	0.00	N
	ATOM	943	CA	GLY	A	135	23.167	18.218	22.117	0.00	C

- 256 -

	ATOM	944	C	GLY	A	135	22.074	18.675	23.063	0.00	C
	ATOM	945	O	GLY	A	135	20.979	19.053	22.631	0.00	O
	ATOM	946	N	ASP	A	136	22.369	18.638	24.359	0.00	N
	ATOM	947	CA	ASP	A	136	21.414	19.046	25.387	0.00	C
5	ATOM	948	CB	ASP	A	136	21.914	18.588	26.770	0.00	C
	ATOM	949	C	ASP	A	136	21.162	20.564	25.400	0.00	C
	ATOM	950	O	ASP	A	136	20.124	21.024	25.886	0.00	O
	ATOM	951	CG	ASP	A	136	21.783	17.075	26.982	0.00	C
	ATOM	952	OD2	ASP	A	136	20.834	16.471	26.436	0.00	01-
10	ATOM	953	OD1	ASP	A	136	22.618	16.492	27.714	0.00	O
	ATOM	954	N	SER	A	137	22.109	21.332	24.868	0.00	N
	ATOM	955	CA	SER	A	137	21.989	22.791	24.823	0.00	C
	ATOM	956	CB	SER	A	137	23.048	23.390	23.896	0.00	C
	ATOM	957	C	SER	A	137	20.610	23.287	24.388	0.00	C
15	ATOM	958	O	SER	A	137	19.993	22.752	23.456	0.00	O
	ATOM	959	OG	SER	A	137	24.352	23.234	24.427	0.00	O
	ATOM	960	N	GLY	A	138	20.148	24.332	25.070	0.00	N
	ATOM	961	CA	GLY	A	138	18.854	24.904	24.782	0.00	C
	ATOM	962	C	GLY	A	138	17.803	24.224	25.629	0.00	C
20	ATOM	963	O	GLY	A	138	16.706	24.748	25.809	0.00	O
	ATOM	964	N	GLY	A	139	18.150	23.057	26.160	0.00	N
	ATOM	965	CA	GLY	A	139	17.222	22.297	26.982	0.00	C
	ATOM	966	C	GLY	A	139	16.617	23.021	28.176	0.00	C
	ATOM	967	O	GLY	A	139	17.104	24.070	28.604	0.00	O
25	ATOM	968	N	SER	A	140	15.555	22.438	28.729	0.00	N
	ATOM	969	CA	SER	A	140	14.858	23.024	29.870	0.00	C
	ATOM	970	CB	SER	A	140	13.423	22.500	29.948	0.00	C
	ATOM	971	OG	SER	A	140	12.971	22.037	28.691	0.00	O
	ATOM	972	C	SER	A	140	15.532	22.736	31.198	0.00	C
30	ATOM	973	O	SER	A	140	16.162	21.691	31.389	0.00	O
	ATOM	974	N	LEU	A	141	15.393	23.683	32.115	0.00	N
	ATOM	975	CA	LEU	A	141	15.967	23.558	33.448	0.00	C
	ATOM	976	CB	LEU	A	141	17.175	24.482	33.639	0.00	C
	ATOM	977	CG	LEU	A	141	17.722	24.420	35.073	0.00	C
35	ATOM	978	CD1	LEU	A	141	18.323	23.047	35.334	0.00	C
	ATOM	979	CD2	LEU	A	141	18.749	25.518	35.297	0.00	C
	ATOM	980	C	LEU	A	141	14.851	23.945	34.405	0.00	C
	ATOM	981	O	LEU	A	141	14.398	25.081	34.422	0.00	O
	ATOM	982	N	LEU	A	142	14.409	22.987	35.199	0.00	N
40	ATOM	983	CA	LEU	A	142	13.341	23.220	36.150	0.00	C
	ATOM	984	CB	LEU	A	142	12.230	22.198	35.913	0.00	C
	ATOM	985	CG	LEU	A	142	11.289	22.306	34.719	0.00	C
	ATOM	986	CD1	LEU	A	142	10.674	20.933	34.463	0.00	C
	ATOM	987	CD2	LEU	A	142	10.219	23.350	34.996	0.00	C
45	ATOM	988	C	LEU	A	142	13.702	23.168	37.629	0.00	C
	ATOM	989	O	LEU	A	142	14.745	22.671	38.029	0.00	O
	ATOM	990	N	ALA	A	143	12.788	23.701	38.424	0.00	N
	ATOM	991	CA	ALA	A	143	12.880	23.759	39.875	0.00	C
	ATOM	992	CB	ALA	A	143	13.159	25.178	40.345	0.00	C
50	ATOM	993	C	ALA	A	143	11.434	23.368	40.165	0.00	C
	ATOM	994	O	ALA	A	143	10.557	24.221	40.225	0.00	O
	ATOM	995	N	GLY	A	144	11.175	22.072	40.287	0.00	N
	ATOM	996	CA	GLY	A	144	9.810	21.642	40.513	0.00	C
	ATOM	997	C	GLY	A	144	9.058	21.945	39.232	0.00	C
55	ATOM	998	O	GLY	A	144	9.457	21.487	38.154	0.00	O
	ATOM	999	N	ASN	A	145	7.984	22.723	39.322	0.00	N
	ATOM	1000	CA	ASN	A	145	7.241	23.066	38.122	0.00	C
	ATOM	1001	CB	ASN	A	145	5.736	22.848	38.321	0.00	C
	ATOM	1002	CG	ASN	A	145	5.144	23.751	39.384	0.00	C
60	ATOM	1003	OD1	ASN	A	145	5.382	24.962	39.396	0.00	O
	ATOM	1004	ND2	ASN	A	145	4.351	23.166	40.281	0.00	N
	ATOM	1005	C	ASN	A	145	7.503	24.496	37.650	0.00	C
	ATOM	1006	O	ASN	A	145	6.716	25.049	36.886	0.00	O
	ATOM	1007	N	GLN	A	146	8.613	25.086	38.093	0.00	N
65	ATOM	1008	CA	GLN	A	146	8.968	26.455	37.702	0.00	C
	ATOM	1009	CB	GLN	A	146	9.234	27.314	38.942	0.00	C
	ATOM	1010	CG	GLN	A	146	8.080	27.367	39.916	0.00	C
	ATOM	1011	CD	GLN	A	146	6.875	28.097	39.363	0.00	C
	ATOM	1012	OE1	GLN	A	146	5.735	27.705	39.615	0.00	O
70	ATOM	1013	NE2	GLN	A	146	7.117	29.172	38.617	0.00	N
	ATOM	1014	C	GLN	A	146	10.205	26.492	36.798	0.00	C
	ATOM	1015	O	GLN	A	146	11.277	25.999	37.169	0.00	O
	ATOM	1016	N	ALA	A	147	10.055	27.084	35.618	0.00	N
	ATOM	1017	CA	ALA	A	147	11.160	27.188	34.660	0.00	C
75	ATOM	1018	CB	ALA	A	147	10.642	27.698	33.309	0.00	C
	ATOM	1019	C	ALA	A	147	12.253	28.124	35.183	0.00	C
	ATOM	1020	O	ALA	A	147	11.958	29.233	35.625	0.00	O
	ATOM	1021	N	GLN	A	148	13.508	27.679	35.124	0.00	N

- 257 -

	ATOM	1022	CA	GLN	A	148	14.637	28.481	35.593	0.00	C
	ATOM	1023	CB	GLN	A	148	15.576	27.627	36.435	0.00	C
	ATOM	1024	CG	GLN	A	148	14.939	27.023	37.667	0.00	C
	ATOM	1025	CD	GLN	A	148	14.283	28.062	38.553	0.00	C
5	ATOM	1026	OE1	GLN	A	148	13.074	28.016	38.797	0.00	O
	ATOM	1027	NE2	GLN	A	148	15.075	29.005	39.040	0.00	N
	ATOM	1028	C	GLN	A	148	15.440	29.128	34.466	0.00	C
	ATOM	1029	O	GLN	A	148	15.723	30.325	34.501	0.00	O
	ATOM	1030	N	GLY	A	149	15.818	28.330	33.472	0.00	N
10	ATOM	1031	CA	GLY	A	149	16.578	28.852	32.349	0.00	C
	ATOM	1032	C	GLY	A	149	16.762	27.783	31.290	0.00	C
	ATOM	1033	O	GLY	A	149	16.104	26.742	31.348	0.00	O
	ATOM	1034	N	VAL	A	150	17.628	28.041	30.311	0.00	N
	ATOM	1035	CA	VAL	A	150	17.896	27.061	29.261	0.00	C
15	ATOM	1036	CB	VAL	A	150	17.568	27.604	27.848	0.00	C
	ATOM	1037	CG1	VAL	A	150	16.053	27.737	27.694	0.00	C
	ATOM	1038	CG2	VAL	A	150	18.256	28.936	27.611	0.00	C
	ATOM	1039	C	VAL	A	150	19.351	26.630	29.329	0.00	C
	ATOM	1040	O	VAL	A	150	20.210	27.368	29.809	0.00	O
20	ATOM	1041	N	THR	A	151	19.630	25.431	28.844	0.00	N
	ATOM	1042	CA	THR	A	151	20.985	24.914	28.873	0.00	C
	ATOM	1043	CB	THR	A	151	20.980	23.429	28.536	0.00	C
	ATOM	1044	OG1	THR	A	151	20.057	22.771	29.412	0.00	O
	ATOM	1045	CG2	THR	A	151	22.361	22.828	28.748	0.00	C
25	ATOM	1046	C	THR	A	151	21.954	25.675	27.984	0.00	C
	ATOM	1047	O	THR	A	151	21.756	25.796	26.779	0.00	O
	ATOM	1048	N	SER	A	152	23.007	26.192	28.607	0.00	N
	ATOM	1049	CA	SER	A	152	24.020	26.956	27.898	0.00	C
	ATOM	1050	CB	SER	A	152	24.382	28.193	28.723	0.00	C
30	ATOM	1051	OG	SER	A	152	25.262	29.047	28.021	0.00	O
	ATOM	1052	C	SER	A	152	25.264	26.127	27.603	0.00	C
	ATOM	1053	O	SER	A	152	25.673	26.005	26.450	0.00	O
	ATOM	1054	N	GLY	A	153	25.859	25.561	28.648	0.00	N
	ATOM	1055	CA	GLY	A	153	27.047	24.740	28.483	0.00	C
35	ATOM	1056	C	GLY	A	153	27.702	24.415	29.817	0.00	C
	ATOM	1057	O	GLY	A	153	27.151	24.724	30.872	0.00	O
	ATOM	1058	N	GLY	A	154	28.876	23.794	29.771	0.00	N
	ATOM	1059	CA	GLY	A	154	29.589	23.443	30.984	0.00	C
	ATOM	1060	C	GLY	A	154	30.688	22.439	30.708	0.00	C
40	ATOM	1061	O	GLY	A	154	31.161	22.322	29.579	0.00	O
	ATOM	1062	N	SER	A	155	31.101	21.703	31.736	0.00	N
	ATOM	1063	CA	SER	A	155	32.149	20.701	31.572	0.00	C
	ATOM	1064	CB	SER	A	155	33.416	21.148	32.296	0.00	C
	ATOM	1065	OG	SER	A	155	33.180	21.231	33.688	0.00	O
45	ATOM	1066	C	SER	A	155	31.700	19.354	32.128	0.00	C
	ATOM	1067	O	SER	A	155	30.690	19.268	32.836	0.00	O
	ATOM	1068	N	GLY	A	156	32.460	18.307	31.805	0.00	N
	ATOM	1069	CA	GLY	A	156	32.142	16.970	32.283	0.00	C
	ATOM	1070	C	GLY	A	156	31.101	16.231	31.458	0.00	C
50	ATOM	1071	O	GLY	A	156	30.856	16.564	30.302	0.00	O
	ATOM	1072	N	ASN	A	157	30.495	15.211	32.051	0.00	N
	ATOM	1073	CA	ASN	A	157	29.470	14.434	31.369	0.00	C
	ATOM	1074	CB	ASN	A	157	30.115	13.390	30.450	0.00	C
	ATOM	1075	CG	ASN	A	157	31.077	12.472	31.188	0.00	C
55	ATOM	1076	OD1	ASN	A	157	30.669	11.681	32.038	0.00	O
	ATOM	1077	ND2	ASN	A	157	32.365	12.575	30.863	0.00	N
	ATOM	1078	C	ASN	A	157	28.578	13.766	32.410	0.00	C
	ATOM	1079	O	ASN	A	157	28.788	13.932	33.610	0.00	O
	ATOM	1080	N	CYS	A	158	27.580	13.021	31.948	0.00	N
60	ATOM	1081	CA	CYS	A	158	26.661	12.337	32.840	0.00	C
	ATOM	1082	CB	CYS	A	158	25.304	12.169	32.155	0.00	C
	ATOM	1083	SG	CYS	A	158	24.426	13.754	31.973	0.00	S
	ATOM	1084	C	CYS	A	158	27.181	11.000	33.350	0.00	C
	ATOM	1085	O	CYS	A	158	26.592	10.393	34.244	0.00	O
65	ATOM	1086	N	ARG	A	159	28.288	10.538	32.784	0.00	N
	ATOM	1087	CA	ARG	A	159	28.862	9.271	33.215	0.00	C
	ATOM	1088	CB	ARG	A	159	29.714	8.662	32.099	0.00	C
	ATOM	1089	CG	ARG	A	159	28.922	8.198	30.890	0.00	C
	ATOM	1090	CD	ARG	A	159	29.852	7.660	29.817	0.00	C
70	ATOM	1091	NE	ARG	A	159	30.711	8.703	29.260	0.00	N1+
	ATOM	1092	CZ	ARG	A	159	30.273	9.714	28.517	0.00	C
	ATOM	1093	NH1	ARG	A	159	28.980	9.826	28.237	0.00	N
	ATOM	1094	NH2	ARG	A	159	31.128	10.610	28.049	0.00	N
	ATOM	1095	C	ARG	A	159	29.716	9.462	34.467	0.00	C
75	ATOM	1096	O	ARG	A	159	29.634	8.675	35.405	0.00	O
	ATOM	1097	N	THR	A	160	30.533	10.510	34.481	0.00	N
	ATOM	1098	CA	THR	A	160	31.400	10.785	35.628	0.00	C
	ATOM	1099	CB	THR	A	160	32.874	10.925	35.185	0.00	C

- 258 -

	ATOM	1100	OG1	THR	A	160	32.966	11.897	34.138	0.00	O
	ATOM	1101	CG2	THR	A	160	33.404	9.605	34.676	0.00	C
	ATOM	1102	C	THR	A	160	31.000	12.048	36.396	0.00	C
	ATOM	1103	O	THR	A	160	31.525	12.320	37.475	0.00	O
5	ATOM	1104	N	GLY	A	161	30.068	12.812	35.836	0.00	N
	ATOM	1105	CA	GLY	A	161	29.622	14.028	36.490	0.00	C
	ATOM	1106	C	GLY	A	161	30.200	15.295	35.878	0.00	C
	ATOM	1107	O	GLY	A	161	31.194	15.262	35.150	0.00	O
	ATOM	1108	N	GLY	A	162	29.577	16.426	36.180	0.00	N
10	ATOM	1109	CA	GLY	A	162	30.061	17.681	35.646	0.00	C
	ATOM	1110	C	GLY	A	162	29.414	18.909	36.250	0.00	C
	ATOM	1111	O	GLY	A	162	28.785	18.856	37.318	0.00	O
	ATOM	1112	N	THR	A	163	29.592	20.023	35.547	0.00	N
	ATOM	1113	CA	THR	A	163	29.057	21.322	35.934	0.00	C
15	ATOM	1114	CB	THR	A	163	30.179	22.248	36.440	0.00	C
	ATOM	1115	OG1	THR	A	163	30.861	21.621	37.535	0.00	O
	ATOM	1116	CG2	THR	A	163	29.604	23.576	36.896	0.00	C
	ATOM	1117	C	THR	A	163	28.414	21.948	34.695	0.00	C
	ATOM	1118	O	THR	A	163	29.052	22.077	33.650	0.00	O
20	ATOM	1119	N	THR	A	164	27.152	22.342	34.810	0.00	N
	ATOM	1120	CA	THR	A	164	26.452	22.945	33.680	0.00	C
	ATOM	1121	CB	THR	A	164	25.290	22.053	33.208	0.00	C
	ATOM	1122	OG1	THR	A	164	25.744	20.700	33.075	0.00	O
	ATOM	1123	CG2	THR	A	164	24.768	22.536	31.869	0.00	C
25	ATOM	1124	C	THR	A	164	25.878	24.298	34.060	0.00	C
	ATOM	1125	O	THR	A	164	25.354	24.466	35.167	0.00	O
	ATOM	1126	N	PHE	A	165	25.981	25.256	33.139	0.00	N
	ATOM	1127	CA	PHE	A	165	25.470	26.607	33.369	0.00	C
	ATOM	1128	CB	PHE	A	165	26.521	27.662	33.021	0.00	C
30	ATOM	1129	CG	PHE	A	165	27.818	27.507	33.769	0.00	C
	ATOM	1130	CD1	PHE	A	165	28.758	26.554	33.380	0.00	C
	ATOM	1131	CD2	PHE	A	165	28.107	28.319	34.858	0.00	C
	ATOM	1132	CE1	PHE	A	165	29.957	26.427	34.071	0.00	C
	ATOM	1133	CE2	PHE	A	165	29.302	28.187	35.541	0.00	C
35	ATOM	1134	CZ	PHE	A	165	30.224	27.242	35.146	0.00	C
	ATOM	1135	C	PHE	A	165	24.242	26.834	32.505	0.00	C
	ATOM	1136	O	PHE	A	165	24.170	26.334	31.386	0.00	O
	ATOM	1137	N	PHE	A	166	23.276	27.586	33.020	0.00	N
	ATOM	1138	CA	PHE	A	166	22.067	27.854	32.262	0.00	C
40	ATOM	1139	CB	PHE	A	166	20.860	27.130	32.880	0.00	C
	ATOM	1140	CG	PHE	A	166	21.062	25.643	33.076	0.00	C
	ATOM	1141	CD2	PHE	A	166	20.371	24.721	32.295	0.00	C
	ATOM	1142	CD1	PHE	A	166	21.936	25.165	34.050	0.00	C
	ATOM	1143	CE2	PHE	A	166	20.549	23.339	32.484	0.00	C
45	ATOM	1144	CE1	PHE	A	166	22.117	23.788	34.243	0.00	C
	ATOM	1145	CZ	PHE	A	166	21.423	22.879	33.460	0.00	C
	ATOM	1146	C	PHE	A	166	21.765	29.344	32.173	0.00	C
	ATOM	1147	O	PHE	A	166	22.066	30.122	33.086	0.00	O
	ATOM	1148	N	GLN	A	167	21.187	29.736	31.046	0.00	N
50	ATOM	1149	CA	GLN	A	167	20.822	31.122	30.802	0.00	C
	ATOM	1150	CB	GLN	A	167	20.737	31.366	29.291	0.00	C
	ATOM	1151	CG	GLN	A	167	19.786	32.464	28.875	0.00	C
	ATOM	1152	CD	GLN	A	167	20.300	33.840	29.234	0.00	C
	ATOM	1153	OE1	GLN	A	167	21.329	34.282	28.722	0.00	O
55	ATOM	1154	NE2	GLN	A	167	19.589	34.525	30.126	0.00	N
	ATOM	1155	C	GLN	A	167	19.449	31.262	31.442	0.00	C
	ATOM	1156	O	GLN	A	167	18.500	30.600	31.020	0.00	O
	ATOM	1157	N	PRO	A	168	19.322	32.107	32.481	0.00	N
	ATOM	1158	CD	PRO	A	168	20.334	32.973	33.113	0.00	C
60	ATOM	1159	CA	PRO	A	168	18.013	32.270	33.132	0.00	C
	ATOM	1160	CB	PRO	A	168	18.261	33.395	34.138	0.00	C
	ATOM	1161	CG	PRO	A	168	19.716	33.237	34.470	0.00	C
	ATOM	1162	C	PRO	A	168	16.926	32.611	32.108	0.00	C
	ATOM	1163	O	PRO	A	168	17.180	33.288	31.116	0.00	O
65	ATOM	1164	N	VAL	A	169	15.711	32.149	32.373	0.00	N
	ATOM	1165	CA	VAL	A	169	14.578	32.379	31.487	0.00	C
	ATOM	1166	CB	VAL	A	169	13.465	31.328	31.802	0.00	C
	ATOM	1167	CG1	VAL	A	169	12.914	31.542	33.204	0.00	C
	ATOM	1168	CG2	VAL	A	169	12.370	31.401	30.786	0.00	C
70	ATOM	1169	C	VAL	A	169	13.962	33.788	31.427	0.00	C
	ATOM	1170	O	VAL	A	169	13.638	34.273	30.358	0.00	O
	ATOM	1171	N	ASN	A	170	13.802	34.455	32.560	0.00	N
	ATOM	1172	CA	ASN	A	170	13.213	35.793	32.554	0.00	C
	ATOM	1173	CB	ASN	A	170	13.128	36.329	33.979	0.00	C
75	ATOM	1174	CG	ASN	A	170	12.215	35.486	34.843	0.00	C
	ATOM	1175	OD1	ASN	A	170	11.177	35.008	34.373	0.00	O
	ATOM	1176	ND2	ASN	A	170	12.587	35.298	36.107	0.00	N
	ATOM	1177	C	ASN	A	170	13.859	36.822	31.635	0.00	C

- 259 -

	ATOM	1178	O	ASN	A	170	13.166	37.586	30.975	0.00	O
	ATOM	1179	N	PRO	A	171	15.192	36.873	31.590	0.00	N
	ATOM	1180	CD	PRO	A	171	16.217	36.299	32.476	0.00	C
5	ATOM	1181	CA	PRO	A	171	15.768	37.872	30.684	0.00	C
	ATOM	1182	CB	PRO	A	171	17.258	37.857	31.043	0.00	C
	ATOM	1183	CG	PRO	A	171	17.466	36.517	31.673	0.00	C
	ATOM	1184	C	PRO	A	171	15.484	37.551	29.209	0.00	C
	ATOM	1185	O	PRO	A	171	15.601	38.418	28.338	0.00	O
10	ATOM	1186	N	ILE	A	172	15.101	36.307	28.935	0.00	N
	ATOM	1187	CA	ILE	A	172	14.798	35.896	27.570	0.00	C
	ATOM	1188	CB	ILE	A	172	14.811	34.374	27.403	0.00	C
	ATOM	1189	CG2	ILE	A	172	14.516	34.018	25.947	0.00	C
	ATOM	1190	CG1	ILE	A	172	16.164	33.801	27.813	0.00	C
	ATOM	1191	CD1	ILE	A	172	16.196	32.269	27.764	0.00	C
15	ATOM	1192	C	ILE	A	172	13.386	36.369	27.251	0.00	C
	ATOM	1193	O	ILE	A	172	13.113	36.885	26.166	0.00	O
	ATOM	1194	N	LEU	A	173	12.488	36.179	28.210	0.00	N
	ATOM	1195	CA	LEU	A	173	11.102	36.587	28.038	0.00	C
	ATOM	1196	CB	LEU	A	173	10.279	36.158	29.252	0.00	C
20	ATOM	1197	CG	LEU	A	173	10.263	34.645	29.486	0.00	C
	ATOM	1198	CD1	LEU	A	173	9.465	34.308	30.759	0.00	C
	ATOM	1199	CD2	LEU	A	173	9.671	33.965	28.251	0.00	C
	ATOM	1200	C	LEU	A	173	11.031	38.105	27.869	0.00	C
	ATOM	1201	O	LEU	A	173	10.287	38.617	27.037	0.00	O
25	ATOM	1202	N	GLN	A	174	11.831	38.807	28.662	0.00	N
	ATOM	1203	CA	GLN	A	174	11.896	40.259	28.641	0.00	C
	ATOM	1204	CB	GLN	A	174	12.665	40.752	29.870	0.00	C
	ATOM	1205	CG	GLN	A	174	12.868	42.259	29.923	0.00	C
	ATOM	1206	CD	GLN	A	174	11.664	43.006	30.461	0.00	C
30	ATOM	1207	OE1	GLN	A	174	10.532	42.811	30.003	0.00	O
	ATOM	1208	NE2	GLN	A	174	11.904	43.876	31.438	0.00	N
	ATOM	1209	C	GLN	A	174	12.555	40.817	27.381	0.00	C
	ATOM	1210	O	GLN	A	174	12.219	41.909	26.933	0.00	O
	ATOM	1211	N	ALA	A	175	13.493	40.078	26.808	0.00	N
35	ATOM	1212	CA	ALA	A	175	14.164	40.552	25.604	0.00	C
	ATOM	1213	CB	ALA	A	175	15.378	39.681	25.306	0.00	C
	ATOM	1214	C	ALA	A	175	13.238	40.580	24.394	0.00	C
	ATOM	1215	O	ALA	A	175	13.276	41.512	23.595	0.00	O
	ATOM	1216	N	TYR	A	176	12.396	39.561	24.276	0.00	N
40	ATOM	1217	CA	TYR	A	176	11.462	39.458	23.161	0.00	C
	ATOM	1218	CB	TYR	A	176	11.571	38.063	22.535	0.00	C
	ATOM	1219	CG	TYR	A	176	12.990	37.700	22.173	0.00	C
	ATOM	1220	CD1	TYR	A	176	13.761	38.551	21.381	0.00	C
	ATOM	1221	CE1	TYR	A	176	15.075	38.249	21.073	0.00	C
45	ATOM	1222	CD2	TYR	A	176	13.574	36.528	22.643	0.00	C
	ATOM	1223	CE2	TYR	A	176	14.890	36.213	22.335	0.00	C
	ATOM	1224	CZ	TYR	A	176	15.636	37.083	21.553	0.00	C
	ATOM	1225	OH	TYR	A	176	16.959	36.817	21.285	0.00	O
	ATOM	1226	C	TYR	A	176	10.004	39.742	23.500	0.00	C
50	ATOM	1227	O	TYR	A	176	9.135	39.574	22.646	0.00	O
	ATOM	1228	N	GLY	A	177	9.736	40.165	24.733	0.00	N
	ATOM	1229	CA	GLY	A	177	8.366	40.457	25.131	0.00	C
	ATOM	1230	C	GLY	A	177	7.469	39.232	25.065	0.00	C
	ATOM	1231	O	GLY	A	177	6.295	39.326	24.711	0.00	O
55	ATOM	1232	N	LEU	A	178	8.033	38.080	25.421	0.00	N
	ATOM	1233	CA	LEU	A	178	7.323	36.807	25.390	0.00	C
	ATOM	1234	CB	LEU	A	178	8.275	35.694	24.937	0.00	C
	ATOM	1235	CG	LEU	A	178	8.981	35.724	23.581	0.00	C
	ATOM	1236	CD1	LEU	A	178	10.077	34.688	23.584	0.00	C
60	ATOM	1237	CD2	LEU	A	178	8.006	35.441	22.454	0.00	C
	ATOM	1238	C	LEU	A	178	6.737	36.403	26.741	0.00	C
	ATOM	1239	O	LEU	A	178	7.221	36.821	27.794	0.00	O
	ATOM	1240	N	ARG	A	179	5.698	35.573	26.688	0.00	N
	ATOM	1241	CA	ARG	A	179	5.008	35.060	27.875	0.00	C
65	ATOM	1242	CB	ARG	A	179	3.519	35.439	27.872	0.00	C
	ATOM	1243	CG	ARG	A	179	3.193	36.849	28.356	0.00	C
	ATOM	1244	CD	ARG	A	179	1.760	37.239	27.989	0.00	C
	ATOM	1245	NE	ARG	A	179	1.401	38.565	28.490	0.00	N1+
	ATOM	1246	CZ	ARG	A	179	1.070	38.825	29.751	0.00	C
70	ATOM	1247	NH1	ARG	A	179	1.044	37.844	30.646	0.00	N
	ATOM	1248	NH2	ARG	A	179	0.773	40.066	30.117	0.00	N
	ATOM	1249	C	ARG	A	179	5.118	33.541	27.794	0.00	C
	ATOM	1250	O	ARG	A	179	5.043	32.978	26.707	0.00	O
	ATOM	1251	N	MET	A	180	5.313	32.882	28.931	0.00	N
75	ATOM	1252	CA	MET	A	180	5.422	31.428	28.955	0.00	C
	ATOM	1253	CB	MET	A	180	5.866	30.936	30.329	0.00	C
	ATOM	1254	CG	MET	A	180	7.257	31.311	30.768	0.00	C
	ATOM	1255	SD	MET	A	180	8.400	30.052	30.227	0.00	S

- 260 -

	ATOM	1256	CE	MET	A	180	7.622	28.610	30.892	0.00	C
	ATOM	1257	C	MET	A	180	4.034	30.856	28.712	0.00	C
	ATOM	1258	O	MET	A	180	3.034	31.444	29.118	0.00	O
	ATOM	1259	N	ILE	A	181	3.967	29.715	28.042	0.00	N
5	ATOM	1260	CA	ILE	A	181	2.690	29.085	27.781	0.00	C
	ATOM	1261	CB	ILE	A	181	2.726	28.266	26.464	0.00	C
	ATOM	1262	CG2	ILE	A	181	1.534	27.294	26.399	0.00	C
	ATOM	1263	CG1	ILE	A	181	2.711	29.237	25.270	0.00	C
	ATOM	1264	CD1	ILE	A	181	2.740	28.556	23.910	0.00	C
10	ATOM	1265	C	ILE	A	181	2.613	28.211	29.023	0.00	C
	ATOM	1266	O	ILE	A	181	3.458	27.357	29.238	0.00	O
	ATOM	1267	N	THR	A	182	1.598	28.457	29.845	0.00	N
	ATOM	1268	CA	THR	A	182	1.398	27.724	31.090	0.00	C
	ATOM	1269	C	THR	A	182	0.212	26.770	31.163	0.00	C
15	ATOM	1270	O	THR	A	182	-0.098	26.231	32.241	0.00	O
	ATOM	1271	CB	THR	A	182	1.315	28.733	32.273	0.00	C
	ATOM	1272	OG1	THR	A	182	0.199	28.407	33.111	0.00	O
	ATOM	1273	CG2	THR	A	182	1.137	30.133	31.739	0.00	C
	ATOM	1274	N	THR	A	183	-0.448	26.534	30.036	0.00	N
20	ATOM	1275	CA	THR	A	183	-1.593	25.623	30.045	0.00	C
	ATOM	1276	C	THR	A	183	-1.754	25.043	28.647	0.00	C
	ATOM	1277	O	THR	A	183	-1.274	25.608	27.675	0.00	O
	ATOM	1278	CB	THR	A	183	-2.909	26.342	30.433	0.00	C
	ATOM	1279	OG1	THR	A	183	-3.716	25.460	31.228	0.00	O
25	ATOM	1280	CG2	THR	A	183	-3.690	26.738	29.184	0.00	C
	ATOM	1281	N	ASP	A	184	-2.402	23.896	28.532	0.00	N
	ATOM	1282	CA	ASP	A	184	-2.573	23.318	27.213	0.00	C
	ATOM	1283	C	ASP	A	184	-4.035	23.091	26.918	0.00	C
	ATOM	1284	O	ASP	A	184	-4.380	22.208	26.174	0.00	O
30	ATOM	1285	CB	ASP	A	184	-1.810	22.005	27.113	0.00	C
	ATOM	1286	CG	ASP	A	184	-0.464	22.056	27.794	0.00	C
	ATOM	1287	OD1	ASP	A	184	0.296	23.029	27.577	0.00	O
	ATOM	1288	OD2	ASP	A	184	-0.152	21.080	28.527	0.00	O1-
	TER	1289		ASP	A	184					
35	ATOM	1290	N	ALA	B	14	37.553	22.457	29.194	0.00	N1+
	ATOM	1291	H	ALA	B	14	36.582	22.364	28.935	0.00	H
	ATOM	1292	H	ALA	B	14	37.991	23.157	28.614	0.00	H
	ATOM	1293	H	ALA	B	14	38.021	21.572	29.065	0.00	H
	ATOM	1294	CA	ALA	B	14	37.649	22.863	30.616	0.00	C
40	ATOM	1295	C	ALA	B	14	36.345	22.665	31.400	0.00	C
	ATOM	1296	O	ALA	B	14	36.364	21.816	32.304	0.00	O
	ATOM	1297	CB	ALA	B	14	38.235	24.270	30.658	0.00	C
	ATOM	1298	N	ALA	B	15	35.261	23.393	31.094	0.00	N
	ATOM	1299	CA	ALA	B	15	35.165	24.394	30.026	0.00	C
45	ATOM	1300	C	ALA	B	15	34.368	23.941	28.790	0.00	C
	ATOM	1301	O	ALA	B	15	34.957	23.330	27.892	0.00	O
	ATOM	1302	CB	ALA	B	15	34.779	25.773	30.573	0.00	C
	ATOM	1303	N	ALA	B	16	33.028	24.069	28.763	0.00	N
	ATOM	1304	CA	ALA	B	16	32.304	23.388	27.683	0.00	C
50	ATOM	1305	C	ALA	B	16	31.144	24.054	26.918	0.00	C
	ATOM	1306	O	ALA	B	16	30.114	24.490	27.453	0.00	O
	ATOM	1307	CB	ALA	B	16	32.420	21.850	27.713	0.00	C
	ATOM	1308	H	ALA	B	16	32.544	24.608	29.452	0.00	H
	ATOM	1309	N	HIS	B	17	31.370	24.111	25.600	0.00	N
55	ATOM	1310	CA	HIS	B	17	30.508	24.676	24.521	0.00	C
	ATOM	1311	C	HIS	B	17	29.820	23.558	23.756	0.00	C
	ATOM	1312	O	HIS	B	17	30.487	22.621	23.291	0.00	O
	ATOM	1313	CB	HIS	B	17	31.473	25.545	23.683	0.00	C
	ATOM	1314	CG	HIS	B	17	30.806	26.351	22.601	0.00	C
60	ATOM	1315	ND1	HIS	B	17	30.728	26.028	21.264	0.00	N
	ATOM	1316	CD2	HIS	B	17	30.170	27.551	22.772	0.00	C
	ATOM	1317	CE1	HIS	B	17	30.054	27.014	20.648	0.00	C
	ATOM	1318	NE2	HIS	B	17	29.694	27.965	21.525	0.00	N
	ATOM	1319	H	HIS	B	17	32.233	23.710	25.292	0.00	H
65	ATOM	1320	N	TYR	B	18	28.491	23.661	23.613	0.00	N
	ATOM	1321	CA	TYR	B	18	27.651	22.538	23.244	0.00	C
	ATOM	1322	C	TYR	B	18	26.791	22.741	21.978	0.00	C
	ATOM	1323	O	TYR	B	18	25.936	21.904	21.762	0.00	O
	ATOM	1324	CB	TYR	B	18	26.869	22.044	24.476	0.00	C
70	ATOM	1325	CG	TYR	B	18	27.638	21.257	25.527	0.00	C
	ATOM	1326	CD1	TYR	B	18	27.073	20.996	26.793	0.00	C
	ATOM	1327	CD2	TYR	B	18	28.818	20.596	25.160	0.00	C
	ATOM	1328	CE1	TYR	B	18	27.702	20.099	27.685	0.00	C
	ATOM	1329	CE2	TYR	B	18	29.420	19.668	26.020	0.00	C
75	ATOM	1330	CZ	TYR	B	18	28.855	19.410	27.276	0.00	C
	ATOM	1331	OH	TYR	B	18	29.519	18.595	28.139	0.00	O
	ATOM	1332	H	TYR	B	18	28.022	24.521	23.872	0.00	H
	ATOM	1333	N	ASP	B	19	27.328	23.446	20.986	0.00	N

- 261 -

	ATOM	1334	CA	ASP	B	19	27.252	23.065	19.573	0.00	C
	ATOM	1335	C	ASP	B	19	25.957	22.335	19.178	0.00	C
	ATOM	1336	O	ASP	B	19	24.855	22.851	19.367	0.00	O
	ATOM	1337	CB	ASP	B	19	27.381	24.271	18.655	0.00	C
5	ATOM	1338	CG	ASP	B	19	28.399	25.369	18.926	0.00	C
	ATOM	1339	OD1	ASP	B	19	28.777	25.568	20.105	0.00	O
	ATOM	1340	OD2	ASP	B	19	28.588	26.117	17.941	0.00	O1-
	ATOM	1341	H	ASP	B	19	28.092	24.050	21.252	0.00	H
	ATOM	1342	N	GLU	B	20	26.024	21.140	18.622	0.00	N
10	ATOM	1343	CA	GLU	B	20	27.219	20.341	18.451	0.00	C
	ATOM	1344	C	GLU	B	20	27.848	20.634	17.079	0.00	C
	ATOM	1345	O	GLU	B	20	27.311	20.147	16.091	0.00	O
	ATOM	1346	CB	GLU	B	20	26.641	18.934	18.532	0.00	C
	ATOM	1347	CG	GLU	B	20	26.790	18.174	19.836	0.00	C
15	ATOM	1348	CD	GLU	B	20	26.391	16.720	19.643	0.00	C
	ATOM	1349	OE1	GLU	B	20	26.614	16.043	20.673	0.00	O1-
	ATOM	1350	OE2	GLU	B	20	26.569	16.221	18.501	0.00	O
	ATOM	1351	H	GLU	B	20	25.129	20.696	18.442	0.00	H
	ATOM	1352	N	ALA	B	21	29.122	21.069	17.024	0.00	N
20	ATOM	1353	CA	ALA	B	21	29.859	21.221	15.768	0.00	C
	ATOM	1354	C	ALA	B	21	30.422	19.894	15.208	0.00	C
	ATOM	1355	O	ALA	B	21	31.618	19.821	14.879	0.00	O
	ATOM	1356	CB	ALA	B	21	30.954	22.295	15.900	0.00	C
	ATOM	1357	OXT	ALA	B	21	29.677	18.897	15.088	0.00	O1-
25	ATOM	1358	H	ALA	B	21	29.585	21.298	17.880	0.00	H
	TER	1359		ALA	B	21					

EXAMPLE 21

Oxidative Stability of ASP

This Example describes experiments conducted to determine the oxidative stability of the ASP protease and mutant proteases. The resistance to oxidation of *Cellulomonas* 69B4 protease was compared to that of: a BPN'-variant protease (BPN'-variant 1; Genencor; See, RE 34,606 [incorporated herein by reference], for a description of this enzyme); a GG36 variant protease (GG36-variant 1; Genencor; See e.g., U.S. Pat. Nos. 5,955,340 and 5,700,676, herein incorporated by reference); and PURAFECT protease (Genencor).

The assay was conducted by incubating a sample of the protease with 0.1 M H₂O₂. A 2.0 ml volume of 0.1 M Borate buffer (45.4 gm NaB₄O₇ · 10 H₂O), pH 9.45 containing 0.1 M H₂O₂ and 100 ppm protease was incubated at 25°C for 20 minutes and assayed for enzyme activity.

The enzyme activity was determined as follows: 50 µl of the incubation mixture was combined with 950 µl 0.1 M Tris buffer, pH 8.6 and a sample from 10 µl was taken and added to 990 µl AAPF substrate solution, conc. 1 mg/ml, in 0.1 M Tris / 0.005% TWEEN®, pH 8.6. The rate of increase in absorbance at 410 nm due to release of *p*-nitroaniline was monitored. The results obtained for these proteases are provided in Figure 31. As indicated in this graph, protease 69B4 showed greatly enhanced stability under oxidative conditions relative to the subtilisin proteases.

- 262 -

EXAMPLE 22**Chelate Stability of ASP**

In this Example, experiments to determine the chelate stability of ASP are described. The resistance to the presence of a chelator of 69B4 protease was assayed by incubating an aliquot of the enzyme with 10 mM EDTA in 50 mM Tris, pH 8.2. The same enzyme preparations as used in Example 21 were used in these experiments.

In specific, a volume of 2.0 ml 50 mM Tris buffer, pH 8.2, containing 10 mM EDTA and 100 ppm protease was incubated at 45°C for 100 minutes and assayed for enzyme activity as follows: 50 µl of the incubation mixture was combined with 950 µl 0.1 M Tris buffer, pH 8.6 and a sample from 10 µl was taken and added to 990 µl AAPF substrate solution, conc. 1 mg/ml, in 0.1 M Tris / 0.005% TWEEN®, pH 8.6

The rate of increase in absorbance at 410 nm due to release of p-nitroaniline was monitored. The results obtained for these four proteases are shown in Figure 32. As indicated by these results, protease 69B4 showed greatly enhanced stability in the presence of a chelator than BPN' variant-1, PURAFECT®, or GG36 variant-1.

EXAMPLE 23**Thermal Stability of ASP**

In this Example, experiments conducted to determine the thermostability of ASP protease are described. In one set of experiments, 69B4 protease was tested for resistance to thermal inactivation in solution. As in Examples 21 and 22, a BPN' variant (BPN'-variant-1), PURAFECT®, and a GG36 variant (GG36-variant-1) were also tested and compared with ASP.

The thermal inactivation was performed by incubating a volume of 2.0 ml 50 mM Tris buffer, pH 8.0, containing 100 ppm protease at 45°C for 300 minutes and assayed for enzyme activity as follows: 50 µl of the incubation mixture was combined with 950 µl 0.1 M Tris buffer, pH 8.6 and a sample from 10 µl was taken and added to 990 µl AAPF substrate solution, conc. 1 mg/ml, in 0.1 M Tris / 0.005% TWEEN®, pH 8.6. The rate of increase in absorbance at 410 nm due to release of p-nitroaniline was monitored. The results of these four proteases are shown in Figure 33. As shown by these results, protease 69B4 showed enhanced or comparative thermal stability at 45 degrees centigrade than the BPN' variant, PURAFECT®, or the GG36 variant.

In addition to the above experiments, an alternative method for determining the thermostability of ASP was also tested. In these experiments, a temperature gradient between 57°- 62 °C was used. The thermal inactivation (using a Thermocycler –MTP plate

- 263 -

DNA Engine Tetad; MJ Research) was performed by incubating a volume of 180 μ l 100 mM Tris buffer, pH 8.6, containing 1 mM CaCl_2 and 5 ppm protease for 60 minutes and assayed for enzyme activity as follows: 10 μ l was taken and added to 190 μ l AAPF substrate solution, conc. 1 mg/ml, in 0.1 M Tris / 0.005% TWEEN®, pH 8.6. The rate of increase in absorbance at 410 nm due to release of *p*-nitroaniline was monitored (at 25°C). The results of 4 proteases are shown in Figure 34.

EXAMPLE 24

pH profile of ASP Protease on DMC Substrate

In this Example, experiments conducted to determine the pH profile of the ASP protease are described. The *Cellulomonas* 69B4 protease of the present invention, isolated and purified by methods described herein and three currently used subtilisin proteases (PURAFFECT®, BPN'-variant 1, GG36-variant-1) described in Examples 21-23, were analyzed for their ability to hydrolyze a commercial synthetic substrate, di-methyl casein ("DMC"/ Sigma C-9801) in the pH range from 4 to 12.

The DMC method described at the beginning of the Experimental section was used, with modifications, as indicated below. Briefly, a 5 mg/ml DMC substrate solution was prepared in the appropriate buffer (5 mg/ml DMC, 0.005% (w/w) TWEEN-80® (polyoxyethylene sorbitan mono-oleate, Sigma P-1754)). The appropriate DMC buffers were composed as follows: 40 mM MES for pH 4 and 5 ; 40 mM HEPES for pH 6 and 7, 40 mM TRIS for pH 8 and 9; and 40 mM Carbonate for pH 10, 11 and 12.

For the determination, 180 μ l of each pH-substrate solution was transferred into 96 well microtiter plate and were pre-incubated at 37°C for twenty minutes prior to enzyme addition. The respective enzyme solutions (BPN'-variant-1; GG36-variant-1; PURAFFECT®; and 69B4 protease) were prepared, containing about 25 ppm and 20 μ l of these enzyme solutions. These enzyme solutions were pipetted into the substrate-containing wells in order to achieve a 2.5 ppm final enzyme concentration in each well. The 96 well plate containing enzyme-substrate mixtures was incubated at 37°C and 300 rpm for one hour in an IKS-Multitron incubator/shaker.

A 2,4,6-trinitrobenzene sulfonate ("TNBS") color reaction method was used to determine the amount of peptides and amino acids release from DMC substrate. The free amino groups (of the peptides and amino acids) react with 2,4,6-trinitro-benzene sulfonic acid to form a yellow colored complex. The absorbance was measured at 405 nm in a SpectraMax 250 MTP Reader.

- 264 -

The TNBS assay was conducted as follows. A 1 mg/ml solution of TNBS (5% 2,4,6 trinitrobenzene sulfonic acid/Sigma-P2297) was prepared in reagent buffer A (2.4 g NaOH, 45.4 g Na₂B₄O₇·10H₂O dissolved by heating in 1000ml). Then, 60 µl per well were aliquoted into a 96-well plate and 10 µl of the incubation mixture described above were added to each well and mixed for 20 minutes at room temperature. Then, 200 µl of reagent B (70.4 g NaH₂PO₄·H₂O and 1.2 g Na₂SO₃ in 2000 ml) were added to each well and mixed to stop the reaction. The absorbance at 405 nm was measured in a SpectraMax 250 MTP Reader. The absorbance value was corrected for a blank (without enzyme).

The data in Table 24-1 show the comparative ability of the 69B4 protease to hydrolyze such substrate versus proteases from a known mutant variants (BPN' variant-1 and GG36 variant-1).

Also, as shown in Figure 35, the serine protease of the present invention showed comparative or increased hydrolysis of DMC substrate with an optimal DMC-hydrolysis activity over a broad pH range from 7 to 12.

Table 24-1. TNBS Response

Enzyme	TNBS response (OD405 nm)								
	pH4	pH5	pH6	pH7	pH8	pH9	pH10	pH11	pH12
BPN' variant-1	0.095	0.174	0.482	0.749	0.813	0.847	0.730	0.683	0.590
GG36 variant-1	0.228	0.172	0.499	0.740	0.958	1.062	1.068	1.175	1.136
Purafect®	0.042	0.202	0.545	0.783	0.956	1.130	1.102	1.188	1.174
69B4	0.252	0.218	0.575	0.742	0.803	0.965	0.762	0.741	0.729

EXAMPLE 25

pH Stability of ASP Protease

In this Example, experiments conducted to determine the pH stability of the ASP protease are described. As in Examples 21-24, two currently used subtilisin proteases (PURAFACT® and BPN'-variant-1) were also tested.

The respective enzyme solutions (*i.e.*, BPN'-variant-1, PURAFECT®, and 69B4 protease) were prepared containing 90 ppm protease in 0.1 M Citrate buffer, pH 3, 4, 5 and 6. Then, 10 ml tubes containing 1 ml of buffered enzyme solutions were placed in a GFL

- 265 -

1083 water bath set at 25°C, 35°C and 45°C respectively, for 60 minutes. AAPF activity was determined for each enzyme sample at time 0 and 60 minutes as described above. The remaining enzyme activity was calculated and the results are provided in Table 25-1 below, and are shown in Figures 25-28).

As indicated by the data in Table 25-1, the ASP protease is exceptional stable at pH 3, 4, 5, and 6, at temperatures between 25°C and 45°C, as compared to the BPN' variant-1 and PURAFECT®.

Table 25-1. pH Stability Data									
pH	BPN' Variant-1			PURAFECT®			ASP		
	25°	35°	45°	25°	35°	45°	25°	35°	45°
pH 3	39	1	0	42	2	0	97	109	95
pH 4	92	35	1	55	7	0	106	105	102
pH 5	112	82	12	95	68	8	114	115	106
pH 6	113	99	59	104	96	63	95	104	104

EXAMPLE 26

Stability and Specificity of ASP

In this Example, experiments conducted to determine the stability and specificity differences between ASP, ASP mutants, and FNA are described. These experiments were performed by formulating liquid TIDE® detergent (Procter & Gamble) with calcium formate (an anionic surfactant titrant), borate (a P1 binder/inhibitor), and glycerol (water ordering), either independently of or in combination with each other. The enzyme was tested under these conditions and the residual enzyme activity was determined over time at a fixed temperature.

The experiments are described in greater detail below. Unformulated liquid TIDE® detergent (*i.e.*, without added enzyme stabilizing chemicals) was divided into eleven aliquots. Then, glycerol, borax, or calcium formate were added to the detergent aliquots in the proportions shown in Table 26-1.

Table 26-1. Detergent Additives (%)			
Aliquot #	% Glycerol	% Borax	% Calcium Formate
1	5	0	.1

- 266 -

2	2.5	1.5	.05
3	5	3	0
4	0	3	0
5	2.5	1.5	.05
6	0	0	.1
7	0	3	.1
8	0	0	0
9	5	0	0
10	2.5	1.5	.05
11	5	3	.1

Each aliquot was pre-warmed to 90°F, and either FNA, ASP (wild-type) or an ASP R18 variant was added to approximately one gram per liter protease. After thorough mixing, a portion was removed and assayed for activity with synthetic AAPF-pNA substrate, as described above. After the assay, each aliquot was placed back into a 90°F oven. The assay process was repeated over time, and the decline in activity at T0 was plotted as a % T0 activity remaining.

Surprisingly, it was found that ASP did not have the same calcium formate or glycerol dependency as FNA. Furthermore, it was determined that borate (alone) had the most dramatic effect on stabilizing ASP. It was also found that the addition of stabilizing chemicals provided significant benefits to the wild-type ASP, as well as the ASP R18 variant, indicating that the variant site is independent of the borate-activated site.

EXAMPLE 27

LAS Stability of ASP

In this Example, experiments conducted to determine the stability of ASP to anionic surfactants are described. LAS (linear alkyl sulfonate), an anionic surfactant, is a component of HDL detergents known to inactivate enzymes. The methods used are described above.

It was determined that wild-type ASP incubated in LAS dissolved in Tris HCl pH 8.6 is inactivated (See, Table 27-1, below). Further study revealed that inactivation is rapid (See, Table 27-2). As LAS is a negatively charged molecule, the hypothesis that electrostatic attraction of LAS with positively charged amino-acid side chains of ASP was the cause of the LAS sensitivity, was developed. To test this hypothesis, arginine residues (wild-type ASP contains no lysine residues), were mutated to other amino-acids.

Incubation of these mutants in 0.05%(w/v) LAS in Tris HCl pH8.6, for one hour revealed that all arginine replacement mutants were more stable than wild-type ASP. In contrast, non-arginine replacement mutations that were also tested for LAS stability were

- 267 -

generally not improved compared to wild-type (*See*, Table 27-3). Subsequent multiple arginine replacement mutations revealed that the enzyme is substantially more stable than the wild-type enzyme, and more stable than single arginine replacement mutations (*See*, Table 27-4).

Another anionic surfactant that is used in HDL detergents is AES. Wild-type ASP was found to be unstable in high concentrations of AES (*See*, Table 27-5). The mutant ASP R18 was found to be more stable than wild-type in AES (*See*, Table 27-5). Also, the rate of inactivation of activity by 5% AES was found to be higher for the wild-type than the ASP R18 mutant (*See*, Table 27-6). These results confirm that replacement of arginine residues of ASP improves the stability of ASP in anionic detergents in general. It is not intended that the present invention be limited to any specific anionic detergents or mutations. Indeed, it is contemplated that various anionic detergents (as well as other detergents) will find use in the present invention, as will various ASP mutants.

Table 27-1. Inactivation of ASP by LAS in Tris HCl pH 8.6

%LAS (w/v)	% Activity of Control
Control (0 LAS)	100
0.01	87
0.03	77
0.06	59
0.10	47
0.30	31
0.60	20
1.00	12

Table 27-2. Time-course of ASP Inactivation by 0.1% LAS

Time (secs)	% Remaining Activity
0	100
60	45
120	26
240	20
600	11

- 268 -

Table 27-3. Stability of ASP and Single Mutants
(Incubated 0.05% LAS in Tris HCl, pH 8.6, for 60 mins.)

	Mutant	% Remaining Activity of 0 LAS Control
5	Wild-type	18
	R14L	47
	R16I	49
	R16L	56
10	R16Q	51
	R35F	43
	R127A	59
	R127K	31
	R127Q	52
15	R159K	25
	T36S	11
	G65Q	22
	Y75G	7
	N76L	17
20	S76V	17

Table 27-4. Stability of ASP and Multiple Arginine Replacements
(Incubated 0.05% LAS in Tris HCl, pH 8.6. for 60mins)

	Mutant	% Remaining Activity of 0 LAS Control
30	Wild-type	27.5
	ASP R-1	98.8
	ASP R-2	69.6
	ASP R-3	100.2
35	ASP R-7	103.9
	ASP R-10B	98.9
	ASP R-18	100.9
	ASP R23	79.4

40 In this Table,
 R-1=R16Q/R35F/R159Q
 R-2=R159Q
 R-3=R16Q/R123L
 R-7=R14L/R127Q/R159Q
 45 R-10B=R14L/R179Q
 R-18=R123L/R127Q/R179Q.
 R-21=R16Q/R79T/R127Q
 R-23=R16Q/R79T

50

- 269 -

Table 27-5. Inactivation of ASP and ASP Mutant R-18 by AES in Tris HCl pH8.6**%Remaining activity of 0% AES control**

% AES(v/w)	Wild-type ASP	ASP R-18
0	100	100
1	70	94
5	32	57

Table 27-6. Time-course of ASP and Mutant R-18 Inactivation by 5% AES in Tris HCl, pH 8.6**% Remaining Activity of 0% AES Control**

Time (Mins)	Wild-type ASP	ASP R-128
0	100	100
90	99	105
4020	15	83

EXAMPLE 28**Determination of ASP Autolysis Sites in the Presence and Absence of LAS Detergent**

In this Example, experiments conducted to determine the ASP autolysis sites in the presence and absence of LAS are described. ASP autolysis was evaluated in a buffer with and without LAS (dodecylbenzene-sulfonic acid). Autolysis peptide assignments were made based on molecular weight and sequence of each peptide (from MS and MS/MS data, respectively).

ASP (at concentration of 0.35ug/uL) was incubated (at 4°C) in a 100mM Tris pH 8.6 with and without 0.1%LAS (dodecylbenzene-sulfonic acid). Aliquots were taken at time periods from 0 to 30 min of incubation and autolysis was terminated by an addition of TFA (final concentration 1%). Aliquots (10μL) were analyzed by liquid chromatography coupled with electrospray tandem mass spectrometry (LC-ESI-MS/MS). Peptides were resolved using an HPLC system (model 1100, Agilent Technologies) using a reversed-phase column (Vydac C4, 0.3mmID x 150mm), and a gradient from 0 to 100% solvent B (0.1%formic acid in acetonitrile) in 60 min at a flow rate of 5μL/min (generated using a static split from a pump flow rate of 250uL/min). Solvent A consisted of 0.1% formic acid in water; and solvent B was 0.1% formic acid in acetonitrile.

Mass spectra were acquired using ion trap mass spectrometer (model LCQ Classic, Thermo). The mass spectrometer was tuned for optimum detection of m/z of 785 and

- 270 -

operated with spray voltage of 2.5kV, and a heated capillary at 250°C. Mass spectra were acquired with injection time of 500 msec and 5 microscans. Tandem MS spectra were acquired in data-dependent mode, with the most intense peak selected and fragmented with a normalized collision energy of 35%. For relative peptide quantitation, peak areas were determined using vendor software. The identity of the autolysis peptides was determined using a database search program (TurboSequest, Thermo) run on a database containing ASP sequence. Database searches were performed with no enzyme selected, threshold of 10000, dta file parameters (peptide m/z error of 1.7, group 11, minimum ion count 15), and database parameters (peptide error of 2.2, MS/MS ions error of 0.0, both B,Y ions).

Without LAS in the sample buffer, ASP cleavages were primarily observed at the termini and in the middle of the molecule (positions Y9, F47, Y59, F165, Q174, Y176; See Table 28-1, below). Relative quantitative data for observed peptides and intact ASP was plotted over the course of the experiment (See, Figure 25, Panel A). The majority of the ASP remained intact and only 1% was in the form of cleaved peptides (protein:peptide ratio of 99:1) These data indicated that the majority of ASP remains intact, folded, and resistant to further autolytic cleavage.

With 0.1% LAS in the sample buffer, ASP cleavages were observed throughout the protein (positions Y9, T40, F47, Y57, F59, R61, L69, F165, Q174, Y176). The majority of the ASP was in the peptide form after 10min (See, Figure 25, Panel B). After 60 min, the protein:peptide ratio was <1:99. These data indicate that ASP is totally unfolded in the presence of LAS detergent, thus extensive cleavage throughout the sequence was observed. The observed autolysis cleavage sites under the two conditions are summarized in the following Table. In this Table, the amino acids preceding and following the periods are the amino acids that immediately precede and follow the autolysis peptide. The sequence between the periods indicates the sequence of the autolysis peptides observed.

Table 28-1. ASP Autolysis Peptides Observed With and Without 0.1% LAS

Peptide Sequence	Start -End	Calculated Mass (Da)	Measured Mass (Da)	Observed in 0.1%LAS	Observed in 0% LAS
-.FDVIGGNAY.T (SEQ ID NO:631)	[1-9]	954.5	954.4	Y	Y
T.ANPTGTF.A (SEQ ID NO:632)	[41-47]	706.3	706.3	Y	N
F.AGSSFPGNDY.A (SEQ ID NO:633)	[48-57]	1013.4	1013.3	Y	N
F.AGSSFPGNDYAF.V (SEQ ID NO:634)	[48-59]	1231.5	1231.4	Y	Y

- 271 -

R.TGAGVNLLA (SEQ ID NO:635)	[62-69]	743.3	743.4	Y	N
F.FQPVNPI.L (SEQ ID NO:636)	[166-172]	813.4		N	N
F.FQPVNPILQ.A (SEQ ID NO:637)	[166-174]	1054.6	1054.5	Y	Y
F.FQPVNPILQAY.G (SEQ ID NO:638)	[166-176]	1288.7	1288.5	Y	Y

EXAMPLE 29**Use of Reversible Inhibitors to Reduce LAS-Induced Degradation of ASP**

In this Example, experiments conducted to assess the use of reversible inhibitors to reduce LAS-induced degradation of ASP are described. Benzamidine (BZA) is a known reversible inhibitor of serine proteases. Using the standard succ-AAPF-pNA assay as described above, BZA was shown to inhibit the activity of approximately 2µg/ml ASP, with complete inhibition occurring at 1000mM (1M), as indicated in Table 29-1, below:

Table 29-1 Inhibition of ASP	
BZA Conc. mM	Assay Rate
0	0.83
1	0.85
10	0.82
100	0.42
1000	0.02

Approximately 200µg/ml ASP was then incubated with 0.1% LAS and with, and without 1M BZA for up to 4 days. Enzyme activity was measured at different time points by addition of 10µl incubated sample to 990 µl of assay solution. This reduces the BZA concentration to 10mM, which by reference to the table above is not inhibitory. Therefore, any loss of activity will be due to enzyme degradation. As indicated in the results below, enzyme incubated with 0.1% LAS and without BZA lost all activity (*i.e.*, it was degraded), while enzyme incubated with 0.1% LAS and 1M BZA, retained activity over the 4 day time-course of the study, demonstrating that inhibition of ASP activity prevents degradation by LAS.

- 272 -

Table 29-2. Assay Rate Results for Enzyme Incubated with 0.1% LAS, With/Without BZA		
Time	ASP+0.1%LAS	ASP+0.1%LAS+1M BZA
30 secs	0.755	0.761
30 mins	0.685	0.781
18 hrs	0.067	0.761
4 days	0.004	0.853

5

EXAMPLE 30**Testing of Mutant ASPs**

10 In addition to the tests described above, tests were conducted on various mutants of ASP. The methods described above in Example 1 were used. In the following Tables, "Variant Code" provides the wild-type amino acid, the position in the amino acid sequence, and the replacement amino acid (*i.e.*, "F001A" indicates that the phenylalanine at position 1 in the amino acid sequence has been replaced by alanine in this particular variant).

15

Keratin Hydrolysis

The table (Table 30-1) below provides the keratin hydrolysis data obtained for the ASP variants which show activity on this substrate in the keratin assay as described above ("Protease Assay with Keratin in Microtiter Plates"). The values are relative to wild type (WT) and calculated as described in the assay procedure. Values greater than 1 are
20 indicative of better activity than WT ASP.

Table 30-1. Keratin Hydrolysis Results

25

Variant code	Keratin hydrolysis relative
F001T	1.24
F001D	1.13
F001H	1.04
F001M	1.01
F001E	1.01

V003L	1.08
I004E	1.00
N007L	1.18
A008E	1.18
A008G	1.13
A008D	1.04
T010N	1.27
T010E	1.20
T010D	1.13

T010G	1.04
I011A	1.01
G012D	1.17
G013S	1.16
G013M	1.03
G013A	1.01
R014L	1.52
R014Q	1.49
R014I	1.40

- 273 -

R014D	1.36
R014N	1.29
R014G	1.28
R014T	1.21
R014M	1.21
R014K	1.18
R014A	1.12
R014S	1.12
R014W	1.07
R014P	1.04
R014H	1.03
S015W	1.20
S015T	1.05
R016A	1.04
R016S	1.03
R016Q	1.03
I019V	1.11
N024E	2.44
N024A	1.72
N024T	1.55
N024Q	1.40
N024V	1.28
N024L	1.26
N024H	1.26
N024M	1.14
N024F	1.05
N024S	1.03
R035E	1.60
R035L	1.47
R035Q	1.42
R035F	1.41
R035A	1.37
R035K	1.26
R035T	1.22
R035H	1.18
R035M	1.17
R035Y	1.16
R035W	1.13
R035S	1.12
R035D	1.07
R035N	1.03
R035V	1.02
T036I	6.82
T036S	1.34
T036G	1.34
T036N	1.22
T036D	1.16
T036H	1.13
T036P	1.03
T036L	1.01

A038R	1.77
A038D	1.51
A038H	1.30
A038N	1.28
A038F	1.22
A038L	1.19
A038S	1.18
A038Y	1.17
A038T	1.10
A038V	1.07
A038G	1.03
A038I	1.01
T040V	1.11
A041N	1.17
A041D	1.17
A041I	1.07
A041L	1.03
T044E	1.03
A048E	1.09
G049A	1.36
G049S	1.26
G049H	1.16
G049F	1.13
G049L	1.04
G049T	1.00
S051D	1.33
S051Q	1.18
S051H	1.12
S051V	1.11
S051T	1.09
S051M	1.01
G054D	1.71
G054E	1.23
G054N	1.06
G054L	1.02
G054I	1.00
N055E	1.30
N055F	1.25
N055Q	1.05
R061M	1.20
R061T	1.16
R061E	1.15
R061H	1.10
R061S	1.09
R061N	1.08
R061K	1.07
R061V	1.01
T062I	1.00
G063D	1.18
G063V	1.07

A064I	1.40
A064N	1.21
A064Y	1.19
A064L	1.17
A064V	1.17
A064H	1.16
A064F	1.15
A064P	1.15
A064T	1.13
A064Q	1.13
A064M	1.13
A064S	1.11
A064W	1.09
A064G	1.01
G065P	1.42
G065D	1.29
G065Q	1.29
G065S	1.25
G065T	1.25
G065V	1.23
G065L	1.21
G065Y	1.16
G065A	1.05
G065R	1.02
N067D	1.36
N067G	1.20
N067T	1.12
N067E	1.12
N067S	1.10
N067H	1.09
N067A	1.08
N067Q	1.07
N067L	1.05
L068H	1.07
L069S	1.35
L069H	1.23
L069V	1.03
A070D	1.20
A070H	1.16
A070G	1.13
A070S	1.04
Q071G	1.20
Q071H	1.14
Q071D	1.13
Q071S	1.10
Q071A	1.07
Q071N	1.06
Q071I	1.06
V072I	1.11
N073T	1.95

- 274 -

N073S	1.07
N074G	1.75
Y075G	1.42
Y075F	1.24
S076D	1.69
S076V	1.48
S076E	1.47
S076Y	1.45
S076T	1.25
S076L	1.25
S076N	1.24
S076I	1.22
S076W	1.17
S076Q	1.13
S076A	1.08
G077T	2.13
G077S	1.21
G077N	1.06
G078D	1.35
G078A	1.27
G078S	1.07
G078N	1.07
G078V	1.03
G078T	1.00
R079G	1.48
R079D	1.44
R079P	1.43
R079A	1.31
R079E	1.31
R079L	1.25
R079V	1.25
R079T	1.23
R079M	1.23
R079S	1.23
R079C	1.02
V080L	1.03
Q081E	1.22
Q081D	1.12
Q081V	1.10
Q081H	1.10
Q081P	1.01
A083E	1.27
A083L	1.05
A083I	1.03
H085Q	1.26
H085T	1.22
H085L	1.14
H085M	1.10
H085A	1.06
H085S	1.02

T086D	1.33
T086E	1.24
T086I	1.08
T086L	1.07
T086Q	1.07
T086G	1.06
T086A	1.05
T086N	1.01
A088E	1.01
A088F	1.00
P089E	1.04
V090P	1.51
V090S	1.42
V090I	1.34
V090T	1.22
V090N	1.10
V090A	1.08
V090L	1.06
S092G	1.20
S092A	1.12
S092C	1.06
A093D	1.20
A093S	1.12
A093E	1.09
S099N	1.27
S099V	1.23
S099D	1.21
S099T	1.21
S099I	1.08
T101S	1.14
W103M	1.17
T107E	1.32
T107S	1.30
T107V	1.23
T107H	1.23
T107M	1.21
T107I	1.17
T107N	1.12
T107A	1.10
T107Q	1.03
T107K	1.01
T109E	1.36
T109I	1.11
T109G	1.10
T109A	1.10
T109L	1.08
T109P	1.05
T109H	1.03
T109N	1.00
A110S	1.10

A110T	1.03
A110H	1.01
L111E	1.08
N112E	1.61
N112D	1.42
N112Q	1.36
N112L	1.27
N112V	1.23
N112Y	1.20
N112I	1.13
N112S	1.06
N112R	1.04
S113T	1.21
S114A	1.12
V115A	1.15
T116E	1.34
T116Q	1.28
T116F	1.09
T116S	1.02
T121E	1.35
T121D	1.15
T121S	1.05
R123E	1.63
R123D	1.57
R123I	1.48
R123F	1.40
R123A	1.30
R123L	1.30
R123Q	1.29
R123N	1.24
R123H	1.22
R123T	1.16
R123Y	1.15
R123S	1.12
R123G	1.11
R123V	1.09
R123W	1.07
R123K	1.07
G124A	1.06
I126L	1.06
R127A	1.38
R127Q	1.23
R127H	1.19
R127S	1.19
R127K	1.17
R127Y	1.15
R127E	1.14
R127F	1.11
R127T	1.04
R127C	1.01

- 275 -

T129S	1.31
A132S	1.03
P134A	1.04
S140A	1.02
L142V	1.31
A143N	1.07
N145E	1.33
N145D	1.14
N145T	1.10
N145S	1.07
N145Q	1.07
V150L	1.01
N157D	1.01
R159E	1.61
R159F	1.37
R159N	1.30
R159Q	1.28
R159D	1.23
R159K	1.20
R159C	1.19
R159S	1.10
R159A	1.10
R159L	1.09
R159Y	1.08
R159H	1.08

R159V	1.08
R159G	1.06
R159M	1.06
T160E	1.19
T160D	1.02
G161K	1.04
T163D	1.11
T163I	1.08
T163C	1.03
Q167T	1.02
N170Y	2.23
N170D	1.38
N170L	1.12
N170A	1.06
N170C	1.04
N170G	1.04
I172T	6.27
A175E	1.04
G177M	1.01
R179V	1.60
R179T	1.53
R179D	1.48
R179N	1.42
R179E	1.42
R179M	1.41

R179A	1.39
R179I	1.38
R179K	1.32
R179Y	1.27
R179L	1.11
R179W	1.06
I181L	1.96
I181S	1.07
T182V	1.14
T182L	1.02
T183E	1.19
T183I	1.17
T183Q	1.07
T183D	1.05
D184E	1.02
S185N	1.11
S185D	1.03
S185M	1.03
S185G	1.01
G186N	2.05
S187H	1.05
S187E	1.01
S188E	1.08

DMC Assay

- 5 The following table (Table 30-2) provides the variants with improved specific activity on casein. The activity on casein as substrate for all variants was determined as described above ("Protease Assay with Dimethylcasein (96 wells), With or Without Preheating of the Protease for Activity and Thermostability Assays"). The values in the table provide relative values for each variant compared to the activity of the WT enzyme (*i.e.*, each value is the
- 10 quotient of (variant activity)/(wild type activity)). Every variant with a value higher than 1 is better than WT.

Table 30-2. DMC Assay Results

Variant code	Casein specific activity relative to wild type
F001T	1.19

F001A	1.11
F001G	1.00
D002G	1.24
D002Q	1.24
D002A	1.12
D002H	1.10

D002N	1.10
V003L	1.33
V003I	1.28
V003T	1.17
I004V	1.07
I004Q	1.02

- 276 -

N007L	1.56
N007S	1.25
N007A	1.22
N007H	1.11
N007I	1.11
N007V	1.06
A008G	1.12
A008K	1.09
Y009V	1.06
T010G	1.18
T010K	1.12
T010Q	1.01
I011Q	1.28
I011A	1.26
I011T	1.16
I011S	1.11
I011L	1.06
G012W	1.11
G012R	1.02
G013M	1.09
G013S	1.08
R014E	1.27
S015F	1.09
S015A	1.03
I019V	1.04
N024A	2.48
N024E	2.37
N024T	1.70
N024Q	1.70
N024V	1.62
N024M	1.48
N024H	1.45
N024L	1.34
N024F	1.21
N024S	1.10
I028L	1.16
A030S	1.11
R035F	1.20
R035D	1.01
T036I	14.08
T036G	2.46
T036N	2.13
T036S	2.08
T036W	1.84
T036P	1.69
T036H	1.67
T036D	1.61
T036Y	1.48
T036V	1.48
T036R	1.38

T036F	1.36
T036L	1.33
T036C	1.12
A038R	3.72
A038F	1.45
A038D	1.39
A038S	1.38
A038H	1.36
A038L	1.30
A038N	1.24
A038K	1.17
A038V	1.17
A038Y	1.14
A038I	1.11
A038I	1.11
A038G	1.09
A038T	1.00
T039A	1.01
T040V	1.21
T040S	1.09
A041N	1.13
A041I	1.02
N042H	1.18
N042K	1.01
T046K	1.01
F047I	1.17
F047M	1.13
F047V	1.01
G049F	1.32
G049K	1.16
G049A	1.16
G049L	1.12
G049W	1.08
G049H	1.07
G049T	1.06
G049S	1.01
S051A	1.47
S051Q	1.14
S051F	1.13
S051H	1.09
G054D	1.66
G054R	1.33
G054L	1.32
G054H	1.32
G054K	1.24
G054M	1.24
G054A	1.23
G054I	1.22
G054Q	1.21
G054N	1.05

G054E	1.03
N055F	1.54
N055Q	1.17
N055K	1.11
N055H	1.09
N055E	1.00
Y057M	1.00
R061M	1.20
R061S	1.08
R061T	1.02
T062I	1.22
G063V	1.21
G063W	1.12
G063Q	1.09
G063D	1.08
G063H	1.07
G063R	1.05
A064W	1.34
A064H	1.28
A064N	1.26
A064Y	1.26
A064R	1.22
A064F	1.21
A064K	1.19
A064M	1.19
A064S	1.18
A064L	1.18
A064I	1.16
A064Q	1.11
A064T	1.11
A064V	1.10
A064P	1.01
A064G	1.00
G065P	1.57
G065R	1.56
G065V	1.48
G065Y	1.46
G065S	1.40
G065T	1.38
G065Q	1.37
G065L	1.26
G065A	1.16
G065H	1.12
G065I	1.07
G065D	1.05
V066H	1.46
V066D	1.45
V066I	1.29
V066L	1.25
V066E	1.24

- 277 -

V066A	1.23
V066M	1.10
V066N	1.10
V066G	1.08
V066T	1.03
N067G	1.38
N067L	1.30
N067K	1.29
N067A	1.25
N067H	1.22
N067T	1.19
N067D	1.18
N067S	1.16
N067Q	1.14
N067R	1.13
N067Y	1.12
N067V	1.12
N067F	1.11
N067M	1.06
N067E	1.05
L068W	1.10
L068H	1.05
L068P	1.04
L069S	2.13
L069H	1.60
L069V	1.27
L069W	1.14
L069K	1.05
L069R	1.02
L069N	1.01
A070H	1.53
A070S	1.33
A070D	1.24
A070G	1.09
A070P	1.07
A070W	1.04
Q071I	1.46
Q071K	1.41
Q071G	1.40
Q071M	1.33
Q071H	1.28
Q071A	1.26
Q071N	1.26
Q071S	1.19
Q071D	1.16
Q071F	1.14
Q071L	1.11
Q071R	1.10
Q071T	1.06
V072I	1.17

N073T	2.73
N073S	1.28
N073H	1.12
N074G	1.87
Y075I	1.37
Y075G	1.36
Y075F	1.34
S076W	1.77
S076Y	1.69
S076V	1.51
S076L	1.44
S076N	1.20
S076T	1.18
S076I	1.18
S076E	1.17
S076R	1.14
S076A	1.13
S076Q	1.11
S076K	1.09
S076K	1.09
S076H	1.05
G077T	2.50
G077S	1.34
G077Y	1.21
G077N	1.18
G077Q	1.02
G077R	1.02
G078A	1.64
G078S	1.35
G078H	1.31
G078T	1.29
G078D	1.25
G078N	1.23
G078I	1.19
G078V	1.19
G078R	1.18
G078M	1.01
R079P	1.24
R079G	1.20
V080H	1.24
V080L	1.22
V080F	1.15
Q081V	1.33
Q081K	1.30
Q081H	1.24
Q081I	1.13
Q081D	1.11
Q081P	1.07
Q081E	1.03
Q081R	1.01

A083N	1.13
A083M	1.09
A083G	1.08
A083L	1.08
A083H	1.07
A083I	1.03
A083E	1.02
A083V	1.02
H085Q	1.41
H085T	1.26
H085R	1.22
H085L	1.22
H085K	1.15
H085M	1.01
T086A	1.21
T086G	1.08
T086N	1.08
T086I	1.08
T086L	1.08
T086E	1.03
T086K	1.03
T086H	1.02
A088K	1.05
P089N	1.19
P089V	1.05
P089Y	1.02
P089T	1.00
V090P	1.62
V090I	1.30
V090S	1.26
V090A	1.12
V090T	1.11
V090L	1.10
V090F	1.02
S092G	1.25
S092C	1.07
A093Q	1.08
A093T	1.07
A093H	1.01
S099T	1.02
G102Q	1.09
W103M	1.54
W103I	1.33
W103Y	1.01
H104K	1.22
H104R	1.04
T107S	1.17
T107V	1.14
T107M	1.12
T107H	1.12

- 278 -

T107R	1.07
T107K	1.03
T107N	1.01
T107Q	1.01
T109I	1.30
T109H	1.23
T109A	1.22
T109P	1.20
T109R	1.19
T109L	1.19
T109G	1.16
T109N	1.09
T109V	1.07
T109E	1.06
A110T	1.11
A110S	1.11
N112I	1.11
N112R	1.08
N112G	1.06
N112L	1.04
N112Q	1.03
N112H	1.00
S114G	1.37
T116F	1.45
T116R	1.06
T116H	1.04
T116G	1.01
P118A	1.45
P118F	1.39
P118R	1.37
P118H	1.24
P118I	1.19
P118Q	1.17
P118K	1.16
P118E	1.13
P118G	1.00
E119R	1.94
E119K	1.28
E119Q	1.04
E119G	1.02
E119L	1.00
R123E	1.20
R123I	1.11
R123K	1.05
R123D	1.03
I126L	1.20
R127F	1.20
T129S	1.20
E133Q	1.10
P134R	1.06

S140G	1.03
L142V	1.12
L142M	1.08
A143N	1.12
A143S	1.11
N145I	1.26
N145Q	1.25
N145E	1.24
N145G	1.16
N145T	1.14
N145L	1.11
N145S	1.07
N145F	1.04
N145R	1.04
N145P	1.00
Q146D	1.06
V150L	1.26
V150M	1.14
T151L	1.13
S155H	1.01
R159F	1.49
R159E	1.10
R159Y	1.07
R159K	1.04
R159N	1.01
G161K	1.08
T163I	1.13
F166Y	1.07
Q167N	1.16
Q167E	1.09
N170Y	2.76
N170D	1.15
N170L	1.12
N170A	1.11
N170C	1.05
N170R	1.03
N170P	1.01
P171T	1.02
Q174I	1.08
Q174L	1.02
A175V	1.04
A175T	1.02
A175H	1.02
G177M	1.42
G177S	1.09
G177R	1.04
R179V	1.63
R179M	1.36
R179D	1.33
R179I	1.31

R179N	1.29
R179Y	1.29
R179T	1.27
R179L	1.23
R179K	1.23
R179A	1.22
R179E	1.22
R179W	1.06
R179F	1.06
T182V	1.20
T182W	1.02
T182Q	1.01
T183I	1.35
T183K	1.19
T183M	1.14
T183R	1.09
T183L	1.07
T183Q	1.07
T183E	1.05
T183H	1.02
D184F	1.18
D184R	1.18
D184H	1.14
D184Q	1.10
D184T	1.03
D184I	1.03
D184V	1.01
S185I	1.15
S185V	1.11
S185W	1.09
S185N	1.07
S185K	1.06
S185P	1.03
S185L	1.02
P189Y	1.06
P189W	1.02
P189R	1.01
I181H	1.37
I181G	1.12
I181N	1.15
G186V	1.49
G186E	1.54
G186I	1.41
G186L	1.05
G186N	1.01
S187P	1.63
S187E	1.12
S187T	1.29
S187L	1.12
S188M	1.25

- 279 -

S188L	1.04
-------	------

Thermostability Assays

The data in the following table (Table 30-3) represent the relative thermostability data of variants of ASP relative to the stability of the WT ASP stability under these conditions. The stability was measured by determining casein activity before and after incubation at elevated temperature (See, "Thermostability Assays" above). The table contains the relative thermostability values compared to WT under these conditions. It is the quotient of (Variant residual activity/WT residual activity). A value greater than one indicates higher thermostability.

Table 30-3. Thermostability Assay Results

Variant code	Thermo stability relative
V003R	1.53
I004D	1.89
I004P	1.89
I004G	1.66
A008G	1.16
Y009E	2.04
Y009P	2.04
T010Y	1.64
T010F	1.53
T010W	1.49
T010L	1.26
T010C	1.21
T010E	1.10
T010D	1.09
T010M	1.06
T010V	1.06
T010S	1.03
G012D	1.86
G012A	1.15
G012H	1.14
G012V	1.06
G012I	1.06
G012S	1.00
R014H	1.08
R014I	1.08
R014K	1.08
R014N	1.08
R014Q	1.08
R014S	1.08
R014T	1.08
S015Q	1.23
S015R	1.23

S015C	1.22
S015T	1.16
S015N	1.16
S015H	1.13
S015F	1.07
S015A	1.04
S015M	1.04
S015I	1.03
R016K	1.07
R016I	1.06
S018E	2.18
A022C	2.27
A022S	1.94
A022T	1.55
N024T	1.49
N024S	1.25
N024E	1.12
N024G	1.12
N024Q	1.04
N024K	1.04
N024A	1.01
N024V	1.01
G025S	1.25
G026I	2.50
G026K	2.50
G026L	2.50
G026Q	2.50
G026V	2.50
G026W	2.50
G026E	2.11
F027V	2.50
F027W	2.50
F027I	1.36
I028P	2.50
I028W	1.99

I028T	1.78
T029E	2.50
A030M	2.13
A030N	2.13
A030P	1.75
A030Y	1.57
G031M	2.13
G031H	1.65
G031V	1.63
G031N	1.55
G031A	1.15
H032A	1.37
H032C	1.01
H032R	1.01
C033M	2.13
C033L	2.04
C033N	1.85
C033E	1.85
C033D	1.36
C033T	1.01
C033K	1.01
R035H	1.08
R035Q	1.08
R035V	1.08
R035W	1.08
R035H	1.08
R035T	1.08
R035Y	1.05
T036V	1.13
T036I	1.09
T036K	1.08
T036P	1.08
A038D	1.60
A038C	1.43
A038Y	1.07

- 280 -

T039R	1.72
T039V	1.19
T039Q	1.11
T039K	1.07
T039W	1.07
T039L	1.03
T039P	1.03
T040D	2.33
T040Q	2.33
T040H	2.24
T040P	1.73
T040N	1.55
T040G	1.07
A041S	1.31
A041D	1.07
P043D	2.33
P043H	2.33
P043K	2.33
P043L	2.33
P043N	2.12
P043G	1.53
T044V	1.03
G045V	2.06
G045A	1.82
T046Y	1.68
T046V	1.66
T046W	1.43
T046F	1.32
T046Q	1.01
A048P	1.96
A048V	1.05
A048E	1.04
G049A	1.22
S051V	1.32
S051C	0.99
P053N	1.00
G054E	1.00
Y057N	1.65
Y057M	1.55
F059K	2.17
F059W	1.33
F059C	1.07
T062R	1.92
T062G	1.44
A070P	1.89
A070G	1.43
Q071Y	1.35
Q071A	1.21
Q071F	1.06
N073P	2.08

N074F	1.36
S076A	1.00
R079T	1.58
R079V	1.31
R079M	1.01
Q081A	1.92
Q081S	1.65
Q081P	1.57
Q081G	1.54
Q081H	1.52
Q081D	1.51
Q081F	1.43
Q081E	1.39
Q081C	1.13
Q081T	1.08
A083H	1.62
A083M	1.35
A083E	1.23
A083F	1.20
A083R	1.14
A083S	1.00
G084C	2.08
G084P	2.08
G084V	1.17
G084M	1.17
T086S	1.39
T086I	1.20
T086M	1.12
T086A	1.11
T086H	1.08
T086D	1.06
T086N	1.05
T086V	1.04
A087S	1.20
A087E	1.12
P089W	2.22
P089A	1.27
V090A	1.35
V090M	1.18
V090I	1.11
V090T	1.03
G091L	2.22
G091K	1.06
S092T	1.14
A093S	1.66
A093D	1.19
A093Q	1.06
A093Q	1.06
A093N	1.06
A093G	1.02

R096C	1.92
R096F	1.75
R096E	1.57
S099A	1.80
S099G	1.17
T100A	1.70
T100D	1.18
T100Q	1.16
T100E	1.08
T101S	1.14
W103N	1.20
C105E	1.89
C105G	1.89
C105K	1.89
C105M	1.89
C105N	1.89
C105S	1.89
C105P	1.72
C105W	1.69
C105T	1.28
C105Y	1.22
C105A	1.21
C105L	1.18
T107S	1.30
T107L	1.24
T107Q	1.24
T107A	1.17
T107F	1.14
T107R	1.11
T107K	1.10
T107H	1.02
T107M	1.00
A110G	1.15
L111K	1.17
L111R	1.10
N112D	1.08
N112E	1.08
N112G	1.08
N112H	1.08
N112Q	1.08
N112R	1.07
N112L	1.03
N112P	1.03
N112F	1.01
S113M	1.08
S113N	1.08
S113R	1.08
S113T	1.08
S113C	1.04
S113H	1.01

- 281 -

S113F	1.00
S113I	0.99
V115I	1.18
V115L	1.14
V115T	1.05
T116Q	1.13
T116E	1.09
T116L	1.03
Y117K	1.41
Y117Q	1.41
Y117R	1.41
Y117V	1.41
P118T	1.12
P118R	1.08
P118Q	1.03
P118S	1.02
E119L	1.24
E119V	1.03
T121E	1.54
T121D	1.23
T121A	1.15
T121S	1.05
T121H	1.03
V122C	1.02
R123W	1.73
R123F	1.67
R123Y	1.58
R123N	1.53
R123L	1.39
R123I	1.39
R123T	1.35
R123Q	1.20
R123K	1.18
R123V	1.11
L125A	1.45
L125M	1.38
R127K	1.41
R127Q	1.41
R127F	1.21
R127Y	1.09
R127D	1.03
R127E	1.03
T128A	1.89
T128V	1.89
T128G	1.88
T128S	1.48
T128C	1.47
T129W	2.50
T129Y	1.30
V130T	1.13

V130C	1.07
A132C	1.19
P134W	1.18
S137R	1.92
S140P	1.88
L141C	1.33
L142M	1.10
A143H	1.19
G144A	1.14
G144V	1.10
G144D	1.02
G144I	1.00
G144E	0.99
Q146P	1.53
Q146Y	1.02
A147E	2.00
A147C	1.08
V150N	1.12
T151C	1.30
T151A	1.07
G153K	1.23
G153V	1.23
G154L	1.17
G154R	1.14
G154E	1.13
S155P	1.92
S155R	1.92
S155W	1.78
S155K	1.69
S155Y	1.66
S155F	1.48
S155T	1.18
S155V	0.99
G156I	1.92
G156L	1.92
G156P	1.81
G156V	1.08
G156E	1.03
C158H	2.00
C158G	1.57
C158M	1.49
R159K	1.56
R159T	1.26
R159V	1.15
R159Q	1.14
T160I	1.48
T160E	1.27
T160Q	1.14
T160L	1.09
T160D	1.04

T160R	1.04
G161L	2.13
G161V	2.13
G161I	1.50
G161K	1.24
G162P	1.32
G162L	1.11
T163I	1.19
T163V	1.02
T164G	1.83
T164L	1.54
F165T	1.01
F165D	0.99
F166S	1.44
F166C	1.29
F166A	1.20
F166G	1.01
Q167L	1.79
Q167N	1.08
P168Y	1.45
P168I	1.17
N170E	1.32
N170D	1.17
N170L	1.06
N170V	0.99
Q174H	1.11
Q174L	1.06
Q174R	1.06
Q174V	1.03
Y176P	1.48
Y176K	1.06
Y176D	1.03
G177N	1.18
G177K	1.03
R179K	1.21
M180L	1.30
T182L	1.14
T182V	1.01
T183P	1.26
T183I	1.17
T183A	1.13
T183S	1.11
T183V	1.06
D184E	1.04
S185R	1.32
S185Q	1.08
G186S	1.65
G186P	1.23
S187R	1.02
S187G	1.00

- 282 -

S188A	1.44
S188E	1.42
S188V	1.42
S188T	1.36
S188M	1.26

S188G	1.23
S188C	1.16
S188H	1.01
P189S	1.16
P189S	1.16

P189D	1.04
P189K	1.04
P189Y	1.03
P189F	0.99

BMI-LVJ 1 Performance Assays

The following table (Table 30-4) provides the data obtained for selected variants in the BMI-LVJ 1 performance assay (See, "Microswatch Assay for Testing Protease Performance"). The table shows performance indices, which were calculated as described above for the variants, which show improved performance compared to the WT enzyme. Those variants, which have a performance index greater than 1, have an improved performance.

Table 30-4. BMI-LVJ 1 Performance Assay Results

Variant code	BMI US LVJ-1 liquid detergent [perf. Index]
F001T	1.06
D002Q	1.14
D002E	1.05
D002P	1.01
V003L	1.24
V003I	1.12
N007L	1.14
A008G	1.09
A008D	1.07
A008E	1.04
A008M	1.03
A008K	1.01
T010E	1.10
T010Q	1.08
T010L	1.08
T010D	1.02
T010G	1.01
I011Q	1.18
I011A	1.13
I011T	1.12
I011S	1.11
I011L	1.06

G012D	1.08
G012Y	1.07
G012N	1.05
G012L	1.03
G012Q	1.00
R014I	1.25
R014M	1.20
R014L	1.11
R014E	1.09
R014N	1.08
R014P	1.08
R014G	1.03
R014Q	1.03
S015E	1.09
S015G	1.04
R016Q	1.14
R016L	1.14
R016N	1.11
R016G	1.11
R016I	1.09
R016A	1.09
R016M	1.03
I019V	1.02
N024E	1.36
N024A	1.31
N024T	1.21
N024Q	1.19
N024V	1.17

N024H	1.14
N024M	1.13
N024L	1.12
N024S	1.07
N024W	1.00
R035F	1.23
R035L	1.14
R035A	1.06
R035D	1.03
R035H	1.03
T036I	9.16
T036N	1.77
T036G	1.64
T036S	1.61
T036P	1.49
T036D	1.41
T036H	1.25
T036Y	1.25
T036L	1.18
T036W	1.15
T036F	1.05
A038R	1.55
A038L	1.18
A038S	1.16
A038Y	1.12
A038N	1.10
A038D	1.09
A038F	1.08

- 283 -

A038V	1.06
T040V	1.10
T040S	1.02
A041N	1.09
A041I	1.04
N042H	1.11
T046Q	1.05
F047V	1.02
A048Q	1.26
G049A	1.15
G049F	1.11
G049H	1.09
G049S	1.07
G049T	1.02
G049V	1.01
S050F	1.04
S051Q	1.10
S051T	1.07
S051D	1.05
S051A	1.05
S051V	1.03
S051M	1.01
S051H	1.01
G054D	1.48
G054Q	1.17
G054E	1.16
G054N	1.14
G054I	1.14
G054L	1.11
G054M	1.09
G054A	1.08
G054H	1.00
N055F	1.07
N055E	1.01
Y057M	1.00
R061V	1.13
R061K	1.12
R061M	1.11
R061H	1.08
R061S	1.06
R061T	1.06
T062I	1.02
A064H	1.15
A064F	1.14
A064Y	1.13
A064W	1.10
A064N	1.10
A064T	1.09
A064S	1.08
A064V	1.06

A064Q	1.04
A064I	1.04
A064L	1.02
A064G	1.02
G065P	1.28
G065Q	1.27
G065T	1.19
G065Y	1.19
G065S	1.17
G065L	1.13
G065V	1.11
G065R	1.10
V066H	1.15
V066D	1.07
V066E	1.02
N067L	1.25
N067S	1.23
N067A	1.19
N067Y	1.16
N067G	1.14
N067V	1.14
N067Q	1.13
N067T	1.10
N067F	1.08
N067M	1.07
N067K	1.06
N067D	1.02
N067H	1.02
N067C	1.01
L068H	1.02
L069S	1.29
L069H	1.14
L069W	1.06
L069V	1.02
A070G	1.12
A070P	1.09
A070D	1.01
Q071I	1.14
Q071H	1.13
Q071F	1.12
Q071D	1.11
Q071L	1.09
Q071T	1.06
Q071Y	1.04
Q071S	1.04
Q071A	1.03
V072I	1.04
N073T	1.67
N074G	1.28
Y075G	1.37

Y075F	1.30
Y075I	1.18
S076W	1.49
S076L	1.39
S076Y	1.37
S076T	1.30
S076V	1.30
S076I	1.25
S076D	1.22
S076N	1.20
S076A	1.16
S076E	1.14
G077T	1.48
G077S	1.11
G077N	1.07
G078D	1.24
G078A	1.12
G078N	1.10
G078H	1.04
G078S	1.02
R079P	1.20
R079G	1.13
R079D	1.12
R079C	1.02
V080L	1.11
V080H	1.09
V080Q	1.04
Q081P	1.22
Q081V	1.02
Q081K	1.01
Q081H	1.01
A083N	1.03
A083E	1.03
H085Q	1.42
H085L	1.30
H085R	1.23
H085K	1.19
H085F	1.13
H085Y	1.11
H085T	1.10
H085M	1.05
H085V	1.02
T086N	1.07
T086D	1.05
T086R	1.01
T086Q	1.00
T086I	1.00
T086V	1.00
A088F	1.12
A088H	1.04

- 284 -

P089D	2.85
P089N	1.11
P089V	1.07
P089T	1.00
V090I	1.12
V090P	1.10
V090T	1.06
V090L	1.01
S092A	1.21
S092G	1.11
A093T	2.26
A093S	2.15
A093D	1.10
A093E	1.06
A093Q	1.05
A093H	1.00
R096K	1.02
S099W	1.50
S099N	1.38
S099A	1.22
S099D	1.15
S099T	1.14
S099G	1.09
S099E	1.03
S099V	1.01
G102Q	1.01
W103M	1.01
H104S	1.05
T107H	1.02
T107N	1.01
T107S	1.01
T109E	1.15
T109N	1.03
T109I	1.02
L111E	1.10
L111D	1.07
L111T	1.01
N112E	1.14
N112L	1.11
N112Q	1.09
N112D	1.08
N112G	1.07
N112A	1.01
N112H	1.01
S113A	1.13
S113G	1.12
S113M	1.04
S114G	1.25
S114A	1.05
V115T	1.03

T116F	1.15
T116E	1.02
P118E	1.02
T121D	1.13
T121E	1.11
T121S	1.04
R123I	1.24
R123F	1.22
R123L	1.15
R123Q	1.12
R123E	1.10
R123K	1.07
R123P	1.03
R123W	1.02
R123H	1.01
G124A	1.01
L125V	1.06
R127A	1.44
R127S	1.36
R127Q	1.36
R127K	1.28
R127L	1.25
R127H	1.25
R127Y	1.23
R127F	1.22
R127T	1.19
R127G	1.16
R127V	1.01
T129S	1.03
A132V	1.22
A132C	1.03
P134E	1.14
P134G	1.06
P134A	1.01
S140A	1.07
L142V	1.09
L142M	1.02
A143N	1.21
A143S	1.05
A143H	1.01
N145D	1.06
N145S	1.02
V150L	1.07
N157D	1.17
R159F	1.63
R159E	1.43
R159K	1.29
R159H	1.28
R159N	1.22
R159Y	1.17

R159D	1.17
R159V	1.12
R159C	1.11
R159L	1.10
R159A	1.06
R159W	1.02
T160E	1.12
T160D	1.02
G161K	1.15
G161E	1.10
T163D	1.13
T163I	1.06
N170Y	1.34
N170D	1.09
N170L	1.08
N170G	1.03
N170A	1.00
P171S	1.03
P171V	1.01
A175V	1.05
G177M	1.03
R179V	1.19
R179T	1.11
R179K	1.10
R179N	1.09
R179D	1.07
R179E	1.06
R179A	1.03
R179I	1.01
R179M	1.01
R179F	1.00
I181Q	1.24
I181H	1.07
I181T	1.00
T182V	1.05
T182L	1.00
T183I	1.10
T183V	1.03
T183S	1.01
D184F	1.34
D184H	1.15
D184R	1.11
D184T	1.08
D184I	1.07
D184Q	1.06
D184L	1.05
S185I	1.09
S185W	1.08
S185L	1.05
S185L	1.05

- 285 -

S185M	1.04
S185G	1.01
G186V	1.27
G186E	1.20
G186I	1.17
G186L	1.06
G186T	1.03

G186Q	1.01
G186R	1.00
S187P	1.24
S187Q	1.13
S187E	1.08
S187T	1.04
S188Q	1.06

S188M	1.03
S188L	1.01
P189T	1.05
P189N	1.02
P189I	1.01

BMI-Low pH Performance Assays

The table below (Table 30-5) provides the data obtained for the ASP variants which show activity on this substrate in the microswatch assays under low pH conditions (See, Microswatch Assay for Testing Protease Performance) using TIDE®. The table provides performance indices, which were calculated as described above for the variants which show improved performance compared to WT. Variants that have a performance index greater than 1 have improved performance.

Table 30-5. BMI-Low pH Performance Assays

Variant code	BMI US LVJ-1 liquid detergent [perf. Index]
F001T	1.06
V003L	1.11
V003I	1.03
I004M	1.11
N007L	1.08
A008R	1.53
A008V	1.46
A008T	1.44
A008S	1.25
A008E	1.20
A008L	1.20
A008N	1.19
A008H	1.15
A008P	1.13
A008D	1.08
A008Q	1.07
T010Q	1.04
T010L	1.04
T010D	1.01
I011T	1.14
I011S	1.05
G012D	1.00
R014L	1.32
R014M	1.25

R014E	1.21
R014I	1.16
R014Q	1.16
R014N	1.07
R014K	1.05
R014D	1.01
S015E	1.05
R016Q	1.22
R016L	1.08
R016I	1.07
R016W	1.05
R016N	1.02
I019V	1.04
N024E	1.61
N024A	1.52
N024T	1.35
N024Q	1.25
N024L	1.21
N024M	1.15
N024V	1.15
N024H	1.14
N024F	1.06
N024S	1.03
R035F	1.36
R035L	1.21
R035A	1.14
R035E	1.13
R035D	1.08
R035H	1.07
T036I	9.02

T036N	1.69
T036G	1.63
T036S	1.59
T036P	1.41
T036D	1.28
T036V	1.19
T036W	1.07
T036H	1.06
T036L	1.02
T036F	1.02
A038R	1.89
A038F	1.41
A038S	1.32
A038L	1.26
A038D	1.25
A038H	1.20
A038N	1.13
A038I	1.10
A038Y	1.08
A038V	1.02
A038T	1.00
T040V	1.14
T040S	1.01
A041N	1.10
A041I	1.04
F047I	1.01
A048E	1.04
G049L	1.16
G049A	1.10
G049F	1.06

- 286 -

G049N	1.06
G049T	1.04
G049S	1.04
S051A	1.35
S051D	1.25
S051Q	1.12
S051F	1.09
S051T	1.08
S051H	1.06
G054D	1.67
G054I	1.22
G054L	1.21
G054E	1.20
G054Q	1.16
G054A	1.16
G054M	1.10
G054N	1.06
G054H	1.01
G054K	1.01
N055F	1.69
N055E	1.35
N055S	1.25
N055Q	1.15
N055V	1.09
N055T	1.02
F059W	1.01
R061M	1.35
R061T	1.22
R061V	1.15
R061S	1.07
R061N	1.02
R061K	1.02
R061Q	1.02
T062I	1.14
G063V	1.25
G063D	1.18
G063P	1.13
G063Q	1.12
A064N	1.28
A064H	1.24
A064S	1.23
A064Q	1.21
A064R	1.19
A064M	1.15
A064T	1.15
A064I	1.14
A064W	1.14
A064F	1.11
A064L	1.11
A064V	1.09

A064K	1.06
A064Y	1.05
G065P	1.66
G065Q	1.49
G065S	1.35
G065Y	1.32
G065T	1.26
G065R	1.22
G065D	1.16
G065A	1.12
G065L	1.05
G065V	1.04
V066D	1.21
V066E	1.08
N067G	1.41
N067V	1.39
N067L	1.32
N067T	1.31
N067D	1.25
N067M	1.25
N067F	1.24
N067S	1.24
N067Y	1.23
N067C	1.20
N067A	1.18
N067Q	1.13
N067R	1.11
N067K	1.07
N067E	1.07
N067H	1.06
L068T	1.03
L068H	1.01
L069S	1.79
L069H	1.64
L069W	1.26
L069V	1.21
L069Q	1.12
A070S	1.18
A070P	1.12
A070G	1.10
Q071M	1.15
Q071D	1.10
Q071S	1.03
N073T	1.77
N074G	1.61
Y075G	1.58
Y075F	1.40
S076V	1.71
S076Y	1.71
S076I	1.55

S076D	1.55
S076L	1.46
S076W	1.42
S076N	1.40
S076E	1.25
S076C	1.22
S076T	1.18
S076Q	1.17
S076A	1.11
S076K	1.07
S076H	1.00
G077T	1.86
G077Q	1.13
G077N	1.10
G077S	1.03
G078D	1.23
R079P	1.89
R079C	1.34
R079G	1.32
R079E	1.29
R079D	1.28
R079L	1.12
R079A	1.02
Q081V	1.31
Q081I	1.11
Q081E	1.10
Q081H	1.10
Q081L	1.07
Q081K	1.06
Q081D	1.06
Q081A	1.01
A083N	1.27
A083I	1.16
A083D	1.12
A083M	1.07
A083L	1.04
A083E	1.02
A083G	1.00
H085Q	1.24
H085L	1.19
H085R	1.12
H085N	1.08
H085T	1.08
H085F	1.05
H085K	1.04
T086A	1.27
T086I	1.24
T086L	1.22
T086F	1.21
T086E	1.15

- 287 -

T086M	1.11
T086D	1.07
T086C	1.04
T086Q	1.04
T086G	1.03
A088F	1.15
P089V	1.07
P089T	1.07
V090P	1.50
V090S	1.38
V090I	1.32
V090T	1.23
V090N	1.22
V090L	1.16
V090A	1.07
S092C	1.20
S092G	1.12
S092A	1.02
A093D	1.31
A093E	1.30
A093Q	1.09
R096K	1.15
T101S	1.16
W103M	1.18
W103Y	1.18
H104M	1.01
H104K	1.00
T107N	1.42
T107S	1.30
T107M	1.24
T107A	1.20
T107E	1.20
T107Q	1.15
T107H	1.11
T107V	1.10
T109E	1.46
T109I	1.31
T109A	1.28
T109G	1.21
T109H	1.13
T109N	1.13
T109L	1.10
T109F	1.01
A110S	1.19
A110T	1.13
A110N	1.05
N112E	1.24
N112D	1.20
N112Q	1.07
N112A	1.05

N112L	1.04
S113A	1.07
S113G	1.04
S113M	1.03
S113E	1.00
S114G	1.20
S114T	1.05
S114A	1.03
T116F	1.12
T116G	1.06
T116E	1.06
T116Q	1.00
P118E	1.00
T121E	1.46
T121D	1.31
T121L	1.12
T121G	1.06
R123E	1.42
R123D	1.35
R123I	1.34
R123F	1.29
R123L	1.20
R123P	1.18
R123Q	1.14
R123A	1.12
R123H	1.12
R123K	1.11
R123N	1.01
G124N	1.04
G124T	1.00
L125V	1.17
I126L	1.26
R127A	1.38
R127S	1.31
R127Q	1.26
R127L	1.26
R127K	1.26
R127H	1.25
R127Y	1.21
R127T	1.19
R127F	1.18
R127G	1.06
R127V	1.04
T129S	1.20
T129G	1.14
A132V	1.19
A132S	1.08
E133D	1.06
P134A	1.25
P134E	1.23

P134D	1.15
P134G	1.09
S140A	1.15
L142V	1.28
L142M	1.02
A143N	1.25
A143M	1.03
A143S	1.03
N145S	1.36
N145E	1.32
N145Q	1.15
N145G	1.13
N145P	1.12
N145T	1.09
N145L	1.06
N145F	1.01
Q146D	1.12
Q146F	1.02
T151V	1.18
N157D	1.04
R159F	1.67
R159E	1.60
R159C	1.50
R159Y	1.31
R159D	1.30
R159K	1.25
R159Q	1.22
R159N	1.20
R159H	1.17
R159A	1.16
R159L	1.09
R159V	1.08
R159W	1.06
R159P	1.06
R159M	1.03
T160E	1.08
G161E	1.33
G161K	1.11
G161Q	1.05
T163D	1.25
T163I	1.00
T163C	1.00
F166Y	1.12
P168S	1.06
N170Y	2.54
N170D	1.20
N170C	1.19
N170L	1.06
N170L	1.06
N170P	1.02

- 288 -

N170H	1.00
P171M	1.18
P171V	1.03
I172V	1.28
A175T	1.13
A175V	1.12
A175F	1.02
Y176L	1.08
G177M	1.62
G177S	1.08
G177Q	1.08
R179V	1.70
R179M	1.44
R179I	1.39
R179Y	1.37
R179N	1.35
R179T	1.30
R179L	1.30
R179K	1.30
R179A	1.30
R179D	1.27

R179E	1.22
R179W	1.20
R179G	1.08
R179F	1.06
M180D	1.31
I181Q	1.07
I181C	1.01
I181L	1.00
I181T	1.00
T182V	1.23
T182W	1.11
T182L	1.07
T182Q	1.06
T182P	1.05
T183I	1.25
T183E	1.16
T183Q	1.14
T183K	1.10
T183L	1.10
T183A	1.05
T183D	1.05

T183V	1.05
T183R	1.04
T183M	1.03
D184F	1.00
G186E	1.42
G186V	1.34
G186I	1.21
G186L	1.11
G186P	1.09
G186T	1.09
G186A	1.03
S187P	1.39
S187T	1.18
S187E	1.11
S187L	1.07
S187Q	1.04
S187V	1.02
S188E	1.09
S188P	1.04

Scrambled Egg Assay (ADW) Performance

The following table (Table 30-6) provides the data obtained for selected variants in the scrambled egg performance assay (See, "Scrambled Egg Assay") using Detergent Composition I. The table shows performance indices, which were calculated as described above for the variants, which show improved performance compared to the WT enzyme. Those variants, which have a performance index greater than 1, have an improved performance.

Table 30-6. Scrambled Egg Assay Performance Results

Variant code	ADW [perf. Index]
F001T	1.00
D002A	1.06
D002N	1.05
T010G	1.36
T010A	1.25
T010L	1.14
T010F	1.03
T010M	1.03
T010V	1.03
T010Q	1.02

T010S	1.01
I011A	1.20
I011S	1.20
I011T	1.18
I011L	1.02
G012I	1.12
G012Y	1.08
G012R	1.05
G012Q	1.04
R014M	1.26
R014G	1.14
R014A	1.10
S015G	1.14

S015F	1.14
S015E	1.13
S015H	1.08
R016K	1.15
R016N	1.12
R016A	1.10
R016H	1.03
I019V	1.02
A022V	1.23
N024E	1.67
N024T	1.46
N024Q	1.31
N024A	1.28

- 289 -

N024L	1.15
N024V	1.12
N024H	1.03
G034A	1.28
T036I	6.72
T036S	1.32
T036G	1.30
T036N	1.18
T036V	1.11
T036W	1.06
T036Y	1.05
T036D	1.02
T036P	1.02
T036F	1.01
A038T	1.27
A038F	1.24
A038M	1.00
T046K	1.10
F047I	1.05
F047V	1.02
G049F	1.17
G049A	1.13
G049L	1.10
G049H	1.05
G049S	1.02
G049V	1.01
S051A	1.13
Y057M	1.05
G063V	1.08
G063W	1.01
G063D	1.01
A064H	1.11
A064R	1.08
A064Y	1.07
A064W	1.07
A064V	1.06
A064T	1.05
A064N	1.05
A064K	1.04
A064Q	1.04
A064L	1.04
A064I	1.02
G065V	1.17
G065T	1.11
G065S	1.10
G065L	1.10
G065A	1.07
G065P	1.04
G065D	1.03
L069S	1.39

L069H	1.19
L069V	1.06
A070S	1.09
Q071I	1.15
Q071F	1.09
Q071M	1.05
Q071H	1.03
Q071D	1.02
Q071L	1.01
N073T	1.89
N074G	1.12
Y075F	1.10
Y075G	1.07
S076W	1.26
S076V	1.22
S076Y	1.21
S076D	1.13
S076L	1.12
S076E	1.09
S076R	1.09
S076N	1.08
S076A	1.07
S076Q	1.05
S076H	1.05
S076T	1.05
S076I	1.04
S076K	1.04
G077T	1.87
G078T	1.08
G078A	1.06
G078S	1.05
G078R	1.03
G078D	1.00
R079L	1.07
R079G	1.07
R079S	1.05
R079T	1.04
R079V	1.03
R079D	1.01
R079A	1.01
V080A	1.13
V080L	1.11
H085T	1.05
T086Q	1.03
T086A	1.02
A088F	1.04
P089A	1.03
V090I	1.17
V090P	1.13
A093S	1.04

A093Q	1.02
S099N	1.14
S099V	1.12
S099Q	1.05
S099I	1.01
T107R	1.13
T107K	1.12
T107S	1.10
T107H	1.09
T107F	1.09
T107I	1.07
T107M	1.07
T107V	1.06
T107A	1.06
T107L	1.04
T107W	1.02
T109R	1.07
T109I	1.06
T109V	1.02
A110S	1.01
N112S	1.31
S114A	1.11
S114T	1.09
V115A	1.04
T116A	1.10
T116S	1.03
P118F	1.06
P118R	1.05
E119R	1.27
T121L	1.05
T121S	1.03
T121Q	1.02
G124T	1.03
L125Q	1.02
R127F	1.15
T128S	1.10
T129S	1.11
P134R	1.89
P134E	1.49
P134L	1.48
P134H	1.29
P134V	1.23
P134D	1.13
P134T	1.11
P134S	1.08
S140A	1.33
L142V	1.24
A143S	1.06
N145D	1.01
V150L	1.12

- 290 -

T151L	1.07
G154S	1.01
R159F	1.39
R159K	1.15
R159Y	1.06
R159Q	1.00
G161K	1.11
T163I	1.15
T164G	1.11
F166Y	1.13
F166V	1.07
Q167N	1.13

N170Y	1.24
N170D	1.03
N170G	1.02
L178V	1.08
R179V	1.16
R179K	1.10
R179T	1.05
T182V	1.22
T182L	1.04
T183I	1.08
T183S	1.02
D184T	1.05

D184Q	1.03
G186S	1.34
G186E	1.26
G186V	1.19
G186I	1.11
G186A	1.05
G186L	1.02
S187E	1.02
S187T	1.02
S188A	1.19
S188M	1.07
S188G	1.02

Las Stability

The following table (Table 30-7) shows all variants, which have an improved stability compared to the WT-ASP. All variants were tested and the calculations determined according to the protocol shown above (See, "LAS Stability Assay"). The table provides the residual activity after incubation for the variants. Under these conditions the average of the WT value was found to be 10.59% residual activity. All variants with a higher activity are improved with respect to the WT molecule.

Table 30-7. LAS Stability Assay Results

Variant code	LAS stability [residual Activity (%)]
F001P	21.73
F001N	16.59
F001R	11.13
D002P	22.43
D002I	20.86
D002V	20.15
D002T	19.97
D002M	15.20
D002N	13.27
D002F	12.71
D002A	12.13
D002C	11.50
A008G	33.00
A008T	20.39
A008R	18.33
A008P	14.19
T010L	24.24

T010C	24.00
T010Y	20.40
T010Q	19.48
T010D	18.06
T010E	17.48
T010F	17.10
T010M	14.94
T010W	12.63
I011W	50.85
I011E	26.05
I011T	23.20
I011Q	22.59
G012D	41.99
G012Q	28.25
G012N	27.52
G012V	27.44
G012S	24.06
G012I	23.30
G012H	19.43
G012Y	16.33
G012P	15.10

G012R	13.43
G012A	12.15
G012L	11.15
G012W	10.66
G013E	18.82
G013D	16.72
G013K	10.79
G013K	10.79
R014E	71.80
R014D	64.85
R014T	45.51
R014G	31.47
R014S	30.62
R014I	26.03
R014A	25.60
R014Q	25.38
R014C	23.91
R014N	23.61
R014M	18.47
R014H	15.72
R014L	15.35

- 291 -

R014P	12.43
S015R	57.77
S015H	53.39
S015C	50.38
S015E	25.99
S015Y	23.97
S015M	19.73
S015F	17.11
S015N	16.21
S015G	14.44
S015L	12.00
S015A	11.84
S015T	11.83
S015I	10.89
R016E	34.61
R016T	27.36
R016C	25.97
R016V	25.79
R016D	22.22
R016Q	19.87
R016I	19.83
R016S	10.71
A022C	27.48
A022S	25.99
N024E	23.54
N024T	18.16
N024G	15.54
N024S	14.04
N024F	13.05
N024V	11.86
I028V	14.49
R035E	88.92
R035D	76.48
R035Q	49.08
R035V	49.02
R035S	47.13
R035T	44.84
R035N	42.49
R035A	42.38
R035C	41.31
R035P	32.50
R035H	27.88
R035M	25.29
R035K	15.26
T036C	25.91
T036V	20.77
A038D	47.40
A038C	34.28
A038T	12.27
A041D	24.80

A041C	23.37
A041T	18.58
A041S	15.58
N042D	15.04
N042C	13.16
T044E	33.74
T044C	17.24
T046V	40.22
T046F	34.46
T046E	34.01
T046Y	27.10
T046C	23.20
F047R	46.98
F047V	20.38
F047I	12.72
A048E	29.23
G049C	64.06
G049Q	49.53
G049E	48.76
G049H	47.79
G049A	43.93
G049V	43.28
G049N	29.58
G049L	24.93
G049S	19.86
G049F	16.65
G049K	15.46
G049T	11.73
S051L	19.79
S051A	15.12
S051C	14.59
S051G	14.33
P053C	11.51
P053N	10.68
G054C	26.41
G054E	19.88
G054Q	12.71
G054K	11.71
N055G	33.29
N055A	15.31
D056L	42.96
D056F	17.11
Y057G	27.33
F059W	31.25
R061E	30.95
R061V	26.22
R061M	26.01
R061T	23.33
R061K	20.21
R061Q	18.05

G063D	13.79
A064C	15.65
G065D	14.73
V066N	16.37
A070M	21.09
A070G	15.83
A070P	14.86
Q071L	11.17
Y075W	10.97
G078H	12.06
R079T	16.18
R079V	15.24
R079L	12.03
V080E	10.65
Q081P	18.28
Q081G	15.49
Q081A	14.60
Q081E	14.36
Q081H	14.02
Q081S	13.51
Q081D	13.17
Q081Y	13.15
Q081F	12.61
Q081I	11.93
Q081W	11.89
Q081C	11.40
A083H	17.04
A083D	15.14
A083E	14.66
A083Y	12.54
A083V	11.93
A083N	11.52
A083M	11.35
A083F	11.21
A083I	10.80
H085P	10.62
T086E	16.60
T086I	13.95
T086C	13.70
T086W	13.45
T086V	12.92
T086Y	10.97
T086F	10.78
T086D	10.70
A087E	20.99
A087C	17.19
A087P	11.78
A088F	18.06
A088E	14.11
A088V	13.47

- 292 -

A088H	10.95
P089D	10.88
V090C	12.71
G091Q	23.98
S092T	17.35
S092I	11.15
S092C	10.93
S092L	10.60
A093H	14.05
S099A	28.58
S099G	22.20
S099K	17.98
S099Q	17.50
S099H	15.09
T100A	27.16
T100R	22.31
T100K	22.07
T100Q	15.53
T100C	11.47
W103L	20.25
H104M	10.65
T107R	26.61
T107H	12.35
T109E	24.23
T109K	17.25
N112P	25.16
N112E	17.68
N112D	15.90
S113C	35.77
S113A	16.28
S113D	14.68
S113H	13.27
S114C	22.24
S114E	16.60
S114D	11.86
T116C	16.41
T116N	14.90
T116G	14.42
T116A	11.29
P118R	28.25
P118K	23.28
P118C	16.70
P118A	15.98
P118W	15.50
P118G	14.55
P118H	13.73
P118F	12.80
P118Y	11.29
E119G	32.98
E119Y	29.43

E119R	26.97
E119T	26.28
E119V	24.47
E119N	20.71
E119A	19.95
E119L	15.83
E119S	15.80
E119Q	14.68
T121E	36.49
T121L	34.33
T121F	23.82
T121A	17.78
T121D	16.73
T121V	14.25
T121Q	12.39
T121G	12.17
T121S	11.93
T121N	11.51
R123D	48.24
R123Y	47.97
R123C	46.46
R123E	44.33
R123N	40.60
R123H	39.41
R123T	34.97
R123W	33.83
R123F	30.58
R123S	30.56
R123Q	25.60
R123V	24.71
R123M	18.54
R123A	17.24
R123K	16.38
R123G	16.12
R123I	16.04
G124D	25.10
G124N	12.84
L125Q	25.77
L125M	14.90
R127E	36.18
R127S	31.24
R127D	29.46
R127Q	27.92
R127K	25.25
R127A	21.74
R127C	16.40
R127T	14.31
R127Y	13.61
R127H	12.89
R127F	10.69

T128A	21.49
T128V	12.94
V130C	12.97
A132S	19.09
A132P	11.71
P134R	22.20
S140P	21.06
L141M	18.59
L141C	12.46
A143H	10.95
G144E	12.63
N145E	12.29
Q146D	12.05
T151L	46.42
T151C	26.57
T151V	17.57
S155C	38.40
S155W	30.61
S155Y	23.95
S155I	22.60
S155V	21.53
S155E	19.78
S155T	17.58
S155F	17.11
S155Q	12.59
N157D	18.83
R159T	28.61
R159E	27.00
R159Q	25.25
R159D	23.12
R159V	22.92
R159S	22.29
R159K	20.78
R159N	19.95
R159C	19.24
R159A	19.09
R159M	15.74
R159L	14.00
R159H	12.56
R159Y	11.23
T160D	15.18
T160E	11.72
T163D	23.84
T163C	19.09
T163Q	14.20
T163R	11.15
F165W	28.00
F165E	23.57
F165H	21.46
F165S	14.33

- 293 -

Q167E	64.13
Q167S	12.59
V169A	12.75
N170D	29.08
N170C	23.07
N170L	14.63
N170G	13.30
N170A	12.77
N170P	12.72
I172A	20.40
Q174C	16.62
Q174S	14.76
Q174T	14.54
Q174V	13.40
Q174H	11.18
A175T	16.19
G177D	24.74
G177E	21.37
G177C	14.01
G177N	11.53
R179E	25.06

R179D	24.16
R179C	20.71
R179V	20.09
R179I	19.51
R179T	19.20
R179Y	17.89
R179M	16.74
R179S	16.12
R179N	16.11
R179F	15.67
R179W	15.56
R179L	15.12
R179A	14.35
R179K	12.30
M180L	25.64
M180I	12.31
I181C	11.51
T182L	12.63
T183D	13.51
T183E	13.32
S185D	14.31

S185C	13.10
S185Y	10.74
S185N	10.73
G186E	14.36
G186P	13.48
G186C	11.96
S187E	15.92
S187F	13.28
S187L	12.26
S187C	11.34
S187W	11.21
S187G	10.83
S187A	10.72
S187V	10.71
S187H	10.66
S188E	15.00
S188C	12.56
S188T	11.89
S188G	11.15
S188V	10.68

5

EXAMPLE 31**Determination of ASP Cleaning Activity**

In this Example, experiments conducted to determine the cleaning activity of ASP under various conditions, as well as the properties of the various wash conditions are described.

10

There is a wide variety of wash conditions including varying detergent formulations, wash water volume, wash water temperature, and length of wash time. Thus, detergent components such as proteases must be able to tolerate and function under adverse environmental conditions. For example, detergent formulations used in different areas have different concentrations of their relevant components present in the wash water. For example, a European detergent typically has about 3000-8000 ppm of detergent components in the wash water, while a Japanese detergent typically has less than 800 (*e.g.*, 667 ppm) of detergent components in the wash water. In North America, particularly the United States, detergent typically have about 800 to 2000 (*e.g.*, 975 ppm) of detergent components present in the wash water.

20

Latin American detergents are generally high suds phosphate builder detergents and the range of detergents used in Latin America can fall in both the medium and high

- 294 -

detergent concentrations, as they range from 1500 ppm to 6000 ppm of detergent components in the wash water. Brazilian detergents typically has approximately 1500 ppm of detergent components present in the wash water. However, other high suds phosphate builder detergent geographies, not limited to other Latin American countries, may have high detergent concentration systems up to about 6000 ppm of detergent components present in the wash water.

In light of the foregoing, it is evident that concentrations of detergent compositions in typical wash solutions throughout the world varies from less than about 800 ppm of detergent composition ("low detergent concentration geographies"), for example about 667 ppm in Japan, to between about 800 ppm to about 2000 ppm ("medium detergent concentration geographies"), for example about 975 ppm in U.S. and about 1500 ppm in Brazil, to greater than about 2000 ppm ("high detergent concentration geographies"), for example about 3000 ppm to about 8000 ppm in Europe and about 6000 ppm in high suds phosphate builder geographies.

The concentrations of the typical wash solutions are determined empirically. For example, in the U.S., a typical washing machine holds a volume of about 64.4 L of wash solution. Accordingly, in order to obtain a concentration of about 975 ppm of detergent within the wash solution, about 62.79 g of detergent composition must be added to the 64.4 L of wash solution. This amount is the typical amount measured into the wash water by the consumer using the measuring cup provided with the detergent.

As a further example, different geographies use different wash temperatures. The temperature of the wash water in Japan is typically less than that used in Europe. For example, the temperature of the wash water in North America and Japan can be between 10 and 30°C (*e.g.*, about 20°C), whereas the temperature of wash water in Europe is typically between 30 and 50°C (*e.g.*, about 40°C).

As a further example, different geographies may have different water hardness. Water hardness is typically described as grains per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$. Hardness is a measure of the amount of calcium (Ca^{2+}) and magnesium (Mg^{2+}) in the water. Most water in the United States is hard, but the degree of hardness varies from area to area. Moderately hard (60-120 ppm) to hard (121-181 ppm) water has 60 to 181 parts per million (*i.e.*, parts per million converted to grains per U.S. gallon is ppm # divided by 17.1 equals grains per gallon) of hardness minerals. Table 31-1 provides ranges of water hardness.

Table 31-1. Water Hardness Ranges

Water	Grains per Gallon	Parts per Million
-------	-------------------	-------------------

- 295 -

Soft	less than 1.0	less than 17
Slightly hard	1.0 to 3.5	17 to 60
Moderately hard	3.5 to 7.0	60 to 120
Hard	7.0 to 10.5	120 to 180
Very hard	greater than 10.5	greater than 180

European water hardness is typically greater than 10.5 (*e.g.*, 10.5-20.0) grains per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$ (*e.g.*, about 15 grains per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$). North American water hardness is typically greater than Japanese water hardness, but less than European water hardness. For example, North American water hardness can be between 3 to 10 grains, 3-8 grains or about 6 grains. Japanese water hardness is typically lower than North American water hardness, typically less than 4, for example 3 grains per gallon mixed $\text{Ca}^{2+}/\text{Mg}^{2+}$.

The present invention provides protease variants that provide improved wash performance in at least one set of wash conditions and typically in multiple wash conditions.

As described herein, the protease variants are tested for performance in different types of detergent and wash conditions using a microswatch assay (See above, and U.S. Pat. Appln. Ser. No. 09/554,992; and WO 99/34011, both of which are incorporated by reference herein). Protease variants are tested for other soil substrates also in a similar fashion.

In the experiments conducted to determine cleaning activity of ASP, the following methods were used. Incubators (Innova 4330 Model Incubator, New Brunswick) was pre-warmed for 60 minutes to 40°C for "European" conditions and for 20°C for "Japanese" conditions. Blood-Milk-Ink swatches (EMPA 116) were obtained from the Swiss Federal Laboratories for Material Testing and from CFT Research, and were modified by exposure to 0.03 % hydrogen peroxide for 30 minutes at 60°C., then dried. Circles of 1/4" diameter were cut from the dried swatches and placed vertically, one per well, in a 96 well microplate.

Protease samples of ASP were diluted in 10 mM NaCl, 0.005% TWEEN®-80 to provide the desired concentration of 10 ppm (protein). To provide "North American wash conditions," 1 gram per liter TIDE® laundry detergent (Procter & Gamble) without bleach was prepared in deionized water, and a concentrated stock of calcium and magnesium was added to result in a final water hardness value of 6 grains per gallon. To provide "European wash conditions," 7.6 gram per liter ARIEL® REGULAR laundry detergent (Procter & Gamble) without bleach was prepared in deionized water, and a concentrated stock of calcium and magnesium was added to result in a final water hardness value of 15 grains per

- 296 -

gallon. To provide "Japanese wash conditions," 0.67 gram per liter PURE CLEAN laundry detergent (Procter & Gamble) without bleach was prepared in deionized water, and a concentrated stock of calcium and magnesium was added to result in a final water hardness value of 3 grains per gallon.

5 In yet another detergent composition to provide "Japanese wash conditions with North American detergent formulation," 0.66 gram per liter Detergent Composition III without bleach was prepared in deionized water, and a concentrated stock of calcium and magnesium was added to result in a final water hardness value of 3 grains per gallon.

10 The detergent solutions were allowed to mix for 15 minutes and were then filtered through a 0.2 micron cellulose acetate filter. A 190 μ l of the respective detergent solution was then added to the appropriate wells of a microplate. Then, 10 μ l of the enzyme preparation were added to the filtered detergent in order to obtain a final concentration 0.25-3.0 ppm (micrograms per milliliter) of enzyme, for a total volume of 200 μ l. The microplate was then sealed to prevent leakage, placed in a holder on an incubator/shaker set to 20°C
15 and 350/400 RPM and allowed to shake for one hour.

The plate was then removed from the incubator/shaker and an aliquot of 100 μ l of solution was removed from each well, and placed on a fresh Costar microtiter plate (Corning). The absorbance at 405 nm wavelength was read for each aliquot on a Microtiter plate reader (SpectraMax 340, Molecular Devices), and reported. The detergent
20 composition and incubation conditions in the microswatch assay are set forth in Table 31-2.

Table 31-2. Detergent Composition and Incubation Conditions

Geography	Detergent	Water Hardness	Enzyme dosage	Temperature	Swatch
Powder detergent					
European	Ariel Regular 7.6 g/l	15 gpg Ca/Mg=4/1	0.25 – 3.0 ppm	40°	Superfix
North American	Detergent Comp. III 1.0 g/l	6 gpg Ca/Mg=3/1	0.25 – 3.0 ppm	20°	3K
Japanese	Pure Clean 0.66 g/l	3 gpg Ca/Mg=3/1	0.25 – 3.0 ppm	20°	3K
Japanese	Detergent Comp. III	3 gpg	0.25 – 3.0 ppm	20°	3K
(pseudo)	0.66 g/l	Ca/Mg=3/1			
Liquid detergent	Liquid-Tide®	6 gpg	0.25 – 3.0 ppm	20°	3K

- 297 -

(1.5 ml/L)					
------------	--	--	--	--	--

The dose response curves depicting absorbance at 405 nm as a function of concentration (ppm in well), for PURAFECT® (Genencor), OPTIMASE® (Genencor),
5 RELEASE™ (Genencor; GG36-variant described above), and ASP are provided in Figures 23-27).

As indicated in Figure 26, under North American conditions, in liquid TIDE® detergent, the ASP protease showed enhanced cleaning performance as compared to PURAFECT®, RELEASE™ and OPTIMASE™ proteases under the same conditions. Under
10 Japanese conditions, in Detergent Comp. III powder (0.66 g/l), ASP showed enhanced or the same cleaning performance as compared to PURAFECT®, RELEASE™ and OPTIMASE™ proteases under the same conditions (See, Figure 27). Under European conditions, in ARIEL® REGULAR powder detergent, the ASP protease showed enhanced cleaning performance as compared to PURAFECT®, RELEASE™ and OPTIMASE™
15 proteases under the same conditions (See, Figure 28). In both tests, ASP and OPTIMASE™ provided results that were 2 to 10 times the absorbance at 405 nm as compared to PURAFECT® and RELEASE™. Under Japanese conditions, in PURE CLEAN powder detergent (See, Figure 29), the ASP protease showed enhanced and comparative cleaning performance as compared to PURAFECT®, RELEASE™ and OPTIMASE™
20 proteases under the same conditions. Under North American conditions, in Detergent Composition III powder detergent (See, Figure 30), the ASP protease showed enhanced or comparative cleaning performance as compared to PURAFECT®, RELEASE™ and OPTIMASE™ proteases under the same conditions.

EXAMPLE 32

Liquid Fabric Cleaning Compositions

This Example provides liquid fabric cleaning compositions that find use in conjunction with the present invention. These compositions are contemplated to find
30 particular utility under Japanese machine wash conditions, as well as for applications involving cleaning of fine and/or delicate fabrics. Table 32-1 provides a suitable composition. However, it is not intended that the present invention be limited to this specific formulation, as many other formulations find use with the present invention.

- 298 -

Table 32-1. Liquid Fabric Cleaning Composition	
Component	Amount (%)
AE2.5S	2.16
AS	3.30
N-Cocoyl N-methyl glucamine	1.10
Nonionic surfactant	10.00
Citric acid	0.40
Fatty acid	0.70
Base	0.85
Monoethanolamine	1.01
1,2-Propanediol	1.92
EtOH	0.24
HXS	2.09
Protease.sup.1	0.01
Amylase	0.06
Minors/inerts to 100%	

EXAMPLE 33**Liquid Dishwashing Compositions**

5 This Example provides liquid dishwashing compositions that find use in conjunction with the present invention. These compositions are contemplated to find particular utility under Japanese dish washing conditions. Table 33-1 provide suitable compositions. However, it is not intended that the present invention be limited to this specific formulation, as many other formulations find use with the present invention.

Table 33-1. Liquid Dishwashing Compositions		
Component	A	B
AE1.4S	24.69	24.69
N-cocoyl N-methyl glucamine	3.09	3.09
Amine oxide	2.06	2.06
Betaine	2.06	2.06
Nonionic surfactant	4.11	4.11

- 299 -

Hydrotrope	4.47	4.47
Magnesium	0.49	0.49
Ethanol	7.2	7.2
LemonEase	0.45	0.45
Geraniol/BHT	---	0.60/0.02
Amylase	0.03	0.005
Protease	0.01	0.43
Balance to 100%		

EXAMPLE 34**Liquid Fabric Cleaning Compositions**

The proteases of the present invention find particular use in cleaning compositions. For example, it is contemplated that liquid fabric cleaning composition of particular utility under Japanese machine wash conditions be prepared in accordance with the invention. In some preferred embodiments, these compositions comprise the following components shown in Table 34-1.

Table 34-1. Liquid Fabric Cleaning Composition	
Component	Amount (%)
AE2.5S	15.00
AS	5.50
N-Cocoyl N-methyl glucamine	5.50
Nonionic surfactant	4.50
Citric acid	3.00
Fatty acid	5.00
Base	0.97
Monoethanolamine	5.10
1,2-Propanediol	7.44
EtOH	5.50
HXS	1.90
Boric Acid	3.50
Ethoxylated tetraethylenepentamine	3.00
SRP	0.30

- 300 -

Protease	0.069
Amylase	0.06
Cellulase	0.08
Lipase	0.18
Brightener	0.10
Minors/inerts to 100%	

EXAMPLE 35**Granular Fabric Cleaning Compositions**

In this Example, various granular fabric cleaning compositions that find use with the present invention are provided. The following Tables provide suitable compositions. However, it is not intended that the present invention be limited to these specific formulations, as many other formulations find use with the present invention.

Table 35-1. Granular Fabric Cleaning Compositions

Component	Formulations			
	A	B	C	D
Protease1	0.10	0.20	0.03	0.05
Protease2			0.2	0.15
C13 linear alkyl benzene sulfonate	22.00	22.00	22.00	22.00
Phosphate (as sodium tripolyphosphate)	23.00	23.00	23.00	23.00
Sodium carbonate	23.00	23.00	23.00	23.00
Sodium silicate	14.00	14.00	14.00	14.00
Zeolite	8.20	8.20	8.20	8.20
Chelant (diethylenetriamine-petaacetic acid)	0.40	0.40	0.40	0.40
Sodium sulfate	5.50	5.50	5.50	5.50
Water	Balance to 100%			

Table 35-2. Granular Fabric Cleaning Compositions

Component	Formulations			
	A	B	C	D
Protease1	0.10	0.20	0.30	0.05
Protease2			0.2	0.1
C12 alkyl benzene sulfonate	12.00	12.00	12.00	12.00
Zeolite A (1-10 micrometer)	26.00	26.00	26.00	26.00
C12-C14 secondary (2,3) alkyl sulfate, Na salt	5.00	5.00	5.00	5.00
Sodium citrate	5.00	5.00	5.00	5.00
Optical brightener	0.10	0.10	0.10	0.10

- 301 -

Sodium sulfate	17.00	17.00	17.00	17.00
Fillers, water, minors	Balance to 100%			

The following laundry detergent compositions are contemplated to provide particular utility under European machine wash conditions.

5

Table 35-3. Granular Fabric Cleaning Compositions			
Component	Formulations		
	A	B	C
LAS	7.0	5.61	4.76
TAS			1.57
C45AS	6.0	2.24	3.89
C25E25	1.0	0.76	1.18
C45E7			2.0
C25E3	4.0	5.5	
QAS	0.8	2.0	2.0
STPP			
Zeolite	25.0	19.5	19.5
Citric acid	2.0	2.0	2.0
NaSKS-6	8.0	10.6	10.6
Carbonate I	8.0	10.0	8.6
MA/AA	1.0	2.6	1.6
CMC	0.5	0.4	0.4
PB4		12.7	
Percarbonate			19.7
TAED		3.1	5.0
Citrate	7.0		
DTPMP	0.25	0.2	0.3
HEDP	0.3	0.3	0.3
QEA 1	0.9	1.2	1.0
Protease1	0.02	0.05	0.035
Lipase	0.15	0.25	0.15
Cellulase	0.28	0.28	0.28
Amylase	0.4	0.7	0.3
PVPI/PVNO	0.4		0.1
Photoactivated bleach (ppm)	15 ppm	27 ppm	27 ppm
Brightener 1	0.08	0.19	0.19
Brightener 2		0.04	0.04
Perfume	0.3	0.3	0.3
Effervescent granules (malic acid 40%, sodium bicarbonate 40%, sodium	15	15	5

- 302 -

carbonate 20%)			
Silicon antifoam	0.5	2.4	2.4
Minors/inerts to 100%	Balance to 100%		

EXAMPLE 36**Detergent Formulations**

In this Example, various detergent formulations which find use with ASP and/or ASP variants are provided. It is understood that the test methods provided in this section must be used to determine the respective values of the parameters of the present invention.

In the exemplified detergent compositions, the enzymes levels are expressed by pure enzyme by weight of the total composition and unless otherwise specified, the detergent ingredients are expressed by weight of the total compositions. The abbreviated component identifications therein have the following meanings:

Table 36-1. Definitions Used in this Example

LAS	: Sodium linear C ₁₁₋₁₃ alkyl benzene sulfonate.
TAS	: Sodium tallow alkyl sulphate.
C _{xy} AS	: Sodium C _{1x} - C _{1y} alkyl sulfate.
C _{xy} Ez	: C _{1x} - C _{1y} predominantly linear primary alcohol condensed with an average of z moles of ethylene oxide.
C _{xy} AEzS	: C _{1x} - C _{1y} sodium alkyl sulfate condensed with an average of z moles of ethylene oxide. Added molecule name in the examples.
Nonionic	: Mixed ethoxylated/propoxylated fatty alcohol e.g. Plurafac LF404 being an alcohol with an average degree of ethoxylation of 3.8 and an average degree of propoxylation of 4.5.
QAS	: R ₂ .N+(CH ₃) ₂ (C ₂ H ₄ OH) with R ₂ = C ₁₂ -C ₁₄ .
Silicate	: Amorphous Sodium Silicate (SiO ₂ :Na ₂ O ratio = 1.6-3.2:1).
Metasilicate	: Sodium metasilicate (SiO ₂ :Na ₂ O ratio = 1.0).
Zeolite A	: Hydrated Aluminosilicate of formula Na ₁₂ (AlO ₂ SiO ₂) ₁₂ .27H ₂ O
SKS-6	: Crystalline layered silicate of formula δ-Na ₂ Si ₂ O ₅ .
Sulfate	: Anhydrous sodium sulphate.
STPP	: Sodium Tripolyphosphate.
MA/AA	: Random copolymer of 4:1 acrylate/maleate, average molecular weight about 70,000-80,000.

- 303 -

AA	: Sodium polyacrylate polymer of average molecular weight 4,500.
Polycarboxylate	: Copolymer comprising mixture of carboxylated monomers such as acrylate, maleate and methacrylate with a MW ranging between 2,000-80,000 such as Sokolan commercially available from BASF, being a copolymer of acrylic acid, MW4,500.
BB1	: 3-(3,4-Dihydroisoquinolinium)propane sulfonate
BB2	: 1-(3,4-dihydroisoquinolinium)-decane-2-sulfate
PB1	: Sodium perborate monohydrate.
PB4	: Sodium perborate tetrahydrate of nominal formula $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$.
Percarbonate	: Sodium percarbonate of nominal formula $2\text{Na}_2\text{CO}_3 \cdot 3\text{H}_2\text{O}_2$.
TAED	: Tetraacetyl ethylene diamine.
NOBS	: Nonanoyloxybenzene sulfonate in the form of the sodium salt.
DTPA	: Diethylene triamine pentaacetic acid.
HEDP	: 1,1-hydroxyethane diphosphonic acid.
DETPMP	: Diethyltriamine penta (methylene) phosphonate, marketed by Monsanto under the Trade name Dequest 2060.
EDDS	: Ethylenediamine-N,N'-disuccinic acid, (S,S) isomer in the form of its sodium salt
Diamine	: Dimethyl aminopropyl amine; 1,6-hexane diamine; 1,3-propane diamine; 2-methyl-1,5-pentane diamine; 1,3-pentanediamine; 1-methyl-diaminopropane.
DETBCHD	: 5, 12- diethyl-1,5,8,12-tetraazabicyclo [6,6,2] hexadecane, dichloride, Mn(II) salt
PAAC	: Pentaamine acetate cobalt(III) salt.
Paraffin	: Paraffin oil sold under the tradename Winog 70 by Wintershall.
Paraffin Sulfonate	: A Paraffin oil or wax in which some of the hydrogen atoms have been replaced by sulfonate groups.
Aldose oxidase	: Oxidase enzyme sold under the tradename Aldose Oxidase by Novozymes A/S
Galactose oxidase	: Galactose oxidase from Sigma
Protease	: Proteolytic enzyme sold under the tradename Savinase, Alcalase, Everlase by Novo Nordisk A/S, and the following from Genencor International, Inc: "Protease A" described in US RE 34,606 in Figures 1A, 1B, and 7, and at column 11, lines 11-37; "Protease B" described in US5,955,340 and US5,700,676 in Figures 1A, 1B and 5, as well as Table 1; and "Protease C" described in US6,312,936 and US 6,482,628 in Figures 1-3 [SEQ ID 3], and at column 25, line 12, "Protease D" being the variant 101G/103A/104I/159D/232V/236H/245R/248D/252K (BPN' numbering) described in WO 99/20723.
Amylase	: Amylolytic enzyme sold under the tradename Purafect® Ox Am described in WO 94/18314, WO96/05295 sold by Genencor; Natalase®, Termamyl®, Fungamyl® and Duramyl®, all available from Novozymes A/S.
Lipase	: Lipolytic enzyme sold under the tradename Lipolase Lipolase Ultra by Novozymes A/S and Lipomax by Gist-Brocades.

- 304 -

Cellulase	: Cellulytic enzyme sold under the tradename Carezyme, Celluzyme and/or Endolase by Novozymes A/S.
Pectin Lyase	: Pectaway® and Pectawash® available from Novozymes A/S.
PVP	: Polyvinylpyrrolidone with an average molecular weight of 60,000
PVNO	: Polyvinylpyridine-N-Oxide, with an average molecular weight of 50,000.
PVPVI	: Copolymer of vinylimidazole and vinylpyrrolidone, with an average molecular weight of 20,000.
Brightener 1	: Disodium 4,4'-bis(2-sulphostyryl)biphenyl.
Silicone antifoam	: Polydimethylsiloxane foam controller with siloxane-oxyalkylene copolymer as dispersing agent with a ratio of said foam controller to said dispersing agent of 10:1 to 100:1.
Suds Suppressor	: 12% Silicone/silica, 18% stearyl alcohol, 70% starch in granular form.
SRP 1	: Anionically end capped poly esters.
PEG X	: Polyethylene glycol, of a molecular weight of x.
PVP K60 ®	: Vinylpyrrolidone homopolymer (average MW 160,000)
Jeffamine ® ED-2001	: Capped polyethylene glycol from Huntsman
Isachem ® AS	: A branched alcohol alkyl sulphate from Enichem
MME PEG (2000)	: Monomethyl ether polyethylene glycol (MW 2000) from Fluka Chemie AG.
DC3225C	: Silicone suds suppresser, mixture of Silicone oil and Silica from Dow Corning.
TEPAE	: Tetraethylenepentaamine ethoxylate.
BTA	: Benzotriazole.
Betaine	: $(\text{CH}_3)_3\text{N}^+\text{CH}_2\text{COO}^-$
Sugar	: Industry grade D-glucose or food grade sugar
CFAA	: C_{12} - C_{14} alkyl N-methyl glucamide
TPKFA	: C_{12} - C_{14} topped whole cut fatty acids.
Clay	: A hydrated aluminum silicate in a general formula $\text{Al}_2\text{O}_3\text{SiO}_2 \cdot x\text{H}_2\text{O}$. Types: Kaolinite, montmorillonite, atapulgite, illite, bentonite, halloysite.
pH	: Measured as a 1% solution in distilled water at 20°C.

The following Table (Table 36-2) provides liquid laundry detergent compositions that are prepared.

- 305 -

Table 36-2. Liquid Laundry Detergent Compositions					
Component	I	II	III	IV	V
LAS	24.0	32.0	6.0	8.0	6.0
C ₁₂ -C ₁₅ AE _{1.8} S	-	-	8.0	11.0	5.0
C ₈ -C ₁₀ amido propyl dimethyl amine	2.0	2.0	2.0	2.0	1.0
C ₁₂ -C ₁₄ alkyl dimethyl amine oxide	-	-	-	-	2.0
C ₁₂ -C ₁₅ AS	-	-	17.0	7.0	8.0
CFAA	-	5.0	4.0	4.0	3.0
C ₁₂ -C ₁₄ Fatty alcohol ethoxylate	12.0	6.0	1.0	1.0	1.0
C ₁₂ -C ₁₈ Fatty acid	3.0	-	4.0	4.0	3.0
Citric acid (anhydrous)	6.0	5.0	3.0	3.0	2.0
DETPMP	-	-	1.0	1.0	0.5
Monoethanolamine	#	#	5.0	5.0	2.0
Sodium hydroxide	-	-	2.5	1.0	1.5
Propanediol	12.7	14.5	13.1	10.	8.0
Ethanol	1.8	2.4	4.7	5.4	1.0
DTPA	0.5	0.4	0.3	0.4	0.5
Pectin Lyase	-	-	-	0.005	-
Amylase	0.001	0.002	-		-
Cellulase	-	-	0.0002	-	0.0001
Lipase	0.1	-	0.1	-	0.1
ASP	0.05	0.3	0.08	0.5	0.2
Protease A	-	-	-	-	0.1
Aldose Oxidase	-	-	0.3	-	0.003
DETBCHD	-	-	0.02	0.01	-
SRP1	0.5	0.5	-	0.3	0.3
Boric acid	2.4	2.4	2.8	2.8	2.4
Sodium xylene sulfonate	-	-	3.0	-	-
DC 3225C	1.0	1.0	1.0	1.0	1.0
2-butyl-octanol	0.03	0.04	0.04	0.03	0.03
Brightener 1	0.12	0.10	0.18	0.08	0.10
Balance to 100% perfume / dye and/or water					

added to product to adjust the neat pH of the product to about 4.2 for (I) and about 3.8 for (II).

- 306 -

The following Table (36-3) provides hand dish liquid detergent compositions that are prepared.

5

Table 36-3. Hand Dish Liquid Detergent Compositions						
Component	I	II	III	IV	V	VI
C ₁₂ -C ₁₅ AE _{1.8} S	30.0	28.0	25.0	-	15.0	10.0
LAS	-	-	-	5.0	15.0	12.0
Paraffin Sulfonate	-	-	-	20.0	-	-
C ₁₀ -C ₁₈ Alkyl Dimethyl Amine Oxide	5.0	3.0	7.0	-	-	-
Betaine	3.0	-	1.0	3.0	1.0	-
C ₁₂ poly-OH fatty acid amide	-	-	-	3.0	-	1.0
C ₁₄ poly-OH fatty acid amide	-	1.5	-	-	-	-
C ₁₁ E ₉	2.0	-	4.0	-	-	20.0
DTPA	-	-	-	-	0.2	-
Tri-sodium Citrate dihydrate	0.25	-	-	0.7	-	-
Diamine	1.0	5.0	7.0	1.0	5.0	7.0
MgCl ₂	0.25	-	-	1.0	-	-
ASP	0.02	0.01	0.03	0.01	0.02	0.05
Protease A	-	0.01	-	-	-	-
Amylase	0.001	-	-	0.002	-	0.001
Aldose Oxidase	0.03	-	0.02	-	0.05	-
Sodium Cumene Sulphonate	-	-	-	2.0	1.5	3.0
PAAC	0.01	0.01	0.02	-	-	-
DETBCHD	-	-	-	0.01	0.02	0.01
Balance to 100% perfume / dye and/or water						

The pH of these compositions is about 8 to about 11

- 307 -

Table 36-4 provides liquid automatic dishwashing detergent compositions that are prepared.

Table 36-4. Liquid Automatic Dishwashing Detergent Compositions

Component	I	II	III	IV	V
STPP	16	16	18	16	16
Potassium Sulfate	-	10	8	-	10
1,2 propanediol	6.0	0.5	2.0	6.0	0.5
Boric Acid	4.0	3.0	3.0	4.0	3.0
CaCl ₂ dihydrate	0.04	0.04	0.04	0.04	0.04
Nonionic	0.5	0.5	0.5	0.5	0.5
ASP	0.1	0.03	0.05	0.03	0.06
Protease B	-	-	-	0.01	-
Amylase	0.02	-	0.02	0.02	-
Aldose Oxidase	-	0.15	0.02	-	0.01
Galactose Oxidase	-	-	0.01	-	0.01
PAAC	0.01	-	-	0.01	-
DETBCHD	-	0.01	-	-	0.01
Balance to 100% perfume / dye and/or water					

5

Table 36-5 provides laundry compositions which may be prepared in the form of granules or tablets that are prepared.

Table 36-5. Laundry Compositions

Base Product	I	II	III	IV	V
C ₁₄ -C ₁₅ AS or TAS	8.0	5.0	3.0	3.0	3.0
LAS	8.0	-	8.0	-	7.0
C ₁₂ -C ₁₅ AE ₃ S	0.5	2.0	1.0	-	-
C ₁₂ -C ₁₅ E ₅ or E ₃	2.0	-	5.0	2.0	2.0
QAS	-	-	-	1.0	1.0
Zeolite A	20.0	18.0	11.0	-	10.0
SKS-6 (dry add)	-	-	9.0	-	-
MA/AA	2.0	2.0	2.0	-	-
AA	-	-	-	-	4.0
3Na Citrate 2H ₂ O	-	2.0	-	-	-
Citric Acid (Anhydrous)	2.0	-	1.5	2.0	-
DTPA	0.2	0.2	-	-	-
EDDS	-	-	0.5	0.1	-
HEDP	-	-	0.2	0.1	-
PB1	3.0	4.8	-	-	4.0
Percarbonate	-	-	3.8	5.2	-
NOBS	1.9	-	-	-	-
NACA OBS	-	-	2.0	-	-
TAED	0.5	2.0	2.0	5.0	1.00
BB1	0.06	-	0.34	-	0.14
BB2	-	0.14	-	0.20	-
Anhydrous Na Carbonate	15.0	18.0	8.0	15.0	15.0

- 308 -

Table 36-5. Laundry Compositions

Base Product	I	II	III	IV	V
Sulfate	5.0	12.0	2.0	17.0	3.0
Silicate	-	1.0	-	-	8.0
ASP	0.03	0.05	1.0	0.06	0.1
Protease B	-	0.01	-	-	-
Protease C	-	-	-	0.01	-
Lipase	-	0.008	-	-	-
Amylase	0.001	-	-	-	0.001
Cellulase	-	0.0014	-	-	-
Pectin Lyase	0.001	0.001	0.001	0.001	0.001
Aldose Oxidase	0.03	-	0.05	-	-
PAAC	-	0.01	-	-	0.05
Balance to 100% Moisture and/or Minors*					

* Perfume, Dye, Brightener / SRP1 / Na Carboxymethylcellulose/ Photobleach / MgSO₄ / PVPVI/ Suds suppressor /High Molecular PEG/Clay.

Table 36-6 provides liquid laundry detergent formulations which are prepared.

5

Table 36-6. Liquid Laundry Detergent Formulations

Component	I	I	II	III	IV	V
LAS	11.5	11.5	9.0	-	4.0	-
C ₁₂ -C ₁₅ AE _{2.85} S	-	-	3.0	18.0	-	16.0
C ₁₄ -C ₁₅ E _{2.5} S	11.5	11.5	3.0	-	16.0	-
C ₁₂ -C ₁₃ E ₉	-	-	3.0	2.0	2.0	1.0
C ₁₂ -C ₁₃ E ₇	3.2	3.2	-	-	-	-
CFAA	-	-	-	5.0	-	3.0
TPKFA	2.0	2.0	-	2.0	0.5	2.0
Citric Acid (Anhydrous)	3.2	3.2	0.5	1.2	2.0	1.2
Ca formate	0.1	0.1	0.06	0.1	-	-
Na formate	0.5	0.5	0.06	0.1	0.05	0.05
Na Culmene	4.0	4.0	1.0	3.0	1.2	-
Sulfonate						
Borate	0.6	0.6	-	3.0	2.0	3.0
Na Hydroxide	6.0	6.0	2.0	3.5	4.0	3.0
Ethanol	2.0	2.0	1.0	4.0	4.0	3.0
1,2 Propanediol	3.0	3.0	2.0	8.0	8.0	5.0
Mono- ethanolamine	3.0	3.0	1.5	1.0	2.5	1.0
TEPAE	2.0	2.0	-	1.0	1.0	1.0
ASP	0.03	0.05	0.01	0.03	0.08	0.02
Protease A	-	-	0.01	-	-	-
Lipase	-	-	-	0.002	-	-
Amylase	-	-	-	-	0.002	-
Cellulase	-	-	-	-	-	0.0001
Pectin Lyase	0.005	0.005	-	-	-	-
Aldose Oxidase	0.05	-	-	0.05	-	0.02
Galactose oxidase	-	0.04				

- 309 -

Table 36-6. Liquid Laundry Detergent Formulations

Component	I	I	II	III	IV	V
PAAC	0.03	0.03	0.02	-	-	-
DETBCHD	-	-	-	0.02	0.01	-
SRP 1	0.2	0.2	-	0.1	-	-
DTPA	-	-	-	0.3	-	-
PVNO	-	-	-	0.3	-	0.2
Brightener 1	0.2	0.2	0.07	0.1	-	-
Silicone antifoam	0.04	0.04	0.02	0.1	0.1	0.1
Balance to 100% perfume/dye and/or water						

Table 36-7 provides compact high density dishwashing detergents that are prepared.

Table 36-7. Compact High Density Dishwashing Detergents

Component	I	II	III	IV	V	VI
STPP	-	45.0	45.0	-	-	40.0
3Na Citrate 2H ₂ O	17.0	-	-	50.0	40.2	-
Na Carbonate	17.5	14.0	20.0	-	8.0	33.6
Bicarbonate	-	-	-	26.0	-	-
Silicate	15.0	15.0	8.0	-	25.0	3.6
Metasilicate	2.5	4.5	4.5	-	-	-
PB1	-	-	4.5	-	-	-
PB4	-	-	-	5.0	-	-
Percarbonate	-	-	-	-	-	4.8
BB1	-	0.1	0.1	-	0.5	-
BB2	0.2	0.05	-	0.1	-	0.6
Nonionic	2.0	1.5	1.5	3.0	1.9	5.9
HEDP	1.0	-	-	-	-	-
DETPMP	0.6	-	-	-	-	-
PAAC	0.03	0.05	0.02	-	-	-
Paraffin	0.5	0.4	0.4	0.6	-	-
ASP	0.072	0.053	0.053	0.026	0.059	0.01
Protease B	-	-	-	-	-	0.01
Amylase	0.012	-	0.012	-	0.021	0.006
Lipase	-	0.001	-	0.005	-	-
Pectin Lyase	0.001	0.001	0.001	-	-	-
Aldose Oxidase	0.05	0.05	0.03	0.01	0.02	0.01
BTA	0.3	0.2	0.2	0.3	0.3	0.3
Polycarboxylate	6.0	-	-	-	4.0	0.9
Perfume	0.2	0.1	0.1	0.2	0.2	0.2
Balance to 100% Moisture and/or Minors*						

*Brightener / Dye / SRP1 / Na Carboxymethylcellulose/ Photobleach / MgSO₄ / PVPVI/ Suds suppressor /High Molecular PEG/Clay.

The pH of the above compositions is from about 9.6 to about 11.3.

- 310 -

Table 36-8 provides tablet detergent compositions of the present invention that are prepared by compression of a granular dishwashing detergent composition at a pressure of 13KN/cm² using a standard 12 head rotary press:

Table 36-8. Tablet Detergent Compositions								
Component	I	II	III	IV	V	VI	VII	VIII
STPP	-	48.8	44.7	38.2	-	42.4	46.1	36.0
3Na Citrate 2H ₂ O	20.0	-	-	-	35.9	-	-	-
Na Carbonate	20.0	5.0	14.0	15.4	8.0	23.0	20.0	28.0
Silicate	15.0	14.8	15.0	12.6	23.4	2.9	4.3	4.2
Lipase	0.001	-	0.01	-	0.02	-	-	-
Protease B	0.01	-	-	-	-	-	-	-
Protease C	-	-	-	-	-	0.01	-	-
ASP	0.01	0.08	0.05	0.04	0.052	0.023	0.023	0.029
Amylase	0.012	0.012	0.012	-	0.015	-	0.017	0.002
Pectin Lyase	0.005	-	-	0.002	-	-	-	-
Aldose Oxidase	-	0.03	-	0.02	0.02	-	0.03	-
PB1	-	-	3.8	-	7.8	-	-	8.5
Percarbonate	6.0	-	-	6.0	-	5.0	-	-
BB1	0.2	-	0.5	-	0.3	0.2	-	-
BB2	-	0.2	-	0.5	-	-	0.1	0.2
Nonionic	1.5	2.0	2.0	2.2	1.0	4.2	4.0	6.5
PAAC	0.01	0.01	0.02	-	-	-	-	-
DETBCHD	-	-	-	0.02	0.02	-	-	-
TAED	-	-	-	-	-	2.1	-	1.6
HEDP	1.0	-	-	0.9	-	0.4	0.2	-
DETPMP	0.7	-	-	-	-	-	-	-
Paraffin	0.4	0.5	0.5	0.5	-	-	0.5	-
BTA	0.2	0.3	0.3	0.3	0.3	0.3	0.3	-
Polycarboxylate	4.0	-	-	-	4.9	0.6	0.8	-
PEG 400-30,000	-	-	-	-	-	2.0	-	2.0
Glycerol	-	-	-	-	-	0.4	-	0.5
Perfume	-	-	-	0.05	0.2	0.2	0.2	0.2
Balance to 100% Moisture and/or Minors*								

*Brightener / SRP1 / Na Carboxymethylcellulose/ Photobleach / MgSO₄ / PVPVI/ Suds suppressor /High Molecular PEG/Clay.

The pH of these compositions is from about 10 to about 11.5.

The tablet weight of these compositions is from about 20 grams to about 30 grams.

Table 36-9 provides liquid hard surface cleaning detergent compositions of the present invention that are prepared.

Table 36-9. Liquid Hard Surface Cleaning Detergent Compositions

Component	I	II	III	IV	V	VI	VII
------------------	----------	-----------	------------	-----------	----------	-----------	------------

- 311 -

Table 36-9. Liquid Hard Surface Cleaning Detergent Compositions

Component	I	II	III	IV	V	VI	VII
C ₉ -C ₁₁ E ₅	2.4	1.9	2.5	2.5	2.5	2.4	2.5
C ₁₂ -C ₁₄ E ₅	3.6	2.9	2.5	2.5	2.5	3.6	2.5
C ₇ -C ₉ E ₆	-	-	-	-	8.0	-	-
C ₁₂ -C ₁₄ E ₂₁	1.0	0.8	4.0	2.0	2.0	1.0	2.0
LAS	-	-	-	0.8	0.8	-	0.8
Sodium culmene sulfonate	1.5	2.6	-	1.5	1.5	1.5	1.5
Isachem ® AS	0.6	0.6	-	-	-	0.6	-
Na ₂ CO ₃	0.6	0.13	0.6	0.1	0.2	0.6	0.2
3Na Citrate 2H ₂ O	0.5	0.56	0.5	0.6	0.75	0.5	0.75
NaOH	0.3	0.33	0.3	0.3	0.5	0.3	0.5
Fatty Acid	0.6	0.13	0.6	0.1	0.4	0.6	0.4
2-butyl octanol	0.3	0.3	-	0.3	0.3	0.3	0.3
PEG DME-2000®	0.4	-	0.3	0.35	0.5	-	-
PVP	0.3	0.4	0.6	0.3	0.5	-	-
MME PEG (2000) ®	-	-	-	-	-	0.5	0.5
Jeffamine ® ED-2001	-	0.4	-	-	0.5	-	-
PAAC	-	-	-	0.03	0.03	0.03	-
DETBCHD	0.03	0.05	0.05	-	-	-	-
ASP	0.07	0.05	0.08	0.03	0.06	0.01	0.04
Protease B	-	-	-	-	-	0.01	-
Amylase	0.12	0.01	0.01	-	0.02	-	0.01
Lipase	-	0.001	-	0.005	-	0.005	-
Pectin Lyase	0.001	-	0.001	-	-	-	0.002
PB1	-	4.6	-	3.8	-	-	-
Aldose Oxidase	0.05	-	0.03	-	0.02	0.02	0.05

Balance to 100% perfume / dye and/or water

The pH of these compositions is from about 7.4 to about 9.5.

EXAMPLE 37**Animal Feed Comprising ASP**

The present invention also provides animal feed compositions comprising ASP

- 312 -

and/or ASP variants. In this Example, one such feed, suitable for poultry is provided. However, it is not intended that the present invention be limited to this specific formulation, as the proteases of the present invention find use with numerous other feed formulations. It is further intended that the feeds of the present invention be suitable for administration to any animal, including but not limited to livestock (*e.g.*, cattle, pigs, sheep, etc.), as well as companion animals (*e.g.*, dogs, cats, horses, rodents, etc.). The following Table provides a formulation for a mash, namely a maize-based starter feed suitable for administration to turkey poults up to 3 weeks of age.

Table 37-1. Animal Feed Composition	
Ingredient Amount	(wt. %)
Maize	36.65
Soybean meal (45.6% CP)	55.4
Animal-vegetable fat	3.2
Dicalcium phosphate	2.3
Limestone	1.5
Mineral premix	0.3
Vitamin premix	0.3
Sodium chloride	0.15
DL methionine	0.2

In some embodiments, this feed formulation is supplemented with various concentrations of the protease(s) of the present invention (*e.g.*, 2,000 units/kg, 4,000 units/kg and 6,000 units/kg).

All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. However, the citation of any publication is not to be construed as an admission that it is prior art with respect to the present invention.

Having described the preferred embodiments of the present invention, it will appear to those ordinarily skilled in the art that various modifications may be made to the disclosed embodiments, and that such modifications are intended to be within the scope of the present invention.

- 313 -

Those of skill in the art readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The compositions and methods described herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. It is readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.